



GALVESTON COUNTY, TEXAS

COMMISSIONERS COURT 722 Moody, County Courthouse, Galveston, TX 77550 (409) 766-2244

Mark Henry Ryan Dennard Kevin O'Brien Stephen Holmes Ken Clark
County Judge Commissioner, Precinct 1 Commissioner, Precinct 2 Commissioner, Precinct 3 Commissioner, Precinct 4

SPECIAL MEETING-AGENDA **August 26, 2013 – 10:00 AM**

CONSENT AGENDA: ALL ITEMS MARKED WITH A SINGLE ASTERISK (*) ARE PART OF THE CONSENT AGENDA AND REQUIRE NO DELIBERATION BY THE COMMISSIONERS COURT. ANY COMMISSIONERS COURT MEMBER MAY REMOVE AN ITEM FROM THIS AGENDA TO BE CONSIDERED SEPARATELY.

In accordance with the provisions of the Americans with Disabilities Act (ADA), persons in need of a special accommodation to participate in this proceeding shall, within three (3) days prior to any proceeding contact the County Judge's office at 722 Moody, Galveston, Texas 77550 (409) 766-2244.

Call to Order

Consent Agenda

- *1. Consideration of a *Resolution honoring Marilyn Simmons for her many years of dedicated service to the County of Galveston* submitted by Commissioner, Precinct 4.

Action Agenda

2. Commissioner, Precinct 1

- a. Consideration of approving RH Customer Agreement for Placement Services with Robert Half Technology.

3. Community Services

- a. **Break into Executive Session.**
- b. **Executive Session:** Texas Government Code Section 551.071, Consultation with Attorney: Rendering legal advice about pending or contemplated litigation or on a matter in which the duty of the attorney to the County under the Texas Disciplinary Rules of Professional Conduct conflicts with the Open Meetings Act relating to the functions of the Galveston County Medical Examiner's Office.
- c. **Reconvene into Special Meeting.**
- d. Consideration of terminating appointment of current Medical Examiner of Galveston County, Texas and appointing new Medical Examiner of Galveston County, Texas from among the following physicians.

1. Persons to be considered for appointment from among:

Judith F. Aronson
Paul J. Boor
Gerald A. Campbell
Benjamin B. Gelman
Hal K. Hawkins
Nobby C. Mambo
Harminder S. Narula
Juan P. Olano
Bill A. Rampy
Landon C. Stout, Jr.
David H. Walker

- e. Consideration of appointing Deputy Medical Examiners under the new person appointed as Medical Examiner of Galveston County, Texas from among the following physicians.

1. Persons to be considered for appointment from among:

Judith F. Aronson
Paul J. Boor
Gerald A. Campbell
Benjamin B. Gelman
Hal K. Hawkins
Nobby C. Mambo
Harminder S. Narula
Juan P. Olano
Bill A. Rampy
Landon C. Stout, Jr.
David H. Walker

- f. Consideration of First Amendment to the Interlocal Cooperation Agreement with UTMB relating to the Galveston County Medical Examiner's Office to effect a six month extension (i.e., through February 28, 2014) and change of appointments.
- g. Reconsideration of Resolution issued by the Commissioners Court on August 20, 2013 relating to adopting Eligibility Standards, Application, Documentation, and Verification Procedures, Optional Health Care Services and Authorizing Publication of Public Notice on Galveston County Indigent Health Care.

4. **County Legal**

- a. **Break into Executive Session.**

- b. **Executive Session:** Texas Government Code Section 551.071, Consultation with Attorney: Rendering legal advice about pending or contemplated litigation or on a matter in which the duty of the attorney to the County under the Texas Disciplinary Rules of Professional Conduct conflicts with the Open Meetings Act relating to the termination of the existing Galveston County Jail Inmate Health Services Agreement and implementation of interim inmate health care services.
- c. **Reconvene into Special Meeting.**
- d. Consideration of authorizing Boon-Chapman to provide jail inmate medical management services and to implement on-site clinical medical services with CareHere, LLC. for the Galveston County Jail on an interim basis beginning no later than October 1, 2013 and ending at the conclusion of the mobilization period specified in a contract for inmate medical services to be awarded at the conclusion of a request for proposal process conducted by the Galveston County Purchasing Agent.

5. **Professional Services**

- a. Consideration of Budget Amendment:
 - 1. 13-077-0826-A
District Attorney-Request for exception from the limitations of Human Resource policy HR 009 (H) (1).
- b. Submission of the County Auditor's certification of available resources for the Galveston County Auto Crimes Task Force Grant (#2014-T01-Galvesto-00035) for FY 2014 and request for approval of acceptance of the grant award and budget submitted by the County Auditor and Grants Manager.

6. **Sheriff**

- a. Consideration of approval to ratify the cooperative working agreement between Galveston County and the City of Galveston.
- b. Consideration of approval to ratify the cooperative working agreement between Galveston County and the City of La Marque.
- c. Consideration of approval to ratify the cooperative working agreement between Galveston County and the City of Santa Fe.

Adjourn

WORKSHOP AGENDA

1 Budget follow-up and discussion.

Appearances before Commissioners Court

A speaker whose subject matter as submitted relates to an identifiable item of business on this agenda will be requested by the County Judge or other presiding court members to come to the podium where they will be limited to three minutes (3). A speaker whose subject matter as submitted does not relate to an identifiable item of business on this agenda will be limited to three minutes (3) and will be allowed to speak before the meeting is adjourned. Please arrive prior to the meeting and sign in with the County Clerk.

AGENDA ITEM #2.a.



GALVESTON COUNTY, TEXAS COMMISSIONERS COURT Contract Approval Request

To Be Completed By Department							
1. Date of Request: 8/21/2013		2. Contract Type: <input checked="" type="radio"/> Expense Revenue Other			3. Renewal Contract: Yes / <input checked="" type="radio"/> No		
4. Department Name: County Judge				5. Department Contact:			
6. Description: RH Customer Agreement for Placement Services							
7. IFAS PEID No:		8. IFAS Req No:		9. Orgkey:		10. Object Code:	
11. Vendor: Robert Half Technology				12. Vendor Contract No:			
13. Requested Legal Review: <input checked="" type="radio"/> Yes / <input type="radio"/> No (Explain if No)							
Expenditure Budget / Revenue Projections							
14. Fund Name	15. Fund #	16. Current Year Budgeted	17. Current Year Projected	18. Year 2 Projected	19. Year 3 Projected	20. Year 4 Projected	21. Year 5 Projected
22. Totals:							
To Be Completed By Purchasing Department							
Contract Start Date: TBD		Auto Renewal Contract: Yes / No		Bid No: N/A			
Contract End Date: TBD		Contract # Issued By Purchasing: CM13307					

Term 1 yr from executed contract
Signatures

Approved By:	Signature	Date
Department Head:		
Purchasing Agent:		8-21-2013
County Legal:		08/21/2013
Contract listed in Budget Documentation: Yes / No		
County Budget Office:		

RH Customer Agreement for Placement Services

This RH Customer Agreement for Placement Services (the "Agreement") governs transactions by which you retain the Services of Robert Half International Inc., doing business through its division Robert Half Technology ("RH") to assist County of Galveston, Texas ("you" or "your") in meeting its staffing needs.

1.1 Definitions

"Branch" means the RH branch located at the address identified on page 2 of in this Agreement.

"Services" means when RH conducts searches for candidates for direct hire by you.

"Placement Letter" means the letters RH sends to you prior to, and after, you hire a candidate referred by RH.

1.2 Agreement Structure

RH provides additional terms for Services in documents called "Placement Letters" which are also part of this Agreement. All transactions under this Agreement will have a Placement Letter. In order to initiate Services, you will provide RH with notice (e.g., via telephone, e-mail, facsimile or mail) describing the Services you need. RH will promptly reply to such request and indicate whether RH will or will not provide the requested Services. If RH elects to provide the requested Services, RH will send you a Placement Letter.

If there is a conflict among the terms in the various documents, those of this Agreement prevail over those of a Placement Letter.

You accept the terms in a Placement Letter by 1) signing them, 2) using the Services, or allowing others to do so, or 3) making any payment for the Services. Services become subject to this Agreement when RH accepts your order by 1) sending you a Placement Letter, or 2) providing the Services.

1.3 Charges and Payment

If within twelve (12) months following the date a candidate was presented to you, you (or an affiliate or any other entity as a result of referrals by you) hire the candidate (either as an employee, consultant or independent contractor), you agree to pay to RH a fee based upon the candidate's annual starting salary according to the Pricing Section below. RH reserves the right to include as annual salary any expected bonus, commission or guaranteed increase in salary that is part of the initial employment offer. Part time employment fees will be calculated on the equivalent full-time salary multiplied by the percentage of time the employee works.

All fees are due and owing at the time the candidate accepts employment with you. You agree to pay RH no later than fifteen (15) calendar days from the invoice date. If the candidate's employment with you terminates for any reason other than reorganization, elimination of position, takeover or material change in job responsibility within the applicable guarantee period, RH will refund a pro rata portion of the fee paid or issue a pro rata credit for such amount in the event RH provides a replacement. If the full fee is paid by you to RH within fifteen (15) days of the invoice date, a ninety (90) calendar day pro rata guarantee will be in effect. Otherwise, a thirty (30) calendar day pro rata guarantee will be in effect. The refund or credit will be equal to 1/90th or 1/30th, as applicable, multiplied by the number of calendar days remaining in the guarantee period as of the last day of employment with you.

If any authority imposes a duty, tax, levy, or fee, excluding those based on RH's net income, upon any transaction under this Agreement, you agree to pay that amount as specified in an invoice or supply exemption documentation.

1.4 Changes to the Agreement Terms

For a change to be valid, both of us must sign it. Additional or different terms in any written communication from you (such as a purchase order) are void.

1.5 Limitation of Liability

Under no circumstances is RH liable for special, incidental, or indirect damages or for any consequential damages (including lost profits, business, revenue, goodwill, or anticipated savings), even if informed of the possibility.

1.6 Severability

In the event that any provision of this Agreement is held to be invalid or unenforceable, the remaining provisions of this Agreement remain in full force and effect.

1.7 Agreement Term

This Agreement will continue for a period of one year after the last date listed below, unless terminated earlier. Either of us may terminate this Agreement on thirty days' written notice to the other.

Either of us may terminate this Agreement if the other does not comply with any of its terms, provided the one who is not complying is given written notice and reasonable time to comply.

Any terms of this Agreement which by their nature extend beyond the Agreement termination remain in effect until fulfilled, including the payment obligations set forth in Section 1.3 above, and apply to each party's respective successors and assignees.

1.8 Reference Checks

RH usually checks references only by asking specific questions to select past employers with regard to skills and work history. RH has not engaged in any verification process other than these reference checks (e.g., RH has not screened for drug use, administered a medical exam or conducted a criminal background or credit check.). You should conduct such additional reference inquiries of previous employers or verify such other items as you deem appropriate for the position.

1.9 Candidate Information

You agree to hold in confidence the identity of any RH candidate and the candidate's resume, social security number and other legally protected personal information, and you agree to implement and maintain reasonable security procedures and practices to protect such information from unauthorized access, use, modification or disclosure.

1.10 Warranties

RH MAKES NO EXPRESS OR IMPLIED WARRANTIES REGARDING THE SERVICES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTY OF QUALITY, PERFORMANCE, MERCHANTABILITY OR FITNESS FOR ANY PURPOSE.

1.11 Pricing

The fee shall equal 20% of the candidate's annual starting salary.

This Agreement and its Placement Letters are the complete agreement regarding these transactions, and replace any prior oral or written communications between the Branch and you regarding these transactions. This Agreement is only applicable to, and the only Robert Half International Inc. branch and division obligated under this Agreement are, the Robert Half Technology division of the Branch.

By signing below, both parties agree to the terms of this Agreement. Once signed, 1) any reproduction of this Agreement or Placement Letters made by reliable means (for example, photocopy or facsimile) is considered an original and 2) all Services ordered under this Agreement are subject to it.

Agreed to:
[Insert Client Name]

Agreed to:
Robert Half International Inc.

By _____
Authorized signature

By _____
Authorized signature

Name (type or print): Mark Henry, County Judge

Name (type or print): Emily S. Besser

Date: 8/8/2013

Date: 8/8/2013

Customer address: 722 Moody Ave., Galveston, Texas 77550

RH address: 1300 Post Oak Blvd Houston, TX 77056

After signing, please return a copy of this Agreement to the "RH address" shown above.

Addendum A

Charges and Payments

Robert Half Technology agrees to amend the guarantee from the 90 day pro-rated guarantee to a 90 day full guarantee.

AGENDA ITEM #3.d.



PUBLIC VERIFICATION / PHYSICIAN PROFILE

PHYSICIAN

NAME: JUDITH F ARONSON MD

DATE: 08/21/2013

THE INFORMATION IN THIS BOX HAS BEEN VERIFIED
BY THE TEXAS MEDICAL BOARD

Date of Birth: 1958

License Number: J1183 Full Medical License

Issuance Date: 06/17/1992

Expiration Date of Physician's Registration Permit: 11/30/2013

Registration Status: ACTIVE

Registration Date: 08/15/1994

Disciplinary Status: NONE

Disciplinary Date: NONE

Licensure Status: NONE

Licensure Date: NONE

Medical School of Graduation:

At the time of licensure, TMB verified the physician's graduation from medical school as follows:
UNIV OF NORTH CAROLINA AT CHAPEL HILL SCH OF MED, CHAPEL HILL

Medical School Graduation Year: 1985

TMB Filings, Actions and License Restrictions

The Texas Medical Board has the following board actions against this physician. (This may include any formal complaints filed by TMB, as well as petitions and/or responses related to licensure contested matters, at the State Office of Administrative Hearings.)

NONE

Investigations by TMB of Medical Malpractice

Section 164.201 of the Act requires that: the board review information relating to a physician against whom three or more malpractice claims have been reported within a five year period. Based on these reviews, the following investigations were conducted with the listed resolutions.

NONE

Status History

Status history contains entries for any updates to the individual's registration, licensure or disciplinary status types (beginning with 1/1/78, when the board's records were first automated). Entries are in reverse chronological order; new entries of each type supersede the previous entry of that same type. These records do not display status type. Should you have any questions, please contact our Customer Information Center at 512-305-7030 or verificic@tmb.state.tx.us

Status Code: AC**Effective Date:** 08/15/1994**Description:** ACTIVE**Status Code:** DQ**Effective Date:** 11/30/1993**Description:** DELINQUENT-NON PAYMENT**Status Code:** AC**Effective Date:** 11/23/1993**Description:** ACTIVE**Status Code:** DQ**Effective Date:** 09/15/1992**Description:** DELINQUENT-NON PAYMENT**Status Code:** LI**Effective Date:** 06/17/1992**Description:** LICENSE ISSUED

THE INFORMATION IN THIS BOX WAS REPORTED BY THE LICENSEE AND
HAS NOT BEEN VERIFIED BY THE TEXAS MEDICAL BOARD

Gender: FEMALE***Ethnicity:** WHITE**Race:** WHITE

* We are in the process of transitioning from the current ethnic origin values to federal standards for race and Hispanic origin. The transition period will allow time for individuals to submit updated race and Hispanic origin data to the TMB.

Place of Birth: DISTRICT OF COLUMBIA**Current Primary Practice Address:**

THE DEPT OF PATHOLOGY 0747

301 UNIVERSITY BLVD

GALVESTON , TX 77555-0747

Years of Active Practice in the U.S. or Canada:

The physician reports that he/she has actively practiced medicine in the United States or Canada for **15** year(s).

Years of Active Practice in Texas:

The physician reports that, of the above years he/she has actively practiced in the State of Texas for **13** year(s).

Specialty Board Certification

The physician reports that he/she holds the following specialty certifications issued by a board that is a member of the American Board of Medical Specialties or the Bureau of Osteopathic Specialists:

Specialty Certification: AMERICAN BOARD OF PTH/ANATOMIC PATHOLOGY

Date: 1990

Primary Specialty

The physician reports his/her primary practice is in the area of PATHOLOGY.

Secondary Specialty

The physician did not report a secondary practice area.

Name, Location and Graduation Date of All Medical Schools Attended

Name: UNIVERSITY OF NORTH CAROLINA

Location: CHAPEL HILL USA

Graduation Date: 05/1985

Graduate Medical Education In The United States Or Canada

Program Name: UNIV OF NORTH CAROLINA

Location: CHAPEL HILL, NC

Begin Date: 09/1992

Type: FELLOWSHIP

End Date: 08/1994

Specialty: RESEARCH

Program Name: UNIVERSITY OF TX MEDICAL BRANCH

Location: GALVESTON

Begin Date: 01/1989

Type: RESIDENCY

End Date: 08/1991

Specialty: PATHOLOGY ANATOMIC

Program Name: UNIV OF WASHINGTON

Location: SEATTLE, WA

Begin Date: 06/1985

Type: RESIDENCY

End Date: 01/1988

Specialty: ANATOMIC PATHOLOGY

Hospital Privileges

The physician reports that he/she has hospital privileges in the following in the State of Texas:

Hospital: UNIVERSITY OF TX

Location: GALVESTON TX

Utilization Review

The physician did not report whether he/she provides utilization review.

NONE REPORTED

Patient Services

Accessibility: The physician reports that the patient service area **is** accessible to persons with disabilities as defined by federal law.

Language Translation Services: The physician reports that the following language translation services are provided for patients: LANGUAGE ASSISTANCE SERVICES AVAILABLE 24 HRS

Medicaid Participant: The physician reports that he/she **does not** participate in the Medicaid program.

Awards, Honors, Publications and Academic Appointments

Optional Information

The physician may optionally report descriptions of up to five such honors and has reported the following:

Description: PROFESSOR DEPT OF PATHOLOGY AND VICE CHAIR FOR EDUCATION

Description: DISTINGUISHED TEACHING PROFESSOR, UTMB

Description: SCHOLAR, JOHN P. MCGOVERN ACADEMY OF OSLERIAN MEDICINE, 2004-2009

Description: L. CLARKE STOUT, JR PROFESSOR IN ANATOMIC PATHOLOGY

Description: UTMB CLASS OF 1947 EXCELLENCE IN EDUCATION AWARD

Malpractice Information

Section 154.006(b)(16) of the Act requires that: a physician profile display a description of any medical malpractice claim against the physician, not including a description of any offers by the physician to settle the claim, for which the physician was found liable, a jury awarded monetary damages to the claimant, and the award has been determined to be final and not subject to further appeal. The physician has the following reportable claims.

Description: NONE

Criminal History

Self-Reported Criminal Offenses:The physician is required to report a description of (1) "any conviction for an offense constituting a felony, a Class A or Class B misdemeanor, or a Class C misdemeanor involving moral turpitude" and (2) "any charges reported to the board to which the physician has pleaded no contest, for which the physician is the subject of deferred adjudication or pretrial diversion, or in which sufficient facts of guilt were found and the matter was continued by a court of competent jurisdiction."

The physician has reported the following:

Description: NONE

Criminal history information is also obtained by TMB from the Texas Department of Public Safety. Resulting action, if any, will be reported under the TMB Action and Non-Disciplinary Restrictions section above.

Disciplinary Actions By Other State Medical Boards

The physician has reported the following:

Description: NONE

Physician Assistant Supervision

To obtain primary source verifications, click name

Description: NONE

Advanced Practice Nurse Delegation

To obtain primary source verifications, click name

Description: NONE

Summary of all License/Permit Types

Issue Date:	Type:
07/03/1989	<u>INSTITUTIONAL PERMIT</u>
06/17/1992	<u>LICENSED PHYSICIAN</u>
03/12/1992	<u>PHYSICIAN TEMPORARY LICENSE</u>

[Agency](#) | [Contact Us](#) | [Employment](#) | [Compact w/ Texans](#) | [Open Records](#) | [Privacy Policy](#) | [Site Map](#) |
[Search TX State Sites](#) | [TX Homeland Security](#) | [TX Occupations Code](#) |
[Texas.gov](#) | [Poison Control Center Services](#) | [Accessibility Policy](#)

CURRICULUM VITAE

NAME: Judith F. Aronson, M.D.

Date: March, 2012

PRESENT POSITION AND ADDRESS (March 2012):

Professor and Vice Chair for Education
Department of Pathology
301 University Blvd.
University of Texas Medical Branch
Galveston, TX 77555-0747
Tel: (409) 772-6547
FAX: (409) 772-9045
Email: jaronson@utmb.edu

BIOGRAPHICAL BACKGROUND:

Date of Birth: [REDACTED]
Place of Birth: Washington, DC
Home Address: [REDACTED]
Phone: [REDACTED]
Social Security: [REDACTED]
Citizenship: USA

EDUCATION:

09/1976-05/1980 B.S.
Molecular Biophysics and Biochemistry (*cum laude*)
Yale University
New Haven, CT

08/1981-05/1985 M.D.
University of North Carolina
Chapel Hill, NC

BOARD CERTIFICATION:

08/30/1990 American Board of Anatomic Pathology

Judith F. Aronson, M.D.

LICENSURE INFORMATION:

06/17/1992	Texas Medical License #J1183; Active
05/ 22/1993	North Carolina Medical License #36643; Inactive
03/04/1987	Washington State Medical License #025209 MD00024560; Inactive

PROFESSIONAL AND TEACHING EXPERIENCE:

09/2007- present	Professor Department of Pathology UTMB
2003-present	Vice Chair for Education Department of Pathology UTMB
09/2001-08/2007	Associate Professor with tenure Department of Pathology UTMB
2000-present	Director, Autopsy Service Department of Pathology University of Texas Medical Branch Galveston, TX
1994-2001	Assistant Professor Department of Pathology University of Texas Medical Branch Galveston, TX
1994-present	Member, WHO Collaborating Center for Tropical Diseases University of Texas Medical Branch Galveston, TX
2000-present	Full Member Graduate School of Biomedical Sciences University of Texas Medical Branch Galveston, TX

PROFESSIONAL AND TEACHING EXPERIENCE: (continued)

- | | |
|----------------|--|
| 1995-2000 | Associate Member
Graduate School Biomedical Sciences
Experimental Pathology Program
University of Texas Medical Branch
Galveston, TX |
| 1998-2000 | Associate Member
Graduate School of Biomedical Sciences
Microbiology and Immunology Program
University of Texas Medical Branch |
| 1998-2000 | Associate Director
Autopsy Service
University of Texas Medical Branch Hospitals
Galveston, TX |
| 1993-1994 | Clinical Instructor
Autopsy Service
Department of Pathology
University of North Carolina
Chapel Hill, NC |
| 1992-1994 | Post-doctoral Fellow (mentor, Robert E. Johnston, Ph.D.)
Department of Microbiology and Immunology
University of North Carolina
Chapel Hill, NC |
| 1991-1992 | Assistant Professor
Department of Pathology
University of Texas Medical Branch
Galveston, TX |
| 1989-1991 | McLaughlin Post-doctoral Fellow (mentor, Thomas R. Jerrells, Ph.D.)
Department of Pathology
University of Texas Medical Branch
Galveston, TX |
| 1988 (Apr-Dec) | Physician and Pathologist
Curran Lutheran Hospital
Zorzor, Liberia, West Africa |

Judith F. Aronson, M.D.

PROFESSIONAL AND TEACHING EXPERIENCE: (continued)

1988 (Feb-Mar)	Special study period Department of Infectious and Parasitic Diseases Armed Forces Institute of Pathology Washington, DC
1985-1988	Residency training in Anatomic Pathology University of Washington Affiliated Hospitals Seattle, WA

RESEARCH ACTIVITIES:

I have a long-standing interest in the study of pathogenesis of infectious diseases, particularly experimental animal models of acute viral diseases including viral hemorrhagic fevers and arbovirus encephalitides. Because of my training as a pathologist, I am most interested in disease mechanisms and tissue-based studies of infectious agent localization and host responses.

Grant support:

Current:

NIH/NIAID (PI: James Leduc, PI)

Role: (J. Aronson, Associate Director)

**"Galveston National Laboratory Operations
"Experimental Pathology Core"**

Agency: 5 UC7 AI070083/1 UC7AI094660

Period: 05/30/06-04/30/2012 (20% effort/2.40 cm)

Amount: \$1,426,786

The objective of this core is to provide histology services to the GNL.

NIH/NIAID (PI: Barret Alan D.; PD: Geisbert, Thomas W.)

Role: Pathologist

"Animals Models of Infectious Diseases Part A: Small Animal Models (Task Order A20)"

Agency: HHSN2722010000401

Period: 09/01/2011 - 02/28/2013 (5% effort/.60 cm)

Amount: \$599,367

The objective is to establish a Syrian Golden Hamster Model for Filoviruses.

UTMB Academy of Master Teachers, Sterling-Turner Endowed Professorship in Teaching Excellence

"Translational Research Track for Medical Students: Developing Interprofessional Collaborative Competencies for Translational Research"

Period: 2010-2012

\$8000 per year

Judith F. Aronson, M.D.

Past:

NIH (Hellmich, PI)

"Studies in Gastrointestinal Endocrinology"

Agency: P01 DK035608 (5%)

Period: 06/01/05-03/31/11

Amount: \$65,545

Goals of Core F: "Histopathology Core" To provide a repository of tissues, immunohistochemical reagents and reagents for in situ hybridization studies.

Role: Co-Investigator

NIH/NIAID (Gorenstein, PI)

"Biodefense Proteomics Collaboratory"

Agency: 5 U01 AI054827

RESEARCH ACTIVITIES (continued):

Period: 4/15/03-3/31/09 (5% / .60 cc months)

Amount: \$272,302

In vitro enzymatic combinatorial selection and split-synthesis chemical combinatorial methods will be used to develop a "ThioAptamer Chip" (TACH™) for proteomics- a diagnostic tool to identify and quantify the differential expression of key proteins in response to pathogens of concern for bioterrorism threat.

NIH/NIAID (Walker)

"Region VI Center for Biodefense and Emerging Infectious Diseases"

Agency: 1 U54 AI 057156

Period: 09/04/03-02/29/09(5% / .60 cc months)

Amount: \$10,041,176 (year 4 - direct cost)

To develop and maintain a strong infrastructure and multifaceted research and development activities that will provide the scientific information and translational research capacity to make the next generation of therapeutics, vaccines, and diagnostics against the CDC Category A-C agents.

NIH/NIAID (Dennis Hruby, PI; S. Paessler subcontract)

"Antiviral Drugs Against Junin Virus-Caused Lethal Disease in Guinea Pig Model"

Agency: SBIR R44 AI056525

Period: 11/01/2005-07/31/2008 (5% / .60 cc months)

Amount: \$579,388.00 (direct costs)

The objective of this Arenavirus Challenge Grant program is to advance the NWAV-specific antiviral lead (ST-294) through pre-clinical studies, animal efficacy and IND-enabling toxicology, in order to submit a pre-IND application and have drug material ready for human safety studies. My group is working on the animal model development and in vitro and in vivo efficacy protocols (Collaboration with SIGA).

Judith F. Aronson, M.D.

- 2003-2005 NIH/NIAID "Cytokine Patterns in Guinea Pig Arenavirus Disease", R03. Principal Investigator (5% effort). \$100,000 (direct costs).
- 2002-2003 NIH, "Aptamer Screening for Bioterrorism Agent Therapeutics", SBIR, Phase I. PI of UTMB subcontract (5%) (Manfred Koller, Oncosis, Inc., PI). \$44,016 direct costs for UTMB Subcontract.
- 2001-2003 DARPA. DAAD 19-01-1-0379 "Thioaptamers for Therapeutic targeting of pathogenic and human proteomes." Co-Investigator (10%), (R. Shope, P.I.). \$794,642 (direct costs) .
- 2001-2005 NIH. "Early events in diclofenac enteropathy". Co-Investigator (2%) (M. Moslen, P.I.) \$250,000 (direct costs).
- 2000-2001 Institute for Advanced Technology, "Countermeasures for Arenaviruses". Co-Investigator (10%), (R. Shope, P.I.). \$262,200 (direct costs)
- 1997-00 DARPA "Structure-Based Design of Acute Counter-Measures to Alphaviruses, Flaviviruses, and Arenaviruses". Co-Investigator (10%), (R. Shope, P.I.) \$820,007 (direct costs)
- 1996-00 NIH Program Project, "Mechanisms of Emergence of Zoonotic Viral Pathogens". Co-Investigator (5%), (R. Tesh, P.I.) \$428,877 (direct costs), AI39800
- 1995-1997 John Sealy Memorial Endowment Fund "Molecular Determinants of Virulence in a Guinea Pig Model of Arenavirus Hemorrhagic Fever". Principal Investigator, \$30,000.
- 1993 NIAID Clinical Investigator Award "Molecular genetics of Venezuelan equine encephalitis virus pathogenesis". Principal Investigator. \$243,916 (direct costs) (Award offered but not accepted due to move to UTMB.)
- 1989-1991 James W. McLaughlin Research Fellowship in Infection and Immunity, The University of Texas Medical Branch. "Macrophage function and pathogenesis of arenavirus infection in guinea pigs", Principal Investigator. \$77,958.

COMMITTEE RESPONSIBILITIES:

International: None

National: Abstract review committee US Canadian Academy of Pathology, 2010, 2011

State/Regional: University of Texas Academy of Health Sciences Education, Faculty Development Team.

COMMITTEE RESPONSIBILITIES (continued):

UTMB:

- 2010-present: Member, MyChart Steering Committee
- 2009-present: Member, Biorepository Oversight Committee, Institute for Translational Sciences
- 2010-present: Member, Old Red Anatomical Museum Task Force
- 2011-2012: Co-chair, Old Red Anatomical Museum Task Force
- 2009- 2010: Team leader, Faculty Development Team, UTMB Academy of Master Teachers
- 2000-present: Member, Pathology Quality Management Committee
- 1999-2003: Member, McLaughlin Fellowship Committee
- 1997-2000 Member, Institutional Review Board
- 1999 Member, Task Force on Infectious Disease Genomics
- 1996, 2005-8: Member, UTMB/TDCJ Physician's Peer Review Committee
- 1998 Member, Get out the CRUD Task Force
- 1997 Member, Junior Faculty Committee, UTMB Presidential Search

School of Medicine, UTMB:

- 2009-2012: Member, School of Medicine Appointment, Promotion and Tenure Committee
- 2006-2009,
2010-2013: Member, School of Medicine, Academic Planning and Policies Committee
- 2006 Chair, LCME Self-study Task Force, Subcommittee for Medical School Faculty
- 2001-2008: Member, M.D., Ph.D. Advisory Committee
- 2004: Chair, M.D., Ph.D. Program Curriculum Subcommittee
- 2001-2004: Member, School of Medicine, Curriculum Committee (elected)
- 2000-2001: Member, Integrated Medical Curriculum, Course Directors Committee
- 1998-2008: Member, Integrated Medical Curriculum, Pathobiology and Host Defense Course Committee
- 2000-2008: Member, Integrated Medical Curriculum, Molecules, Cells, and Tissues Course Committee
- 1999 Member, Task Force for revision of "Molecules, Cells, and Tissues" Course

Judith F. Aronson, M.D.

- 1998 Member, Integrated Medical Curriculum, Gross Anatomy and Radiology Course Committee
- 1997-1998 Member, Interactive Learning Track, Examination Committee
- 1998 Liaison Committee on Medical Education Self-Study, Chair, Subcommittee on Continuing Medical Education

Graduate School of Biomedical Sciences, UTMB:

- 2006-2008 Member, Graduate School of Biomedical Sciences, Curriculum Committee
- 2002 Member, Graduate School of Biomedical Sciences, Admissions Committee
- 2000-2001: Member, Graduate School of Biomedical Sciences, Recruitment Committee

Departmental Committees, Pathology, UTMB:

- 2011-2012: Chair, APT committee, Department of Pathology
- 2010-2011: Chair, Tenure Review Committee, Department of Pathology
- 2009-2011: Chair, Education Leadership Committee and Medical Education Committee
- 2007-2010: Member, APT committee, Department of Pathology
- 2008-2011: Member, Tenure Review Committee, Department of Pathology (Chair, 2009-2010)
- 2004-2007: Chair, Medical Education Committee
- 2003-2004: Member, Cytopathology Faculty Search Committee
- 2003-2004: Member, Autopsy Pathologist Search Committee
- 2002: Member, Clinical and Translational Research Committee
- 2000-2008: Member, Pathology Patient Services Quality Management Committee
- 2002-2008: Member, Experimental Pathology Graduate Program, Curriculum and Academic Planning and Committee
- 2000-2001: Member, Self-Study Committee for Pathology Department External Review
- 2001 Member, Ad Hoc Strategic Planning Committee for Pathology Clinical Services
- 2000-2002: Member, Pathology Education in the Integrated Medical Curriculum Committee
- 2000 Member, Forensic Pathologist Search Committee
- 1995-1998: Member, Medical School Pathology Course Committee
- 1996-2002: Member, Admissions and Recruitment Committee, Experimental Pathology Graduate Program (Co-Chair 1999-2002)
- 1999-2000: Member, Student Evaluation and Advisory Committee, Experimental Pathology Graduate Program
- 1996-present: Member, Pathology Residency Advisory Committee
- 1996-present: Member, George Dock Scholar Review Committee
- 1995-1998 Member, Student Travel Fund Committee
- 1997-1998 Member, Meyer Bodansky Memorial Lectureship Committee

1998 Member, Autopsy Faculty Search Committee

Departmental Committees, Microbiology and Immunology, UTMB:

2001-2008: Member, Graduate Program in Microbiology and Immunology, Curriculum Committee
1998-2000: Member, Graduate Program in Microbiology and Immunology, Recruitment Committee
1998 Member, Virologist Search Committee, Department of Microbiology and Immunology

TEACHING RESPONSIBILITIES AT UTMB:

TEACHING RESPONSIBILITIES, SCHOOL OF MEDICINE

Medical Course in Pathology, Traditional curriculum:

Block Co-ordinator, Infectious Diseases section (1995-8)
Laboratory Instructor Term III (1995-8) (48 hours/year)
Case development for laboratory exercise, "Infectious disease pathology" (1995-1998)
Lecturer, Term III (1995-8) (4 hrs/year)
"Immunologic aspects of inflammation" (1995-1998)
"Concepts in infectious disease pathogenesis" (1995-1998)
"Survey of infectious disease pathology" (1995-1998)
"Diagnosis of pneumonia (with Drs. Woods and Boyars) (1998)
"Roundtable, infectious diseases" (with Drs. Cooper, Shope, Doughty) (1996)

TEACHING RESPONSIBILITIES AT UTMB (cont'd):

Medical School, Interactive Learning Track:

Co-director, Pathology Correlates (1997)
Director, Pathology Correlates (1998)

Medical Course, Integrated Medical Curriculum:

Director, Translational Research Track: 2010-present

Laboratory Director for Instructional Management Office: 2006-present

Great Syndromes course: Director: 2008-present

Lecturer: "Fever" (1 hr) 2008-2009

Co-developer, "Design-A-Case" with incorporated WebSlides

PBL facilitator 2008, 2009, 2010 (24 hrs)

Pathobiology and Host Defenses Course: Co-Director, 2001-2004

PBL Facilitator, inter-professional group of graduate students and medical students (2012)

Lecturer: "Pathology of chronic inflammation and repair" (1 hr.) (1999)

Lecturer: "Innate Immunity" (1 hr.) (2000-2008)

Judith F. Aronson, M.D.

Lecturer: "Pediatric Pathology" (1 hr.), (2003, 2004, 2006, 2007, 2008, 2009, 2010, 2011) Week leader, Cell injury section (developed PBL case and 2 laboratories) (1998-2004).

Laboratory Instructor: (32 hrs./yr.) (1999-2011)

Developer of WebSlide based tutorials: 2005-6

Renal, Fluid and Electrolytes Course : Laboratory Instructor (2 hrs.) (1999-2003)

Gastrointestinal and Nutrition Course: Laboratory Instructor (8 hrs.) (1999-2010)

Cardiovascular/Pulmonary Course: Laboratory Instructor (8 hours) (1999-2010)

Coordinator of laboratories: 2009

Developer of on-line SoftChalk tutorial: 2009

Molecules, Cells, and Tissues Course: Co-Director, 2000

Laboratory Instructor, Microanatomy (12 hours): (2000-2010)

TEACHING RESPONSIBILITIES AT UTMB (cont'd):

Gross Anatomy and Radiology Course:

Organized supplementary exercise attendance (gross autopsy conference) and Pathology demonstrations in anatomy laboratories (5 hours) (1998, 2005-2010);

Participated in case development with emphasis on integrative learning issues between other first year courses (2001)

Basic Science and Humanities Selectives Course: Course committee member, 2002-present

TEACHING RESPONSIBILITIES, GRADUATE SCHOOL OF BIOMEDICAL SCIENCES:

Graduate Program, Human Pathophysiology and Translational Medicine, Institute of Translational Sciences:

Member, curriculum and recruitment committees (2008-2011)

Practice of Translational Science Module 1, 2011 (4 contact hours)

Practice of Translational Science Module 2, 2011 (6 contact hours)

Practice of Translational Science Module 3, 2012 (12 contact hours)

Pathobiology and Host Defense for HPTM students, 50 contact hours as Facilitator for inter-professional PBL group

Basic Biomedical Sciences Curriculum, Integrative Systems Modules:

Microorganisms and Infectious Disease:

"Pathogenesis of viral diseases: hemorrhagic fevers" (1 hr.) (2002-2009)

"Viral pathogenesis: Immunopathology and cytokine-mediated pathology" (1.5 hr/yr.) (2000, 2001)

Inflammation: "Granulomatous inflammation" (1.0 hr) (2000-2004); "Chronic Inflammation" (1.0 hr) (2005-20010)

Tropical Diseases: "Lassa Fever" (1.0 hr) (2001)

Graduate Program in Experimental Pathology:

Pathobiology of Human Disease: “Immunopathology” (4.0 hrs.) (2002-2012);
Acute viral diseases; hemorrhagic fevers (4.0 hrs., 2002-2011)

Special Topics Course, Journal Club for Fundamentals of Pathology (10 hours)
(2000)

Fundamentals of Pathology: Course co-director, (1998, 1999)

Lecturer (1995-1999) (3 hours/year):

“Introduction to Immunology”, “Innate Immunity”, “Immunity in Infectious Diseases”

Infectious Disease Pathogenesis :

“Innate Immunity” (2004, 2005): 1.5 hours

“Immunopathogenesis of arenavirus disease” (2004, 2005): 1.5 hrs

“Pathogenesis of West Nile Virus Infection” (2004, 2005): 0.75 hours

“HIV pathogenesis (1996) (3 hours)

“LCMV Immunopathogenesis” (1998) (3 hours)

Pathogenesis of Viral Disease: “Pathogenesis of disease syndromes caused by
arenaviruses” (2006) (2 hours)

Biothreat Agents and Biodefense: “Introduction to the immune response” (1.5 hr)
(2003-2009)

“Lassa fever” (1.5 hr) (2003-2010)

Tropical Diseases: (1996, 1998) (1.5 hours)

“Lassa Fever”

Teaching in Pathology (name changed to Teaching Skills I and II, 2010):

Course Director (2003-2012)

Small group sessions (1995-1998) (8 hours)

Graduate Program in Microbiology and Immunology:

Virology: Arenaviruses (2002-2009) (1 hr)

Introduction to Virology: “Animal Models in Virology” (1.5 hours) (1997)

TEACHING RESPONSIBILITIES, SCHOOL OF ALLIED HEALTH SCIENCES:

Occupational Therapy Program:

Pathophysiology in Disease, 2 lectures on Immunopathology,
2001,2002 (2.0 hr.)

TEACHING RESPONSIBILITIES AT UTMB, OTHER:

HIV Autopsy Conference, Internal Medicine, Infectious Diseases Division
(1 hour monthly, 1998)

Internal Medicine Residents Autopsy Conference: Quarterly, 2000-2002

Pathology Residency Program:

One-on-one teaching in autopsy service (1994-2011)

Introduction to Autopsy (2000-2006) (2.0 hr.)

Diagnosis of infectious diseases at autopsy (2006)

STUDENTS AND FELLOWS MENTORED:

Post-doctoral fellows:

- 1995 Norman Dong, M.D., autopsy fellow. Research project entitled "Histopathologic changes in Hepatitis C and HIV co-infection: an autopsy study."
- 2004-2008 Eric Vela, Ph.D. , post-doctoral research fellow. Research project "Mechanisms of arenavirus entry into host cells". Supported by NIH Training grant T32 AI07536

Ph.D. students:

- 2007: Tiffany Ethridge, Ph.D Student rotation project: Creation of Pichinde virus enveloped MLV-pseudotypes and characterization of their tropisms
- 2004: Brian Friedrich, Ph.D student, rotation project: Effect of pro-inflammatory cytokines on Pichinde virus replication in cultured cells
- 2004: Eric Bailey, M.D., Ph.D. student, rotation project: "Permissiveness of primary macrophages from outbred guinea pigs to Pichinde virus infection"
- 2003: Jeffrey Jordan, M.D, Ph.D. student, rotation project: Pathogenesis of Pichinde virus infection of guinea pigs after intranasal inoculation
- 2003: Heather McSharry, doctoral student, rotation project: "Immunolocalization of Pichinde virus in fixed tissue macrophages of infected guinea pigs"
- 2002: Lucy Perrone, doctoral student, rotation project: "Cellular localization of thioaptamers in macrophages"
- 2002: Melissa Herbst, doctoral student, rotation project: "Development of a bioassay for guinea pig Gamma interferon"
- 2002: Elena Sbrana, doctoral student, rotation project: "Cell-cell spread of Pichinde virus".
- 2001-2005 Erin Scott (née Webb), doctoral student: "Cytokine patterns in guinea pig model of arenavirus hemorrhagic fever". Current position, Medical Writer, Complete Publication Solutions, Horsham PA.
- 1995-2001 Kathleen Marriott, doctoral student. Recipient of UTMB James W. McLaughlin Research Fellowship in Infection and Immunity, "The role of interferon in the pathogenesis of Pichinde virus infection of guinea pigs".
- 1998-2002 Amy Shurtleff, doctoral student. Supported by NIH Training Grant on Tropical and Emerging Diseases and James W. McLaughlin Fellowship Fund. "Contribution of the complement system to the

pathogenesis of Pichinde virus infection of guinea pigs”. Current position, Scientist, USAMRIID, Frederick, MD

2000 Erin Webb, graduate student, laboratory rotation. “Apoptosis during experimental infection of guinea pigs with Pichinde virus”.

1998 Brian Sims, graduate student in Experimental Pathology, rotation project, “Interleukin-8 in Pichinde virus infection of guinea pigs

Other Students:

1999 Annie Chao, High School student, High School Summer Research Program.

2008: Joyce Chen: Ball High School student, High School Summer Research Program

Pathology residents: Over the years, I have had teaching and mentoring interactions with over 50 residents in Pathology. Selected trainees are listed below.

Satish Chundru, DO. 1999-2004. During eight months of autopsy elective time in his final year, he served as “Autopsy Chief Resident”. He co-authored a research project entitled “The effect of a required autopsy exercise on medical student attitudes about autopsy and accuracy of death certification”. Current Position: Deputy Chief Medical Examiner, Travis County TX Medical Examiner’s Office

Dwayne Wolf, M.D., Ph.D. 1995-1998. Current position: Deputy Chief Medical Examiner, Harris County Medical Examiner’s Office.

Juan P.Olano, M.D. Dates 1992-1997. Current position. Professor, Department of Pathology, UTMB, Director, Pathology Residency Training Program.

Claudia Molina, M.D., 1996-2001. Current position: Surgical Pathologist, The Methodist Hospital, Houston, TX.

Medical student mentoring activities:

1998 Alberto Montero, medical student McLaughlin Fellow. “Cytotoxic T lymphocyte function during experimental infection of guinea pigs with the arenavirus Pichinde”.

2010 Ashley Garrett, Medical Student Summer Research Project, co-mentored with Dr. Charles Fulhorst

2011 Kael Kuster, Medical Student Summer Research Project, co-mentored with Drs. Cong and Gong

Judith F. Aronson, M.D.

2006-present: I am a faculty mentor for one of the Osler Student Societies in the School of Medicine (Asclepius). This entails approximately monthly interactions with students in social, mentoring, discussion group, or community service activities. Examples include food and clothing drives for community charities, reading and discussion of essays on professionalism and humanism in medicine, group attendance at cultural events related to medicine, and service projects for hospital and community.

2006-present: Faculty sponsor, Pathology Student Association

2004-2010: Osler Scholar, mentoring of Osler student scholars: As an Osler Scholar in the John P. McGovern Academy of Oslerian Medicine, I have worked closely with several Osler student scholars on projects related to the pathology museum creation. Several Osler student scholars have “shadowed” me in the autopsy suite, where we discuss pathology and clinical correlations, often in conjunction with clinical Osler scholars representing hematology, family medicine, neonatology, internal medicine, pediatrics, surgery.

Dissertation Committees:

Amy Shurtleff, “The role of complement in the pathogenesis of Pichinde virus infected guinea pigs, a model for human Lassa Fever.” Chair of committee, Defense, May 2002.

Kathleen Marriott, “Studies in Pichinde virus pathogenesis: Viral tropism and the interferon response”. Chair of Committee, Defense August 2001.

Jason Huang, “Characterization of the viruses isolated from long-term nonprogressors of HIV infection”. Member of committee, Defense, August 2000

Ed Murphey, “Direct and immunomodulatory effects of administration of a low dose of tumor necrosis factor in animal models of shock”. Member of Committee, Defense, December 2000.

Joan Nichols, “Tracking Influenza A virus entry and infection: Implications for the immune response”. Member of Committee, Defense, August 1999.

Tzu (Jack) Wu, “Efficacy And Mechanisms Of Action Of B16 Melanoma Cells Exposed *In Vitro* To Long-Term Interferon Alpha Treatment As A Tumor Vaccine In Mice.” Member of Committee, Defense, March 2000.

Patricia Aguilar, “Comparison of North American and South American Strains of Eastern equine encephalitis virus” Member, of Committee, Defense, May 2005.

Darci Smith, “Transmission and Pathogenesis of Venezuelan Equine Encephalitis Virus”. Member of Committee, Defense, April 2006.

Judith F. Aronson, M.D.

Erin P. Scott, "Cytokine Patterns In A Comparative Model Of Arenavirus Infection: Implications For Virulence And Control Of Viral Replication In Guinea Pig Macrophages" Chair of Committee, Defense, July 2005.

Slobodan Paessler, "Venezuelan equine Encephalitis Pathogenesis and Vaccine Development", Member of Committee, Defense, 2006

Michael Carter, "Anti-inflammatory Treatments in Spinal Cord Injury", Member of Committee, Defense, December, 2006

Bradley Schneider, "Role of Mosquito Saliva on Host immune Response and Pathogenesis of Arboviruses", Member of Committee, Defense, 2006

Heather Stevenson, "Ehrlichiosis: Understanding immune mechanisms that lead to the development of fatal disease" Member of Committee. Defense, 2007.

Brian Friedrich, "Characterization of cellular factors important for HIV replication". Member of committee. Defense Oct 2010

Joanie Kenney, Adaptation of Venezuelan equine encephalitis virus enzootic strains to enzootic mosquito vectors, Member of Committee, Defense, 2011

William Lawrence, "The effects of anthrax toxins on cardiac physiology", Member of committee, Defense, Jan 2011

Kenneth Plante, "Production and testing of a novel live-attenuated Chikungunya vaccine." Member of committee, 2011-

Katie Taylor, The host response to Venezuelan equine encephalitis virus, Member of committee, Defense, March 2012.

Ashley Grant, "Attenuation mechanism of arenaviruses". Member of committee, Defense, March 2012.

Hope Liu, The differentiation and expansion of CD4 T cells in inflammatory bowel disease. Member of committee, 2011-

Veronica Calderon, "Mycobacterium TB and HIV co-infection in a humanized mouse model". Member of Committee, 2011-

MEMBERSHIP IN PROFESSIONAL SOCIETIES:

American Society for Virology (past)
American Society of Tropical Medicine and Hygiene (past)
American Society for Investigative Pathology (past)
College of American Pathologists
Group for Research in Pathology Education
International Association of Medical Science Educators
United States and Canadian Academy of Pathology

SCIENTIFIC SESSIONS CHAIRED:

Convenor, Workshop on Arenaviruses and Rhabdoviruses, American Society for Virology, 23rd Annual Meeting, Montreal, July 10-14, 2004

Moderator, Platform Session, Autopsy Pathology, US and Canadian Academy of Pathology, Annual meeting, Boston MA, March 9-13, 2009.

HONORS AND AWARDS:

2010	Nominated, Arnold P. Gold Foundation Humanism in Medicine Award, AAMC
2010	UTMB Experimental Pathology Graduate Student Organization, Award for Excellence in Teaching and Mentoring
2010	American Medical Women's Association, Women in Medicine Pre-clinical award
2010	Sterling-Turner Endowed Professorship in Teaching Excellence
2010	Nominated, UTMB Humanism in Medicine Award and Arnold P. Gold Foundation Humanism in Medicine Award
2009	UTMB Experimental Pathology Graduate Student Organization, Award for Excellence in Teaching and Mentoring
2008	Third Place Award, Outstanding Poster Presentation, UTMB Academy of Master Teachers 2008 Education Symposium
2007	American Medical Women's Association, Women in Medicine Pre-clinical award
2009	Minnie Stevens Piper Master Teacher Award, UTMB Academy of Master Teachers
2009	Member (elected), University of Texas Academy of Health Science Education
2007	Member (elected), UTMB Academy of Master Teachers
2006	L. Clarke Stout, Jr. Professorship in Anatomic Pathology
2006	American Medical Women's Association, Women in Medicine Pre-clinical award
2005	Paul Brindley Distinguished Scholar, UTMB Dept of Pathology
2005	First Place Award for Poster Category: Learner assessment/Curriculum Evaluation, 1st Annual UTMB Education Retreat

- 2004 Elected Member, John P. McGovern Academy of Oslerian Medicine, UTMB
- 2004 UTMB nominee, Alpha Omega Alpha Robert J. Glaser Distinguished Teacher Award
- 2003 American Medical Women's Association Women in Medicine Award
- 2003 UTMB, Experimental Pathology Graduate Student Organization Award for Teaching and Mentoring
- 2002 UTMB School of Medicine, Class of 1947 Excellence in Education Award
- 2000 UTMB School of Medicine, Class of 1947 Excellence in Education Award
- 1999 Best Anatomic Pathology Faculty Award, UTMB Pathology
- 1998 Distinguished Faculty Award, Interactive Learning Track, School of Medicine, UTMB
- 1985 Alpha Omega Alpha, University of North Carolina
- 1985 Janet M. Glasgow Memorial Achievement Citation, American Medical Women's Association, University of North Carolina

ADDITIONAL INFORMATION:

Ad hoc reviewer for American Journal of Tropical Medicine and Hygiene, Journal of Virology, Journal of Infectious Diseases, Clinical and Diagnostic Laboratory Immunology, Tuberculosis, PLoS Neglected Tropical Diseases, Emerging Infectious Diseases

Graduate, Medical Education Scholars Program (1997-8)

Clinical/administrative activities:

As an academic autopsy pathologist, I am a strong proponent of the teaching and clinical value of the autopsy in modern medical care. Since 2000, I have been the Director of UTMB's busy autopsy service, which sets the standard for hospital autopsy services in terms of case load and quality of autopsy work-ups. UTMB performs approximately 350 academic autopsies per year, and this service is recognized by UTMB physicians, surgeons, medical students, and Correctional Managed Care for its quality and responsiveness. Currently, the division includes 6 faculty pathologists and 1 faculty level pathologist's assistant. The autopsy service is fully staffed with a combination of talented and dedicated faculty, including junior and senior pathologists with a breadth of subspecialty expertise. Under my leadership, the division has maintained a strong reputation and visibility in the hospital, and has taken on major roles in the coordination of death certification for hospital patients, communication with the Galveston County Medical Examiner's Office, process improvement for death reporting and autopsy consenting, training residents and nursing staff in decedent affairs procedures, and coordination with organ and tissue procurement agencies. Since 2001, the autopsy has been re-introduced into medical education at both pre-clinical and clinical levels and communication of autopsy results from pathologists to clinicians and families has been enhanced.

PUBLISHED JOURNAL ARTICLES (PEER-REVIEWED):

1. Richards R, ARONSON JF, Schoenbechler M, Diggs C, Alving, C. Antibodies reactive with liposomal phospholipids are produced during experimental *Trypanosoma rhodesiense* infection in rabbit. J Immunol 130:1390, 1983.
2. Dumler JS, Brouqui P, ARONSON JF, Taylor J, Walker DH. Identification of *Ehrlichia* in human tissue. NEJM 325:1109-1110, 1991.
3. ARONSON JF, Herzog NK, Jerrells TR. Pathological and virological features of arenavirus disease in guinea pigs: Comparison of two Pichinde virus strains. Am J Pathol 145: 228-235, 1994.
4. ARONSON JF, Herzog NK, Jerrells TR. Tumor necrosis factor plays a role in the pathogenesis of guinea pig arenavirus disease. Am J Trop Med Hyg 52:262-269, 1995.
5. Grieder FB, Davis NL, ARONSON JF, Charles PC, Sellon DC, Suzuki K, Johnston RE. Specific restrictions in the progression of Venezuelan equine encephalitis virus induced disease resulting from single amino acid changes in the glycoproteins. J Virol 206:994-1006, 1995.
6. Kaphalia BS, Khan MF, Carroll RM, ARONSON, JF, Ansari GAS. Subchronic toxicity of 2-chloroethanol and 2-bromoethanol in rats. Res Comm Pharmacol Toxicol, 1:173-186, 1996.
7. Trgovcich J, ARONSON JF, Johnston RE. Fatal Sindbis virus infection of neonatal mice in the absence of encephalitis. Virology 224:73-83, 1996.
8. Trgovcich J, Ryman K, Extrom P, Eldridge JC, ARONSON JF, Johnston RE. Sindbis virus infection of neonatal mice results in a severe stress response. Virology 227:234-238, 1997.
9. Haubold EM, ARONSON JF, Cowan DF, McGinnis MR, Cooper Jr.CR. Isolation of fungal rDNA from bottlenose dolphin skin infected with *Loboia loboia*. Med Mycol 36:263-7, 1998.
10. Zhang L, Marriott K, ARONSON JF. Sequence analysis of the small RNA segment of guinea-pig passaged Pichinde virus variants. Am J Trop Med Hyg 61: 220-225, 1999.

PUBLISHED JOURNAL ARTICLES (continued):

11. Trgovich J, ARONSON JF, Eldridge JC, Johnston RE. TNF α , interferon and stress response induction as a function of age-related susceptibility to fatal Sindbis virus infection of mice. *Virology* 263:339-48, 1999.
12. Wolf DA, ARONSON JF, Rajaraman S, Veasey SP. Wischniewski ulcers and acute pancreatitis in two hospitalized patients with cirrhosis, portal vein thrombosis, and hypothermia. *J Forensic Sci* 44:1082-5, 1999.
13. Yang X-B, Fennewald S, Luxon BA, ARONSON JF, Herzog NK and Gorenstein DG. Aptamers containing thymidine 3'-O-phosphorodithioates: Synthesis and Binding to Nuclear Factor- κ B. *Bioorg Med Chem Lett* 9:3357-3362, 1999.
14. ARONSON JF, Grieder FB, Davis NL, Charles PC, Knott T, Brown K, Johnston RE. A single-site mutant and revertants arising *in vivo* define early steps in the pathogenesis of Venezuelan equine encephalitis virus. *Virology* 270:111-123, 2000.
15. Ahmed AE, ARONSON J, Jacob S: Induction of oxidative stress and TNF-alpha secretion by dichloroacetonitrile; a water disinfectant by-product, as possible mediators of apoptosis or necrosis in a murine macrophage cell line (RAW). *Toxicol in vitro*. 14(3):199-210, 2000.
16. Atchison CR, West, AB, Balakumaran A, Hargus SJ, Pohl LR, Daiker DH, ARONSON JF, Hoffman WE, Shipp BK, and Moslen MT. Drug-enterocyte adducts: Possible causal factor for diclofenac enteropathy in rats. *Gastroenterology* 119:1537-1547 (2000).
17. Zhang L, Marriott KA, Harnish DG, ARONSON JF. Reassortant analysis of guinea pig virulence of Pichinde virus variants. *Virology*, 290(1): 30-38 (2001)
18. Fennewald SM, ARONSON JF, Zhang L, Herzog NK. Alterations in NF- κ B and RBP-J κ by arenavirus infection of macrophages *in vitro* and *in vivo*. *J Virol*, 76(3):1154-1162 (2002).
19. Lele SM, Milazzo ML, Graves K, ARONSON JF, West AB, Fulhorst CF. Pathology of Whitewater Arroyo viral infection in *Neotoma albigula* (white-throated woodrat). *Journal of Comparative Pathology*, 128(4): 289-92 (2002.)
20. Yang X, Bassett SE, Li X, Luxon BA, Herzog NK, Shope RE, ARONSON J, Prow TW, Leary JF, Kirby R, Ellington AD, Gorenstein DG. Construction and selection of bead-bound combinatorial oligonucleoside phosphorothioate and phosphorodithioate aptamer libraries designed for rapid PCR-based sequencing. *Nucleic Acids Research* 30(23): e132 (2002).

PUBLISHED JOURNAL ARTICLES (continued):

21. Smith MB, Molina CM, Schnadig VJ, Boyars MC, ARONSON J. Pathologic Features Of *Mycobacterium Kansasii* Infection In Patients With The Acquired Immune Deficiency Syndrome (AIDS) Arch Pathol Lab Med 127:554-560 (2003).
22. Yang XB, Li X, Prow TW, Reece LM, Bassett SE, Luxon BA, Herzog NK, ARONSON J, Shope RE, Leary JF, and Gorenstein DG. Immunofluorescence assay and flow-cytometry selection of bead-bound aptamers. Nucl Acids Res 31(10): E54 (2003)
23. Gonzalez-Salazar D, Estrada-Franco JG, ARONSON JF, Weaver SC. Equine Amplification And Virulence Of Subtype IE Venezuelan Equine Encephalitis Viruses Isolated During The 1993 And 1996 Mexican Epizootics. Emerging Infectious Diseases 9(2): 161-8 (2003)
24. Bassett SE, Fennewald SM, King DJ, Li X, Herzog NK, Shope R, ARONSON JF, Luxon BA, Gorenstein DG. Combinatorial selection and edited combinatorial selection of phosphorothioate aptamers targeting human nuclear factor-kappaB RelA/p50 and RelA/RelA. Biochemistry 43(28): 9105-15 (2004).
25. Paessler S, Aguilar P, Anishchenko M, Wang HQ, ARONSON J, Campbell G, Cararra A, and Weaver SC. The golden hamster as an animal model for eastern equine encephalitis virus-induced vasculitis/encephalitis and its use in studies of virus entrance into the brain. Journal of Infectious Diseases 189(11): 2072-6 (2004).
26. Walling DM, Andritsos LA, Etienne W, Payne DA, ARONSON JF, Flaitz CM, Nichols CM: Molecular markers of clonality and identity in Epstein-Barr virus-associated B-cell lymphoproliferative disease. *Journal of Medical Virology* 74(1):94-101 (2004).
27. Granwehr BP, Lillibridge KM, Higgs, S, Mason PW, ARONSON JF, Campbell GA, Barrett ADT. West Nile virus: Where are we now? *The Lancet Infectious Diseases* 4 (9): 547-56 (2004).
28. Carrara A-S, Gonzales M., Ferro C, Tamayo M., ARONSON J, Paessler S., Anishchenko M., Boshell J., Weaver SC. Venezuelan Equine Encephalitis Virus Infection of spiny rats. *Emerging Infectious Diseases* 11(50): 663-669 (2005).

PUBLISHED JOURNAL ARTICLES (continued):

29. Holbrook, MR, ARONSON JF, Campbell GA, Jones S, Feldmann H, and Barrett ADT. An animal model for the tick-borne Flavivirus Omsk hemorrhagic fever virus. *Journal of Infectious Diseases*, 191 (1): 100-8 (2005).
30. Ramirez-Alcatara V, Castaneda-Hernandez G, Rampy BA, ARONSON JF, Treinen-Moslen, M. Attenuated gastropathy but not enteropathy of cholestyramine complex with diclofenac in rats. *Drug Development Research*, 64(10):19-27 (2005).
31. Duarte AG, Sattar F, Granwehr B., ARONSON J, Wang Z, Lick S. Disseminated acanthamoebiasis after lung transplantation, *Journal of Heart and Lung Transplantation*, 25(2):237-240 (2006).
32. Bowick G, Fennewald SM, Elsom BL, ARONSON JF, Luxon BA, Gorenstein DG, Herzog, NK. Differential signaling networks induced by mild and lethal hemorrhagic fever virus infections, *J Virol* 80(20):10248-10252 (2006)
33. Santoso, JT, Lee, CM, ARONSON J. Discrepancy of death diagnosis in gynecologic oncology, *Gynecologic Oncology* 101(2):311-4 (2006).
34. Fennewald SM, Scott EP, Zhang L, Yang X, ARONSON JF, Gorenstein DG, Luxon BA, Shope RE, Beasley DWC, Barrett ADT, Herzog NK. Thioaptamer decoy targeting of AP-1 proteins influences cytokine expression and the outcome of arenavirus infection. *Journal of General Virology*, 88:981-90 (2007).
35. Yang X, Wang H, Beasley DW, Volk DE, Zhao X, Luxon BA, Lomas LO, Herzog NK, ARONSON JF, Barrett AD, Leary JF, Gorenstein DG. Selection of thioaptamers for diagnostics and therapeutics. *Ann N Y Acad Sci*. 2006 Oct;1082:116-9. PubMed PMID: 17145932.
36. Bowick, GC, Fennewald SM, Scott EP, Zhang L, Elsom BL, ARONSON JF, Spratt HM, Luxon BA, Gorenstein DG, Herzog NK. Identification of differentially activated cell-signaling networks associated with hemorrhagic fever virus pathogenesis using systems kinomics. *J Virol* 81(4):1923-33 (2007)
37. Schnadig VJ, Molina CP, ARONSON JF. Cytodiagnosis in the autopsy suite: A tool for improving quality and education. *Archives Pathol Lab Med* 131(7):1056-62 (2007).

PUBLISHED JOURNAL ARTICLES (continued):

38. Vela EM, Zhang L, Colpitts, TM, Davey RA, ARONSON JF. Arenavirus entry occurs through a cholesterol-dependent, non-caveolar, clathrin-mediated endocytic mechanism. *Virology* 369(1):1-11 (2007).
39. Vela EM, Bowick GC, Herzog NK, ARONSON JF. Genistein treatment of cells inhibits arenavirus infection. *Antiviral Research* 77:153-6 (2008).
40. Vela EM, Colpitts TM, Zhang L, Davey RA, ARONSON JF. Pichinde virus is trafficked through a dynamin-2 endocytic pathway that is dependent on cellular Rab5- and Rab7-mediated endosomes. *Arch Virol.* 153(7):1391-6 (2008).
41. Yun NE, Linde NS, Dzubia N, Zacks MA, Smith JN, Smith JK, ARONSON JF, Chumakova OV, Lander HJ, Peters CJ, Paessler S. Pathogenesis of XJ and Romero strains of Junin virus in two strains of guinea pigs. *Am J Trop Med Hyg* Aug 79(2):275-82 (2008).
42. Adams AP, ARONSON JF, Tardif SD, Patterson JF, Brasky KM, Geiger R, de la Garza M, Carrion R Jr, Weaver SC. Common marmosets (*Callithrix jacchus*) as a nonhuman primate model to assess the virulence of Eastern Equine Encephalitis Virus strains. *J Virol* 82(18):9035-41 (2008).
43. Scott EP, ARONSON JF. Cytokine patterns in a comparative model of arenavirus hemorrhagic fever in guinea pigs. *J Gen Virol* 89(Pt 10):2569-79 (2008).
44. Lan S., McLay L, ARONSON J, Ly Hinh, Liang Y. Genome comparison of virulent and avirulent strains of the arenavirus Pichinde. *Archives of Virology*, 153(7):1241-50 (2008)
45. Vela EM, Bowick GC, Herzog NK, ARONSON JF. Exploring kinase inhibitors as therapies for human arenavirus infections. *Future Virology*, 3(3):243-251(2008).
46. Bowick GC, Fennewald SM, Zhang L, Yang X, Aronson JF, Shope RE, Luxon BA, Gorenstein DG, Herzog NK. Attenuated and lethal variants of Pichindé virus induce differential patterns of NF-kappaB activation suggesting a potential target for novel therapeutics. *Viral Immunol.* 2009 Dec;22(6):457-62. PubMed PMID: 19951183.
47. Franco DM, ARONSON JF, Hawkins HK, Gallagher JJ, Mendoza L, McGinnis MR, Williams-Bouyer, N. Systemic *Pythium insidiosum* in a Pediatric Burn Patient. *Burns*, 36(5): e68-71 (2010). PubMed PMID: 19875237

PUBLISHED JOURNAL ARTICLES (continued):

48. Kolokoltsova O., Nadezda NE, Poussard AL, Smith JK, Salazar Gross MS, Walker A, Tseng C-T K, ARONSON JF, and S Paessler. Mice lacking alpha/beta and gamma interferon receptors are susceptible to Junin virus infection. *J Virol* 84(24):13063-7 (2010). PubMed PMID: 20926559.
49. Bowick GC, Soman KV, Wang H, ARONSON JF, Luxon BA, Lomas LO, Gorenstein DG, Herzog NK. Proteomic analysis of *Pichinde virus* infection identifies differential expression of prothymosin- α . *J Biomed Biotechnol* 2010; 2010 pii:956823. Epub 2010 April 18. PMID: 20706531.
50. Welte T, ARONSON J, Gong B, Rachamalla A, Mendell N, Tesh R, Paessler S, Born W, O'Brien R, and T Wang. Vgamma4⁺ T cells regulate host immune response to West Nile Virus infection. *FEMS Immunology and Medical Microbiology*,63(2):183-92 (2011)
51. Chao, C, Carmical JR, Ives KL, Wood TG, ARONSON JF, Gomez GA, Djukom CD, and MR Hellmich. CD133+ colon cancer cells are more interactive with the tumor microenvironment than CD133- cells. *Lab Invest* 92(3):420-436 (2012).

BOOK CHAPTERS:

1. ARONSON J. "Viral Hemorrhagic Fevers", in *Color Atlas and Text of Pulmonary Pathology*. Cagle PT ed. Lippincott, Williams and Wilkins, Philadelphia. 2005. Chapter 95, part 10.

MISCELLANEOUS PUBLICATIONS:

1. ARONSON JF, Scimeca J, Harris D, Walker DH. An immunohistologic demonstration of *Ehrlichia canis*. *Ann NY Acad Sci* 590:148-156, (1990).
2. ARONSON JF, Valbuena GA, Hellmich MR, and GK Asimakis. Translational Research Track for Medical Students: Developing inter-professional collaborative competencies for translational research. *Medical Science Educator* 21 (1S):37-41 (2011).

ABSTRACTS:

1. Alfant M, ARONSON JF, Edelson P. Mechanism of concanavalin A stimulation of pinocytosis in mouse macrophages. *International Association for Dental Research, 59th General Session, March 19-22, 1981.*

ABSTRACTS (continued):

2. Brown V, ARONSON JF, Jerrells T. Diminished lymphocyte proliferation and IL-2 production by lymphocytes from guinea pigs infected with Pichinde virus. American Association of Immunologists, 74th Annual Meeting, June 3-7, 1990.
3. ARONSON JF, Brown V, Jerrells T. Monokine production and pathogenesis of arenavirus infection in guinea pigs. Abstracts of the American Association of Immunologists, 74th Annual Meeting, June 3-7, 1990.
4. Dumler JS, ARONSON JF, Walker DH. Human Ehrlichiosis: Pathologic findings in three fatal cases. United States and Canadian Academy of Pathology Annual Meeting, March 17-22, 1991.
5. Dumler JS, Brouqui P, ARONSON JF, Walker DH. Immunohistologic demonstration of ehrlichiae in fatal human ehrlichiosis. 9th Sesqui-annual meeting of the American Society for Rickettsiology and Rickettsial Diseases, May 1-5, 1991.
6. ARONSON JF, Herzog N, Jerrells T. The role of tumor necrosis factor in the pathogenesis of arenavirus disease in guinea pigs: Comparison of two Pichinde virus strains. FASEB, American Association of Pathologists, April 5-9, 1992.
7. ARONSON JF, Herzog N, Jerrells T. Macrophages and monokines in guinea pig arenavirus disease. International Congress for Infectious Diseases, June 7-11, 1992.
8. Grieder FB, Davis NL, ARONSON JF, Johnston RE. Molecular genetics of Venezuelan equine encephalitis virus pathogenesis in mice. Keystone Symposium: Molecular Immunology of virus infections. J Cell Biochem Suppl 17D, p. 65, 1993.
9. Trgovcich J, ARONSON JF, McKnight KL, Johnston RE. Pathology of Sindbis virus infection in neonatal mice. Third Southeastern Virology conference, 1994.
10. Adesokan A, Adegboyega P, Kocurek JN, ARONSON JF, Neal D, Cowan DF. Differential expression of glutathione-S-transferase in normal, premalignant and malignant prostatic glandular epithelium. United States and Canadian Academy of Pathology Annual Meeting, 1995.
11. Salas R, Tesh R, Manzione N, Fulhorst C, Utrera A, Duno G, ARONSON JF, Miller E, Ksiazek T. Investigation of a familial outbreak of Venezuelan hemorrhagic fever. American Society of Tropical Medicine and Hygiene, 44th annual meeting, 1995.

ABSTRACTS (continued):

12. Atchison C, Hargus S, ARONSON JF, Hoffman W, Daiker D, Pohl L, West AB, Moslen M. Diclofenac protein adducts detected in multiple tissues by immunohistochemistry. Abstracts of the American Society for Investigative Pathology Annual Meeting, June 1996.
13. Atchison CR, Hargus SJ, ARONSON JF, Hoffmann NE, Daiker DH, Pohl LR, West AB, Moslen MT. Diclofenac decreases serum alkaline phosphatase isozymes and forms protein adducts in multiple tissues. American Association for the Study of Liver Diseases, 47th Annual Meeting, November 1996.
14. Dong NP, Pencil SD, ARONSON JF. Histopathological changes of chronic hepatitis C virus infection are reduced in AIDS patients. American Society of Clinical Pathologists, Annual Meeting, October 1996.
15. Marriott K, Nichols J, Roberts N, Zhang L, ARONSON JF. Comparative Pathogenesis of passaged Pichinde virus variants in guinea pigs. American Society for Investigative Pathology, Annual Meeting, April 1996.
16. Marriott K, Nichols T, Roberts NJ, Zhang L, ARONSON JF. Comparative Pathogenesis of two passage-related Pichinde virus variants in guinea pigs. American Society for Virology, 16th Annual Meeting, July 1997.
17. Marriott K, Zhang L, ARONSON J. Role of interferon in the pathogenesis of Pichinde virus infection of guinea pigs. American Society for Virology, 17th Annual Meeting, July 1998. Abstract #W11-7.
18. Shurtleff AC, ARONSON JF. Direct Viral cytopathic effect is not a mechanism of spleen necrosis in Pichinde virus infection of guinea pigs. American Society for Virology, 17th Annual Meeting, July 1998, Abstract #P28-7.
19. Marriott K, Sims B, ARONSON JF. Virulent Pichinde virus is resistant to antiviral effects of interferon. Sixteenth Annual Texas Regional Immunology Conference, November, 1998.
20. Fennewald S, Yang XB, Venkitachalam S, Volk DE, ARONSON JF, Luxon B, Gorenstein D and Herzog N. Development of novel thioated DNA aptamers which bind to NF κ B. Oncogene Meeting, June, 1999.
21. ARONSON JF and Zhang L. Reassortant analysis of Guinea Pig Virulence of Pichinde virus variants. American Society for Virology, 18th Annual Meeting, July 10-14, 1999. Abstract #P20-4.

ABSTRACTS (continued):

22. Shurtleff AC and ARONSON JF. In vitro sensitivity of Pichinde virus variants to serum complement. American Society for Virology, 18th Annual Meeting, July 10-14, 1999. Abstract #P20-5
23. Eyzaguirre EJ, Milazzo ML, ARONSON JF, Fulhorst CF. Histomorphological changes and virus-specific antigen distribution in *Sigmodon alstoni* experimentally infected with Cano Delgadito virus (Family *Bunyaviridae*, genus *Hantavirus*). American Society of Tropical Medicine and Hygiene, 48th Annual Meeting, November 28-December 2, 1999. Abstract #404.
24. Shurtleff AC and ARONSON JF. Mechanisms of Complement pathway activation by Pichinde virus variants and the implications for pathogenesis. Keystone Symposia, Genetics, Pathogenesis and Ecology of Emerging Viral Diseases, January 24-30, 2000.
25. Lele SM, Milazzo ML, Graves, K, ARONSON J, West AB, Fulhorst CF. Virus localization and pathology in *Neotoma albigula* (family: Muridae) experimentally infected with Whitewater Arroyo virus (Arenaviridae). United States and Canadian Academy of Pathology Annual Meeting, March 2000.
26. Fennewald SM, ARONSON JF, Zhang L, Herzog NK. Induction of inflammatory cytokines and alterations in transcription factors by arenavirus infection in a macrophage cell line. 11th International Conference on Negative Strand Viruses, June 24-29, 2000, Abstract #123.
27. Shurtleff AC and ARONSON JF. Mechanisms of Complement pathway activation by Pichinde virus variants and the implications for pathogenesis. 11th International Conference on Negative Strand Viruses, June 24-29, 2000. Abstract #240.
28. Marriott K, Zhang L, ARONSON JF. Comparative tropisms of attenuated and virulent Pichinde virus variants and their reassortants. 11th International Conference on Negative Strand Viruses, June 24-29, 2000. Abstract #245.
29. Gupta R, Bismar M, Chundru S, ARONSON J, Badalamenti J, Agraharkar M. Pan-hemispheric infarction: A complication of cuffed catheter. Ninth Annual Clinical Nephrology Meeting, American Journal of Kidney Diseases 35(4):A13, 2000.
30. Fennewald SM, ARONSON JF, Herzog NK. Alterations in transcription factors by arenavirus infection of macrophages both *in vitro* and *in vivo*. American Society for Virology, 20th Annual Meeting, July 21-25, 2001. Abstract #P17-1.

ABSTRACTS (continued):

31. Shurtleff AC, Zhang L, ARONSON JF. Serum complement coating of Pichinde virus leads to viral inactivation, but not complement mediated enhancement. American Society for Virology, 20th Annual Meeting, July 21-25, 2001. Abstract #P20-1.
32. Shurtleff AC, Zhang L, ARONSON JF. Mannan binding lectin pathway activation drives classical complement pathway inactivation of Pichinde virus, a model arenavirus for the study of human Lassa Fever. American Society for Virology, 21st Annual Meeting, July 2-24, 2002. Abstract #W34-8.
33. Fennewald S.M., ARONSON JF, Herzog NK. Macrophage transcription factors and cytokines respond to RNA virus (Arenavirus) infection and double-stranded RNA. American Society for Virology, 21st Annual Meeting, July 2-24, 2002. Abstract #20-5.
34. Weaver S, Brault A, Estrada-Franco J, Navarro R, Gonzalez D, Moncayo A, Ludwig G, ARONSON J, Powers A. Emergence of endemic Venezuelan equine Encephalitis in Southern Mexico. XIIth International Congress of Virology, July 27-Aug 1, 2002, Paris. Abstract # V-88.
35. Bigler T, Duarte A, ARONSON J. Comparison Of Clinical And Post-Mortem Diagnoses In A Critically Ill Prison Population. American Journal of Respiratory and Critical Care Medicine 165 (8): A30. International Conference, American Thoracic Society, May 17-22, Atlanta GA.
36. Walling DM, Andristos LG, Etienne W, Payne DA, ARONSON JF, Flaitz CM, Nichols CM. Markers Of Clonality And Identity In EBV-Associated Lymphoproliferative Disorders Of Immunocompromised Hosts. The 10th Biennial Meeting of the International Association for Research on Epstein-Barr Virus and Associated Diseases, Cairns Australia, July 2002.
37. Scott EP, Perrone LA, Zhang L, Fennewald SM, Elsom B, Yang XB, Gorenstein D, Herzog NK, and ARONSON JF. The effect of transcription factor thioaptamers on TNF- α and IL-8 expression in primary guinea pig macrophages: Therapeutic implications in a guinea pig model of arenavirus disease. Twelfth International Conference on Negative Strand Viruses, Pisa Italy, June 14-19, 2003.
38. Asimakis, G., ARONSON J, Frye A. "Use of group quizzes to encourage application of basic sciences issues related to clinical problems in problem-based learning groups". International Association of Medical Science Educators, Annual Meeting, Washington, DC, 2003.

ABSTRACTS (continued):

39. Holbrook M, ARONSON J, Campbell G, Jones S, Feldmann H, Barrett A. An Animal Model For The Viscerotropic Tick-Borne Flavivirus Omsk Hemorrhagic Fever Virus And Comparison To The Neurotropic Powassan Virus. American Society for Virology, 23rd Annual Meeting, July 10-14, 2004, Montreal, Quebec, Canada. Abstract #W8-7.
40. Scott EP, ARONSON JF. Cytokine Patterns In Guinea Pig Arenavirus Infection. American Society for Virology, 23rd Annual Meeting, July 10-14, 2004, Montreal, Quebec, Canada. Abstract #W9-3.
41. Fennewald SM, Webb E, Zhang L, Yang XB, ARONSON JF, Gorenstein DG, Luxon B, Shope RE, Herzog NK. Thioaptamer Decoy Targeting Of Host Transcription Factors Influences Cytokine Expression And The Outcome Of Arenavirus Infections. American Society for Virology, 23rd Annual Meeting, July 10-14, 2004, Montreal, Quebec, Canada. Abstract #W9-5
42. Ramirez-Alcantara V, Castaneda-Hernandez G, Rampy BA, ARONSON JF, and Treinen-Moslen M, Cholestyramine co-treatment does not alter diclofenac enteropathy in rats. Gulf Coast Digestive Disease Center Annual Research Forum, June 2004
43. Ramirez-Alcantara V, Kaphalia L, ARONSON JF, Kanz MF and Treinen-Moslen M. Responses of MRP2- deficient TR rats to repeated diclofenac exposure. Society of Toxicology, Annual Meeting, March 2005
44. Kaphalia L, ARONSON JF, Nethery KA, and Treinen-Moslen M, TEMPO attenuation of diclofenac adduction and enteropathy. Society of Toxicology, Annual Meeting, March 2005
45. Scott EP, ARONSON JF. Early and late cytokine responses in a guinea pig model of arenavirus hemorrhagic fever. American Society for Virology, 24th Annual Meeting, June 18-22, 2005, State College, PA.
46. Chundru S, Grafe M, ARONSON JF. "The effects of a required autopsy experience on medical student perception about autopsy and familiarity with death certification". Poster presentation, 1st Annual UTMB Education Retreat. Sept 30-Oct 1, 2005.
47. Vela EM, Davey RA, ARONSON JF. Arenavirus entry is dependent on cell membrane cholesterol. Thirteenth International Conference on Negative Strand Viruses. Salamanca, Spain, June 17-22, 2006.

ABSTRACTS (continued):

48. Fennewald SM, Elson BL, Bowick, GC, Zhang L, ARONSON JF, Gorenstein DG, Herzog NK. Macrophage infection by arenaviruses causes a change in the transcription factors that respond to interferons. Thirteenth International Conference on Negative Strand Viruses. Salamanca, Spain, June 17-22, 2006.
49. Bowick GC, Fennewald SM, Elsom BL, Scott EP, Spratt HM, Luxon BA, Gorenstein DG, ARONSON JF, Herzog NK. Use of a novel kinomics approach and pathway analysis to identify hemorrhagic fever virus-induced cell signaling changes. Thirteenth International Conference on Negative Strand Viruses. Salamanca, Spain, June 17-22, 2006.
50. Crim JP, ARONSON JF, Castro CY. Severe cellular rejection in a patient with familial idiopathic pulmonary fibrosis: Case presentation and review of the literature. Poster 19, CAP meeting, Sept 10-13, 2006. Published in Archives Pathol Lab Med 130:1362 (2006).
51. Miller B, Collins TR, ARONSON JF, Smith DE, Cowan DF. Integration of Pathology with Gross Anatomy in the UTMB Medical School Curriculum. Presented at College of American Pathologists 2006 Annual Meeting, Sept 10-13, 2006, San Diego. Published in Archives Pathol Lab Med 130 (9):1375 (2006).
52. Vela EM, Davey RA, ARONSON JF. The delineation of the entry pathway utilized by arenaviruses. American Society for Virology, 26th Annual Meeting, July 14-28, 2007, Corvallis, OR. Abstract #P1-6.
53. Adams, AP, Pitts JD, Bowen RA, ARONSON JF, Weaver, SC. Emergence and pathogenesis of Venezuelan equine encephalitis virus subtype IE. American Society for Virology, 26th Annual Meeting, July 14-28, 2007, Corvallis, OR. Abstract #P10-3.
54. ARONSON J, Ayala A, Asimakis A. Evolution of virtual microscopy applications in the Integrated Medical Curriculum. Poster Presented at UTMB Academy of Master Teachers Educational Symposium, May 2008.
55. ARONSON J, Ayala A, Rubin N, Given R, Asimakis G. Applications of virtual microscopy across the pre-clinical curriculum at UTMB. Demonstration presented at UTMB Academy of Master Teachers Educational Symposium, May 2008.

ABSTRACTS (continued):

56. ARONSON J, Ayala A, Asimakis G. Natural history of virtual microscopy adoption in a multi-disciplinary pre-clinical medical curriculum. International Association of Medical Science Educators. 12th annual meeting, July 24-30, 2008, Salt Lake City, UT. Abstract # IM1
57. ARONSON JF and Ayala A. Interactive histopathology tutorials using WebSlides®: Electronic demonstration. International Association of Medical Science Educators. 12th annual meeting, July 24-30, 2008, Salt Lake City, UT. Abstract #TR1
58. Yang W., Cao Y, Duan CJ, ARONSON J, Chao C, Hellmich MR, Ko TC. Inhibition of BMP/Smad1/5/8 signaling pathway deteriorates cerulein-induced acute pancreatitis. Digestive Disease Week, New Orleans LA May 1-5, 2010. Gastroenterology 138:S282, 2010
59. Grise J, ARONSON J, McCoid M. *Hic locus est ubi more gaudet succerrere vitae* (This is the place where death delights to help the living). UTMB Academy of Master Teachers Annual Education Symposium, May 2010.
60. McCoid M, ARONSON JF. Resuscitating the UTMB historical gross pathology collection. UTMB Academy of Master Teachers Annual Education Symposium, May 2010.
61. Valbuena G., ARONSON J, Hellmich M. Integration of POGIL pedagogy into graduate and medical student training in translational biomedical research. Poster presented at POGIL South-Central Regional Meeting, Norman, OK, July 7-9, 2010.
62. Han S, Gomez GA, Englander EW, Rastellini C, Ko TC, Hellmich MR, Chao C, ARONSON J, Quertermous T, Kundu RK, and G Greeley. Apelin reduces pancreatic inflammation during acute pancreatitis. Digestive Disease Week, Chicago, May 7-10, 2011.
63. Han E, Englander EW, Rastellini C, Ko TC, Hellmich MR, Chao C, ARONSON JF, Quertermous T, Kundu R, Greeley GH. Anti-inflammatory activity of apelin in acute pancreatitis. Pancreas 39: 1322 (2010).
64. Kim SO, Rastellini C, Wei J, Patrikeev I, Motamedi M, ARONSON JF, Greeley FH, Ko TC, Cao Y, Falzon M, Evers BM, Saito H, and MR Hellmich. Evaluation of cerulein-induced acute pancreatitis in mice with micro-computed tomography imaging. Pancreas 39:1327 (2010).

ABSTRACTS (continued):

65. Cao, Y, Gao X, Yang W, ARONSON J, Varughese MG, Deng X, Duan C, Chao C, Greeley GH, Hellmich MR, and TC Ko. Induction of gremlin, a bone morphogenetic protein antagonist, during the development of chronic pancreatitis. Digestive Disease Week, Chicago, May 7-10, 2011.
66. ARONSON JF, Valbuena GA, Hellmich MR, Asimakis, GK. Translational Research Track for Medical Students: Developing inter-professional collaborative competencies for translational research. 7th Annual Innovations in Health Science Education conference, The University of Texas Academy of Health Science Education, May 2011.
67. Judith F. Aronson and Barbara L. Thompson. Learning anatomy and pathology in Osler's era: UTMB's collection of 1400 specimens in an 1892 vintage learning environment. Presented at the 41st Annual Meeting of the American Osler Society, May 1-4, 2011, Philadelphia PA.
68. ARONSON JF, Valbuena G, Hellmich MR, Frye A, and GK Asimakis. Interprofessional components of a new medical student translational research track. Presented at The International Association of Medical Science Educators 15th Annual Meeting, St. Petersburg FLA, Jun 18-21, 2011
69. Valbuena G, ARONSON J, Frye A, and Hellmich MR. Curriculum Development for a New Ph.D. Program in Translational Research. Annual meeting of the Southern Group on Educational Affairs. Houston, Texas, April 2011.

PUBLICATIONS IN PRESS:

1. Yun N, Poussard A, Seregin A, Walker A, Smith J, ARONSON J, Smith J, Soong L and S Paessler. Functional interferon system is required for clearance of Lassa virus. *Journal of Virology*, 2012
2. Judy BM, Taylor K, Deeraksa A, Johnston RK, Endsley JJ, Vijayakumar S, ARONSON JF, Estes DM, and A Torres. Prophylactic application of CpG oligonucleotides augments the early host response and confers protection in acute melioidosis. *PLoS One*, 2012

PUBLICATIONS SUBMITTED:

1. Asimakis, GK, Ainsworth MA, ARONSON J, Frye AW, Lieberman SA, and JP Rabek. Evolution of student assessment following implementation of an Integrated Medical Curriculum: Contribution to improved outcomes. Submitted, Medical Teacher, 2011.
2. Blanton LS, ARONSON JF, Burnham JP, Gorena AL, and AS Lea. Septic pulmonary emboli: A report of 36 cases and review of the literature. Submitted to Medicine, 2012.

INVITED LECTURES AT SYMPOSIA AND CONFERENCES:

- April 2011 Guest speaker, Willed Body Memorial, organized by Vesalius Student Society, UTMB School of Medicine
- June, 2011 Guest Speaker, 2011 Medical Student Summer Research Program, UTMB Galveston
- May, 2011 Workshop, co-taught with Oma Morey, Ph.D. "Transforming Passive Lectures to Interactive Learning Experiences". Academy of Master Teachers Education Symposium, Galveston TX
- Nov, 2011 Invited speaker, Coaching: Climbing to Success, Faculty Development Conference "Appointment, Promotion, and Tenure", Galveston TX
- Mar, 2009 Binford-Dammin Society of Infectious Disease Pathologists, Companion Meetings, USCAP Annual Meeting, Boston MA. "Dengue Shock and Hemorrhagic Fever"
- Feb, 2007 Invited speaker, UTMB, Osler Club, sponsored by John P. McGovern Academy for Oslerian Medicine. "Seeing for Oneself: Osler and the Autopsy"
- Aug 2006 Invited Speaker, UTMB Correctional Managed Care, Summer Conference, Houston Texas. "A Role for Autopsy in Correctional Medicine".
- July 2004 Invited Speaker, UTMB Correctional managed Care, Summer Conference, Houston Texas. "A Role for Autopsy in Correctional Medicine"
- July 2003: Invited speaker at American Association for Clinical Chemistry Annual Meeting, July 20-24, 2003, Philadelphia PA. Participant in Workshop session "Biodefense and Emerging Pathogens: Tactics, Targets, and Technology". Lecture entitled "Are we prepared to face the threat from Arenavirus hemorrhagic fevers?"



PUBLIC VERIFICATION / PHYSICIAN PROFILE

PHYSICIAN

NAME: PAUL J BOOR MD

DATE: 08/21/2013

THE INFORMATION IN THIS BOX HAS BEEN VERIFIED
BY THE TEXAS MEDICAL BOARD

Date of Birth: 1946

License Number: E7833 Full Medical License

Issuance Date: 06/14/1977

Expiration Date of Physician's Registration Permit: 05/31/2015

Registration Status: ACTIVE

Registration Date: 01/01/1978

Disciplinary Status: NONE

Disciplinary Date: NONE

Licensure Status: NONE

Licensure Date: NONE

Medical School of Graduation:

At the time of licensure, TMB verified the physician's graduation from medical school as follows:
TUFTS UNIV SCH OF MED, BOSTON

Medical School Graduation Year: 1972

TMB Filings, Actions and License Restrictions

The Texas Medical Board has the following board actions against this physician. (This may include any formal complaints filed by TMB, as well as petitions and/or responses related to licensure contested matters, at the State Office of Administrative Hearings.)

NONE

Investigations by TMB of Medical Malpractice

Section 164.201 of the Act requires that: the board review information relating to a physician against whom three or more malpractice claims have been reported within a five year period. Based on these reviews, the following investigations were conducted with the listed resolutions.

NONE

Status History

Status history contains entries for any updates to the individual's registration, licensure or disciplinary status types (beginning with 1/1/78, when the board's records were first automated). Entries are in reverse chronological order; new entries of each type supersede the previous entry of that same type. These records do not display status type. Should you have any questions, please contact our Customer Information Center at 512-305-7030 or verificic@tmb.state.tx.us

Status Code: AC**Effective Date:** 01/01/1978**Description:** ACTIVE

THE INFORMATION IN THIS BOX WAS REPORTED BY THE LICENSEE AND
HAS NOT BEEN VERIFIED BY THE TEXAS MEDICAL BOARD

Gender: MALE***Ethnicity:** WHITE**Race:** WHITE

* We are in the process of transitioning from the current ethnic origin values to federal standards for race and Hispanic origin. The transition period will allow time for individuals to submit updated race and Hispanic origin data to the TMB.

Place of Birth: NEW JERSEY**Current Primary Practice Address:**

UTMB-PATHOLOGY- 0609

301 UNIVERSITY

GALVESTON , TX 77555-0338

Years of Active Practice in the U.S. or Canada:

The physician reports that he/she has actively practiced medicine in the United States or Canada for **38** year(s).

Years of Active Practice in Texas:

The physician reports that, of the above years he/she has actively practiced in the State of Texas for **32** year(s).

Specialty Board Certification

The physician reports that he/she holds the following specialty certifications issued by a board that is a member of the American Board of Medical Specialties or the Bureau of Osteopathic Specialists:

Specialty Certification: AMERICAN BOARD OF PTH/ANATOMIC PATHOLOGY**Date:** 1982**Primary Specialty**

The physician reports his/her primary practice is in the area of PATHOLOGY.

Secondary Specialty

The physician did not report a secondary practice area.

Name, Location and Graduation Date of All Medical Schools Attended

Name: NONE

Location: BOSTON, MA, USA

Graduation Date: 06/1972

Name: TUFTS MEDICAL SCHOOL

Location: BOSTON MA/USA

Graduation Date: 1972

Graduate Medical Education In The United States Or Canada

Program Name: PATHOLOGY DEPT. PETER BENT BRIGHAM HOSPI

Location: BOSTON, MA

Begin Date: 1968

Type: INTERNSHIP

End Date: 1977

Specialty: PATH

Hospital Privileges

The physician reports that he/she has hospital privileges in the following in the State of Texas:

Hospital: UTMB HOSPITALS

Location: GALVESTON TX

Hospital: SHRINERS BURNS HOSPITAL

Location: GALVESTON, TX

Utilization Review

The physician did not report whether he/she provides utilization review.

NONE REPORTED

Patient Services

Accessibility: The physician reports that the patient service area is accessible to persons with disabilities as defined by federal law.

Language Translation Services: The physician reports that the following language translation services are provided for patients: SPANISH

Medicaid program.

Awards, Honors, Publications and Academic Appointments

Optional Information

The physician may optionally report descriptions of up to five such honors and has reported the following:

Description: PROFESSOR

Malpractice Information

Section 154.006(b)(16) of the Act requires that: a physician profile display a description of any medical malpractice claim against the physician, not including a description of any offers by the physician to settle the claim, for which the physician was found liable, a jury awarded monetary damages to the claimant, and the award has been determined to be final and not subject to further appeal. The physician has the following reportable claims.

Description: NONE

Criminal History

Self-Reported Criminal Offenses:The physician is required to report a description of (1) "any conviction for an offense constituting a felony, a Class A or Class B misdemeanor, or a Class C misdemeanor involving moral turpitude" and (2) "any charges reported to the board to which the physician has pleaded no contest, for which the physician is the subject of deferred adjudication or pretrial diversion, or in which sufficient facts of guilt were found and the matter was continued by a court of competent jurisdiction."

The physician has reported the following:

Description: NONE

Criminal history information is also obtained by TMB from the Texas Department of Public Safety. Resulting action, if any, will be reported under the TMB Action and Non-Disciplinary Restrictions section above.

Disciplinary Actions By Other State Medical Boards

The physician has reported the following:

Description: NONE

Physician Assistant Supervision

To obtain primary source verifications, click name

Description: NONE

Advanced Practice Nurse Delegation

To obtain primary source verifications, click name

Description: NONE

Summary of all License/Permit Types

Issue Date:
06/14/1977

Type:
LICENSED PHYSICIAN

[Agency](#) | [Contact Us](#) | [Employment](#) | [Compact w/ Texans](#) | [Open Records](#) | [Privacy Policy](#) | [Site Map](#) |
[Search TX State Sites](#) | [TX Homeland Security](#) | [TX Occupations Code](#) |
[Texas.gov](#) | [Poison Control Center Services](#) | [Accessibility Policy](#)

CURRICULUM VITAE

NAME: Paul J. Boor, M.D.

DATE: October 2012

PRESENT POSITION AND ADDRESS:

Professor
Department of Pathology
Mary Moody Northen 2.206B
University of Texas Medical Branch
Galveston, TX 77555-0438
Tel: (409) 772-2813
FAX: (409) 747-1763
E-mail: pboor@utmb.edu

BIOGRAPHICAL:

Date of Birth: [REDACTED]
Place of Birth: Elizabeth, NJ
Citizenship: USA
Business Address: 301 University Blvd.
Mary Moody Northen Pavilion
Route 0438
Galveston, TX 77555-0438
(409) 772-2813
Current Address: [REDACTED]
Telephone: [REDACTED]

EDUCATION:

1968 B.S., Biology, Union College, Schenectady, NY
1972 M.D., Medicine, Tufts University Medical School, Boston, MA
1972-75 Resident in Pathology, Peter Bent Brigham Hospital, Boston, MA
(1975 Chief Resident in Pathology, Peter Bent Brigham Hospital)
1975-76 Research Associate, Peter Bent Brigham Hospital, Boston, MA

BOARD CERTIFICATION:

Certified in Anatomic Pathology by the American Board of Pathologists, 1982

LICENSURE INFORMATION:

Massachusetts, 38065, 1972 – 07/31/2012
Texas, E7833, 1977 – 05/31/2013

PROFESSIONAL AND TEACHING EXPERIENCE:

1974-77 Clinical Fellow in Pathology, Pathology Laboratory Instructor, Infectious Disease (1973-76) and Cardiovascular (1975-76) Blocks, Harvard Medical School, Boston, MA

- 1975-76 Instructor, New England Institute of Anatomy, Boston, MA
- 1977-81 Assistant Professor, Department of Pathology, University of Texas Medical Branch University of Texas Medical Branch, Galveston, TX
- 1977-present Member, Faculty of Graduate School of Biomedical Sciences, University of Texas Medical Branch, Galveston, TX
- 1979 January and February, Guest Investigator, National Heart, Lung and Blood Institute, Ultrastructure Section, Bethesda, MD
- 1979 NIOSH Consultant and Reviewer of Criteria Document "Standards for Occupational Exposure to Aliphatic Monoamines"
- 1980 June 2-5, Guest Lecturer, Departments of Pathology and Pharmacology, University of Bologna, Bologna, Italy
- 1981-present Deputy Medical Examiner, Galveston County, TX
- 1981-86 Associate Professor, Department of Pathology, UTMB
- 1982 September-November, Guest Lecturer and Investigator, Departments of Pathology, Cardiology and Oncology, University of Bologna, Bologna, Italy
- 1983-1992 Director, Chemical Pathology Laboratory, Department of Pathology, University of Texas Medical Branch, Galveston, TX
- 1986-present Professor, Department of Pathology, University of Texas Medical Branch, Galveston, TX
- 1988-1994 Vice Chairman for Research, Department of Pathology, University of Texas Medical Branch, Galveston, TX
- 1995-present Member, Scientific Staff, Shriners Burns Hospital, Galveston, TX
Member, Consultant Medical Staff, Shriners Burns Hospital, Galveston, TX

RESEARCH ACTIVITIES:

Area of Research:

I am interested in how the larger blood vessels of the body are injured by toxic chemicals in our environment. The area of greatest concentration for this work is the muscular wall of blood vessels, or the "media." Experimental drugs and other chemicals that protect against injury (or predispose to injury) are under investigation in the hope that someday we may be able to manipulate the blood vessel wall to delay the commonest degenerative diseases, with the greatest human morbidity and mortality, including atherosclerosis and aneurysm. The toxic chemicals under study are relevant to the environment, and include components of cigarette smoke. Past emphasis has been on the metabolism of vasculotoxic amines to aldehydes, but recent work has defined how glutathione-S-transferases act in the defense of vascular wall against reactive oxygen species, both in vivo and in vitro. The role of these defense mechanisms during cellular injury of the vascular wall by atherosclerosis has been a long-term objective. New directions have been undertaken into the area of "developmental vasculotoxicity," or injury occurring in utero, or during development of immature individuals.

Perhaps the most exciting new direction of the laboratory has been the development of a model of dissecting aortic aneurysm. Our initial studies into this small animal model revealed several pathways of fibrillogenesis of collagen and elastin that may prove to be targets of toxic insult early in life, or even during embryologic development, resulting in this deadly disease which is just now coming to be recognized as a common killer of young persons. An important aspect of the studies are recent experiments with the industrial compound n-(2-

aminoethyl) ethanolamine, which we have recently shown to induce dissecting aneurysms. These studies were coordinated with and were partially funded by the Ethyleneamines Product Stewardship Discussion Group, an industrial group that includes the DOW and BASF chemical companies. Presently, an R21 proposal to the NIH for this work received an outstanding score (9th percentile) and is pending definitive funding.

Grant Support:

Current:

R01-AA-016364
NIH
"Hepatic Steatosis and the Lipid Metabolome"
(G.A.S. Ansari, Principal Investigator)
\$1,847,800
09/01/07 – 08/31/13

5R01ES01630202
NIH
"Oxidative Stress and Autoimmunity"
(M.F. Khan, Principal Investigator)
\$1,604,375
12/01/07 – 11/30/12

NS-11255-32A2
NIH
"Peripheral and Central Sensitization in Pain"
(Chung, Principal Investigator)
\$6,837,723
04/01/08 – 03/31/13

Pending:

NIH 1R21ES022821; (Principal Investigator, PJ Boor), "Atomic Force Microscopic Studies of Dissecting Aneurysm" 04/01/13 - 03/31/15 total request: \$420,750

Proposal to UTMB Institute for Translational Sciences (Principal Investigator, K. Fujise), "Establishing a new biomarker for atherosclerosis" total award: \$70,000

Past:

HL-21327; Young Investigator Research Award: "Molecular Mechanisms of Chemical Mycardiopathies," 7/1/77 - 6/30/80; \$146,627

HL-26189; "Mechanism of Myocardial Injury by Aliphatic Amines"; Principal Investigator; \$165,681; 7/1/80 - 6/30/83.

HL-00929; Research Career Development Award: "Molecular Cardiovascular Toxicology"; \$218,956 (total award); 9/1/81 - 8/31/86.

HL-26189; "Molecular Basis of Cardiovascular Injury" (Principal Investigator); \$581,741; 7/1/83 - 6/30/92.

ES-05245; "1,1-Dichloroethylene: Plasma Membrane Injury" (Fellowship Mentor); Mary F. Kanz, National Research Service Award 1/1/84 - 6/30/84.

T35 HL-07615 (Principal Investigator), "Short Term Research Training: Students in Professional

Schools"; \$236,767 (total award); 7/1/83 - 4/31/92.

John Sealy Memorial Endowment Fund, New Creative Idea Award, "Mesenchymal Amine Oxidases"; (Principal Investigator), \$59,974; 9/1/90-8/31/92.

ES-07254, "Molecular Mechanisms for Environmental Injury"; (Training Grant, Co-Investigator); \$172,786; 7/1/90-6/30/95.

John Sealy Memorial Endowment Fund, Bridging Grant; "Mechanisms of Cardiovascular Injury by Toxic Amines" (Principal Investigator), \$15,000; 1/1/92 - 12/31/92

UTMB Center on Aging, "Aortic Elastin and Aging"; (Principal Investigator), \$10,000; 6/1/94-5/31/95

American Heart Association, Texas Affiliate; "Hyperthyroidism Potentiates Aging Effects in the Heart"; (Co-Investigator), \$38,000; 7/1/94-6/30/96

HL-26189 (Principal Investigator), "Mechanism of Toxic Injury in Vascular Tissue" \$118,057 (current year); 7/1/94-6/30/99

Astra Arcus USA, Inc. (Grant-in-Aid), "Development of *in vitro* system to assess vascular toxicity of NOS-inhibitors" (Principal Investigator), \$20,000; 1/1/97 - 3/31/98

F32 ES 058424-01 (Fellowship Mentor), "Calcium overload and apoptosis in vascular toxicity" Daniel J. Conklin, National Research Service Award; 7/1/98-6/30/99

NIH, SBIR Phase II 2R44 HL54397-02 (M. Motamedi, Principal Investigator), "Catheter for Simultaneous Mapping and Laser Ablation" \$256,373; 3/1/97 – 2/28/00 (5%)

John Sealy Memorial Endowment Fund, Bridging Grant, "Allylamine-Induced Cardiac and Vascular Injury" (Principal Investigator), \$15,000, 7/1/98-6/30/99

UTMB, Center on Aging: "Aging and a Model of Aortic Aneurysm" (Principal Investigator), \$3,000; 11/1/01-10/31/02

NIH, National Institute of Aging, RO3 AGI-8094 (Principal Investigator), "Cellular and Molecular Studies of Abdominal Aortic Aneurysm" \$90,000; 4/01/00 – 3/31/02

Hill and Parker, P.C., Award #462540 (Principal Investigator), "Effect of Fenfluramine/Dexfenfluramine on Cardiac Valves" \$36,000; 11/01/00 – 11/30/04.

NIH, RO1 ES-4815, (G.A.S. Ansari, Principal Investigator), "Lipid Conjugates of Xenobiotics" 6/01/00 – 05/31/05, \$875,000 (5%)

NIH, RO1 ES-06476, (M. Firoze Khan, Principal Investigator), "Splenic Toxicity of Aniline" 8/01/00 – 7/31/05 \$1,328,750 (10%)

Shriners Burns Hospital, Start-Up Grant #8260 "The Role of the Connective Tissue Enzyme, SSAO, in Human Burn Wound Healing" (Principal Investigator) \$25,000/year, 3/01/01-2/28/02.

NIH, RO1 AA13171-01A2 (Principal Investigator: B.S. Kaphalia) "Fatty Acid Ethyl Esters in Ethanol-induced Pancreatitis" 08/01/02–07/31/07.

Shriners Burns Hospitals, Project #8750 (Principal Investigator), "The Role of the Connective Tissue Enzyme, SSAO, in Human Burn Wound Healing" \$103,190/year, 01/01/02 – 12/31/04

Ethyleneamines Product Stewardship Discussion Group, Ludwigshafan, Germany, (Principal Investigator), "In Vitro Enzyme Assays with AEEA in Rat and Human Tissue" \$12,556, total award, 10/15/03 – 08/30/04.

NIH, R21-ES013038, (Principal Investigator) "Fetal basis of dissecting aortic aneurysm", 04/01/04 – 03/31/07.

NIH, R01-HL65416, (Principal Investigator) "Glutathione S- transferases: Oxidative Stress in Early Atherosclerosis" \$1,490,000; 04/01/02- 03/31/08.

NIH 5R01 CA10466106 (Subcontract – Paul Boor, UTMB Principal Investigator) "Role of Ralbp 1 in Xenobiotic and Radiation Resistance" 11/01/07 – 05/31/09, \$79,563

Contract #63755, Ethyleneamines Product Stewardship Discussion Group, Ludwigshafan, Germany (Principal Investigator) "Disruption of Collagen Metabolism as an Underlying Defect in Developmental Dissecting Aortic Aneurysm Induced by In Utero Exposure to N-(2-aminoethyl)ethanolamine— Correlative Studies" \$76,800; 06/01/09-05/31/10

NIH R01-ES-06476 (M.F. Khan, Principal Investigator) "Splenic Toxicity of Aniline", \$200,689; 08/01/05 – 07/31/12

COMMITTEE RESPONSIBILITIES:

A. National

Central Research Review Committee, American Heart Association, Texas Affiliate (1987-1992)
Research Allocations and Advisory Committee, American Heart Association, Texas Affiliate (1990-present; Co-Chairperson, 1994-1995)
Research Fellowship Program Task Force, American Heart Association, Texas Affiliate (1991-1992)
Veteran's Administration Research Service, Cardiology Merit Reviewer (1988-1997)
Medical Research Council of Canada, Ad Hoc Grant Reviewer (1993)
Study Section, NIEHS RO3 Awards: "Biomarkers of Oxidative Stress" (1997)
Study Section, NIH ALTOX-4; ad hoc Reviewer (1998)
Cardiovascular Study Section, Tobacco-related Disease Research Program, University of California (1998-2000)
Study Section, NHLBI "Highly Active Antiretroviral Therapy (HAART) Cardiovascular Toxicities" (2002-2003)
NIEHS Workshop: "The Role of Environmental Agents in Cardiovascular Disease", August, 2002
American Heart Association, Western States Affiliate, Peer Review Committee 2B (2002-2005)
Study Section, RFA:ES-03-010 "The Role of Air Pollutants in Cardiovascular Disease" (2004)
Study Section, VA Review; Merit Awards (2003-2009)
Cardiovascular Study Section, Tobacco-related Disease Research Program, University of California (2005-2011)
American Diabetes Association: Grant Reviewer (2006-present)
USCAP Abstract Review Board (2009-present)

B. UTMB

John Sealy Memorial Endowment Committee (1988-1991);
hoc reviewer (1992-1994)
Appointment, Promotions and Tenure committee (1987-1990)
Nominating Committee (1987-1989)
Committee on Research (1986-1989), Chairman 1988-1989
Residency Advisory Committee (1980-1989)

Chemical Safety Committee (1992-1994)
Academic Planning Committee (1992-1995)
Business Affairs/Research Forum (1992-1993)
Environmental Toxicology Task Force (1992-1993)
Cell Biology Initiative Task Force (1994), Chairman
Environmental Toxicology White Paper Task Force (1994), Chairman
Environmental Toxicology Advisory Committee (1995-present)
Basic Science Core Medical School Course (Molecules/Cells/Tissue) Design Committee (1997-1998)
Basic Science Core Medical School Course (Cardiology/Pulmonary) Design Committee (1997-1999)
LCME Self-Study Task Force (1998)
Faculty Senate Member (2001-2002)
Faculty Performance Evaluation Committee (2004-2005)
LCME Self-Study Task Force (2006); Study Group: Governance and Administration
Faculty Performance Evaluation Committee (elected) 2007-2010 and 2012-2015

C. Departmental

Biohazards Committee (1980-1981)
Pathology Librarian (1977-1983)
Departmental Appointment, Promotions and Tenure Committee (1987-Present; Chairman, 1988-1990)
Department of Pathology Grand Rounds Review Committee, (1997-98)
Faculty Compensation Plan Oversight Committee, 1996-present (Chairperson, 1997-1998)
George Dock Scholar Committee (Chairperson) 1996 – present
Pathology Graduate Program: Curriculum and Academic Planning Committee, 1995-1999 (Chairperson 1995–1998)
Graduate Program: Admissions and Recruitment Committee, Member, 1996-present
Graduate Program: Student Evaluation and Advisory Committee, 2004-present
Graduate Program: Executive Committee, Member, 1995-1998
Student Travel Award Committee, Member, 1996-present
Departmental Appointment, Promotion and Tenure Committee, 2003-2006 and 2009-2011; Chair, 2004-2006 and 2010-2011

D. Other:

Program Coordinator, American Heart Association Jesse H. Jones Research Fellowship, UTMB (1985-1988)
Faculty Advisor, UTMB National Student Research Forum (1988-1989)

TEACHING RESPONSIBILITIES:

A. TEACHING RESPONSIBILITIES AT U.T.M.B.:

a. Teaching:

School of Medicine:

Lecturer and Block Leader: Cardiac Pathology (1977-1998)
Lecturer and Block Leader: Pulmonary Pathology (1977-1983)
Lecturer: Bone and Joint Pathology (1980-1987)
Pathology Medical Student Course Committee (1994-1997)
Pathology Course Test Subcommittee (1994-1998)

Pathology Residency Advisory Committee (1991-1997)
Committee member: Pathobiology and Host Defense (1999-2001)
Lecturer, committee member: Cardiovascular-Pulmonary Core (1999-present)
Lecturer: Pathobiology and Host Defense (1999-present)
Lecturer, committee member: Molecules, Cells and Tissue Core (1998-1999); case contributor (1998-2001)
Laboratory Facilitator: Molecules, Cells and Tissue; Pathobiology of Human Disease; Cardiovascular-Pulmonary Core; Gastrointestinal-Nutrition Core (1998-present)
Lecturer, Prematriculation Reinforcement and Enrichment Program (2001-present)
Lecturer, Great Syndromes Course, "Heart Failure" 2005-present

Graduate School:

Lecturer: General Toxicology (INTD 6485), 1989-1996
Lecturer: Introduction to Research (PATH 6210), 1990-present
Lecturer: Fundamentals of Pathology (PATH 6503), 1990-present
Lecturer: Cardiovascular Toxicology I and II (PATH 6242), 1992-present
Pathology Graduate Program: Curriculum and Academic Planning Committee, Chairperson (1998-2000);
Admissions and Recruitment Committee, Member; (1999-2004)
Graduate Executive Committee, Member, 1995-2000
Graduate School: Curriculum Committee, Member, 1995-1998
Graduate School: Awards Committee, 1996-present
Graduate School: Co-Director, Cardiovascular and Respiratory Systems Course (BBSC6111), 2001-2003
Lecturer: Introductory Pharmacokinetics, Pharmacology/Toxicology Department (), 2004-present
Graduate School: Co-Director, Basic Human Pathobiology (PATH 6266), 2003 - present

b. Students/Mentees/Advisees/Trainees:

Ph.D. Students:

Maura Pagnoni, Ph.D., 1990 (Visiting Predoctoral Student, University of Bologna, Italy);
"Histochemical Alterations During Acute Vascular Toxic Injury"

c. Chair/Member of Ph.D. Supervisory Committee for:

Mary Abreu, Ph.D., 1983 (Member, Thesis Committee); "Effect of Lead Exposure on the Development of the Sympathetic Nervous System in the Heart"

Samir Doudar, Ph.D., 1983 (Member, Thesis Committee); "Drug Interactions in Acetaminophen Hepatotoxicity"

Elizabeth Patterson Cannon, Ph.D., 1987 (Member, Thesis Committee); "A Study of Alterations in Vascular Function Related to Changes in Tissue Calcium"

Gulzar S. Sandhu, Ph.D., 1989 (Member, Thesis Committee); "Mechanism of Adenine Nucleotide Loss from Rat Heart Mitochondria during Ischemia"

Hari Bhat, Ph.D., 1990 (Member, Thesis Committee); "Chloroacetic Acids and Chloroethanols: Interaction with Lipids and Toxicity"

Roy Dyer, Ph.D., 1996 (Member, Thesis Committee); "Evidence for Differential Regulation of NF-Kappa B and C-Rel During Pre-B Cell Differentiation."

Avrudainambi Ramalingam, Ph.D., 1997 (Member, Thesis Committee); "Glucocorticoid Regulation of Cyclin/Cdk Activity in Fibroblasts."

Lee Skipper (Preliminary Dissertation Committee, Member, 1996)

Beth Turnbull (Preliminary Dissertation Committee, Member, 1997)

Elsa M. Haubold (Preliminary Dissertation Committee, Member, 1997)

John Piper (Dissertation Committee, Member, 1996-1998); "Protective Role of Glutathione S-Transferases Against Oxidative Stress."

Roger Vertrees, Ph.D. Mentor (Preliminary Dissertation Committee, Member, 1998; Dissertation Committee Chairman, 1998-1999); "Pathobiology of Thermal Stress in Normal, Transformed and Malignant Lung Cells."

Shannon Langford, Ph.D. Mentor (Preliminary Dissertation Committee, Chairman, 1996; Dissertation Committee, Chairman 1997-1999); "Role of Semicarbazide Sensitive Amine Oxidase in Extracellular Matrix of Blood Vessel Wall."

Amy Shurtleff (Preliminary Dissertation Committee, 1998)

Shannon Schmura (Preliminary Dissertation Committee Chairman, 1998-1999)

Russell Carmichel (Preliminary Dissertation Committee, Member, 1998)

Neil G. Haycocks (Dissertation Committee, Chair, 1998; Dissertation Committee, 2000)

Ivorlyne Greene (Preliminary Dissertation Committee, 2000)

Danyl Hermes (Preliminary Dissertation Committee, Member, 2001)

Tarl Prow (Preliminary Dissertation Committee, Member, 2001)

Yusong Yang, Department of Pharmacology and Toxicology (Dissertation Committee, Member, 2001)

Kelly Mericle (Preliminary Dissertation Committee, Member, 2000; Dissertation Committee, 2003); "Modulation of Fatty Acid Ethyl Ester Synthase In Vivo and In Vitro"

Charles Todd Davis (Preliminary Dissertation Committee, Member, 2003); "Indirect Mechanisms of IFN- γ during the Immune Response to Fatal and Non-fatal Encephalitis Induced by Sindbis Virus"

Melissa M. Herbst (Preliminary Dissertation Committee, Member, 2003); "The Immunoregulatory Function of CEACAM1 in Gonococcal Infection"

Heather McSharry (Preliminary Dissertation Committee, Member, 2004)

Elena Sbrana (Preliminary Dissertation Committee, Member, 2004)

Bradley Schneider (Preliminary Dissertation Committee, Member, 2004); "Role of *Borrelia hermsii* Variable Major Proteins-7 and -33 in Tick Dissemination and Transmission to Host"

Heather Stevenson (Preliminary Dissertation Committee, Member, 2005); "Francisella Tularensis Virulence and Macrophage Apoptosis."

Anita Reno (Preliminary Dissertation Committee, Member, 2005; Dissertation Committee, Member, 2005-present) "Pathologic Effect of Cocaethylene on the Vascular Endothelium."

Mike Woods (Dissertation Committee, Member, 2005); "Mechanisms of Increased Microvascular Permeability in Rickettsioses"

Michele A. Zacks (Preliminary Dissertation Committee, Member, 2005); "Biological Studies of GPI-Anchoring in *T. Cruzi*"

Liang Ma (Preliminary Dissertation Committee, Member, 2007; Dissertation Committee, 2008-2010); "The Effects of Pathogenic Missense Mutations on Adhesive Property of CDH23."

Allison Mayo (Preliminary Dissertation Committee, Member, 2008); "Ebola Virus (EBOV) VP24 Inhibits Transcription and Replication of the EBOV Genome."

Amy Shuh (Preliminary Dissertation Committee, Member, 2008); "In vitro studies of IFN-beta regulation of hepatitis C replication."

Shelly Renee Wilson (Preliminary Dissertation Committee Member and Dissertation Committee Member, 2008-2011) Department of Pharmacology and Toxicology); "Ah Receptor Transcriptional Regulation Through PAI1, a Novel DNA Binding Site."

Farooq Nasar (Preliminary Dissertation Committee Member, 2010) "Tail, Fas-L and PD-1 and apoptosis in SIV/HIV infection."

Eliza Fuhr (Preliminary Dissertation Committee Member, 2010) "Interference by *Wolbachia pipentis* with dengue virus infection."

Olga A. Kolokoltsova (Preliminary Dissertation Committee Member, 2011) "Mechanism of type I IFN induction in response to Dengue virus."

Sydney Ramirez (Preliminary Dissertation Committee Member, 2012) "DC-SIGN as a receptor for phleboviruses."

Chair/Member of Masters Thesis Supervisory Committee for:

Renee C. Aversano, M.S., 1982 (Thesis Advisor); "Doxorubicin Cardiotoxicity: A Histochemical Survey"

Sheila Trumble, M.S., 1982 (Member, Thesis Committee); "A Quantitative Ultrastructural and Biochemical Study of Microtubules following Acute Carbon Tetrachloride Poisoning"

Pamela Jean Benes, M.S., 1986 (Member, Thesis Committee); "Antigenicity of Campylobacter pyloritis"

Douglas E. Wilson, M.S., 1986 (Member, Thesis Committee); "Phosphate-Induced Efflux of Adenine Nucleotides from Isolated Rat Heart Mitochondria"

Ernest Rudolph Anders, III, M.D., M.S., 1987 (Member, Thesis Committee); "Characterization of the Effect of Calcium Channel Blockers and Potassium Induced Depolarization on the Rate by Which Calcium-Depleted Sarcoplasmic Reticulum Reaccumulates Calcium in Smooth Muscle"

Amirali S. Popatia, M.D., M.S., 1988 (Member, Thesis Committee); "The Tissue Renin-Angiotensin System in the Two-Kidney One-Clip (2K-1C) Goldblatt Model of Hypertension: Gene Expression Studies"

Irfan Khan Sandozi, M.S. 1991 (Member, Thesis Committee); "Parathyroid Hormone Related Peptide Gene Expression in Human Tissues"

Praphul Misra, M.S. 1994 (Thesis Advisor); "Glutathione-S-Transferase (GST) 8-8 is Localized in Smooth Muscle Cells of Rat Aorta and is Induced in an Experimental Model of Atherosclerosis".

MEMBERSHIP IN SCIENTIFIC SOCIETIES:

American Heart Association
American Association for the Advancement of Science
Galveston County Medical Society
Houston Society of Clinical Pathologists
International Society for Heart Research
International Society for the Study of Xenobiotics
New York Academy of Sciences
Sigma XI Scientific Research Society
Society for Cardiovascular Pathology (Founding Member in 1985)
Society of Toxicologic Pathology
Society of Toxicology
Texas Medical Association
Texas Society of Pathologists (Scientific Program Chairman, 1988;
Residents/Fellows Seminar Committee, 1989-1993)
U.S. and Canadian Academy of Pathology

HONORS:

National Research Service Award, 1975 - 1977
Young Investigator Research Award, 1977 - 1980
Research Career Development Award, 1981 - 1986
Researcher of the Year Award, Pathology Department, 1998

ADDITIONAL INFORMATION:

A. Reviewer:

Alcohol, Thomas R Jerrells, Editor
Ambulatory Child Health, Francis Page Glascoe, Editor
American Journal of Cardiology, W.C. Roberts, Editor
American Journal of Physiology: Heart and Circulation Physiology, R. John Solaro, Associate Editor
Archives of Pathology and Laboratory Medicine
Arteriosclerosis, Thrombosis and Vascular Biology
Biochemical Pharmacology, O.C. Sartorelli, Regional Editor (USA)
Bulletin of Environmental Contamination and Toxicology, G.A.S. Ansari, Associate Editor
Canadian Journal of Physiology and Pharmacology
Cardiovascular Pathology, Avrum I. Gotlieb Jagdish Butany, Co-editors
Cardiovascular Research, Michel J. Janse, Editor
Cardiovascular Toxicology, Y. James Kang, Editor-in-Chief
Clinical Cancer Research, Beverly A. Teicher, Editor

Diabetes, P.E. Cruer, Editor
European Journal of Pharmacology, W.H. Gispen, Editor
Fundamental and Applied Toxicology, R.A. Neal, Editor
Free Radical Biology and Medicine
Gastroenterology, Gregory J. Gores, Associate Editor
Hypertension, E.D. Frohlich, Editor
Journal of the American College of Toxicology
Journal of Forensic Sciences
Journal of Histochemistry and Cytochemistry, P.J. Anderson, Editor
Journal of Molecular and Cellular Cardiology, L.H. Opie, Editor
Journal of Nutrition, A. Catherine Ross, Editor
Journal of Pharmacology and Experimental Therapeutics, David Robertson, Raouf Khalil
Associate Editors
Journal of Pharmacy and Pharmacology
Journal of Toxicology and Environmental Health, S. Kacew, Editor
Molecular and Cellular Biochemistry, Naranjan S. Dhalla, Editor
Toxicology, R.F. Crampton, Editor-in-Chief, H. Witschi, Associate Editor (USA)
Toxicology and Applied Pharmacology, E. Bresnick, Editor; M. Firoze Khan, Assoc. Editor
Toxicology Letters, James P. Kehrer, Editor

B. Editorial Board:

Toxicology, 1994-2001
Toxicology and Applied Pharmacology, 1994-2007
Cardiovascular Toxicology, 2000-2006

C. Community Service:

Community Advisory Board, Infectious Diseases and Maximum Containment Laboratory

BIBLIOGRAPHY:

PUBLISHED:

A. ARTICLES IN PEER-REVIEWED JOURNALS:

1. Boor PJ, Schoene WC. Fetal cerebellar tissue associated with a primitive neuroepithelial tumor in ovarian teratoma. *The Canadian Journal of Neurological Sciences* 2: 139-140, 1975.
2. Tilney NL, Boor PJ. Host response to implanted dacron grafts. *Arch. Surg.* 10:1469-1472, 1975.
3. Boor PJ, Reynolds ES, Moslen MT. Neurotoxicity of digitoxin in adult and newborn rats: Drug distribution. *Arch. Inter. Pharm. Ther.* 224(1): 4-12, 1976.
4. Boor PJ, Reynolds ES. A simple planimetric method for determination of left ventricular and necrotic myocardial mass. *Am. J. Clin. Pathol* 68(3): 389-392, 1977.
5. Boor PJ, Reynolds ES. Myocardial infarct size: Clinicopathologic agreement and discordance. *Human Pathol* 8(6): 685-695, 1977.
6. Szabo S, Bailey KA, Boor PJ, Jaeger RJ. Acrylonitrile and tissue glutathione: Differential effect of acute and chronic interactions. *Biochem. Biophys. Res. Comm.* 79(1): 32-37, 1977.
7. Moslen MT, Reynolds ES, Boor PJ, Bailey K, Szabo S. Trichloroethylene induced deactivation of

- cytochrome P450 and loss of liver glutathione *in vivo*. Res. Comm. Chem. Pathol. Pharmacol. 16(1): 109-120, 1977.
8. Boor PJ, Swanson MR. Papillary-cystic neoplasm of the pancreas. Am. J. Surg. Pathol. 3(1): 69-75, 1979.
 9. Boor PJ, McAllister PR. Juxtaposition of the atrial appendages. Human Pathol 10(3):347-349, 1979.
 10. Boor PJ. Cardiac glutathione: Diurnal rhythm and variation in drug induced cardiomyopathy. Res. Comm. Chem. Pathol. Pharmacol. 24(1) :27-36, 1979.
 11. Boor PJ, Ferrans VJ, Jones M, Kawanami O, Thiedemann KU, Herman EH, Roberts WC. Tubuloreticular structures in myocardium, an ultrastructural study. J. Molec. Cell. Cardiol. 11: 967-979, 1979.
 12. Boor PJ, Moslen MT, Reynolds ES. Allylamine cardiotoxicity: I. Sequence of pathologic events. Toxicol Appl Pharmacol 50: 581-592, 1979.
 13. Boor PJ, Nelson TJ, Chieco P. Allylamine cardiotoxicity: II. Histopathology and histochemistry. Am J Pathol 100: 739-764, 1980.
 14. Evans AT, Korndorffer WE, Boor PJ. Sudden death of two brothers while playing basketball: Familial hypertrophic cardiomyopathy. Texas Med. 76(9): 48-51, 1980.
 15. Reynolds ES, Moslen MT, Boor PJ, Jaeger RT. 1,1-Dichloro-ethylene hepatotoxicity: Time-course of glutathione changes and biochemical aberrations. Am J Pathol 101:331-344, 1980.
 16. Boor PJ, Nelson TJ. Allylamine cardiotoxicity: III. Protection by semicarbazide and *in vivo* derangement of monoamine oxidase. Toxicology 18: 87-102, 1980.
 17. Boor PJ. Studies of hypotension and cardiac flow in isoproterenol-induced myocardial necrosis. Exptl. Molec. Pathol. 34:110-121, 1981.
 18. Nelson TJ, Boor PJ. Allylamine cardiotoxicity: IV. Metabolism to acrolein by cardiovascular tissue. Biochem. Pharmacol. 31: 509-514, 1982.
 19. Boor PJ, Ferrans VJ. Ultrastructural alterations in allylamine induced cardiomyopathy: Early lesions. Lab Invest 47: 76-86, 1982.
 20. Van Ding T, Boor PJ, Garza JR. Massive pulmonary embolism following delivery in a patient with sickle cell trait. Amer. J. Ob. Gyn. 143:722-724, 1982.
 21. Boor PJ, Nelson TJ. Biotransformation of the cardiovascular toxin, allylamine, by rat and human cardiovascular tissue. J. Molec. Cell. Cardiol. 14:679-682, 1982.
 22. Aversano R, Boor PJ. Histochemical alterations in acute and chronic doxorubicin cardiotoxicity. J. Molec. Cell. Cardiol. 15: 543-553, 1983.
 23. Aversano R, Boor PJ. Acute doxorubicin-induced cardiac arrhythmias during ether anesthesia. Res. Comm. Chem. Pathol. Pharmacol. 41: 345-348, 1983.
 24. Chieco P, Boor PJ. Use of low temperatures for glutathione histochemical stain. J. Histochem. Cytochem. 31:975-976, 1983.
 25. Chieco P, Normanni P, Boor PJ. Improvement in soluble dehydrogenase histochemistry by nitroblue tetrazolium uptake before incubation: A qualitative and quantitative study. Stain Technol. 59: 201-211,

1984.

26. Chieco P, Boor PJ. Quantitative histochemistry in pathology and toxicology: An evaluation of the original two-wavelength method of Ornstein. *Lab Invest* 50: 355-362, 1984.
27. Ghanayem BI, Ahmed AE, Boor PJ. Acetyl salicylic acid-induced gastric mucosal lesions: no role of gastric glutathione. *Res. Comm. Chem. Pathol. Pharmacol.* 45:153-156, 1984.
28. Ghanayem BI, Boor PJ, Ahmed AE. Gastric glutathione depletion mediates acrylonitrile-induced gastric ulceration. *J. Pharmacol. Exp. Ther.* 232:570-577, 1985.
29. Douidar S, Boor PJ, Ahmed AE. Potentiation of hepatotoxic effect of acetaminophen by prior administration of salicylate. *J. Pharmacol. Exp. Ther.* 233:242-248, 1985.
30. Boor PJ. Allylamine cardiovascular toxicity V: Tissue distribution and toxicokinetics after oral administration. *Toxicology* 35: 167-177, 1985.
31. Hysmith RM, Boor PJ. Allylamine vascular toxicity VI: Subcellular distribution in rat aorta. *Toxicology* 35: 179-187, 1985.
32. Boor PJ, Ferrans VJ. Ultrastructural alterations in allylamine cardiovascular toxicity: late myocardial and vascular lesions. *Am J Pathol* 121: 39-54, 1985.
33. Boor PJ, Ansari GAS. A high performance liquid chromatographic method for quantitation of acrolein in biological samples. *J. Chromatogr. Biomed. Appl.* 375:159-164, 1986.
34. Hysmith RM, Boor PJ. Comparative toxicity of the cardiovascular toxin allylamine to porcine aortic smooth muscle and endothelial cells. *Toxicology* 38: 141-150, 1986.
35. Arnold JR, Boor PJ. Improved transmission electronmicroscopy (TEM) of cultured cells through a "floating sheet" method. *J. Ultrastr. Molec. Struct. Res.* 24:30-36, 1986.
36. Arnold JR, Boor PJ. A new method of processing cultured cells for transmission electronmicroscopy: The floating sheet. *J Tissue Cult Methods* 10(4): 223-226, 1986.
37. Hysmith RM, Welch TK, Boor PJ. The comparative study of cardiovascular toxins utilizing a sensitive indicator of sublethal toxic injury. *In Vitro Cell Devel. Biol.* 23:129-133, 1987.
38. Hysmith RM, Boor PJ. *In vitro* expression of benzylamine oxidase activity in cultured porcine aortic smooth muscle cells *J Cardiovasc Pharmacol* 9:668-674, 1987.
39. Ahmed AE, Grissom M, el-Azhary R, Haque A, Boor PJ, Costanzi J. Studies on the mechanism of CCNU-induced hepatotoxicity II: Biochemical and morphological characterization of the injury and its prevention by phenobarbital. *Canc. Chemother. Pharmacol.* 19: 103-108, 1987.
40. Kretschmer NW, Boor PJ, el-Azhary R, Ahmed AE, Reynolds ES. Studies on the mechanism of CCNU hepatotoxicity III: Ultra-structural study of bile ducts. *Canc. Chemother Pharmacol* 19: 109-117, 1987.
41. Hysmith RM, Boor PJ. Binding of [¹⁴C]-allylamine to isolated mitochondria and rat heart and aorta. *Toxicology* 44: 13-29, 1987.
42. Boor PJ, Hysmith RM. Allylamine cardiovascular toxicity: A Review. *Toxicology* 44:129-144, 1987.
43. Boor PJ, Sanduja R, Nelson TJ, Ansari GAS. *In vivo* metabolism of the cardiovascular toxin, allylamine. *Biochem. Pharmacol.* 36:4347-4353, 1987.

44. Ansari GAS, Kaphalia B, Boor PJ. Selective pancreatic toxicity of palmitoylpentachlorophenol. *Toxicology* 46: 57-63, 1987.
45. Sanduja R, Ansari GAS, Boor PJ. Simultaneous determination of myocardial creatine phosphate and adenine nucleotides by reverse-phase high performance liquid chromatography. *Biomed Chromatogr* 2: 156-158, 1987.
46. Stout LC, Boor PJ, Horton E. Myofibroblastic proliferation on mitral valve chordae tendineae. A distinctive lesion associated with alcoholic liver disease. *Human Pathology* 19: 720-725, 1988.
47. Hysmith RM, Boor PJ. Role of benzylamine oxidase in the cytotoxicity of allylamine toward aortic smooth muscle cells. *Toxicology* 51: 133-145, 1988.
48. Hysmith RM, Boor PJ. Purification of cellular and extracellular benzylamine oxidase from cultured porcine aortic smooth muscle cells. *Biochem Cell Biol* 66: 821-829, 1988.
49. Sanduja R, Ansari GAS, Boor PJ. 3-Hydroxypropylmercapturic acid: A biologic marker of exposure to allylic and related compounds. *J Appl Toxicol* 9(4): 235-238, 1989.
50. Rutledge JM, Boor PJ. Eisenmenger's: A case study and review of the syndrome and complex. *Am J Cardiovasc Pathol* 2: 285-294, 1989.
51. Boor PJ, Hysmith RM, Sanduja R. A role for a new vascular enzyme in the metabolism of xenobiotic amines. *Circ. Res.* 66:249-252, 1990.
52. Boor PJ, Kretschmer, N. Increased DNA synthesis in the heart during acute allylamine cardiotoxicity. *Res. Comm. Chem. Pathol. Pharmacol.* 68:3-11, 1990.
53. Arnold JR, Hysmith RM, Boor PJ. The ultracytochemical demonstration of extramitochondrial monoamine oxidase activity. *Biogenic Amines* 7: 127-143, 1990.
54. Kumar D, Hysmith RM, Boor PJ. Allylamine and β -aminopropionitrile induced vascular injury: an *in vivo* and *in vitro* study. *Toxicol Appl Pharmacol* 103: 288-302, 1990.
55. Sklar JL, Anderson PG, Boor PJ. Allylamine and acrolein toxicity in perfused rat hearts. *Toxicol Appl Pharmacol* 107: 535-544, 1991.
56. Anderson PG, Digerness SB, Sklar JL, Boor PJ. Use of the isolated perfused heart for evaluation of cardiac toxicity. *Toxicol Pathol* 18: 497-510, 1991.
57. Boor PJ, Khan MF, Kaphalia BS, Jerrells TR, Ansari GAS. Synergistic vascular toxicity and fatty acid anilides in the Toxic Oil Syndrome. *J. Am. Coll. Cardiol.* 18:1824-1828, 1991.
58. Tipnis UR, Boor PJ. Inhibition of polyamine synthesis impairs the secretion of atrial natriuretic peptide. *Regulatory Peptides*, 37: 227-236, 1992.
59. Kaphalia BS, Khan MF, Boor PJ, Ansari GAS. Toxic response to repeated oral administration of 2-chloroethyl linoleate in rats. *Res. Commun. Chem. Pathol. Pharmacol.* 76:209-222, 1992.
60. Boor PJ, Trent MB, Lyles GA, Tao M, Ansari, GAS. Methylamine metabolism to formaldehyde by a vascular enzyme. *Toxicology*, 73: 251-258, 1992.
61. Tipnis UR, Tao M, Boor PJ. Purification and characterization of semicarbazide-sensitive amine oxidase from porcine aorta. *Cell Mol Biology* 38: 575-584, 1992.

62. Awasthi S, Boor PJ. Semicarbazide protection from in vivo oxidant injury of vascular tissue by allylamine. *Tox. Letters* 66: 157-163, 1993.
63. Khan MF, Kaphalia BS, Boor PJ, Ansari GAS. Subchronic toxicity of aniline hydrochloride in rats. *Arch Environ. Contam. Toxicol.* 24:368-374, 1993.
64. Awasthi S, Boor PJ. Lipid peroxidation and oxidative stress during acute allylamine-induced cardiovascular toxicity. *J. Vasc. Res.* 31:33-41, 1994.
65. Trent MB, Boor PJ. Vascular amine oxidase activities during synergistic vasculotoxicity. *Toxicology* 89: 67-77, 1994.
66. Tipnis UR, Haile C, Boor PJ, Gutkowska J. Polyamine regulation of atrial natriuretic peptide in cultured cardiocytes. *Reg. Peptides* 52: 75-84, 1994.
67. Boor PJ, Gottlieb AI, Joseph EC, Kerns WD, Roth RA, Tomaszewski KE. Contemporary Issues in Toxicology: Chemical-Induced Vasculature Injury. *Toxicol. Appl. Pharmacol.* 132:177-195, 1995.
68. Misra P, Srivastava SK, Singhal SS, Awasthi S, Awasthi YC, Boor PJ. Glutathione-S-Transferase (GST) 8-8 is localized in smooth muscle cells of rat aorta and is induced in an experimental model of atherosclerosis. *Toxicol. Appl. Pharmacol.* 133: 27-33, 1995.
69. Khan MF, Boor PJ, Kaphalia BS, Alcock NW, Ansari, GAS. Hematopoietic toxicity of linoleic acid anilide: Importance of Aniline. *Fund. Appl. Toxicol.* 25(2): 224-232, 1995.
70. Langford SD, Boor PJ. Oleander Toxicity: An examination of human and animal toxic exposures. *Toxicology* 109: 1-13, 1996.
71. Adegboyega PA, Haque AK, and Boor PJ. Extensive myocytolysis as a marker of sudden cardiac death. *Cardiovasc. Pathol.* 5:315-321, 1996.
72. Khan MF, Boor PJ, Gu Y, Alcock NW and Ansari GAS. Oxidative stress in the splenotoxicity of aniline. *Fundam. Appl. Toxicol.* 35:22-30, 1997.
73. Khan MF, Wu X, Kaphalia BS, Boor PJ and Ansari, GAS. Acute hematopoietic toxicity of aniline in rats. *Toxicol. Lett.* 92:31-37, 1997.
74. Awasthi S and Boor PJ. Allylamine and β -aminopropionitrile-induced vascular injury: Enhanced expression of high-molecular-weight proteins. *J. Toxicol. and Environ. Health.* 52:101-116, 1997.
75. Amrikachi M, Lopez L, Cutler D and Boor PJ. Lactobacillus endocarditis: a chronic active infection. *Cardiov. Path.* 6:341-344, 1997.
76. Adegboyega P, Adesokan A, Haque A and Boor PJ. Sensitivity and specificity of triphenyl tetrazolium chloride in the gross diagnosis of acute myocardial infarcts. *Arch. Pathol. Lab. Med.* 121:1063-1068, 1997.
77. Conklin DJ and Boor PJ. Allylamine Cardiovascular Toxicology: Evidence for Aberrant Vasoreactivity in Rats. *Toxicol. App. Pharmacol.* 148:245-251, 1998.
78. Khan MF, Green SM, Ansari, GAS and Boor PJ. Phenylhydroxylamine: Role in Aniline-Associated Splenic Oxidative Stress and Induction of Subendocardial Necrosis. *Toxicol. Sci.* 42:64-71, 1998.
79. Kumar D, Trent MB and Boor PJ. Allylamine & β -Aminopropionitrile Induced Aortic Medial Necrosis: Mechanisms of Synergism. *Toxicology* 125:107-115, 1998.

80. He, NG, Awasthi, S, Singhal, SS, Trent, MB, and Boor, PJ. The role of glutathione S-transferases as a defense against reactive electrophiles in the blood vessel wall. *Toxicol. Appl. Pharmacol.* 152:83-89, 1998.
81. Lick SD, Sankar AB and Boor, PJ. Heart Donation After Lightning Strike. *J. Heart Lung Transplant.* 17:1034-1035, 1998.
82. Conklin, DJ, Langford, SD, and Boor, PJ. Contribution of Serum and Cellular Semicarbazide-Sensitive Amine Oxidase to Amine Metabolism and Cardiovascular Toxicity. *Toxicol. Sci.* 46:386-392, 1998.
83. Langford, SD, Trent, MB, Balakumaran, A, and Boor, PJ. Developmental Vasculotoxicity Associated with Inhibition of Semicarbazide-Sensitive Amine Oxidase. *Toxicol. Appl. Pharmacol.* 155:237-244, 1999.
84. Ware, DL, Boor, PJ, Yang C, Gowda, A, Motamedi, M. Slow Intramural Heating with Diffused Laser Light: A Novel Method for Ablation of Post-Infarction Ventricular Tachycardia. *Circulation* 99:1630-1636, 1999.
85. Khan, MF, Wu, X, Boor, PJ, and Ansari, GAS. Oxidative Modification of Lipids and Proteins in Aniline-Induced Splenic Toxicity. *Toxicol. Sci.* 48:134-140, 1999.
86. He N, Singhal SS, Awasthi S, Zhao T and Boor PJ. Role of Glutathione S-transferase 8-8 in Allylamine Resistance of Vascular Smooth Muscle Cells *in Vitro*. *Toxicol. Appl. Pharmacol.* 158:177-185, 1999.
87. Khan, MF, Wu, X, Alcock, NW, and Boor, PJ. Iron exacerbates aniline-associated splenic toxicity. *J. Toxicol. Environ. Hlth. Part A*, 57:101-112, 1999.
88. Conklin, DJ, Trent MB, and Boor PJ. The role of plasma semicarbazide-sensitive amine oxidase in allylamine and β -aminopropionitrile cardiovascular toxicity: mechanisms of myocardial protection and aortic media injury in rats. *Toxicology* 138:137-154, 1999.
89. Otero, FJ, Boor, PJ, and Sheahan, RG. Doxorubicin Induced Cardiomyopathy. *A. J. Med. Sci.* 320 (1): 59-68, 2000.
90. Tipnis, UR, He, G-Y, Li, S, Campbell, G, Boor, PJ. Attenuation of isoproterenol-mediated myocardial injury in rat by an inhibitor of polyamine synthesis. *Cardiovasc. Pathol.* 9:273-280, 2000.
91. Ware, DL, Boor, PJ, Yang C, Gowda A, Motamedi M. Ventricular arrhythmias following thermal damage of epicardial tissue: Possible causes and clinical implications. *Pacing and Cardiac Electrophysiology* 23: 1375-1380, 2000.
92. Vertrees, RA, Zwischenberger, JB, Boor, PJ, Pencil, SD. Oncogenic *ras* results in increased cell kill due to defective thermoprotection in lung cancer cells. *Ann. Thoracic Surg.* 69: 1675-1780, 2000.
93. Vertrees, RA, Deyo, DJ, Quast, M, Wei, G, Lightfoot, KM, Boor, PJ, Zwischenberger, JB. Development of human to murine orthotopic xenotransplanted lung cancer model. *J. Invest. Surg.* 13: 1-10, 2000.
94. Slukvin, II, Boor, P, and Jerrells, TR. Initiation of alcoholic fatty liver and hepatic inflammation with a specific recall immune response in alcohol-consuming C57Bl/6 mice. *Clin Exp Immunol.* 125: 123-133, 2001.
95. Langford, SD, Trent MB, Boor PJ. Cultured rat vascular smooth muscle cells are resistant to methylamine toxicity: No correlation to semicarbazide-sensitive amine oxidase. *Cardiovasc. Toxicol* 1:

51-60, 2001.

96. Conklin DJ, Boyce, CL, Trent, MB, Boor, PJ. Amine metabolism: a novel path to coronary artery vasospasm. *Toxicol. Appl. Pharmacol* 175: 149-159, 2001.
97. Srivastava, S., Conklin, D.J., Boor, PJ, Liu, S.Q., Srivastava, S.K., and Bhatnagar, A. Identification of biochemical pathways for the metabolism of oxidized low-density lipoprotein-derived aldehyde, 4-hydroxy trans-2-nonenal, in vascular smooth muscle cells. *Atherosclerosis* 158: 339-350, 2001.
98. Khan, MF, Wu, X., Tipnis, UR, Ansari, GAS, Boor PJ, Protein adducts of malondialdehyde And 4-hydroxynonenal in livers of iron-loaded rats: quantitation and localization. *Toxicology* 173: 193-201, 2002.
99. Langford, SD, Trent, MB, Boor, PJ. Semicarbazide-Sensitive Amine Oxidase and Extracellular Matrix Deposition by Smooth-Muscle Cells. *Cardiovas Toxicol.* 2:141-150, 2002.
100. Trent, MB, Conklin, DJ, Boor, PJ. Culture Medium Enhances Semicarbazide-Sensitive Amine Oxidase Activity. *In Vitro Cell. Dev. Biol-Animal* 38:523-528, 2002.
101. Sharma, R, Yang, Y, Sharma, A, Dwivedi, S, Popov, VL, Boor PJ, Singhal, SS, Awasthi S, Awasthi YC. Mechanisms and Physiological Significance of the Transport of 4-Hydroxynonenal-Glutathione Conjugate in Human Lens Epithelial Cells. *Invest Ophthal Visual Sci* 44:3438-3449, 2003.
102. Khan MF, Wu X, Ansari GAS, Boor PJ. Malondialdehyde-protein adducts in the spleens of aniline-treated rats: Immunohistochemical detection and localization. *J Toxicol Environ Health, Part A* 66: 93-102, 2003.
103. Khan MF, Wu X, Boor PJ, Ansari GAS. Nitrotyrosine formation in splenic toxicity of aniline. *Toxicology* 194: 95-102, 2003.
104. Conklin, DJ, Cowley, HR, Wiechmann, RJ, Johnson, GH, Trent, MB, Boor PJ. Vasoactive Effects of Methylamine in Isolated Human Blood Vessels: Role of Semicarbazide-Sensitive Amine Oxidase, Formaldehyde, and Hydrogen Peroxide. *Am. J. Physiol. Heart Circ. Physiol.* 286:H667-676, 2004.
105. Yang, Y, Yang, Y, Trent, MB, He, N, Lick, SD, Zimniak, P, Awasthi, YC. Boor, PJ. Glutathione-S-Transferase A4-4 modulates oxidative stress in endothelium: possible role in human atherosclerosis. *Atherosclerosis* 173:211-221, 2004.
106. Dugas, TR, Kanz, MF, Hebert, VY, Hennard, KL, Liu, H., Santa Cruz, V, Conklin, D, Boor, PJ. Vascular medial hyperplasia following chronic, intermittent exposure to 4,4'-methylenedianiline. *Cardiovas. Tox.* 4:85-96, 2004.
107. Vertrees, RA, Nason, R, Hold, MD, Leeth, AM, Schmalstieg, FC, Boor PJ, Zwischenberger JB. Smoke/burn injury-induced respiratory failure elicits apoptosis in ovine lungs and cultured lung cells, ameliorated with arteriovenous CO₂ Removal. *Chest* 125:1472-1482, 2004.
108. Awasthi, S, Singhal, SS, Yadav S, Singhal J, Drake K, Nadkar A, Zajac E, Wickramarachchi D, Rowe N, Yacoub A, Boor P, Dwivedi S, Dent P, Jarman WE, Berchmans J, Awasthi YC. RLIP76 is a major determinant of radiation sensitivity. *Cancer Res* 65:6022-6028, 2005.
109. Vertrees, RA, Gokul, CD, Popov, VL, Coscio, AM, Goodwin, TJ, Zwischenberger, JB, Boor, PJ. Synergistic interaction of hyperthermia and gemcitabine in lung cancer. *Cancer Biol & Therapy* 4:1144-1153, 2005.
110. Vertrees, RA, Das, GC, Coscio, AM, Xie, J, Zwischenberger, JB, Boor PJ. A mechanism of hyperthermia-induced apoptosis in RAS-transformed lung cells. *Mol Carcinog.* 44:111-121, 2005.

111. Gong, B, Trent, MB, Srivastava, D, Boor, PJ. Chemical-induced, nonlethal, developmental model of dissecting aortic aneurysm. *Birth Defects Research (Part A)* 76:29-38, 2006.
112. Dwivedi, S, Sharma, R, Sharma, A, Zimniak, P, Ceci, JD, Awasthi, YC, Boor, PJ. The course of CCl₄ induced hepatotoxicity is altered in mGSTA4-4 null (-/-) mice. *Toxicology* 218:58-66, 2006.
113. Boor, PJ, Yang, Y, Gong, B. Role of the media in vascular injury: atherosclerosis and dissection. *Toxicol Path.* 34:1-6, 2006.
114. Gong, B., Boor, PJ. The role of amine oxidases in xenobiotic metabolism. *Expert Opin Drug Metab Toxicol.* 2:559-571, 2006.
115. Conklin, DJ, Bhatnagar, A, Cowley, HR, Johnson, GH, Wiechmann, RJ, Sayre, LM, Trent, MB, Boor PJ. Acrolein generation stimulates hypercontraction in isolated human blood vessels. *Toxicol Appl Pharm.* 217(3):277-288, 2006.
116. Wang, L, Yang, Y, Dwivedi, S, Xu, Y, Chu, ET, Li, J, Fitchett, K, Boor, PJ. Manipulating Glutathione-S-Transferases may prevent the development of tolerance to nitroglycerin. *Cardiovasc. Toxicol.* 6(2):131-144, 2006.
117. Gong, B, Asimakis, GK, Chen, Z, Albrecht, TB, Boor, PJ, Pappas, TC, Bell, B, Motamedi, M. Whole-body hyperthermia induces up-regulation of vascular endothelial Ggrowth factor accompanied by neovascularization in cardiac tissue. *Life Sciences*, 79:1781-1788, 2006.
118. Bhopale, KK, Wu, H, Boor, PJ, Popov, VL, Ansari, GAS, Kaphalia, BS. Metabolic basis of ethanol-induced hepatic and pancreatic injury in hepatic alcohol dehydrogenase deficient deer mice. *Alcohol* 39:179-188, 2006.
119. Singhal SS, Singhal J, Yadav S, Dwivedi S, Boor PJ, Awasthi YC, Awasthi S. Regression of Lung and Colon Cancer Xenografts by Depleting or Inhibiting RLIP76 (Ral-Binding Protein 1). *Cancer Res.* 67(9):4382-4389, 2007.
120. Cai P, Konig R, Boor PJ, Khan MF, Kaphalia BS, Ansari GAS. Immuno- and Hepato-toxicity of Dichloroacetic Acid in MRL +/+ and B6C3F1 Mice. *J. Immunotox.* 4:107-115, 2007
121. Huang M-H, Wang H-Q, Roeske W, Birnbaum Y, Wu Y, Yang N-P, Lin Y, Ye Y, McAdoo D, Hughes M, Lick S, Boor P, Lui C, Uretsky B. Mediating 2-Adrenergic Receptor: Role of Intrinsic Cardiac Adrenergic Cells. *Am J Physiol: Heart and Circ Physiol* 293: 376-384, 2007.
122. Cai P, Konig R, Khan MF, Kaphalia BS, Boor PJ, Ansari GAS. Immuno- and Hepatotoxicity of Dichloroacetic Acid in MRL +/+ and B6C3F1 mice. *J Immunotox* 4: 107-115, 2007.
123. Xu Y, Gong B, Yang Y, Awasthi YC, Woods ME, Boor PJ. Glutathione-S-Transferase Protects against Oxidative Injury of Endothelial Cell Tight Junctions. *Endothelium* 14: 333-343, 2007.
124. Gong B, Sun J, Vargas G, Chang Q, Xu Y, Srivastava D, Boor PJ. Nonlinear Imaging Study of Extracellular Matrix in Chemical-Induced, Developmental Dissecting Aortic Aneurysm: Evidence for Defective Collagen Type III. *Birth Defects Res (Part A)* 82: 16-24, 2008.
125. Vertrees RA, Zwischenberger JB, Boor PJ, Popov V, McCarthy M, Solley TN, Goodwin T. Cellular Differentiation in Three-Dimensional Lung Cell Cultures. *Cancer Biol Therapy* 7: 1-8, 2008.
126. Gong B, Bell B, Boor PJ, Albrecht TB, Asimakis GK, Motamedi M. Cardiac preconditioning with local laser-induced hyperthermia *J Surg Res.* 149(2):177-183. 2008

127. Cai P, Konig R, Boor PJ, Kondraganti, S, Khan MF, Kaphalia BS, Ansari GAS. Chronic exposure to trichloroethene causes SLE-like disease in female MRL+/+ mice. *Toxicol Appl Pharmacol* 228:68-75, 2008.
128. Ma H, Wang J, Abdel-Rahman SZ, Boor PJ, Khan MF. Oxidative DNA damage and its repair in rat spleen following subchronic aniline exposure. *Toxicol Appl Pharmacol* 233:247-253, 2008.
129. Yang Y, Yang Y, Xu Y, Lick SD, Awasthi YC, Boor PJ. Endothelial Glutathione-S-Transferase A4-4 Protects Against Oxidative Stress and Modulates iNOS Expression through NF- κ B Translocation. *Toxicol. Appl. Pharmacol.* 230: 187-196, 2008.
130. Lick SD, Vaidya S, Kollar AC, Boor PJ, Vertrees RA. Peri-operative alemtuzumab (Campath-1H) and plasmapheresis for high-PRA positive lymphocyte crossmatch heart transplant: a strategy to shorten left ventricular assist device support. *J Heart Lung Transplant.* 2008 Sep 27. (9):1036-9 Epub 2008 Jul 26.
131. Jackson LN, Chen LA, Larson SA, Silva SR, Rychahou PG, Boor PJ, Li J, DeFreitas G, Stafford WL, Townsend CM Jr, Evers BM. Development and characterization of a novel in vivo model of carcinoid syndrome. *Clin. Canc. Res.* 15(8): 2747-2755, 2009.
132. Xu Y, Gong B, Yang Y, Awasthi YC, Boor PJ. Adenovirus-Mediated Overexpression of Glutathione-S-transferase Mitigates Transplant Arteriosclerosis in Rabbit Carotid Allografts. *Transplantation.* 89(4):409-16, 2010
133. Wang G, Ma H, Boor PJ, Sadagopa Ramanujam VM, Ansari GAS, Khan MF. Up-regulation of heme oxygenase-1 in rat spleen following aniline exposure. *Free Radic Biol Med* 48:513-518, 2010.
134. Kaphalia BS, Bhopale KK, Kondraganti S, Wu H, Boor PJ, Ansari GAS. Pancreatic injury in hepatic alcohol dehydrogenase-deficient deer mice after subchronic exposure to ethanol. *Toxicol Appl Pharmacol.* 246(3):154-162, 2010.
135. Treumann S, Schneider S, Gröters S, Moore NP, Boor PJ. Spontaneous occurrence of dissecting aneurysms in the region of the ductus arteriosus in 4 day old rats. *Toxicol Pathol* 39:969-974, 2011.
136. Fernando H, Bhopale KK, Boor PJ, Ansari GAS, Kaphalia BS. Hepatic lipid profiling of deer mice fed ethanol using ^1H and ^{31}P NMR spectroscopy: A dose-dependent subchronic study. *Toxicol Appl Pharmacol.* 264:361–369, 2012.
137. Gong B, Ma L, Liu Y, Gog Q, Shelite T, et al. Rickettsiae induce microvascular hyperpermeability via phosphorylation of VE-Cadherins: Evidence from atomic force microscopy and biochemical studies. *PLoS Negl Trop Dis* 6(6): doi:10.1371/journal.pntd. 0001699.

B. OTHER:

Letters and Editorials:

1. Boor PJ. "The Last Puritan" - reply to a Conscientious Student (Letter to the Editor) *New Engl. J. Med.* 284(16): 923, 1971.
2. Boor PJ. "Infarct Size Measurement" - (Letter to the Editor). *Circulation* 60: 966-967, 1979.
3. Boor PJ. "Amines and the Heart" - (Invited Editorial). *Arch Pathol. Lab. Med.* 111: 930-932, 1987.

Book Reviews:

1. *Cardiovascular Pathophysiology*, GG Ahumada (Ed.), Oxford University Press, reviewed in Arch Pathol 111: 1183, 1987.
2. *Cardiovascular Toxicology*, (2nd Edition), D Acosta, Jr (Ed.) Raven Press, NY, reviewed in Toxicol Letters 67: 1993.

Book Chapters:

1. Boor PJ, Nelson TJ, Moslen MT, Chieco P, Ahmed AE, Reynolds ES. Allylamine cardiovascular toxicity: modulation of the monoamine oxidase system and biotransformation to acrolein. In: *Industrial and Environmental Xenobiotics*, edited by Gut I, Miroslav C, Plaa GL, Berlin Heidelberg, Springer-Verlag, pp. 369-375, 1981.
2. Boor PJ. Allylamine cardiotoxicity: Metabolism and Mechanism. In: *Advances in Experimental Medicine and Biology*, Vol. 161, "Myocardial Injury", edited by John J. Spitzer, Plenum Publishing Corporation, pp. 533-541, 1983.
3. Boor PJ. The Vascular Toxicity of Xenobiotics. In: *Cellular and Molecular Toxicity*, edited by D. Acosta, CRC Press, Boca Raton, pp 1-18, 1990.
4. Ansari GAS, Kaphalia BS, Boor PJ. Palmitoylpentachlorophenol: Formation and toxicity. In: *Biomembranes in Health and Disease*, Vol. 1., edited by AMK Kidwai, RK Upretic, PK Ray, Today and Tomorrow's, New Delhi, pp. 217-224, 1991.
5. Awasthi YC, Zimniak P, Awasthi S, Singhal SS, Srivastava SK, Piper JT, Chaubey M, Petersen DR, He Nong-gao, Sharma R, Singh SV, Khan MF, Ansari GAS, Boor PJ. A new group of glutathione S-transferases with protective role against lipid peroxidation. In: *Glutathione S-transferases: Structure, Function and Clinical Implications*, edited by NPE Vermeulen, GJ Mulder, H Nieuwenhuys, WHM Peters and PJ van Bladeren. Taylor and Francis, Great Britain, pp. 111-124, 1996.
6. Boor PJ, Langford SA. Pathogenesis of Medial Lesions caused by Chemical Agents. In: *Cardiovascular Toxicology*, Vol. 6., *Comprehensive Toxicology*, edited by IG Sipes, CA McQueen, AJ Gandolfi, Elsevier Science, pp. 309-332, 1997.
7. Boor PJ. Cardiovascular System. In: *Toxicology*, edited by H Marquardt, SG Schafer, R McClellan, F Welsch. Academic Press, pp. 587-599, 1999.
8. Boor PJ. The arterial media as a target of injury by chemicals. In *Cardiovascular Toxicology* 3rd Edition. D. Acosta, ed. Academic Press, San Diego, CA. pp 557-582, 2001.
9. Yang Y, Boor PJ. Glutathione-S-Transferases and Oxidative Injury of Cardiovascular Tissues. In *Toxicology of Glutathione Transferases*, edited by Y.C. Awasthi. Taylor & Francis, pp. 257-276, 2006.
10. Boor PJ, Conklin, DJ. The Arterial Media as a Target of Structural and Functional Injury by Chemicals in *Cardiovascular Toxicology*, 4th Edition, Daniel Acosta, ed; Informa Healthcare Publishing, New York, New York. pp. 667-691, 2008.
11. Boor PJ. Morphological Evaluation of the Heart and Blood Vessels. In: Charlene A. McQueen, *Comprehensive Toxicology*, volume 6, Oxford: Academic Press, pp. 161-177, 2010

C. ABSTRACTS AND PRESENTATIONS:

1. Boor PJ, Reynolds ES, Fishbein MC. A rapid planimetric method for quantitating left ventricular and necrotic myocardial mass. Am J Pathol 82:26a, 1976.

2. Szabo S, Reynolds ES, Komanicky P, Moslen MT, Boor PJ, Melby JC. Acute and chronic effects of nucleophilic alkenes on adrenal and thyroid gland structure and function. V International Congress of Endocrinology, Hamburg, Fed. Rep. Germany, pp.176, 1976.
3. Szabo S, Boor PJ, Oelwang MC, Bailey KA. Pathogenesis of acrylonitrile poisoning: Role of glutathione and coagulation changes. International Congress on Toxicology, Toronto, Canada, 1977.
4. Boor PJ, Reynolds ES. Myocardial necrosis induced by allylamine. Am J Pathol 86(2): 49a, 1977.
5. Boor PJ, Reynolds ES, Dammin GJ, Bailey KA. Allylamine-induced myocardial damage: Protection by monoamine oxidase inhibitors. Fed Proc 36(3): 397, 1977.
6. Reynolds ES, Moslen MT, Boor PJ, Bailey KA, Szabo S. Trichloroethylene-induced deactivation of liver endoplasmic reticulum and glutathione depletion. Toxicol Appl Pharmacol 41(1): 217, 1977.
7. Boor PJ, Moslen MT. Allylamine cardiotoxicity and cardiac MAO: Modulation by MAO inhibitors. Toxicol Appl Pharmacol 48(1): A94, 1979.
8. Nelson TJ, Boor PJ. Allylamine inhibition of monoamine oxidase: Antagonism by semicarbazide. Toxicol Appl Pharmacol 48(1):A18 1979.
9. Ahmed AE, Boor PJ, Patel K. Pharmacokinetics, distribution and binding of ¹⁴C-ring Melphalan. Fed. Proc. 38, 1979.
10. Boor PJ, Nelson TJ, Marchiondo A, Chieco P. Morphological localization of monoamine oxidase in normal and fibrotic rat heart. Circ 60: II-150, 1979.
11. Boor PJ, Nelson TJ. Hemodynamic and metabolic studies of allylamine-induced myocardial necrosis. Soc. Toxicol. Meetings, Washington, DC, 1980.
12. Boor PJ, Nelson TJ. *In vivo* evidence of metabolism of the cardiovascular toxin, allylamine, to acrolein. Toxicologist 1(1): 53, 1981.
13. Boor PJ, Nelson TJ. An improved method for the ultracytochemical demonstration of monoamine oxidase in rat heart. Meeting of the International Society for Heart Research, Burlington, Vermont, 1981.
14. Evans RD, Boor PJ. Reduced and oxidized glutathione alterations induced by the cardiovascular toxin, allylamine. Fed Proc 41(3): 380, 1982.
15. Boor PJ, Evans RD. Organ distribution, excretion, and toxicokinetics of the cardiovascular toxin, allylamine. Fed Proc 41(3): 446, 1982.
16. Ghanayem BI, Boor PJ, Ahmed AE. Acrylonitrile-induced gastrointestinal bleeding and necrosis in rats. Toxicologist 2(2): 110 and Pharmacologist 24(3): 110, 1982.
17. Boor PJ. Allylamine Cardiotoxicity: Metabolism and Mechanism. Invited presentation for the International Society for Heart Research, American Section, New Orleans, LA. J Molec Cell Cardiol 14(Suppl. 1): 21, 1982.
18. Ghanayem BI, Boor PJ, Ahmed AE. Gastric glutathione depletion mediates acrylonitrile-induced gastric ulceration. The Toxicologist, 3:41. (Awarded honorable mention, Hoffman-LaRoche Graduate Student Award for meritorious research, Society of Toxicology Meeting, Las Vegas, 1983).

19. Boor PJ. Allylamine Cardiotoxicity: Ultrastructural lesions. Proceedings of the First Annual Meeting of the Florida Society for Electron Microscopy, pp 25, 1983.
20. Doudar S, Boor PJ, Ahmed AE, Reynolds ES. Potentiation of the hepatotoxic effect of acetaminophen by prior administration of salicylate in mice. *Pharmacologist* 25: 887, 1983.
21. Boor PJ, Ferrans VJ. Ultrastructural lesions in acute and chronic allylamine-induced cardiomyopathy. *J Molec Cell Cardiol* 15(Suppl 4): 21, 1983.
22. Chieco P, Boor PJ, Biagi GL, Contelli-Forti G. Metodologie Microfotometriche Nell' Analisi di Reazioni Istochimiche in Tossicologia. XIX Congresso della Socita' Italiana D'Istochimica, Perugia, Italy, October, 1983.
23. Kretschmer NW, Boor PJ, el-Azhary RA, Reynolds ES, Ahmed AE. Study of bile ducts in portal areas and common bile duct in CCNU hepato-toxicity. *Lab Invest* 50: 32A, 1984.
24. Hysmith, RM, Boor PJ. Subcellular distribution of ¹⁴C-allylamine in rat aorta. *J. Molec Cell Cardiol* 16(Suppl. 1): 19, 1984.
25. Boor PJ, Kretschmer NW. Increased DNA synthesis in the heart during acute allylamine cardiotoxicity. *J Molec Cell Cardiol* 16(Suppl 1): 8, 1984.
26. Sklar JL, Boor PJ. Allylamine and acrolein toxicity in perfused rat heart. 26th National Student Research Forum, pp. 43, 1985.
27. Arnold JR, Hysmith RM, Boor PJ. Ultracytochemical demonstration of monoamine oxidase (MAO) in rat heart and aorta. *J Molec Cell Cardiol* 17(Suppl 2): 4A, 1985.
28. Hysmith RM, Arnold JR, Boor PJ. *In vitro* vascular cytotoxicity in response to the cardiovascular toxin allylamine. *J Molec Cell Cardiol* 17(Suppl 2): 37A, 1985.
29. Anderson PG, Boor PJ, Digerness SB, Bishop SP. Characterization of acute allylamine cardiotoxicity using the isolated perfused rat heart model. Veterinary Pathology Meeting, Denver, CO, December, 1985.
30. Hysmith RM, Welch TK, Boor PJ. Inhibition of uridine uptake in cultured vascular smooth muscle cells as a rapid, sublethal cytotoxicity assay for cardiovascular toxins. *The Toxicologist* 6: 205, 1986.
31. Arnold JR, Harrison RL, Hysmith RM, Boor PJ. An improved "floating sheet" method for ultracytochemical preparation of cultured cells for toxic studies. *The Toxicologist* 6: 303,
32. Boor PJ, Sklar JL, Anderson PG. Allylamine toxicity in perfused rat hearts. *The Toxicologist* 6: 201, 1986.
33. Boor PJ. Mechanisms of aliphatic amine cardiovascular toxicity. Gordon Conference (invited speaker), New Hampshire, August, 1986.
34. Stout LC, Boor PJ. Proliferative myointimal cell lesions on mitral valve chordae. Presented at the 11th Annual Hugh Lofland Conference on Arterial Wall Metabolism, May 13-16, Bolton's Landing, New York, 1986.
35. Stout LC, Boor PJ. Myofibroblastic proliferation on mitral valve chordae tendineae. A distinctive lesion associated with alcoholic liver disease. *Lab Invest* 56: 77A, 1987.

36. Boor PJ, Hysmith RM, Sanduja R. Metabolism of the cardiovascular toxin allylamine by the vascular enzyme benzylamine oxidase. *Lab Invest* 56: 8A, 1987.
37. Boor PJ, Sanduja R, Hysmith RM, Ansari GAS. Allylamine cardiovascular toxicity: *In vivo* evidence of metabolism to acrolein. *The Toxicologist* 7: 93, 1987.
38. Sanduja R, Boor PJ. *In vivo* effect of allylamine on myocardial creatinine phosphate and adenosine nucleotides determined by HPLC and ³¹P-NMR. *J Molec Cell Cardiol* 19 (Suppl.IV): 80, 1987.
39. Hysmith RM, Boor PJ. A novel phenotype transforming protein isolated from injured aortic smooth muscle cells. *J Molec Cell Cardiol* 19(Suppl. IV): 2, 1987.
40. Kumar D, Boor PJ. Allylamine and β -aminopropionitrile acute aortic necrosis in rats. Presented at the Texas Society of Pathologists, January 29, 1988.
41. Kumar D, Boor PJ. Allylamine and β -aminopropionitrile-induced acute vascular lesions in rats. *Lab Invest* 58: 51A, 1988.
42. Sanduja R, Sordahl LA, Boor PJ. *In vivo* effect of allylamine on high energy phosphates determined by HPLC and ³¹P-NMR. Presented at the American Heart Association Galveston-Houston Conference for Cardiovascular Research, February 1988.
43. Boor PJ, Hysmith RM, Sanduja R. Toxic metabolism by semicarbazide sensitive amine oxidase of porcine smooth muscle cells. (3rd Amine Oxidases International Workshop, pp. 129-130, Florence, Italy, September 1, 1988) *Pharmacol. Res. Commun.* 20 (Suppl. 4):173-175, 1988.
44. Boor PJ, Kumar D, Trent MB, Chieco P. Toxic vascular smooth muscle degeneration and necrosis: synergism of two aliphatic amines. *Proceedings of the VIII Congress of the Italian Society of Toxicology*, pp. 19, 1989.
45. Chieco P, Melchiorri C, Boor PJ. Damaged mitochondrial function in aorta wall following treatment with allylamine and β -aminopropionitrile. *VIII Congress of the Italian Society of Toxicology*, pp. 43, 1989.
46. Boor PJ. The vascular toxicity of xenobiotics (Invited presentation to the American Society for Pharmacology and Experimental Therapeutics). *The Pharmacologist* 31: 110, 1989.
47. Boor PJ, Trent MB, Lyles GA, Ansari GAS. Methylamine metabolism to formaldehyde by a vascular enzyme. *The Toxicologist* 10: 31, 1990.
48. Trent MB, Kumar D, Boor PJ. *In vivo* effects of allylamine and β -aminopropionitrile on lysyl oxidase and semicarbazide-sensitive amine oxidase. *The Toxicologist* 10: 32, 1990.
49. Tao M, Tipnis UR, Boor PJ. Purification and characterization of semicarbazide-sensitive amine oxidase from porcine aorta. *The Toxicologist* 10: 32, 1990.
50. Boor PJ. Basic Concepts of Vascular Toxicology (Invited presentation in the Continuing Education Course "Target Organ Toxicity" for the Society of Toxicology) Miami Beach, 1990.
51. Awasthi S, Trent MB, Boor PJ. Protective effect of semicarbazide on allylamine induced lipid peroxidation in aorta mitochondria. *Gulf Coast Society of Toxicology*, 1990.
52. Boor PJ. Chemical mediators of injury to arterial smooth muscle. *World Health Organization Meeting on Toxic Oil Syndrome*, Geneva, Switzerland, 1990.

53. Tipnis UR, Trent MB, Boor PJ. Impairment in the secretion of atrial natriuretic peptide by inhibition of polyamine synthesis. *FASEB J* 5: A672, 1991.
54. Tipnis UR, Boor PJ, Brown PJ. Allylamine-induced loss of fibronectin receptors in rat aorta. *Toxicologist* 11: 336, 1991.
55. Boor PJ, Pagnoni M, Chieco P, Trent MB, Awasthi S. Histo-chemical and chemical study of allylamine + β -aminopropionitrile vascular toxicity. *Toxicologist* 11: 336, 1991.
56. Awasthi S, Boor PJ. Oxidative stress and lipid peroxidation in acute allylamine-induced cardiovascular toxicity. *Toxicologist* 11: 337, 1991.
57. Hackstadt T, Moos A, Boor PJ. Experimental Q Fever Endocarditis, Presented at the Ninth Sesqui-Annual Meeting of American Society for Rickettsiology and Rickettsial Diseases, Galveston, Texas, May 1-5, 1991.
58. Tipnis UR, Boor PJ. Putrescine restores the basal and stimulated secretion atrial natriuretic peptide inhibited by Difluoromethylornithine. Presented at the American Physiology Society Am. Soc. Physiol. 34:262, 1991.
59. Ansari GAS, Kaphalia BS, Khan MF, Boor PJ. Fatty acid conjugates of xenobiotics: formation and toxicity. 2nd Congress of Toxicology in Developing Countries, New Delhi, India, November 24-28, 1991.
60. Khan MF, Kaphalia BS, Boor PJ, Ansari GAS. Subchronic toxicity of aniline hydrochloride in rats. *FASEB J* 6(5): A1913, 1992.
61. Trent MB, Tipnis UR, Kumar D, Boor PJ. Is atrial natriuretic factor involved in allylamine and β -aminopropionitrile induced diuretic effects? *The Toxicologist*, 12: 145, 1992.
62. Kaphalia BS, Khan MF, Boor PJ, Ansari GAS. Toxicity evaluation of 2-chloroethyl linoleate in rats. *The Toxicologist* 12: 382, 1992.
63. Boor PJ. United States and Canadian Academy of Pathology Specialty Conference: "Cardiovascular Pathology", presented at the USCAP Meeting, March 19, 1992, Atlanta, GA.
64. Kumar D, Trent MB, Boor PJ. Allylamine (AA) & β -aminopropionitrile (β APN)-induced aortic medial necrosis: Possible mechanism of synergism. *The Toxicologist* 13(1): 310, 1993.
65. Boor PJ. Toxicity of Primary Amines to the Vascular Media. Presented at the Society of Toxicology Annual Meeting in the Symposium "Chemically-induced vascular injury", *The Toxicologist* 13(1): 18, 1993.
66. Gowda A, Kronenberg M, Motamedi M, Johnston A, Boor PJ, Rastegar S, Miller, G. Use of intravascular ultrasound for characterizing the mechanical properties of arteries. 11th Annual meeting on Biomedical Engineering Research, Houston, TX, Feb. 13-15, 1993.
67. Tipnis UR, Haile C, Boor PJ, Gutkowska J. Polyamine regulation of atrial natriuretic peptide in cultured cardiocytes. *Journal of Molecular and Cellular Cardiology*, 25(III): 223, 1993.
68. Misra P, Trent MB, Boor PJ. Growth characteristics of cultured vascular smooth muscle cells (VSMC) in rats of different ages. 1993 Annual Meeting of the Gulf Coast Chapter of the Society of Toxicology, Galveston, TX, November 18-20, 1993.
69. Wait JB, Trent MB, Boor PJ. The role of semicarbazide-sensitive amine oxidase (SSAO) in vascular development. *Toxicologist*, 14: 377, 1994.

70. Adegboyega P, Haque AK, Boor PJ. Acute myocytolysis: A useful marker of myocardial ischemia in sudden cardiac death. 1994 Annual Meeting of the United States and Canadian Academy of Pathology, 1994.
71. Ware DL, Motamedi M, Pohl J, Bell A, Boor PJ. First report on application of diode laser for photocoagulation of canine myocardium. The International Society for Optical Engineering, Los Angeles, CA, January 22-29, 1994.
72. Khan MF, Boor PJ, Kaphalia BS, Ansari GAS. Splenic toxicity of linoleic acid anilide and its hydrolysis products: Evidence of iron overload. *Toxicologist*, 14: 396, 1994.
73. Ibrahim MA, Kronenberg MW, Boor PJ, Gojer B, Ahmad M, Motamedi M. Atherectomy and angioplasty improve compliance and reduce thickness of iliac arteries - an *in vivo* ultrasound study. *Circulation* 90, No. 4, Part 2: I-534, 1994.
74. Ware DL, Boor PJ, Motamedi M. Diode laser ablation of ventricular myocardium: Lesion morphology and arrhythmia risk. North American Society of Pacing and Electrophysiology, 16 Annual Scientific Sessions, December 1, 1994.
75. Tipnis UR, Haile C, Boor PJ. Role of ornithine decarboxylase in cardiac hypertrophy. *J. Mol Cell Cardiol* 26(VII): 59, 1994.
76. Boor PJ. Pathophysiology of Environmental Vascular Toxins; Plenary Session to the American College of Veterinary Pathologists, Montreal, Quebec, Canada, November, 1994.
77. Misra P, Srivastava SK, Singhal SS, Awasthi S, Awasthi YC, Boor PJ. Glutathione-S-Transferase (GST) 8-8 is localized in smooth muscle cells of rat aorta and is induced in an experimental model of atherosclerosis. Presented in the Young Investigators Scientific Session of the Society for Cardiovascular Pathology, US Cap Meeting, Toronto, Canada, 1995.
78. Awasthi YC, Zimniak P, Srivastava SK, Awasthi S, Piper JT, Petersen DR, Sharma R, Khan MF, Ansari GAS, Boor PJ. Induction of a new group of glutathione S-transferase, involved in protection mechanisms against lipid peroxidation, by allylamine and iron. *ISSX Proceedings* 7: 50, 1995.
79. Ware DL, Boor PJ, Motamedi M. Intramyocardial laser photocoagulation of the left ventricle: A Novel Technique for Treatment of Ventricular tachycardia. *Circulation* 92 (Supplement I): I-683, 1995.
80. Stout L, Langford SD and Boor PJ. Semicarbazide-Sensitive Amine Oxidase Activity in Young, Aged, and Hyperthyroid Rat Tissues. University of Texas Medical Branch Summer Student Research Forum, Galveston, TX, August, 1996.
81. Langford SD, Balakumaran A, Trent MB and Boor PJ. Inhibition of Semicarbazide-Sensitive Amine Oxidase Activity: Possible Functional Consequences. *FASEB J.* 10(6):A1015, 1996.
82. Boor PJ, Langford SD, Balakumaran A, and Trent MB. Toxin-Induced Models of Aortic Injury: The Role of Amine Oxidases in Collagen and Elastin Alterations. New York Academy of Sciences. Conference on Abdominal Aortic Aneurysm, New York, NY 1996.
83. Langford SD, Trent MB, and Boor PJ. Effects of Inhibiting Semicarbazide-Sensitive Amine Oxidase on Extracellular Matrix. *Toxicologist*, 30(1):338, 1996.
84. Khan MF, Gu Y, Alcock NW, Boor PJ and Ansari GAS. Oxidative Stress in Splenotoxicity of Aniline. *Toxicologist*, 30(1):339, 1996.
85. Awasthi YC, Zimniak P, Awasthi S, Singhal SS, Srivastava SK, Piper JT, Chaubey M, Peterson DR,

- He N-G, Sharma R, Singh SV, Khan MF, Ansari GAS, Boor PJ. A new group of glutathione S-transferase with protective role against lipid peroxidation. In: Proceedings of International Workshop on Glutathione-S- transferases, Taylor & Francis, pp 111-124, 1996.
86. Wait JB, Balakumaran A, Bukoski RD, Langford SD, Trent MB and Boor PJ. Aortic Elastin and Aging. Symposium on Aging, University of Texas Medical Branch at Galveston. Galveston, Texas, July, 1996.
87. Ware DL, Motamedi M, Boor PJ, Yang C, Gowda A and Bell B. Percutaneous, Slow Intramyocardial Heating: Electrogram and Tissue Changes Associated with Direct Midmyocardial Photocoagulation. *Pacing Clin. Electrophysiol.* 20:11-161, 1997.
88. Ware DL, Motamedi M, Boor PJ, Yang C, Gowda A, and Bell B. Delivery of Intramyocardial, Diffused Laser Light for Ventricular Tachycardia. Society of Photo-Optical Instrumentation Engineers Proceedings 2130:150-155, 1997.
89. Langford SD, Trent MB, Conklin DC, He NG, and Boor PJ. Methylamine Toxicity in Rat Vascular Smooth Muscle Cells. *FASEB J.* 11(3):A546, 1997.
90. Conklin DJ and Boor PJ. Cardiovascular Effects of Allylamine and β -Aminopropionitrile Exposure in Rats. *FASEB J.* 11(3):A261, 1997.
91. Langford SD, Trent MB, He NG, Conklin DJ, Balakumaran A, Wait JB and Boor PJ. Importance of a Novel Enzyme to Vascular Pathology and Aging. International Symposium on Coronary Thrombosis and Atherosclerosis, December 4-5, 1997.
92. Langford SD, Trent MB, Boor PJ. Semicarbazide-Sensitive Amine Oxidase (SSAO), Extracellular Matrices and the Aging Aorta. *FASEB*, April 18-22, 1998.
93. He NG, Singhal SS, Awasthi S, Trent MB and Boor PJ. The Role of Glutathione S-Transferase Isoform GST8-8 in the Defense Against Reactive Electrophiles by Vascular Smooth Muscle Cells. *Toxicologist* 42:203, 1998.
94. Boor PJ, He NG, Singhal SS and Awasthi S. Role of Glutathione S-Transferase8-8 in Allylamine-Resistance of Smooth Muscle Cells *In Vitro*. *Toxicologist* 42:203, 1998.
95. Conklin DJ, Langford SD and Boor PJ. Serum and Cellular Semicarbazide-Sensitive Amine Oxidase in Amine Cytotoxicity and Metabolism. *Toxicologist* 42:203, 1998.
96. Boor PJ, Langford SD, Trent MB and Balakumaran A. Developmental Vasculotoxicity Associated with Inhibition of Semicarbazide-Sensitive Amine Oxidases. *Toxicologist* 48:278, 1999.
97. Langford SD, Trent MB and Boor PJ. Collagen and Elastin Deposition by Vascular Smooth Muscle Cells in Response to inhibition of Semicarbazide-Sensitive Amine Oxidase. *Toxicologist* 48:297, 1999.
98. Amparan D, Trent MB, and Boor PJ. Semicarbazide-sensitive Amine Oxidase Activity in Whole Rat Aortic Rings. Symposium of the Summer Undergraduate Research Program, University of Texas Medical Branch at Galveston. Galveston, Texas, August 12, 1999.
99. Vertrees RA, Deyo DJ, Quast M, Wei G, Lightfoot KM, Boor PJ, Zwischenberger JB. An Orthotopic Xenotransplanted Murine Model of lung Cancer. *J Invest Surg* (Sept 4):226, 1999.
100. Vertrees RA, Zwischenberger JB, Boor PJ, Pencil SD. Oncogenic Ras reduces HSC70 resulting in defective thermotolerance with an increase in programmed cell death. *FASEB J* 792, 1999.

101. Boor PJ, Trent MB, Langford SD. A model of aortic aneurysm: involvement of tissue amine oxidase and aging. Abstracts of American Federation for Aging Research Meeting. p26, 2000.
102. Adam D, Boor PJ, Callingham B, Carpeno C, Feve B, Zorzano A, Yu PH, Tipton K. Physiological and pathological implications of semicarbazide-sensitive amine oxidase (SSAO), also known as vascular adhesion molecule (VAP-1). 6th Internet World Congress for Biomedical Sciences (INABIS 2000), #21, p13, 2000.
103. Boor PJ and Langford SD. Manipulation of semicarbazide-sensitive amine oxidase (SSAO) in *in vivo* models. 6th Internet World Congress for Biomedical Sciences (INABIS 2000), #101, p14, 2000.
104. Vertrees RA, Zwischenberger JB, Pencil SD, Boor PJ. Heat shock destroys RAF-1 and induces apoptosis in lung cancer cells. (FASEB-ASIP-2001).
105. Vertrees RA, Zwischenberger JB, Boor PJ. The synergistic effect of hyperthermia and Gemcitabine on lung cancer cells. (AACR-2001).
106. Waxman S., Sriram V., Ashitkov T., Hu Z., Medford D., Boor PJ. Safety of Poly-N-Acetylglucosamine in the Pericardial Space: A Novel Vehicle for Local Cardiac Drug Delivery. American Heart Association Meeting, 2001.
107. Waxman S, Sriram V, Ashitkov TV, Hu Z, Medford DJ, Boor PJ, Demcheva M, Vournakis JN. Safety of poly-N-acetylglucosamine in the pericardial space: A novel vehicle for local cardiac drug delivery. *Circulation* 104(2):729, 2001.
108. Vertrees RA, Zwischenberger JB, Boor PJ. Optimized Synergistic Effect when Hyperthermia Precedes 2', 2' Difluorodeoxycytidine (dFdC, Gemcitabine) by 24 Hours. *AACR J*, 2001, #1973.
109. Vertrees RA, Zwischenberger JB, Pencil SD, Boor PJ. Hyperthermia Attenuates Expression of Raf-1 Inducing Apoptosis in Ras-Transformed Lung Cells. *FASEB J*, 2001, #15131.
110. Leeth A, Vertrees R, Logrono R, Boor PJ, Zwischenberger JB. Evaluation of Combination Hyperthermia and Gemcitabine Therapy in Treating Ectopic Human Lung Cancer. American Burn Association Meeting, April 2002.
111. Vertrees RA, Leeth A, Zwischenberger JB, Chumley C, Martinez JA, Boor PJ. Hyperthermia-Induced Death Receptor-Mediated Apoptosis by Suppression of RAF-1 Activation in Non Small Cell Lung Cancer Cells. *Am Assoc CA Res*, 2002; 43, #4421, p. 891.
112. Boor PJ, Hawkins HK, Trent MB, Yang Y, Herndon DN. A Role for the Connective Tissue Enzyme, Semicarbazide-Sensitive Amine Oxidase (SSAO), in Wound Healing. *Proceedings of the American Burn Association* 23(2):S127, 2002.
113. Leeth A, Vertrees RA, Logrono R, Boor PJ, Zwischenberger JB. Evaluation of Combination Hyperthermia and Gemcitabine Therapy in Treating Ectopic Human Lung Cancer. *Proceed Am Assoc CA Res*, 2002, 43, #4698, p. 949.
114. Boor PJ, Hawkins HK, Trent MB, Yang Y, Herndon DN. Human Tissue Studies on the Connective Tissue Enzyme, Semicarbazide-Sensitive Amine Oxidase (SSAO) in Burn Wound Healing. *J Surg Res* 107, 308, 2002.
115. Dugas TR, Jones BC, Mifflin RC, Santa Cruz V, Boor PJ, Kanz MK. Vascular Smooth Muscle Cell Proliferation Following Chronic, Intermittent Exposure to 4,4'-Methylenedianiline. *Toxicologist* 66(S-1):288, 2003.

116. Wu X, Boor PJ, Khan MF. Immunochemical Detection and Localization of Malondialdehyde-Protein Adducts in the Spleens of Aniline-Treated Rats. *Toxicologist* 66(S1):90, 2003.
117. Conklin DJ, Kranig DA, Mueller HR, Johnson G, Wiechmann R, Trent MB, Boor PJ. Allylamine Induces Vasospasm in Human Coronary Artery Bypass Graft Blood Vessels In Vitro: Role of Semicarbazide-Sensitive Amine Oxidase. *Toxicologist* 72(S-1):36, 2003.
118. Yang, Y, Yang Y, He N, Trent MB, Awasthi Y, Boor PJ. The Role of Glutathione S-transferase A4-4 in Endothelial Cell Defense Against Cytotoxicity Due to Oxidative Stress. *Toxicologist* 72(S-1):286, 2003.
119. Khan MF, Wu X, Boor PJ, Ansari GS. Nitrotyrosine and Splenic Toxicity of Aniline. *Toxicologist* 72(S-1):78, 2003.
120. Vertrees RA, Zwischenberger JB, Leeth AM, Boor PJ, Popov V, McCarthy M, Goodwin T. Development of a Three-Dimensional Model of Normal and Malignant Lung Cells. *Am. Assoc. for Cancer Res.*, #3055, 2004.
121. Leeth AM, Vertrees RA, Goluszko E, Boor PJ, Zwischenberger JB. Oncogenic Ras Increases Bax Expression in Human Lung Cells in a p53 Dependent Mechanism Via the JNK Pathway. *Am. Assoc. for Cancer Res.*, #5018, 2004.
122. Dwivedi S, Sharma R, Sharma A, Awasthi YC, Boor PJ. MGSTA4-4 null (-/-) Mice Alters the Course of CCl₄ Induced Hepatotoxicity. *Toxicologist* 78(S-1): 306, #1487, 2004.
123. Yang Y, Yang Y, Trent MB, Lick SD, Zimniak P, Awasthi YC, Boor PJ. Mechanism of Glutathione S-transferase A4-4 in Protection Against Oxidative Stress Induced Apoptosis in Endothelium. *Toxicologist* 78(S-1): 306, #1486, 2004.
124. Gong B, Trent MB, Oberhauser AF, Srivastava D, Boor PJ. A Developmental Model of Dissecting Aortic Aneurysm. *Endothelium* 10(6): 371, 2004.
125. Boor PJ, Hawkins HK, Trent MB, Xue HH, McCauley RL, Herndon DN. The Connective Tissue Enzyme, Semicarbazide-Sensitive Amine Oxidase (SSAO), in Burn Wound Healing. *J Burn Care Rehab* 25:S149, #205, 2004.
126. Conklin DJ, Cowley H, Xiong N, Johnson G, Wiechmann R, Sayre L, Trent MB, Boor PJ. Allylamine-induced Vasospasm In Vitro: Role of Acrolein, Hydrogen Peroxide, Semicarbazide-Sensitive Amine Oxidase Activity and Extracellular Ca⁺⁺. *Toxicologist*, 2004.
127. Yang Y, Yang Y, Awasthi YC, Boor PJ. Glutathione-S-Transferase A4-4 Modulates iNOS Expression Through NF- κ B Translocation. *Toxicologist* 84(S-1): 374, 2005.
128. Gong B, Sun J, Vargas G, Boor PJ. Morphologic Imaging of Extracellular Matrix in Chemical-Induced Developmental Dissecting Aortic Aneurysm Using Multiphoton Florescence and Second Harmonic Generation Microscopy. *Toxicologist* 84(S-1): 168-169, 2005.
129. Bhopale K, Wu H, Boor P, Ansari GA, Kaphalia BS. Pancreatic and Hepatic Ethanol Toxicity in Hepatic Alcohol Dehydrogenase Deficient Deer Mice: Morphological and Biochemical Characterization. *Toxicologist* 84(S-1): 318, 2005.
130. Wang L, Yang Y, Xu Y, Boor PJ. Reducing Oxidative Stress Through Manipulating Glutathione-S-Transferases May Prevent the Development of Tolerance to Nitroglycerin. *Circulation* 112:17, 2005.
131. Boor PJ, Yang, Y, Gong B. Role of the Media in Vascular Injury:Atherosclerosis and Dissection, pg 47. The Society of Toxicologic Pathology, 24th Annual Meeting, Washington, D.C., 2005.

132. Dwivedi S, Yang Y, Awasthi YC, Boor PJ. Transfection with Human GSTA4-4 Enhances Resistance to Oxidative Stress and Activation of Growth Factors in Vascular Smooth Muscle Cells Via Bad Pathway. *Toxicologist* 90(1): 104, 2006.
133. Gong B, Wang L, Sun J, Vargas G, Boor PJ. Quantitative Morphologic Assessment on Extracellular Matrix in Chemical-Induced Developmental Dissecting Aortic Aneurysm using Multiphoton Florescence and Second Harmonic Generation Microscopy. *Toxicologist* 90(1): 60, 2006.
134. Yang Y, Yang Y, Xu Y, Popov VL, Boor PJ. Immunolocalization of GSTA4-4 in Endothelial Cells and Possible Role in Protection against Apoptosis and Atherosclerosis. *Toxicologist* 102(1):410, 2008.
135. Ma H, Wang J, Abdel-Rahman S, Boor P, Khan M. Oxidative DNA Damage and its Repair in the Spleens of Rats Exposed to Aniline. *Toxicologist* 102(1): 15, 2008.
136. Kondraganti S, Boor PJ, Khan FM, Konig R, Kaphalia BS, Ansari GA. Apoptosis Precedes Multi-Organ Inflammation in MRL+/+ Mice Chronically Exposed to TCE. *Toxicologist* 102(1): 71, 2008.
137. Xu Y, Yang Y, Ruiz J, Boor PJ. A dissecting aortic aneurysm model induced by N-(2-aminoethyl) ethanalamine in rat. *The Toxicologist* 108 (1): 47, 2009
138. Yang, Y., Xu, Y., Sinha, M., Luxon, B. and Boor, P.J. RNA interference of HGSTA4in human aortic vascular smooth muscle cells results in significant changes in gene expression. *The Toxicologist* 108 (1): 323, 2009
139. Kondraganti, S., Boor, P.J., Khan, M.F., Konig, R., Kaphalia, B.S., Ansari, G.A.S. Compromised kupffer cells could lead to TCE-mediated SLE-like disease. *The Toxicologist* 108 (1): 240, 2009.
140. Fernando, H., Kondraganti, S., Bhopale, K., Neerathilingam, M., Volk, D E., Kaphalia, B.S., Luxon, B.A., Boor, P.J. and Ansari, G.A.S. Lipidomics of alcohol-induced fatty liver. *The Toxicologist* 108 (1): 240, 2009.
141. Ma, H., Wang, J., Boor, P.J. and Khan, M.F. Increased formation of MDA-DNA adducts in aniline-induced splenic toxicity. *The Toxicologist* 108 (1): 345, 2009.
142. Khan MF, Ma H, Wang J, Ansari GAS, Boor PJ. Heme oxygenase-1 induction in rat spleen following aniline exposure. *Experimental Biology 2009, New Orleans, LA, April 18-22, 2009* (Abstract # LB402).
143. Kondraganti S, Khan S, Boor PJ, Khan MF, Konig R, Kaphalia BS, Ansari GAS. Trichloroethene induces apoptosis in HepG2 cells and impairs clearance of apoptotic cells by RAW cells. *49th Annual Meeting of Society of Toxicology, Salt Lake City, March 7-11, 2010.*
144. Wang J, Ma H, Boor PJ, Sadagopa Ramanujam VM, Ansari GAS, Khan MF. Up-regulation of heme oxygenase-1 in rat spleen following aniline exposure. *49th Annual Meeting of Society of Toxicology, Salt Lake City, March 7-11, 2010.*
145. Ma H, Wang J, Hazra TK, Abdel-Rahman S, Boor PJ, Khan MF. Induction of the base excision repair glycosylase NIEL1/2 in aniline-induced splenic toxicity. *49th Annual Meeting of Society of Toxicology, Salt Lake City, March 7-11, 2010.*
146. Xu Y, Treumann S, Rossbacher R, Schneider S, Boor PJ. Extracellular matrix changes in the

dissecting aortic aneurysm caused by N-(2-aminoethyl) ethanolamine in rat. 49th Annual Meeting of Society of Toxicology, Salt Lake City, March 7-11, 2010.

PUBLICATIONS - IN PRESS:

1. Cooke RK, Cowan, DF, Boor PJ, Duarte AG. Incomplete pulmonary artery dissection in a patient with pulmonary hypertension. Submitted to Chest.
2. Havins J, Lick S, Boor PJ, Ahmad, M. Real-time 3D transesophageal echocardiography in the assessment of partial posteromedial papillary muscle rupture. Submitted to Circ. Imaging
3. Kondraganti S, König R, Boor PJ, Khan S, Kaphalia BS, Khan MF, Ansari GAS. Mechanistic evaluation of trichloroethene-mediated autoimmune hepatitis-like disease in female MRL+/+ mice. The Open Toxicol. J. 2012. (In Press).



PUBLIC VERIFICATION / PHYSICIAN PROFILE

PHYSICIAN

NAME: GERALD ALAN CAMPBELL MD

DATE: 08/21/2013

THE INFORMATION IN THIS BOX HAS BEEN VERIFIED
BY THE TEXAS MEDICAL BOARD

Date of Birth: 1947

License Number: G9717 Full Medical License

Issuance Date: 06/10/1986

Expiration Date of Physician's Registration Permit: 02/28/2015

Registration Status: ACTIVE

Registration Date: 06/10/1986

Disciplinary Status: NONE

Disciplinary Date: NONE

Licensure Status: NONE

Licensure Date: NONE

Medical School of Graduation:

At the time of licensure, TMB verified the physician's graduation from medical school as follows:
UNIV OF TEXAS, SOUTHWESTERN MED SCH, DALLAS

Medical School Graduation Year: 1977

TMB Filings, Actions and License Restrictions

The Texas Medical Board has the following board actions against this physician. (This may include any formal complaints filed by TMB, as well as petitions and/or responses related to licensure contested matters, at the State Office of Administrative Hearings.)

NONE

Investigations by TMB of Medical Malpractice

Section 164.201 of the Act requires that: the board review information relating to a physician against whom three or more malpractice claims have been reported within a five year period. Based on these reviews, the following investigations were conducted with the listed resolutions.

NONE

Status History

Status history contains entries for any updates to the individual's registration, licensure or disciplinary status types (beginning with 1/1/78, when the board's records were first automated). Entries are in reverse chronological order; new entries of each type supersede the previous entry of that same type. These records do not display status type. Should you have any questions, please contact our Customer Information Center at 512-305-7030 or verificic@tmb.state.tx.us

Status Code: AC**Effective Date:** 06/10/1986**Description:** ACTIVE

THE INFORMATION IN THIS BOX WAS REPORTED BY THE LICENSEE AND
HAS NOT BEEN VERIFIED BY THE TEXAS MEDICAL BOARD

Gender: MALE***Ethnicity:** WHITE**Race:** WHITE

* We are in the process of transitioning from the current ethnic origin values to federal standards for race and Hispanic origin. The transition period will allow time for individuals to submit updated race and Hispanic origin data to the TMB.

Place of Birth: KENTUCKY**Current Primary Practice Address:**

UTMB

301 UNIVERSITY BLVD

GALVESTON , TX 77555-0750

Years of Active Practice in the U.S. or Canada:

The physician reports that he/she has actively practiced medicine in the United States or Canada for **29** year(s).

Years of Active Practice in Texas:

The physician reports that, of the above years he/she has actively practiced in the State of Texas for **25** year(s).

Specialty Board Certification

The physician reports that he/she holds the following specialty certifications issued by a board that is a member of the American Board of Medical Specialties or the Bureau of Osteopathic Specialists:

Specialty Certification: AMERICAN BOARD OF PTH/ANATOMIC PATHOLOGY**Date:** 1986**Specialty Certification:** AMERICAN BOARD OF PTH/NEUROPATHOLOGY**Date:** 1986

Primary Specialty

The physician reports his/her primary practice is in the area of NEURO-PATHOLOGY.

Secondary Specialty

The physician reports his/her secondary practice is in the area of ANATOMIC PATHOLOGY.

Name, Location and Graduation Date of All Medical Schools Attended

Name: UNIV TX SOUTHWESTERN

Location: DALLAS, TEXAS, USA

Graduation Date: 06/1977

Graduate Medical Education In The United States Or Canada

Program Name: DUKE UNIVERSITY MEDICAL CENTER

Location: DURHAM, NC

Begin Date: 07/1981

Type: RESIDENCY

End Date: 07/1985

Specialty: ANATOMIC PATHOLOGY AND NEUROPATHOLOGY

Hospital Privileges

The physician reports that he/she has hospital privileges in the following in the State of Texas:

Hospital: UNIVERISTY OF TEXAS MEDICAL BRANCH

Location: GALVESTON, TEXAS

Utilization Review

The physician did not report whether he/she provides utilization review.

NONE REPORTED

Patient Services

Accessibility: The physician reports that the patient service area **is** accessible to persons with disabilities as defined by federal law.

Language Translation Services: The physician reports that the following language translation services are provided for patients: SPANISH, OTHERS

Medicaid Participant: The physician reports that he/she **does** participate in the Medicaid program.

Awards, Honors, Publications and Academic Appointments

Optional Information

The physician may optionally report descriptions of up to five such honors and has reported the following:

Description: FELLOW, COLLEGE OF AMERICAN PATHOLOGISTS

Description: PROFESSOR OF PATHOLOGY, UTMB

Description: FELLOW, AMERICAN SOCIETY OF CLINICAL PATHOLOGISTS

Malpractice Information

Section 154.006(b)(16) of the Act requires that: a physician profile display a description of any medical malpractice claim against the physician, not including a description of any offers by the physician to settle the claim, for which the physician was found liable, a jury awarded monetary damages to the claimant, and the award has been determined to be final and not subject to further appeal. The physician has the following reportable claims.

Description: NONE

Criminal History

Self-Reported Criminal Offenses:The physician is required to report a description of (1) "any conviction for an offense constituting a felony, a Class A or Class B misdemeanor, or a Class C misdemeanor involving moral turpitude" and (2) "any charges reported to the board to which the physician has pleaded no contest, for which the physician is the subject of deferred adjudication or pretrial diversion, or in which sufficient facts of guilt were found and the matter was continued by a court of competent jurisdiction."

The physician has reported the following:

Description: NONE

Criminal history information is also obtained by TMB from the Texas Department of Public Safety. Resulting action, if any, will be reported under the TMB Action and Non-Disciplinary Restrictions section above.

Disciplinary Actions By Other State Medical Boards

The physician has reported the following:

Description: NONE

Physician Assistant Supervision

To obtain
primary source
verifications,
click name

Description: NONE

Advanced Practice Nurse Delegation

To obtain
primary source
verifications,
click name

Description: NONE

Summary of all License/Permit Types

Issue Date:

06/10/1986

Type:

LICENSED PHYSICIAN

[Agency](#) | [Contact Us](#) | [Employment](#) | [Compact w/ Texans](#) | [Open Records](#) | [Privacy Policy](#) | [Site Map](#) |
[Search TX State Sites](#) | [TX Homeland Security](#) | [TX Occupations Code](#) |
[Texas.gov](#) | [Poison Control Center Services](#) | [Accessibility Policy](#)

Gerald A. Campbell, Ph.D., M.D.

LICENSURE INFORMATION:

02/01/1986 – 02/28/2013	State of Texas Medical License No. G9717 active
02/01/1984 – 01/31/1996	State of North Carolina Medical License No. 28848 Expired 1/31/96, inactive
10/01/1978 – 09/30/1995	State of Maryland Medical License No. D21663 Expired 9/30/95, inactive

PROFESSIONAL AND TEACHING EXPERIENCE:

8/2009-Present	Director, Anatomic Pathology Department of Pathology The University of Texas Medical Branch Galveston, Texas
9/2008-Present	Professor with Tenure Department of Pathology The University of Texas Medical Branch Galveston, Texas
9/2000-8/2008	Associate Professor with Tenure Department of Pathology The University of Texas Medical Branch Galveston, Texas
9/2006-Present	Assistant Director (Administrative responsibility in absence of Director and Associate Director; responsibility for digital imaging and archiving systems) Autopsy Division The University of Texas Medical Branch Galveston, Texas
9/1993 – 8/2000	Associate Professor Department of Pathology The University of Texas Medical Branch Galveston, Texas

Gerald A. Campbell, Ph.D., M.D.

1987 - Present	Member of Graduate Faculty Experimental Pathology Graduate Program Graduate School for Biomedical Sciences University of Texas Medical Branch Galveston, Texas
8/1/1985 – 12/31/98	Director, Division of Neuropathology Department of Pathology The University of Texas Medical Branch Galveston, Texas
8/85 - 8/1993	Assistant Professor Department of Pathology The University of Texas Medical Branch Galveston, Texas
1/1985 - 7/1985	Research Associate Department of Pathology Duke University Medical Center Durham, NC 27710
7/1981 - 12/1984	Resident in Anatomic Pathology and Neuropathology Duke University Medical Center Durham, NC 27710
8/1978 - 6/1981	Staff Fellow Laboratory of Preclinical Studies National Institute on Alcohol Abuse and Alcoholism 12501 Washington Avenue Rockville, MD 20852
6/1977 – 7/1978	Staff Fellow Laboratory of Neuropharmacology National Institute of Mental Health St. Elizabeth's Hospital Washington, DC
6/1972 - 8/1974	Research Assistant Physics Department The University of Texas at Austin Austin, TX

Gerald A. Campbell, Ph.D., M.D.

- | | |
|-------------|--|
| 1998 – 1999 | John Sealy Foundation Endowment Grant 2504-98, PI: Reuben Matalon, M.D., Ph.D.
“Knock-out mouse for Canavan disease”
Co-investigator |
| 1999 - 2004 | NIH-RO1 NS38562-01. PI: Reuben Matalon, M.D., Ph.D.
“Knock-out mouse for Canavan disease”
Co-investigator |

COMMITTEE RESPONSIBILITIES:

UTMB:

- | | |
|----------------|--|
| 2008 | Clinical Neuroscience Development Task Force |
| 2004-Present | Pathology and Host Defense Course Committee and Co-director |
| 1994 - Present | Neuroscience and Human Behavior Course Committee |
| 1998 – 1999 | Academic Technology Committee |
| 1997 - 1999 | New Curriculum Task Force, Return to Basic Science Design Committee |
| 1991 - 1996 | IPE Course Committee |
| 1991 - 1992 | Graduate School Subcommittee (of Curriculum Committee) for Ethics Course |
| 1990 - 1995 | Alternate Curriculum (ILT) Design Task Force |
| 9/90 | Representative, UTMB Faculty Retreat |
| 1987 - 1989 | Search Committee for Chairman of Pediatrics |

Departmental:

- | | |
|----------------|---|
| 2008 | Department Academic Review Self-Study Clinical Sub-Committee |
| 2003 - Present | Pathology Education Committee |
| 2003 - Present | Pathology Residency Advisory Committee |
| 2002 | Experimental Pathology Graduate Program, Pathobiology Course Committee |
| 2002 | Neuropathogenesis Program Planning Committee |
| 2000 - 2001 | Department Academic Review Self-Study Committee |
| 2000 - Present | Experimental Pathology Graduate Program, Curriculum and Academic Planning Committee |
| 1999 - Present | Pathology Quality Management Executive Committee (co-chair) |
| 1999 - Present | Pathology Quality Management Committee |
| 1997 - 2000 | Experimental Pathology Graduate Program, Awards Committee |
| 1996 - 2000 | Pathology Oversight Committee |

Gerald A. Campbell, Ph.D., M.D.

1994 - 1997	Pathology Medical School Course Committee
1991 - 1995	Pathology Quality Management Committee
1987 - 1995	Experimental Pathology Graduate Program, Academic Planning Committee
1987 - 1996	Experimental Pathology Graduate Program, Curriculum and Program Review Committee
1988 - 1991	Chair, subcommittee for Experimental Pathology Doctoral Program Proposal (co-author of proposal)
1990	Pathology Patient Services Strategic Planning Task Force

TEACHING RESPONSIBILITIES (UTMB):

Medical School:

2004 – Present	Pathology and Host Defense Course: Co-director and member of course committee, lab instructor (currently 12 contact hours/term)
1986 – Present	Neuroscience and Human Behavior Course: Instructor (lecture, laboratory, small group) and Member of Course Committee (currently 33 contact hours/term)
2000 – Present	Dermatology, Hematology and Musculoskeletal System Course: Lecture on histology and pathology of muscle, bones and joints (currently 4 contact hours/term)
1993 – Present	Director, Neuropathology Elective for 4 th year Medical Students (4 week elective) (est. avg. 10-30 contact hours/year)
1997 – 2004	Director, Neuropathology component of 4 th year Neurology course. (2 week selective) (20-40 contact hours/year)
1985 – 1999	Pathology Course: Lecturer and laboratory instructor (responsible for content and organization of laboratory block on neuropathology)

Residency Program: (Pathology, Neurology, Neurosurgery, Ophthalmology)

1993 - Present	Eye pathology lectures for ophthalmology residents and participation in Ophthalmology conferences (13 contact hours/year)
1985 - Present	Lectures to pathology residents (current: 3 contact hours/year)

Gerald A. Campbell, Ph.D., M.D.

1985 - Present	Small group neuropathology microscopic slide sessions (current: 50 contact hours/year)
1987 - Present	Neuroscience and neuropathology review lectures for neurology and neurosurgery residents (2-4 contact hours/year)
1985 - Present	Individual teaching - resident rotations in neuropathology (est. avg. contact hours: 20-50/year)

Graduate School:

2004 – Present	Teaching in Pathology: Co-director
2004 – 2007	Pathogenesis of Infectious Disease (PATH 6360) (1 lecture contact hour/year)
1999 – 2003	Cell Biology Course: Small Group Discussion Leader (2 facilitation contact hours/term)
2000 – 2003	Principles of CNS Sensory-Motor Integration Module (BBSC 6114): Co-Director and Lecturer (2 contact hours/term)
1998 – 2003	Pathobiology of Disease (PATH 6435): Block Coordinator and Lecturer (4 contact hours/term)
1994 – 2008	Neuroscience Course: Small Group Discussion Leader for MD/PhD Program enrichment (2 contact hours/term)
1986 – 1999	Introduction to Research (PATH 6210): Lecturer
1989 – 1997	Fundamentals of Pathology (PATH 6504): Course Director/Co-Director and Lecturer

Student Supervision:

2005 - 2007	Jinying Yan – neuroscience graduate student Role: Ph.D. committee member (Supervisor: Dr. Willis) Thesis title: The role of substance P and its signaling pathways in central sensitization.
2004 - 2005	Slobodon Paessler – experimental pathology graduate student, Role: Ph.D. committee member and co-mentor (Supervisor: Dr. Weaver) Thesis title: Venezuelan equine encephalitis virus pathogenesis and vaccine development.
1998 - 2003	Bi-Hung Peng – experimental pathology graduate student Role: Mentor and supervisor for Ph.D. thesis. Thesis title: Characterization of a structural domain of human occludin responsible for binding to tight junction scaffolding proteins.

Gerald A. Campbell, Ph.D., M.D.

- 1999 - 2002 Shannon Schmura Martin– experimental pathology graduate student
Role: Ph.D. committee member (Supervisor: Dr. Grafe)
Project topic: Involvement of poly (ADP-ribose) polymerase in the progression of cell death in a model of perinatal hypoxic-ischemic brain injury,
- 1999 - 2001 Carl Saab – neuroscience graduate student
Role: Ph.D. committee member (Supervisor: Dr. Willis)
Thesis title: The role of cerebellum in the regulation of nociception.
- 1996 - 2001 Vicente Santa Cruz – experimental pathology graduate student,
Role: Ph.D. committee member (Supervisor: Dr. Kanz)
Project topic: Methylene dianiline biliary toxicity.
- 1995 - 2000 Arun Balakumaran – experimental pathology graduate student
Role: Ph.D. committee member (Supervisor: Dr. Moslen)
Project title: Calcium channel blockers and thymic apoptosis
- 1995 - 1998 Hong Xie – experimental pathology graduate student
Role: Ph.D. committee member (Supervisor: Dr. Barrett)
Thesis title: Mutations in the genome of yellow fever 17D-204 vaccine virus accumulate in the non-structural protein genes.
- 1994 - 1997 Bi-Hung Peng – experimental pathology graduate student
Role: Mentor and supervisor for master’s thesis.
Thesis title: Role of astrocytes in the clearance albumin after blood-brain barrier injury.
- 1993 - 1996 Suzanne Woodward – experimental pathology graduate student
Role: Ph.D. committee member (Supervisor: Dr. Moslen)
Thesis title: Biliary secretion of marker solutes and proteins by rats with 1,1-dichloroethylene-induced bile canalicular injury.
- 1993 - 1994 P. Stroemer - neuroscience program graduate student
Role: Ph.D. committee member (Supervisor: Dr. Hulsebosch)
Thesis title: Axonal remodeling and behavioral recovery following cortical infarction.

Gerald A. Campbell, Ph.D., M.D.

- 1992 - 1993 Diana Yin – pathology graduate student
Role: Master’s degree committee member (Supervisor: Dr. Moslen)
Thesis title: Age and alcoholism related changes in seminiferous tubules and detoxification enzymes of human testes.
- 1993 P. Misra - pathology graduate student
Role: Supervisor for research rotation
Project topic: Immunohistochemical investigation of c-fos activation in brain during alcohol withdrawal.
- 1992 - 1993 H. Balasubramanian - pathology graduate student
Role: Supervisor for research rotation
Project topic: Effects of alcohol dependence and withdrawal on enkephalin receptor activity.
- 1992 - 1993 Russell Clark - first year allied health student
Role: Supervisor for research work under work-study program
Project topic: Patterns of Purkinje cell loss in cerebellar vermis in human alcoholics, postmortem analysis of brain tissue.
- 1992 Leonard Velsor - pathology graduate student
Role: Supervisor for research rotation
Project topic: immunohistochemical investigation of c-fos activation in brain during alcohol withdrawal.
- 1990 - 1991 Michael Walter - first year medical student
Role: Supervisor for research work under work-study program and NIH Summer Research Program (1991)
Project topic: Development rat alcohol withdrawal model in rat.

MEMBERSHIP IN SCIENTIFIC AND PROFESSIONAL SOCIETIES:

(* denotes elected membership):

- 1886 - Present American Association for the Advancement of Science
1987 - Present Galveston County Medical Society
1987 - Present Texas Medical Association
1987 - Present American Society of Clinical Pathologists *
1987 - Present Sigma Xi Scientific Research Society *
1988 - Present Texas Society of Pathologists
1988 - Present American Association of Neuropathologists *
1990 - Present International Society of Neuropathology

Gerald A. Campbell, Ph.D., M.D.

1991 - Present	American Society for Investigative Pathology, Inc. *
1991 - Present	Society for Neuroscience *
2003 – Present	American Society for Biochemistry and Molecular Biology *
2006 - Present	American Physical Society

HONORS:

1969	Phi Beta Kappa
1969	B.S. with Highest Distinction
1969	Woodrow Wilson Honorary Fellow
1969	National Science Foundation Fellow

UTMB Teaching Awards:

Resident/Fellow Education:

2000-2001	“Best Anatomic Pathology Faculty Award”
2003-2004	“Best Anatomic Pathology Faculty Award”
2006-2007	“Appreciation Award for Outstanding Dedication and Commitment to Resident and Fellow Education”

ADDITIONAL INFORMATION:

Editorial Board Member:

7/93 - 8/99	Journal of Neuropathology and Experimental Neurology, MN Hart, Editor
-------------	--

Journal Article Reviews:

2005	Acta Neuropathologica (1 article)
2004 - 2006	Cellular and Molecular Life Sciences (4 articles)
1998 - 2007	Clinical Neuropathology (2 articles)
2005	Emerging Infectious Diseases (1 article)
2002	Experimental Brain Research (1 article)
2005 - 2007	International Journal of Developmental Neuroscience (2 articles)
1991 - 2007	Journal of Neuropathology and Experimental Neurology (more than 30 articles)
1990 - 1992	Journal of Neurosurgery (2 articles)
2006	Pediatric and Developmental Pathology (1 article)

Gerald A. Campbell, Ph.D., M.D.

Ad hoc Grant Reviews:

1991 - 1992

Ad hoc member, Neuroscience and Behavior
Subcommittee, NIAAA

Clinical Laboratory Inspection:

2000

CAP Inspector, UTMB Team; Neuromuscular Laboratory,
Washington University, St. Louis, Missouri.

Gerald A. Campbell, Ph.D., M.D.

PUBLISHED:

ARTICLES IN PEER-REVIEWED JOURNALS:

1. Campbell, G.A.; Matzner, R.A. A model for peaking of galactic gravitational radiation. *J. Math. Phys.* 14:1-6; 1973.
2. Campbell, G.A.; Crawford, I.L. A gated electronic switch for stimulation and recording with a single electrode. *Brain Res. Bull.* 5:485-486; 1980.
3. Campbell, G.A.; Eckardt, M.J.; Majchrowicz, E.; Marietta, C.A.; Weight, F.F. Ethanol - withdrawal syndrome associated with both general and localized increases in glucose uptake in rat brain. *Brain Res.* 237:517-522; 1982.
4. Piatt, J.H.; Campbell, G.A. Pineal region meningioma: report of two cases and literature review. *Neurosurg.* 12:369-376; 1983.
5. Abou-Donia, M.B.; Makkawy, H.M.; Campbell, G.A. Pattern of neurotoxicity of n-hexane, methyl n-butyl ketone, 2,5-hexanediol, and 2,5 hexanedione alone and in combination with O-ethyl O-4-nitrophenyl phenylphosphonothioate in hens. *J. Toxicol. Environ. Health* 16:85-100; 1985.
6. Abou-Donia, M.B.; Lapadula, D.M.; Campbell, G.A.; Abdo, K.M. The joint neurotoxic action of inhaled methyl butyl ketone vapor and dermally applied O-Ethyl O-4-nitrophenyl phenylphosphonothioate in hens: potentiating effect. *Toxicol. Applied Pharmacol.* 79:69-82; 1985.
7. Lapadula, D.M.; Patton, S.E.; Campbell, G.A.; Abou-Donia, M.B. Characterization of delayed neurotoxicity in the mouse following chronic oral administration of tri-o-cresyl phosphate. *Toxicol. Applied Pharmacol.* 79:83-90; 1985.
8. Abou-Donia, M.B.; Lapadula, D.M.; Campbell, G.A.; Timmons, P.R. The synergism of n-hexane neurotoxicity by methyl isobutyl ketone following subchronic (90 days) inhalation in hens: induction of hepatic microsomal cytochrome P-450. *Toxicol. Applied Pharmacol.* 81:1-16; 1985.
9. Campbell, G.A.; Eckardt, M.J.; Weight, F.F. Dopaminergic mechanisms in subthalamic nucleus of rat: analysis using horseradish peroxidase and microiontophoresis. *Brain Res.* 333:261-270; 1985.
10. Eckardt, M.J.; Campbell, G.A.; Marietta, C.A.; Majchrowicz, E.; Wixon, H.N.; Weight, F.F. Cerebral 2-deoxyglucose uptake in rats during ethanol withdrawal and postwithdrawal. *Brain Res.* 366:1-9; 1986.

Gerald A. Campbell, Ph.D., M.D.

11. Piatt, J.H.; Campbell, G.A.; Oakes, W.J. Papillary meningioma of the oculomotor nerve in an infant. Case report. *J. Neurosurg.* 64:808-812; 1986.
12. Marietta, C.A.; Eckardt, M.J.; Campbell, G.A.; Majchrowicz, E.; Weight, F.F. Glucose uptake in brain during withdrawal from ethanol, phenobarbital, and diazepam. *Alcohol. Clin. Exp. Res.* 10:1-4; 1986.
13. Shyn, P.B.; Campbell, G.A.; Guinto, F.C.; Crofford, M.J. Primary intracranial ependymoblastoma presenting as spinal cord compression due to metastasis. *Child's Nerv. Syst.* 2:323-325; 1986.
14. Lapadula, D.M.; Tilson, H.A.; Campbell, G.A.; Abou-Donia, M.B. Neurotoxic effects of combined treatment of 2,5-hexanedione and triethyllead chloride. *J. Toxicol. Environ. Health* 21:483-492; 1987.
15. Somkuti, S.G.; Tilson, H.A.; Brown, H.R.; Campbell, G.A.; Lapadula, D.M.; Abou-Donia, M.B. Lack of delayed neurotoxic effect after tri-o-cresyl phosphate treatment in male Fischer 344 rats: biochemical, neurobehavioral, and neuropathological studies. *Fundam. Appl. Toxicol.* 10:199-205; 1988.
16. Eckardt, M.M.; Campbell, G.A.; Marietta, C.A.; Majchrowicz, E.; Weight, F.F. Acute ethanol administration selectively alters localized cerebral glucose metabolism. *Brain Res.* 444:53-58; 1988.
17. Bradley, R.H.; Kent, T.A.; Eisenberg, H.M.; Quast, M.J.; Ward, G.A.; Campbell, G.A.; Hillman, G. Middle cerebral artery occlusion in rats studied by magnetic resonance imaging. *Stroke* 20:1032-1036; 1989.
18. Bhat, H.; Kanz, M.F.; Campbell, G.A.; Ansari, G.A.S. Ninety day subchronic toxicity study of chloroacetic acids in rats. *Fundam. Appl. Toxicol.* 17:240-253; 1991.
19. Seidel, M.F.; Simard, J.M.; Hunter, S.F.; Campbell, G.A. Isolation of arteriolar microvessels and culture of smooth muscle cells from cerebral cortex of guinea pig. *Cell Tissue Res.* 265:579-587; 1991.
20. Eckardt, M.J.; Campbell, G.A.; Marietta, C.A.; Majchrowicz, E.; Rawlings, R.; Weight, F.F. Ethanol dependence and withdrawal selectively alter localized cerebral glucose utilization. *Brain Res.* 584:244-250; 1992.
21. McGinnis, M.R.; Campbell, G.A.; Gourley, W.K.; Lucia, H.L. Phaeohyphomycosis caused by *Bipolaris specifera*: an informative case. *Eur. J. Epidemiol.* 8:383-386; 1992.

Gerald A. Campbell, Ph.D., M.D.

22. Gelman, B.B.; Rodriguez-Wolf, M.G.; Wen, J.; Kumar, S.; Campbell G.A.; Herzog, N. Siderotic cerebral macrophages in the acquired immunodeficiency syndrome.
23. Yin, Y.M.; Haque, A.K.; Campbell, GA; Moslen, MT. Aging-associated declines in the antioxidant enzymes of human testis. *Adv. Exp. Med. Biol.* 366:418-419; 1994.
24. Jaffey, P.B.; To, G.T.; Xu, H-J.; Hu S-X.; Benedict, W.F.; Donoso, L.A.; Campbell, G.A. Retinoblastoma-like phenotype expressed in medulloblastomas. *J. Neuropathol. Exp. Neurol.* 54:664-672; 1995.
25. Cao, J.X.; Haolin, N.; Wills, M.R.; Campbell, G.A.; Sil, B.K.; Ryman, K.D.; Kitchen, I.; Barrett, A.D.T. Passage of Japanese encephalitis virus in HeLa cells results in attenuation of virulence in mice. *J. Gen. Virol.* 76:2757-2764; 1995.
26. Balakumaran, A.; Campbell, G.A.; Moslen, M.T. Calcium channel blockers induce thymic apoptosis in vivo in rats. *Toxicol. Appl. Pharmacol.* 139:122-127; 1996.
27. Jaffey, P.B.; Varma, S.; DeMay, R.M.; McLucas, E.J.; Campbell, G.A. Blast-like cells in the cerebrospinal fluid of young infants. *Am. J. Clin. Pathol.* 105:544-547; 1996.
28. Jaffey, P.B.; English, P.W.; Campbell, G.A.; Rubin, S.A.; Haque, A.K. Escherichia coli lobar pneumonia: fatal infection in a patient with mental retardation. *S. Med. J.* 89:628-630; 1996.
29. Ryman, K.D.; Xie, H.; Ledger, T.N.; Campbell, G.A.; Barrett, A.D.T. Antigenic variants of yellow fever virus with an altered neurovirulence phenotype in mice. *Virology* 230:376-380; 1997.
30. Zhang, W.; Khanna, P.; Chan, L.L.; Campbell, G.A.; Ansari, N.H. Diabetes-induced apoptosis in rat kidney. *Biochem. Molec. Med.* 61:58-62; 1997.
31. Xie, H.; Ryman, K.D.; Campbell, G.A.; Barrett A.D.T. Mutation in NS5 protein attenuates mouse neurovirulence of yellow fever 17D vaccine virus. *J. Gen. Virol.* 79:1895-1899; 1998.
32. Ryman, K.D.; Ledger, T.N.; Campbell, G.A.; Watowich, S.J.; Barrett A.D.T. Mutation in a 17D-204 vaccine substrain-specific envelope protein epitope alters the pathogenesis of yellow fever virus in mice. *Virology* 244:59-65; 1998.
33. Molina, C.P.; Hawkins, H.; Campbell, G.; Rowe, T.; Grafe, M. Case of the month: Congenital cerebral primitive neuroectodermal tumor (PNET). *Brain Pathol.* 9:605-606; 1999.
34. Agraharkar, A.; Gokhale, S.; Le, L.; Rajaraman, S.; Campbell, G.A. Cardiopulmonary manifestations of Henoch-Schonlein purpura. *Am. J. Kidney Dis.* 35: 319-322; 2000.

Gerald A. Campbell, Ph.D., M.D.

35. Nauta, H.J.W.; Soukup, V.M.; Fabian, R.H.; Lin, J.T.; Grady, J.J.; Williams, C.G.; Campbell, G.A.; Westlund, K.; Willis, W.D. Punctate midline myelotomy for the relief of visceral cancer pain. *J. Neurosurg.* 92:125-130; 2000.
36. Matalon, R.; Rady, P.L.; Platt, K.A.; Skinner, H.B.; Quast, M.J.; Campbell, G.A.; Matalon, K.; Ceci, J.D.; Tying, S.K.; Nehls, M.; Surendan, S.; Wei, J.; Ezell, E.L.; Szucs, S. Knock-out mouse for Canavan disease: a model for gene transfer to the central nervous system. *J. Gene Med.* 2:165-175; 2000.
37. Segal, E.I.; Tang, R.A.; Lee, A.G.; Roberts, D.I.; Campbell, G.A. Orbital apex lesion as the presenting manifestation of sarcoidosis. *J. Neuro-Ophthalmol.* 20:156-158; 2000.
38. Stuart, C.A.; Wen, G.; Peng, B.; Popov, V.L.; Hudnall, S.D.; Campbell, G.A. GLUT3 expression in human skeletal muscle. *Am. J. Physiol. Endocrinol. Metab.* 279:E855-E861; 2000.
39. Chen, J.W.; Lin, J.; Madamanchi, N.; Trier, T.T.; Campbell, G. Apoptosis occurs in a new model of thermal brain injury. *J. Biomed. Sci.* 7:459-465; 2000.
40. Tipnis, U.R.; He, G.Y.; Li, S.Z.; Campbell, G.; Boor, P.J. Attenuation of isoproterenol-mediated myocardial injury in rat by an inhibitor of polyamine synthesis. *Cardiovascular Pathol.* 9:273-280; 2000.
41. Choudhary, S.; Zhang, F.; Campbell, G.A.; Chan, L.L.; Thompson, E.B.; Ansari, N.H. Cellular lipid peroxidation end-products induce apoptosis in human lens epithelial cells. *Free Radic. Biol. Med.* 32(4):360-369; 2002.
42. Mansour, A.M.; Saad, A.J.; Haque, A.K.; Campbell, G.A.; Frangieh, G.T. Ocular pathology in acquired immunodeficiency syndrome. *Comp. Ther.* 28:155-159; 2002.
43. Molina, C.P.; Chaljub, G.; Campbell, G.A. Pathologic quiz case: A 37-year-old man with spinal cord compression. *Arch. Pathol. Lab. Med.*, 127:827-829; 2003.
44. Surendran, S.; Rady, P.L.; Michals-Matalon, K.; Quast, M.J.; Rassin, D.K.; Campbell, G.A.; Ezell, E.L.; Wei, J.; Tying, S.K.; Szucs, S.; Matalon, R. Expression of glutamate transporter, GABRA6, serine proteinase inhibitor 2 and low levels of glutamate and GABA in the brain of knock-out mouse for Canavan disease. *Brain Res. Bull.* 61(4):427-435; 2003
45. Matalon, R.; Surendran, S.; Rady, P.L., Quast, M.J.; Campbell, G.A.; Matalon, K.M.; Tying, S.K.; Peden, C.S.; Wei, J.; Ezell, E.L.; Muzyczka, N.; Mandel, R.J. Adeno-associated virus-mediated aspartoacylase gene transfer to the brain of knockout mouse for Canavan disease. *Mol. Ther.*, 7:580-7; 2003.

Gerald A. Campbell, Ph.D., M.D.

46. Raja, V.; Campbell, G.A. Unusual Cases Involving the CNS and Nasal Sinuses: CASE 2. Sinonasal Undifferentiated Carcinoma. *J. Clin. Oncol.*, 21:3877-3880; 2003
47. Peng, B.H.; Lee, J.C.; Campbell, G.A. In vitro protein complex formation with cytoskeleton anchoring domain of occludin identified by limited proteolysis. *J. Biol. Chem.* 278(49):49644-51; 2003.
48. Surendran, S.; Campbell, G.A.; Tying, S.K.; Matalon, K.; McDonald, J.D.; Matalon, R. High levels of orexin A in the brain of the mouse model for phenylketonuria: possible role of orexin A in hyperactivity seen in children with PKU. *Neurochem. Res.* 28:1891-1894; 2003.
49. Paessler, S.; Aguilar, P.; Anishchenko, M.; Wang, H.Q.; Aronson, J.; Campbell, G.A.; Cararra, A.S.; Weaver, S.C. The hamster as an animal model for eastern equine encephalitis--and its use in studies of virus entrance into the brain. *J. Infect. Dis.* 189:2072-2076; 2004.
50. Surendran, S.; Campbell, G.A.; Tying, S.K.; Matalon, R. Aspartoacylase gene knockout results in severe vacuolation in the white matter and gray matter of the spinal cord in the mouse. *Neurobiol. Dis.* 18:385-389; 2005.
51. Holbrook, M.R.; Aronson, J.F.; Campbell, G.A.; Jones, S.; Feldmann, H.; Barrett, A.D.T. An animal model for the tick-borne flavivirus Omsk hemorrhagic fever virus. *J. Infect. Dis.* 191:100-8; 2005.
52. Peng, B.H.; White, M.A.; Campbell, G.A.; Robert, J.J.; Lee, J.C.; Sutton, R.B. Crystallization and preliminary X-ray diffraction of the ZO-binding domain of human occludin. *Acta Cryst.* F61:369-371; 2005.
53. Ahmed, A.E.; Campbell, G.A.; Jacob, S. Neurological impairment in fetal mouse brain by drinking water disinfectant byproducts. *Neurotoxicol.* 26:633-640; 2005.
54. Ahmed, A.E.; Jacob, S.; Campbell, G.A.; Hassan, H.M.; Perez-Polo, J.R.; Johnson, K.M. Fetal Origin of Adverse Pregnancy Outcome: The Water Disinfectant Byproduct Chloroacetonitrile Induces Oxidative Stress and Apoptosis in Mouse Fetal Brain. *Brain Res. Dev. Brain Res.* 159:1-11; 2005.
55. Schneider, B.S.; Soong, L.; Girard, Y.A.; Campbell, G.A.; Mason, P.; Higgs, S. Potentiation of West Nile encephalitis by mosquito feeding. *Viral Immunol.* 19:74-82; 2006.
56. Matalon, R.; Surendran, S.; Campbell, G.A.; Michals-Matalon, K.; Tying, S.K.; Grady, J.; Cheng, S.; Kaye, E. Hyaluronidase increases the biodistribution of acid alpha-1,4 glucosidase in the muscle of Pompe disease mice: An approach to enhance the efficacy of enzyme replacement therapy. *Biochem. Biophys. Res. Commun.* 350(3):783-7; 2006.

Gerald A. Campbell, Ph.D., M.D.

57. Paessler, S.; Yun, N.E.; Judy, B.M.; Dziuba, N.; Grund, A.H.; Zacks, M.A.; Frolov, I.; Campbell, G.A.; Weaver, S.C.; Estes, D.M. Alpha-beta T cells provide protection against lethal encephalitis in the murine model of VEEV infection. *Virology* 367:307-23; 2007.
58. Hauck, E.F.; Vu, L.; Campbell, G.A.; Nauta, H.J. Intraventricular ganglioglioma. *J. Clin. Neurosci.* 15:1291-3; 2008.
59. Duarte, A.G.; Terminella, L.; Smith, J.T.; Myers, A.C.; Campbell, G.A.; Lick, S. Restoration of cough reflex in lung transplant recipients. *Chest* 134:310-16; 2008.
60. Gasco, J.; Franklin, B.; Rangel-Castilla, L.; Campbell, G.A.; Eltorkey, M.; Salinas, P. Primary angioleiomyoma of the cerebellum: A new location for a rare entity. Case report and literature review. *J. Neurosurg.* 110:670-4; 2008.
61. Zhang, M.; Shoeb, M.; Goswamy, J.; Liu, P.; Xiao, T. L.; Hogan, D.; Campbell, G. A.; and Ansari, N. H. Overexpression of aldehyde dehydrogenase 1A1 reduces oxidation-induced toxicity in SH-SY5Y neuroblastoma cells. *J. Neurosci. Res.* 88:686-694; 2010.
62. Zhang, M.; Shoeb, M.; Liu, P.; Xiao, T.; Hogan, D.; Wong, I. G.; Campbell, G. A.; and Ansari, N. H. Topical metal chelation therapy ameliorates oxidation-induced toxicity in diabetic cataract. *J. Toxicol. Environ. Health A* 74:380-391. 2011.

OTHER:

Dissertation

1. Campbell, G.A. The Optics of Relativistic Sources in a Spherically-Symmetric Gravitational Field. Dissertation, The University of Texas at Austin, January; 1975.

Reviews

1. Granwehr B.P.; Lillibridge K.M.; Higgs S.; Mason P.W.; Aronson J.F.; Campbell G.A.; Barrett A.D.T. West Nile virus: where are we now? *Lancet Infect. Dis.* 4:547-556; 2004.

Book Chapters

1. Beckman, J.S.; Campbell, G.A.; Hannan, C.J.; Karfias, C.S.; Freeman, B.A. Involvement of superoxide and xanthine oxidase with death due to cerebral ischemia-induced seizures in gerbils. In: *Superoxide and Superoxide Dismutase in Chemistry, Biology and Medicine, Proceedings of the 4th International Conference on Superoxide and Superoxide Dismutase, Rome, Italy, 1-6*

Gerald A. Campbell, Ph.D., M.D.

September, 1985, Rotilio G, ed., Elsevier Science Publishers, Amsterdam, pp. 602-607; 1986.

2. Campbell, G.A. The pathology of penetrating wounds of the brain and its enclosures. In: Aarabi B.; Kaufman H.H., eds. *Missile Wounds of the Head and Neck*, American Association of Neurological Surgeons, Park Ridge, Illinois, pp. 73-92; 1999.
3. Campbell, G.A. Imaging, image analysis and computer-assisted quantitation: applications for electronic imaging in pathology. In: Cowan D.F., ed. *Informatics for the Clinical Laboratory*. Springer Verlag, New York, 2002.

Book Review

1. Campbell, G.A. Book Review: Clinical Brain Imaging. J.C. Mazziotta and S. Gilman, eds., F.A. Davis, Philadelphia, 1992. *J. Neuropathol. Exp. Neurol.* 52:181; 1993.

ABSTRACTS:

1. Campbell, G.A.; Weight, F.F. Action of microiontophoretic administration of dopamine on subthalamic nucleus in the rat. *Society for Neuroscience Abstracts*, p.442; 1978.
2. Campbell, G.A.; Eckardt, M.J., Weight, F.F. Afferent connections to the subthalamic nucleus of rat studied with horseradish peroxidase. *Society for Neuroscience Abstracts*, p. 68; 1979.
3. Campbell, G.A.; Eckardt, M.J.; Majchrowicz, E.; Marietta, C.A.; Weight, F.F. Changes in glucose utilization in the brain during the withdrawal syndrome in ethanol-dependent rats. *Society for Neuroscience Abstracts*, p.313; 1981.
4. McLendon, R.E.; Campbell, G.A.; Coffey, C.E.; Vogel, F.S.; Burger, P.C. Multiple infarcts and Alzheimer's disease mimicking Huntington's disease. U.S. and Canadian Academy of Pathology, 1986. *Lab. Invest.* 54:41A; 1986.
5. Kumar, S.; Campbell, G.A. Early cerebrovascular changes in acquired immunodeficiency syndrome (AIDS): perivascular iron pigment deposition and mural thickening of parenchymal blood vessels. *Am. Assoc. Neuropathologists*, 1989. *J. Neuropathol. Exp. Neurol.* 48:315; 1989.
6. Gelman, B.B.; Rodriguez, M.G.; Campbell, G.A. Altered oligodendroglial iron proteins in human immunodeficiency virus infection. *Am. Assoc. Neuropathologists*, 1990. *J. Neuropathol. Exp. Neurol.* 49:325; 1990.
7. Saad, A.J.; Mansour, A.M.; Frangieh, G.; Haque, A.; Campbell, G.A. Ocular pathology in 27 autopsy cases of acquired immunodeficiency syndrome (AIDS). *A.R.V.O.*; 1991.

Gerald A. Campbell, Ph.D., M.D.

8. Klein, G.L.; Campbell, G.A.; Hodsman, A.B.; Strong, M.J.; Alcock, N.W.; Richardson, C.J.; Garruto, R.M. Histochemical detection of aluminum in bone but not in brain of infants on parenteral nutrition. Society for Pediatric Research, 1991. *Pediatric Research* 4:105A; 1991.
9. Yin, Y.M.; Campbell, G.A.; Haque, A.K.; Moslen M.T. Age related changes in seminiferous tubules and the detoxification enzymes in human testis. International Symposium on Free Radicals in Diagnostic Medicine, Buffalo, NY; 1993.
10. Yin; Y.M., Campbell G.A.; Haque A.K.; Moslen, M.T. Age and alcoholic related changes in seminiferous tubules and the detoxification enzymes in human testis. Annual Focus on Aging Meeting, Galveston, TX; 1993.
11. Jaffey, P.B.; To, G.T.; Donoso, L.A.; Campbell, G.A. Retinoblastomatous features in medulloblastoma. Am. Assoc. Neuropathologists, 1993. *J Neuropathol Exp Neurol* 52:325; 1993.
12. Balasubramanian, H.; Campbell, G.A.; Moslen, M.T. Induction of apoptosis in the thymus by 2-methoxyethanol: rapidity and dose-response in the male rat. Society of Toxicology; 1994.
13. Peng, B.-H.; Campbell, G.A. Cytomegalovirus infection correlates with blood-brain barrier injury in the acquired immunodeficiency syndrome (AIDS). Am. Assoc. Neuropathologists, 1995. *J. Neuropathol. Exp. Neurol.* 54:451; 1995.
14. Balakumaran, A.; Campbell, G.A.; Compton, R.; Moslen, M.T. The calcium channel blocker, diltiazem, is an apoptotic immunotoxin. Gulf Coast Society of Toxicology; 1996.
15. Ansari, N.H.; Zhang, W.; Chan, L.-N.; Campbell, G.A.; Ahmad, H. Role of free radicals in diabetic retinopathy. Tex-Mex Border Health Symposium; 1996.
16. Ansari, N.H.; Zhang, W.; Campbell, G.A.; Chan, L.L. Hyperglycemia-induced apoptosis. American Diabetes Association; 1996.
17. Ansari, N.H.; Zhang, W.; Campbell, G.A.; Chan, L.L. Hyperglycemia induces apoptosis: evaluation of cell death in diabetic rat tissues. Society of Toxicology; 1997.
18. Peng, B.-H.; Campbell, G.A. Serum albumin uptake by normal human astrocytes in culture. American Association of Neuropathologists; 1997.
19. Peng, B.-H.; Campbell, G.A. Serum albumin clearance by normal human astrocytes in culture. American Association of Neuropathologists; 1998.
20. Peng, B.-H.; Campbell, G.A. Tight junction development in cultured brain endothelial cells. American Association of Neuropathologists; 2000.

Gerald A. Campbell, Ph.D., M.D.

21. Stuart, C.A.; Wen, G.; Peng, B.-H.; Hudnall, S.D.; Campbell, G.A. Contributions from T-tubules and peripheral nerves to human muscle GLUT-3. *Diabetes* 49 (Suppl 1): A277; 2000.
22. Peng, B.H.; Lee, J.C.; Campbell, G.A. Cytoskeleton anchoring domain of occludin identified by limited proteolysis. 8th Structural Biology Symposium, UTMB, Galveston, TX, May, 2003.
23. Hernandez, L.; Gothreaux, P.; Collins, G.; Shih, L.; Campbell, G. Digital Pathological Image Analysis and Cell Segmentation. *Proc. IEEE Computational Systems Bioinformatics(CSB2005)*, p.398, and *Proc. Int. Workshop on Bioimage Data Mining & Informatics (CSB2005 Workshop & Posters)* p.373; 2005.
24. Zhang, M.; Xiao, T.; Campbell, G.A.; Ansari, N.H. A Novel Approach Towards Prevention of Oxidation-Induced Cataractogenesis. *A.R.V.O.*; 2006.
25. Hernandez, L.; Gothreaux, P.; Shih, L.; Campbell, G. Toward Real-Time Biopsy Image Analysis and Cell Segmentation. *International Conference on Image Processing, Computer Vision, & Pattern Recognition, Las Vegas, NV, June 2006.*
26. Barnhart, E.; Campbell, G.A. Hydrocephalus, a fatal complication of sarcoidosis. *College of American Pathologists Annual Meeting, San Diego, CA, September, 2006. Arch. Pathol. Lab. Med.* 130:1399, 2006.
27. Fuller, G.N.; Takei, H.; Aldape, K.D.; Cangelosi, J.C.; Campbell, G.A. The mitosis-specific antibody anti-phospho-histone H3 (pHH3) provides rapid reliable mitotic index quantitation for choroid plexus neoplasms. *Society for Neuro-Oncology, Orlando, FL, November, 2006.*
28. Crim, J.; Campbell, G.A. Adult T-cell leukemia and myelopathy in a patient with chronic HTLV-1 infection. *College of American Pathologists Annual Meeting, Chicago, IL, October, 2007.*
29. Tyler, R.D.; Saunders, G.; Jortner, B.; Righter, D.; Mandell, J.; Campbell, G.A. The case of the “wondering” goat. *36th annual Southeastern Veterinary Pathology Conference, University of Georgia Veterinary Diagnostic & Investigational Laboratory, Tifton, GA, May, 2008.*
30. Duarte, A.G.; Myers, A.C.; Campbell, G.A. Quantitative assessment of airway innervation in lung transplant recipients. *American Thoracic Society, May, 2008.*
31. Madhavarao, C.N., Arun, P., Szucs, S., Bhatia, G., Campbell, G.A., Matalon, R., Moffett, J.R., Mog, S., Hamilton, K.R., Grunberg, N.E., Namboodiri, A.M.A. *Translational Studies*

Gerald A. Campbell, Ph.D., M.D.

of Acetate Supplementation Using Glycerol triacetate as a Therapeutic Approach to Canavan Disease. American Academy of Neurology, Chicago, IL, April, 2008.

32. Chumakova, O.V.; Peng, B.H.; Zacks, M.A.; Campbell, G.A.; Yun, N.E.; Smith, J.N.; Smith, J.K.; Linde, N.S.; Linde, J.J.; Paessler, S. Early peramivir treatment prevents encephalitis in ferrets infected with highly pathogenic avian influenza A (H5N1) virus. American Society for Virology, Ithaca, NY, July, 2008.
33. Duarte, A.G.; Campbell, G.A.; Valentine, V.G.; Myers, A.C. Quantitative analysis of nerve density across airway anastomosis in lung transplant recipients. International Society for Heart and Lung Transplantation, Chicago, IL, April, 2010.
34. Duarte, A.G.; Campbell, G.A.; Valentine, V.G.; Myers, A.C. Increase in neural density across airway anastomosis associated with allograft age. American Thoracic Society, New Orleans, May, 2010.
35. Olar, A.; Tran, D.; Vidya, D.; Mehta, P.; Ellezam, B.; Mohila, C.A.; Campbell, G.A.; Powell, S.Z.; Fuller, G.N.; Aldape, K.D.; Adesina, A.M. PI3K/AKT pathway is preferentially activated in anaplastic pilocytic astrocytoma. USCAP, Vancouver, B.C., March, 2012.



PUBLIC VERIFICATION / PHYSICIAN PROFILE

PHYSICIAN

NAME: BENJAMIN BARUCH GELMAN MD **DATE:** 08/21/2013

**THE INFORMATION IN THIS BOX HAS BEEN VERIFIED
BY THE TEXAS MEDICAL BOARD**

Date of Birth: 1949

License Number: H5556 Full Medical License

Issuance Date: 06/13/1989

Expiration Date of Physician's Registration Permit: 08/31/2014

Registration Status: ACTIVE

Registration Date: 08/28/1989

Disciplinary Status: NONE

Disciplinary Date: NONE

Licensure Status: NONE

Licensure Date: NONE

Medical School of Graduation:

At the time of licensure, TMB verified the physician's graduation from medical school as follows:
UNIV OF CINCINNATI COLL OF MED, CINCINNATI

Medical School Graduation Year: 1983

TMB Filings, Actions and License Restrictions

The Texas Medical Board has the following board actions against this physician. (This may include any formal complaints filed by TMB, as well as petitions and/or responses related to licensure contested matters, at the State Office of Administrative Hearings.)

NONE

Investigations by TMB of Medical Malpractice

Section 164.201 of the Act requires that: the board review information relating to a physician against whom three or more malpractice claims have been reported within a five year period. Based on these reviews, the following investigations were conducted with the listed resolutions.

NONE

Status History

Status history contains entries for any updates to the individual's registration, licensure or disciplinary status types (beginning with 1/1/78, when the board's records were first automated). Entries are in reverse chronological order; new entries of each type supersede the previous entry of that same type. These records do not display status type. Should you have any questions, please contact our Customer Information Center at 512-305-7030 or verificic@tmb.state.tx.us

Status Code: AC**Effective Date:** 08/28/1989**Description:** ACTIVE**Status Code:** LI**Effective Date:** 06/13/1989**Description:** LICENSE ISSUED

THE INFORMATION IN THIS BOX WAS REPORTED BY THE LICENSEE AND
HAS NOT BEEN VERIFIED BY THE TEXAS MEDICAL BOARD

Gender: MALE***Ethnicity:** WHITE**Race:** WHITE

* We are in the process of transitioning from the current ethnic origin values to federal standards for race and Hispanic origin. The transition period will allow time for individuals to submit updated race and Hispanic origin data to the TMB.

Place of Birth: OHIO**Current Primary Practice Address:**

UTMB

DEPT OF PATHOLOGY, RT 0609

GALVESTON , TX 77555-0608

Years of Active Practice in the U.S. or Canada:

The physician reports that he/she has actively practiced medicine in the United States or Canada for **25** year(s).

Years of Active Practice in Texas:

The physician reports that, of the above years he/she has actively practiced in the State of Texas for **24** year(s).

Specialty Board Certification

The physician reports that he/she holds the following specialty certifications issued by a board that is a member of the American Board of Medical Specialties or the Bureau of Osteopathic Specialists:

Specialty Certification: AMERICAN BOARD OF PTH/ANATOMIC PATHOLOGY**Date:** 1988

Specialty Certification: AMERICAN BOARD OF PTH/NEUROPATHOLOGY

Date: 1988

Primary Specialty

The physician reports his/her primary practice is in the area of PATHOLOGY.

Secondary Specialty

The physician reports his/her secondary practice is in the area of NEURO-PATHOLOGY.

Name, Location and Graduation Date of All Medical Schools Attended

Name: UNIV CINCINNATI

Location: CINCINNATI,OHIO/USA

Graduation Date: 06/1983

Graduate Medical Education In The United States Or Canada

Program Name: UNIV N CAROLINA

Location: CHAPEL HILL, NC

Begin Date: 07/1983

Type: INTERNSHIP

End Date: 06/1984

Specialty: PATHOLOGY

Program Name: NONE

Location: CHAPEL HILL, NC

Begin Date: 07/1984

Type: RESIDENCY

End Date: 06/1986

Specialty: PATHOLOGY

Program Name: NONE

Location: NONE

Begin Date: 07/1986

Type: FELLOWSHIP

End Date: 06/1988

Specialty: NEUROPATHOLOGY

Hospital Privileges

The physician reports that he/she has hospital privileges in the following in the State of Texas:

Hospital: UTMB HOSPITALS

Location: GALVESTON

Utilization Review

The physician did not report whether he/she provides utilization review.

Patient Services

Accessibility: The physician reports that the patient service area **is** accessible to persons with disabilities as defined by federal law.

Language Translation Services: The physician did not report whether he/she provided any language translation services for patients.

Medicaid Participant: The physician reports that he/she **does** participate in the Medicaid program.

Awards, Honors, Publications and Academic Appointments

Optional Information

The physician may optionally report descriptions of up to five such honors and has reported the following:

Description: PROFESSOR OF PATHOLOGY UNIV TX MEDICAL BRANCH.

Description: DIRECTOR, TEXAS NEUROAIDS RESEARCH CENTER

Malpractice Information

Section 154.006(b)(16) of the Act requires that: a physician profile display a description of any medical malpractice claim against the physician, not including a description of any offers by the physician to settle the claim, for which the physician was found liable, a jury awarded monetary damages to the claimant, and the award has been determined to be final and not subject to further appeal. The physician has the following reportable claims.

Description: NONE

Criminal History

Self-Reported Criminal Offenses:The physician is required to report a description of (1) "any conviction for an offense constituting a felony, a Class A or Class B misdemeanor, or a Class C misdemeanor involving moral turpitude" and (2) "any charges reported to the board to which the physician has pleaded no contest, for which the physician is the subject of deferred adjudication or pretrial diversion, or in which sufficient facts of guilt were found and the matter was continued by a court of competent jurisdiction."

The physician has reported the following:

Description: NONE

Criminal history information is also obtained by TMB from the Texas

Department of Public Safety. Resulting action, if any, will be reported under the TMB Action and Non-Disciplinary Restrictions section above.

Disciplinary Actions By Other State Medical Boards

The physician has reported the following:

Description: NONE

Physician Assistant Supervision

To obtain primary source verifications, click name

Description: NONE

Advanced Practice Nurse Delegation

To obtain primary source verifications, click name

Description: NONE

Summary of all License/Permit Types

Issue Date:
06/13/1989

Type:
LICENSED PHYSICIAN

January 1, 2012

CURRICULUM VITAE

NAME: BENJAMIN B. GELMAN

PRESENT POSITIONS AND ADDRESS:

- Professor, Departments of Pathology, and Neuroscience and Cell Biology
The University of Texas Medical Branch (UTMB), Galveston, Texas 77550
- Director, Texas NeuroAIDS Research Center, UTMB
- Associate Director, Neuropathology Section, Department of Pathology, UTMB
- Member, Graduate School of Biomedical Sciences, UTMB
- Member, Neuroscience Graduate Program, UTMB
- Member, Center on Drug Addiction, UTMB
- Investigator, Center for AIDS Research (CFAR), Baylor College of Medicine

Department of Pathology, Route 0609
University of Texas Medical Branch
Galveston, Texas 77555-0609

BIOGRAPHICAL:

Date of Birth:

Place of Birth:

Home Address:

Citizenship:

Social Security:

Family:

[REDACTED]
Lorain, Ohio

[REDACTED]
USA

[REDACTED]
Married 1975, Diane A. Gruen. Three children, Jacob (1979),
Emily (1982), Allyson (1989)

Business Address:

Dept of Pathology Route 0609
University of Texas Medical Branch
Galveston, TX 77555-0609
Phone: (409)-772-5316
FAX: (409)-772-5220
bgelman@utmb.edu

Home Address:

[REDACTED]

EDUCATION:

- 1971 A.B. Ohio University, Athens, Ohio
 Major: Renaissance Literature; Minor: Biochemistry
- 1978 Ph.D. Department of Environmental Health
 University of Cincinnati College of Medicine, Cincinnati, Ohio
 Dissertation: Lead neurotoxicity and the free radical oxidation of
 biomembranes. Professor I.A. Michaelson, Supervisor
- 1979 Postdoctoral Fellow, Department of Biological Chemistry
 University of Cincinnati College of Medicine, Cincinnati, Ohio
 Professor E I Gruenstein, Supervisor
- 1983 M.D. University of Cincinnati College of Medicine, Cincinnati, Ohio

BOARD CERTIFICATION:

- 1984 Diplomate, National Board of Medical Examiners
- 1988 American Board of Pathology, Anatomic and Neuropathology

LICENSURE:

- 1987-present State of North Carolina License # 32369; expires 12/07
- 1989-present State of Texas License # H5556; expires 8/31/14

PROFESSIONAL AND TEACHING EXPERIENCE {AND DUTIES}:

- 2001-present Professor of Pathology with Tenure
 Department of Pathology and Neuroscience and Cell Biology
 University of Texas Medical Branch
 Galveston, Texas
- 2001-present Investigator, Center for AIDS Research (CFAR)
 Baylor College of Medicine
 Houston, TX
- 1998-present Director, Texas NeuroAIDS Research Center
 University of Texas Medical Branch
 Galveston, Texas

{Duties and responsibilities: 1) Successfully composed competitive applications and renewals for four separately funded multidisciplinary translational research projects that are actively funded by the National Institutes of Health; 2) Perform duties of the Principal Investigator in four multi-center, multidisciplinary clinical research projects currently funded by the NIH at over \$2.1 million dollars direct costs annually; 3) Assembled and supervised over 20 doctoral-level scientists and physician coinvestigators at three academic medical centers across three Texas cities (Galveston, Houston, Dallas); 4) Supervise and extramurally fund eleven full-time nondoctorate FTE professionals in project administration and laboratory science; 5) Supervise

coordination of protocols across research sites; 6) Supervise separately-funded quality assurance programs for neurology, pathology, psychiatry, and substance abuse with investigators in New York, Los Angeles, and San Diego program; 7) Supervise compliance with Institutional Review Boards, OHRP, and HIPAA regulations pertaining to research using human subjects; 8) Serve as Chairman of the National Steering Committee of the NIH National NeuroAIDS Tissue Consortium (NNTC); 9) Serve on or chair multiple NNTC subcommittees; 10) Maintain one of four national brain specimen repositories and database resource; 11) Ship data and specimens for AIDS research around the world; 12) Site PI for CNS HIV Antiretroviral Effects Research Consortium (CHARTER), a six-site consortium for the clinical study of neurological effects of HIV (Johns Hopkins University, Washington University St. Louis, University of Washington, UC San Diego, Mount Sinai, UTMB); 13) Serve on CHARTER peripheral neuropathy subcommittee; 14) Served as a special consultant to the NIH several times regarding establishment of nationwide clinical databases for HIV research; 15) Chaired numerous special NIH review panels on multidisciplinary clinical research}.

1989-present Full Member
Graduate School for Biomedical Sciences
University of Texas Medical Branch
Galveston, Texas

1988-present Associate Director, Division of Neuropathology
The University of Texas Medical Branch
Galveston, Texas

{Duties and responsibilities: 1) One-half to one-third of neuropathology on-call services, including surgical and general autopsy services, also provide coverage for the Ophthalmic Pathology service; 2) Assist director in supervising two laboratory technicians and secretary; 3) Plan division budgets, prepare for laboratory inspections, initiate and perform quality assurance program; and assist with leading divisional meetings; 4) Assist with consultations with hospital administrators and assist with coordination of autopsy and surgical pathology services}.

2001-2002 Summer Investigator
Marine Biological Laboratory, Woods Hole, MA

2003-2004 Member, Center for Biodefense and Emerging infectious Diseases
University of Texas Medical Branch
Galveston, TX

1999-2004 Full Member
World Health Organization Collaborating Center for Tropical Disease
University of Texas Medical Branch
Galveston, Texas

1993-2001 Associate Professor with Tenure
Departments of Pathology and Anatomy and Neurosciences
The University of Texas Medical Branch

Galveston, Texas

1990-1997 Director, Pathology Residency Program
 The University of Texas Medical Branch
 Galveston, Texas

{Duties and responsibilities: 1) Developed revised AP and CP curricula for 25 pathology residents and 5 annual fellows; 2) Supervised 7 different chief residents; 3) Managed the day-to-day resident service coverage and scheduling with various service directors; 4) Prepared for and hosted ACGME Residency Review Committee 5-year site visit (result: complete compliance with no citations or deficiencies); 5) Regularly evaluated resident performance orally and in writing and dealt with performance deficiencies, promotions and terminations; 6) Recruited seven full classes of first year residents into the program; 7) Served on UTMB Graduate Medical Education Advisory Board; 8) Chaired two internal residency review panels; 9) Attended multiple national meetings on GME curriculum development and served on the Pathology Residency Program Directors Section of the National Association of Pathology Chairmen. 10) A pathology intern recruited during my tenure was awarded intern of the year at UTMB, which was the first time a pathology house officer was ever honored that way; 11) Hosted award ceremonies and presented over 30 certificates of completion to graduating residents; 12) Managed budgets for a large residency program; 13) Became familiar with matters pertaining to the risks of drug dependency in resident physicians and was involved with formulating "contracts" and arranging for rehabilitation; 14) Maintained regular contact with the American Board of Pathology regarding qualifications of residents for examinations and admission to diplomacy}.

1990-1993 Assistant Professor
 Department of Anatomy and Neurosciences
 The University of Texas Medical Branch
 Galveston, Texas

1988-1993 Assistant Professor
 Department of Pathology
 The University of Texas Medical Branch
 Galveston, Texas

1987-1988 Research Assistant Professor
 Department of Pathology
 University of North Carolina at Chapel Hill
 Chapel Hill, North Carolina

1985-1987 Clinical Instructor
 Department of Pathology
 University of North Carolina at Chapel Hill
 Chapel Hill, North Carolina

1985-1987 Resident and Fellow in Neuropathology
 North Carolina Memorial Hospital

University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

1983-1985 Resident in Anatomic Pathology
North Carolina Memorial Hospital and Department of Pathology
University of North Carolina at Chapel Hill Chapel Hill, North Carolina

1980 Toxicologist, United States Environmental Protection Agency
Health Effects Research Branch, Cincinnati, Ohio

1979-1983 Medical Student, University of Cincinnati College of Medicine, and Instructor
of Biological Chemistry, Cincinnati, Ohio

1978-1979 Instructor, Department of Biological Chemistry University of
Cincinnati College of Medicine, Cincinnati, Ohio;
Prof. E.I. Gruenstein, Supervisor

RESEARCH ACTIVITIES:

A. Areas of Research: HIV Neuropathogenesis; Synapse neurochemistry; Macrophage and
microglial cell activation in the nervous system. Peripheral Neuropathy

B. Current Grant Support:

10/1/98 – 5/31/13 1U01MH083507 (formerly R24 NS45491 and R24 MH59656)
Title: Texas NeuroAIDS Research Center (Gelman, PI)
Organizations: National Institute of Mental Health(NIMH)
Role: Principal Investigator. 30% effort
Direct costs: \$3,589,475/5 years

2003 - 2015 N01 MH22005
Title: CNS/HIV Anti-Retroviral Therapy Effect Research
(CHARTER) (Gelman, PI on subcontract)
Organization: National Institute of Mental Health (NIMH)
Role: PI on subcontract to U. of California - San Diego. 5% effort
Direct Costs: Highly variable over the years: over \$5 million thus far and about 600,000
projected through 2015

9/25/06 – 8/31/11 R01 MH79886
Title: Dopamine Systems and Neuropsychiatric Changes in HIV/AIDS
Organization: National Institute of Mental Health (NIMH)
Role: Principal Investigator. 20% effort
Direct costs: \$ 835,000 five years

9/25/10 – 8/31/15 R01 NS072005

Title: The Synaptic Protein Economy in HIV/AIDS
Organization: National Institute of Neurological Disease and Stroke (NINDS)
Role: Principal Investigator, 25% effort
Direct costs: \$ 1,250,000 five years

C. Pending Grant Support under Review

None

D. Past Grant Support

2003 – 2007 R01 MH69200

Title: HIV and the Proteasome in the Aging Human Brain
Organization: National Institute of Mental Health (NIMH)
Role: Principal Investigator. 20% effort
Direct costs: \$ 534,502 over four years.
(Continuation was made via a new grant funded via NINDS).

9/26/00 - 9/31/06 R01 DC04970

Title: Myelopathy and Neuropathy During Changing HIV Burden (Gelman, PI)
Organization: National Institute on Deafness and Other Communicative Disorders (NIDCD)
Role: Principal Investigator. 20% effort
Direct costs: \$1,404,082/5 years (no cost extension 2006)

6/1/00 – 5/30/03 R24-MH59656S1

Title: Texas Center or AIDS Neuropathogenesis Research, Quality Assurance (Gelman, PI)
Organization: National Institute of Mental Health (NIMH) and National Institute of Neurological Disease and Stroke (NINDS)
Role: Principal Investigator.
Direct costs: \$314,602

12/1/98 - 1/30/02 R01 NS38414

Title: Lipid mediators in HIV Neurotransmitter Dysfunction (O'Brien, PI)
Organization: National Institutes of Health (NINDS)
Role: Coinvestigator. 7% effort
Direct costs: \$1,302,341

1998 - 2000

University of Texas Medical Branch Program on Aging
Title: Persistent HIV infection and biological aging of the human brain
Organization: UTMB Sealy Center on Aging, 5% effort
Role: Principal Investigator
Amount: \$10,000 per annum.

- 1992 - 1993 NS 30821, National Institute of Neurological Diseases and Stroke
Title: Magnetic resonance of spinal cord injury
Organization: National Institutes of Health
Role: Neuropathology subcontract principal investigator
Amount: \$ 33,391 annual direct costs
- 1991 - 1992 CYBERONICS
Title: Neuropathological evaluation of electrode implanted vagus nerves
Organization: Cyberonics Inc.
Role: Principal Investigator
Amount: \$ 13,000 annual direct costs
- 1987 - 1991 R23 NS 24326
Title: Macrophages in Toxicant-Induced Demyelination
Organization: National Institute of Neurologic Disease and Stroke (NINDS)
Role: Principal Investigator
Amount: \$ 106,898 total direct costs
- 1990 - 1991 University of Texas Medical Branch Small Grants Program
Title: Endoneurial Apolipoproteins in Diabetic Neuropathy
Organization: UTMB Small Grants Program
Role: Principal Investigator
Amount: \$ 15,000 annual direct costs
- 1984 - 1985 Southern Medical Association
Title: Serum proteolytic enzymes in patients with a hypercoagulable state,
Organization: Southern Medical Association
Role: Principal Investigator
Amount: \$ 2,500 annual direct costs

COMMITTEE RESPONSIBILITIES AND PANEL MEMBERSHIPS:

National:

- 2003-present Development Award Review Committee, Center for AIDS Research, Baylor College of Medicine
- 2002-present NIH: National Institute of Mental Health, CNS/HIV AntiRetroviral Effects Research (CHARTER) Steering Committee Member.
- 2002-present NIH: National Institute of Mental Health, CHARTER peripheral neuropathy subcommittee
- 1998-present NIH: National Institute of Health; Chairman, Neuropathology Subcommittee, National NeuroAIDS Tissue Consortium Steering Committee
- 1998-present NIH: National Institutes of Health, Voting Member (1 of 7), Steering Committee, National NeuroAIDS Tissue Consortium (NNTC)
- 2001-2007 NIH: National Institutes of Health, NAED Study Section, regular member

- (NeuroAIDS and End Organ Diseases)
- 2007 NIH, Chair, Scientific Review Group, NIAAA, Special Emphasis Panel 2007/05 ZAA1 BB (10) (1), 05/16/2007..
- 2007 NIH, Vice Chair, Steering Committee, National NeuroAIDS Tissue Consortium
- 2007 NIH, Chair, Scientific review group. ZRG1 AARR-D (05) (M). 3/12/2007.
- 2006 NIH: Scientific review group. ZGM1 CBB-5 (MR). National Institute of General Medical Sciences (NIGMS). Biological Materials Repository for the NIGMS-funded Protein Structure Initiative (PSI). July 14, 2006
- 2006 Organizing Committee, 7th International Symposium on NeuroVirology May 30 through June 3, 2006, Philadelphia, Pennsylvania.
- 2005 NIH: Scientific Review Group. ZAI1-JB-A-J3. National Institute of Allergy and Infectious Disease, December 5,6, 2005.
- 2004 NIH: Chairman, Steering Committee, National NeuroAIDS Tissue Consortium, second term
- 2004 NIH: Chair, Scientific Review Group ZAI-ML-A-J1. National Institute of Allergy and Infectious Disease, October, 26, 2004.
- 2004 NIH: Co-Chair, NIH Scientific Review Group: ZMH1 BRB-S (11). National Institute of Mental Health, July 22, 2004.
- 2003 NIH: Chair, Scientific Review Group ZAI1-PRJ-A-J1. National Institute of Allergy and Infectious Disease. December 10, 2003.
- 2003 NIH: Vice-Chair, Steering Committee, National NeuroAIDS Tissue Consortium
- 2003 NIH: National Institute of Health NINDS Study Section ad hoc, NSDC, February 21, 2003.
- 2002 NIH: Chair, Scientific Review Group, National Institutes of Health IFCN-4 Study Section (Functional and Cognitive Neuroscience), December 18, 2002.
- 2002 NIH: National Institute of Mental Health, ad hoc consultant, April 15, Bethesda, MD
- 2002 NIH: National Institutes of Health Study Section, ZNS1-SRB-A (02), January 10, 2002
- 2002 NIH: Chair, National Institute of Neurological Diseases and Stroke, Infectious Disease Breakout, "Workshop on Brain Banking, March 11, 2002
- 2001 NIH: National Institutes of Health, ad hoc consultant to the National Institute of Mental Health
- 2001 NIH: National Institutes of Health Study Section AARR-5, ad hoc panelist
- 2001 NIH: National Institutes of Health Study Section, ad hoc ZMH1-NRB-W-02
- 2001 Reviewer, Alzheimer's Association
- 2000-2003 American Association of Neuropathologists, Member, Awards Committee,
- 2000 NIH: National Institute of Mental Health, Invited participant, Conference On HAART Impact, May 24-26, 2000
- 1998-1999 NIH: National Institute of Health, Member, Database Subcommittee, National NeuroAIDS Tissue Consortium
- 2000 NIH: National Institutes of Health Study Section ZMH1-T-04, ad hoc panelist.
- 2000-2001 NIH: Chair, National Steering Committee, National Institute of Health National NeuroAIDS Tissue Consortium (NNTC)
- 1998-1999 NIH: Vice Chair, National Institute of Health NNTC Steering Committee

1998 NIH: Chair, National Institutes of Health Year 2000 AIDS Neuropathology
Consensus Conference Planning Committee

Institutional/UTMB:

2003-present Member, Doris Duke Selection Committee
2006-present Member and Chair, Dissertation Committee, Trung Nguyen, Neuroscience
2003 Member, Anatomy and Neuroscience Chair Search Committee
2001 Member, PhD Qualifying Examination Committee, Dora Bocangel, Neuroscience
1991-1997 Graduate Medical Education Advisory Committee
1997 Member, Graduate Medical Advisory Committee Internal Residency Review
(Surgery Residency)
1997-2001 Member, Neuroscience Course Design Committee, New Curriculum
1993 Microbiology Department Academic Review Committee
1993 Chair, Graduate Medical Advisory Committee Internal Residency Review
(Radiology Residency)
1990-1992 Member, Dissertation Committee, George Jackson, Biochemistry
1995-1999 Member, Dissertation Committee, Romulo de Castro, Biochemistry
1997-1999 Member, Dissertation Committee, Christopher Eddleman, Physiology
1998-2001 Member, New Curriculum Neuroscience Course Committee
1998 Liaison Committee for Medical Education Taskforce Subcommittee
on Governance and Administration
1998-2003 Member, Pathobiology Course Committee, Environmental Pathology Block
1999 Member, Center of Excellence Taskforce for Clinical Neuroscience

Departmental:

2007-present Tenure Review Committee, appointed member
2001-present Appointments promotion and tenure committee, elected member
2001-2002 Ad hoc Committee on Strategic Planning
1991-1992 Pathology Department Academic Review Committee
1991-1997 Chair, Pathology Residency Advisory Committee
1990-1995 Pathology Curriculum Committee
1989-1992 Pathology Ph.D. Academic Planning Committee
1989-1991 Pathology Ph.D. Bulletin Committee
1997-present George Dock Scholarship Committee

TEACHING RESPONSIBILITIES:

UTMB Medical School:

1988-present Lecturer, Neuropathology Grand Rounds (8 contact hours/year)
1988-present Lecturer, Neurology/Neurosurgery Grand Rounds (3 contact hours/year)
1988-present Lecturer, Pathology Grand Rounds (one contact hour/year)
1988-present Lecturer, Pathology Resident's Conference (one contact hours/year)

- 1996-present Lecturer, University of Texas Medical Branch program on aging seminar (1 contact hour)
- 1999-present Laboratory instructor and tutorial facilitator, Neuroscience Course, New Curriculum (45 hours)
- 1999-2003 Lecturer and laboratory block coordinator, Pathobiology Course, New Curriculum (5 hours).
- 1999-2000 Laboratory coordinator, Neuroscience Course, New Curriculum (4 hours)
- 1998-1999 Lecturer, Medicine/Texas Department of Criminal Justice Residents Conference (3 contact hours)
- 1998-1999 Lecturer, Medicine/Texas Department of Criminal Justice Residents Conference (3 contact hours)
- 1997-1999 Interactive Learning Track Resource Faculty (Certificate for 3.5 contact hours in 1998).
- 1996-1999 Instructor for Neuropathology course for 4th year neurology course for medical students (two hours per week; 100 per year).
- 1996-2000 Lecturer, Ophthalmic Pathology Resident's Conference (six contact hours)
- 1988-1999 Lecturer, Neuropathology and Neuropathology Laboratory to medical students (11 contact hours/year)
- 1988-1999 Laboratory Instructor, General Pathology Course (40 contact hours/year)
- 1988-1997 Lecturer, Neuroscience Review for Neurology Residents (6 contact hours/year)
- 1997-1999 Introduction to Physical Examination (IPE), small group leader (14 contact hours)
- 1997-1999 Introduction to Physical Examination interviewing course small group leader (21 contact hours)

UTMB Graduate School:

- 1989-present Lecturer, Introduction to Research Course (2 contact hours/year)
- 1997-present Lecturer, Integrative Neurobiology Course (NEUR 6330) "Neuropathology of aging" (1.5 contact hours)
- 1990-2000 Lecturer, Neurochemistry to graduate students in Neurosciences Graduate Program: "Biochemistry of Myelin." (4 contact hours/year)
- 1996-2000 Presenter, Ophthalmic Pathology Grand Rounds Presenter (est. four hours)
- 1989-2001 Lecturer, Fundamentals of Pathology Course Environmental Pathology (5 contact hours/year)
- 1992-1994 Lecturer, Molecular Neurobiology Course: "Molecular Biology of Myelin Protein" (2 contact hours/year)
- 1992-1994 Course Coordinator and Lecturer "Neuropathology for neuroscience and anatomy Ph.D. curriculum (12 contract hours/year; not offered in 1995-6)

UTMB Graduate Students and Fellows:

- 1989-1991 Xuemo Fan (Masters Thesis Advisor)
Nerve Growth Factor Receptor Expression During the Initiation of Remyelination (Results published in J Neurosci Res, 1992)
- 1991-1992 Anuradha Vittalrao (Masters Thesis Advisor)

- 1992-1995 Activated Microglia and Macrophages in the Myelopathy of Acquired Immunodeficiency Syndromes (Results published in Arch Pathol Lab Med, 1992)
Shailaja Dholakia (Masters Thesis Advisor)
- 1991-1992 Labile Structural Genes in the Central Nervous System of Patients With Acquired Immunodeficiency Syndrome (Results published in Arch Pathol Lab Med and Lab Invest, 1996 and 1997)
Pamela B. Jaffey, MD (Fellowship mentor)
Demyelination, remyelination, and endoneurial macrophage response in diabetic rats (Results published in J Comp Neurol, 1996)
- 1992-1993 Fei Fayan, MD (Fellowship mentor)
In vitro macrophage activation by specific myelin antigens
- 1995-1996 Juan Olano, MD (Fellowship mentor)
Quantifying apoptosis in banked human brains using flow cytometry (Results published in J Neuropathol Exp Neurol, 1996)
- 1994-1995 Pier Luigi DiPatre MD, PhD (Fellowship mentor)
Microglial cell activation in human hippocampus in Alzheimer's disease: partial linkage with neurofibrillary tangles (Results published in J Neuropathol Exp Neurol, 1997)
- 1995-1997 Dwayne Wolfe, MD (Fellowship mentor)
Characterization of myelin protein genes in AIDS myelopathy (Results published in Lab Investigation, 1997)
- 2002- 2003 Edore Adewuya MBBS (Fellowship mentor)
Synaptic protein expression and macrophage activation in HIV dementia
- 2004-present Trung P. Nguyen (MD PhD Program)
HIV-associated changes in neuronal proteasome activity
- 2004-2005 Erica Schwartz (Neuroscience Program Ph D student)
Localization of ion channels in dysfunctional brain cortex

MEMBERSHIP IN SCIENTIFIC SOCIETIES:

- 2004-present American Society for Investigative Pathology
- 2001-present International Society for NeuroVirology
- 2000-present International Brain Research Organization, Paris
- 1990-present American Association of Neuropathologists
- 1990-present Society for Neuroscience
- 1978-present American Association for the Advancement of Science
- 1980-2007 American Medical Association
- 1990-1995 Texas Medical Association
- 1990-1995 Galveston County Medical Society
- 1990-1997 Pathology Residency Program Directors Section
American Association of Pathology Chairmen
- 1984-1986 Southern Medical Association
- 1987-1990 College of American Pathologists

HONORS:

- 2006 First Honorable Mention for the Moore Award. Senior author on the best clinicopathological presentation. American Association of Neuropathologists and World Congress of Neuropathology, San Francisco, CA, September 11.
- 2006 Researcher of the Year, 12th Annual Department of Pathology Research Day
- 1984-1985 Southern Medical Association Research Award
- 1984 University Research Council Award, University of North Carolina at Chapel Hill, Chapel Hill, NC
- 1983 American Society of Anesthesiologists Preceptorship in Anesthesiology
- 1979-1980 Muscular Dystrophy Association of America Postdoctoral Fellowship Award
- 1976-1978 Chemical Industry Institute of Toxicology Predoctoral Fellowship
- 1975-1976 NIEHS Predoctoral Trainee

ADDITIONAL INFORMATION

REVIEWS AND EDITORIAL CONTRIBUTIONS BY INVITATION:

- 1989-present *Arch Pathol Lab Med*, KW McClatchey, Editor*
- 1992-present *J. Neuropathol Exp Neurol*, MN Hart, Editor*
- 1993-present *Annals of Neurology*, RS Fishman, Editor*
- 1996-present *Int. Journal of Developmental Neuroscience*, R Perez-Polo, Editor*
- 1999-present *Brain Pathology*, Harry Vinters, Editor
- 2001-present *Journal of Neuroscience*, Gordon M. Shepherd, Editor*
- 2002-present *American Journal of Pathology*, Jay McDonald, Editor*
- 2002-present *Journal of NeuroVirology*, Kamel Khalili, Editor*
- 2005-present *Spinal Cord*, LS Illis, Editor*
- 2005-present *Brain Research Reviews* Pierre Magistretti, Editor
- 2006-present *Journal of Neuroimmunology*, Cedric Raine, Editor*
- 2006-present *Journal of Neuroscience Research*, Jean de Vellis, Editor*
- 2006-present *Journal of Neuroimmune Pharmacology*, Howard Gendelman, Editor*
- 2007-present *Journal of Neuroinflammation*, Robert Mraz, Editor*
- 2007-present *Neuroscience & Biobehavioral Reviews*, Verity Brown Editor*
- 2007-present *Journal of Proteome Research*, Gyorgy Marko-Varga, Editor*
- 2007-present *Neurology*, John Noseworthy, Editor-In-Chief*
- 2007-2007 *The Medical Letter*, Gianna Zuccotti, Editor*
- 2007-2007 *Journal of Immunology*, Robert R. Rich, Editor*
- 2004-2005 *Neurochemistry International*, Michael Robinson, Editor
- 2000-2002 *Glia*, Bruce R. Ransom, Editor
- 1997-2003 *FASEB Journal*, V. Marchesi, Editor
- 1994-1995 *Journal of Neuroscience Research*, B Haber, Editor
- 1993-1996 *NeuroToxicology*, DA Fox, Editor
- 1992-1993 *Brain Research*, DP Purpura, Editor
- 1992-1993 *Bull Envir Contam Tox*, GAS Ansari, Editor
- 1990-1994 *J. Neurosurgery*, TM Sundt Jr., Editor

EDITORIAL BOARDS:

1999-2004 Full Member, Editorial Board, *Journal of Neuropathology and Experimental Neurology*

2009-2014 Full Member, Editorial Board, *Journal of Neuropathology and Experimental Neurology*

PRESENTATION BY INVITATION (past 16 years)

- February 27, 1995: "Current concepts in AIDS dementia." Grand Rounds, University of Texas Medical Branch, Galveston, Texas
- November 3, 1997: "Myelin basic protein in AIDS myelopathy." Grand Rounds, University of Texas Medical Branch, Galveston, Texas
- Dec. 1, 1998: "Obtaining autopsy consent: The Galveston, Texas experience."
National Institutes of Health Conference on HIV/CNS Tissue Network, Bethesda, MD.
- June 16, 1999: "NNTC: A multicenter brain distribution cooperative with a prospective clinical database." Brain Banking Symposium, Annual meeting of the American Association of Neuropathologists, June 16, 1999.
- August 19, 1999: "Texas progress: NNTC National Steering Committee", New York, New York.
- February 7, 2000: "A new genus of free-living ameba causing encephalitis in humans: *Sappinia diploidea*." Grand Rounds, University of Texas Medical Branch at Galveston.
- May 17, 2000: "Protozoan infections of the CNS." Houston Society of Clinical Pathology, Galveston, Texas.
- June 22, 2000: "The National NeuroAIDS Tissue Consortium: A new resource to support studies on neuropathogenesis for HIV." Co-presented with Dr. Igor Grant at "Neuroscience of HIV Infection 2000", Edinburgh, Scotland
- July 10, 2000: "Amebic meningoencephalitis" Presentation at Infectious Disease Conference, Texas Tech University at El Paso, El Paso, TX
- May 21, 2001: "Peripheral Neuropathy, Myelopathy and Disability: Persistent Challenge in the Era of Effective HIV Suppression" University of Alabama at Birmingham, Birmingham, Alabama
- January 29, 2002: "NeuroAIDS Research in the HAART era." Center for AIDS Research Seminar Series, Baylor College of Medicine, Houston, TX
- February 4, 2002: "Acquired Sodium Channelopathy in HIV-associated Distal Sensory Neuropathy." Grand Rounds, University of Texas Medical Branch at Galveston, Galveston TX
- March 12, 2002: "Neuropathologic Consensus in NeuroAIDS Research: Time for a review?" International Workshop on Brain Banking, National Institute of Neurologic Disease and Stroke, Bethesda, Md.
- June 22, 2002: Moderator, Platform session on infection and toxic disease, National Association of Neuropathologists.
- October 17, 2002: "CNS/HIV AntiRetroviral Effects Research at the Texas Center for NeuroAIDS Research." CHARTER Organization Meeting, San Diego, CA.
- November 16, 2002: "The Role of Brain Banking in Establishing a Multidisciplinary

- Neuroscience Research Agenda." Alzheimer's Basic Research Conference, League City, TX.
- November 21, 2002: "Host Genetic Polymorphism and HIV associated dementia." Co-author of presentation given by Dr. Ramon Diaz-Arrastia: Viral and Host Genetic Factors Regulating HIV/CNS Disease, Washington Marriott, Washington, D.C.
- February 10, 2003: "Macrophages, proteases, and HIV Dementia." Center for AIDS Research, Baylor College of Medicine.
- May 10, 2003: "Neuropathological Resources for Dementia Research in Galveston, Texas." Second Alzheimer's Disease Consortium Conference, League City, TX
- September 4, 2003: "Impact of aging and other neurologic disorders on viral-associated CNS diseases" 5th International Symposium on NeuroVirology, Baltimore, MD.
- October 2, 2003: "From genomics, to proteomics, to kinomics." The role of brain protein-protein interaction and turnover in neuroAIDS." Johns Hopkins University, Baltimore MD.
- October 3, 2003: "Inflammation and the neuronal proteasome in HIV-associated dementia." Molecular virology Division, St. Luke's-Roosevelt Hospital Center & Columbia University College of Physicians and Surgeons, New York, New York.
- November 18, 2003: "The neuropathological standard of HIV dementia: is all that 'gitters' gold?" Center on Neurovirology, Temple University, Philadelphia, PA.
- May 25, 2004: "Subcortical Dementia in HIV Infection is an Acquired Neuronal Channelopathy: Gene Expression in Human Brain Specimens." University of Nebraska Center for Neurovirology and Neurodegenerative Disorders.
- June 5, 2004: "HIV-associated Dementia is an Acquired Channelopathy. Gene Expression Profiling from the National NeuroAIDS Tissue Consortium. Presented at the "Molecular Markers and Mechanisms of HIV induced nervous system diseases." National Institutes of Health, Bethesda MD.
- September 10, 2004: Neuronal Channelopathies: A Neuroprotective Strategy to Prevent HIV Dementia. Sixth International Symposium on Neurovirology and HIV Neuroprotection Workshop, Sardinia, Italy.
- February 2, 2005: "Neurodegeneration versus neuronal dysfunction in HIV-associated dementia. The role of transcriptional channelopathies" 33d Annual Meeting International Neuropsychology Society, Saint Louis MO.
- December 12, 2005: "Abnormal Striatal Dopaminergic Synapses in HIV Encephalitis. Center for AIDS Research, Baylor/UT Houston, Houston, TX.
- February 21, 2006: "The future of Pathology and the MD-PhD track." MD-PhD program luncheon address. University of Texas Medical Branch at Galveston.
- April 6, 2006: "Dopamine Receptors are Neurochemically Abnormal in HIV Encephalitis." Society for Neuroimmune Pharmacology, 12th Annual Meeting, Santa Fe, New Mexico
- May 3, 2006: "Dysfunctional brain circuits in subcortical dementia" Researcher of the Year Presentation, 12th Annual Department of Pathology Research Day, Galveston, Texas.
- September 18, 2006: "Brain proteasomes, HIV infection, and dementia." Pathology Grand Rounds, University of Texas Medical Branch, Galveston, TX.
- December 4, 2006: "HIV hijacks the proteasome in HIV dementia." Grand Rounds, Cornell University, New York, New York.
- April 16, 2007: "HIV hijacks the proteasome in HIV dementia; implications for synaptic transmission. Evolving Mechanisms of HIV Neuropathogenesis in the HAART Era:

- Domestic and Global Issues." Venice-San Servolo, Italy.
- September 25, 2007: "Trends in clinical NeuroAIDS Research." Thomas Street Clinic and Baylor College of Medicine Doctor's Conference. Houston, TX.
- November 5, 2007: "HIV infection is associated with two different dementias." Temple University Department of Neuroscience, Philadelphia, PA.
- July 25, 2008" "The NNTC: Future Research Directions and Opportunities for Collaboration in the NeuroAIDS Community." Strategic Planning Meeting for Domestic and International NeuroAIDS Research, National Institute of Health, Hyatt Regency Bethesda Hotel, Bethesda, MD.
- April 21, 2009: "Innate immunity and synaptic protein turnover in HIV-dementia. 15th Annual meeting, Society for Neuroimmune Pharmacology. Wuhan, China.
- May 22, 2009: "CNS Immunity Modulates Synaptic Protein Economy in HIV Encephalitis." Department of Pathology, University of Houston Health Science Center.
- June 3, 2009: "Hemachromatosis (HFE) gene polymorphisms and HIV-associated brain pathology at autopsy: Results of a neuroAIDS DNA bank study" International Society of Neurovirology Annual Meeting, Symposium 1, Miami Beach, FL.
- October 23, 2009: "Anatomic and molecular brain pathology in HIV infection. Third Meeting on HIV Infection and the Central Nervous System. Stresa – Lago Maggiore, Italy.
- November 18, 2009: "Current status of HIV-associated neurocognitive disorders." Department of Pharmacology, University of Missouri, Kansas City Missouri.
- December 12, 2009: "HIV-associated dementia with and without encephalitis: At least two diseases and two therapies." Department of Pharmacology, University of Nebraska.

ARTICLES IN PEER-REVIEWED PUBLICATIONS:

Book Chapters

1. GELMAN BB. The Neuropathology of HIV. Chapter 18 in *Handbook of Clinical Neurology*, volume 84 (3d series), *HIV/AIDS and the Nervous System*. P. Portegies, J.R. Berger, Editors, Elsevier B.V., pp. 291-307, 2007.

GELMAN BB and Moore DH. HIV-1 Neuropathology. Chapter 7.4 in *Neurology of AIDS, Third Edition*. HE Gendelman, SH Fox, SA Lipton, IP Everall, I Grant, S Swindells, Editors, Oxford University Press, in production.

Articles

1. GELMAN BB, Michaelson IA, Bus JS. The effect of lead on oxidative hemolysis and erythrocyte defense mechanisms in the rat. *Toxicol Appl Pharmacol* 45:119-129, 1978.
2. GELMAN BB, Michaelson, IA. Neonatal lead toxicity and *in vitro* lipid peroxidation of rat brain. *J Toxicol Environ Health* 5:671-682, 1979.
3. GELMAN BB, Michaelson IA, Bornschein RL. Brain lipofuscin concentration and oxidant defense enzymes in lead poisoned neonatal rats. *J Toxicol Environ Health* 5:683-

698, 1979.

4. GELMAN BB, Papa L, Davis MH, and Gruenstein E. Decreased lysosomal dipeptidyl aminopeptidase-I activity in cultured human skin fibroblasts in Duchenne's muscular dystrophy. *J Clin Invest* 65:1298-1406, 1980.
5. GELMAN BB, Davis MH, Morris RE, and Gruenstein E. Structural changes in lysosomes from cultured human fibroblasts in Duchenne's muscular dystrophy. *J Cell Biol* 88:329-337, 1981.
6. Davis MH, GELMAN BB, and Gruenstein E. Decreased structure-linked latency of dipeptidyl aminopeptidase-I activity in Duchenne's muscular dystrophy fibroblasts. *Neurology* 32:486-491, 1982.
7. Rifai N, Christenson RN, GELMAN BB, and Silverman LM. Automated determination of apolipoprotein E in cerebrospinal fluid. *Clin Chem* 32:2207-8, 1986.
8. GELMAN BB, Goodrum JF, Bouldin TW, and Krigman MR. Apolipoprotein E is released by rat sciatic nerve during segmental demyelination and remyelination. *J Neuropathol Exp Neurol* 46:644-652, 1987.
9. Rifai N, Christenson RH, GELMAN BB, and Silverman LM. Cerebrospinal fluid apolipoprotein E and IgG indexes during exacerbation and remission of multiple sclerosis. *Clin Chem* 33:1155-1157, 1987.
10. GELMAN BB, Rifai N, Christenson RN, and Silverman LM. Cerebrospinal fluid and plasma apolipoprotein concentrations in patients with multiple sclerosis. *Ann Clin Lab Sci* 18:46-52, 1988.
11. Nolte KB, GELMAN BB. Intracerebral hemorrhage associated with cocaine abuse. *Arch Pathol Lab Med* 113:812-813, 1989.
12. GELMAN BB, Goodrum JF, and Bouldin TW. Macrophage apolipoprotein synthesis and endoneurial distribution as a response to segmental demyelination. *J Neuropathol Exp Neurol* 50:383-407, 1991.
13. Fan X and GELMAN BB. Schwann cell nerve growth factor receptor expression during initiation of remyelination. *J Neuroscience Res* 31:58-67, 1992.
14. GELMAN BB, Rodriguez MG, Wen J, Campbell GA, Herzog N. Siderotic cerebral macrophages in the acquired immunodeficiency syndrome. *Arch Pathol Lab Med* 116:509-516, 1992.
15. GELMAN BB and Guinto FC Jr. Morphometry, histopathology, and tomography of cerebral atrophy in the acquired immunodeficiency syndrome. *Ann Neurol* 32:32-40,

- 1992.
16. GELMAN BB. Diffuse microgliosis associated with cerebral atrophy in the acquired immunodeficiency syndrome. *Ann Neurol* 34:65-70, 1993.
 17. Kent TA, GELMAN BB, Casper K, Langsjoen HS, Levin HS, Hillman GR. Neuroimaging in HIV infection: Neuropsychological and pathological correlation. In: Grant I and Martin A, eds. *Neuropsychology of HIV Infection*. New York, NY: Oxford University Press, pp. 260-275, 1994.
 18. GELMAN BB. Iron in CNS disease. *J Neuropathol Exp Neurol* 54:477-486, 1995.
 19. Jaffey PB, GELMAN BB. Increased vulnerability to demyelination in streptozotocin diabetic rats. *J Comp Neurol* 373:55-61, 1996.
 20. GELMAN BB, Wolf DA, Olano JP, Linthicum LC. Incarceration and the acquired immunodeficiency syndrome: autopsy results in Texas prison inmates. *Human Pathology* 27:1282-1287, 1996.
 21. Olano JP, Wolf DA, Keherly MJ, GELMAN BB. Quantifying apoptosis in banked human brains using flow cytometry. *J Neuropathol Exp Neurol* 55:1164-1172, 1996.
 22. GELMAN BB, Dholakia S, Casper K, Kent TA, Cloyd MW, Freeman DH Jr. Expansion of the cerebral ventricles and correlation with AIDS neuropathology in 232 patients. *Arch Pathol Lab Med* 120:866-871, 1996.
 23. Nichols MM, GELMAN BB, Gilbert-Barness E. Autolyzed brain tissue beneath dermis of thigh and back. *Arch Pediatr Adolesc Med* 150:997-8, 1996.
 24. DiPatre PL, GELMAN BB. Microglial cell activation in aging and Alzheimer's disease: partial correlation with neurofibrillary tangle burden. *J Neuropathol Exp Neurol* 56:137-143, 1997.
 25. Wolf DA, Keherly MJ, Maggio WW, GELMAN BB. Chondromyxoid fibroma of the brain. *Arch Pathol Lab Med* 121:626-630, 1997.
 26. Wolf DA, Dholakia S, Cloyd MW, GELMAN BB. Proteolysis in the myelopathy of acquired immunodeficiency syndrome: preferential loss of the C-8 component of myelin basic protein. *Lab Invest* 77(5):513-523, 1997.
 27. GELMAN BB, Wolf DA, Rodriguez-Wolf M, West B, Haque A, Cloyd MW. Mononuclear phagocyte hydrolytic enzyme activity associated with cerebral HIV infection. *Am J Pathol* 151:1437-1446, 1997.
 28. Singh IP, Chopra AK, Coppenhaver DH, GELMAN BB, Poast J, Baron S. A broadly

- antiviral substance in the human nervous system. *J Neuroimmunol* 85:168-173, 1998.
29. Haque AK, Myers JL, Hudnall SD, GELMAN BB, Lloyd RV, Payne D, Borucki M. Pulmonary lymphomatoid granulomatosis in acquired immunodeficiency syndrome: Lesions with Epstein-Barr virus infection. *Modern Pathology* 11:347-356, 1998.
 30. Wang L, GELMAN BB, Konig R, Cloyd MW. A novel mechanism of CD4 lymphocyte depletion involves effects of HIV on resting lymphocytes: Induction of lymph node homing and apoptosis upon secondary signaling through homing receptors. *J Immunol* 162:268-276, 1999.
 31. Painter TJ, Chaljub G, Asthi R, GELMAN BB. Meningeal melanocytoma of the basal meninges and upper cervical meninges. *Amer J Neuroradiol* 21:1349-1353, 2000.
 32. GELMAN BB, Trier TT, Chaljub G, Borokowski J, Nauta HJW. Oncocytoma in melanocytoma of the spinal cord. *Neurosurgery* 47:756-759, 2000.
 33. GELMAN BB, Nader R, Popov V, Borkowski J, Rauf S, Chaljub G, Visvesvara, Nauta H. Encephalitis due to *Sappinia diploidea*. *JAMA* 285:2450-2451, 2001.
 34. Morgello, S, GELMAN BB, Grant E, Singer E, Vinters H and Kozlowski P. The National NeuroAIDS Tissue Consortium. *Neuropathology and Applied Neurobiology* 27:326-335, 2001.
 35. Schuenke KI and GELMAN BB. Human microglial cell isolation from adult autopsy brain: Brain pH, regional variation, and infection with HIV-1. *J Neurovirol* 9:346-357, 2003.
 36. GELMAN BB, Popov V, Chaljub G, Nader R, Rauf S, Nauta H, and Visvesvara GS. Neuropathology and ultrastructural features of encephalitis due to *Sappinia diploidea*. *J Neuropathol Exp Neurol* 62:990-998, 2003.
 37. Diaz-Arrastia R, Gong Y, Kelly CJ, GELMAN BB. Host Genetic Polymorphisms in HIV-Related Neurological Disease. *J Neurovirol.* 10, Suppl 1:67-73, 2004.
 38. Woods, SP, Rippeth, JD, Frol, AB, Levy, JK, Ryan, E, Soukup, VM, Hinkin, CH, Lazzaretto, D, Cherner, M, Marcotte, TD, GELMAN BB, Morgello, S, Singer, EJ, Grant, I, and Heaton, RK. Interrater reliability of clinical ratings and neurocognitive diagnoses in HIV. *Journal of Clinical and Experimental Neuropsychology*, 26, 759-778, 2004.
 39. GELMAN BB, Schuenke KW. Brain aging in AIDS: Increased ubiquitin-protein conjugate and correlation with decreased synaptic protein but not A β -stained diffuse plaque. *J Neurovirol.* 10:98-108, 2004.
 40. deCastro R Jr, Hughes MG, Xu G-Y, Clifton C. Calingasan NY, GELMAN BB, McAdoo

- DJ. Evidence that infiltrating neutrophils do not release reactive oxygen species in the site of spinal cord injury. *Experimental Neurology* 189:414-424, 2004.
41. Smit TK, Brew BJ, Tourtellotte WW, Morgello S, GELMAN BB, Saksena NK. Independent evolution of human immunodeficiency virus (HIV) drug resistance mutations in diverse areas of the brain in HIV-infected patients, with and without dementia, on antiretroviral treatment. *J Virology* 78:10133-10148, 2004.
 42. GELMAN BB, Soukup VM, Keherly MJ, Schuenke KW, Holzer CE, Richey JL, Lahart C. Acquired Neuronal Channelopathies in HIV-associated Dementia. *J Neuroimmunology* 157:111-119, 2004.
 43. GELMAN BB, Soukup VM, Holzer CE III, Fabian RH, Schuenke KW, Keherly MJ, Richey FJ. Lysosome Expansion in White Matter: Potential Correlate of Altered Membrane Turnover in HIV-associated Dementia. *J AIDS* 39:422-425, 2005.
 44. Saunders M, Eldeen MB, Valle LD, Reiss K, Peruzzi F, Mameli G, GELMAN BB, Khalili K, Amini S, and Sawaya BE. P73 modulates HIV-1 Tat transcription and apoptotic activities in human astrocytes. *Apoptosis* 10:1419-1431, 2005 (first published online, Oct 2005).
 45. Amini S, Mameli G, Del Valle L, Saunders M, Reiss K, GELMAN BB, Khalili K, and Sawaya BE. (2005) p73 interacts with HIV-1 Tat in astrocytic cells and prevents its acetylation on Lysine 28. *Mol Cell Biol* 25(18): 8126-8138, 2005.
 46. GELMAN BB, Spencer JA, Holzer CE III, Soukup VM. Abnormal striatal dopaminergic synapses in National NeuroAIDS Tissue Consortium subjects with HIV encephalitis. *J Neuroimmune Pharmacol* 1:410-420, 2006.
 47. Morgello S, Holzer CE III, Ryan E, Young C, Naseer M, Castellon SA, Frol AB, Atkinson JH, GELMAN BB, Grant I, Singer EJ. Inter-rater reliability of the Psychiatric Research Interview for Substance and Mental Disorders in an HIV-Infected Cohort: Experience of the National NeuroAIDS Tissue Consortium. *Int J Methods in Psychiatric Res* 15:131-138, 2006.
 48. Shah M, Smit TK, Morgello S, Tourtellotte W, GELMAN BB, Brew BJ, Saksena NK. Env gp120 sequence analysis of HIV type 1 strains from diverse areas of the brain shows preponderance of CCR5 usage. *AIDS Res Hum Retroviruses* 22(2):177-81, 2006.
 49. Letendre SL, Marquie-Beck J, Ellis RJ, Woods SP, Best B, Clifford DB, Collier AC, GELMAN BB, Marra C, McArthur JC, McCutchan JA, Morgello S, Simpson D, Alexander TJ, Durelle J, Heaton R, Grant I, The Charter Group. The role of cohort studies in drug development: Clinical evidence of antiviral activity of serotonin reuptake inhibitors and HMG-CoA reductase inhibitors in the central nervous system. *J Neuroimmune Pharmacol* 2:120-127, 2007.

50. Reynolds AD, Glanzer JG, Kadiu I, Ricardo-Dukelow M, Chaudhuri A, Ciborowski P, Cerny R, GELMAN BB, Thomas MP, Mosley RL, Gendelman HE. Nitrated alpha-synuclein-activated microglial profiling for Parkinson's disease. *J Neurochem*. 104(6):1504-25, 2008.
51. Letendre SL, Marquie-Beck J, Capparelli EV, Best B, Clifford DB, Collier AC, GELMAN BB, McArthur JC, McCutchan JA, Morgello S, Simpson D, Grant I, Ellis RJ, and the CHARTER Group (2008). Validation of the CNS Penetration-Effectiveness (CPE) Score for Quantifying Antiretroviral Penetration into the Central Nervous System. *Arch Neurol*.; 65(1):65-70, 2008
52. Ellis RJ, Marquie-Beck J, Delaney P, Alexander T, Clifford DB, McArthur JC, Simpson DM, Ake C, Collier AC, GELMAN BB, McCutchan JA, Morgello S, Grant I, and the CHARTER Group. Human immunodeficiency virus protease inhibitors and risk for peripheral neuropathy. *Ann Neurol* 64:566-572, 2008.
53. Best BM, Letendre SL, Brigid E, Clifford DB, Collier AC, GELMAN BB, McArthur JC, McCutchan JA, Simpson DM, Holland DT, Grant I, Ellis R, Capparelli EV, and the CHARTER Study Group. Low Atazanavir Concentrations in Cerebrospinal Fluid. *AIDS* 23(1):83-7, 2009.
54. Qvarnstrom Y, da Silva AJ, Schusster FL, GELMAN BB, Visvesvara G. Molecular confirmation of *Sappinia pedata* as a causative agent of amoebic encephalitis. *J Infect Dis* 199:1139-1142, 2009.
55. Overall I, Vaida F, Khanlou N, Lazzaretto D, Achim C, Letendre S, Moore D, Ellis R, Cherner M, GELMAN BB, Morgello S, Singer E, Grant I, Masliah E and the National NeuroAIDS Tissue Consortium (NNTC). Cliniconeuropathologic correlates of human immunodeficiency virus in the era of antiretroviral therapy. *J Neurovirology* 15:360-370, 2009.
56. GELMAN BB, Nguyen TN. Synaptic proteins linked to HIV-1 infection and immunoproteasome induction: proteomic analysis of human synaptosomes. *J Neuroimmune Pharmacology* 5:92-102, 2010.
57. Nguyen TN, Soukup VM, GELMAN BB. Persistent hijacking of brain proteasomes in HIV-associated dementia. *Am J Pathol*. 176: 893-902, 2010.
58. Ellis RJ, Rosario D, Clifford D, McArthur JC, Simpson D, Alexander T, GELMAN BB, Grant I. Continued high prevalence and adverse clinical impact of HIV-associated sensory neuropathy in the era of combination antiretroviral therapy (CART): The CHARTER study. *Arch Neurol* 67(5):552-558, 2010.
59. Nestic O, Guest JD, Zivadinovic D, Narayana PA, Herrera JJ, Grill RJ, Mokkapatil VU,

- GELMAN BB, Lee J. Aquaporins in Spinal Cord Injury: The Janus Face of AQP4. *Neuroscience*. 2010 Jul 28;168(4):1019-35. Epub 2010 Jan 28, 2010.
60. Morral JA, Davis AN, Qian J, GELMAN BB, Koeppen AH. Pathology and pathogenesis of sensory neuropathy in Friedreich's ataxia. *Acta Neuropathol* 120::97-108, 2010.
61. Heaton RK, Clifford DB, Franklin DR, Woods SP, Ake C, Vaida F, Ellis RJ, Letendre SL, Marcotte TD, Atkinson JH, Rivera-Mindt M, Vigil OR, Taylor MJ, Collier AC, Marra CM, GELMAN BB, McArthur JC, Morgello S, Simpson DM, McCutchan JA, Abramson I, Gamst A, Fennema-Notestine C, Jernigan TL, Wong J, Grant I. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. *Neurology* 2010;75(23):2087-96, 2010.
62. Croteau D, Letendre S, Best BM, Ellis RJ, Breidinger S, Clifford D, Collier A, GELMAN BB, Marra C, Mbeo G, McCutchan A, Morgello S, Simpson D, Way L, Vaida F, Ueland S, Capparelli E, Grant I; CHARTER Group. Total raltegravir concentrations in cerebrospinal fluid exceed the 50-percent inhibitory concentration for wild-type HIV-1. *Antimicrob Agents Chemother* 54(12):5156-60, 2010.
63. Best BM, Koopmans PP, Letendre SL, Capparelli EV, Rossi SS, Clifford DB, Collier AC, GELMAN BB, Mbeo G, McCutchan JA, Simpson DM, Haubrich R, Ellis R, Grant I; on behalf of the CHARTER Group. Efavirenz concentrations in CSF exceed IC50 for wild-type HIV. *J Antimicrob Chemother* 266(2):354-357, 2010. PMID:21098541. PubMed Central PMCID: PMC3019085.
64. Robinson-Papp J, Morgello S, Vaida F, Fitzsimons C, Simpson DM, Elliott KJ, Al-Lozi M, GELMAN BB, Clifford D, Marra CM, McCutchan JA, Atkinson JH, Dworkin RH, Grant I, Ellis R. Association of self-reported painful symptoms with clinical and neurophysiologic signs in HIV-associated sensory neuropathy. *Pain*. 2010 Dec;151(3):732-6. Epub 2010 Sep 20.
65. Heaton RK, Franklin DR, Ellis RJ, McCutchan JA, Letendre SL, Leblanc S, Corkran SH, Duarte NA, Clifford DB, Woods SP, Collier AC, Marra CM, Morgello S, Mindt MR, Taylor MJ, Marcotte TD, Atkinson JH, Wolfson T, GELMAN BB, McArthur JC, Simpson DM, Abramson I, Gamst A, Fennema-Notestine C, Jernigan TL, Wong J, Grant I; CHARTER Group; HNRC Group. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. *J Neurovirol* 17:3-16, 2011.
66. Lin K, Taylor MJ, Heaton R, Franklin D, Jernigan T, Fennema-Notestine C, McCutchan A, Atkinson JH, Ellis RJ, McArthur J, Morgello S, Simpson D, Collier AC, Marra C, GELMAN BB, Clifford D, Grant I. Effects of traumatic brain injury on cognitive functioning and cerebral metabolites in HIV-infected individuals. *J Clin Exp Neuropsychol* 33(3):326-34, 2011.

67. Cysique LA, Franklin D Jr, Abramson I, Ellis RJ, Letendre S, Collier A, Clifford D, GELMAN BB, McArthur J, Morgello S, Simpson D, McCutchan JA, Grant I, Heaton RK. Normative data and validation of a regression based summary score for assessing meaningful neuropsychological change. *J Clin Exp Neuropsychol*. 2011 Mar 7:1-18. [Epub ahead of print]. PMID:21391011.
68. Lin K, Taylor MJ, Heaton R, Franklin D, Jernigan T, Fennema-Notestine C, McCutchan A, Atkinson JH, Ellis RJ, McArthur J, Morgello S, Simpson D, Collier AC, Marra C, GELMAN BB, Clifford D, Grant I for the CHARTER group. Effects of traumatic brain injury on cognitive functioning and cerebral metabolites in HIV-infected individuals. *J Clin Exptl Neuropsychology iFirst*, 1–9, 2011.
69. Jernigan, TL, Archibald SL, Fennema-Notestine C, Taylor MJ, Theilmann RJ, Julaton MD, Notestine RJ, Wolfson T, Letendre SL, Ellis RJ, Heaton RK, Gamst AC, Franklin DR, Clifford DB, Collier AC, GELMAN BB, Marra CM, McArthur JM, McCutchan JA, Morgello S, Simpson DM, Grant I and the CHARTER Group. Clinical factors related to brain structure in HIV: The CHARTER Study. *J Neurovirol* 17(3):248-257, 2011.
70. Moore, D.J., Arce, M., Moseley, S., McCutchan, J.A., Marquie-Beck, J., Franklin, D.R., Vaida, F., Achim, C., McArthur, J., Morgello, S., Simpson, D.M., GELMAN BB, Collier, A.C., Marra, C.M., Clifford, D.B., Heaton, R.K., Grant, I., the CHARTER Group, and the HNRC Group (in press). Family History of Dementia Predicts Worse Neuropsychological Functioning Among HIV Infected Persons. *The Journal of Neuropsychiatry and Clinical Neurosciences*, 2011.
71. Byrd, D, Morgello, S, GELMAN BB, Grant I. Neurocognitive Impact of Substance Use in HIV Infection. *J AIDS* in press 2011.
72. Mukerjee R, J. Robert Chang, Luis Del Valle, Asen Bagashev, Monika M. Gayed, Randolph B. Lyde, Brian J. Hawkins, Eugen Brailoiu, Eric Cohen, Chris Power, S. Ausim Azizi, Benjamin GELMAN BB, and Bassel E. Sawaya. Deregulation of microRNAs by HIV-1 Vpr leads to the development of neurocognitive disorders. *J Biol Chem* in press 2011.
73. Bari A, Scott Letendre; Grant, Igor; Ellis, Ronald; Tanya Wolfson; Allen McCutchan; David Clifford; Ann Collier; GELMAN BB.; Justin McArthur; Christina Marra; Susan Morgello; David Simpson Clinical Variables Identify Seronegative HCV Co-infection in HIV-Infected Individuals *J Clin Virol* in press.

PUBLISHED ABSTRACTS:

1. GELMAN BB, Michaelson IA. The effect of lead on oxidative hemolysis and erythrocyte defense mechanisms in the rat. *Pharmacologist* 19:134, 1977.

2. GELMAN BB, Bus, JS. An interaction between chronic lead exposure and acute phenylhydrazine administration in the rat. *Toxicol Appl Pharmacol* 41:152, 1977.
3. GELMAN BB. Lead Toxicity and the Free Radical Oxidation of Biomembranes. Dissertation Abstracts. Ann Arbor, 1978.
4. Davis MH, GELMAN BB, Gruenstein E. Decreased structure-linked latency of dipeptidyl aminopeptidase-I in Duchenne muscular dystrophy fibroblasts. *Am Soc Cell Biol* 1980.
5. Davis MH, GELMAN BB, Morris RE, Gruenstein E. Lysosomal abnormalities in Duchenne muscular dystrophy fibroblasts. *Biophysical Soc*, 1980.
6. GELMAN BB, Goodrum JF, Bouldin TW, Krigman MR. Apolipoprotein E is released by rat sciatic nerve during segmental demyelination and remyelination. *J Cell Biol* 103:229a, 1986.
7. Goodrum JF, Novicki D, GELMAN BB, and Bouldin TW. Cells from explant cultures of adult rat sciatic nerve produce apolipoprotein E. *J Neurochem* 48:S184, 1987.
8. Rifai N, Silverman LM, GELMAN BB, and Christenson RH. Changes of cerebrospinal fluid IgG and apolipoprotein E indices in patients with multiple sclerosis during demyelination and remyelination. Presented to the Academy of Clinical Laboratory Physicians, June 3, 1987.
9. GELMAN BB, Goodrum JF, Rifai N, Bouldin TW. Apolipoprotein E is released by rat sciatic nerve during lead neuropathy. *J Neuropathol Exp Neurol* 46:367, 1987.
10. Rifai N, GELMAN BB, Christenson RH, and Silverman LM. Cerebrospinal fluid apolipoprotein E index in patients with multiple sclerosis during remission. *Am Assoc Clin Chem*, 1987.
11. GELMAN BB, Goodrum JF, Earnhardt TS, and Bouldin TW. Secretion of apolipoprotein E by endoneurial macrophages in response to demyelination of sciatic nerve. *J Neuropathol Exp Neurol* 47:24, 1988.
12. GELMAN BB, Rodriguez MG, Campbell GA. Altered oligodendroglial iron proteins in human immunodeficiency virus infection. *J Neuropathol Exp Neurol* 49:325, 1990.
13. Fan X, GELMAN BB. Nerve growth factor receptor expression during initiation of remyelination. *J Neuropathol Exp Neurol* 49:312, 1990.
14. GELMAN BB, and Guinto FC Jr. Anatomy, histopathology, epidemiology, and tomography of cerebral atrophy in the acquired immunodeficiency syndrome. *J Neuropathol Exp Neurol* 50:324, 1991.

15. GELMAN BB. Cerebral atrophy in AIDS patients associated with increased microglial cell and GFAP+ astroglial density in frontal cortex. *J Neuropathol Exp Neurol* 51:374, 1992.
16. Rodriguez-Wolf M, GELMAN BB. Distribution of endoneurial macrophages is linked to specific stages, regions, and rates of axonal regeneration and remyelination. *J Neuropathol Exp Neurol* 51:357, 1992.
17. Jaffey PB, GELMAN BB. Demyelination, remyelination, macrophage apolipoprotein E, and Schwann cell NGF receptor in diabetic rats. *J Neuropathol Exp Neurol* 51:346, 1992.
18. Vittalrao A, GELMAN BB. Diffuse microgliosis: a highly prevalent anomaly in the nervous system of 117 patients with AIDS. *J Neuropathol Exp Neurol* 52:272, 1993.
19. Dholakia SR, GELMAN BB. Brain ventricular expansion in AIDS: roles of Cytomegalovirus and human immunodeficiency virus. *J Neuropathol Exp Neurol* 54:450, 1995.
20. DiPatre PL, GELMAN BB. Hippocampal microglial cell activation is not correlated with plaque and tangle densities in Alzheimer's disease. *Lab Invest* 72:135A, 1995.
21. Imbing F, Haque AK, GELMAN BB, Hudnall SD. Pulmonary lymphoproliferative lesions in AIDS: An association with Epstein-Barr virus. *Lab Invest* 72:148A, 1995.
22. GELMAN BB. Increased prevalence of CNS bacterial infections in Texas prison inmates with AIDS. *J Neuropathol Exp Neurol* 54:449, 1995.
23. De Castro R, GELMAN BB, McAdoo DJ. Myeloperoxidase is released by neutrophils in traumatic spinal cord injury. *J Neurotrauma* 13(10):603, 1996.
24. Wolf DA, Dholakia SR, Olano J, GELMAN BB. Characterization of myelin basic protein (MBP) and proteolipid protein (PLP) isoforms in the myelopathy of acquired immunodeficiency syndrome (AIDS). *J Neuropathol Exp Neurol* 55:659, 1996.
25. GELMAN BB, Wolf DA, Olano JP. Increased cerebral lysosomal enzyme activity in patients with the acquired immunodeficiency syndrome. *J Neuropathol Exp Neurol* 55:659, 1996.
26. Olano JP, Wolf DA, Keherly MJ, GELMAN BB. Terminal deoxynucleotidyl transferase-labeled DNA strand breaks in isolated brain nuclei detected using flow cytometry. *J Neuropathol Exp Neurol* 55:616, 1996.
27. Keherly MJ, Maggio WW, GELMAN BB, Wolf DA. Northern analysis of

- proto-oncogene expression in human gliomas. Soc Neurosci Abstr 22:947, 1996.
28. Singh IP, Chopra AK, Coppenhaver DH, GELMAN BB, Poast J, Baron S. A broadly antiviral substance in the human nervous system. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans LA. Sept 15-18, 1996.
 29. Singh IP, Chopra AK, Coppenhaver DH, GELMAN BB, Poast J, Baron S. A broadly antiviral substance in the human nervous system. *J Interferon Cyto Res* 17:S101, 1997.
 30. Wolf DA, Rodriguez-Wolf M, GELMAN BB. Preferential degradation of C8 isomer in the myelopathy of AIDS. UTMB Pathology Department Research Symposium, May 27, 1997.
 31. Sing IP, Chopra AK, Coppenhaver DH, GELMAN BB, Poast J, Baron S. A broadly antiviral substance in the human nervous system. ISICR Annual meeting, San Diego, CA, 1997.
 32. GELMAN BB, Wolf DA, Rodriguez-Wolf M. Apolipoprotein E phenotype and brain immune activation in nondemented male and female subjects. *J Neuropathol Exp Neurol* 56:617, 1997.
 33. Wolf DA, Rodriguez-Wolf M, GELMAN BB. Charge microheterogeneity of myelin basic protein as the basis of selective vulnerability? A regional analysis in human nervous system. *J Neuropathol Exp Neurol* 56:603, 1997.
 34. GELMAN BB and Rodriguez-Wolf M. Co expression of ferritin and class II histocompatibility antigen in activated microglia: Lack of correlation with A β , APOE, and neuritic plaque counts in Alzheimer's disease. *J Neuropathol Exp Neurol* 57:495, 1998.
 35. GELMAN BB. Age-associated ubiquitination of brain protein in the acquired immunodeficiency syndrome. University of Texas Medical Branch Forum on Aging, September 29, 1999.
 36. Zaman F, Wong B, GELMAN BB, Hudnall SD. NonHodgkin lymphoma presenting as a right eyelid mass. Presented UTMB Spring Ophthalmology Meeting, March 20, 1999.
 37. Zaman F, Wong B, GELMAN BB, Hudnall SD. NonHodgkin lymphoma presenting as a right eyelid mass. Presented at Wills Eye Institute, Philadelphia PA, May 19, 1999.
 38. GELMAN BB. Age-associated neuromorphology in the acquired immunodeficiency syndrome. *J Neuropathol Expt Neurol* 58:517, 1999.
 39. Borkowski JL, Smith M, Wang, L, GELMAN BB. Coccidioidomycosis presenting as a solitary cerebellar mass. Presented at the Texas Society of Pathologists Houston, Texas.

Feb 11, 2000.

40. GELMAN BB, Nader R, Rauf S, Popov V, Borkowski J, Chaljub G, Nauta H. A new genus of free-living ameba producing human encephalitis: *Sappinia diploidea*. *J Neuropathol Expt Neurol* 59: 427, 2000.
41. Nader R, GELMAN BB, Chaljub G, Visvesvara G, Rauf S, Nauta H. Brain abscess caused by a new species of free-living ameba. Presented at "100 Years of Neurosurgery." McGill University, May 15, 2000.
42. Grant I, *GELMAN BB, Morgello S, Singer, E, Kozlowski P: The National NeuroAIDS Tissue Consortium: A new resource to support studies on neuropathogenesis for HIV. Presented and *primary authorship shared* with Dr. Grant. *J Neurovirology* 6:244, 2000.
43. Martinez, F and GELMAN BB. Vacuolar myelopathy and body mass index in AIDS patients. Texas Society of Pathologists, Galveston, Texas, January 26, 2001 (First place in resident research competition).
44. GELMAN BB, Schuenke KW, Fishman HM. HIV gp120, human CSF and brain extract decrease sodium current in voltage clamped squid giant axons. *J Neuropathol Exptl Neurol* 61:447, 2002.
45. Schuenke, KW and GELMAN BB: Isolation and HIV infection of microglia derived from autopsy brain specimens. *J Neurovirol* 8 (Suppl 1): 72, 2002.
46. Diaz-Arrastia R, Gong Y, Fair S, Smith D, GELMAN BB. Polymorphism in the promoter region of the TNF gene is associated with multinucleated giant cells and microglial nodules in patients dying from HIV infection. *Soc Neurosci*, 2002.
47. GELMAN BB, Soukup VM, Schuenke, KW. Increased subcortical brain lysosomal enzyme activity is correlated with decreased neurocognitive function in HIV/AIDS: a multisite analysis using the National NeuroAIDS Tissue Consortium cohort. *J Neuropathol Exp Neurol* 62:539, 2003.
48. Carlson D, GELMAN BB. Auditory Function in Patients with HIV/AIDS. November Nov 14 2003 Chicago, IL *American Speech Language Hearing Association Leader* 8 (15), 2003.
49. Grant, I, GELMAN BB, Morgello S, Singer EJ. National NeuroAIDS Tissue Consortium [NNTC]. *J Neurovirol* 9 (Suppl 3):113, 2003.
50. GELMAN BB and Schuenke KW. Brain Aging in AIDS: Increased ubiquitin–protein conjugate is correlated with decreased synaptic protein but not altered A beta–plaque accumulation. *J Neurovirol* 9 (Suppl 3):26, 2003.

51. GELMAN BB, Schuenke KW, Soukup VM. Abnormal white matter genes drive an acquired channelopathy in subcortical dementia associated with HIV infection. *J Neuropathol Exp Neurol.* 63:553, 2004
52. Grant, I, GELMAN BB, Morgello S, Singer E. National NeuroAIDS Tissue Network [NNTC]. International AIDS Conference, Bangkok Thailand, 11-16 July, 2004.
53. GELMAN BB, Soukup VM, Keherly MJ. Neuronal channelopathies: A neuroprotective strategy to prevent HIV dementia. *J Neurovirology*:10: 5, 2004.
54. Nguyen, T, Keherly MJ, GELMAN BB. Ubiquitin, proteasome, and brain protein turnover anomalies in older people with HIV infection. University of Texas Medical Branch Forum on Aging. September 15, 2004.
55. Nguyen T, Spencer JA, GELMAN BB. Synthesis of brain immunoproteasomes in HIV dementia and encephalitis: Implications for turnover and misfolding of neuronal protein. University of Texas Medical Branch Forum on Aging, October, 2005 (First place prize for student presentation), 2005
56. Wong JK, Pillai SK, Ellis RO, Letendre S, McCutchan, JA, McArthur J, Morgello S, Simpson D, GELMAN BB, Clifford D, Collier A, Mara C, Marcotte T, Grant I for the CHARTER group. Discordance of genotypic resistance between CSF and plasma virus in a multicenter observational cohort. Conference on Retroviruses and Opportunistic Infections. February 5-9, 2006.
57. Best B, Letendre S, Patel P, Clifford D, Collier A, GELMAN BB, McArthur J, McCutchan JA, Simpson D, Holland D, Grant I, Capparelli E, and the CHARTER Study Group. Low Atazanavir Concentrations in Cerebrospinal Fluid. Conference on Retroviruses and Opportunistic Infections. February 5-9, 2006.
58. GELMAN, BB, Spencer JS, Soukup VM, Holzer, CH III. Dopamine synapses are abnormal in HIV encephalitis. *J Neuroimmune Pharmacology*, 2006.
59. Sherman SJ, Morgello S, Singer EJ, Grant I, GELMAN, BB, Brandt D. National NeuroAIDS Tissue Consortium, Society for Neuroscience Annual Meeting, 2006.
60. GELMAN, BB, Spencer JS, Holzer CH III, Soukup VM. Circuit specific abnormalities of dopamine synapses are present in NNTC brain specimens with HIV encephalitis. *J Neurovirol* 12 (suppl 1):30, 2006.
61. Nguyen TP, Soukup VM, Spencer JS, GELMAN BB. Persistent hijacking of brain proteasomes in HIV dementia: Data from National NeuroAIDS Tissue Consortium Specimens. *J Neurovirol* 12 (Suppl 1):60, 2006.

62. Brandt DK, Sherman SJ, GELMAN BB, Singer EJ, Grant I, Morgello S. The National NeuroAIDS Tissue Consortium. *J Neurovirol* 12 (suppl 1):9, 2006.
63. Nguyen, TP, Soukup, VM, Spencer J, GELMAN, BB. Persistent "hijacking" of brain proteasomes in HIV dementia: Data from National NeuroAIDS Tissue Consortium Specimens. *Brain Pathology* 16 (Suppl) 1:S15, 2006 (won First Honorable Mention for the Moore Award for the best clinicopathological presentation at the American Association of Neuropathologists Annual Meeting in San Francisco, CA, September 11, 2006).
64. Nguyen T, Spencer JA, GELMAN BB. Persistent "hijacking" of brain proteasomes in HIV dementia. University of Texas Medical Branch Forum on Aging, October, 2006 (First place prize for student presentation, second straight year), 2006.
65. Letendre S, Capparelli E, Best B, Clifford D, Collier A, GELMAN BB, McArthur J, McCutchan J, Simpson D, Ellis R, and the CHARTER Group. Better antiretroviral penetration into the central nervous system is associated with lower CSF viral load. 13th Conference on Retroviruses and Opportunistic Infections; Denver, CO. Abstract 74. February 5-8, 2006.
66. Best B, Letendre S, Patel P, Clifford D, Collier A, GELMAN BB, McArthur J, McCutchan J, Simpson D, Capparelli E. Low atazanavir concentrations in cerebrospinal fluid. 13th Conference on Retroviruses and Opportunistic Infections, Denver, CO. Abstract 576. February 5-8, 2006;
67. Henninger DE, Byrd D, Franklin D, Heaton RK, Morgello S, Rivera-Mindt M, and the CHARTER Group. Aging and HIV Infection: The Relationship Between Neuropsychological and Vocational Functioning. 59th Scientific Meeting of the Gerontological Society of America, Dallas, TX. November 16-20, 2006.
68. Letendre SL, Marquie-Beck J, Clifford DB, Collier AC, GELMAN, BB, Marra C, McArthur JC, McCutchan JA, Morgello S, Simpson D, Alexander TJ, Durelle J, Best B, Heaton R, Grant I, Ellis RJ and the CHARTER Group. Clinical Evidence of Antiviral Activity of Serotonin Reuptake Inhibitors and HMG-CoA Reductase Inhibitors in the Central Nervous System. 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles Convention Center, Los Angeles, CA, February 25-28, 2007.
69. Jernigan T, Letendre SL, Archibald S, Durelle J, Clifford D, Collier A, GELMAN, BB, McArthur JC, McCutchan JA, Morgello S, Simpson D, Heaton R, Grant I, Ellis RF and the CHARTER Group. Chemokines in CSF Are Associated with White Matter and Cortical Gray Matter Volumes in HIV-infected Individuals. 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles Convention Center, Los Angeles, CA. February 25-28, 2007.
70. Best, BM, Scott L, Letendre, Steven S, Rossi, David B, Clifford, Ann C, Collier,

- GELMAN BB, Justin C. McArthur, J. Allen McCutchan, Susan Morgello, Ronald J. Ellis and the CHARTER Group. Low Exposure to Paroxetine and Sertraline, but not to Citalopram, Escitalopram and Fluoxetine in HIV-infected Patient. 14th Conference on Retroviruses and Opportunistic Infections. February 25-28, 2007 at the Los Angeles Convention Center in Los Angeles, CA, 2007.
71. Letendre S, Daniel McClernon, Jennifer Marquie-Beck, Patricia Vidal, David Clifford, Ann Collier, GELMAN, BB, Justin McArthur, J. Allen McCutchan, Susan Morgello, Igor Grant, Ronald J. Ellis, and the CHARTER Group. Presence of HIV RNA in Cerebrospinal Fluid that is ‘Undetectable’ with the Ultrasensitive Assay. 14th Conference on Retroviruses and Opportunistic Infections. February 25-28, 2007 at the Los Angeles Convention Center in Los Angeles, CA, 2007.
72. Biswas B, Collier AC, GELMAN BB, McArthur JC, Morgello S, McCutchan JA, Clifford DB, and the CHARTER Group. Associations Between Adherence and Neurocognitive Performance Among HIV-infected individuals: Is near perfect adherence necessary? 2nd International Conference on HIV Treatment Adherence: Jersey City, NJ. March 8-10, 2007.
73. Henninger DE, Franklin D, Heaton RK, Morgello S, Rivera-Mindt M, GELMAN BB and the CHARTER Group. A Model of HIV Infection, Aging, Neuropsychological and Vocational Functioning, and Employment. 5th Annual Conference of the American Academy of Clinical Neuropsychology, Denver, CO. June 7-9, 2007.
75. Henninger DE, Franklin D, Heaton RK, Morgello S, Rivera Mindt, M, GELMAN BB and the CHARTER Group A Model of HIV Infection, Aging, and Neuropsychological Functioning to Predict Vocational-Functioning and Employment American Academy of Clinical Neuropsychology Annual Meeting, 2007.
76. Brandt DK, Morgello, S, GELMAN BB, Elyse J. Singer, Igor Grant, Seth Sherman1, and the NNTC Group. NATIONAL NEUROAIDS TISSUE CONSORTIUM. Conference on Retroviruses and Opportunistic Infections. February 25-28, 2007 at the Los Angeles Convention Center in Los Angeles, CA, 2007.
77. Jung S-L, Archibald S, Hesselink J, Taylor M, Letendre SL, Clifford D, Collier A, GELMAN BB, McArthur JC, McCutchan JA, Morgello S, Simpson D, Heaton R, Grant I, Ellis RJ, Jernigan T, and the CHARTER Group. Clinical Correlates of Different White Matter Lesion Types in HIV-infection. Radiological Society of North America, 2007.
78. GELMAN BB, Singer EJ, Grant I, Sherman S, Morgello S, Brandt DK. and the NNTC Group. The National NeuroAIDS Tissue Consortium. 8th International Symposium on Neurovirology. Oct 29, San Diego California, 2007.
79. Nguyen TP, Soukup V, GELMAN BB. Persistent “hijacking” of brain proteasomes in HIV-Associated dementia. 11th Annual forum on Aging. Best Student Poster Award.

October 3, 2007.

80. Jernigan TL, Taylor MJ, Archibald S, Woods SP, Abramson I, Clifford D, Collier A, Ellis RJ, Gamst AC, GELMAN BB, Heaton R, Letendre S, Marcotte T, Marra C, McArthur JC, McCutchan JA, Morgello S, Simpson D, Grant I, and the CHARTER Group. White Matter Damage and Cortical Volume Loss Affect Different Cognitive and Motor Functions in HIV-infected Individuals. *J Internat Neuropsychol Soc*, 2008.
81. Franklin DR, Woods SP, Vigil OR, Meyer R, Young Casey, C, Marquie-Beck J, Ellis RJ, Heaton RK, Letendre S, Abramson I, Marcotte T, Gamst A, Wong J, Jernigan T, Taylor MJ, Collier A, Clifford D, GELMAN BB, McArthur JC, Morgello S, Simpson D, McCutchan JA, Grant I, Atkinson JH and the CHARTER Group. Group Test-Retest Reliability and Reliable Change Indices for the Medical Outcomes Survey HIV (MOS-HIV). 15th Conference on Retroviruses and Opportunistic Infections. February 25-28, 2008.
82. Best, B, Letendre S, Koopmans P, Clifford D, Collier A, GELMAN BB, McArthur J, Simpson D, Capparelli E, Ellis R and the CHARTER Group. Low Tenofovir Concentrations in Cerebrospinal Fluid. 15th Conference on Retroviruses and Opportunistic Infections. February 25-28, 2008.
83. Everall IP, Vaida F, Letendre S, Lazzaretto D, GELMAN BB, Morgello S, Singer E, Masliah E, Grant I. Reducing the Risk of Primary HIV Brain Pathology by Antiretrovirals Conference on Retroviruses and Opportunistic Infections. February 25-28, 2008.
84. Clifford D, Kauwe J, Teshome M, Shah A, Spinner M, Morris J, Holtzman D and Fagan A., and CHARTER and NNTC GROUPS. Abnormal CSF Amyloid b42 Levels Link HIV-associated Cognitive Disease and Alzheimer's Disease. 15th Conference on Retroviruses and Opportunistic Infections, Boston, Abstract 396b p. 198. February 3-6, 2008.
85. Baird R, Byrd D, Borod J, Golub S, Morgello S, the Manhattan HIV Brain Bank, and the CHARTER Group. The Effects of Educational Quality on the Cognitive Performance of Minority and Caucasian HIV+ Subjects. 36th Annual Meeting of the International Neuropsychological Society, February 6-9, 2008; Waikoloa, HI.
86. Gongvatana A, Schweinsburg B, Taylor MJ, Theilmann RJ, Letendre SL, Alhasoon OM, Jacobus J, Woods SP, Franklin DR, Jernigan TL, Frank LR, Grant I, the CHARTER Group, and the HNRC Group. HIV-Associated White Matter Tract Injury and Neurocognitive Impairment in the HAART Era. 36th Annual Meeting of the International Neuropsychological Society, February 6-9, 2008; Waikoloa, HI.
87. Harrison TB, Schweinsburg BC, Jacobus J, Theilmann RJ, Taylor MJ, Woods SP, Gongvatana A, Franklin DR, Ellis RJ, Letendre SL, Heaton RK, Frank LR, Grant I,

- Jernigan TL, the CHARTER Group, and the HNRC Group. Abnormal White Matter Signal and Lower CD4 Nadir Independently Predict Lower White Matter Fractional Anisotropy in HIV-infected Individuals. 36th Annual Meeting of the International Neuropsychological Society, February 6-9, 2008; Waikoloa, HI.
88. Jacobus J, Schweinsburg BC, Theilmann RJ, Taylor MJ, Woods SP, Harrison TB, Gongvatana A, Franklin DR, Letendre SL, Ellis RJ, Heaton RK, Frank LR, Grant I, Jernigan TL, the CHARTER Group, and the HNRC Group. Neurocognitive Performance Predicts Altered White Matter Fractional Anisotropy in HIV-infected Individuals. 36th Annual Meeting of the International Neuropsychological Society, February 6-9, 2008; Waikoloa, HI.
89. Schweinsburg BC, Jacobus JJ, Taylor MJ, Harrison TB, Theilmann RJ, Woods SP, Letendre SL, Ellis RJ, Frank LR, Franklin DR, Heaton RK, Grant I, Jernigan TL, the CHARTER Group, and the HNRC Group. Neurochemical Markers of Cellular Integrity Predict White Matter Anisotropy in HIV Infection. 36th Annual Meeting of the International Neuropsychological Society, February 6-9, 2008; Waikoloa, HI.
90. Taylor MJ, Jernigan TL, Schweinsburg BC, Woods SP, Abramson I, Clifford D, Collier A, Ellis RJ, Gamst AC, GELMAN BB, Heaton RK, Letendre S, Marcotte T, Marra C, McArthur JC, McCutchan JA, Morgello S, Simpson D, Grant I, and the CHARTER Group. Frontal White and Gray Matter Integrity Measured by Proton Magnetic Resonance Spectroscopy Predict Different Neuropsychological Functions in HIV-infected Individuals. 36th Annual Meeting of the International Neuropsychological Society, February 6-9, 2008; Waikoloa, HI.
91. Ellis RJ, Marquie-Beck J, Delaney P, Alexander T, Ake C, Clifford D, McArthur JC, Simpson D, Collier A, GELMAN BB, McCutchan JA, Morgello S, Grant I, and the CHARTER Group. Use of Protease Inhibitors Does Not Independently Contribute to Distal Polyneuropathy in HIV Infection. 15th Conference on Retroviruses and Opportunistic Infections; February 3-6, 2008; Boston, MA.
92. Pillai SK, Pasutti WD, McCutchan JA, Marra C, Clifford D, GELMAN BB, Simpson S, McArthur J, Grant I, Wong JK. Validation of a V3-Based Genetic Biomarker of HIV-1 Neurovirulence. 15th Conference on Retroviruses and Opportunistic Infections; February 3-6, 2008; Boston, MA.
93. Gelman BB and Soukup VM. Abnormal dopamine synapses in HIV-1 infection drive circuit specific neurocognitive impairment. *J Neuropathol Exp Neurol* 67:500, 2008.
94. Shanina E, GELMAN BB, Smith RG. Thiamine deficiency in HIV associated NRTI neuropathy. *Ann Neurol* 64 Suppl 12:S62, 2008.
95. Ellis RJ, Rosario D, Clifford D, McArthur JC, Simpson D, Alexander T, GELMAN BB, Grant I. Persisting High Prevalence of HIV Distal Sensory Peripheral Neuropathy

- (DSPN) in the Era of Combination Antiretroviral Therapy (CART): Correlates in the CHARTER Study. 16th Conference on Retroviruses and Opportunistic Infections, February 8-11, Montreal, Canada, 2009.
96. Best, B, Clifford D, Collier A, GELMAN BB, McArthur J, McCutchan A, Morgello S, Grant I and The CHARTER Group. Efavirenz Concentrations Consistently Exceed Wild-type IC50 in Cerebrospinal Fluid: CHARTER Findings. 16th Conference on Retroviruses and Opportunistic Infections, February 8-11, Montreal, Canada, 2009.
 97. Bharti A, Letendre S, Wolfson T, Clifford D, Collier A, GELMAN BB, McArthur J, McCutchan A, Morgello S, Grant I and The CHARTER Group. Clinical Risk Factors Identify Seronegative HCV Co-infection in Substantial Minority, 2009.
 98. McCutchan A, Marquie-Beck J, Letendre S, Heaton, RK, Marra C, Clifford D, GELMAN BB, McArthur J, Morgello S, Grant I. Contributions of Metabolic Syndrome (MS) to Cognitive Impairment (CI) in the CART. Era16th Conference on Retroviruses and Opportunistic Infections, February 8-11, Montreal, Canada, 2009.
 99. Heaton R, Franklin D, Clifford D, Woods S, Rivera-Mindt M, Vigil O, Taylor M, Marcotte T, Atkinson H, GELMAN BB, Grant I. HIV-associated Neurocognitive Impairment (NCI) Remains Prevalent in the era of Combination Antiretroviral Therapy (CART): the CHARTER Study. 16th Conference on Retroviruses and Opportunistic Infections, February 8-11, Montreal, Canada, 2009.
 100. Ances B, Rosario D, Vaida F, Marques-Beck J, Ellis RJ, Simpson D, Clifford D, McArthur J, GELMAN BB, McCutchan JA, and the CNS HIV Antiretroviral Therapy Effects Research (CHARTER) Metabolic Study Group. Metabolic Syndrome (MetS) Risk Factors are Not Elevated in HIV Associated Distal Sensory Polyneuropathy (DSPN). 16th Conference on Retroviruses and Opportunistic Infections, February 8-11, Montreal, Canada, 2009.
 101. Letendre S, McClernon D, Ellis RJ, Muñoz-Moreno J, Clifford D, Collier A, GELMAN BB, Marra C, McArthur J, McCutchan A, Morgello S, Simpson D, Heaton R, Grant I and the CHARTER Group. Persistent HIV in the Nervous System During Treatment is Associated with Worse Antiretroviral Neuroeffectiveness and Cognitive Impairment. 16th Conference on Retroviruses and Opportunistic Infections, February 8-11, Montreal, Canada, 2009.
 102. GELMAN BB, Chen T, Lisinicchia J, Carmical R, Starkey J, Luxon B, Morgello S, Masliah E, Commins D, Brandt D, Singer E, Grant I and the National NeuroAIDS Tissue Consortium. Brain gene array reveals CNS adaptation and two different kinds of HIV-associated neurocognitive disorder. American Association of Neuropathologists 85th Annual Meeting, San Antonio, Texas, June 14, 2009. J Neuropathol Expt Neurol 68:576, 2009.

103. Heaton R, Franklin D, Clifford D, Woods SP, Rivera Mindt M, Vigil MS Taylor M, Marcotte T, Atkinson JH, GELMAN BB, Morgello S, Collier A, McArthur J, Grant I. Continued Prevalence of HIV-associated Neurocognitive Impairment (NCI) in the Era of Combination Antiretroviral Therapy (CART) and the Role of Comorbidities: The CHARTER Study. International Society of Neurovirology, June 2009.
104. Bharti A, Scott Letendre, Tanya Wolfson, David Clifford, Ann Collier, GELMAN BB, Justin McArthur, Allen McCutchan, Susan Morgello, and Igor Grant. Clinical Risk Factors Identify Seronegative HCV Co-infection in Substantial Minority of CHARTER Participants. International Society of Neurovirology, June 2009.
105. Ellis RJ, Rosario D, Clifford D, McArthur JC, Simpson D, Alexander T, Marra C, GELMAN BB, Atkinson JH, Dworkin RH, Grant I. Neuropathic Pain Contributes to an Excess of Unemployment and Disability in HIV Infection: the CHARTER study. International Society of Neurovirology, June 2009.
106. Muñoz-Moreno JA, Letendre S, McClernon D, Ellis RJ, LeBlanc S, Rosario D, Clifford D, Collier A, GELMAN BB, Marra C, McArthur J, McCutchan JA, Morgello S, Simpson D, Franklin D, Heaton RK, Grant I, and the CHARTER Group. Persistent HIV in the central nervous system during treatment is associated with worse antiretroviral therapy penetration and cognitive impairment. International Society of Neurovirology, June 2009.
107. Kallianpur AR, Hulgán T, Wen W, Canter JA, Haas DW, GELMAN BB. Hemochromatosis (HFE) Gene Polymorphisms and HIV-Associated Brain Pathology at Autopsy: Results of a NeuroAIDS DNA Bank Study. International Society of Neurovirology, June 2009.
108. Koeppen A, GELMAN BB, et al. Schwann cell pathology in sensory neuropathy of Friedreich's ataxia (FRDA). 134th Annual Meeting of the American Neurological Association in Baltimore, MD., Poster # WIP-17, October 13th, 2009.
109. Jayraan Badiee, David J. Moore, Florin Vaida, Donald Franklin, Ben Gouaux, J. Allen McCutchan, J. Hampton Atkinson, Robert K. Heaton, Justin McArthur, Susan Morgello, David Simpson, Ann Collier, Christina Marra, GELMAN BB, David Clifford, Igor Grant, and the CHARTER Group. Suicidality and Neuropsychological Impairment in HIV-Infected Persons. International Neuropsychological Society Meeting, February 2010.
110. Kenny Lin, Michael J Taylor Ph.D., Donald Franklin, Robert K. Heaton Ph.D., Igor Grant M.D., GELMAN BB and the CHARTER group. Effects of Mild Traumatic Brain Injury on Cognitive Functioning and Cerebral Metabolites in HIV+ Individuals. International Neuropsychological Society Meeting, February 2010.
111. Muhammad Al-Lozi, Ronald Ellis, Florin Vaida, Chelsea FitzSimons, J. Allen McCutchan, Justin McArthur, Susan Morgello, David Simpson, Ann Collier, Christina Marra, Benjamin Gelman, David Clifford, Scott Letendre, Igor Grant, for the CHARTER

- Group, Peripheral Nerve Function in HIV-infection: Electrophysiological and Quantitative Sensory Test Results in the CHARTER Study. American Association of Neurology. 2010.
112. Letendre, S, FitzSimmons, C, Ellis R, Clifford D, Collier A, GELMAN BB, McArthur J, Vaida F, Heaton R, Grant I. Correlates of CSF viral loads in 1221 volunteers of the CHARTER group. 17th Conference on Retroviruses and Opportunistic Infections, #172, February 16-19, San Francisco, CA, 2010.
 113. Ellis R, Heaton R, Letendre S, Badiee J, Munoz-Moreno J, Vaida F, Clifford D, GELMAN BB, Simpson D, Grant I. Higher CD4 nadir is associated with reduced rates of HIV-associated neurocognitive disorders in the CHARTER Study: Potential implications for early treatment initiation. #429, 17th Conference on Retroviruses and Opportunistic Infections, February 16-19, San Francisco, CA, 2010.
 114. Letendre, S, Ellis R, Deutsch R, Clifford D, Marra C, McCutchan A, Morgello S, Simpson D, Heaton R, GELMAN BB, Grant I and the CHARTER Group. Correlates of time-to-loss-of-viral-response in CSF and plasma in the CHARTER cohort. #430, 17th Conference on Retroviruses and Opportunistic Infections, February 16-19, San Francisco, CA, 2010.
 115. GELMAN BB, Chen T, Lisinicchia J, Carmical R, Starkey J, Luxon B, Morgello S, Masliah E, Commins D, Brandt D, Singer E, Grant I and the National NeuroAIDS Tissue Consortium. Brain gene array reveals CNS adaptation and two different kinds of HIV-associated neurocognitive disorder. #404, 17th Conference on Retroviruses and Opportunistic Infections, February 16-19, San Francisco, CA, 2010.
 116. Ellis, R, Badiee J, Letendre S, Vaida F, Franklin D, Heaton R, Clifford D, Collier C, Marra C, GELMAN B, McArthur J, Morgello S, Simpson D, McCutchan JA, Grant I and the CHARTER Group. Nadir CD4 is a Predictor of HIV Neurocognitive Impairment (NCI) in the era of Combination Antiretroviral Therapy (CART): Results from the CHARTER Study. International AIDS Society Meeting in Vienna, Austria, 2010
 117. Rivera-Mindt M, Taylor M, Marcotte T, Atkinson JH, Collier A Marra C, GELMAN BB, McArthur J, Morgello S, Simpson D, McCutchan JA, Grant I, and the CHARTER and HNRC Groups. Increased Rate of HIV Neurocognitive Impairment (NCI) among non-AIDS Cases in the Post-CART versus Pre-CART era. International AIDS Society Meeting in Vienna, Austria, 2010.
 118. Doyle E. Patton, Steven P. Woods, Donald Franklin, Jr., GELMAN BB, Robert K. Heaton, Igor Grant for The CHARTER Group. Relationship of Medication Management Test-Revised (MMT-R) performance to neuropsychological functioning and antiretroviral adherence in adults with HIV. International Neuropsychological Society Conference, 2010.

119. Heaton R, Franklin D, Ellis R, Letendre S, LeBlanc S, Woods S, Clifford D, Rivera-Mindt M, Taylor M, Marcotte T, Atkinson JH, Collier A, Marra C, GELMAN BB, McArthur J, Morgello S, Simpson D, McCutchan JA, Grant I and the CHARTER and HNRC Groups. HIV-associated Neurocognitive Disorders Before and During the Era of Combination Antiretroviral Therapy International Neuropsychological Society Conference, 2010.
120. Morgan EE, Woods SP, Bloss C, Letendre S, Franklin DO, GELMAN BB, Grant I, Heaton RK, and the CHARTER Group. APOE Genotype Predicts Moderate-to-Severe Neurocognitive Impairment in Caucasian HIV Seropositive Individuals. International Neuropsychological Society Conference, 2010.
121. Malvar JS, Ellis R, Vaida F, Robinson-Papp J, Atkinson H, Fan J, FitzSimons C, Collier A, McCutchan JA, McArthur J, Morgello S, Simpson D, Marra C, GELMAN BB, Clifford D, Letendre S, Grant I and the CHARTER group. Predictors of incident distal neuropathic pain in HIV-infected individuals in the era of combination antiretroviral therapy. 10th International Symposium on NeuroVirology, Milan, Italy, 2011.
122. Christina Marra, R Deutsch, A Collier, S Morgello, S Letendre, D Clifford, B GELMAN, J McArthur, A McCutchan, I Grant, and CHARTER Group. Neurocognitive Impairment in HIV-infected Patients with Past Syphilis 18th Conference on Retroviruses and Opportunistic Infections, Boston MA, 2011.
123. Scott Letendre, D Croteau, R Ellis, D Clifford, B GELMAN, C Marra, J McArthur, A McCutchan, D Simpson, I Grant, and CHARTER Group. Lower CSAR Are Associated with Global Neurocognitive Impairment in Antiretroviral-treated People with HIV. 18th Conference on Retroviruses and Opportunistic Infections, Boston MA, 2011.
124. Asha Kallianpur, R Ellis, C Marra, D Simpson, J McArthur, D Clifford, B GELMAN, A McCutchan, S Letendre, I Grant, and CHARTER Group. Impact of Genetic Variation in Iron Transport Pathways on Neuropathy Morbidity during ART: Results from the CHARTER Genome-wide Study. 18th Conference on Retroviruses and Opportunistic Infections, Boston MA, 2011.
125. E Holzinger, Todd Hulan, R Ellis, D Samuels, D Clifford, A Collier, B GELMAN, S Morgello, S Letendre, I Grant, and CHARTER Group. Full Sequence mtDNA Variation and HIV-SN in the CHARTER Cohort. 18th Conference on Retroviruses and Opportunistic Infections, Boston MA, 2011.
126. George Hightower, J Wong, S Letendre, A Umlauf, R Ellis, C Ignacio, R Heaton, GELMAN, Grant I, Richman D, Smith D, and CHARTER Group. Higher HIV-1 Genetic Diversity Is Associated with AIDS and Neuropsychological Impairment. 18th Conference on Retroviruses and Opportunistic Infections, Boston MA, 2011.
127. Brookie Best, S Letendre, D Croteau, E Capparelli, D Clifford, B GELMAN, C Marra, J

McArthur, D Simpson, I Grant, and CHARTER Group. Therapeutic DRV and ETR Concentrations in CSF. 18th Conference on Retroviruses and Opportunistic Infections, Boston MA, 2011.

128. GELMAN BB, T Chen, J Lisinicchia, D Freeman, and V Soukup. Abnormal Opioid Neuropeptide Expression in HIV Encephalitis. 18th Conference on Retroviruses and Opportunistic Infections, Boston MA, 2011.

129. Clifford D, R Ellis, C Marra, D Simpson, J McArthur, D Clifford, B GELMAN, A McCutchan, S Letendre, I Grant, and CHARTER Group. APOE Genotype is not related to Neurocognitive Function in HIV: 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention Rome, Italy, 17-20 July 2011.

PUBLICATIONS SUBMITTED:

J. Robinson-Papp, B.B. Gelman, I. Grant, E. Singer, G. Gensler and S. Morgello for the National NeuroAIDS Tissue Consortium. Substance abuse increases the risk of neuropathy in an HIV-infected cohort.

Letendre S, Marquie-Beck J, Capparelli E, Best B, Clifford D, Collier AC, GELMAN BB, McArthur JC, McCutchan JA, Morgello S, Simpson D, Grant I, Ellis RJ, and the CHARTER Group. Better Antiretroviral Penetration into the Central Nervous System is Associated with Lower CSF Viral Load. Submitted.

Ellis RJ, Marquie-Beck, J, Delaney P, Alexander T, Clifford D, McArthur JC, Simpson D, Ake C, Collier AC, GELMAN BB, McCutchan, JA, Morgello SM, Grant I and the CHARTER Group. Protease Inhibitors and Peripheral Neuropathy. Submitted.

George K. Hightower, B.A.¹, Joseph K. Wong, M.D.², Scott L. Letendre, M.D.¹, Anya A. Umlauf, Ph.D.¹, Ronald J. Ellis, M.D., Ph.D.^{1,3}, Caroline C. Ignacio¹, B.S., Robert K. Heaton, Ph.D.¹, Ann C. Collier, M.D.⁴, Christina M. Marra, M.D.⁴, David B. Clifford, M.D.⁵, Benjamin B. Gelman, M.D., Ph.D.⁶, Justin C. McArthur, M.B.B.S.⁷, Susan Morgello, M.D.⁸, David M. Simpson, M.D.⁸, JA McCutchan, M.D.¹, Igor Grant, M.D.^{1,3}, Susan J. Little, M.D.¹, Douglas D. Richman M.D.^{1,3}, Davey M. Smith, M.D.^{1,3} and the CHARTER Study Group* Higher HIV-1 Genetic Diversity is Associated with AIDS and Neuropsychological Impairment.

Bharti et al., Clinical Variables Identify Seronegative HCV Co-infection in HIV-Infected Individuals. Journal of Clinical Virology in press

PUBLICATIONS IN PREPARATION:

GELMAN BB, Cook, D, Chen T, Soukup VM, Kolson DL. Interferon gamma induces depression of cortical GABAergic systems in HIV associated dementia.

Benjamin B. Gelman MD, PhD

GELMAN BB, Chen T, Lisiniccia J, Soukup VM. Decreased expression mu and kappa endorphins is linked with abnormal dopaminergic transmission in HIV- associated dementia.

GELMAN BB, Chen, T, Cook D, Kolson DL. Gene expression of HIV encephalitis compared to putative *in vitro* models of HIV-associated neurodegeneration.



PUBLIC VERIFICATION / PHYSICIAN PROFILE

PHYSICIAN

NAME: HAL KENNETH HAWKINS MD

DATE: 08/21/2013

THE INFORMATION IN THIS BOX HAS BEEN VERIFIED
BY THE TEXAS MEDICAL BOARD

Date of Birth: 1945

License Number: G6525 Full Medical License

Issuance Date: 06/13/1984

Expiration Date of Physician's Registration Permit: 05/31/2015

Registration Status: ACTIVE

Registration Date: 12/12/1988

Disciplinary Status: NONE

Disciplinary Date: NONE

Licensure Status: NONE

Licensure Date: NONE

Medical School of Graduation:

At the time of licensure, TMB verified the physician's graduation from medical school as follows:
DUKE UNIV SCH OF MED, DURHAM

Medical School Graduation Year: 1972

TMB Filings, Actions and License Restrictions

The Texas Medical Board has the following board actions against this physician. (This may include any formal complaints filed by TMB, as well as petitions and/or responses related to licensure contested matters, at the State Office of Administrative Hearings.)

NONE

Investigations by TMB of Medical Malpractice

Section 164.201 of the Act requires that: the board review information relating to a physician against whom three or more malpractice claims have been reported within a five year period. Based on these reviews, the following investigations were conducted with the listed resolutions.

NONE

Status History

Status history contains entries for any updates to the individual's registration, licensure or disciplinary status types (beginning with 1/1/78, when the board's records were first automated). Entries are in reverse chronological order; new entries of each type supersede the previous entry of that same type. These records do not display status type. Should you have any questions, please contact our Customer Information Center at 512-305-7030 or verificic@tmb.state.tx.us

Status Code: AC**Effective Date:** 12/12/1988**Description:** ACTIVE**Status Code:** DQ**Effective Date:** 09/01/1988**Description:** DELINQUENT-NON PAYMENT**Status Code:** AC**Effective Date:** 06/13/1984**Description:** ACTIVE

THE INFORMATION IN THIS BOX WAS REPORTED BY THE LICENSEE AND
HAS NOT BEEN VERIFIED BY THE TEXAS MEDICAL BOARD

Gender: MALE***Ethnicity:** WHITE**Race:** WHITE

* We are in the process of transitioning from the current ethnic origin values to federal standards for race and Hispanic origin. The transition period will allow time for individuals to submit updated race and Hispanic origin data to the TMB.

Place of Birth: OKLAHOMA**Current Primary Practice Address:**

UTMB-DEPARTMENT OF PATHOLOGY
300 UNIVERSITY AVE., RT 1220
GALVESTON , TX 77555

Years of Active Practice in the U.S. or Canada:

The physician reports that he/she has actively practiced medicine in the United States or Canada for **41** year(s).

Years of Active Practice in Texas:

The physician reports that, of the above years he/she has actively practiced in the State of Texas for **29** year(s).

Specialty Board Certification

The physician reports that he/she holds the following specialty certifications issued by a board that is a member of the American Board of Medical Specialties or the Bureau of Osteopathic Specialists:

Specialty Certification: AMERICAN BOARD OF PTH/PEDIATRIC PATHOLOGY

Date: 1990

Specialty Certification: AMERICAN BOARD OF PTH/ANATOMIC PATHOLOGY

Date: 1975

Primary Specialty

The physician reports his/her primary practice is in the area of PATHOLOGY.

Secondary Specialty

The physician did not report a secondary practice area.

Name, Location and Graduation Date of All Medical Schools Attended

Name: DUKE UNIVERSITY

Location: DURHAM/USA

Graduation Date: 05/1972

Graduate Medical Education In The United States Or Canada

Program Name: UNIVERSITY FLORIDA

Location: GAINESVILLE, FL

Begin Date: 09/01/1982

Type: FELLOWSHIP

End Date: 08/31/1983

Specialty: PEDIATRIC PATH

Program Name: DUKE UNIVERSITY

Location: DURHAM, NC

Begin Date: 07/1972

Type: RESIDENCY

End Date: 06/1975

Specialty: ANATOMIC PATHOLOGY

Hospital Privileges

The physician reports that he/she has hospital privileges in the following in the State of Texas:

Hospital: UTMB JOHN SEALY HOSPITAL

Location: GALVESTON, TX

Hospital: SHRINERS BURNS HOSPITAL

Location: GALVESTON, TX

Utilization Review

The physician did not report whether he/she provides utilization review.

NONE REPORTED

Patient Services

Accessibility: The physician reports that the patient service area **is** accessible to persons with disabilities as defined by federal law.

Language Translation Services: The physician reports that the following language translation services are provided for patients: SPANISH MANY OTHERS

Medicaid Participant: The physician reports that he/she **does** participate in the Medicaid program.

Awards, Honors, Publications and Academic Appointments

Optional Information

The physician may optionally report descriptions of up to five such honors and has reported the following:

Description: PROFESSOR WITH TENURE, THE UNIVERSITY OF TEXAS MEDICAL BRANCH

Malpractice Information

Section 154.006(b)(16) of the Act requires that: a physician profile display a description of any medical malpractice claim against the physician, not including a description of any offers by the physician to settle the claim, for which the physician was found liable, a jury awarded monetary damages to the claimant, and the award has been determined to be final and not subject to further appeal. The physician has the following reportable claims.

Description: NONE

Criminal History

Self-Reported Criminal Offenses:The physician is required to report a description of (1) "any conviction for an offense constituting a felony, a Class A or Class B misdemeanor, or a Class C misdemeanor involving moral turpitude" and (2) "any charges reported to the board to which the physician has pleaded no contest, for which the physician is the subject of deferred adjudication or pretrial diversion, or in which sufficient facts of guilt were found and the matter was continued by a court of competent jurisdiction."

The physician has reported the following:

Description: NONE

Criminal history information is also obtained by TMB from the Texas Department of Public Safety. Resulting action, if any, will be reported under the

TMB Action and Non-Disciplinary Restrictions section above.

Disciplinary Actions By Other State Medical Boards

The physician has reported the following:

Description: NONE

Physician Assistant Supervision

To obtain
primary source
verifications,
click name

Description: NONE

Advanced Practice Nurse Delegation

To obtain
primary source
verifications,
click name

Description: NONE

Summary of all License/Permit Types

Issue Date:
06/13/1984

Type:
LICENSED PHYSICIAN

Agency | Contact Us | Employment | Compact w/ Texans | Open Records | Privacy Policy | Site Map |
Search TX State Sites | TX Homeland Security | TX Occupations Code |
Texas.gov | Poison Control Center Services | Accessibility Policy

CURRICULUM VITAE

NAME: HAL K. HAWKINS, M.D., Ph.D.

DATE: March 2012

PRESENT POSITION:

Professor
Department of Pathology, Rt. 0747
University of Texas Medical Branch
Galveston, TX 77555-0605
Tel: (409) 770-6635
Pager: 643-4047
Cellular: (713) 447-7570
Fax: (409) 770-6973
E-MAIL: hhawkins@utmb.edu

BIOGRAPHICAL:

Date of Birth:

[REDACTED]

Place of Birth:

Bartlesville, Oklahoma

Citizenship:

U.S.A.

Home Address:

[REDACTED]

SOCIAL SECURITY NUMBER:

[REDACTED]

EDUCATION:

1963 – 1966	Rice University, Houston, Texas – (major in biochemistry)
1968 – 1971	Duke University Graduate School of Arts and Sciences, Durham, North Carolina – Ph.D. Dissertation: Lysosome stability in lethal cell injury. Advisor: Benjamin Trump
1966 – 1972	Duke University Medical School, Durham, North Carolina – M.D.
1972 – 1975	Residency in Anatomic Pathology, Duke University Medical Center, Durham, North Carolina
1982 – 1983	Fellowship in Developmental and Pediatric Pathology, University of Florida, Gainesville, Florida

PROFESSIONAL AND TEACHING EXPERIENCE:

2002 – Present	Professor Department of Pathology University of Texas Medical Branch Galveston, Texas
----------------	--

2002- Present	Professor Department of Pediatrics (secondary) University of Texas Medical Branch
1994 – Present	Member Graduate School of Biomedical Sciences University of Texas Medical Branch
1993 – 2002	Associate Professor Department of Pathology University of Texas Medical Branch
1993 – 2002	Associate Professor Department of Pediatrics (secondary) University of Texas Medical Branch
1983 – 1993	Assistant Professor Department of Pathology Baylor College of Medicine Houston, Texas
1991 – 1993	Assistant Professor Department of Pediatrics (secondary) Baylor College of Medicine Houston, Texas
1979 – 1983	Assistant Professor Department of Pathology and Laboratory Medicine Emory University Atlanta, Georgia (leave of absence for fellowship training, 1982-83)
1973 – 1979	Assistant Professor Department of Pathology Duke University Durham, North Carolina

OTHER APPOINTMENTS:

2011	Medical Director, Clinical Laboratories Shriners Hospitals for Children Galveston Burns Hospital
1996 – 2008	Head, Department of Pathology Shriners Hospitals for Children Galveston Burns Hospital
1993 – Present	Co-Director, Pathology and Morphology Core Laboratory, Shriners Hospitals for Children Galveston Burns Hospital
1993 – Present	Medical Director, Electron Microscopy Laboratory, Department of Pathology University of Texas Medical Branch

RESEARCH ACTIVITIES:

A. Areas of research:

My major research interests are in the inflammatory and reparative reactions to tissue injury. Current work is directed at elucidating the mechanisms involved in the responses of the respiratory tract to inhalation of toxic smoke, especially those involving neural reactions to toxic compounds in smoke and the effects of CGRP and other neuropeptides.

B. Currently funded grant support:

I serve as co-director and P.I. of the pathology and morphology core facility of the Shriners Hospitals for Children, Galveston Unit, which functions primarily to provide support to multiple investigators involved in basic and applied burn research and to develop new projects and improved methodology for studies of injured tissues. Shriners Hospitals for Children funds this lab for calendar year 2012 with direct costs of \$200,826. I also have a Shriners grant focused on study of the role of neuropeptides in smoke inhalation injury in a large animal model that is funded for \$182,875 for 2012.

COMMITTEE RESPONSIBILITIES:

- National: Slide Survey Committee, Society for Pediatric Pathology, 2010-present
Education Committee, Society for Pediatric Pathology, 2007-present
- Local: Shriners Burns Hospital, Medical Executive Committee, 1996-present
Advisory Board, UTMB Academy of Master Teachers, 2007-present
Academic Planning and Policy Committee, 2011-14.

TEACHING RESPONSIBILITIES:

A. Medical school:

Lecture in PHD course. Serve as laboratory instructor in the MCT, PHD, CVP and GIN courses. Also supervise students in the elective in pediatric pathology.

B. Graduate school of biomedical sciences:

Co-director, modular course, Fundamentals of Inflammation, BBSC 6210.

Course director, PATH 6266, Pathobiology of Human Disease, for second-year students.

Committees:

Exp. Path. Curriculum and Academic Planning Committee, 2011 - present

Served on Preliminary Examination Committees for:

- E. D. Murphey
- Kathleen Marriott
- Vicente Santa Cruz
- Ray Stowe
- Adrian Billings
- Arun Balakumaran
- Marcela Diaz
- Robert Cox
- Michelle Zacks
- Danyel Tacker
- Ted Whitworth
- Kate McElroy
- Amber Engel
- Kimberly Nethery
- Michael Woods
- Yvette Girard
- Heather Stephenson
- Eleanor Deardorff (chair)
- Joan Kenney

- Trevor Pitcher (chair)
- Allison Mayo (chair)
- Kenneth Plante
- Ashley Grant (chair)
- John Nuckols
- Eliza Fuhr
- Olga Kolokoltsova
- Sandra Mayer

Served as member of Dissertation Supervisory Committees for:

- E. D. Murphey
- Roque Ramirez (MS in Biomedical Sciences program)
- Toby Smith
- Marc Jeschke, MD (Master of Medical Science)
- Robert Cox
- Amy Shurtleff
- Danyel Tacker
- Monica Longo
- Aimalohie Esechie
- Lauren Foresman
- Fangxian Lu
- Ludwik Branski
- Tiffany Etheridge
- Linda Sousse

C. Graduate medical education:

Teach residents in pediatric and perinatal pathology and diagnostic electron microscopy.

DIAGNOSTIC SERVICE RESPONSIBILITIES:

Supervise and sign out pediatric and perinatal autopsies, 48 weeks per year.
 Sign out surgical pathology reports on placentas, 48 weeks per year.
 Sign out pediatric tumor cases and other pediatric surgicals 48 weeks per year.

MEMBERSHIP IN SCIENTIFIC SOCIETIES:

1971	Microscopy Society of America
1975	U.S.-Canadian Academy of Pathology
1975	Society for Pediatric Pathology (slide survey committee)
1985	Texas Society for Microscopy (President, 1993-1994)
1987	New York Academy of Sciences
1988	Sigma Xi
1990	Society for Diagnostic Ultrastructural Pathology
1996	American Burn Association
2008	International Society for Burn Injuries

BOARD CERTIFICATION:

Certificate in Anatomic Pathology, American Board of Pathology, 1975

Certificate of special qualification in pediatric pathology, American Board of Pathology, 1990

LICENSURE:

Texas State Board of Medical Examiners, #G6525. Expiration date: 5/31/2013

HONORS AND AWARDS:

- 1968 Medical Scientists Training Program scholarship, Duke University, Durham, NC
- 1966 Full scholarship, Duke University Medical School, Durham, NC
- 1962 Fleming Scholarship, Oklahoma Medical Research Foundation, Oklahoma City

INVITED PRESENTATIONS:

- 1989 Organized symposium on "Abnormal expression of human macromolecules" for The national meeting of the Electron Microscopy Society of America, San Antonio, TX.
- 1991 Organized international symposium on Golgi structure and function in honor of Hilton Mollenhauer, for the Texas Society of Electron Microscopy, Nassau Bay, TX. (Published in Protoplasma 172:1-26, 1993.)
- 1992, 1993 Presented workshops on colloidal gold immunolabeling at meetings of the Texas Society for Electron Microscopy.
- 2005 Invited presentation on perinatal pathology at IAP 2005, the Fourth Asia-Pacific Pathology Conference, Beijing, China
Invited presentation at the DaVinci Society, Camogli, Italy
- 2007 Invited presentation on the forensic autopsy, at "Advances in Laboratory Medicine," King Abdulaziz University Hospital, Jeddah, Saudi Arabia

SERVICE AS REVIEWER:

Review manuscripts for Clinical Science, American Journal of Physiology, Journal of Pathology, Journal of Burn Care and Research and Journal of Perinatology. Also, review grant proposals for the biotechnology program of the state of Arizona.

BIBLIOGRAPHY:

ARTICLES IN PEER REVIEWED JOURNALS:

1. Kelly JW, Clabaugh WA, Hawkins HK. Photographic cytophotometry with a dual microscope, II. *J Histochem Cytochem* 12:600-04, 1964.
2. Dudley AW, Hawkins HK. Mineralization of the central nervous system in pseudopseudohypoparathyroidism (PPH). *J Neurol Neurosurg Psych* 33:147-52, 1970.
3. Saladino AJ, Hawkins HK. Ion movements in cell injury: Effects of the cationic detergent cetyl pyridinium chloride on the ultrastructure and function of the toad bladder. *Am J Pathol* 64:271-94, 1971.
4. Hawkins HK, Ericsson JLE, Biberfeld P, Trump BF. Lysosome and phagosome stability in lethal cell injury. *Am J Pathol* 68:255-88, 1972.
5. Stone RA, Tisher CC, Hawkins KH, Robinson RR. Juxtaglomerular hyperplasia and hyperreninemia in progressive systemic sclerosis complicated by acute renal failure. *Am J Med* 56:119-23, 1974.
6. Kane RD, Hawkins HK, Miller JA, Noce PS. Microscopic pulmonary tumor emboli associated with dyspnea. *Cancer* 36:1473-82, 1975.

ARTICLES IN PEER REVIEWED JOURNALS: (Cont'd)

7. Schwartz JN, Cashwell F, Hawkins HK, Klintworth GK: Necrotizing retinopathy with herpes zoster ophthalmicus. *Arch Pathol Lab Med* 100:386-91, 1976.
8. Mitchener JS, Bradford WD, Shelburne JD, Hawkins HK. Cellular autophagocytosis induced by deprivation of serum and amino acids in HeLa cells. *Am J Pathol* 83:485-98, 1976.
9. Shelburne JD, Ingram P, Hawkins HK, Waters MD. X-ray mapping of lysosomal inclusions. *Scan Elect Microscopy* 485-500, 1976.
10. Klintworth GK, Reed JW, Hawkins KH, Ingram P. Calcification of soft contact lenses in patient with dry eye and elevated calcium concentration in tears. *Invest Ophthalmol Visual Sci* 16:158-61, 1977.
11. Bradford WD, Hawkins HK. Rocky mountain spotted fever in childhood. *Am J Dis Child* 131:1228-232, 1977.
12. Gosden RG, Hawkins HK, Gosden CA. Autofluorescent particles of human uterine muscle cells. *Am J Pathol* 91:155-74, 1978.
13. Jennings RB, Hawkins HK, Lowe JE, Hill ML, Klotman S, Reimer KA. Relation between high energy phosphate and lethal injury in myocardial ischemia in the dog. *Am J Pathol* 92:187-214, 1978.
14. Sharov VG, Jennings RB, Lowe J, Reimer K, Hawkins HK. On the importance of changes in cardiomyocytes in the development of acute cardiac insufficiency in experimental myocardial infarction. *Arkiv Patologiyeh (Moscow)* 41:9-14, 1979.
15. Klintworth GK, Hawkins HK, Smith CF. Acridine orange particles in cultured fibroblasts – a comparative study of systemic mucopolysaccharidoses types IH and II and normal controls. *Arch Pathol Lab Med* 103:297-299, 1979.
16. Lowe JE, Hawkins HK, Jennings RB. Relationship between depletion of high energy phosphate compounds and lethal ischemic myocardial cell injury. *Surg Forum* 29:247-250, 1979.
17. Kim TH, Hargreaves HK, Brynes RK, Hawkins HK, Lui VK, Woodard J. Ragab AH. Pretreatment testicular biopsy in childhood acute lymphocytic leukemia. *Lancet* ii: 657-658 Sept. 26, 1981.
18. Walker DH, Hawkins HK, Hudson P. Fulminant rocky mountain spotted fever: Its pathologic characteristics associated with glucose-6-phosphate dehydrogenase deficiency. *Arch Pathol Lab Med* 107:121-125, 1983.
19. Guyton RA, Dorsey LM, Silberman MS, Hawkins HK, Williams WW, Hatcher CR. The broadly based pericardial flap: A tissue for atrial wall replacement that grows. *J Thor Cardio Surg* 87:619-625, 1984.
20. Trulock TS, Ricketts RR, Verras A, Kim TH, Hawkins HK, Woodard JR. Wilms' tumor arising in horseshoe kidney. *Urology* 25:306-309, 1985.
21. Hawkins EP, Finegold MJ, Hawkins HK, Krischer JK, Starling KA, Weinberg A. Nongerminomatous malignant germ cell tumors in children. A review of 89 cases from the Pediatric Oncology Group, 1971-1984. *Cancer* 58:2579-2584, 1986.
22. Hashimoto K, Bale GF, Hawkins HK, Langston C, Pritzker MS. Congenital self-healing reticulohistiocytosis (Hashimoto-Pritzker type). *Int J Dermatol* 25:516-523, 1986.
23. Hawkins EP, Hawkins HK, Armstrong D. Lymphocyte autofluorescence: A screening procedure for neurodegenerative diseases. *Pediatr Neurol* 2:160-166, 1986.

ARTICLES IN PEER REVIEWED JOURNALS: (Cont'd)

24. Donnelly WH, Hawkins HK. Optimal examination of the normally formed perinatal heart. *Hum Pathol* 18:55-60, 1987.
25. Hawkins HK, Camacho-Velasquez JV. Rhabdomyosarcoma in children: Correlation of form and prognosis in one institution's experience. *Am J Surg Pathol* 11(7):531-542, 1987.
26. Gospe SM, Armstrong DL, Gresik MV, Hawkins HK. Life-threatening congestive heart failure as the presentation of centronuclear myopathy. *Pediatr Neurol* 3:117-120, 1987.
27. Carlson JA, Rogers BB, Sifers RN, Hawkins HK, Finegold MJ, Woo LS. Multiple tissues express alpha-1-antitrypsin in transgenic mice and man. *J Clin Invest* 82:26-36, 1988.
28. Lifschitz CH, Hawkins HK, Guerra C, Byrd N. Anaphylactic shock due to cow's milk protein hypersensitivity in a breast-fed infant. *J Pediatr Gastroenterol Nutr* 7:141-144, 1988.
29. Kessler BH, Cochran WS, Wagner ML, Hawkins HK, Klish WJ. Graft-versus-host disease: Gastrointestinal involvement with a rectovaginal fistula. *J Pediatr Gastroenterol Nutr* 7:288-292, 1988.
30. Hawkins HK, Rehm LS. Immunogold labeling in pathology. *TSEM Journal* 19:15-20, 1988.
31. Katz JA, Mahoney DH, Shukla LW, Smith CW, Gresik MV, Hawkins HK. Endovascular papillary angioendothelioma in the spleen. *Pediatr Pathol* 8:185-193, 1988.
32. Fine JD, Eady RA J, Levy ML, Hejtmancik JF, Courtney KG, Carpenter RJ, Holbrook KA, Hawkins HK. Prenatal diagnosis of dominant and recessive dystrophic epidermolysis bullosa: Application and limitations in the use of KF-1 and LH 7:2 monoclonal antibodies and immunofluorescence mapping technique. *J Invest Dermatol* 91:465-471, 1988.
33. Diaz DM, Smith RJH, Adams JM, Hawkins KH. Tracheal agenesis: A case report and literature review. *Arch Otolaryngol* 115:741-745, 1989.
34. Sharif DS, Huhta JC, Marantz P, Hawkins HK, Yoon GY. Two-dimensional echocardiographic determination of ventricular septal defect size: Correlation with autopsy. *Am Heart J* 117:1333-1336, 1989.
35. Sifers RN, Rogers BB, Hawkins HK, Finegold MJ, Woo SLC. Elevated synthesis of human alpha-1-antitrypsin hinders the secretion of murine alpha-1-antitrypsin from hepatocytes of transgenic mice. *J Biol Chem* 264(15):696-700, 1989.
36. Benke TA, Clark JW, Wisoff PJ, Schneider S, Balasubramaniam C, Hawkins HK, Laurent J, Perling L, Shehab A. Comparative study of suture and laser-assisted anastomoses in rat sciatic nerves. *Lasers Surg Med* 9:602-615, 1989.
37. Truong LD, Rangdaeng S, Cagle P, Ro JY, Hawkins H, Font RL. The diagnostic utility of desmin: A study of 584 cases. *Am J Clin Pathol* 93:305-314, 1990.
38. Hawkins EP, Krischer JP, Smith BE, Hawkins HK, Finegold MJ. Nasopharyngeal carcinoma in children—a retrospective review and demonstration of Epstein-Barr viral genomes in tumor cell cytoplasm: A report of the Pediatric Oncology Group. *Hum Pathol* 21:801-810, 1990.
39. Rabinovitz RS, Hartley CJ, Michael LH, Hawkins KH, Sekela ME, Noon GP. Implantable sensor for intraoperative and postoperative monitoring of blood flow: A preliminary report. *J Vasc Surg* 12:148-157, 1990.
40. Lewis LL, Hawkins HK, Edwards MS. Disseminated mucormycosis in an infant with methylmalonic aciduria. *Pediatr Infect Dis J* 9:851-854, 1990.

ARTICLES IN PEER REVIEWED JOURNALS: (Cont'd)

41. Smith CW, Entman ML, Lane CL, Beaudet AL, Ty TI, Youker K, Hawkins HK, Anderson DC. Adherence of neutrophils to canine cardiac myocytes *in vitro* is dependent on intercellular adhesion molecule-1. *J Clin Invest* 88:1216-1223, 1991.
42. Hawkins KH, Heffelfinger SC, Anderson DC. Leukocyte adhesion deficiency: Clinical and postmortem observations. *Pediatr Pathol* 12:119-130, 1992.
43. Hawkins HK, Rehm LS, Zhu JY. Colloidal gold labeling of sections and cell surfaces. *Ultrastruct Pathol* 16:61-70, 1992.
44. Hayani A, Mahoney DH Jr, Hawkins HK, Steuber CP, Hurwitz R, Fernbach DJ. Soft-tissue sarcomas other than rhabdomyosarcoma in children. *Med Pediatr Oncol* 20:114-118, 1992.
45. Dominey AM, Hawkins HK, Levy ML. Congenital cutaneous and subcutaneous nodules. *Pediatr Dermatol* 9:304-306, 1992.
46. Rowen JL, Correa AG, Sokol DM, Hawkins HK, Levy ML, Edwards MS. Invasive aspergillosis in neonates: Report of five cases and literature review. *Pediatr Infect Dis J* 11:576-582, 1992.
47. Dore M, Hawkins HK, Entman ML, Smith CW. Production of a monoclonal antibody against canine GMP-140 (P-selection) and studies of its vascular distribution in canine tissues. *Vet Pathol* 30:213-222, 1993.
48. Ackermann MR, Kehrl ME Jr, Hawkins HK, Amenson JL, Gallagher JE. Identification of β_2 integrins in bovine neutrophils by scanning electron microscopy in the backscatter mode and transmission electron microscopy. *Vet Pathol* 30:296-298, 1993.
49. Kukielka GL, Hawkins HK, Michael L, Manning AM, Youker K, Lane C, Entman ML, Smith CW, Anderson DC. Regulation of intercellular adhesion molecule-1 (ICAM-1) in ischemic and reperfused canine myocardium. *J Clin Invest* 92:1504-1516, 1993.
50. Margraf LR, Finegold MJ, Stanley LA, Major A, Hawkins HK, DeMayo FJ. Cloning and tissue-specific expression of the cDNA for the mouse Clara cell 10 kD protein: Comparison of endogenous expression to rabbit uteroglobin promoter-driven transgene expression. *Am J Resp Cell Mol Biol* 9:231-238, 1993.
51. Sligh JE, Ballantyne CM, Rich SS, Hawkins HK, Smith CW, Bradley A, Beaudet AL. Inflammatory and immune responses are impaired in mice deficient in intercellular adhesion molecule 1. *Proc Nat Acad Sci* 90:8529-8533, 1993.
52. Youker KA, Hawkins HK, Kukielka GL, Perrard JL, Michael LH, Ballantyne CM, Smith CW, Entman ML. Molecular evidence for a border zone vulnerable to inflammatory reperfusion injury. *Trans Assoc Am Physicians* 106:145-154, 1994.
53. Murray JC, Gmoser DJ, Barnes DA, Oshman D, Hawkins HK, Gresik MV, Dreyer ZE. Isolated bone relapse during hematologic remission in childhood acute lymphoblastic leukemia: Report of a metatarsal relapse and review of the literature. *Med Pediatr Oncol* 23:153-157, 1994.
54. Kukielka GL, Youker KA, Hawkins HK, Perrard JL, Michael LH, Ballantyne CM, Smith CW, Entman ML. Regulation of ICAM-1 and IL-6 in myocardial ischemia: Effect of reperfusion. *Ann NY Acad Sci* 723:258-270, 1994.
55. Rossen RD, Michael LH, Hawkins HK, Youker K, Dreyer WJ, Baughn RE, Entman ML. Cardiocalyx-protein complexes and initiation of complement activation after coronary artery occlusion. *Circ Res* 75:546-555, 1994.
56. Jevon GP, Dunne WM Jr, Hawkins HK, Armstrong DL, Musser JM. Fatal group A streptococcal meningitis and toxic-shock-like syndrome: Case report. *Clin Infect Dis* 18:91-93, 1994.

ARTICLES IN PEER REVIEWED JOURNALS: (Cont'd)

57. Youker KA, Hawkins HK, Kukielka GL, Perrard JL, Michael LH, Ballantyne CM, Smith CW, Entman ML. Molecular evidence for induction of intracellular adhesion molecule-1 in the viable border zone associated with ischemia-reperfusion injury of the dog heart. *Circulation* 89:2736-2746, 1994.
58. Kukielka GL, Smith CW, LaRosa GL, Manning AM, Mendoza LH, Daly TJ, Hughes BJ, Youker KA, Hawkins HK, Michael LH, Rot A. Interleukin-8 gene induction in the myocardium after ischemia and reperfusion *in vivo*. *J Clin Invest* 95:89-103, 1995.
59. Jones D, Kay M, Craigen W, McCabe E, Hawkins HK, Dominey A. Coal-black hyperpigmentation at birth in a child with congenital adrenal hypoplasia. *J Am Acad Dermatol* 33:323-326, 1995.
60. Cheirif J, Narkiewicz-Jodko JB, Hawkins HK, Bravenec JS, Quinones MA, Mickelson JK. Myocardial contrast echocardiography: Relation of collateral perfusion to extent of injury and severity of contractile dysfunction in a canine model of coronary thrombosis and reperfusion. *J Am Coll Cardiol* 26:537-546, 1995.
61. Mickelson JK, Kukielka G, Bravenec JS, Mainolfi E, Rothlein R, Hawkins HK, Kelly JH, Smith CW. Differential expression and release of CD54 induced by cytokines. *Hepatology* 22:866-875, 1995.
62. Herndon DN, Hawkins HK, Nguyen TT, Pierre E, Cox R, Barrow RE. Characterization of growth hormone enhanced donor site healing in patients with large cutaneous burns. *Ann Surg* 221(6):649-659, 1995.
63. Hartley CJ, Youker KA, Zhu J, Hall SR, Hawkins HK. Myocardial ischemia and reperfusion: A murine model. *Am J Physiol* 269:H2147-2154, 1995.
64. Kumar N, Sapire DW, Lockhart LH, McCombs JL, Hawkins HK, Van Mierop LHS. Letter to the Editor: Atrioventricular septal defect with pulmonary atresia in DiGeorge anomaly: Expansion of the cardiac Phenotype. *Am J Med Genetics* 61:89-91, 1996.
65. Hawkins HK, Entman ML, Zhu JY, Youker KA, Berens K, Dore M, Smith CW. Acute inflammatory reaction after myocardial ischemic injury and reperfusion. Development and use of a neutrophil-specific antibody. *Am J Pathol* 148(6):1957-1969, 1996.
66. Ballantyne CM, Masri BM, Clubb FJ, Radovancevic B, Smith CW, Hawkins HK, Frazier OH, Willerson JT. Increased expression of ICAM-1 in a case of accelerated coronary artery disease after heart transplantation. *Tex Heart Inst J* 23:293-295, 1996.
67. Birdsall HH, Green D, Trial J, Youker KA, Burns AR, MacKay CR, LaRosa GJ, Hawkins HK, Smith CW, Michael LH, Entman ML, Rossen RD: Complement C5a, TFG- β 1, and MCP-1, in sequence, induce migration of monocytes into ischemic canine myocardium within the first one to five hours after reperfusion. *Circulation* 95:684-692, 1997.
68. Kumar AG, Ballantyne CM, Michael LH, Kukielka GL, Youker KA, Lindsay ML, Hawkins HK, Birdsall HH, MacKay CR, LaRosa GJ, Rossen RD, Smith CW, Entman ML. Induction of monocyte chemoattractant protein-1 in the small veins of the ischemic and reperfused canine myocardium. *Circulation* 95:693-700, 1997.
69. Shin CS, Han JU, Kim JL, Schenarts PJ, Traber LD, Hawkins H, Traber DL. Heparin attenuated neutrophil infiltration but did not affect renal injury induced by ischemia reperfusion. *Yonsei Med J* 38:133-141, 1997.
70. Pierre EJ, Barrow RE, Hawkins HK, Nguyen TT, Sakurai Y, Desai MH, Wolfe RR, Herndon DN. Effects of insulin on wound healing. *J Trauma: Injury, Infection, and Critical Care* 44(2):342-345, 1998.

ARTICLES IN PEER REVIEWED JOURNALS: (Cont'd)

71. Klein GL, Dallas JS, Hawkins HK, Swischuk LE, McCauley RL. Congenital linear sebaceous nevus syndrome. *J Bone Min* 13(6):1056-1057, 1998.
72. Alagappan A, Shattuck KE, Rowe T, Hawkins H. Massive intracranial immature teratoma with extracranial extension into oral cavity, nose, and neck. *Fetal Diagn Ther* 13:321-324, 1998.
73. Bidani A, Hawkins HK, Wang CZ, Heming TA. Dose dependence and time course of smoke inhalation injury in a rabbit model. *Lung* 177:111-122, 1999
74. Jiang Z, Nagata N, Molina E, Bakaletz LO, Hawkins HK, Patel JA. Fimbria-mediated enhanced attachment of nontypeable *Haemophilus influenzae* to respiratory syncytial virus-infected respiratory epithelial cells. *Inf Immun* 67(1):187-192, 1999.
75. Banerji TK, Maitra JR, Basu A, Hawkins HK. Lithium-induced alterations in the testis of the Roseringed parakeet (*Psittacula krameri*): evidence for significant changes and disruption in the spermatogenic activity. *Endocr Res* 25(1):35-49, 1999.
76. Sakurai H, Schmalstieg F, Traber L, Hawkins H, Traber D. Role of L-selectin in physiological manifestations after burn and smoke inhalation injury in sheep. *J Appl Physiol*, 86:1151-1159, 1999.
78. Jeschke MG, Barrow RE, Hawkins HK, Chrysopoulo MT, Perez-Polo JR, Herndon DN. Effect of multiple gene transfers of insulinlike growth factor I complementary DNA gene constructs in rats after thermal injury. *Archives Surg* 134:1137-1141, 1999.
79. Jeschke MG, Barrow RE, Hawkins HK, Yang K, Hayes RL, Lichtenbelt BJ, Perez-Polo JR, Herndon DN. IGF-1 gene transfer in thermally injured rats. *Gene Therapy* 6:1015-1020, 1999.
80. Molina CP, Hawkins H, Campbell G, Rowe T, Grafe M. Case of the month: January 1999 – Fetus with echogenic mass in third ventricle. *Brain Path* 9:605-606, 1999.
81. Jeschke MG, Barrow RE, Hawkins HK, Tao Z, Perez-Polo JR, Herndon DN. Biodistribution and feasibility of non-viral IGF-1 gene transfers in thermally injured skin. *Lab Invest* 80:151-158, 2000.
82. Elgio GI, Traber DL, Hawkins HK, Kramer GC. Burn resuscitation with two doses 4 ml/kg hypertonic saline dextran provides sustained fluid sparing. A 48-h prospective study in conscious sheep. *J Trauma* 49:251-263, 2000.
83. Bi LX, Simmons DJ, Hawkins H, Cox R, Mainous E. Comparative morphology of the marrow sac. *Anat Rec* 260:410-415, 2000.
84. Popnikolov NK, Payne Da, Hudnall SD, Hawkins HK, Kumar M, Norris BA, Elghetany MT. CD13-positive anaplastic large cell lymphoma of T-cell origin - A diagnostic and histogenetic problem. *Arch Pathol Lab Med* 124: 1804-1808, 2000.
85. Friedman NR, Pachigolla R, Deskin RW, Hawkins HK. Optimal technique to diagnose primary ciliary dyskinesia. *Laryngoscope* 110:1548-1551, 2000.
86. Schenarts PJ, Schmalstieg FC, Hawkins H, Bone HG, Traber LD, Traber DL. Effects of an L-selectin antibody on the pulmonary and systemic manifestations of severe smoke inhalation injuries in sheep. *J Burn Care Rehabil* 21:229-240, 2000.
87. Walden JL, Garcia H, Hawkins H, Crouchet JR, Traber L, Gore DC. Both dermal matrix and epidermis contribute to an inhibition of wound contraction. *Ann Plast Surg* 45:162-166, 2000.

ARTICLES IN PEER REVIEWED JOURNALS: (Cont'd)

88. Tao Z, Herndon D, Hawkins H, Wood T, Perez-Polo R. Insulin-like growth factor-I cDNA gene transfer *in vitro* and *in vivo*. *Biochem Genet* 38:41-55, 2000.
89. Murphey ED, Chattopadhyay N, Bai M, Kifor O, Harper D, Traber D, Hawkins HK, Brown EM, Klein GL. Up-regulation of the parathyroid calcium-sensing receptor following burn injury in sheep: a potential contributory factor to post-burn hypocalcemia. *Crit Care Med* 28:3885-90, 2000.
90. Soejima K, Traber LD, Schmalstieg FC, Hawkins H, Jodoin JM, Szabo C, Szabo E, Varig L, Salzman A, Traber DL. Role of nitric oxide in vascular permeability after combined burn and smoke inhalation injury. *Am J Respir Crit Care Med* 163:745-752, 2001.
91. Jeschke MG, Low JF, Spies M, Vita R, Hawkins HK, Herndon DN, Barrow RE. Cell proliferation, apoptosis, NF-kappaB expression, enzyme, protein, and weight changes in livers of burned rats. *Am J Physiol Gastrointest Liver Physiol* 280:G1314-20, 2001.
92. Ventura KC, Hawkins H, Smith MB, Walker DH. Fatal neonatal echovirus 6 infection: autopsy case report and review of the literature. *Mod Pathol* 14:85-90, 2001.
93. Banerji TK, Maitra SK, Dey M, Hawkins HK. Gametogenic responses of the testis in spotted munia (*Lonchura punctulata*, Aves) to oral administration of lithium chloride. *Endocr Res* 27:345-56, 2001.
94. Chiles LR, Christian MM, McCoy DK, Hawkins HK, Yen AH, Raimel SS. Langerhans cell histiocytosis in a child while in remission for acute lymphocytic leukemia. *J Am Acad Dermatol* 45:S233-4, 2001.
95. Cox RA, Soejima K, Burke AS, Traber LD, Herndon DN, Schmalstieg FC, Traber DL, Hawkins HK. Enhanced pulmonary expression of endothelin-1 in an ovine model of smoke inhalation injury. *J Burn Care Rehab* 22:375-83, 2001.
96. Sporri S, Chopra V, Egger N, Hawkins HK, Motamedi M, Dreher E, Schneider H. Effects of 5-aminolaevulinic acid on human ovarian cancer cells and human vascular endothelial cells *in vitro*. *J Photochem Photobiol B* 64:8-20, 2001.
97. Sakurai H, Nozaki M, Traber LD, Hawkins HK, Traber DL. Microvascular changes in large flame burn wound in sheep. *Burns* 28:3-9, 2002.
98. Wolfe RR, Martini WZ, Irtun O, Hawkins HK, Barrow RE. Dietary fat composition alters pulmonary function in pigs. *Nutrition* 18:647-53, 2002.
99. Syed S, Haque AK, Hawkins HK, Sorensen PH, Cowan DF. Desmoplastic small round cell tumor of the lung. *Arch Pathol Lab Med* 126:1226-8, 2002.
100. Murakami K, Bjertnaes LJ, Schmalstieg FC, McGuire R, Cox RA, Hawkins HK, Herndon DN, Traber LD, Traber DL. A novel animal model of sepsis after acute lung injury in sheep. *Crit Care Med* 30:2083-90, 2002.
101. Murakami K, McGuire R, Cox RA, Jodoin JM, Bjertnaes LJ, Katahira J, Traber LD, Schmalstieg FC, Hawkins HK, Herndon DN, Traber DL. Heparin nebulization attenuates acute lung injury in sepsis following smoke inhalation in sheep. *Shock* 18:236-41, 2002.
102. Katahira J, Murakami K, Schmalstieg FC, Cox R, Hawkins H, Traber LD, Traber DL. Role of anti-L-selectin antibody in burn and smoke inhalation injury in sheep. *Am J Physiol Lung Cell Mol Physiol* 283:L1043-50, 2002.

ARTICLES IN PEER REVIEWED JOURNALS: (Cont'd)

103. Shimoda K, Murakami K, Enkhbaatar P, Traber LD, Cox RA, Hawkins HK, Schmalstieg FC, Komjati K, Mabley JG, Szabo C, Salzman AL, Traber DL. Effect of poly (ADP-ribose) synthetase inhibition on burn and smoke inhalation injury in sheep. *Am J Physiol Lung Cell Mol Physiol* 285:L240-9, 2003.
104. Murakami K, Enkhbaatar P, Shimoda K, Mizutani A, Cox RA, Schmalstieg FC, Jodoin JM, Hawkins HK, Traber LD, Traber DL. High-dose heparin fails to improve acute lung injury following smoke inhalation in sheep. *Clin Sci* 104:349-56, 2003.
105. Chandra A, Katahira J, Schmalstieg FC, Murakami K, Enkhbaatar P, Cox RA, Hawkins HK, Traber LD, Herndon DN, Traber DL. P-selectin blockade fails to improve acute lung injury in sheep. *Clin Sci* 104:313-21, 2003.
106. Murakami K, McGuire R, Cox RA, Jodoin JM, Schmalstieg FC, Traber LD, Hawkins HK, Herndon DN, Traber DL. Recombinant antithrombin attenuates pulmonary inflammation following smoke inhalation and pneumonia in sheep. *Crit Care Med* 31:577-83, 2003.
107. Enkhbaatar P, Murakami K, Shimoda K, Mizutani A, Traber L, Phillips GB, Parkinson JF, Cox R, Hawkins H, Herndon D, Traber D. The inducible nitric oxide synthase inhibitor BBS-2 prevents acute lung injury in sheep after burn and smoke inhalation injury. *Am J Respir Crit Care Med* 167:1021-1026, 2003.
108. Enkhbaatar P, Murakami K, Shimoda K, Mizutani A, McGuire R, Schmalstieg F, Cox R, Hawkins H, Jodoin J, Lee S, Traber L, Herndon D, Traber DL. Inhibition of neuronal nitric oxide synthase (nNOS) by 7-nitroindazole attenuates acute lung injury in an ovine model. *Am J Physiol Regul Integr Comp Physiol* 285:R366-72, 2003.
109. Murakami K, Cox RA, Hawkins HK, Schmalstieg FC, McGuire RW, Jodoin JM, Traber LD, Traber DL. Cepharanthin, an alkaloid from *Stephania cepharantha*, inhibits increased pulmonary vascular permeability in an ovine model of sepsis. *Shock* 20:46-51, 2003.
110. Cox RA, Burke AS, Soejima K, Murakami K, Katahira J, Traber LD, Herndon DN, Schmalstieg FC Jr., Traber DL, Hawkins HK. Airway obstruction in sheep with burn and smoke inhalation injuries. *Am J Resp Cell Mol Biol* 29:295-302, 2003.
111. Enkhbaatar P, Murakami K, Shimoda K, Salsbury J, Cox R, Hawkins H, Traber L, Herndon D, Traber D. Ketorolac attenuates cardiopulmonary derangements in sheep with combined burn and smoke inhalation injury. *Clin Sci* 105:621-8, 2003.
112. Enkhbaatar P, Murakami K, Shimoda K, Mizutani A, Traber L, Phillips G, Parkinson J, Salsbury JR, Biondo N, Schmalstieg F, Burke A, Cox R, Hawkins H, Herndon D, Traber D. Inducible nitric oxide synthase dimerization inhibitor prevents cardiovascular and renal morbidity in sheep with combined burn and smoke inhalation injury. *Am J Physiol Heart Circ Physiol* 285:H2430-6, 2003.
113. Murakami K, Enkhbaatar P, Shimoda K, Cox RA, Burke AS, Hawkins HK, Traber LD, Schmalstieg FC, Salzman AL, Mabley JG, Komjati K, Pacher P, Zsengeller Z, Szabo C, Traber DL. Inhibition of poly (ADP-ribose) polymerase attenuates acute lung injury in an ovine model of sepsis. *Shock* 21:126-33, 2004.
114. Dasu MRK, Hawkins HK, Barrow RE, Xue H, Herndon DN. Gene expression profiles from hypertrophic scar fibroblasts before and after IL-6 stimulation. *J Pathol* 202:476-85, 2004.
115. Enkhbaatar P, Murakami K, Cox R, Westphal M, Morita N, Brantley K, Burke A, Hawkins H, Schmalstieg F, Traber L, Herndon D, Traber D. Aerosolized tissue plasminogen inhibitor improves pulmonary function in sheep with burn and smoke inhalation. *Shock* 22:70-5, 2004.
116. Dasu MR, Barrow RE, Hawkins HK, McCauley RL. Gene expression profiles of giant hairy naevi. *J Clin Pathol* 57:849-55, 2004.

ARTICLES IN PEER REVIEWED JOURNALS: (Cont'd)

117. de Oliveira GV, Sanford AP, Murphy KD, de Oliveira HM, Wilkins JP, Wu X, Hawkins HK, Kitten G, Chinkes DL, Barrow RE, Herndon DN. Growth hormone effects on hypertrophic scar formation: A randomized controlled trial of 62 burned children. *Wound Repair Regen* 12:404-11, 2004.
118. Diven SC, Angel CA, Hawkins HK, Rowen JL, Shattuck KE. Intestinal zygomycosis due to *Absidia corymbifera* mimicking necrotizing enterocolitis in a preterm neonate. *J Perinatol*. 24:794-6, 2004.
119. Oliveira GV, Shimoda K, Enkhbaatar P, Jodoin J, Burke AS, Chinkes DL, Hawkins HK, Herndon DN, Traber L, Traber D, Murakami K. Skin nitric oxide and its metabolites are increased in nonburned skin after thermal injuries. *Shock* 22:278-82, 2004.
120. Barrow RE, Mlcak R, Barrow LN, Hawkins HK. Increased liver weights in severely burned children: Comparison of ultrasound and autopsy measurements. *Burns* 30:565-8, 2004.
121. Oliveira GV, Chinkes D, Mitchell C, Oliveras G, Hawkins HK, Herndon DN. Objective assessment of burn scar vascularity, erythema, pliability, thickness, and planimetry. *Dermatol Surg* 31:48-58, 2005.
122. de Oliveira GV, Hawkins HK, Guedes AC, Pinto LF, Oliveras G, Kitten GT, Sanchez R. Comel-Netherton syndrome in brothers and expression of cytokeratins. *J Am Acad Dermatol* 52:725-6, 2005.
123. Cox RA, Enkhbaatar P, Burke AS, Katahira J, Shimoda K, Chandra A, Traber LD, Herndon DN, Hawkins HK, Traber DL. Effects of a dual endothelin-1 receptor antagonist on airway obstruction and acute lung injury in sheep following smoke inhalation and burn injury. *Clin Sci* 108:265-72, 2005.
124. Barrow RE, Przkora R, Hawkins HK, Barrow LN, Jeschke MG, Herndon DN. Mortality related to gender, age, sepsis, and ethnicity in severely burned children. *Shock* 23:485-7, 2005.
125. Morgan PB, Chundru S, Hatch SS, Hawkins HK, Adegboyega A, Eltorky MA. Uncommon malignancies. Case 1. Low-grade myofibroblastic sarcoma of the breast. *J Clin Oncol* 23:6249-51, 2005.
126. Barrow RE, Hawkins HK, Aarsland A, Cox R, Rosenblatt J, Barrow LN, Jeschke MG, Herndon DN. Identification of factors contributing to hepatomegaly in severely burned children. *Shock* 24:523-8, 2005.
127. Cox RA, Burke AS, Oliveras G, Enkhbaatar P, Traber LD, Zwischenberger JB, Jeschke MG, Schmalstieg FC, Herndon DN, Traber DL, Hawkins HK. Acute bronchial obstruction in sheep: Histopathology and gland cytokine expression. *Exp Lung Res* 31:819-37, 2005.
128. Pereira CT, Barrow RE, Sterns AM, Hawkins HK, Kimbrough CW, Jeschke MG, Lee JO, Sanford AP, Herndon DN. Age-dependent differences in survival after severe burns: a unicentric review of 1,674 patients and 179 autopsies over 15 years. *J Am Coll Surg* 202:536-48, 2006.
129. Westphal M, Cox RA, Traber LD, Morita N, Enkhbaatar P, Schmalstieg FC, Hawkins HK, Maybauer DM, Maybauer MO, Murakami K, Burke AS, Westphal-Varghese BB, Rudloff HE, Salisbury JR, Jodoin JM, Lee S, Traber DL. Combined burn and smoke inhalation injury impairs ovine hypoxic pulmonary vasoconstriction. *Crit Care Med* 34:1428-36, 2006.
130. Morita N, Traber MG, Enkhbaatar P, Westphal M, Murakami K, Leonard SW, Cox RA, Hawkins HK, Herndon D, Traber LD, Traber DL. Aerosolized alpha-tocopherol ameliorates acute lung injury following combined burn and smoke inhalation injury in sheep. *Shock* 25:277-82, 2006.

ARTICLES IN PEER REVIEWED JOURNALS: (Cont'd)

131. Palmieri TL, Enkhbaatar P, Bayliss R, Traber LD, Cox RA, Hawkins HK, Herndon DN, Greenhalgh DG, Traber DL. Continuous nebulized albuterol attenuates acute lung injury in an ovine model of combined burn and smoke inhalation. *Crit Care Med* 34:1719-24, 2006.
132. Enkhbaatar P., Murakami K, Traber LD, Cox R, Parkinson JF, Westphal M, Esechie A, Morita N, Maybauer MO, Maybauer DM, Burke AS, Schmalstieg FC, Hawkins HK, Herndon DN, Traber DL. The inhibition of inducible nitric oxide synthase in ovine sepsis model. *Shock* 25:522-7, 2006.
133. Zhang XJ, Hegggers JP, Chinkes DL, Wolf SE, Hawkins HK, Wolfe RR. Topical Sulfamylon cream inhibits DNA and protein synthesis in the skin donor site wound. *Surgery* 139:633-9, 2006.
134. Maybauer MO, Maybauer DM, Fraser JF, Traber LD, Westphal M, Enkhbaatar P, Cox RA, Huda R, Hawkins HK, Morita N, Murakami K, Mizutani A, Herndon DN, Traber DL. Recombinant human activated protein C improves pulmonary function in ovine acute lung injury resulting from smoke inhalation and sepsis. *Crit Care Med* 34:2432-8, 2006.
135. Wang Z, Velagaleti GVN, Eltorky MA, Tang WW, Hawkins HK, Jones EA, Northup J, Panova N, Qiu S. Cytogenetic and molecular studies of an unusual case of multiple primary alveolar rhabdomyosarcomas: Low-level chromosomal instability and reciprocal translocation t(6;11). *Exp Mol Pathol* 82:58-62, 2007.
136. Sun X, Hawkins H, Castro CY, Eltorky MA. Immunohistochemical and ultrastructural analysis of a poorly differentiated pediatric age Sertoli-Leydig cell tumor. *Exp Mol Pathol* 82:63-7, 2007.
137. Cox RA, Burke AS, Traber DL, Herndon DN, Hawkins HK. Production of pro-inflammatory polypeptides by airway mucous glands and its potential significance. *Pulm Pharmacol Ther* 20:172-7, 2007.
138. Traber DL, Hawkins HK, Enkhbaatar P, Cox RA, Schmalstieg FC, Zwischenberger JB, Traber LD. The role of the bronchial circulation in the acute lung injury resulting from burn and smoke inhalation. *Pulm Pharmacol Ther* 20:163-6, 2007.
139. Maybauer MO, Maybauer DM, Fraser JF, Traber LD, Westphal M, Cox RA, Huda R, Nakano YY, Enkhbaatar P, Hawkins HK, Herndon DN, Traber DL. Ceftazidime improves hemodynamics and oxygenation in ovine smoke inhalation injury and septic shock. *Intensive Care Med* 33:1219-27, 2007.
140. Baregamian N, Rychahou PG, Hawkins HK, Evers BM, Chung DH. Phosphatidylinositol 3-kinase pathway regulates hypoxia-inducible factor-1 to protect from intestinal injury during necrotizing enterocolitis. *Surgery* 142:295-302, 2007.
141. Schmalstieg FC, Keeney SE, Rudloff HE, Palkowetz KH, Cevallos M, Zhou X, Cox RA, Hawkins HK, Traber DL, Zwischenberger JB. Arteriovenous CO₂ removal improves survival compared to high frequency percussive and low tidal volume ventilation in a smoke/burn sheep acute respiratory distress syndrome model. *Ann Surg* 246:512-23, 2007.
142. Zhang XJ, Wu X, Wolf SE, Hawkins HK, Chinkes DL, Wolfe RR. Local insulin-zinc injection accelerates skin donor site wound healing. *J Surg Res* 142:90-6, 2007.
143. Gore DC, Hawkins HK, Chinkes DL, Chung DH, Sanford AP, Herndon DN, Wolf SE. Assessment of adverse events in the demise of pediatric burn patients. *J Trauma* 63:814-8, 2007.
144. Minohara Y, Boyd DK, Hawkins HK, Ernst PB, Patel J, Crowe SE. The effect of the *cag* pathogenicity island on binding of *Helicobacter pylori* to gastric epithelial cells and the subsequent induction of apoptosis. *Helicobacter* 12:583-90, 2007.

ARTICLES IN PEER REVIEWED JOURNALS: (Cont'd)

145. Murphy KD, Rose MW, Chinkes DL, Meyer WJ III, Herndon DN, Hawkins HK, Sanford AP. The effects of gammahydroxybutyrate on hypermetabolism and wound healing in a rat model of large thermal injury. *J Trauma* 63:1099-107, 2007.
146. Ragouilliaux CJ, Keeney SE, Hawkins HK, Rowen JL. Maternal factors in extremely low birth weight infants who develop spontaneous intestinal perforation. *Pediatrics* 120:e1458-64, 2007.
147. Murakami K, Enkhbaatar P, Yu YM, Traber LD, Cox RA, Hawkins HK, Tompkins RG, Herndon D, Traber DL. L-arginine attenuates acute lung injury after smoke inhalation and burn injury in sheep. *Shock* 28:477-83, 2007.
148. Cox RA, Mlcak RP, Chinkes DL, Jacob S, Enkhbaatar P, Jaso J, Parish LP, Traber DL, Jeschke MG, Herndon DN, Hawkins HK. Upper airway mucus deposition in lung tissue of burn trauma victims. *Shock* 29:356-61, 2008.
149. Jacob S, Deyo DJ, Cox RA, Traber DL, Hawkins HK. Assessment of lung inflammation in a mouse model of smoke inhalation and burn injury: strain-specific differences. *Toxicol Mech Methods* 18:551-9, 2008.
150. Westphal M, Enkhbaatar P, Schmalstieg FC, Kulp GA, Traber LD, Morita N, Cox RA, Hawkins HK, Westphal-Varghese BB, Rudloff HE, Maybauer DM, Maybauer MO, Burke AS, Murakami K, Saunders F, Horvath EM, Szabo C, Traber DL. Neuronal nitric oxide synthase inhibition attenuates cardiopulmonary dysfunctions after combined burn and smoke inhalation injury in sheep. *Crit Care Med* 36:1196-1204, 2008.
151. Esechie A, Kiss L, Olah G, Horvath EM, Hawkins H, Szabo C, Traber DL. Protective effect of hydrogen sulfide in a murine model of combined burn and smoke inhalation-induced acute lung injury. *Clin Sci* 115:91-7, 2008.
152. Hamahata A, Enkhbaatar P, Kraft ER, Lange M, Leonard SW, Traber MG, Cox RA, Schmalstieg FC, Hawkins HK, Whorton EB, Horvath EM, Szabo C, Traber LD, Herndon DN, Traber DL. Gamma-tocopherol nebulization by a lipid aerosolization device improves pulmonary function in sheep with burn and smoke inhalation injury. *Free Radic Biol Med* 45:425-33, 2008.
153. Mizutani A, Enkhbaatar P, Esechie A, Traber LD, Cox RA, Hawkins HK, Deyo DJ, Murakami K, Noguchi T, Traber DL. Pulmonary changes in a mouse model of combined burn and smoke inhalation-induced injury. *J Appl Physiol* 105:678-84, 2008.
154. Murphy KD, Mushkudiani IA, Kao D, Levesque AY, Hawkins HK, Gould LJ. Successful incorporation of tissue-engineered porcine small-intestinal submucosa as substitute flexor tendon graft is mediated by elevated TGF-beta-1 expression in the rabbit. *J Hand Surg* 33:1168-78, 2008.
155. Lange M, Connelly R, Traber DL, Hamahata A, Cox RA, Nakano Y, Bansal K, Esechie A, von Borzyskowski S, Jonkam C, Traber LD, Hawkins HK, Herndon DN, Enkhbaatar P. Combined neuronal and inducible nitric oxide synthase inhibition in ovine acute lung injury. *Crit Care Med* 37:223-9, 2009.
156. Cox RA, Jacob S, Oliveras G, Murakami K, Enkhbaatar P, Traber L, Schmalstieg FC, Herndon DN, Traber DL, Hawkins HK. Pulmonary expression of nitric oxide synthase isoforms in sheep with smoke inhalation and burn injury. *Exp Lung Res* 35:104-18, 2009.
157. Cox RA, Burke AS, Jacob S, Oliveras G, Murakami K, Shimoda K, Enkhbaatar P, Traber LD, Herndon DN, Traber DL, Hawkins HK. Activated nuclear factor kappa B and airway inflammation after smoke inhalation and burn injury in sheep. *J Burn Care Res* 30:489-98, 2009.

ARTICLES IN PEER REVIEWED JOURNALS: (Cont'd)

158. Lange M, Enkhbaatar P, Traber DL, Cox RA, Jacob S, Mathew BP, Hamahata A, Traber LD, Herndon DN, Hawkins HK. Role of calcitonin gene-related peptide (CGRP) in ovine burn and smoke inhalation injury. *J Appl Physiol* 107:176-84, 2009.
159. Jacob S, Deyo DJ, Cox RA, Traber DL, Hawkins HK. Mechanisms of toxic smoke inhalation and burn injury: Role of neutral endopeptidase and vascular leakage in mice. *Toxicol Mech Methods* 19:191-6, 2009.
160. Esechie A, Enkhbaatar P, Traber DL, Jonkam C, Lange M, Hamahata A, Djukom C, Whorton EB, Hawkins HK, Traber LD, Szabo C. Beneficial effect of a hydrogen sulphide donor (sodium sulphide) in an ovine model of burn and smoke-induced acute lung injury. *Brit J Pharmacol* 158:1442-53, 2009.
161. Oliveira GV, Hawkins HK, Chinkes D, Burke A, Pasqua Tavares AL, Ramos-e-Silva M, Albrecht TB, Kitten GT, Herndon DN. Hypertrophic versus non hypertrophic scars compared by immunohistochemistry and laser confocal microscopy: type I and III collagens. *Int Wound J* 6:445-51, 2009.
162. Williams FN, Herndon DN, Hawkins HK, Lee JO, Cox RA, Kulp GA, Finnery CC, Chinkes DL, Jeschke MG. The leading causes of death after burn injury in a single pediatric burn center. *Crit Care* 13:R183, 2009.
163. Jacob S, Deyo DJ, Cox RA, Jacob RK, Herndon DN, Traber DL, Hawkins HK. Substance P antagonist CP-96345 blocks lung vascular leakage and inflammation more effectively than its stereoisomer CP-96344 in a mouse model of smoke inhalation and burn injury. *Toxicol Mech Methods* 20:197-203, 2010.
164. Saunders FD, Westphal M, Enkhbaatar P, Wang J, Pazdrak K, Nakano Y, Hamahata A, Jonkam CC, Lange M, Connelly R, Kulp GA, Cox RA, Hawkins HK, Schmalstieg FC, Horvath E, Szabo C, Traber LD, Whorton E, Herndon DN, Traber DL. Molecular biological effects of selective neuronal nitric oxide synthase inhibition in ovine lung injury. *Am J Physiol Lung Cell Mol Physiol* 298:L427-36, 2010.
165. Franco DM, Aronson JF, Hawkins HK, Gallagher JJ, Mendoza L, McGinniss MR, Williams-Bouyer N. Systemic pythium insidiosum in a pediatric burn patient. *Burns* 36:e68-71, 2010.
166. Jonkam C, Zhu Y, Jacob S, Rehberg S, Kraft E, Hamahata A, Nakano Y, Traber LD, Herndon DN, Traber DL, Hawkins HK, Enkhbaatar P, Cox RA. Muscarinic receptor antagonist therapy improves acute pulmonary dysfunction after smoke inhalation injury in sheep. *Crit Care Med* 38(12):1-10, 2010.
167. Jacob S, Kraft R, Zhu Y, Jacob RK, Herndon DN, Traber DL, Hawkins HK, Cox RA. Acute secretory cell toxicity and epithelial exfoliation after smoke inhalation injury in sheep: an electron and light microscopic study. *Toxicol Mech Methods* 20:504-9, 2010.
168. Sousse LE, Yamamoto Y, Enkhbaatar P, Rehberg SW, Wells SM, Leonard S, Traber MG, Yu YM, Cox RA, Hawkins HK, Traber LD, Herndon DN, Traber DL. Acute lung injury-induced collagen deposition is associated with elevated asymmetric dimethylarginine and arginase activity. *Shock* 35:282-8, 2011.
169. Rivero HG, Lee JO, Herndon DN, Mecott GA, Kulp GA, Kraft R, Brooks NC, Dibildox-Gonzalez M, Hawkins HK, Jeschke MG. The role of acute pancreatitis in pediatric burn patients. *Burns* 37:82-5, 2011.
170. Lee JO, Gauglitz GG, Herndon DN, Hawkins HK, Halder SC, Jeschke MG. Association between dietary fat content and outcomes in pediatric burn patients. *J Surg Res* 166:e83-90, 2011.

ARTICLES IN PEER REVIEWED JOURNALS: (Cont'd)

171. Kraft R, Kulp GA, Herndon DN, Emdad F, Williams FN, Hawkins HK, Leonard KR, Jeschke MG. Is there a difference in clinical outcomes, inflammation and hypermetabolism between scald and flame burn? *Pediatr Crit Care Med* 12:e275-81, 2011.
172. Maybauer DM, Maybauer MO, Szabo C, Cox RA, Westphal M, Kiss L, Horvath EM, Traber LD, Hawkins HK, Saltzman AL, Southan GJ, Herndon DN, Traber DL. The peroxynitrite catalyst WW-85 improves pulmonary function in ovine septic shock. *Shock* 35:148-55, 2011.
173. Morita N, Enkhbaatar P, Maybauer DM, Maybauer MO, Westphal M, Murakami K, Hawkins HK, Cox RA, Traber LD, Traber DL. Impact of bronchial circulation on bronchial exudates following combined burn and smoke inhalation injury in sheep. *Burns* 37:465-73, 2011.
174. Westphal M, Rehberg S, Maybauer MO, Maybauer DM, Enkhbaatar P, Westphal-Varghese BB, Schmalstieg FC, Morita N, Cox RA, Hawkins H, Whorton E, Traber DL. Cardiopulmonary effects of low-dose arginine vasopressin in ovine acute lung injury. *Crit Care Med* 39:357-63, 2011.
175. Asmussen S, Bartha E, Olah G, Sbrana E, Rehberg SW, Yamamoto Y, Enkhbaatar P, Hawkins HK, Ito H, Cox RA, Traber LD, Traber DL, Szabo C. The angiotensin-converting enzyme inhibitor captopril inhibits poly(ADP-ribose) polymerase activation and exerts beneficial effects in an ovine model of burn and smoke injury. *Shock* 36:402-9, 2011.
176. Zhou X, Wang D, Castro CY, Hawkins H, Lynch JE, Liu X, Zwischenberger JB. A pulmonary hypertension model induced by continuous pulmonary air embolization. *J Surg Res* 170:e11-6, 2011.
177. Lee JO, Gauglitz GG, Herndon DN, Hawkins HK, Haider SC, Jeschke MG. Association between dietary fat content and outcomes in pediatric burn patients. *J Surg Res* 166:e83-90, 2011.
178. Sousse LE, Jonkam CC, Traber DL, Hawkins HK, Rehberg SW, Traber LD, Herndon DN, Enkhbaatar P: *Pseudomonas aeruginosa* is associated with increased lung cytokines and asymmetric dimethylarginine compared with methicillin-resistant *Staphylococcus aureus*. *Shock* 36:466-70, 2011.
179. Hamahata A, Enkhbaatar P, Lange M, Cox RA, Hawkins HK, Sakurai H, Traber LD, Traber DL. Direct delivery of low-dose 7-nitroindazole into the bronchial artery attenuates pulmonary pathophysiology after smoke inhalation and burn injury in an ovine model. *Shock* 36:575-9, 2011.
180. Sbrana E, Suter MA, Abramovici AR, Hawkins HK, Moss JE, Patterson L, Shope C, Aagaard-Tillery K. Maternal tobacco use is associated with increased markers of oxidative stress in the placenta. *Am J Obstet Gynecol* 205:246e1-7, 2011.
181. Pinar H, Koch MA, Hawkins H, Heim-Hall J, Shehata B, Thorsten VR, Carpenter M, Lowichik A, Reddy UM. The Stillbirth Collaborative Research Network (SCRN) placental and umbilical cord examination protocol. *Am J Perinatol* 28:781-92, 2011.
182. Pinar H, Koch MA, Hawkins H, Heim-Hall J, Shehata B, Thorsten VR, Chin S, Willinger M, De la Monte. The stillbirth collaborative research network neuropathologic examination protocol. *Am J Perinatol* 28:793-802, 2011.
183. Baregamian N, Song J, Papaconstantinou J, Hawkins HK, Evers BM, Chung DH. Intestinal mitochondrial apoptotic signaling is activated during oxidative stress. *Pediatr Surg Int* 27:871-7, 2011.

ARTICLES IN PEER REVIEWED JOURNALS: (Cont'd)

184. Sousse LE, Yamamoto Y, Enkhbaatar P, Rehberg SW, Wells SM, Leonard S, Traber MG, Yu Y-M, Cox RA, Hawkins HK, Traber LD, Herndon DN, Traber DL. Acute lung injury-induced collagen deposition is associated with elevated asymmetric dimethylarginine and arginase activity. *Shock* 35:282-8, 2011.
185. Maybauer MO, Maybauer DM, Fraser JF, Westphal M, Szabo C, Cox RA, Hawkins HK, Traber LD, Traber DL. Combined recombinant human activated protein C and ceftazidime prevent the onset of acute respiratory distress syndrome in severe sepsis. *Shock* 37:170-6, 2012.

ABSTRACTS AND PRESENTATIONS:

1. Hawkins HK, Saladino AJ. Structural-functional aspects of cellular swelling-disruption produced by surface active agents. *Fed Proc* 27:247, 1968.
2. Hawkins HK, Saladino AJ. Membrane alterations and cell injury due to surfactants. *Fed Proc* 28:445, 1969.
3. Hawkins HK, Kinney TD. Lysosome stability in lethal cell injury. *Fed proc* 29:784, 1970.
4. Hawkins HK, Mergner WJ, Henkens R, Kinney TD, Trump BF. Attempts of resolution of the subunit structure of ferritin and apoferritin by electron microscopy. *Proc 28th Annual Meeting, Electr Microsc Soc Amer (C.J. Arcenaux, ed), Arcenaux, ed), Baton Rouge, LA: Claitor Pub Div. P268, 1970.*
5. Hawkins HK, Ericsson JLE, Trump BF. Lysosomal integrity in cellular necrosis. *Lab Inv* 24:434, 1971.
6. Hawkins HK, Ericsson JLE, Biberfeld P. Lysosome stability following immune cytolysis. *Fed Proc* 30:599, 1971.
7. Mitchener JS, Hawkins HK, Bradford WD, Shelburne JD. Autophagocytosis in serum and amino acid starved HeLa cells. Presented at AAPB Mtg., 1975.
8. Mitchener JS, Hawkins HK. Cellular responses to deprivation of protein and amino acids. *Fed Proc* 34:867, 1975.
9. Banks WD, Bradford WD, Hawkins HK, Sidbury Jr JB. Ultrastructural studies of a new case of Farber's lipogranulomatosis (ceramide lipidosis). *Am J Path* 78:5, 1975.
10. Bradford WD, Shelburne JD, Hawkins HK. Ultrastructural studies on hepatic parenchymal and pancreatic acinar cells in Reye's syndrome. *Am J Path* 82:12, 1976.
11. Jauregui HO, Dyer C, Hawkins HK, Bradford WD, Kinney TD. The effects of iron on the cell cycle of HeLa cells. *Am J Path* 82:77, 1976.
12. Hawkins HK, Lowe JE, Hill ML, Jennings RB. Loss of cell volume and electrolyte control in slices of ischemic myocardium. *Am J Path* 86:44, 1977.
13. Hawkins HK. Reversal of cell membrane injury due to organic mercury by dithiothreitol (DDT). *Fed Proc* 36:1067, 1977.
14. Hawkins HK, Jennings RB, Lowe JE, Hill ML, Riemer KA. Cell volume regulation in severe reversible and lethal acute myocardial ischemic injury. *Fed Proc* 37:495, 1978.
15. Hawkins HK, Sharov VG, Jennings RB. Cell membrane permeability defects demonstrated with colloidal lanthanum early in ischemic cell injury in dog heart. Electron Microscopy 1978: *Proc IX Intl Congress Electr Microsc* 2:306 (Imperial Press Ltd), 1978.

ABSTRACTS & PRESENTATIONS: (Cont'd)

16. Hawkins HK, Ingram P. Silica and silicates contaminate tobacco. *Lab Inv* 40:259, 1979.
17. Shelburne JD, Futknecht WF, Wilder DR, Ingram P, Hawkins HK. Respirable silicon-positive particles in cigarette smoke. *Fed Proc* 38:1155, 1979.
18. Jennings RB, Hawkins HK, Reimer KA, Lowe JE. High energy phosphate in lethal myocardial ischemic injury. *J Mol Cell C* 11 (Supp 1):29, 1979.
19. Hawkins HK, Lou HJ. Epinephrine accelerates ischemic cell membrane injury *in vitro* in dog heart. *Fed Proc* 40:750, 1981.
20. Atkinson GO, Gay Jr BB, Kodroff M, Sones PJ, Hawkins HK. Focal nodular hyperplasia of the liver in children. Presented at the American Roentgen Ray Society annual meeting, 1981.
21. Hargreaves H, Brynes R, Hawkins HK. Detection of minimal infiltrate in testicular biopsies of boys with ALL. *Lab Inv* 46:34a, 1982.
22. Guyton RA, Dorsey LM, Silbrano MS, Hawkins HK, Williams WH, Hatcher CR. The broadly based pericardial flap: A tissue for atrial replacement that grows. *Circulation Supplement* 66(A):195, 1982.
23. Hawkins HK, Langston C. Self-healing reticulohistiocytosis with apparent visceral involvement. *Lab Inv* 52:5p, 1985.
24. Donnelly WH, Hawkins HK. Examining the perinatal heart. Evaluation of a technique during 1000 perinatal autopsies. *Lab Inv* 54:3p, 1986.
25. Hawkins HK, Camacho-Velasquez JV. Rhabdomyosarcoma at Texas Children's Hospital. *Lab Inv* 54:3p, 1986.
26. Hawkins HK, Eady RAJ, Levy ML, Carpenter RC, Hejtmancik JF, Holbrook KA, Fine JD. Prenatal diagnosis of dominant dystrophic epidermolysis bullosa. *Clin Res* 36:58A, 1988.
27. Rogers B, Carlson J, Sifers R, Hawkins HK, Woodard S, Finegold M. Alpha-1-antitrypsin expression in transgenic mice and man. *Mod Pathol* 1:8p, 1988.
28. Smith CW, Marlin Sd, Rothlein R, Toman CJ, Hawkins HK, Anderson DC. LFA-1 and ICAM-1 in neutrophil adherence and transendothelial migration. Society for Leukocyte Biology and Reticulo-Endothelial Society, Washington, DC, Oct 27-30, 1988.
29. Herman GE, Fernbach SD, Hawkins HK, Butler IJ, Naylor ED, McCabe ERB. Apparent SIDS in an infant with an inherited defect in bipterin synthesis. *Pediat Res* 23:773, 1988.
30. Hawkins HK, Smith CW, Anderson DC. The topography and mobility of Mac-1 on human neutrophils (PMNL). *Pediat Res* 23:340A, 1988.
31. Caraway NP, Hawkins HK. Clinicopathologic correlations in malignant rhabdoid tumors. Society for Pediatric Pathology, San Francisco, CA, March 6-7, 1989.
32. Goddard-Finegold J, Adham BI, Michael LH, Hawkins HK. Large endothelial vacuoles in newborn brain after hypertension: Effect of pretreatment with vitamin E. American Pediatric Society and Society for Pediatric Research, 1989.
33. Rabinovitz RS, Hartley CJ, Michael LH, Entman ML, Hawkins HK, Sekela ME, Noon GP. Implantable sensor for intra- and postoperative monitoring of blood flow. NIH Grantee and Contractor's Meeting, Cardiovascular Science and Technology: Basic and Applied, Louisville, KY, Dec. 2-4, 1989.

ABSTRACTS & PRESENTATIONS: (Cont'd.)

34. Hawkins HK, Smith CW, Anderson DC. Deficiency of leukocyte adhesion molecules. Electron Microscopy Society of America, 1989.
35. Anderson DC, Kukielka GL, Michael LH, Youker K, Lane CL, Smith CW, Manning AM, Hawkins HK, Entman ML. Stimulation of ICAM-1 mRNA in ischemic and reperfused canine myocardium. Southern Society for Pediatric Research (Winner, Best Poster by Trainee), 1992.
36. Manning AM, Kukielka GL, Hawkins HK, Michael LH, Smith CW, Entman ML, Anderson DC. Differential expression of ICAM-1, P- and E-selectin in canine myocardial ischemia-reperfusion. Keystone Symposium, Cell Adhesion Mechanisms in Leukocyte Traffic, Jan. 24-31, 1993.
37. Sandberg ET, Sligh JE, Hawkins HK, Beaudet AL. Contact hypersensitivity is delayed in CD18 mutant mice. Symposium on Transgenic Animal Research, 1993.
38. Youker KA, Hawkins HK, Kukielka GL, Michael LH, Ballantyne CM, Smith CW, Entman ML. Molecular evidence for a border zone vulnerable to inflammatory reperfusion injury. American Academy of Physicians, Spring 1993.
39. Zhu Q, Burke A, Evans MJ, Cox R, Hawkins HK. Integrin expression in airway epithelial cells. Texas Society for Electron Microscopy, Galveston, Texas, Oct. 23, 1993.
40. Kukielka GL, Manning AM, Michael LH, Hawkins HK, Mendoza L, Anderson DC, Smith CW, Entman ML. Reperfusion is required for the induction of cytokine and intercellular adhesion molecule-1 (ICAM-1) synthesis in ischemic hearts. American Heart Association, Circ 88:1-5, 1993.
41. Cox RA, Zhu Q, Hawkins HK, Wang CZ, Barrow RE: Expression of fibronectin as an indicator of airway epithelial repair. American Burn Association, Orlando, Florida, Apr 20-23, 1994.
42. Kukielka GL, Smith CW, LaRosa GH, Hughes BH, Mendoza LH, Thurmon LT, Lai JS, Hawkins HK, Youker KA, Michael LH, Entman ML. Interleukin-8 expression following reperfusion of ischemic myocardium. Am Heart Association, Circ 90:1-52, 1994.
43. Cox RA, Zhu Q, Hawkins HK, Barrow RE, Herndon DN. Expression of fibronectin as an indicator of airway epithelial repair. American Burn Association, Orlando, Florida, Apr 20-23, 1994.
44. Kukielka GL, Smith CW, LaRosa GJ, Youker KA, Hawkins HK, Michael LH, Rot A, Entman ML. Regulation of IL-8 induction in ischemic and reperfused myocardium *in vivo*. Presented at Society for Leukocyte Biology, 1994. J Leuk Biol Supp 1994, p24 (Winner of the Young Investigator Award), 1994.
45. Mitchell AT, Kwon WH, Hawkins HK, Burke AS, Harper D, Traber LD, Herndon DN, Phillips LG. Evaluation of Xenoderm as a dermal substrate for cultured epithelial autografts: A porcine wound healing model. American Burn Association, Nashville, TN, 1996.
46. Hawkins HK, Cox RA, Burke AS, Barrow RE. Selective toxicity of acrolein to secretory cells in rabbit tracheal epithelium. American Burn Association, Nashville, TN, 1996.
47. Wang CZ, Heming T, Herndon D, Hawkins HK, Bidani A. Pathological alterations in a rabbit model of smoke inhalation injury. American Burn Association, Nashville, TN, 1996.
48. Burke AS, Cox RA, Hawkins HK. Enhancement of immunohistochemical reactivity using Streck tissue fixative. Texas Society for Microscopy, College Station, TX, 1996.
49. Hawkins HK. Ciliary dyskinesia: combined light and electron microscopy and lung biopsy. Soc. Pediatric Pathology, Minneapolis, MN, 1997.
50. Pierre EJ, Hawkins HK, Herndon DN. Temporal effect of growth hormone on wound healing. American Burn Association, New York, NY, 1997.

ABSTRACTS & PRESENTATIONS: (Cont'd.)

51. Jeschke MG, Barrow RE, Perez-Polo JR, Hawkins HK, Lichtenbelt BJ. IGF-1 gene transfer in thermal trauma. American College of Surgeons Committee on Trauma, South Texas Chapter, Dallas, TX, (Winner, Resident's Award), 1997.
52. Bi LX, Simmons DJ, Hawkins, Mainous E. Morphology of the marrow sac in different species. Texas Mineralized Tissues Society, Corpus Christi, TX, Aug. 1-3, 1997.
53. Jeschke MG, Barrow RE, Hawkins HK, Perez-Polo RJ, Lichtenbelt BJ, Herndon DN. IGF-1 gene transfer in thermal trauma. American Burn Association, Chicago, IL, 1998.
54. Evans MJ, Murphy ME, Van Winkle LS, Cox R, Burke A, Hawkins H, Plopper CG. Differentiation of the fibroblast layer of the epithelial-mesenchymal trophic unit in rat trachea. American Thoracic Society, Apr. 24-29, 1998.
55. Bi LX, Simmons DJ, Hawkins H, Cox, R, Mainous E. Morphology of the marrow sac in different species. 44th Annual Meeting, Orthopaedic Research Society, New Orleans, LA, Mar. 16-19, 1998.
56. Ramirez RJ, Zhang XJ, Chrysopoulou MT, Hawkins HK, Herndon DN, Barrow RE. Ibuprofen modulates tissue perfusion in partial-thickness burns. American Burn Association, Chicago, IL, 1998.
57. Hawkins HK, Brooks E, Ogburn J. A case of ciliary dyskinesia. Society for Ultrastructural Pathology, Aug. 2-7, Asheville, NC, 1998.
58. Lele, M., McCrory D, Garcia GM, Richards T, John SD, Hawkins, HK. Mesoblastic Nephroma with late massive pulmonary metastasis. Southern Medical Association, New Orleans, LA, Nov. 18-22, 1998.
59. Burke AS, Cox RE, Hawkins HK. Evaluation of an automated immunostainer for research applications. Texas Society for Microscopy Fall Meeting, Bandera, TX, 1998.
60. Cox RA, Burke AS, Evans MJ, Traber DL, Barrow RE, Hawkins HK. Exfoliation of single ciliated cells in acute smoke inhalation injury in sheep: Cellular associations. 31st Annual Meeting, American Burn Association, Lake Buena Vista, FL, Mar. 24-27, 1999.
61. Hawkins HK, Linares H, Desai MH, Herndon DN. Declining incidence of burn wound sepsis at autopsy. American Burn Association, Lake Buena Vista, FL, Mar. 24-27, 1999. (See also "Advances in Burn Therapy Cut Mortality from Sepsis", Physician's Weekly, Elsie Rosner, April, 1999.)
62. Hawkins HK, Cox RA, Traber DN. Airway inflammation after smoke inhalation injury. US - Canadian Academy of Pathology, San Francisco, CA, Lab Invest 9:175A, 1999.
63. Cox RA, Burke AS, Soejima K, Traber DL, Hawkins HK. Pulmonary endothelin-1 expression in an ovine model of smoke inhalation injury. IBC's 4th International Conference on Endothelin Inhibitors, Washington, DC, June 7-8, 1999.
64. Cox RA, Burke AS, Soejima K, Traber DL, Hawkins HK. Acute smoke injury promotes endothelin-1 expression. Sixth International Conference on Endothelin, Montreal, Canada, October 10-13, 1999.
65. Hawkins HK, Zwischenberger JB. Pulmonary changes after burns: Scald vs. smoke inhalation. United States and Canadian Academy of Pathology, New Orleans, LA, Mar. 25-31, 2000, Laboratory Invest. 80:5A, 2000

ABSTRACTS & PRESENTATIONS: (Cont'd.)

66. Soejima K, Cox RA, Hawkins HK, Schmalstieg FC, Salzman A, Szabo C. The role of nitric oxide in inflammation after combined burn and smoke inhalation injury. American Thoracic Society, Toronto, Ontario, Canada, May 5-10, 2000.
66. Popnikolov NK, Payne DA, Hudnall SD, Hawkins HK, Kumar M, Elghetany MT. CD13 positive anaplastic large cell lymphoma of T-cell origin: A diagnostic and histogenetic problem. Texas Society of Pathologists, 79th Annual Meeting, Houston, TX, February 11-13, 2000.
67. Hunter GC, Burke AS, Xue XY, Lick SD, Cox RA, Hawkins HK. Vascular Endothelial Growth Factor Expression in Atherosclerotic Plaque and Arterialized Vein Grafts. FASEB, April 3, 2001, Orlando, Florida.
68. Cox RA, Murakami K, Katahira J, Soejima K, Burke AS, Traber LD, Schmalstieg FC, Herndon DN, Traber DL, Hawkins, HK. Measurement of airway casts in an ovine model of smoke inhalation and burn injury. American Burn Association 33rd Annual Meeting, Boston, MA, April 18-21, 2001.
69. Cox RA, Burke AS, Soejima K, Traber LD, Traber DL, Hawkins HK. Quantitation and Composition of airway obstructive casts following inhalation and burn injury in sheep. American Thoracic Society, San Francisco, May 2001.
70. Cox RA, Soejima K, Katahira J, Murakami K, Burke AS, Traber DL, Hawkins HK. Inhibition of inducible nitric oxide synthase decreases airway obstruction in sheep following smoke inhalation and burn injury 24th Annual Conference on Shock, Marco Island, Florida, June 9-12, 2001.
71. Cox RA, Katahira J, Burke AS, Traber L, Schmalstieg, Hawkins HK, Traber D. Effects of a dual Endothelin-1 Receptor Antagonist on Airway Obstruction and Pulmonary Dysfunction in Sheep Following Smoke Inhalation and Burn Injury. 7th International Conference on Endothelin, September 16-19, 2001, Edinburgh, Scotland.
72. Lee JO, Hawkins HK, Herndon DN. Incidence of pancreatitis in burn children found at autopsy: Twenty year review. J Burn Care Rehab 23:S45, 2002.
73. Enkhbaatar P, Murakami K, Cox RA, Hawkins HK, Herndon DN, Schmalstieg F, Traber LD, Traber DL. Inhibition of neuronal nitric oxide synthase (nNOS) attenuates lung injury in septic sheep. J Burn Care Rehab 23:S50, 2002.
74. Burke AS, Cox RA, Barrow RE, Traber D, Hawkins HK. Ovine lung apoptosis after thermal burn and smoke inhalation. J Burn Care Rehab 23:S110, 2002.
75. Van Dinter T Jr., Cox RA, Murakami K, Katahira J, Hawkins HK, Traber DL. Pulmonary pathophysiology following a combined burn and smoke inhalation injury in sheep. J Burn Care Rehab 23:S123, 2002.
76. Cox RA, Burke AS, Beard H, Chandra A, Traber LD, Murakami K, Shimoda K, Herndon DN, Schmalstieg F, Traber DL, Hawkins HK. Ultrastructural assessment of bronchial endothelial cell injury in sheep following smoke inhalation injury. J Burn Care Rehab 23:S124, 2002.
77. Burke AS, Cox RA, Beard H, Chandra A, Shimoda K, Murakami K, Traber LD, Schmalstieg F, Traber DL, Hawkins HK. J Burn Care Rehab 23:S125, 2002.
78. Boor PJ, Hawkins HK, Trent MB, Yang Y, Herndon DN. A role for the connective tissue enzyme, semicarbazide-sensitive amine oxidase (SSAO) in burn wound healing. J Burn Care Rehab 23:S127, 2002.
79. Spies M, Hawkins HK, Burke AS, Herndon DN. Differential expression of matrix metalloproteinases in toxic epidermal necrolysis. J Burn Care Rehab 23:S130, 2002.

ABSTRACTS & PRESENTATIONS: (Cont'd.)

80. Murakami K, Cox R, Hawkins H, Schmalstieg F, Traber LD, Prough D, Herndon DN, Traber DL. Recombinant antithrombin (RhAT) inhibits airway obstruction after smoke inhalation in sheep. Presented at FASEB annual meeting, New Orleans, Louisiana, April 20-24, 2002.
81. Enkhbaatar P, Murakami K, McGuire R, Salsbury J, Jodoin J, Cox R, Hawkins H, Traber L, Traber D. Neuronal nitric oxide synthase regulates tracheal blood flow in septic sheep. Presented at FASEB annual meeting, New Orleans, Louisiana, April 20-24, 2002.
82. Cox RA, Burke AS, Beard H, Chandra A, Shimoda K, Murakami K, Traber LD, Schmalstieg FC, Hawkins HK, Traber DL. Quantitation of neutrophils migration into the airways of sheep following smoke inhalation and burn injury. Presented at FASEB annual meeting, New Orleans, Louisiana, April 20-24, 2002.
83. Murakami K, Enkhbaatar P, Shimoda K, Chandra A, Cox R, Hawkins H, Herndon DN, Traber LD, Traber DL. Role of neuronal nitric oxide synthase (nNOS) in acute lung injury in septic sheep. *Am J Resp Crit Care Med* 165:A383, 2002.
84. Cox RA, Burke AS, Beard H, Chandra A, Traber LD, Shimoda K, Schmalstieg FC, Traber DL, Hawkins HK. Quantitation of NF κ B nuclear expression in bronchial mucus gland cells in sheep after smoke inhalation and burn injury. *Am J Resp Crit Care Med* 165:A508, 2002.
85. Leong M, Haddock NT, Gould LJ, Mushkudiani I., Hawkins H, Phillips LG. VEGF and NO are inversely expressed in burn wound zones in the rat. *J Burn Care Rehab* 24:S46, 2003.
86. Murakami K, Enkhbaatar P, Shimoda K, Chandra A, Thomas K, Cox R, Hawkins H, Traber LD, Herndon DN, Traber DL. Aerosolized recombinant antithrombin attenuates ovine acute lung injury with smoke inhalation and pneumonia. *J Burn Care Rehab* 24:S56, 2003.
87. Enkhbaatar P, Murakami K, Shimoda K, Traber LD, Herndon DN, Hawkins H, Cox R, Traber DL. Tissue plasminogen activator nebulization prevents acute lung injury in sheep with burn and smoke inhalation injury. *J Burn Care Rehab* 24:S56, 2003.
88. Shimoda K, Murakami K, Perenlei E, Traber LD, Cox R, Hawkins H, Schmalstieg FC, Szabo C, Salzman AL, Herndon DN, Traber DL. Effect of poly (ADP-ribose) synthase inhibition on burn and smoke inhalation injury. *J Burn Care Rehab* 24:S56, 2003.
89. Enkhbaatar P., Murakami, K., Cox R, Westphal M, Morita N, Burke A, Hawkins H, Traber L, Herndon, D, Traber D. Aerolized tissue plasminogen activator reduces the degree of acute lung injury in sheep with thermal injury. Abstract D475, Experimental Biology, Washington, DC., April 17-21, 2004.
90. Enkhbaatar P., Murakami, K., Cox R, Westphal M, Morita N, Burke A, Hawkins H, Traber L, Herndon, D, Traber D. Removal of airway casts following combined burn and smoke inhalation injury improves pulmonary function. International Conference, Respiratory and Critical care Medicine, Orlando Fl. May 21-26, 2004
91. Burke, A.S., Cox R.A., Oliveras G., Schmalstieg F.C., Murakami, K. Enkhbaatar P. Traber L.D., Traber D.L., Hawkins H.K. Immunohistochemical localization of nitric oxide synthases in an ovine model of smoke inhalation and burn injury. Abstract B58, Experimental Biology, Washington DC., April 17-21, 2004.
92. Enkhbaatar P, Murakami K, Cox RA, Morita N, Westphal M, Burke AS, Hawkins HK, Traber LD, Herndon DN, Traber DL. Importance of airway clearance in thermal injury associated with smoke inhalation in sheep. *J Burn Care Rehab* 25:S93, 2004.
93. Cox RA, Burke AS, Oliveras G, Murakami K, Enkhbaatar P, Westphal M, Traber LD, Schmalstieg FC, Herndon DN, Traber DL, Hawkins HK. Formation of bronchial casts in sheep after smoke inhalation and burn injury. *J Burn Care Rehab* 25:S94, 2004.

ABSTRACTS & PRESENTATIONS: (Cont'd.)

94. Schmalstieg FC, Morita N, Hawkins HK, Zwischenberger J, Traber DL. Poly (ADP-ribose) polymerase controls interleukin-8 in smoke and burn injured sheep. *J Burn Care Rehab* 25:S94, 2004.
95. Hawkins HK, Chandra A, Shimoda K, Enkhbaatar P, Cox RA, Traber DL. Effects of neurokinin receptor blockade on smoke and burn injury in sheep. *J Burn Care Rehab* 25:S127, 2004.
96. Burke AS, Cox RA, Oliveras G, Murakami K, Traber LD, Schmalstieg FC, Traber DL, Hawkins HK. Localization of P-selectin in smoke and burn injured sheep lung. *J Burn Care Rehab* 25:S130, 2004.
97. Burke AS, Cox RA, Enkhbaatar P, Traber LD, Hawkins HK, Herndon DN, Traber DL, Hunter GC. Upregulation of neuropilin expression in an ovine model of smoke and burn injury. *J Burn Care Rehab* 25:S131, 2004.
98. Boor PJ, Hawkins HK, Trent MB, Xue HH, McCauley RL, Herndon DN. The connective tissue enzyme, semicarbazide-sensitive amine oxidase (SSAO) in burn wound healing. *J Burn Care Rehab* 25:S149, 2004.
99. Oliveira GV, Xue P, Wu X, Kitten GT, Hawkins HK, Herndon D. Quantification and 3D localization of collagens with scanning laser confocal microscopy: a new view of the hypertrophic scar. *J Burn Care Rehab* 25:S122, 2004.
100. Oliveira GV, Chinkes D, Thomas S, Sanford A, Oliveras G, Serghiou M, Hawkins H, Herndon DN. Objective scar evaluation: A prospective study. *J Burn Care Rehab* 25:S163, 2004.
101. Burke AS, Oliveras G, Hunter GC, Enkhbaatar P, Traber LD, Schmalstieg FC, Herndon, DN, Traber DL, Hawkins, HK, Cox RA. Bronchial gland expression of pro-inflammatory mediators in an ovine model of smoke inhalation and burn injury. *J. Histochem Cytochem* 52:S40, 2004.
102. Westphal M, Enkhbaatar P, Morita N, Westphal Varghese BB, Kulp G, Maybauer D, Maybauer M, Schmalstieg FC, Cox RA, Burke AS, Hawkins HK, Traber LD, Traber DL. Neuronal nitric oxide synthase inhibition prevents 3-nitrotyrosine formation and attenuates pulmonary dysfunction in ovine lung injury. *Crit Care Med* 32:50A13, 2005.
103. Schmalstieg FC, Zwischenberger JB, Hawkins HK, Keeney SE, Traber DI. Anti-interleukin-8 modulates neutrophils activation in severe smoke inhalation and burn injury. *J Burn Care Rehab* 26:S48, 2005.
104. Enkhbaatar P, Morita N, Maybauer DM, Maybauer MO, Cox RA, Burke A, Hawkins HK, Traber LD, Herndon DN, Traber DL. Role of airway fibrin formation in pathogenesis of acute lung injury. *J Burn Care Rehab* 26:S78, 2005.
105. Przkora R, Herndon DN, Jeschke MG, Hawkins HK, Barrow LN, Barrow RE. Mortality related to gender, age and sepsis in severely burned children. *J Burn Care Rehab* 26:S130, 2005.
106. Rosenberg M, Rosenberg L, Robert R, Hawkins HK, Meyer W. Assisting families from Latin America with the grief process due to burn related death: Cultural implications. *J Burn Care Rehab* 26:S154, 2005.
107. Burke AS, Enkhbaatar P, Traber LD, Schmalstieg FC, Herndon DN, Hawkins HK, Traber DL, Cox RA. Vascular localization of P-selectin in ovine lung after smoke and burn injury. *FASEB J* 19:124-9, 2005.
108. Burke AS, Enkhbaatar P, Traber LD, Traber DL, Herndon DN, Hawkins HK, Cox RA. Bronchial gland secretion of IL-1 β in sheep after smoke and burn injury. 28th Annual Conference on Shock, Shock Society, Marco Island, Florida, June 4-7, 2005.

ABSTRACTS & PRESENTATIONS: (Cont'd.)

109. Enkhbaatar P, Murakami K, Westphal M, Morita N, Maybauer D, Maybauer M, Cox R, Burke A, Hawkins H, Schmalstieg F, Traber LD, Herndon DN, Traber DL. Effects of aerosolized anticoagulants on pulmonary dysfunction in sheep following burn and smoke inhalation. 11th Congress of the Vienna Shock Society, 2005.
110. Traber DL. Role of poly (ADP ribose) polymerase (PARP) and reactive nitrogen species (RNS) in the pathophysiology of combined burn and inhalation injury. 11th Congress of the Vienna Shock Society, 2005.
111. Hawkins HK. Perinatal and placental pathology: The value of secondary prevention. Presented at the 4th Asia-Pacific Pathology Conference (IAP 2005), Beijing, China, August 24, 2005
112. Cox RA, Burke AS, Hawkins H. Production of pro-inflammatory polypeptides by airway mucous glands and its potential significance: Do glands stimulate inflammation? Presented at the VI International Meeting of the Da Vinci Society on the bronchial circulation, Camogli, Italy, September 24, 2005.
113. Hawkins HK, Jacob S, Deyo D, Cox RA, Traber DL, Parish L, Schmalstieg Jr., Zwischenberger J. Assessment of lung inflammation in a mouse model of smoke inhalation and burn injury. FASEB J 20:A211, 2006
114. Nakano YY, Enkhbaatar P, Traber LD, Maybauer DM, Maybauer MO, Cox RA, Hawkins HK, Herndon DN. Combined antibiotic therapy improves survival in ovine septic shock. FASEB J 20:A1382, 2006
115. Enkhbaatar P, Cox R, Traber LD, Maybauer MO, Maybauer DM, Nakano YY, Hawkins H, Schmalstieg F, Herndon D, Traber DL. Role of inducible nitric oxide synthase in septic shock. FASEB J 20:A1391, 2006.
116. Nakano YY, Enkhbaatar P, Traber LD, Maybauer DM, Maybauer MO, Jonkam CC, Cox RA, Hawkins HK, Herndon DN, Traber DL. Heparin nebulization with recombinant human antithrombin supplementation improves pulmonary gas exchange in sepsis following smoke inhalation injury. J Burn Care Rehab 27:S52, 2006.
117. Enkhbaatar P, Traber LD, Cox RA, Esechie A, Maybauer MO, Hawkins HK, Schmalstieg FC, Herndon DN, Prough D, Traber DL. Effects of intravenously administered recombinant human antithrombin (rhAT) and aerosolized heparin on burn and smoke inhalation-induced acute lung injury. J Burn Care Rehab 27:S126, 2006.
118. Cox RA, Jaso J, Parish L, Mlcak RP, Herndon DN, Hawkins HK. Upper airway mucin deposition in the bronchioles and lung parenchyma of burn victims: Comparison of burn only and combined burn and smoke inhalation injuries. J Burn Care Rehab 27:S127, 2006.
119. Enkhbaatar P, Traber LD, Jonkam CC, Esechie A, Wang J, Cox RA, Hawkins HK, Prough D, Herndon DN, Traber DL. Combined recombinant human antithrombin (rhAT) and heparin therapy ameliorates cardiovascular and renal morbidity in sheep after burn and smoke inhalation. J Burn Care Rehab 28:S49, 2007.
120. Nakano Y, Enkhbaatar P, Wang J, Jonkam CC, Traber LD, Schmalstieg FC, Cox RA, Hawkins HK, Herndon DN, Traber DL. The effect of delayed heparin nebulization in an ovine model of sepsis following smoke inhalation injury. J Burn Care Rehab 28:S135, 2007.
121. Swischuk LE, Hawkins H, Jadhav SP, Palacio DM. Lymphoid hyperplasia of the appendix: Its role in acute purulent appendicitis. Annual meeting of the Society for Pediatric Radiology, 2007.

ABSTRACTS & PRESENTATIONS: (Cont'd.)

122. Hamahata A, Enkhbaatar P, Kraft ER, Leonard SW, Traber MG, Cox RA, Hawkins HK, Traber LD, Herndon DN, Traber DL. Gamma-tocopherol nebulization by a novel lipid aerosolization device improves pulmonary function in sheep with burn and smoke inhalation. *J Burn Care Res* 28:S50, 2007.
123. Saunders GD, Westphal M, Enkhbaatar P, Wang J, Robert C, Hawkins HK, Schmalstieg FC, Traber LD, Herndon DN, Traber DL. Neuronal nitric oxide synthase inhibition attenuates pulmonary dysfunction in ovine acute lung injury. *J Burn Care Res* 28:S134, 2007.
124. Cox RA, Enkhbaatar P, Jacob S, Traber LD, Traber DL, Hawkins HK. Smoke inhalation injury induces bronchial gland proliferation. *J Burn Care Res* 28:S141, 2007.
125. Cox RA, Enkhbaatar P, Jacob S, Traber LD, Traber DL, Hawkins HK. Cholinergic modulation of bronchial obstruction after smoke inhalation and burn injury. *J Burn Care Res* 28:S141, 2007.
126. Cox R, Jacob S, Zhu Y, Carter P, Jeschke M, Cox RA, Enkhbaatar P, Nakano Y, Traber LD, Hawkins HK, Traber DL. Muscarinic receptor antagonist therapy attenuates acute pulmonary dysfunction in sheep after burn and inhalation injury. *J Burn Care Res* 29:S47, 2008.
127. Hamahata A, Enkhbaatar P, Lange M, Nakano Y, Cox RA, Hawkins HK, Traber LD, Herndon DN, Traber DL. Ablation of bronchial artery attenuates pulmonary pathophysiology after smoke inhalation and burn injury in ovine model. *J Burn Care Res* 29:S121, 2008.
128. Cox RA, Jacob S, Traber LD, Hawkins HK, Traber DL, Nakano Y, Enkhbaatar P. Tiotropium bromide nebulization attenuates acute pulmonary dysfunction and airway edema in sheep after inhalation and burn injury. *Am J Resp Crit Care Med* 177:A600, 2008.
129. Hawkins HK, Lange M, Jacob S, Cox RA, Schmalstieg FC Jr., Zwischenberger J, Traber DL, Traber LD. Calcitonin gene related peptide (CGRP) stimulates transvascular fluid flux after combined burn and smoke injury in sheep. *J Burn Care Res* 29:S123, 2008.
130. Lange M, Cox RA, Enkhbaatar P, Jacob S, Traber LD, Traber DL, Hawkins HK. Role of calcitonin gene-related peptide (CGRP) in ovine burn and smoke inhalation injury. *Am J Resp Crit Care Med* 177:A600, 2008.
131. Moss JE, Hawkins HK, Longo M, Saade GR, Aronson JF, Sbrana E. Leading causes of intra-uterine fetal demise in an autopsy case series. *Reprod Sci* 15:258A, 2008.
132. Koutrouvelis AP, Kulp GA, Kraft ER, Jeschke MG, Hawkins HK, Cox RA, Herndon DN. Photokinetic transdermal delivery of cyanocobalamin. *Controlled Release Society Annual Meeting & Exposition, New York, NY, July 12-16, 2008.*
133. Koutrouvelin AP, Kulp GA, Kraft ER, Jeschke MG, Nakano Y, Hawkins HK, Cox RA, Lo GS, Herndon DN, Prough DS. Photokinetic transdermal delivery of a Lidocaine-Prilocaine eutectic mixture. *Controlled Release Society Annual Meeting & Exposition, New York, NY, July 12-16, 2008.*
134. Jonkam C, Enkhbaatar P, Traber LD, Hawkins HK, Traber DL, Cox RA. Pretreatment with a selective muscarinic receptor antagonist prevents pulmonary dysfunction in an ovine model of burn and inhalation injury. 14th International Society for Burn Injury, Montreal, Canada, Sept. 7-11, 2008.
135. Hamahata A, Sakurai H, Enkhbaatar P, Schmalstieg FC, Bansal K, Nakazawa H, Rehberg S, Cox RA, Hawkins HK, Nozake M, Herndon DN, Traber DL. Ablation of bronchial artery attenuates neutrophils activations and inflammatory mediators after smoke inhalation and burn injury in ovine model. *J Burn Care Res* 30:S123, 2009

ABSTRACTS & PRESENTATIONS: (Cont'd.)

136. Zhu Y, Jonkam C, Jacob S, Kraft E, Yamamoto Y, Rehberg S, Traber LD, Traber DL, Hawkins HK, Enkhbaatar P, Cox RA. Tiotropium bromide nebulization enhances airway submucosal gland proliferation after inhalation and burn injury in sheep. American Thoracic Society, New Orleans, LA, May 14-19, 2010.
137. Rivero HG, Herndon DN, Mecott G, Kulp G, Andrade JE, Hawkins H, Jeschke MG. Role of acute pancreatitis in pediatric burn patients. *J Burn Care Res* 30:S127, 2009.
138. Cox RA, Jacob S, Zhu Y, Jeschke M, Herndon DN, Hawkins HK. Airway obstruction and bacterial contamination in burn victims at autopsy: Implications for pneumonia. *Shock* 31(suppl. 1):P23, 2009.
139. Jonkam C, Jacob S, Zhu Y, Kraft E., Yamamoto Y, Rehberg S, Traber LD, Traber DL, Hawkins HK, Enkhbaatar P, Cox RA. Combined tiotropium bromide and tissue plasminogen activator therapies to reduce airway obstruction and improve pulmonary function in sheep after inhalation and burn injury. *J Burn Care Res* 31:S116, 2010.
140. Jacob S, Zhu Y, Jonkam C, Kraft E, Rehberg S, Yamamoto Y, Traber L, Traber D, Enkhbaatar P, Hawkins H, Cox R. Effects of muscarinic antagonist therapy on bronchial submucosal inflammation and edema in sheep after inhalation and burn injury. *Shock* 33(suppl1):P145, 2010.
141. Jacob R, Deyo D, Cox R, Jacob S, Herndon D, Traber D, Hawkins H. Substance P antagonist CP-96345 blocks lung vascular leakage and inflammation more effectively than its stereoisomer CP-96344 in a mouse model of smoke inhalation and burn injury. *Shock* 33(suppl 1):P17, 2010.
142. Sbrana E, Hawkins HK, Moss JE, Saade GR, Niklasson B. Ljungan virus antigen detected in brain and spinal cord from cases of stillbirth. Society for Pediatric Pathology, Banff, Alberta, Canada, October 2010.
143. Cox RA, Zhu Y, Jacob S, traber DL, Palmieri T, Enkhbaatar, Hawkins HK. Effects of bronchodilators on submucosal gland cell proliferation after inhalation and burn injury in sheep. FASEB Summer Research Conference on Lung Epithelium in Health and Disease. Saxtons River, Vermont, August 8-13, 2010.
144. Sbrana E, Suter M, Abramovici A, Hawkins H, Moss J, Patterson L, Shope C, Min H, Showalter L, Aagaard-Tiller K. Maternal tobacco use is associated with increased markers of oxidative stress in the placenta. *Am J Obstet Gynecol* 204:S69, 2011.
145. Kita K, Cox WM, Smith KJ, Cox RA, Hawkins HK, Finnerty CC, Herndon DN. Development of a novel gelatin-fibronectin cell carrier for applying stem cells to wound healing. Wound Healing Society, Dallas, TX, April 2011.
146. Asmussen S, Ito H, Traber LD, Cox RA, Hawkins HK, Enkhbaatar P, Traber DL. Use of 6% HES 130/0.4 in ovine methicillin-resistant *Staphylococcus Aureus* septic shock. Presented at Shock Society annual meeting, Norfolk, VA, June 11-14, 2011.
147. Asmussen S, Bartha E, Yamamoto Y, Ito H, Cox RA, Hawkins HK, Enkhbaatar P, Traber LD, Traber DL, Szabo C. Effects of angiotensin converting enzyme inhibitor treatment on pulmonary and cardiac function in ovine burn and smoke inhalation injury. *Am Burn Assoc.*, Chicago IL, March 29-31, 2011.

BOOK CHAPTERS:

1. Jennings RB, Hawkins HK, Hill ML. Myocardial cell-volume control in ischemic injury. In: Lefer AM, Kelliher GJ, Rovetto MJ, eds. *Pathophysiology and Therapeutics of Myocardial Ischemia*, Jamaica, NY: Spectrum Publications, pp351-365, 1978.

BOOK CHAPTERS: (Cont'd.)

2. Jennings RB, Lowe JE, Hawkins HK, Reimer KA. Ultrastructural changes in acute myocardial ischemic injury. In: Zulch KJ, Kaufmann W, Hossman KA, Hossman V, eds. Brain and Heart Infarct II. Berlin: Springer-Verlag, pp88-103, 1979.
3. Hawkins HK. Reactions of lysosomes of cell injury. In: Trump BF, Arstila AU, eds. Pathobiology of Cell Membranes. Vol. 2. New York: Academic Press, pp251-285, 1980.
4. Jennings RB, Hawkins HK, Lowe JE, Hill ML, Reimer KA. High energy phosphate and cell volume control in lethal cellular injury. In: Energy Transport, Protein Synthesis, and Hormonal Control of Heart Metabolism, 1980.
5. Sharov VG, Jennings RB, Hawkins HK, Seleznev YM, Martynov AV. Comparative study of cardiomyocyte membrane permeability defects in severe myocardial ischemia and upon exposure to isoproterenol using colloidal lanthanum. In: Energy Transport, Protein Synthesis and Hormonal Control of Heart Metabolism, Bethesda, MD: U.S. DHHS, pp373-389, 1980.
6. Jennings RB, Hawkins HK. Ultrastructural changes in acute myocardial ischemia. In: Wildenthal K, ed. Degradative Processes in Heart and Skeletal Muscle. Amsterdam: Elsevier-North Holland, pp295-346, 1980.
7. Jennings RB, Kloner RA, Ganote CE, Hawkins HK, Reimer KA. Changes in capillary fine structure and function in acute myocardial ischemic injury. In: Tillmanns H, Kubler W, eds. Microcirculation of the Heart. Berlin: Springer-Verlag, pp87-97, 1982. 6. Jennings RB, Hawkins HK. Ultrastructural changes in acute myocardial ischemia. In: Wildenthal K, ed. Degradative Processes in Heart and Skeletal Muscle. Amsterdam: Elsevier-North Holland, pp295-346, 1980.
8. Ragab AH, Maurer HM, Lui VKS, Kim TH, Hawkins HK. Malignant tumors of the soft tissues. In: Sutow WW, Vietti T, Fernbach DJ, eds. Handbook of Pediatric Oncology, 3rd ed. St. Louis: C.V. Mosby Co., pp652-683, 1984.
9. Jones DH, Schmalstieg FC, Hawkins HK, Burr BL, Rudloff HE, Krater S, Smith CW, Anderson DC. Characterization of a new mobilizable Mac-1 (CD11b/CD18) pool that co-localizes with gelatinase in human neutrophils. In: Springer TA, Anderson DC, Rosenthal AS, Rothlein R, eds. Leukocyte Adhesion Molecules. New York: Springer-Verlag, pp106-24, 1990.
10. Hawkins HK. Ciliary Dyskinesia. In: Oski's Pediatrics: Principles and practice of Pediatrics, third edition, McMillan et al, eds. Philadelphia: J.B. Lippincott, pp 1240-1242 1999.
11. Hawkins HK, Linares HA. The Burn Problem: The Pathologist's Perspective. In: Total Burn Care, second edition, Herndon DN, ed. Philadelphia, Saunders, 2001.
12. Hawkins HK, Linares HA. The Burn Problem: A Pathologist's Perspective. In: Total Burn Care, third edition, Herndon DN, ed., pp. 566-77, Philadelphia, Saunders, 2007.
13. Hawkins HK, Pereira CT. Pathophysiology of the Burn Scar. In: Total Burn Care, third edition, Herndon DN, ed., pp. 608-19, Philadelphia, Saunders, 2007.



PUBLIC VERIFICATION / PHYSICIAN PROFILE

PHYSICIAN

NAME: NOBBY CHIPO MAMBO MD

DATE: 08/21/2013

**THE INFORMATION IN THIS BOX HAS BEEN VERIFIED
BY THE TEXAS MEDICAL BOARD**

Date of Birth: 1944

License Number: K8320 Full Medical License

Issuance Date: 08/28/1999

Expiration Date of Physician's Registration Permit: 02/28/2014

Registration Status: ACTIVE

Registration Date: 09/20/1999

Disciplinary Status: NONE

Disciplinary Date: NONE

Licensure Status: NONE

Licensure Date: NONE

Medical School of Graduation:

At the time of licensure, TMB verified the physician's graduation from medical school as follows:
UNIV OF ZIMBABWE, GODFREY HUGGINS SCH OF MED, AVONDALE, HARARE

Medical School Graduation Year: 1970

TMB Filings, Actions and License Restrictions

The Texas Medical Board has the following board actions against this physician. (This may include any formal complaints filed by TMB, as well as petitions and/or responses related to licensure contested matters, at the State Office of Administrative Hearings.)

NONE

Investigations by TMB of Medical Malpractice

Section 164.201 of the Act requires that: the board review information relating to a physician against whom three or more malpractice claims have been reported within a five year period. Based on these reviews, the following investigations were conducted with the listed resolutions.

NONE

Status History

Status history contains entries for any updates to the individual's registration, licensure or disciplinary status types (beginning with 1/1/78, when the board's records were first automated). Entries are in reverse chronological order; new entries of each type supersede the previous entry of that same type. These records do not display status type. Should you have any questions, please contact our Customer Information Center at 512-305-7030 or verificic@tmb.state.tx.us

Status Code: AC**Effective Date:** 09/20/1999**Description:** ACTIVE**Status Code:** LI**Effective Date:** 08/28/1999**Description:** LICENSE ISSUED

THE INFORMATION IN THIS BOX WAS REPORTED BY THE LICENSEE AND
HAS NOT BEEN VERIFIED BY THE TEXAS MEDICAL BOARD

Gender: MALE***Ethnicity:** BLACK**Race:** BLACK OR AFRICAN AMERICAN

* We are in the process of transitioning from the current ethnic origin values to federal standards for race and Hispanic origin. The transition period will allow time for individuals to submit updated race and Hispanic origin data to the TMB.

Place of Birth: ZIMBABWE**Current Primary Practice Address:**

MEDICAL EXMINER OFFICE

6607 HIGHWAY 1764

TEXAS CITY , TX 77591

Years of Active Practice in the U.S. or Canada:

The physician reports that he/she has actively practiced medicine in the United States or Canada for **34** year(s).

Years of Active Practice in Texas:

The physician reports that, of the above years he/she has actively practiced in the State of Texas for **7** year(s).

Specialty Board Certification

The physician reports that he/she holds the following specialty certifications issued by a board that is a member of the American Board of Medical Specialties or the Bureau of Osteopathic Specialists:

NONE

Primary Specialty

The physician reports his/her primary practice is in the area of PATHOLOGY.

Secondary Specialty

The physician reports his/her secondary practice is in the area of FORENSIC PATHOLOGY.

Name, Location and Graduation Date of All Medical Schools Attended

Name: UNIV COLLEGE OF RHODESIA

Location: HARARE/ZIMBABWE

Graduation Date: 12/1970

Graduate Medical Education In The United States Or Canada

Program Name: UNIV OF TORONTO

Location: TORONTO ONTARIO CANADA, **Begin Date:** 07/1975

Type: RESIDENCY **End Date:** 06/1976

Specialty: AP

Program Name: UNIV COLL OF IH RHODESIA

Location: MIAMI, FL **Begin Date:** 07/1976

Type: RESIDENCY **End Date:** 12/1976

Specialty: FP

Program Name: UNIV OF TORONTO

Location: HARARE ZIMBABWE, **Begin Date:** 01/1971

Type: INTERNSHIP **End Date:** 12/1971

Specialty: SURG MED

Program Name: MD ANDERSON HOSP

Location: HOUSTON, TX **Begin Date:** 01/1972

Type: RESIDENCY **End Date:** 06/1973

Specialty: AP

Program Name: UNIV. OF RHODESIA

Location: HARARE, ZIMBABWE **Begin Date:** 07/1973

Type: RESIDENCY **End Date:** 06/1975

Specialty: ANATOMICAL PATHOLOGY

Hospital Privileges

The physician reports that he/she has hospital privileges in the following in the State of Texas:

Hospital: UTMB

Location: GALVESTON

Utilization Review

The physician did not report whether he/she provides utilization review.

NONE REPORTED

Patient Services

Accessibility: The physician reports that the patient service area **is not** accessible to persons with disabilities as defined by federal law.

Language Translation Services: The physician reports that the following language translation services are provided for patients: NONE

Medicaid Participant: The physician reports that he/she **does not** participate in the Medicaid program.

Awards, Honors, Publications and Academic Appointments**Optional Information**

The physician may optionally report descriptions of up to five such honors and has reported the following:

Description: ASST PROF OF PATHOLOGY 07/1978 - 06/1983

Description: CLINICAL PROFESSOR OF PATHOLOGY UNIVERSITY OF SASKATCHEWAN COLLEGE OF MEDICINE 1998-2002

Description: ASST. PROFESSOR OF PATHOLOGY 1978-1983

Description: CURRENT POSITION: ASSISTANT MEDICAL EXAMINER INSTITUTE OF FORENSIC SCIENCES - NEWARK, NJ

Description: ASSIST.PROF OF PATHOLOGY. UTMB

Malpractice Information

Section 154.006(b)(16) of the Act requires that: a physician profile display a description of any medical malpractice claim against the physician, not including a description of any offers by the physician to settle the claim, for which the physician was found liable, a jury awarded monetary damages to the claimant, and the award has been determined to be final and not subject to further appeal. The physician has the following reportable claims.

Description: NONE

Self-Reported Criminal Offenses:The physician is required to report a description of (1) "any conviction for an offense constituting a felony, a Class A or Class B misdemeanor, or a Class C misdemeanor involving moral turpitude" and (2) "any charges reported to the board to which the physician has pleaded no contest, for which the physician is the subject of deferred adjudication or pretrial diversion, or in which sufficient facts of guilt were found and the matter was continued by a court of competent jurisdiction."

The physician has reported the following:

Description: NONE

Criminal history information is also obtained by TMB from the Texas Department of Public Safety. Resulting action, if any, will be reported under the TMB Action and Non-Disciplinary Restrictions section above.

Disciplinary Actions By Other State Medical Boards

The physician has reported the following:

Description: NONE

Physician Assistant Supervision

To obtain primary source verifications, click name

Description: NONE

Advanced Practice Nurse Delegation

To obtain primary source verifications, click name

Description: NONE

Summary of all License/Permit Types

Issue Date:

08/28/1999

Type:

LICENSED PHYSICIAN

06/04/1999

PHYSICIAN TEMPORARY LICENSE

[Agency](#) | [Contact Us](#) | [Employment](#) | [Compact w/ Texans](#) | [Open Records](#) | [Privacy Policy](#) | [Site Map](#) |
[Search TX State Sites](#) | [TX Homeland Security](#) | [TX Occupations Code](#) |
[Texas.gov](#) | [Poison Control Center Services](#) | [Accessibility Policy](#)

January 2012

CURRICULUM VITAE

NAME:

Nobby C. Mambo, M.D.
(E-mail address: ncmambo@utmb.edu)

PRESENT POSITION AND ADDRESS:

Deputy Chief Medical Examiner

Galveston County Medical Examiner Office
6607 Highway 1764
Texas City, Texas 77591
(04/2007 to present)

Assistant Professor of Pathology

Department of Pathology
University of Texas Medical Branch
301 University Blvd.
Galveston, Texas 77550
(04/2007 to present)

BIOGRAPHICAL:

Date of birth: [REDACTED]

Citizenship: Canadian

U.S. Status: Permanent resident

Home address: [REDACTED]

Home phone: [REDACTED]

Cell phone: [REDACTED]

EDUCATION:

1965-1970: Attended the University of Rhodesia and studied for University of Birmingham M.B. CHB.

BOARD CERTIFICATION:

12/08/1970: M.B. CHB. (Birmingham) University of Rhodesia
11/28/1976: F.R.C.P. (Canada) Anatomic Pathology
11/13/1996: American Board of Pathology, Certification in Anatomic Pathology
09/09/1997: American Board of Pathology, Certification in Forensic Pathology

LICENSURE INFORMATION:

State of Texas, U.S.A.	K8320	(Active)	08/28/1999 - present
State of Alabama, U.S.A.	23147	(Inactive)	01/01/2000 - 01/01/2009
State of Florida, U.S.A.	ME77902	(Inactive)	12/12/2001 - 12/12/2010
State of New Jersey, U.S.A.	25MA07354200	(Inactive)	01/24/2002 - 01/24/2009
State of Louisiana, U.S.A.	MD. 200882	(Inactive)	03/20/2006 - 03/20/2009

PROFESSIONAL AND TEACHING EXPERIENCE:

07/1978 - 06/1987: Assistant Professor of Pathology, University of Saskatchewan College of Medicine
01/1977 - 06/1977: Assistant Professor of Pathology, College of Medicine, Memorial University of Newfoundland
12/2002 - 04/2007: Associate Medical Examiner, Regional Medical Examiner's Office, Newark, N.J.
04/2007 - Present: Assistant Professor of Pathology, University of Texas Medical Branch, Department of Pathology, Galveston, Texas

POST GRADUATE TRAINING

01/1971 - 12/1971: Rotating internship in Medicine and Surgery, University of Rhodesia Medical School
01/1972 - 06/1973: Senior House Officer in Pathology, University of Rhodesia Medical School
07/1973 - 06/1975: Resident, University of Toronto, Pathology Program, Toronto, Canada
07/1975 - 06/1976: Fellow in Pathology, MD Anderson Hospital & Tumor Institute, Houston, Texas
07/1976 - 12/1976: Senior Resident, University of Toronto, Pathology Program

POST CERTIFICATION TRAINING:

- 07/01/1977 - 06/30/78: Research Fellow in Cardiovascular Pathology, University of Toronto, Toronto, Canada
- 08/01/81 - 08/31/81: Clinical Trainee in Diagnostic Immunocytochemistry, New England Medical Center, Boston
- 06/01/92 - 06/30/92: Practicum in Diagnostic Molecular Pathology, University of Southern California
- 07/01/1996 - 06/30/1997: Fellow in Forensic Pathology, Dade County Medical Examiner Office, Miami, FL

TEACHING RESPONSIBILITIES:

A. TEACHING RESPONSIBILITIES AT UTMB:

a. Teaching:

School of Medicine (SOM):

- Conducted Systems Pathology Laboratory sessions for medical students.
- Took part in autopsy conferences at UTMB.
- Instructed Pathology residents and medical students rotating through the Galveston County Medical Examiner Office.

b. Students/Mentees/Advisees/Trainees:

- Interviewed medical school applicants.

Ph.D. students: Conducted laboratory sessions in Pathology.

STAFF APPOINTMENTS:

- 04/2007 - Present: Assistant Professor of Pathology, University of Texas Medical Branch, Department of Pathology, Galveston, Texas
- 12/2002 - 04/2007: Associate Medical Examiner, Regional Medical Examiner's Office, Newark, NJ
- 10/1986 - 12/2002: Chief Pathologist, Melfort Hospital, Melfort Saskatchewan, Canada
- 07/1983 - 06/1986: Director of Laboratory Medicine, Victoria Hospital, Prince Albert, Saskatchewan, Canada
- 07/1978 - 06/1987: Assistant Professor of Pathology, University of Saskatchewan College of Medicine
- 01/1977 - 06/1977: Assistant Professor of Pathology, College of Medicine, Memorial University of Newfoundland
- 09/1982 - Present: Officer of the World Health Organization

OFFICES HELD:

August - September 1982:	World Health Organization. Consultant into Public Health Laboratory Services in Zimbabwe.
July 1982 - June 1983:	University Council Rep. to Canadian Universities Services Overseas, Saskatchewan Division.
September 1983 - August 1984:	Vice President, Saskatchewan Association of Pathologists.
September 1984 - August 1985:	President, Saskatchewan Association of Pathologists.
October 1997 - December 1998:	President of Medical Staff, Melfort Hospital.
January 1999 - December 2002:	Chief of Medical Staff, Melfort Union Hospital.

MEMBERSHIPS TO PROFESSIONAL SOCIETIES

- Canadian Medical Association
- American Society of Clinical Pathologists
- College of American Pathologists
- International Academy of Pathologists (U.S./Canada Division)
- National Association of Medical Examiners

PUBLISHED:

1. Mambo, N.C., Teratomas in Children: Review of cases in the 0-12 year age group seen at Harare Hospital over ten year period, 1960-1969
Central African Journal of Medicine 20: 231-234, 1974.
2. Houston, W., Pontin, A., Kuhn, T. and Mambo, N.C. Kaposi's sarcoma of the penis. British Journal of Urology 47: 315-318, 1975.
3. Mambo, N.C., Burke, J.S. and Butler, J.J. Primary malignant lymphoma of the breast. Cancer 30: 2033-2040, 1977.
4. Mambo, N.C. and Gallagher, H.S. Carcinoma of the breast: The prognostic significance of the extra nodal extension of axillary disease. Cancer 39: 2280-2285, 1977.
5. Mambo, N.C. Rupture of the heart in a case of myocarditis. Archives of Pathology and Laboratory Medicine 102: 329-330, 1978.
6. Mambo, N.C. Silver, M.D. and Brunson, D.F.V. Bacterial endocarditis in the mitral valve with annular calcification. Canadian Medical Association Journal 119: 323-326, 1978.
7. Mambo, N.C. Temporal (granulomatous) arteritis: A histopathological study of 32 cases. Histopathology 3: 209-221, 1979.

-
8. Mambo, N.C., Silver, M.D., McLaughlin, P.R., Huckell, V.G., McEwan, P.M., Britt, B.A., and Morch, J.E. Malignant hyperthermia susceptibility: A light and electron microscopic study of endomyocardial biopsy specimens from nine patients. *Human Pathology* 11: 381-338, 1980.
 9. Mambo, N.C. Diseases of the pericardium: Morphologic study of surgical specimens from 35 patients. *Human Pathology* 12: 978-987, 1981.
 10. Mambo, N.C. Immunohistochemical study of the Immunoglobulin classes of Plasma Cells in Papillary Syringadenoma. *Virchows Arch. (Pathol. Anat)*. 397:1-6, 1982.
 11. Mambo, N.C. Isoantigen status in Condyloma Acuminata of the Uterine Cervix: An Immunoperoxidase Study. *Am J. Clin. Pathol.* 79: 178-181, 1983.
 12. Kontozoglou, I., Mambo, N.C. The histopathologic features of Lithium associated thyroiditis. *Hum. Pathol.* 14: 737-739, 1983.
 13. Mambo, N.C. Eccrine Spiradenoma: Clinical and pathologic study of 49 tumors. *J. Cut. Pathol.* 10: 312-320, 1983.
 14. Mambo, N.C., Irwin, S.M. Anaplastic Small Cell Neoplasms of the Thyroid. An Immunoperoxidase Study. *Hum. Pathol.* 14: 55-60, 1983.
 15. Kontozoglou, T., Mambo, N.C. Fatal retropleural haematoma complicating internal jugular vein catheterization. *Am. J. For. Med.* 4: 125-127, 1983.
 16. Mambo, N.C. Hyaline cells in a benign Chondroid Syringoma. Report of a case and findings by conventional and electron microscopy. *Am J. Dermatopathol.* 6: 265-272, 1984.
 17. Mambo, N.C. The significant of atypical nuclear changes in benign eccrine spiradenomas: A clinical and pathologic study of 18 cases. *J. J. Cut. Pathol.* 1: 35-44, 1984.
 18. Poster presentation, National Association of Medical Examiners, Thirty Ninth Annual Meeting, Los Angeles, CA., October 14-19: 2005. Mambo, N.C. et al; Unusual Method of Hanging.
 19. Poster presentation. National Association of Medical Examiners, Thirty Ninth Annual Meeting, Los Angeles CA Oct. 14-19, 2005. Hua, Z. Mambo N.C. et al; Facial Dissection in Forensic Pathology.
 20. Poster Presentation .NAME. Thirty Ninth Annual Meeting. Los Angeles .CA Oct.14-19, 2005. Krolikowski , J., Mambo, N.C. et al. Adolescent Suicides; Strategies and Options.
 21. Poster Presentation.NAME Thirty Ninth Annual Meeting. Los Angeles. CA Oct. 14-19, 2005. Krolikowski, J. Mambo, N.C. et al.; Issues in the investigation of a serial killer.





PUBLIC VERIFICATION / PHYSICIAN PROFILE

PHYSICIAN

NAME: HARMINDER SINGH NARULA MD **DATE:** 08/21/2013

THE INFORMATION IN THIS BOX HAS BEEN VERIFIED
BY THE TEXAS MEDICAL BOARD

Date of Birth: 1949

License Number: G2442 Full Medical License

Issuance Date: 08/29/1982

Expiration Date of Physician's Registration Permit: 05/31/2014

Registration Status: ACTIVE

Registration Date: 08/29/1982

Disciplinary Status: NONE

Disciplinary Date: NONE

Licensure Status: NONE

Licensure Date: NONE

Medical School of Graduation:

At the time of licensure, TMB verified the physician's graduation from medical school as follows:
CALCUTTA MED COLL, CALCUTTA UNIV, CALCUTTA, WEST BENGAL

Medical School Graduation Year: 1975

TMB Filings, Actions and License Restrictions

The Texas Medical Board has the following board actions against this physician. (This may include any formal complaints filed by TMB, as well as petitions and/or responses related to licensure contested matters, at the State Office of Administrative Hearings.)

NONE

Investigations by TMB of Medical Malpractice

Section 164.201 of the Act requires that: the board review information relating to a physician against whom three or more malpractice claims have been reported within a five year period. Based on these reviews, the following investigations were conducted with the listed resolutions.

NONE

Status History

Status history contains entries for any updates to the individual's registration, licensure or disciplinary status types (beginning with 1/1/78, when the board's records were first automated). Entries are in reverse chronological order; new entries of each type supersede the previous entry of that same type. These records do not display status type. Should you have any questions, please contact our Customer Information Center at 512-305-7030 or verificic@tmb.state.tx.us

Status Code: AC**Effective Date:** 08/29/1982**Description:** ACTIVE

THE INFORMATION IN THIS BOX WAS REPORTED BY THE LICENSEE AND
HAS NOT BEEN VERIFIED BY THE TEXAS MEDICAL BOARD

Gender: MALE***Ethnicity:** ASIAN OR PACIFIC ISLANDER**Race:** ASIAN

* We are in the process of transitioning from the current ethnic origin values to federal standards for race and Hispanic origin. The transition period will allow time for individuals to submit updated race and Hispanic origin data to the TMB.

Place of Birth: INDIA**Current Primary Practice Address:**

6607 HIGHWAY 1764

TEXAS CITY , TX 77591

Years of Active Practice in the U.S. or Canada:

The physician reports that he/she has actively practiced medicine in the United States or Canada for **28** year(s).

Years of Active Practice in Texas:

The physician reports that, of the above years he/she has actively practiced in the State of Texas for **28** year(s).

Specialty Board Certification

The physician reports that he/she holds the following specialty certifications issued by a board that is a member of the American Board of Medical Specialties or the Bureau of Osteopathic Specialists:

Specialty Certification: AMERICAN BOARD OF PTH/FORENSIC PATHOLOGY**Date:** 1989**Specialty Certification:** AMERICAN BOARD OF PTH/ANATOMIC PATHOLOGY**Date:** 1987

Primary Specialty

The physician reports his/her primary practice is in the area of FORENSIC PATHOLOGY.

Secondary Specialty

The physician reports his/her secondary practice is in the area of PATHOLOGY.

Name, Location and Graduation Date of All Medical Schools Attended

Name: MEDICAL COLLEGE,CALCUTTA UNIVERSITY

Location: CALCUTTA,INDIA

Graduation Date: 1974

Graduate Medical Education In The United States Or Canada

Program Name: METHODIST MEDICAL CENTER

Location: PEORIA, IL

Begin Date: 07/1977

Type: RESIDENCY

End Date: 06/1981

Specialty: PATHOLOGY-ANATOMIC & CLINICAL

Program Name: BAYLOR COLL OF MEDICINE

Location: HOUSTON, TX

Begin Date: 01/1982

Type: FELLOWSHIP

End Date: 06/1984

Specialty: NEUROPATHOLOGY

Hospital Privileges

The physician reports that he/she has hospital privileges in the following in the State of Texas:

NONE

Utilization Review

The physician did not report whether he/she provides utilization review.

NONE REPORTED

Patient Services

Accessibility: The physician reports that the patient service area **is not** accessible to persons with disabilities as defined by federal law.

Language Translation Services: The physician did not report whether he/she provided any language translation services for patients.

Medicaid Participant: The physician reports that he/she **does not** participate in the

Medicaid program.

Awards, Honors, Publications and Academic Appointments

Optional Information

The physician may optionally report descriptions of up to five such honors and has reported the following:

NONE

Malpractice Information

Section 154.006(b)(16) of the Act requires that: a physician profile display a description of any medical malpractice claim against the physician, not including a description of any offers by the physician to settle the claim, for which the physician was found liable, a jury awarded monetary damages to the claimant, and the award has been determined to be final and not subject to further appeal. The physician has the following reportable claims.

Description: NONE

Criminal History

Self-Reported Criminal Offenses:The physician is required to report a description of (1) "any conviction for an offense constituting a felony, a Class A or Class B misdemeanor, or a Class C misdemeanor involving moral turpitude" and (2) "any charges reported to the board to which the physician has pleaded no contest, for which the physician is the subject of deferred adjudication or pretrial diversion, or in which sufficient facts of guilt were found and the matter was continued by a court of competent jurisdiction."

The physician has reported the following:

Description: NONE

Criminal history information is also obtained by TMB from the Texas Department of Public Safety. Resulting action, if any, will be reported under the TMB Action and Non-Disciplinary Restrictions section above.

Disciplinary Actions By Other State Medical Boards

The physician has reported the following:

Description: NONE

Physician Assistant Supervision

To obtain

primary source
verifications,
click name

Description: NONE

Advanced Practice Nurse Delegation

To obtain
primary source
verifications,
click name

Description: NONE

Summary of all License/Permit Types

Issue Date:

08/29/1982

Type:

LICENSED PHYSICIAN

[Agency](#) | [Contact Us](#) | [Employment](#) | [Compact w/ Texans](#) | [Open Records](#) | [Privacy Policy](#) | [Site Map](#) |
[Search TX State Sites](#) | [TX Homeland Security](#) | [TX Occupations Code](#) |
[Texas.gov](#) | [Poison Control Center Services](#) | [Accessibility Policy](#)

CURRICULUM VITAE

NAME:

Harinder Narula, M.D.
(Email address: hanarula@utmb.edu)

PRESENT POSITION AND ADDRESS:

Deputy Medical Examiner, part-time
(Contract Pathologist)

Galveston County Medical Examiner's Office
6607 Hwy. 1764
Texas City, Texas 77591
(01/2007 - present)
*Staff position

Clinical Assistant Professor

Department of Pathology
University of Texas Medical Branch
301 University Blvd.
Galveston, Texas 77550
(01/2007 - present)
*Teaching position

Deputy Medical Examiner, part-time
(Contract Pathologist)

Nueces County Medical Examiner's Office
Corpus Christi, Texas
(12/2007 - present)
*Staff position

Contract Pathologist

El Paso County Medical Examiner's Office
(07/2006 - 09/2006)
*Staff position

Clinical Assistant Professor

Baylor College of Medicine
Baylor College of Pathology
Department of Pathology
One Baylor Plaza
Houston, Texas 77030
(07/1984 - 06/2004)
*Teaching position

Assistant Medical Examiner

Office of Medical Examiner of Harris County
Joseph A. Jachimczyk Forensic Center
1885 Old Spanish Trail
Houston, Texas 77054
(07/1984 to 06/2004) - Retired
*Staff position

BIOGRAPHICAL:

Date of Birth: [REDACTED]
Home address: [REDACTED]
Citizenship: USA
Home phone: [REDACTED]
Cell phone: [REDACTED]

EDUCATION:

07/1967-06/1974: Medical College, Calcutta University, India
07/1966-06/1967: Presidency College, Calcutta University, India

QUALIFICATIONS:

1974: M.B.B.S., Medical College, Calcutta University, India
1967: Pre-Medical, Presidency College, Calcutta, India

POST GRADUATE TRAINING:

01/1982-06/1984: Neuropathology Fellow: Baylor College of Medicine Affiliated Hospitals, Houston, Texas, The Methodist Hospital, Texas Children's Hospital, Ben Taub General Hospital and the Veteran's Hospital
07/1977-06/1981: Pathology Resident: Anatomic and Clinical, Methodist Medical Center of Illinois, Peoria, Illinois
07/1975-05/1976: Senior and Junior Housestaff: Medical College Hospitals, Calcutta, India
07/1974-06/1975: Rotating Internship: Medical College Hospitals, Calcutta, India

BOARD CERTIFICATION:

09/25/1989: Forensic Pathology
11/19/1986: Anatomic Pathology
07/01/1984: Board Eligibility in Neuropathology
07/01/1981: Board Eligibility in Clinical Pathology

LICENSURE INFORMATION:

06/01/1982: State of Texas, U.S.A, License #G2442
(Renewal Date: 05/31/2012)
07/01/1975: State of W. Bengal, India
(Permanent – no renewal date)

RESEARCH EXPERIENCE:

Development and Distribution of Acetylcholine Receptors on Rat Muscle Cells in Culture, by Light Microscopic Autoradiography, Fluorescence Microscopy and Radio Assay.

OTHER RESPONSIBILITIES:

1983-1984: Neuropathology for Pathology Resident, Baylor College of Medicine, Houston, Texas, USA.
1982-1983: Neuroscience course, Medical Students, Baylor College of Medicine, Houston, Texas, USA.
1982: Lecture in Parasitology of the Nervous System at American Society of Medical Technologists Meeting, Houston, Texas.
1980-1981: Pathology Lab for Medical Students, Peoria School of Medicine, Illinois, USA.
1980: Library Consultant, Methodist Medical Centre, Peoria, Illinois, USA.

STAFF APPOINTMENTS:

Assistant Professor of Pathology, University of Texas Medical Branch, Department of Pathology, Galveston, Texas

MEMBERSHIP IN SCIENTIFIC SOCIETIES/PROFESSIONAL ORGANIZATIONS:

Present: American Academy of Forensic Sciences
National Association of Medical Examiners

Past: College of American Pathologists
International Academy of Pathology (U.S. – Canadian)
American Society of Clinical Pathologists
Texas Society of Pathologists
Houston Society of Clinical Pathologists
Harris County Medical Society
Texas Medical Association
American Medical Association
Southern Medical Association

HONORS:


1967-1972: Jagadis Bose National Science Talent Search (W. Bengal, India)

1966: National Science Talent Search (India)

PUBLISHED:

H.S. Narula and S. Bursztajn: "Preferential Distribution of Acetylcholine Receptor Clusters during Development of Cultured Rat Myotubes," JNEN, 42:312, 1983 (abstract).





PUBLIC VERIFICATION / PHYSICIAN PROFILE

PHYSICIAN

NAME: JUAN PABLO OLANO MD

DATE: 08/21/2013

**THE INFORMATION IN THIS BOX HAS BEEN VERIFIED
BY THE TEXAS MEDICAL BOARD**

Date of Birth: 1963

License Number: K7466 Full Medical License

Issuance Date: 05/14/1999

Expiration Date of Physician's Registration Permit: 08/31/2014

Registration Status: ACTIVE

Registration Date: 06/25/1999

Disciplinary Status: NONE

Disciplinary Date: NONE

Licensure Status: NONE

Licensure Date: NONE

Medical School of Graduation:

At the time of licensure, TMB verified the physician's graduation from medical school as follows:
UNIV DEL CAUCA, POPAYAN

Medical School Graduation Year: 1987

TMB Filings, Actions and License Restrictions

The Texas Medical Board has the following board actions against this physician. (This may include any formal complaints filed by TMB, as well as petitions and/or responses related to licensure contested matters, at the State Office of Administrative Hearings.)

NONE

Investigations by TMB of Medical Malpractice

Section 164.201 of the Act requires that: the board review information relating to a physician against whom three or more malpractice claims have been reported within a five year period. Based on these reviews, the following investigations were conducted with the listed resolutions.

NONE

Status History

Status history contains entries for any updates to the individual's registration, licensure or disciplinary status types (beginning with 1/1/78, when the board's records were first automated). Entries are in reverse chronological order; new entries of each type supersede the previous entry of that same type. These records do not display status type. Should you have any questions, please contact our Customer Information Center at 512-305-7030 or verificic@tmb.state.tx.us

Status Code: AC

Effective Date: 06/25/1999

Description: ACTIVE

Status Code: LI

Effective Date: 05/14/1999

Description: LICENSE ISSUED

THE INFORMATION IN THIS BOX WAS REPORTED BY THE LICENSEE AND HAS NOT BEEN VERIFIED BY THE TEXAS MEDICAL BOARD

Gender: MALE

***Ethnicity:** HISPANIC

Race: WHITE - of Hispanic origin

* We are in the process of transitioning from the current ethnic origin values to federal standards for race and Hispanic origin. The transition period will allow time for individuals to submit updated race and Hispanic origin data to the TMB.

Place of Birth: COLOMBIA

Current Primary Practice Address:

301 UNIVERSITY BLVD

GALVESTON , TX 77555-0428

Years of Active Practice in the U.S. or Canada:

The physician reports that he/she has actively practiced medicine in the United States or Canada for **20** year(s).

Years of Active Practice in Texas:

The physician reports that, of the above years he/she has actively practiced in the State of Texas for **20** year(s).

Specialty Board Certification

The physician reports that he/she holds the following specialty certifications issued by a board that is a member of the American Board of Medical Specialties or the Bureau of Osteopathic Specialists:

NONE

Primary Specialty

The physician reports his/her primary practice is in the area of PATHOLOGY.

Secondary Specialty

The physician reports his/her secondary practice is in the area of SELECTIVE PATHOLOGY.

Name, Location and Graduation Date of All Medical Schools Attended

Name: UNIVERSITY OF CAUCA, COLOMBIA

Location: POPAYAN/CAUCA/COLOMBIA

Graduation Date: 12/1987

Graduate Medical Education In The United States Or Canada

Program Name: COOK COUNTY HOSPITAL

Location: CHICAGO, IL

Begin Date: 12/1989

Type: INTERNSHIP

End Date: 02/1990

Specialty: INT MEDICINE

Program Name: UNIVERSITY OF TEXAS MEDICAL BRANCH

Location: GALVESTON, TX

Begin Date: 07/1992

Type: RESIDENCY

End Date: 06/1997

Specialty: PATHOLOGY

Program Name: UNIVERSITY OF TEXAS MEDICAL BRANCH

Location: GALVESTON/TEXAS

Begin Date: 07/1997

Type: FELLOWSHIP

End Date: 06/1999

Specialty: MEDICAL MICROBIOLOGY

Hospital Privileges

The physician reports that he/she has hospital privileges in the following in the State of Texas:

Hospital: UNIVERSITY OF TEXAS MED BRANCH HOSPITALS

Location: GALVESTON

Utilization Review

The physician did not report whether he/she provides utilization review.

NONE REPORTED

Patient Services

Accessibility: The physician reports that the patient service area is accessible to persons with disabilities as defined by federal law.

Language Translation Services: The physician reports that the following language translation services are provided for patients: SPANISH, HEARING IMPAIRED

Medicaid Participant: The physician reports that he/she **does** participate in the Medicaid program.

Awards, Honors, Publications and Academic Appointments

Optional Information

The physician may optionally report descriptions of up to five such honors and has reported the following:

Description: OLANO JP, WALKER DH. DIAGNOSING EMERGING AND RE-EMERGING INFECTIOUS DISEASES. ARCH PATHOL, JAN 2011

Description: GEORGE DOCK DISTINGUISHED PROFESSORSHIP IN PATHOLOGY. UTMB

Description: COWAN DF, OLANO JP. A PRACTICAL GUIDE TO CLINICAL LABORATORY TESTING MALDEN, MASSACHUSSETS. BLACKWELL SCIENCE INC. 1997.

Description: PAUL BRINDLEY DISTINGUISHED SCHOLAR IN PATHOLOGY. UTMB

Description: AMERICA S TOP DOCTORS: 2006-2011; AMERICA S TOP PATHOLOGISTS: 2007-2011

Malpractice Information

Section 154.006(b)(16) of the Act requires that: a physician profile display a description of any medical malpractice claim against the physician, not including a description of any offers by the physician to settle the claim, for which the physician was found liable, a jury awarded monetary damages to the claimant, and the award has been determined to be final and not subject to further appeal. The physician has the following reportable claims.

Description: NONE

Criminal History

Self-Reported Criminal Offenses:The physician is required to report a description of (1) "any conviction for an offense constituting a felony, a Class A or Class B misdemeanor, or a Class C misdemeanor involving moral turpitude" and (2) "any charges reported to the board to which the physician has pleaded no contest, for which the physician is the subject of deferred adjudication or pretrial diversion, or in which sufficient facts of guilt were found and the matter was continued by a court of competent jurisdiction."

Description: NONE

Criminal history information is also obtained by TMB from the Texas Department of Public Safety. Resulting action, if any, will be reported under the TMB Action and Non-Disciplinary Restrictions section above.

Disciplinary Actions By Other State Medical Boards

The physician has reported the following:

Description: NONE

Physician Assistant Supervision

To obtain primary source verifications, click name

Description: NONE

Advanced Practice Nurse Delegation

To obtain primary source verifications, click name

Description: NONE

Summary of all License/Permit Types

Issue Date:	Type:
06/29/1992	<u>INSTITUTIONAL PERMIT</u>
07/01/1997	<u>INSTITUTIONAL PERMIT</u>
05/14/1999	<u>LICENSED PHYSICIAN</u>
04/30/1999	<u>PHYSICIAN TEMPORARY LICENSE</u>

Date: January, 2012

CURRICULUM VITAE

NAME: Juan P. Olano, M.D.

PRESENT POSITION AND ADDRESS: Professor with Tenure
Department of Pathology
Director, Pathology Residency Training Program,
Associate Director, Autopsy Division
Member, Center for Biodefense and Emerging Infectious
Diseases.
University of Texas Medical Branch at Galveston
301 University Blvd.
Galveston, TX 77555-0428

BIOGRAPHICAL: Date of Birth: November 5, 1963
Place of Birth: Popayan, Colombia
Citizenship: USA
Home Address: 2926 Port Rose Ln
League City, TX 77573

EDUCATION: **Feb. 1981-Dec. 1987** - M.D., University of Cauca,
Colombia

July 1992-1997 - Resident in Pathology, University
of Texas Medical Branch (UTMB), Anatomic and
Clinical Pathology Program

1996-1997 - Chief Resident, Pathology Residency
Program, UTMB

July 1997-June 1999 - Post-doctoral Fellowship in
Clinical Microbiology and Experimental Pathology,
Center for Biodefense and Emerging Infectious
Diseases, Center for Tropical Diseases, UTMB

BOARD CERTIFICATION: Diplomate of the American Board of Pathology,
Board certified in Anatomic and Clinical Pathology,
September 11, 2000

LICENSURE INFORMATION: State of Texas # K7466

PROFESSIONAL AND TEACHING EXPERIENCE:
Feb. 1990-Aug., 1990: General Practitioner, Day
Care Centers, Popayan, Colombia

Aug. 1990-April 1992: General practitioner, Red Cross, Cauca Regional Branch

May 1991-April 1992: Medical Coordinator, Red Cross, Cauca Regional Branch

Dec. 1986-1987 Internship, San Jose University Hospital, Popayan, Colombia and Caloto County Hospital, Colombia.

2001-2003 Associate Director, Biosafety Level 3 Laboratories (BSL-3), Center for Biodefense and Emerging Infectious Diseases, UTMB.

1999-2005 Assistant Professor, Department of Pathology, UTMB, Galveston, TX.

2005-2011 Associate Professor, Department of Pathology, UTMB, Galveston, TX

2011-present Professor, Department of Pathology, UTMB, Galveston, TX

2003-present Director, Pathology Residency Training Program, UTMB, Galveston, TX

2000-present Associate Director, Division of Autopsy, UTMB, Galveston, TX.

2007-2008: Interim Director, Clinical Microbiology Fellowship.

2005-present: Director, BSL-3 Confocal Microscopy Core Laboratory. Galveston National Laboratory.

RESEARCH ACTIVITIES:

Area of Research

Rickettsial and Ehrlichial pathogenesis
Development of new diagnostic methods for rickettsioses
Microvascular permeability in rickettsial infections
Animal model development for ehrlichial and rickettsial pathogens.

Grant support

Current

- 2010-2013 Co-investigator (10% effort). Animal Models of Infectious Diseases-Development of a Mouse Model for Scrub Typhus. Task Order HHSN27200001-Task Order A06, NIH/NIAID. Total award, direct cost: \$ 1,530,868
- 2008-2013 Co-investigator. 10% effort. A multiplex serodiagnostics protein microarray. U-01, NIAID. University of California- Irvine. Total award: \$ ~ 450,000 (sub-contract for Dr. Olano).
- 2008-2010 UTMB/Sandia Joint Institute for Biosecurity, Technology Acceleration and Commercialization (JIB-TAC). Post-Doctoral fellowship. Total Award: \$53,000
- 2009-2014 Co-Investigator. 10% effort. Towards the development of a syndrome specific diagnostic tool. Western Regional Centers for Excellence in Biodefense and Emerging Infectious Diseases (WRCE). NIH-NIAID. Total award direct cost \$1,949,180 (Dr. Olano subcontract direct cost: \$524,670).
- 2009-2014 Co-Director. 10% effort. Diagnostics Development Core. Western Regional Centers for Excellence in Biodefense and Emerging Infectious Diseases (WRCE). NIH-NIAID. Total award direct cost: \$\$2,524,958 (Dr. Olano subcontract direct cost: \$517,996).
- 2011-2013 Co-Investigator. 5% effort. Rickettsiae Detection Dipstick. Department of the Army, US Army Research, Development and Engineering Command (Total award for J. Olano: \$110,000). Gregory Zeltzer, M.D., Ph.D. Principal Investigator. Physical Optics Corporation.

Pending

- 2011 Co-Investigator. Palm-Diagnostic Instrument and Electro-modulated Test Chips for Viral and Bacterial Biodefense. Sandia National Laboratories, University of Houston, University of Texas Medical Branch. NIH R-O1.

Past

- 1993-1994 Principal Investigator. Research Project Grant from the Southern Medical Association. "Identification and characterization of marijuana metabolites in rats meconium by using Fluorescent Polarization Immunoassays (FPIA) and Gas Chromatography/Mass spectrometry (GC/MS)". Total award: \$3,000
- 1997-1998 Principal Investigator. George Dock Scholar Award. University of Texas Medical Branch. "Intracellular calcium, actin polymerization and their role in the pathogenesis of rickettsial infections". Total award: \$4,000.
- 1997-2002 Co-Investigator. 10% effort. NIH "Emerging and Re-emerging rickettsioses in Latin America" Fogarty International. Grant #D43 TW000903-05. Total award: \$502,880.

- 1996-2000 Co-Investigator. 25% effort. “Epidemiology of Human Monocytic Ehrlichiosis”, Centers for Disease Control and Prevention(CDC)Grant. (David H. Walker, Principal Investigator). Grant #HR8-CCH 613372. Total award: \$64,000.
- 2001-2005 Co-Investigator. 25% effort. NIH “*Ehrlichia chaffeensis* surface proteins” (David H. Walker, Principal Investigator). Grant #A1031431-11. Total award: \$1,490,000.
- 2001-2003 Co-Investigator. 5% effort. Texas-Mexico border Infectious Disease Monitoring Program, Department of Health and Human Services/Centers for Disease Control and Prevention (CDC) grant. (Robert B. Tesh, Principal Investigator).
- 2001-2003 Principal Investigator. 25% effort. John Sealy Memorial Endowment Fund, “Endothelial Pathobiology in Rickettsial Infections”. Grant #2559-01. Total award: \$70,000.
- 2002-2007 Co-Principal Investigator. 25% effort. “Molecular Pathogenesis of Rickettsioses and Development of Novel Anti-Rickettsial Treatment by Combinatorial Peptide-Based Libraries”. U.S. Army Medical Research and Materiel Command. Peer-Reviewed Medical Research Program. Arthropod Transmitted Infectious Disease. Grant #DAMD-17-02-1-0198. Total award: \$1,284,529.
- 2003-2008 Principal Investigator. 15% effort. “New Diagnostic Methods for Acute Rickettsial Infections”. Project #6, Western Regional Centers for Excellence (WRCE) for Biodefense and Emerging Infections. Grant #U54 AI057156-01. Total award : \$1,493,097.
- 2008-2009 Co-Investigator. 10% effort. Towards the development of a syndrome-specific diagnostic tool. Western Regional Centers for Excellence (WRCE) for Biodefense and Emerging Infections. Direct cost: \$88,033 (sub-contract for Dr. Olano).
- 2008-2009 Co-Investigator. 10% effort. Multiplex serodiagnostic chip for rickettsial diseases. Western Regional Centers for Excellence in Biodefense and Emerging Infectious Diseases (WRCE). Direct cost: \$61,391(for Dr. Olano’s subcontract).
- 2006-2011 Co-Investigator. 14% effort. Small Animal Model Development and Proof-of-Concept Testing of Therapeutics and Vaccines in Small Animal Models of *Burkholderia* and *Rickettsial* Diseases. NIH-NIAID-DMID-03-39 Part C (19). Direct costs: \$3,248,556.

COMMITTEE RESPONSIBILITIES:

International

<u>National</u>	2005 – present:	Biological Threat Characterization Program. Department of Homeland Security.
	2006 – present:	Scientific Coordinating Committee, Biodefense and Emerging Infectious Research Resources Repository (BEI Resources), NIAID.
<u>State/Regional</u>	2011-present	Texas Society of Pathology Educational Foundation Board Member House of Delegates
<u>UTMB</u>	2001 – 2004:	Pathology Patient Services Safety Committee
	2001 – present:	Institutional Biological Safety Committee
	2001 – 2003	Technology and Clinical Applications Task Force
	2003 – present:	Graduate Medical Education Committee
	2005 -- present:	Graduate Medical Education Subcommittee on Operations and working Environment Organizing Committee. Co-Director. 7 th McLaughlin Symposium in Infection and Immunity. The Microcirculation in Acute Viral and Bacterial Infections.
	2007	
	2006 -- present	Member, Institutional Optical Imaging Core
	2005 -- present	Director, BSL-3 Confocal Imaging Core. CBDEID, Galveston National Laboratory.
<u>School</u>		
<u>Departmental</u>	2001, 2008	Department of Pathology, Internal Review Committee
	2001	Department of Pathology Strategic Plan Committee, Endothelial Cell Biology Group
	2002 - 2007	Clinical and Translational Research Working Group, Department of Pathology
	2002 - present	Department of Pathology Website Task Force
	2001 – present	Head, Autopsy Division Research Subcommittee
	2002 – present	Peer-review Departmental Grant Committee, Department of Pathology
	2003 – present	Head, George Dock Scholarship Committee, Department of

Pathology.

	2003 – present	Head, Residency Advisory Committee, Department of Pathology
	2010	Molecular Diagnostics Task Force
<u>Other</u>	1998 – 2001	Member International CAFÉ Society. Consensus approach for ehrlichiosis

Committee Responsibility other than UTMB (optional)

Scientific Sessions Organized

2007. Member, Organizing Committee. McLaughlin Symposium on “The Microcirculation in Acute bacterial and Viral Infections”. Galveston, TX November, 2007.

Scientific Sessions Chaired / Discussion Leader

TEACHING RESPONSIBILITIES

A. TEACHING RESPONSIBILITIES AT UTMB:

a. Teaching:

School of Medicine (SOM): **1992 – 1997** Instructor – Second Year Pathology Course

1999 – present : Laboratory Instructor; Integrated Medical Curriculum Pathobiology course Cardiovascular/Pulmonary, and Gastrointestinal block, and Molecules, Cells and Tissues.

School of Allied Health Sciences (SAHS):

1999-2002. Instructor. Pathology Course.

School of Nursing (SON):

Graduate School (GSBS):

2000 – present: Pathogenic Bacteriology Course, Graduate Program, Department of Microbiology and Immunology

1999 – 2001 MD/ Ph.D. Combined Program, Journal Club Sessions

2003 – present: Biothreat agents and Biodefense course, Department of Pathology

2001 – 2009: Microorganisms and Infectious Disease, Department of Pathology.

2001-present: Pathobiology, Department of

2008-present

American Society for Microcirculation

HONORS:

Cum Laude Graduate: Ranked first among 47 graduates, University of Cauca, School of Medicine and Health Sciences, Dec. 1987

University of Cauca Scholarships: 1985, 1986

UTMB, Excellence in Research, 1993-1994 and 1997-1998

UTMB, Competitive George Dock Scholarship, September 1995

UTMB, Excellence in Pathology, 1996-1997

Texas Society of Pathology, Third place, Podium presentation, 77th Annual meeting, 1998

American Society for Microbiology Travel Award, Microbes, Hemostasis and Vascular Biology Conference, Texas, 1998

James W. McLaughlin Travel Award, UTMB, March, 1999

UTMB, Pathology Trainee Research Session, Excellence in Research, Honorable Mention, 1998

UTMB, Pathology Trainee Research Session, Excellence in Research, Honorable Mention, 1999

UTMB, Outstanding Resident Award, 1998-1999

Commendation for excellence in laboratory instruction in the Pathobiology and host defense course, 2002

Excellence in Teaching Award. UTMB Graduate School of Biomedical Sciences. 2007.

America's Top Pathologists. 2007-2011

America's Top Doctors. 2006-2011

Paul Brindley Distinguished Scholar. 2011

George Dock Distinguished Professorship. 2011

ADDITIONAL INFORMATION:

Editorial Board

Biomedica. National Institute of Health. Colombia. 2007-present

Journal Reviewer/Ad-Hoc Reviewer for

American Journal of Tropical Medicine and Hygiene, 2001-present

Vector Borne and Zoonotic Diseases, 2002-present

New England Journal of Medicine, 2000-present

Antimicrobial Agents and Chemotherapy, 2000-present

Archives of Pathology and Laboratory Medicine, 1999-present

Clinical Infectious Diseases, 2000-present

Journal of Infectious Diseases, 2000-present

Emerging Infectious Disease, 2000-present

Revista Enfermedades Infecciosas. National Institute of Health. Chile. 2008-present.

Abstract reviewer. USCAP annual meeting. 2009-to present

Grant Reviewer for

James W. McLaughlin Fellowship Fund, predoctoral and postdoctoral grants, 2002-present

National Institute of Allergy and Infectious Diseases, 2001-present.

Army Research Office (ARO). Chemical and Biological Defense Basic Research Program. 2006- present.

National Institute of Health. Colombia. 2006-present

Professional Skills (i.e. Faculty mentor, professional development endeavors)

Other : Preliminary Exam Committees, Experimental Pathology Graduate Program

Amber Engle
Melanie Dobbs
Darci Smith
Kimberly Nethery
Eleanor Deardorf
Nicole Arrigo
Amy Shuh
Jessica Lewis
John T. Nuckols
Yan-Jang Huang
Wang Xu

PUBLICATIONS:

A. ARTICLES IN PEER-REVIEWED JOURNALS:

1. **Olano, J.P.**; Borucki, M.; Wen, J.; Haque, A. Massive hepatic steatosis and lactic acidosis in HIV-seropositive patient receiving prophylactic AZT. *Clin. Inf. Dis.* 21:973-976; 1995
2. Gelman, B.B.; Wolf, D.A.; **Olano, J.P.**; Linthicum, L. Environmental influences on the pathology of the acquired immunodeficiency syndrome. Autopsy results in Texas prison inmates. *Human Patho.* 27(12):1282-1287; 1996
3. **Olano, J.P.**; Wolf, W.; Keherly, M.; Gelman, B.B. Quantifying apoptosis in banked human brains using flow cytometry. *J. Neuropath. Exp. Neurol.* 55(11):1164-1172; 1996
4. **Olano, J.P.**; Holmes, H.; Woods, G.L. Evaluation of the Myko AKT latex agglutination test for rapid diagnosis of *Mycobacterium avium* complex infections. *Diag. Microbiol. Infec. Disease.*30:71-74; 1998
5. Sexton, D.J.; Corey R.G.; Carpenter, C.; Kong, L.Q.; Gandhi, T.; Breitschwerdt E, Hegarty B, Chen SM, Feng HM, Yu XJ, **Olano JP**, Walker, D.H.; Dumler, S.J. Dual infection with *Ehrlichia chaffeensis* and a spotted fever group rickettsia. *Emerging Inf. Dis.*4:311-317; 1998

6. **Olano, J.P.**; Masters, E.; Russell, J.; Walker, D.H. Ehrlichial infections. The Cape County Medical Journal.48:7-10; 1998
7. Walker, D.H., and Task Force on Consensus Approach for Ehrlichiosis, Diagnosing Human Ehrlichioses: Current Status and Recommendations. Am. Soc. Micro. News, 66:287-291; 2000
8. Billings, A.N.; Feng, H.M.; **Olano, J.P.**; Walker, D.H. Rickettsial infection in murine models activates an early anti-rickettsial effect mediated by NK cells and associated with production of gamma interferon. Am. J. Trop. Med. Hyg.65:52-56; 2001
9. Sotomayor, E.; Popov, V.L.; Feng, H.M.; Walker, D.H.; **Olano, J.P.** Animal model of human monocytotropic ehrlichiosis. Am. J. Path. 158(2):757-769; 2001
10. Walker, D.H.; **Olano, J.P.**; Feng, H.M. The critical role of cytotoxic T-lymphocytes in immune clearance of rickettsial infection. Infect. Immun. 69:1841-1846; 2001
11. **Olano, J.P.**; Walker, D.H. Current recommendations for diagnosis and treatment of the human ehrlichioses, Inf. in Med.19:318-325; 2002
12. Zhen, L.; Diaz-Montero, M.; Yu, X.J.; **Olano, J.P.**; Feng, H.M.; Walker DH. Identification of CD8 T-lymphocyte epitopes in OmpB of *Rickettsia conorii*. Infect. Immun.71:3920-3926; 2003
13. **Olano, J.P.**; Hogrefe, W.; Seaton, B.; Walker, D.H. Clinical manifestations epidemiology and laboratory diagnosis of human monocytotropic ehrlichiosis in a commercial laboratory setting. Clin. Diag. Lab. Immun. 10:891-896; 2003
14. **Olano, J.P.**; Masters, E.; Hogrefe, W.; Walker, D.H. Human Monocytotropic Ehrlichiosis, Missouri. Emerging Infect. Dis.9:1579-1586; 2003
15. Ismail, N.; Soong, L.; **Olano, J.P.**; Walker, D.H. Overproduction of TNF- α and downregulation of IFN- γ -dominated Th1 response contribute to toxic shock-like syndrome in an animal model of fatal human monocytotropic ehrlichiosis. J. Immunol.172:1786-1800; 2004
16. Gessell-Lee, D.; Popov, V.L.; Boldogh, I.; **Olano, J.P.**; Peterson, J.W. The role of cyclooxygenase enzymes in a murine model of experimental cholera. Infect. Immun. 71(11):6234-6242; 2003
17. Sha, J.; Kozlova, E.V.; Fadl, A.A.; **Olano, J.P.**; Chopra, A.K. Molecular characterization of a glucose inhibition division gene (*gidA*) that regulates virulence of *Aeromonas hydrophila*. Inf Immun.72:1084-1095; 2004
18. Galvao, M.; Dumler, J.S.; Mafra, C.L.; Calic, S.B.; Chamone, C.B.; Cesarino, F. G; **Olano, J.P.**; Walker, D.H. Fatal spotted fever rickettsiosis in the state of Minas Gerais: a re-emerging infectious disease in Brazil. Emerg. Infect. Dis. 9:1402-1406; 2003
19. Feng, H.M.; Whitworth, T.; **Olano, J.P.**; Popov, V.L.; Walker, D.H. Fc-dependent

polyclonal antibodies and antibodies to outer membrane proteins A and B, but not lipopolysaccharide, protect SCID mice against fatal *Rickettsia conorii* infection. *Inf. Immun.* 72:2222-2228; 2004

20. **Olano, J.P.**; Wen, G.; Feng, H.M.; McBride, J.W.; Walker, D.H. Histologic, serologic, and molecular analysis of persistent ehrlichiosis in a murine model. *Am. J. Path.* 165:997-1006; 2004
21. Fadl, A.A.; Sha, J.; Klimpel, G.R.; **Olano, J.P.**; Niesel, D.W.; Chopra AK. The murein lipoprotein is a critical outer membrane component involved in *Salmonella enterica* serovar Typhimurium-associated systemic infection. *Infect Immun.* 73:1081-1096, 2005.
22. Fadl AA, Sha J, Klimpel GR, **Olano JP**, Galindo CL, and Chopra AK . Attenuation of *Salmonella enterica* serovar Typhimurium by altering biological functions of murein lipoprotein and lipopolysaccharide. *Infect. Immun.* 73: 8433-8436; 2005.
23. Wen, G; McBride, JW; Zhang, X; **Olano, JP**. Early diagnosis of rickettsioses by electrochemiluminescence. *Annals of the New York Academy of Sciences.* 2006;1078:590-594
24. Woods ME, Koo P, Wen G, **Olano JP**. Nitric oxide (NO) as a mediator of increased microvascular permeability during rickettsial infections. *Annals of the New York Academy of Sciences.* 2005;1063:239-245
25. Fadl AA, Galindo CL, Sha J, Erova TE, Houston CW, **Olano JP**, and Chopra AK. Deletion of the genes encoding the type III secretion system and cytotoxic enterotoxin alters host responses to *Aeromonas hydrophila* infection. *Microbial Pathogenesis.* 2006;40: 198-210
26. Zavala-Castro JE, Zavala-Velazques JE, Walker DH, Ruiz Arcila EE, Laviada-Molina H, **Olano JP**, Ruiz-Sosa JA, Small MA, Dzul-Rosado KR. Fatal human infection with *Rickettsia rickettsii*, Yucatan, Mexico. *Emerg Infect Dis.* 2006;12:672-674
27. Hidalgo, M., Orejuela L., Fuya, P., Carrillo, P, Hernandez, J., Parra, E., Keng, C., Small, M., **Olano, JP**, Bouyer, D., Castaneda, E., Walker, DH., Valbuena, G. Rocky Mountain spotted fever in Colombia (Tobia fever): A forgotten disease that strikes again. *Emerg Infect Dis.* 2007;13:1058-1061.
28. Woods ME, **Olano JP**. Host defenses to *Rickettsia rickettsii* infection contribute to increased microvascular permeability in human cerebral endothelial cells. *J Clin Immunol.* 2008;28:174-185.
29. Sha J, Agar SL, Wallace BB, **Olano JP**, et.al.. Braun lipoprotein (Lpp) contributes to the virulence of *Yersinia*: Potential role of Lpp in inducing bubonic and pneumonic plague. *Infect Immun.* 2008; 76:1390-40. (PMCID: 2292872).
30. Jordan JM, Woods ME, **Olano JP**, Walker DH. Absence of TLR4 signaling in C3H/HeJ mice predisposes to overwhelming rickettsial infection and decreased protective Th1 responses. *Infect Immun.* 2008;76:3717-24.

31. De Sousa R, Duque L, Pocas J, Torgal J, Bacellar F, **Olano JP**, Walker DH. Lymphangitis in a Portuguese patient infected with *Rickettsia sibirica*. Emerg Infect Dis. 2008;14:530-531. (PMCID: 2570837)
32. Sha J, Erova TE, Alyea RA, Wang S, **Olano JP**, Pancholi V, Chopra AK. Surface-exposed enolase contributes to the pathogenesis of clinical isolate SSU of *Aeromonas hydrophila*. J Bacteriol. 2009;191:3095-3107 (PMCID: 2681796).
33. Cragun WC, Bartlett B, Ellis MW, Hoover AZ, Hoover AZ, Tyring SK, Mendoza N, Vento TJ, Nicholas WL, Eremeeva ME, **Olano JP**, Rapini RP, Paddock CD. The expanding spectrum of eschar-associated rickettsioses in the United States. Arch Dermatol. 2010;146:641-648.

B. OTHER:

Thesis/Dissertation

Mechanisms of increased microvascular permeability in rickettsial infections. Michael Woods. 2007. UTMB, PhD Dissertation.

Proceedings and Symposia

1. **Olano JP**. Improved diagnostics and novel approaches to tick-borne diseases. In Critical Needs and Gaps in Understanding Prevention, Amelioration, and resolution of Lyme and Other Tick-Borne Diseases. The Long-Term and short-Term Outcomes. Workshop Report. Institute of Medicine of the National Academies. The National Academies Press. Washington, D.C. 2011:130-133

Reviews

1. **Olano, J.P.** Cocaine: A global approach. University of Cauca Press 65 pp. 1991.
2. **Olano, J.P.** and Walker, D.H. Human ehrlichioses. In The Medical Clinics of North America. Tick Borne Diseases, Edlow, J.A. (Ed). WB Saunders Co., 86:375-393, 2002.
3. Ismail, N., **Olano, J.P.**, Feng, H.M., Walker, D.H. Current status of immune mechanisms of killing of intracellular pathogens. FEMS Microbiology News letters, 207:111-120, 2002.
4. Walker, D.H., Valbuena, G., **Olano, J.P.** Pathogenic mechanisms of diseases caused by *Rickettsia*. In Rickettsiology: Present and future directions. Hechemi, K.E., Avsic-Zupanc, T., Childs, J.E. and Raoult, D.A., (eds). Annals of the New York Academy of Sciences. Vol 990:1-11, 2003.
5. Walker, D.H., Ismail, N., **Olano, J.P.**, McBride, J., Yu, X.J., Feng, H.M. *Ehrlichia chaffeensis*: a prevalent, life threatening, emerging pathogen.

Transactions of the American Clinical and Climatological Association, 115:375-384, 2004.

6. **Olano JP.** Rickettsial infections. Hechemy KE, Oteo JA, Raoult D, Silverman D, Blanco JR (eds). *Annals of the New York Academy of Sciences*. 2005;1063:187-196.
7. Dong J., **Olano JP.**, McBride J., Walker DH. Emerging Pathogens: Challenges and Successes of Molecular Diagnostics. *J of Molecular Diagnostics*. 10:184-197; 2008. (PMCID: 2329782).
8. **Olano JP**, Walker DH. Diagnosing emerging and reemerging infectious diseases. The pivotal role of the pathologist. *Arch Path Lab Med*. 135:83-92 2011.

Books

Cowan, D.F., **Olano, J.P.** A Practical Guide to Clinical Laboratory Testing, Malden, Massachusetts, Blackwell Science, Inc., 1997.

Book Chapters

1. **Olano, J.P.**, Masters, E., Cullman, L., Hogrefe, W., Yu, X.J., Walker, D.H., Human Monocytotropic Ehrlichiosis (HME): Epidemiological, Clinical and laboratory diagnosis of a newly emerging infectious disease in the United States. In *Rickettsia and Rickettsial Diseases at the turn of the third millenium*. Raoult, D. and Brouqui, P. (Eds). Elsevier, Paris, pp262-268, 1999
2. Galvao, M., Chamone, C.B., Calic, S.B., Machado, M.C., Otoni, M.E.A., Dietze, R., Moron, C., Feng, H.M., **Olano, J.P.**, Walker, D.H. Serologic evidence of spotted fever group Rickettsia in Novo Cruzeiro Municipality-Minas Gerais State-Brazil. In *Rickettsia and Rickettsial Diseases at the turn of the third millenium*. Raoult D and Brouqui P (Eds). Elsevier, Paris, pp 240-263, 1999.
3. Walker, D.H., Zavala-Velasquez, J.E., Ramirez, G., **Olano, J.P.** Emerging infectious diseases in the Americas. In *Rickettsia and Rickettsial Diseases at the turn of the third millenium*. Raoult, D. and Brouqui, P. (Eds), Elsevier, Paris, pp 274-278, 1999.
4. **Olano, J.P.**, Krogstad, D.J., Guerrant, R.L., Weller, P.F. and Walker, D.H. Principles of Parasitism: Host-Parasite interactions. In *Tropical Infectious Diseases: Principles, Pathogens and Practice*. Churchill Livingston, Philadelphia, pp 3-15, 1999.
5. **Olano, J.P.** and Walker, D.H. Ehrlichial infections. In *Clinical Dermatology*. Demis DJ (Ed). Lippincott Williams and Wilkins: Philadelphia, Vol 3 (15-2), 1-10; 1999.

6. **Olano, J.P.** Human Ehrlichioses. In *Infection* 2003. Picazzo, J.J., Bouza E (eds.), Servisistem, Bilbao, Spain.
7. **Olano, J.P.** Rickettsia and Ehrlichia. In *Atlas of Pulmonary Pathology*. Cagle P (Editor). Lippincott Williams & Wilkins. Philadelphia, 2004.
8. **Olano, J.P.** Human Ehrlichioses. In *Tropical Dermatology*. Stephen K. Tyring, Omar Lupi, Ulrich R. Hengge (Eds.), Elsevier Inc. 2006.
9. **Olano, J.P.**, Peters, C.J., Walker, D.H. Distinguishing tropical infectious disease from bioterrorism. In *Tropical Infectious Diseases: Principles, Pathogens and Practice*. Guerrant, R., Walker, D.H., Weller P (eds), 2nd Edition, Elsevier Churchill Livingstone, Philadelphia, 2006:1386-1399.
10. **Olano, J.P.**, Krogstad, D.J., Guerrant, R.L., Weller, P.F. and Walker, D.H. Principles of Parasitism: Host-Parasite interactions. In *Tropical Infectious Diseases: Principles, Pathogens and Practice*, 2nd Edition, Elsevier Churchill Livingstone, Philadelphia, 2006:1-12.
11. **Olano J.P.**, Agüero-Rosenfeld ME. *Ehrlichia*, *Anaplasma* and related intracellular bacteria. In *ASM Manual for Clinical Microbiology*. Murray P., (ed in chief). 9th Edition. American Society for Microbiology Press. Washington DC. 2007.
12. **Olano J.P.** Human Ehrlichioses. In *Rickettsial Diseases*. Raoult D, Parola P, (eds). Informa Health Care, USA, Inc. New York. 2007.
13. Walker DH, Ismail N, **Olano JP**, Valbuena G, McBride JW. Pathogenesis, immunity, pathology and pathophysiology in rickettsial diseases. In *Rickettsial Diseases*. Raoult D, Parola P (eds). Informa Health Care, USA, Inc. New York. 2007.
14. **Olano JP**. Molecular Pathology of lung parasitic infections. In *Molecular Pathology of Lung Diseases* (Cagle P, Zander DS, Jagirdar J, Barrios R, Haque A, Popper H, Eds). Springer Science and Business Media, Inc. Norwell MA. 2007:442-458.
15. **Olano JP**, Walker DH. Agents of emerging infectious diseases. In *Vaccines against bioterrorism and emerging infectious diseases*. Stanberry L, Barrett ADT (eds). Academic Press. 2009
16. **Olano, JP**. Rickettsia and Ehrlichia. In *Atlas of Pulmonary Pathology*. Cagle P (Editor). Lippincott Williams & Wilkins. Philadelphia, 2008:433-434.
17. **Olano JP**. Ehrlichiosis. Carolyn Wong Simpkins (Clinical Editor) *British Medical Journal in Practice*. 2009.
18. **Olano JP**. Ehrlichiosis. Carlos Palacios (Clinical Editor) *British Medical*

Journal in Practice. 2011.

19. McBride JW, **Olano JP**, Ismail N. Ehrlichia. In Molecular Detection of Human Bacterial Pathogens (Dongyou L, Editor). CRC Press. 2011.
20. **Olano JP**. Molecular pathology of parasites. In Parasitic diseases of the lungs (Barrios R. Ed). Springer. (in press, 2011).
21. **Olano JP**, Walker, DH, Guerrant RL, Weller PW. Principles of Host-Parasite interactions. In Tropical Infectious Diseases: principles, pathogens and practice. Walker, DH, Guerrant RL, Weller PW (Eds). 3rd Ed. Elsevier. 2011.
22. **Olano JP**, Peters CJ, Walker DH. Distinguishing Tropical Infectious Diseases from Bioterrorism. In Tropical Infectious Diseases: principles, pathogens and practice. Walker, DH, Guerrant RL, Weller PW (Eds). 3rd Ed. Elsevier. 2011.

Others (online modules, CDs, Manuals)

1. **Olano, J.P.**, Woods, G.L. Tuberculosis: What you do not know can kill you, 1996.
2. **Olano, J.P.**, Ramirez-Prada, G., Chuy, M., Walker, D.H. Tifus epidemico. WHO Collaborating Center for Tropical Diseases, University of Texas Medical Branch, Peruvian Ministry of Health, 1998.
3. **Olano J.P.** Anatomic and Clinical Pathology Residency Program Manual. 2008

C. ABSTRACTS:

1. **Olano, J.P.**, Okorodudu, A., Petersen, J. IgG synthesis within the central nervous system: Evaluation of four proposed mathematical formulae and high resolution electrophoresis. Clin. Chem. 39(6):1134; 1993.
2. Osman, A., **Olano, J.P.**, Petersen, J., Okorodudu, A. Meconium and urine screening for maternal drug abuse during pregnancy: Preliminary results of a 67 patient study. Clin. Chem. 39(6):1238; 1993.
3. Cook, J., Bauerle, J., **Olano, J.P.**, Nichols, M., Campbell, G. Alpers syndrome (AS) masquerading as alternating hemiplegia of childhood (AHC). Pedi. Neurol. 11:81; 1994.
4. **Olano, J.P.**, Okorodudu, A. THC in rat meconium: Analytical and clinical implications. Mod. Path. 8:141A; 1995.
5. **Olano, J.P.**, Nichols, M., Cook, J., Bauerle, J., Campbell, G. Progressive neuronal degeneration of childhood (Alpers disease): A case report with novel findings in brain, muscle and liver. J. Neuropath. Exper. Neurol. 54(3):469; 1995.

6. **Olano, J.P.**, Wolf, D.A., Keherly, M.J., Gelman, B.B. Terminal deoxynucleotidyl transferase-labeled DNA strand breaks in isolated brain nuclei detected using flow cytometry. *J. Neuropath. Experi. Neurol.* 55(5):616; 1996.
7. Wolf, D.A., Dholakia, S.R., **Olano, J.P.**, Gelman, B.B. Characterization of myelin basic protein (MBP) and proteolipid protein (PLP) isoforms in the myelopathy of acquired immunodeficiency syndrome (AIDS). *J. Neuropath. Experi. Neurol.* 55(5):659; 1996.
8. Gelman, B.B., Wolf, D.A., **Olano, J.P.** Increased cerebral lysosomal enzyme activity in patients with the acquired immunodeficiency syndrome. *J. Neuropath. Experi. Neurol.* 55(5):659; 1996.
9. **Olano, J.P.**, Holmes, H., Woods, G.L. Evaluation of Myco AKT Latex agglutination test for the diagnosis of *Mycobacterium avium* complex infections. *Am. J. Clin. Path.* 107:488; 1997.
10. **Olano, J.P.**, Murphy, T., Woods, G.L. Diagnosis of *Mycobacterium avium* complex infections from blood cultures by the Myco AKT Latex agglutination test. *Am. Soc. Micro. Abstracts of the 97th General Meeting.*,1997:570.
11. **Olano, J.P.**, Ramirez-Prada, G., Moscoso, B., Watts, D., Walker, D.H. Epidemic Typhus outbreaks in Cuzco, Peru. *Am. J. Trop. Med. Hygiene.*(Supp.),60(3):282; 1997.
12. Billings, A., **Olano, J.P.**, Feng, H.M., Walker, D.H. Natural killer cells: An integral component of the innate immune defenses in two murine models of rickettsiosis. *Am. J. Trop. Med. Hygiene.* (Suppl), 60(3):324; 1998.
13. **Olano, J.P.**, Walker, D.H. Intracellular events after rickettsial internalization. *Am. J. Trop. Med. Hygiene* (Suppl),61(3):423; 1999.
14. Popov, V.L., Sotomayor, E.A., Feng, H.M., **Olano, J.P.**, Yu, X.J., Dumler, J.S., Walker, D.H. Interaction of ehrlichiae with host cells in a mouse model of fatal monocytotropic ehrlichiosis. *Am. J. Trop. Med. Hyg.* (Suppl)62(3):187-8; 2000.
15. Galvao, M.A.M., Bouyer, D.H., **Olano, J.P.**, Cerqueira, L.R., Walker, D.H. *Rickettsia felis* in *Amblyomma cajennense* ticks, Brazil. International Conference on Rickettsiae and Rickettsial Diseases. Abstract Book, 2002:103.
16. **Olano, J.P.**, Wen, G. Evidence of calmodulin activation in an *in vitro* model of rickettsial infection. *Am. Soc. Invest. Path. FASEB J.* 2002, 16:A202.
17. Li, Z., **Olano, J.P.**, Feng, H., Walker, D.H. Identification of CD8 T-lymphocyte epitopes in OmpB of *Rickettsia conorii*. *Am. Soc. Micro. Abstracts of the 103rd General Meeting*, 2003.

18. **Olano, J.P.**, Wen, G., Feng, H.M., McBride, J.W., Walker, D.H. Histopathological, serological, immunohistochemical and quantitative bacterial burden analysis in a murine model of persistent *Ehrlichia muris* infection. Am. Soc. Rickettsiology. Abstract Book, 2003.
19. Koo, P., **Olano, J.P.** Analysis of microvascular leakage in an *in vitro* model of the brain endothelial barrier by electric cell-substrate impedance sensing (ECIS). Am. Soc. Rickettsiology, Abstract Book, 2003. Department of Defense Peer Reviewed Medical Research Program Investigators Meeting, Abstract Book, 2004.
20. Whitworth, T.J., Feng, H.M., **Olano, J.P.**, Popov, V.L., Walker, D.H. A quantitative ultrastructural analysis of the effects of antibody on *Rickettsia conorii* (Malish 7) vacuolar escape *in vitro* and correlated *in vivo* with a descriptive ultrastructural and immunohistochemical examination. Am. Soc. Rickettsiology, Abstract Book, 2003.
21. Koo, P., Watowich, S., Davey, R., Olano, J.P. Development of combinatorial peptide based libraries (adaptoins) with rickettsicidal activity: preliminary results. Am. Soc. Rickettsiology. Abstract Book, 2003, Department of Defense Peer Reviewed Medical Research Program Investigators Meeting, Abstract Book 2004.
22. Woodside KJ, Naoum J, Zhang S, Belalcazar M, **Olano JP**, Hunter GC. Therapeutic modifications of the fibrous cap of atherosclerotic lesions in Apo-E knock out mice: Differing effects of rosiglitazone, rapamycin and simvastatin. American College of Surgeons South Chapter. Abstract Book. 2004.
23. Koo P, Woods ME, **Olano JP**. *In vitro* studies of microvascular permeability during *Rickettsia rickettsii* infections. International Conference on Rickettsiae and Rickettsial Diseases. Abstract Book. 2005:O23
24. **Olano JP**. Rickettsial infections. International Conference on Rickettsiae and Rickettsial Diseases. Abstract Book. 2005:L3
25. Woods ME, Koo P, Wen G, **Olano JP**. Nitric oxide (NO) as a mediator of increased microvascular permeability during rickettsial infections. International Conference on Rickettsiae and Rickettsial Diseases. Abstract Book.2005:O59.
26. Wen G, McBride J, Zhang X, **Olano JP**. Early diagnosis of rickettsioses by electrochemiluminescence. International Conference on Rickettsiae and Rickettsial Diseases. Abstract Book.2005:P143.
27. Valbuena G, **Olano JP**, Bouyer D, Walker DH. Rocky Mountain spotted fever in Colombia: A forgotten disease strikes again. International Conference on Rickettsiae and Rickettsial Diseases. Abstract Book.2005:P168.
28. Woods ME, Jordan JM, **Olano JP**. Evaluation of Microvascular Permeability, *in vivo*, During Acute Rickettsiosis. Am. Soc. Rickettsiology, Abstract Book.

2006:63.

29. **Olano JP**, Woods ME, Walker DH. Permeability studies on *Rickettsia rickettsii*-infected human cerebral microvascular endothelial cells. Department of Defense Peer Reviewed Medical Research Program Investigators Meeting. Abstract Book.2006:19.
30. Woods ME, Wen G, **Olano JP**. Peroxynitrite-mediated damage during rickettsial infection of human microvascular endothelial cells. Experimental Biology. Late Breaking Abstracts Book. 2006:116.
31. Woods ME, **Olano JP**. The effects of cytokine stimulation on rickettsiae-infected endothelial cells: Behavior and integrity. American Society of Microbiology, Texas Branch Meeting, 2006.
32. Woods ME, **Olano JP**. Comparative analysis of endothelial host cell responses to spotted fever group rickettsiae: Implications for pathogenesis. American Society for Rickettsiology. Abstract Book. 2007:54.
33. **Olano JP**, Wen G, Woods ME, Bouyer D, McBride JW. Diagnosis of acute rickettsial infections by electrochemiluminescence. NIAID RCE Research Meeting. 2007:146
34. Wen G, **Olano JP**. Evaluation of electrochemiluminescence as a diagnostic method for acute rickettsioses. American Society for Rickettsiology. Abstract Book. 2007:34.
35. **Olano JP**, Bouyer D, Parker J, Stanford A. Inhalational animal models of rickettsial infections. American Society for Rickettsiology. Abstract Book. 2009.
36. Willson R, Ruchhoeft P, **Olano JP**. Microfabricated retroreflectors for biomedical assays and diagnostics. Nanoscale Science and Engineering Forum. 2010.
37. Hatch A.V., Renzi R. McCoy R. Van de Vreugde J., Abhyankar V., Olano J.P., Deployable Pathogen Medical Diagnostic System, 2010 NNSA LDRD Symposium, Washington DC, Jun. 2010.
38. Hatch A.V., Renzi R. McCoy R. Van de Vreugde J., Abhyankar V., Olano J.P., Deployable Pathogen Medical Diagnostic System, 5th Annual Sandia LDRD Day, Albuquerque NM, Sep. 2010.
39. **Olano JP**, Ruchoeft P, Willson R. Microfluidics and retroreflector technology for diagnosis of rickettsial infections. 6th International Meeting on Rickettsiae and Rickettsial Diseases. Heraklion, Crete, 2011.
40. **Olano JP**, Mendell N, Wen G, Bouyer D. Development of an inhalational animal model for *R. prowazekii*.

PUBLICATIONS – IN PRESS:

1. **Olano JP.** *Ehrlichia chaffeensis* (Human Monocytotropic Ehrlichiosis), *Anaplasma phagocytophilum* (Human Granulocytotropic Anaplasmosis) and other species. In Infectious Diseases (Restrepo A, Leiderman E, Vesga O, Velez L, Eds). Corporacion para Investigaciones Biologicas, Medellin, Colombia. 2011.

MANUSCRIPTS SUBMITTED

Elisabeth Astrup, Tove Lekva, Giovanni Davì, Kari Otterdal, Francesca Santilli, Erik Øie, Bente Halvorsen, Jan Kristian Damås, Didier Raoult, Giustina Vitale, Juan P. Olano, Thor Ueland, Pål Aukrust. A complex interaction between *Rickettsia conorii* and Dickkopf-1 – potential role in immune escape mechanisms in endothelial cells. Infection and Immunity.

MANUSCRIPTS IN PREPARATION:

Olano JP, Bouyer D, Wen G. Evaluation of electrochemiluminescence as a diagnostic tool for rickettsial infections.

Olano JP, Wen G, Mendell N, Parker J, Bouyer D: Murine animal model for inhalational *Rickettsia rickettsii* infections.

Olano JP. In vitro studies of microvascular permeability with *Rickettsia rickettsii* and *Rickettsia conorii* in human cerebral microvascular endothelial cells.

PAPERS AND CONTINUING EDUCATION PROGRAMS PRESENTED:

INVITED LECTURES AT SYMPOSIA AND CONFERENCES:

1. First International Course on Rickettsial diseases and Epidemic Typhus (Co-organizer), January 12-14, Cuzco, Peru, 1998
2. Epidemic typhus, Guest speaker, Instituto Nacional de Salud, Lima, Peru and Division of Epidemiology, Ministry of Health, Peru, 1998
3. Consensus Approach for Ehrlichiosis CAFÉ Society meeting, Long Beach, California, 1999
4. Gulf Coast Tropical Medicine Association meeting, Texas, 1998, 1999
5. Houston Society of Clinical Pathology, Pathology of Selected and Potential Bioterrorist Agents, 2002

6. U.S./Japan Cooperative Science Program, Houston, TX, 2003, *Enzootic cycles of ehrlichioses in Japan: Implications for human health.*
7. 4th International Conference on Rickettsia and Rickettsial Diseases, Logrono, Spain, 2005. *Rickettsial infections.*
8. *Analysis of antigens of intracellular bacteria for biodefense research: Prospects for establishing collaborations.* Regional Center for Excellence in Biodefense-sponsored workshop. Galveston, 2008.
9. *Emerging and Re-emerging Infectious Diseases: Molecular diagnostic approaches.* Next Generation Diagnostics Summit. Cambridge Healthtech Institute. Washington DC, 2009.
10. *Disaster Planning: Lessons learned from Hurricane Ike.* Department of Pathology. UTMB. PRODS meeting. Seattle, 2009.
11. *Improved Diagnostics and Novel Approaches to Tick-Borne Diseases.* Committee on Lyme Disease and Other Tick-borne Diseases. Institute of Medicine of the National Academies. Washington DC. October, 2010.

Approved by COD: 7/06



PUBLIC VERIFICATION / PHYSICIAN PROFILE

PHYSICIAN

NAME: BILL ALAN RAMPY DO

DATE: 08/21/2013

**THE INFORMATION IN THIS BOX HAS BEEN VERIFIED
BY THE TEXAS MEDICAL BOARD**

Date of Birth: 1959

License Number: M3366 Full Medical License

Issuance Date: 04/07/2006

Expiration Date of Physician's Registration Permit: 05/31/2014

Registration Status: ACTIVE

Registration Date: 05/05/2006

Disciplinary Status: NONE

Disciplinary Date: NONE

Licensure Status: NONE

Licensure Date: NONE

Medical School of Graduation:

At the time of licensure, TMB verified the physician's graduation from medical school as follows:
UNIV OF NORTH TEXAS HLTH SCI CTR, FORT WORTH

Medical School Graduation Year: 1998

TMB Filings, Actions and License Restrictions

The Texas Medical Board has the following board actions against this physician. (This may include any formal complaints filed by TMB, as well as petitions and/or responses related to licensure contested matters, at the State Office of Administrative Hearings.)

NONE

Investigations by TMB of Medical Malpractice

Section 164.201 of the Act requires that: the board review information relating to a physician against whom three or more malpractice claims have been reported within a five year period. Based on these reviews, the following investigations were conducted with the listed resolutions.

NONE

Status History

Status history contains entries for any updates to the individual's registration, licensure or disciplinary status types (beginning with 1/1/78, when the board's records were first automated). Entries are in reverse chronological order; new entries of each type supersede the previous entry of that same type. These records do not display status type. Should you have any questions, please contact our Customer Information Center at 512-305-7030 or verificic@tmb.state.tx.us

Status Code: AC**Effective Date:** 05/05/2006**Description:** ACTIVE**Status Code:** LI**Effective Date:** 04/07/2006**Description:** LICENSE ISSUED

THE INFORMATION IN THIS BOX WAS REPORTED BY THE LICENSEE AND
HAS NOT BEEN VERIFIED BY THE TEXAS MEDICAL BOARD

Gender: MALE***Ethnicity:** WHITE**Race:** WHITE

* We are in the process of transitioning from the current ethnic origin values to federal standards for race and Hispanic origin. The transition period will allow time for individuals to submit updated race and Hispanic origin data to the TMB.

Place of Birth: TEXAS**Current Primary Practice Address:**

UNIVERSITY OF TEXAS MEDICAL
BRANCH AT GALVESTON
GALVESTON , TX 77555-0588

Years of Active Practice in the U.S. or Canada:

The physician reports that he/she has actively practiced medicine in the United States or Canada for 2 year(s).

Years of Active Practice in Texas:

The physician reports that, of the above years he/she has actively practiced in the State of Texas for 2 year(s).

Specialty Board Certification

The physician reports that he/she holds the following specialty certifications issued by a board that is a member of the American Board of Medical Specialties or the Bureau of Osteopathic Specialists:

Specialty Certification: AMERICAN BOARD OF PATHOLOGY**Date:** 2008

Primary Specialty

The physician reports his/her primary practice is in the area of PATHOLOGY.

Secondary Specialty

The physician reports his/her secondary practice is in the area of ANATOMIC PATHOLOGY.

Name, Location and Graduation Date of All Medical Schools Attended

Name: TCOM

Location: FORT WORTH/TEXAS

Graduation Date: 05/1998

Graduate Medical Education In The United States Or Canada

Program Name: UTMB

Location: GALVESTON/TEXAS

Begin Date: 07/1998

Type: RESIDENCY

End Date: 06/2002

Specialty: ANATOMIC PATHOLOGY

Program Name: UTMB

Location: GALVESTON/TEXAS

Begin Date: 07/2001

Type: FELLOWSHIP

End Date: 06/2002

Specialty: SURGICAL PATHOLOGY

Hospital Privileges

The physician reports that he/she has hospital privileges in the following in the State of Texas:

Hospital: UTMB

Location: GALVESTON

Utilization Review

The physician did not report whether he/she provides utilization review.

NONE REPORTED

Patient Services

Accessibility: The physician reports that the patient service area is accessible to persons with disabilities as defined by federal law.

Language Translation Services: The physician did not report whether he/she

provided any language translation services for patients.

Medicaid Participant: The physician reports that he/she **does** participate in the Medicaid program.

Awards, Honors, Publications and Academic Appointments

Optional Information

The physician may optionally report descriptions of up to five such honors and has reported the following:

Description: DISTINGUISHED TEACHING PROFESSOR FOR UT SYSTEM

Malpractice Information

Section 154.006(b)(16) of the Act requires that: a physician profile display a description of any medical malpractice claim against the physician, not including a description of any offers by the physician to settle the claim, for which the physician was found liable, a jury awarded monetary damages to the claimant, and the award has been determined to be final and not subject to further appeal. The physician has the following reportable claims.

Description: NONE

Criminal History

Self-Reported Criminal Offenses:The physician is required to report a description of (1) "any conviction for an offense constituting a felony, a Class A or Class B misdemeanor, or a Class C misdemeanor involving moral turpitude" and (2) "any charges reported to the board to which the physician has pleaded no contest, for which the physician is the subject of deferred adjudication or pretrial diversion, or in which sufficient facts of guilt were found and the matter was continued by a court of competent jurisdiction."

The physician has reported the following:

Description: NONE

Criminal history information is also obtained by TMB from the Texas Department of Public Safety. Resulting action, if any, will be reported under the TMB Action and Non-Disciplinary Restrictions section above.

Disciplinary Actions By Other State Medical Boards

The physician has reported the following:

Description: NONE

Physician Assistant Supervision

To obtain
primary source
verifications,
click name

Description: NONE

Advanced Practice Nurse Delegation

To obtain
primary source
verifications,
click name

Description: NONE

Summary of all License/Permit Types

Issue Date:	Type:
06/29/1998	<u>INSTITUTIONAL PERMIT</u>
04/07/2006	<u>LICENSED PHYSICIAN</u>
03/03/2006	<u>PHYSICIAN TEMPORARY LICENSE</u>

[Agency](#) | [Contact Us](#) | [Employment](#) | [Compact w/ Texans](#) | [Open Records](#) | [Privacy Policy](#) | [Site Map](#) |
[Search TX State Sites](#) | [TX Homeland Security](#) | [TX Occupations Code](#) |
[Texas.gov](#) | [Poison Control Center Services](#) | [Accessibility Policy](#)

CURRICULUM VITAE

Bill A. Rampy, D.O., Ph.D.

PRESENT POSITION AND ADDRESS:

Assistant Professor
Department of Pathology
University of Texas Medical Branch
301 University Blvd Rte 0588
Galveston, Texas 77555
Phone: (409) 772-1718
Email: barampy@utmb.edu

BIOGRAPHICAL:

Home Address:

Phone: ()

Citizenship: USA

EDUCATION:

Residency Experience and Training:

June 29, 1998 - June 30, 2002

University of Texas Medical Branch, Galveston, Texas
Anatomic Pathology Residency Training
Core Pathology Rotations (July 1, 1998 - November 30, 2000)
Autopsy Elective (April 1, 2000-April 30, 2000)
Neuropathology Elective (July, December 1, 2000 - February 28, 2001)
AIDS Neuropathogenesis Research (May 1, 2001 - June 30, 2008)
Cytopathology Elective (May 1, 2001-June 30, 2001)
Surgical Pathology Fellowship (July 1, 2001-June 30, 2002)

Education:

January 8, 1987 - May 15, 1988

Bachelor of Arts in Experimental Psychology, summa cum laude,
University of Texas at Dallas

July 1, 1994 - June 30, 1998

Doctor of Osteopathy, University of Texas Health Science Center at Fort
Worth

June 1, 1998 - August 1, 2000

Doctor of Philosophy in Human Development and Communication
Sciences, Neuroscience and Cognition, University of Texas at Dallas

July 1, 1998 - June 30, 2002

Anatomic Pathology, University of Texas Medical Branch, Galveston,
Texas

July 1, 2001 - June 30, 2002

Fellowship in Surgical Pathology, University of Texas Medical Branch,
Galveston, Texas

BOARD CERTIFICATION:

November 20, 2008 Diplomat of the American Board of Pathology
Anatomic Pathology

LICENSURE INFORMATION:

May 31, 2006 State of Texas, active
License Number: M3366
Expiration Date: May 31, 2012

PROFESSIONAL AND TEACHING EXPERIENCE: (academic; non-academic)

Professional Experience:

September 1, 2011 - Current
Assistant Professor in Pathology Education, University of Texas Medical Branch

October 1, 2009 - August 2011
Clinical Instructor in Pathology Education, University of Texas Medical Branch

May 1, 2004 - October 2009
Pathology Assistant in Surgical Pathology, University of Texas Medical Branch

July 1, 2003 - April 2004
Post-doctoral Fellow in Toxicology funded by National Institute of Environmental Health Sciences, at University of Texas Medical Branch

July 1, 2002 - June 2003
Pathology Instructor at the University of Texas Medical Branch, Autopsy Division

Teaching:

1990 - 1994 Teaching/Research Assistant in undergraduate and graduate neurophysiology and multivariate statistics, Research Assistant in neurohistochemistry and neurophysiology, University of Texas at Dallas/Dallas Neuroscience Associates

1998 - 2003 Teaching Assistant in Medical Student Pathology Laboratory Course University of Texas Medical Branch at Galveston

2001 - 2002 Lecturer at Pathology Lecture Series for ENT Residents, UTMB

2002 - 2003 Lecturer at Anatomic Pathology Residency Lecture Series, UTMB

2002 Lecturer in Occupational Therapy Pathology Processes in Disease Course, UTMB

2002 - 2003 Lecturer at Internal Medicine/Autopsy Lecture Series, UTMB

2004 Lecturer in Fundamentals of Toxicology, Texas A & M at Galveston

2004 - 2009 Lecturer in Fundamentals of Surgical Pathology for Pathology Residents, UTMB

2010 - Current	Course Director of the Gastrointestinal Nutrition Course, School of Medicine curriculum, UTMB
2010 - 2011	Facilitator for School of Medicine curriculum, UTMB Gastrointestinal Nutrition Course
2010 - Current	Laboratory Instructor for the School of Medicine curriculum, UTMB Cardiovascular and Pulmonary Course Gastrointestinal Nutrition Course Molecules, Cells and Tissues Course Pathobiology and Host Defense Course
2010	Lecturer in Experimental Pathology Graduate Program, PATH 6101, UTMB
2010 - Current	Contributor, developer and webmaster for Edublog, Experimental Pathology Graduate Program, PATH 6266, UTMB
2010 - Current	Director, Pathology Informatics Rotation, Pathology Residency Program, UTMB
2011 - Current	Leader of Team Based Learning Committee for School of Medicine Laboratories

CONTINUING EDUCATION AND WORKSHOPS ATTENDED:

2010	Academy of Master Teachers Grand Rounds - Healthcare Education in a Virtual World
2010	Discouraging Disruptive Behavior: A Peer-to-Peer Approach, UTMB Professionalism Committee and the John P. McGovern Academy of Oslerian Medicine presentation
2010	Improving Your Teaching Skills Through Effective Questioning Techniques, Office of Educational Development

COMMITTEES AND MEMBERSHIPS:

2009 - 2012	Executive Team Member of the Group for Research in Pathology Education (G.R.I.P.E.)
2010 - 2012	Executive Team Member of the UTMB Academy of Master Teachers
2010 - 2012	Member of the Education Leadership Committee for the Department of Pathology, UTMB
2011-2012	Member of the Digital Pathology Association (DPA)

HONORS AND AWARDS:

2004	National Institute of Environmental Health Sciences - Environmental Toxicology Training Grant
2009	Academy of Master Teachers Junior Faculty Educational Development Award
2010	First Place, Demonstration Session, at the UTMB Academy of Master Teachers 3 rd Annual Education Symposium
2010	Blackboard Catalyst Committee's Choice Award for Anatomic Pathology Exchange (APEX) project developed in Xythos (iSpace).

ADDITIONAL INFORMATION:

2010 - 2012 Reviewer of submissions for the Research in Medical Education (RIME) section of the Association of American Medical Colleges

2010 - 2011 Judge for the UTMB Department of Pathology Research Trainee Poster Day, 2010

PUBLISHED PEER-REVIEWED ARTICLES:

1. Bernadini, G.L. and **Rampy, B.A.**: Applications of piezoelectric fluid jetting devices to neuroscience research. *Journal of Neuroscience Methods*, 1991, 38:81-88.
2. Frederickson, C.J., **Rampy, B.A.**, Rampy, S.R., and Howell, G.A.: Distribution of histochemically reactive zinc in the forebrain of the rat. *Journal of Chemical Neuroanatomy*, 1992, 5:521-530.
3. Gatalica, Z., Lele, S.M., **Rampy, B.A.**, and Norris, B.A.: The expression of Fhit protein is related inversely to disease progression in patients with breast carcinoma. *Cancer*, 2000, 88:1378-1383.
4. **Rampy, B.A.**, Waxman, I., Xiao, S. and Logroño, R.: Serous cystadenoma of the pancreas with papillary features: A diagnostic pitfall on fine needle aspiration biopsy. *Archives of Pathology & Laboratory Medicine*, 2001, 125:1591-1594.
5. Haque, A.K., Gokhale, S., **Rampy, B.A.**, Adegboyega, P., Duarte, A., and Saldana, M.J.: Pulmonary pathology in sickle cell hemoglobinopathy. *Human Pathology*, 2002, 33:1037-1043.
6. Logroño, R., **Rampy, B.A.** and Adegboyega, P.: Fine needle aspiration cytology of hepatobiliary cystadenoma with mesenchymal stroma. *Cancer Cytopathology*, 2002, 96(1): 37-42.
7. Rosen, E.J., Newlands, S.D. and **Rampy, B.A.**: Cribriform-morular variant of papillary thyroid carcinoma. *Archives of Otolaryngology - Head and Neck Surgery*, 2003, 129: 679-681.
8. Velagaleti, G.V.N., Tapper, J.K., **Rampy, B.A.**, Zhang, S., Hawkins, J.C. and Lockhart, L.H.: A rapid and non-invasive method for detecting tissue limited mosaicism: Detection of i(12)(p10) in buccal smear of a child with Pallister-Killian syndrome. *Genetic Testing*, 2003, 7:219-223.
9. Gokhale, S., Gatalica, Z., Mohammad, A., **Rampy, B.A.** and Velagaleti, G.V.N.: FISH for HER-2/neu in breast cancer: Standardization makes the difference! *Indian Journal of Cancer*, 2004, 41:152-158.
10. Alcántara, V.R., Hernández, G.C., **Rampy, B.A.**, Aronson, J.F. and Treinen-Moslen, M.: Attenuated gastropathy but not enteropathy of Diclofenac-cholestyramine complex in rats. *Drug Development Research Journal*, 2005, 64:19-27.
11. Ge, Y., **Rampy, B.A.**, Xiao, S.: Marked reduction of CD1d expression in colonic mucosal epithelium in patients with microscopic colitis. *Applied Immunohistochemistry & Molecular Morphology* 2006, 14(3):309-313.
12. Oto, A., Eltorkey, M.A., Dave, A., Ernst, E.F., Chen, K., **Rampy, B.**, Chaljub, G. and Nealon, W.: Mimicks of pancreatic malignancy in patients with chronic pancreatitis: correlation of computed tomography imaging features with histopathologic findings. *Current Problems in Diagnostic Radiology*. 2006, 35(5):199-205.
13. Botting, S., **Rampy, B.A.**, Diaz-Arrastia, C.: Prognostic significance of peritumoral lymphatic vessel density and vascular endothelial growth factor receptor 3 in invasive squamous cell cervical cancer. *Translational Oncology*, 2010, 3(3):170-175.
14. Johnson, S.M., Gulhati, P., **Rampy, B.A.**, Han, Y., Rychahou, P.G., Doan, H.Q., Weiss, H.L., Evers, B.M.: Novel expression patterns of PI3K/Akt/mTOR signaling pathway components in colorectal cancer. *Journal of the American College of Surgery* 2010, 210(5):767-76, 776-778.

Book Chapters

1. Finitzo, T., et al., **Rampy, B.A.**: Cortical dysfunction in developmental stutterers. In Peters, H.J. and Hulstijn, W. (Eds.), Proceedings of Nijmegen Conference 2nd International Conference on Speech Motor Dynamics in Stuttering, 1992.

Multimedia Projects

1. Rampy, B.A.: Gross Pathology Photography, Learning material in Multimedia Educational Resource for Learning and Online Teaching, nominated for peer review by the MERLOT Health Sciences Editorial Board, April, 2010.

INVITED LECTURES AT SYMPOSIA AND CONFERENCES:

1. Frederickson, C.J., **Rampy, B.A.**, Rampy, S.R. and Howell, G.A.: TSQ fluorescence survey of zinc-containing bouton densities. Poster at Society for Neuroscience 19th Meeting, Phoenix, 1989.
2. **Rampy, B.A.**: Fluent language production: Classification in stroke based upon measures of quantitative EEG. Podium presentation at the 2nd International Congress on Brain Electromagnetic Topography, Toronto, 1991.
3. **Rampy, B.A.**, Breenwell, D., Adjesoji, B., Orihuela, E., Okorodudu, A.O., Peterson, J.R. and Mohammad, A.A.: Use of serum insulin-like growth factor (IGF-1) and insulin-like growth factor binding proteins (IGF-1BP-3) levels as a tumor marker in prostate cancer (PCA). Poster at American Association of Clinical Chemistry National Meeting, 1999.
4. Ge, Y., **Rampy, B.A.**, Hadden, L. and Xiao, S-Y.: Decreased colonic epithelial CD10 expression in microscopic colitis. Podium presentation at the United States and Canadian Academy of Pathology 91st Annual Meeting, Chicago, 2002.
5. Gokhale, S., Gatalica, Z., Mohammad, A., **Rampy, B.A.** and Velagaleti, G.V.N.: HER-2/neu FISH in breast cancer: Is it the gold standard? Poster presentation at the American Society of Human Genetics 52nd Annual Meeting, Baltimore, 2002.
6. Treinen-Moslen, M., Kaphalia, L., Lemley, L., **Rampy, B.A.**, Atchison, C.R. and Kanz, M.: More renal and less intestinal adduction by the NSAID Diclofenac in MRP2- deficient rats. Poster presentation at the Society of Toxicology 43rd Annual Meeting, Baltimore, 2004.
7. **Rampy, B.A.**: Adducts as an immunohistochemical index for tissue exposure to NSAID metabolites. NIEHS Center Environmental Health Sciences Seminar Series, 2004.
8. Treinen-Moslen, M., Kaphalia, **Rampy, B.A.** and Kanz, M.F.: Resistance of TR rats to enteropathy and hepatotoxicity from repeated treatment with Diclofenac. Poster presentation at the 3rd International Conference on Idiosyncratic Drug Toxicity Potential. San Diego, 2004.
9. **Rampy, B.A.**, Lemley, L.L., Rajaraman, S., Wang, H-Q and Treinen-Moslen, M: Adducts an immunohistochemical index for kidney exposure to Diclofenac metabolites. Poster presentation at the Experimental Biology 2004 - ASPET Program, Washington, D.C., 2004.
10. **Rampy, B.A.** and Kelly, B.: PathSlides: Virtual Microscopy Mentored Video Teaching for Dermatology. Poster presented at the 2nd Annual UTMB Education Symposium. Sponsored by the UTMB Academy of Master Teachers, Galveston, TX., May 2009.
11. **Rampy, B.A.**: PathSlides: Virtual Microscopy Mentored Video Teaching for Dermatology. Podium Presentation at the UT System Innovations in Online Learning Conference, Austin, TX., May 2009.
12. Johnson, S.M., Gulhati, P., **Rampy, B.A.**, Han, Y., Rychahau, P.G., Doan, H.Q., Weiss, H.L. and Evers, B.M.: Novel expression patterns of PI3K/AKT/mTOR signaling pathway components in colorectal cancer. 2009 Annual Meeting of the Southern Surgical Association, Hot Springs, VA, December 2009

13. Cooke, R., **Rampy, B.A.**: Digital Pathology: The Past, the Present and Future Applications. 2010 Texas Society of Pathologists Annual Meeting, Galveston, TX, January 2010.
14. **Rampy, B.A.**, UTMB Academy of Master Teachers Journal Club, "Implementation of a Longitudinal Mentored Scholarly Project: An Approach at Two Medical Schools" March 30, 2010.
15. **Rampy, B.A.**: Gross Pathology Photography. Presentation for the 2011 Winter Meeting of the Group for Research in Pathology Education, Huntington, WV, January 2011.



PUBLIC VERIFICATION / PHYSICIAN PROFILE

PHYSICIAN

NAME: LANDON CLARKE STOUT JR MD

DATE: 08/21/2013

THE INFORMATION IN THIS BOX HAS BEEN VERIFIED
BY THE TEXAS MEDICAL BOARD

Date of Birth: 1933

License Number: E0368 Full Medical License

Issuance Date: 01/13/1973

Expiration Date of Physician's Registration Permit: 08/31/2014

Registration Status: ACTIVE

Registration Date: 01/01/1978

Disciplinary Status: NONE

Disciplinary Date: NONE

Licensure Status: NONE

Licensure Date: NONE

Medical School of Graduation:

At the time of licensure, TMB verified the physician's graduation from medical school as follows:
UNIV OF MARYLAND SCH OF MED, BALTIMORE

Medical School Graduation Year: 1957

TMB Filings, Actions and License Restrictions

The Texas Medical Board has the following board actions against this physician. (This may include any formal complaints filed by TMB, as well as petitions and/or responses related to licensure contested matters, at the State Office of Administrative Hearings.)

NONE

Investigations by TMB of Medical Malpractice

Section 164.201 of the Act requires that: the board review information relating to a physician against whom three or more malpractice claims have been reported within a five year period. Based on these reviews, the following investigations were conducted with the listed resolutions.

NONE

Status History

Status history contains entries for any updates to the individual's registration, licensure or disciplinary status types (beginning with 1/1/78, when the board's records were first automated). Entries are in reverse chronological order; new entries of each type supersede the previous entry of that same type. These records do not display status type. Should you have any questions, please contact our Customer Information Center at 512-305-7030 or verificic@tmb.state.tx.us

Status Code: AC**Effective Date:** 01/01/1978**Description:** ACTIVE

THE INFORMATION IN THIS BOX WAS REPORTED BY THE LICENSEE AND
HAS NOT BEEN VERIFIED BY THE TEXAS MEDICAL BOARD

Gender: MALE***Ethnicity:** WHITE**Race:** WHITE

* We are in the process of transitioning from the current ethnic origin values to federal standards for race and Hispanic origin. The transition period will allow time for individuals to submit updated race and Hispanic origin data to the TMB.

Place of Birth: MISSOURI**Current Primary Practice Address:**

UTMB

DEPT OF PATHOLOGY

GALVESTON , TX 77555-0747

Years of Active Practice in the U.S. or Canada:

The physician reports that he/she has actively practiced medicine in the United States or Canada for **55** year(s).

Years of Active Practice in Texas:

The physician reports that, of the above years he/she has actively practiced in the State of Texas for **40** year(s).

Specialty Board Certification

The physician reports that he/she holds the following specialty certifications issued by a board that is a member of the American Board of Medical Specialties or the Bureau of Osteopathic Specialists:

NONE

Primary Specialty

The physician reports his/her primary practice is in the area of PATHOLOGY.

Secondary Specialty

The physician did not report a secondary practice area.

Name, Location and Graduation Date of All Medical Schools Attended

Name: U OF MARYLAND

Location: BALTIMORE/USA

Graduation Date: 1957

Graduate Medical Education In The United States Or Canada

Program Name: U OF OKLAHOMA HSC

Location: OKLAHOMA CITY, OK

Begin Date: 07/1957

Type: INTERNSHIP

End Date: 06/1958

Specialty: ROTATING

Program Name: NONE

Location: OKLAHOMA CITY, OK

Begin Date: 07/1958

Type: RESIDENCY

End Date: 06/1961

Specialty: INTERNAL MED

Program Name: NONE

Location: NONE

Begin Date: 07/1966

Type: RESIDENCY

End Date: 06/1967

Specialty: PATHOLOGY

Hospital Privileges

The physician reports that he/she has hospital privileges in the following in the State of Texas:

Hospital: UTMB HOSPITAL

Location: GALVESTON

Utilization Review

The physician did not report whether he/she provides utilization review.

NONE REPORTED

Patient Services

Accessibility: The physician reports that the patient service area is accessible to persons with disabilities as defined by federal law.

Language Translation Services: The physician did not report whether he/she provided any language translation services for patients.

Medicaid Participant: The physician reports that he/she **does not** participate in the Medicaid program.

Awards, Honors, Publications and Academic Appointments

Optional Information

The physician may optionally report descriptions of up to five such honors and has reported the following:

Description: PROFESSOR OF PATHOLOGY UTMB GALVESTON TX SINCE 1974

Malpractice Information

Section 154.006(b)(16) of the Act requires that: a physician profile display a description of any medical malpractice claim against the physician, not including a description of any offers by the physician to settle the claim, for which the physician was found liable, a jury awarded monetary damages to the claimant, and the award has been determined to be final and not subject to further appeal. The physician has the following reportable claims.

Description: NONE

Criminal History

Self-Reported Criminal Offenses:The physician is required to report a description of (1) "any conviction for an offense constituting a felony, a Class A or Class B misdemeanor, or a Class C misdemeanor involving moral turpitude" and (2) "any charges reported to the board to which the physician has pleaded no contest, for which the physician is the subject of deferred adjudication or pretrial diversion, or in which sufficient facts of guilt were found and the matter was continued by a court of competent jurisdiction."

The physician has reported the following:

Description: NONE

Criminal history information is also obtained by TMB from the Texas Department of Public Safety. Resulting action, if any, will be reported under the TMB Action and Non-Disciplinary Restrictions section above.

Disciplinary Actions By Other State Medical Boards

The physician has reported the following:

Description: NONE

Physician Assistant Supervision

To obtain
primary source
verifications,
click name

Description: NONE

Advanced Practice Nurse Delegation

To obtain
primary source
verifications,
click name

Description: NONE

Summary of all License/Permit Types

Issue Date:
01/13/1973

Type:
LICENSED PHYSICIAN

[Agency](#) | [Contact Us](#) | [Employment](#) | [Compact w/ Texans](#) | [Open Records](#) | [Privacy Policy](#) | [Site Map](#) |
[Search TX State Sites](#) | [TX Homeland Security](#) | [TX Occupations Code](#) |
[Texas.gov](#) | [Poison Control Center Services](#) | [Accessibility Policy](#)

CURRICULUM VITAE

Landon Clarke Stout, Jr., M.D.

January 31, 2012

PRESENT POSITION

Professor
Department of Pathology (1/2 time as of (April-1998-1)
Room 541A, Clinical Sciences Bldg
The University of Texas Medical Branch
Galveston, Texas 77555-0747

BIOGRAPHICAL

Born Kansas City, Missouri, February 2-1933-20
United States Citizen
Home Address: 3506 Princeton, Galveston, Texas 77554

EDUCATION

University of Maryland	1950-53	Premedical, B.S. 1954
University of Maryland	1953-57	M.D.
University of Oklahoma Medical Center	1957-58	Internship - Rotating
University of Oklahoma Medical Center	1958-61	Resident - Internal Medicine
University of Oklahoma Medical Center	1966-67	Resident - Pathology
University of Oklahoma Medical Center	1967-68	Special Fellow in Pathology (National Heart Institute, USPHS) under Drs. P. Kimmelstiel & A.L. Dee

BOARD CERTIFICATION

American Board of Pathology (Anatomic Pathology) - May, 1973

LICENSURE INFORMATION

State of Texas - E0368, expires 8-31-08

PROFESSIONAL AND TEACHING EXPERIENCE

ACADEMIC APPOINTMENTS

Clinical Assistant in Medicine	1961-62	University of Oklahoma Medical Center
Instructor in Medicine	1962-63	University of Oklahoma Medical Center
Assistant Professor of Medicine	1963-72	University of Oklahoma Medical Center
Assistant Professor of Pathology	1968-71	University of Oklahoma Medical Center
Interim Chairman of Pathology	1970-72	University of Oklahoma Medical Center
Associate Professor of Pathology	1971-72	University of Oklahoma Medical Center
Associate Professor of Pathology	1972-74	University of Texas Medical Branch at Galveston
Professor of Pathology	1974-	University of Texas Medical Branch at Galveston
Member, Experimental Pathology	1973-	University of Texas Medical Branch at Galveston

Graduate School of Biomedical
Sciences

HOSPITAL & DEPARTMENTAL APPOINTMENTS

Attending Physician in Medicine	1962-72	University Hospital and Veterans Admin. Hospital, Oklahoma City Central State Hospital, Norman, Ok.
Assistant Director, General Medicine Clinic & Fourth Yr. Teaching Program	1963-65	Department of Medicine, University of Oklahoma Medical Center
Director, Institute for Comparative Pathology	1965-69	Department of Medicine, University of Oklahoma Medical Center
Director, Primate Colony	1965-69	Department of Medicine, University of Oklahoma Medical Center
Director of Necropsy	1968-72	Department of Pathology, University of Oklahoma Medical Center
Director, Residency Training Program	1969-72	Department of Pathology, University of Oklahoma Medical Center
Interim Chairman	1970-72	Department of Pathology, University of Oklahoma Medical Center
Consultant in Pathology	1971-72	Oklahoma Medical Research Foundation
Director of Necropsy	1972-77	Department of Pathology, University of Texas Medical Branch at Galveston
Director, Residency Training Program	1975-88	Department of Pathology, University of Texas Medical Branch at Galveston
Acting Co-Director, Surgical Pathology	1989-1990	Department of Pathology, University of Texas Medical Branch at Galveston
Associate Director, Surgical Pathology	1996-1998	Department of Pathology, University of Texas Medical Branch at Galveston
Pathologist, Autopsy Service	2004-	Department of Pathology, University of Texas Medical Branch at Galveston

RESEARCH ACTIVITIES

A. Area of research:

1. Studies of diabetic renal glomerular disease in humans.

B. Grant support:

1. Current: None
2. Pending: None.
3. Past: As principal investigator
 - a. A study of experimental diabetes in baboons, The John A Hartford Foundation, Inc; 6/68 to 6/81 (Paul Kimmelstiel was PI from 1968 to 1970), total funds \$339,304
 - b. Emotional stress on atherosclerosis; NIH HE 11064, 1/67 to 2/71, total funds \$49,656
 - c. Ulcerative colitis in Siamang gibbons, NIH AM 13297, 1/69 to 3/72, total funds \$41,517
 - d. Structural and functional studies on renal disease, NIH AM 11332, 9/66 to 9/72 (Paul Kimmelsties was PI from 1966 to 1970), total funds \$247,643
 - e. A pilot study of heart disease in zoo animals, NIH HE 08725, 6/64 to 5/68 (Marshall Groover was PI from 1964 to 1966), total funds \$164,603
 - f. Conference on cardiovascular disease in zoos, NIH HE 10843, 9/66 to 8/67, total funds

4,383

- g. Special fellowship in pathology, NIH, 7/67 to 6/68, total funds \$17,000

COMMITTEE RESPONSIBILITIES

A. National: None

B. University of Texas Medical Branch:

1. Animal Care Committee (1972 to 1979)
2. Evaluation Committee for Three-Year Graduates (1973 to 1990; Chairman, 1983 to 1990)
3. Ad Hoc Interviewer for Admissions Committee (1974 to present)
4. House Staff Committee (1975 to 1984)
5. Biohazards Committee (1976 to 1979)
6. Grading and Promotion Evaluation Committee D (1976 to 1979)
7. Appointment, Promotion and Tenure Committee (7/1/86 to 6/30/87)
8. LCME Self-study Task Force (1993)
9. Medical Staff Executive Committee (1993 to 1995)
10. Operative and Other Invasive Procedures Committee (formerly Tissue Audit Committee), 1989 to 1995, Chairman (1993 to 1995)
11. JCAHO Task Force (1994)
12. Quality of Care Committee (1993 to 1995)
13. Renal/Fluid/Electrolyte Course Design Committee, Co-chair, 1997
14. Renal/Fluid/Electrolyte Course Committee, 1998 to present

C. Department of Pathology

1. Committee of Professors (Chairman, Departmental AP & T Committee, 1987)
2. Secretary for Staff Meetings (1977 to 1992)
3. Coordinating Committee for Pathology Course
4. Residency Advisory Committee

D. Texas Society of Pathologists

- Planning Committee, Residents/Fellows Symposium (1987-1989)

TEACHING RESPONSIBILITIES AT UTMB

A. Medical Students

1. Laboratories in cardiovascular-pulmonary, G.I. (24 contact hours)
2. Lecture in renal course (1 contact hour)
3. Renal Course Committee (10 hours of committee meetings plus preparation, etc.)
4. Instruction of senior medical students taking electives in Autopsy Pathology (10 contact hours)
5. Clinical Advisor to the following students:
1986 Robert H. McKay
Paul S. Carlson
Donald L. Hilton
George Leventon

Robyne G. Rast

1987 Timothy D. Sweo
Thuy Dung Haberkorn
Gwen Fagala

1988 Hans A. Zambrano
Morgan Levy
Paul W. English

- 1989 **Grace Chao**
 Cynthia Smith
 Richard Treadwell
- 1990 Karen Price
 Michael McMahon
 Sabrina Clough
 David Alderman
 Kim Sebring
- 1993 Barbara Adame
 David Marks
- 1994 Marla Barnes
- 2001 Sally Ibrahim
 Omar Hernandez
 Elaine Nelson

B. Inter and Intradepartmental Teaching Conferences for Residents

1. Autopsy Gross-micro Conference (approx. 46 hours)
2. Autopsy Gross Conference (approx. 40 hours)
3. Resident lectures (2 hours)
4. Surgical M&M Conference (approx 20 hours)

SERVICE RESPONSIBILITIES AT UTMB

One half of a full time faculty load on the Autopsy Pathology Service (2004-present)
Member of Autopsy Faculty (2002)

MEMBERSHIP IN SCIENTIFIC SOCIETIES (*elected)

- *American Society for Investigative Pathology
- *American College of Physicians
- *American Diabetes Association, Council on Complications
- *American Gastroenterological Association
- *American Heart Association, Council on Epidemiology
- Galveston County Medical Society
- Texas Medical Association
- Texas Society of Pathologists
- *U.S. and Canadian Academy of Pathology
- *Renal Pathology Society

HONORS

Aesculapian Award nominee for excellence in pre-clinical instruction, University of Oklahoma Medical Center, 1972

Selected as one of several UTMB faculty as outstanding teachers by the 1991 " Centennial Graduating Class".

Senior Faculty Marshall, 1994 Medical School Graduation Ceremony

Selected by the pathology residents as 1999-2000 outstanding Faculty Member – Anatomic Pathology

Appreciation Award from the 2005-2006 pathology residents for Outstanding Dedication and Commitment to Resident and Fellow Education

ADDITIONAL INFORMATION

Organized a National Conference "Conference on Cardiovascular Disease in Zoos," supported by the National Heart Institute, December 3-4, 1966, Oklahoma City, Oklahoma

Ad hoc reviewer for the following journals:

Atherosclerosis

Circulation

Journal of Histochemistry and Cytochemistry

Kidney International

Pediatrics

Science

Hypertension

Nephron

Faculty sponsor for AKK fraternity

Grading abstracts and judging presentations at National Student Research Forum (1975 to present)

Proposed as a candidate for appointment to the 1996-97 Nominating Committee of the American Gastroenterological Association.

PUBLICATIONS

A. Articles in Peer-Reviewed Journals

1. Stout C, Morrow J, Brandt E and Wolf S. Unusually low incidence of death from myocardial infection. Study of an Italian American Community in Pennsylvania. JAMA 188:845-849, 1964.
2. Stout C, Holland CK and Bird RM. Hemoglobin D in an Oklahoma family. Arch Int Med 114:296-300, 1964.
3. Groover ME Jr and Stout C. Neurogenic myocardial necrosis and protective effects of atropine. Angiol 16:180-186, 1965.
4. Groover ME Jr and Stout C. Electrophoretic activity of arterial plasma and experimental thrombi. Angiol 16:651-663, 1965.

5. Groover ME Jr and Stout C. Physiochemical properties of blood in postmyocardial infarction patients and controls. *Angiol* 17:85-95, 1966.
6. Stout C. Circulatory capacity of the coronary arteries. *J Okla State Med Assn* 60:94-96, 1967.
7. Stout C. Clostridial septicemia. *J Okla State Med Assn* 61:447-449, 1968.
8. Stout C and Bohorguez F. Aortic atherosclerosis in hoofed mammals. *J Atheroscler Res* 9:73-80, 1969.
9. Stout C and Lemmon WB. Glomerular capillary endothelial swelling in a pregnant chimpanzee. *Amer J Obstet Gynecol* 105:212-215, 1969.
10. Stout C. Coronary thrombosis without coronary atherosclerosis. *Amer J Cardiol* 24:564-569, 1969.
11. Stout C and Lemmon WB. Predominant coronary and cerebral atherosclerosis in captive nonhuman primates. *Exp Molec Pathol* 10:312-322, 1969.
12. Stout C and Snyder RL. Ulcerative colitis-like lesion in Siamang gibbons. *Gastroenterol* 57:256-261, 1969.
13. Stout C, Wight M and Bruhn J. The Cornell Medical Index in disability evaluations. *Brit J Prev Soc Med* 23:4:251-254, 1969.
14. Stout C. Atherosclerosis in exotic Carnivora and Pinnipedia. *Amer J Path* 57:673-688, 1969.
15. Stout C and Koehl G. Aortic embolism in a newborn infant. *Amer J Dis Child* 120:74-76, 1970.
16. Aljeboori T, Stout C and Ivey M. *Toxocara canis* infection in baboons. II. Distribution of larvae and histopathologic response. *Amer J Trop Med Hyg* 19:815-820, 1970.
17. Stout C and Lemmon WB. Hypertensive-like vascular lesions in a chimpanzee. *Exp Molec Path* 14:151-157, 1971.
18. Massion WH, McNeill JR, Rosenbluth B, Stout C and Brecher G. Effect of biventricular massage on barbiturate-induced circulatory arrest. *J Thoracic Cardiovas Surg* 63:230-234, 1972.
19. Stout C, Hartsuck JM, Howe J and Richardson JL. Atheromatous embolism after subdiaphragmatic aortofemoral bypass and infrarenal aortic ligation. *Arch Path* 93:271-275, 1972.
20. Reynolds DW, Riley HD, LaFont DS, Vorse H, Stout C and Carpenter RL. An outbreak of Reye's syndrome associated with influenza B. *J Pediat* 80:429-432, 1972.
21. Crosby WM, King AI and Stout C. Fetal survival following impact: Improvement with shoulder harness restraint. *Am J Obstet Gynecol* 111:1101-1106, 1972.
22. Bohorquez F and Stout C. Arteriosclerosis in exotic mammals. *Atherosclerosis* 16:225-231, 1972.
23. Bohorquez F and Stout C. Aortic atherosclerosis in exotic avians. *Exp Molec Path* 17:261-273, 1972.
24. Stout C, Hampton JW, Anderson JD and Oruc N. Fatal non-traumatic splenic rupture in hemophilia and the Kasabach-Merritt syndrome. *South Med J* 66:791-795, 1973.
25. Ordway N and Stout C. Thromboembolus to abdominal aorta in a neonate. *J Pediat* 82:143-148, 1973.
26. Ordway N and Stout C. Intrauterine growth retardation, jaundice and hypoglycemia in a neonate. *J Pediat* 83:867-874, 1973.
27. Thompson WM and Stout C. Tachypnea, tachycardia, cyanosis, and mediastinal mass in a neonate. *J Pediat* 84:769-772, 1974.
28. Stout C. Studies on the distribution of lipids within fibrous plaques. *Atherosclerosis* 23:443-450, 1976.

29. Folse DS and Stout C. Endometriosis in a baboon (Papio doguera). *Lab Anim Sci* 28:217-218, 1978.
30. Bojanovski D, Alaupovic P, Kelley JL and Stout C. Isolation and characterization of the major lipoprotein density classes of normal and diabetic baboon (Papio Anubis) plasma. *Atherosclerosis* 31:481-487, 1978.
31. Tyers GFO, Larrrieu AJ, Stout LC, Tonnesen AS and Williams EH. Delayed recurrent massive thromboembolism through a vena caval clip after pulmonary embolectomy. *Chest* 77:114-115, 1980.
32. Alperin JB, Dow PA and Stout LC. A comparison of hemoglobin A_{1c} in human and baboon blood. *Acta Haemat* 61:334-338, 1979.
33. Stout LC and Thorpe LW. Histology of normal aortas in non-human primates with emphasis on diffuse intimal thickening (DIT). *Atherosclerosis* 35:165-180, 1980.
34. Stout LC and Thorpe LW. Histology of normal aortas in birds with emphasis on intimal thickening. *Atherosclerosis* 36:545-558, 1980.
35. Williams EH, Conti VR, Nishimura A, Stout LC and Ferrans V. Early calcific stenosis of aortic and mitral Ionescu-Shiley valves in a patient with bioprosthetic infection. *J Thor and Cardiovas Surg* 82:391-397, 1981.
36. Stout LC. Pathogenesis of diffuse intimal thickening (DIT) in aortas and coronary arteries of 2 1/2 year old miniature pigs. *Exp Molec Pathol* 37:427-432, 1982.
37. Stout LC, Whorton EB and Vaghela M. Pathogenesis of diffuse intimal thickening (DIT) in non-human primate thoracic aortas. *Atherosclerosis* 47:1-6, 1983.
38. Stout LC. Water clear cell hyperplasia mimicking parathyroid adenoma. *Hum Pathol* 16:1075-1076, 1985.
39. Stout LC, Folse DS, Meier J, Crosby WM, Kling R, Williams GR, Price WE, Geyer JR, Padula R, Whorton E and Kimmelstiel P. Quantitative glomerular morphology of the normal and diabetic baboon kidney. *Diabetologia* 29:734-740, 1986.
40. Stout LC, Boor PJ and Whorton EB. Myofibroblastic proliferation on mitral valve chordae tendineae. A distinctive lesion associated with alcoholic liver disease. *Hum Pathol* 19:720-725, 1988. Selected for Yearbook of Pathology & Clinical Pathology, 1990.
41. Stout LC, Kumar S and Whorton EB. Focal mesangiolytic and the pathogenesis of the Kimmelstiel-Wilson nodule. *Hum Pathol* 24:77-89, 1993. Selected for Yearbook of Nephrology, 1994.
42. Stout LC, Kumar S, Whorton EB. Insudative lesions - their pathogenesis and association with glomerular obsolescence in diabetes: A dynamic hypothesis based on single views of advancing human diabetic nephropathy. *Hum Pathol* 25:1213-1227, 1994.
43. Stout LC, Lyon RE, Murray NGB, Barth MH. Pseudointimal biliary epithelial proliferation and Zahn's infarct associated with a 6 month old transjugular intrahepatic portosystemic shunt. *Am J Gastro* 90:126-130, 1995.
44. Stout LC and Whorton EB. Pathogenesis of extra efferent vessel (EEV) development in diabetic glomeruli. *Hum Pathol* 38: 1167-1177, 2007).
45. Sbrana E, Grice J, Stout C, Aronson J. Co-morbidities associated with tuberculosis in an autopsy case series. *Tuberculosis* 1, Suppl 1: S38-S42, Dec 2011

In Press

B. OTHER

(Chapters in Books, Symposia, Invited Reviews, Letters, etc.)

1. Stout C. The treatment of hypogonadism in the middle aged male. *Med Times* 93:1095, 1965.
2. Stout C. The Pennsylvania Study. *J Okla State Med Assn* 58:561-562, 1965.
3. Groover ME Jr and Stout C. Neurogenic myocardial necrosis. In: Raab W, ed. *Prevention of ischemic heart disease: Principles and practice*. Springfield, IL: CC Thomas, p.57, 1966.
4. Brandt E, Stout C, Hampton J and Wolf S. Coronary heart disease among italians and non-italians in Roseto, pennsylvania, and in nearby communities. In: Raab W, ed. *Prevention of ischemic heart disease: Principles and practice*. Springfield, IL: CC Thomas, p. 217, 1966.
5. Groover ME Jr and Stout C. The use of the baboon in the study of psychogenic myocardial necrosis. In: Vagtborg H, ed. *The baboon in medical research, Vol. 1*. Austin, TX: Univ. of Texas Press, p. 539-542, 1965.
6. Groover ME Jr and Stout C. Electrophoretic patterns in the baboon. In: Vagtborg H, ed. *The baboon in medical research, Vol. II*. Austin, TX: Univ. Texas Press, p. 605-615, 1967.
7. Stout C and Groover ME Jr. The effects of environmental manipulation on physiologic parameters - a preliminary report. In: Vagtborg H, ed. *The baboon in medical research, Vol. II*. Univ. of Texas Press, p. 625-631, 1967.
8. Groover ME Jr, Stout C, Ficken R and Smith VS. Alteration in color preference of the kenya baboon during minor illness. In: Vagtborg H, ed. *The baboon in medical research, Vol. II*, Austin, TX: Univ. of Texas Press, p. 617-620, 1967.
9. Stout C. Atherosclerosis in subhuman primates: findings in 63 individuals, 25 species. In: Vagtborg H, ed. *Use of nonhuman primates in drug evaluation*. Austin, TX and London: Univ. of Texas Press, p. 494-504, 1968.
10. Stout C, Ogilvie PW and Lemmon WB. The correlation of behavior and pathology in zoo animals. In: *International Zoo Yearbook, Vol. 9*, London, London: The Zoological Society, p. 197, 1969.
11. Stout C and Groover ME Jr. Spontaneous versus experimental atherosclerosis. *Ann. N.Y. Acad. Sci.* 162, Art. 1:89-98, 1969.
12. Stout C. Atherosclerosis in great apes. In: *Proc 2nd Int Congr Primat, Vol. 3*, Atlanta, Ga. Basel/New York: Karger, p. 177-183 1969.
13. Stout C. Visceral larva migrans. A review. *J. Okla. State Med. Assn.* 62:530-534, 1969.
14. Stout C. The use of animals to study spontaneous arterial disease. *Auburn Vet.*, 26, (1):26-28, 1969.
15. Smith V and Stout C. Effect of phenylcyclidine and pentobarbital in baboons. In: *Proc 2nd Int Congr Primat, Vol. 3*, Atlanta, Ga. Basel/New York: Karger, p. 85, 1969.
16. Stout C. Ischemic Colitis: A review. *J. Okla. State Med. Assn.* 63:576-579, 1970.
17. Stout C. Letter to the Editor, "Relevance of diseases in animals." *New Eng. J. Med.*, 282:754, 1970.
18. Stout C. Letter to the Editor, "Allergic granulomas of gut." *New Eng. J. Med.*, 282:1324, 1970.
19. Stout C. Letter to the Editor, "Haemoglobin and serum cholesterol." *Lancet*, 1:999, 1970.
20. Stout C. Letter to the Editor, "Sympathogenic vascular disease." *New Eng. J. Med.*, 283:1227-1228, 1970.

21. Bohorquez F and Stout C. Aortic Atherosclerosis in Exotic Animals, p1-88, Master's Thesis of F. Bohorquez, University of Oklahoma Health Sciences Center Library, 1972.
22. Stout C and Bohorquez F. Arteriosclerosis and other vascular diseases in zoo and laboratory animals. In: Harmison LT, ed. Research animals in medicine, National Heart and Lung Institute, DHEW Publication No. (NIH) U.S. Gov't. Printing Office, Stock No. 1740-0338, p. 72-333, 1973.
23. Stout C. Human-like diseases in anthropoid apes. In: Bourne GH, ed. Non- human primates and medical research. New York: Academic Press, p. 249-255, 1973.
24. Stout C. Etiology of myointimal cell proliferation. In: Schettler G. and Weizel A, eds. Atherosclerosis III, Proceedings of the third international symposium. Berlin: Springer-Verlag, p. 199-201, 1974.
25. Stout C. Letter to the Editor, "Alcohol and the Liver." *Ann. Int. Med.* 81:124, 1974.
26. Stout C and Bohorquez F. Significance of intimal changes in non-human vertebrates. *Med. Clin. N. Amer.* 58:245-255, 1974.
27. Stout C. Letter to the Editor, "Postmortem examination." *JAMA* 235:22, 1976.
28. Stout C. Mechanism of lipid accumulation and central necrosis in fibrous plaques. In: Day CE, ed. Atherosclerosis drug discovery. New York: Plenum Publishing Co, p. 377, 1976.
29. Stout, L. Clarke. Letter to the Editor, "Auscultation through a shirt," *Ann. Int. Med.* 132: 1006, 2000.

C. ABSTRACTS AND PRESENTATIONS

1. Stout,C., Morrow,J., Brandt,E. and Wolf,S. Unusually low incidence of death from myocardial infarction, *J. Clin.Invest.* 42:985, 1963.
2. Groover,M.E.,Jr. and Stout,C. Neurogenic myocardial necrosis and protective effects of atropine. Presented before the Council on Arteriosclerosis, American Heart Association, Los Angeles, 1963, *Circulation* 28:657, 1963.
3. Stout,C. Coronary artery disease in Roseto, Annual Meeting, Oklahoma Heart Association, Oklahoma City, 1964.
4. Stout,C. Coronary artery disease in Roseto, Presented at the Regional Meeting, American College of Physicians, Hot Springs, Arkansas, 1964.
5. Groover,M.E.,Jr. and Stout,C. Neurogenic myocardial necrosis. Presented at the First International Conference on Preventive Cardiology, Burlington, Vermont, 1964.
6. Hampton,J.W., Stout,C., Brandt,E.N. and Wolf,S. Prevalence of myocardial infarction and related diseases in an Italian-American community, *J.Lab & Clin.Med.*, November, 1964.
7. Brandt,E., Stout,C., Hampton,J. and Wolf,S. Coronary artery disease in Roseto, Pennsylvania, and among Italians and non-Italians in nearby communities. Presented at the First International Conference on Preventive Cardiology, Burlington, Vermont, 1964.
8. Bruhn,J., Hampton,J. and Stout,C. Social factors related to myocardial infarction among Italian-Americans in adjacent communities. Presented at the Annual Conference, Council on Epidemiology, American Heart Association, Chicago, 1964.
9. Wolf,S., Bruhn,J., Hampton,J. and Stout,C. The relation of myocardial infarction to sociological factors among Italians living in Roseto, Pennsylvania and in other American communities. Presented at the Annual Meeting, American College of Physicians, Chicago, 1965.

10. Groover,M.E.,Jr., and Stout,C. Beta lipoprotein mobility as an indication of myocardial infarction and heparin activity. Presented at the Annual Meeting, American College of Angiology, New York, 1965.
11. Groover,M.E.,Jr., and Stout,C. Electrical activity of the blood and atherosclerosis. Presented at the Annual Meeting, International College of Angiology, London, 1965.
12. Groover,M.E.,Jr. and Stout,C. Electrophoretic patterns in the baboon. Presented at the Second International Symposium on the Use of the Baboon in Medical Research, San Antonio, 1965.
13. Stout,C. and Groover,M.E.,Jr. The effects of environmental manipulation on physiologic parameters - a preliminary report. Presented at the Second International Symposium on the Use of the Baboon in Medical Research, San Antonio, 1965.
14. Groover,M.E.,Jr. and Stout,C. Physiochemical character of blood and experimental intra-arterial lesions, *Circulation* 32 (Suppl.): 15,1965.
15. Groover,M.E.,Jr. and Stout,C. Physiochemical changes in blood during emotional stress with allergy and angina pectoris, *Circulation* 32 (Suppl. 2): 15,1965.
16. Stout,C. Atherosclerosis in zoo animals. Presented at the Conference on Mortality Statistics in Zoo Animals, Oklahoma City, December 3-4, 1966.
17. Stout,C. Atherosclerosis in captive subhuman primates: findings in 63 individuals, 25 species. Presented at the Symposium on the Use of Subhuman Primates in Drug Evaluation, May 2-5, 1967, San Antonio, Texas.
18. Stout,C. Atherosclerosis in captive subhuman primates. Presented at the Stewart Wolf Day, Oklahoma City, May 20, 1967.
19. Stout,C. and Groover,M.E.,Jr. Comparative pathology of atherosclerotic lesions. Presented at the Conference on Experimental Medicine and Surgery in Primates, New York Academy of Sciences, September 27-30, 1967.
20. Stout,C. Aortic atherosclerosis in hoofed mammals. Presented at the Midwest Interprofessional Seminar on Diseases Common to Animals and Man, Columbia, Missouri, October, 4-5, 1967.
21. Stout,C. Atherosclerosis in great apes, Second International Congress of Primatology, Jung 30-July 3, 1968, Atlanta, Georgia.
22. Smith,V. and Stout,C. Effect of phenylcyclidine and pentobarbital in baboons. Presented at the Second International Congress of Primatology, June 30-July 3, 1968, Atlanta, Georgia.
23. Stout,C. Predominant coronary and cerebral atherosclerosis in chimpanzees,Scientific Exhibit, Annual Meeting of American Association of Pathologists and Bacteriologists and International Academy of Pathology, March 9-15, 1969, San Francisco, and American Association for Laboratory Animal Science, October 13-17, 1969, Dallas, Texas.
24. Stout,C. Predominant coronary and cerebral atherosclerosis in captive subhuman primates. Presented at The F.A.S.E.B. Annual Meeting, Atlantic City, April 13-18, 1969, *Fed. Proc.* 28:447, 1969.
25. Stout,C. Atherosclerosis in exotic carnivora and pinnipedia. Presented at the Midwest Interprofessional Seminar on Diseases Common to Animals and Man, September 22-23, 1969, Ames, Iowa.
26. Stout,C. Colitits in Siamang gibbons. Presented at the Workshop on Comparative Gastroenterology, N.I.H., April 23, 1970, Bethesda, Maryland.
27. Bohorquez,F. and Stout,C. Aortic atherosclerosis in exotic animals. Presented at the Midwest Interprofessional Seminar on Diseases common to Animals and Man, September 3-4, 1970, Brookings, South Dakota.

28. Stout,C. Morphologic changes suggesting preeclampsia and essential hypertension in chimpanzees. Scientific Exhibit, Annual Meeting of the American Association of Pathologists and Bacteriologist and the International Academy of Pathology, March 6-18, 1971, Montreal.
29. King,A.I., Eppinger,R.H., Crosby,W.M. and Stout,C. Effects of lap belt and three-point restraints on pregnant baboons subjected to deceleration. Presented at the 15th Stapp Car Crash Conference, Coronado, California, November 17-19, 1971.
30. Stout,C. and Bohorquez,F. Arteriosclerosis and other vascular diseases in zoo and laboratory animals. Presented at the National Conference on Research Animals in Medicine, National Heart and Lung Institute, Washington, D.C., January 28-30, 1972.
31. Bohorquez,F. and Stout,C. Aortic atherosclerosis in exotic avians. Presented at the F.A.S.E.B. Annual Meeting, Atlantic City, April 9-14, 1972.
32. Stout,C. and Hampton,J.W. Acquired splenic "hemangioma" in association with coagulation defects and infection, Clin.Res., 20, No. 3:501, 1972
33. Tseng,C.H., Spargo,B.H., Porch,J., Stout,C. and Kimmelstiel,P. Experimental diabetes in baboons. Early glomerular changes. Presented at the 32nd Annual Meeting of the American Diabetes Association, June 24-25, 1972, Washington, D.C. Diabetes, 21 (Suppl.): 338, 1972.
34. Stout,C., Lemmon,W.B., Bohorquez,F. and Gantz,C. Increased aortic myointimal cell proliferation with chronic electric shock in pigs. Presented at the Annual Meeting of Pathologists and Bacteriologists, February 25-March 1, 1973, Washington, D.C., Amer. J. Path. 70:55a, 1973.
35. Stout,C. Etiology of myointimal cell proliferation. Presented at the Third International Symposium on Atherosclerosis, West Berlin, October 25-28, 1973.
36. Stout,C. Mechanisms of lipid accumulation and central necrosis in fibrous plaques. Presented at the First Brook Lodge Symposium on Antiatherosclerosis Drug Discovery, Augusta, Michigan, August 13-15, 1975.
37. Stout,C. and Nichols,M.M. Ischemic heart disease due to unusual anomalies of the left coronary artery in two infants. Presented at the Second Joint Meeting of the Paediatric Pathology Club and the Paediatric Pathology Society, Toronto, September 25-27, 1975.
38. Stout,C. An hypothesis for the function of gelatinous arterial lesions. Presented at F.A.S.E.B. annual meeting, Anaheim, California, April 11-16, 1976. Fed. Proc. 35:207, 1976.
39. Stout C, Kennedy A, Folse D, Beathard G, Granholm N, Padula R, Williams GR, Whorton E, Davis E. and KimmelstielP. Glomerulosclerosis in "secondary" diabetes in baboons. Presented at the American Diabetes Assn. Annual Meeting, San Francisco, June 20-22, 1976. Diabetes 25 (Suppl 1): 349, 1976.
40. Stout,C. Hypothesis on the circulation of lipids within fibrous plaques. Presented at the IVth International Symposium on Atherosclerosis, Tokyo, August 24-28, 1976.
41. Stout,C. Hypothesis on the conversion of simple fibrous plaques into complicated atheromatous plaques. Presented at the Annual Meeting of the International Academy of Pathology, Atlanta, March 6-10, 1978. Lab Invest. 38:37, 1978.
42. Stout,C. Diffuse intimal thickening of aortas in non-human primates. Presented at the F.A.S.E.B. Annual Meeting, Atlantic City, April 9-13, 1978. Fed. Proc. 37:842, 1978.
43. Stout,C., Welford,A., Folse,D., Whorton,E., Davis,E., Crosby,W., Kling,R., Geyer,J. Beathard,G. and Kimmelstiel,P. Increased rate of glomerular capillary basement membrane thickening in pancreatectomized diabetic baboons. Diabetes 28:410, 1979.
44. Alperin,J.B. and Stout,C. Glycosylated hemoglobin (CHO-Hb) in pancreatectomized baboons. Clin. Res. 27:A287, 1979.

45. Stout,C., Folsch,D., Welford,A., Whorton,E., Davis,E., Beathard,G., Crosby,W.M.,Kling,O.R., Williams,G.R., Price,W.E., Geyer,J.R., Padula,R. and Kimmelstiel,P. Diffuse diabetic glomerulosclerosis in pancreatectomized baboons. *Fed.Proc.*39:638, 1980.
46. Stout,C. Effect of turbulence on diffuse intimal thickening of primate thoracic aortas. Presented at the XIII Hugh Lofland Conference on Arterial Wall Metabolism, May 13-15, 1980, Albany, New York.
47. Stout,C. Diffuse intimal thickening (DIT) in aortas and coronary arteries of 2.5 year old miniature pigs. Presented at the XIV Hugh Lofland Conference on Arterial Wall Metabolism, May, 1981, Winston-Salem, North Carolina.
48. Stout,C. Diffuse intimal thickening in human aortas. Presented at 8th Annual Hugh Lofland Conference on Arterial Wall Metabolism. May 25-28, 1983, Welches, Oregon.
49. Stout,L. and Boor,P.J. Myointimal cell proliferation on mitral valve chordae. Presented at the 11th Annual Hugh Lofland Conference on Arterial Wall Metabolism, May 13-16, 1986, Bolton Landing, New York.
50. Stout,C. and Boor,P.J. Myofibroblastic proliferation on mitral valve chordae tendineae. A distinctive lesion associated with alcoholic liver disease. Presented at the 76th Annual Meeting of The International Academy of Pathology, March 9-13, 1987, Chicago, Illinois, *Lab Invest.*56:77A,1987.
51. Stout,L.Clarke, Folsch,Dean and McFadden,Norman. Renal glomerular changes in baboons with long-term poorly controlled pancreatectomy induced diabetes. Presented at the 77th Annual Meeting of the United States and Canadian Academy of Pathology, February 28-March 4, 1988, Washington,D.C.. *Lab Invest.* 58:88A, 1988.
52. Stout, L. Clarke and Whorton, Elbert B. Mesangiolytic and the pathogenesis of nodular diabetic glomerulosclerosis. Presented at the 78th Annual Meeting of the U.S. and Canadian Academy of Pathology, March 5-10, 1989, San Francisco. *Lab. Invest.* 60:92A, 1989.
53. Stout, L. Clarke. Parallels between atherosclerosis and diabetic nodular glomerulosclerosis. Presented at the XXII Annual Hugh Lofland Conference on Arterial Wall Metabolism, May 24-27, 1989, Welches, Oregon.
54. Stout, L. Clarke, Kumar, Shimareet and Whorton, Elbert B. Focal Mesangiolytic. Its morphology and evolution in diabetes. *J Am Soc Nephrol* 2:299, 1991. (Abstract published only, not presented)
55. Stout, L. Clarke, Kumar, Shimareet and Whorton, Elbert B. Insudative lesions. Their pathogenesis and association with glomerular obsolescence in diabetes. Presented at the 82nd Annual Meeting of the U.S. and Canadian Academy of Pathology, New Orleans, March 13-19, 1993. *Lab Invest* 68:119A, 1993.
56. Kim, J.S., Morettin, L.B., Chaljub, G., Phillipott, J., Hannigan, E.V., Stout, L.C. Clinical Stage I carcinoma of the uterine cervix: Comparative evaluation of preoperative and specimen MR imaging with histologic correlation. Exhibit presented at the Annual Meeting of the Radiologic Society of North America, Nov 28-Dec 4, 1995, Chicago, IL.
57. Stout, L. Clarke and Whorton, Elbert B. Increased insudative lesions in multiple exiting efferent capillaries in diabetic glomeruli. Presented at the 89th Annual Meeting of the U.S. and Canadian Academy of Pathology, New Orleans, March 25-31, 2000. *Lab Invest* 80: 178A, 2000.
58. Stout, LC and Wharton, EB. The pathogenesis of extra efferent vessel (EEV) development in diabetes. Presented at the 95th Annual Meeting of the USCAP, Atlanta, GA, Feb 11-17, 2006. *Mod Pathol* 19(Suppl 1): 265A, 2006.

59. Stout, LC, Lyon, RE and Whorton, EB. Anatomy of the glomerular diffuse lesion (DL) in diabetes. Platform presentation at the 96th Annual Meeting of the USCAP, San Diego, CA, Mar 24-30, 2007. Mod Pathol 20(Suppl 2): 275A, 2007.
60. Stout, L Clarke. Pathogenesis of Minimal to Mild Diabetic Glomerulopathy. Poster presentation at the 99th Annual Meeting of the USCAP, Washington, DC, Mar 20-26, 2010. Mod Pathol 23(suppl 1): 346A, 2010
61. Stout, L Clarke. Segmental Collapsing Capillary Tufts (SCCT) in Diabetic Glomeruli. Poster presentation at the 100th Annual Meeting of the USCAP, San Antonio, TX, Feb 26-Mar 4, 2011. Mod Pathol 24(suppl 1): 353A, 2011.
62. Stout, L Clarke. Anatomy of the [Non Kimmelstiel-Wilson Nodule (KWN)] Segmental Mesangial Expansion (SME) in Diabetic Glomeruli. Accepted for poster presentation at the 101st Annual Meeting of the USCAP, Vancouver, Canada, March 17-23, 2012



PUBLIC VERIFICATION / PHYSICIAN PROFILE

PHYSICIAN

NAME: DAVID HUGHES WALKER MD

DATE: 08/21/2013

**THE INFORMATION IN THIS BOX HAS BEEN VERIFIED
BY THE TEXAS MEDICAL BOARD**

Date of Birth: 1943

License Number: H5380 Full Medical License

Issuance Date: 02/24/1989

Expiration Date of Physician's Registration Permit: 11/30/2014

Registration Status: ACTIVE

Registration Date: 03/15/1989

Disciplinary Status: NONE

Disciplinary Date: NONE

Licensure Status: NONE

Licensure Date: NONE

Medical School of Graduation:

At the time of licensure, TMB verified the physician's graduation from medical school as follows:
VANDERBILT UNIV SCH OF MED, NASHVILLE

Medical School Graduation Year: 1969

TMB Filings, Actions and License Restrictions

The Texas Medical Board has the following board actions against this physician. (This may include any formal complaints filed by TMB, as well as petitions and/or responses related to licensure contested matters, at the State Office of Administrative Hearings.)

NONE

Investigations by TMB of Medical Malpractice

Section 164.201 of the Act requires that: the board review information relating to a physician against whom three or more malpractice claims have been reported within a five year period. Based on these reviews, the following investigations were conducted with the listed resolutions.

NONE

Status History

Status history contains entries for any updates to the individual's registration, licensure or disciplinary status types (beginning with 1/1/78, when the board's records were first automated). Entries are in reverse chronological order; new entries of each type supersede the previous entry of that same type. These records do not display status type. Should you have any questions, please contact our Customer Information Center at 512-305-7030 or verificic@tmb.state.tx.us

Status Code: AC**Effective Date:** 03/15/1989**Description:** ACTIVE**Status Code:** LI**Effective Date:** 02/24/1989**Description:** LICENSE ISSUED

THE INFORMATION IN THIS BOX WAS REPORTED BY THE LICENSEE AND
HAS NOT BEEN VERIFIED BY THE TEXAS MEDICAL BOARD

Gender: MALE***Ethnicity:** WHITE**Race:** WHITE

* We are in the process of transitioning from the current ethnic origin values to federal standards for race and Hispanic origin. The transition period will allow time for individuals to submit updated race and Hispanic origin data to the TMB.

Place of Birth: TENNESSEE**Current Primary Practice Address:**

301 UNIVERSITY BLVD

GALVESTON , TX 77555-0609

Years of Active Practice in the U.S. or Canada:

The physician reports that he/she has actively practiced medicine in the United States or Canada for **41** year(s).

Years of Active Practice in Texas:

The physician reports that, of the above years he/she has actively practiced in the State of Texas for **23** year(s).

Specialty Board Certification

The physician reports that he/she holds the following specialty certifications issued by a board that is a member of the American Board of Medical Specialties or the Bureau of Osteopathic Specialists:

Specialty Certification: AMERICAN BOARD OF PATHOLOGY**Date:** 1974

Primary Specialty

The physician reports his/her primary practice is in the area of PATHOLOGY.

Secondary Specialty

The physician did not report a secondary practice area.

Name, Location and Graduation Date of All Medical Schools Attended

Name: VANDERBILT UNIV SCHOOL OF MED

Location: NASHVILLE USA

Graduation Date: 1969

Graduate Medical Education In The United States Or Canada

Program Name: PGY 1

Location: BOSTON, MA

Begin Date: 1969

Type: INTERNSHIP

End Date: 1970

Specialty: PTH

Program Name: NONE

Location: BOSTON, MA

Begin Date: 1970

Type: RESIDENCY

End Date: 1973

Specialty: PTH

Hospital Privileges

The physician reports that he/she has hospital privileges in the following in the State of Texas:

Hospital: UNIV OF TX MEDICAL BRANCH HOSP

Location: GALVESTON

Utilization Review

The physician did not report whether he/she provides utilization review.

NONE REPORTED

Patient Services

Accessibility: The physician reports that the patient service area is accessible to persons with disabilities as defined by federal law.

Language Translation Services: The physician reports that the following language translation services are provided for patients: LANGUAGE ASSISTANT PROGRAM

Medicaid program.

Awards, Honors, Publications and Academic Appointments

Optional Information

The physician may optionally report descriptions of up to five such honors and has reported the following:

Description: DOCTEUR HONORIS CAUSA UIVERSITE DE LA MEDITERRANEE MARSEILLE FRANCE

Description: PROFESSOR & CHAIRMAN DEPT OF PATHOLOGY UNIV OF TX MEDICAL BRANCH

Description: GUERRANT RL WALKER DH WELLER PF (EDS): TROPICAL INFECTIOUS DISEASES

Description: DISTINGUISHED VANDERBILT MEDICAL SCHOOL ALUMNUS FOR 2012

Description: PRESIDENT-ELECT, ASTMH

Malpractice Information

Section 154.006(b)(16) of the Act requires that: a physician profile display a description of any medical malpractice claim against the physician, not including a description of any offers by the physician to settle the claim, for which the physician was found liable, a jury awarded monetary damages to the claimant, and the award has been determined to be final and not subject to further appeal. The physician has the following reportable claims.

Description: NONE

Criminal History

Self-Reported Criminal Offenses:The physician is required to report a description of (1) "any conviction for an offense constituting a felony, a Class A or Class B misdemeanor, or a Class C misdemeanor involving moral turpitude" and (2) "any charges reported to the board to which the physician has pleaded no contest, for which the physician is the subject of deferred adjudication or pretrial diversion, or in which sufficient facts of guilt were found and the matter was continued by a court of competent jurisdiction."

The physician has reported the following:

Description: NONE

Criminal history information is also obtained by TMB from the Texas Department of Public Safety. Resulting action, if any, will be reported under the

TMB Action and Non-Disciplinary Restrictions section above.

Disciplinary Actions By Other State Medical Boards

The physician has reported the following:

Description: NONE

Physician Assistant Supervision

To obtain primary source verifications, click name

Description: NONE

Advanced Practice Nurse Delegation

To obtain primary source verifications, click name

Description: NONE

Summary of all License/Permit Types

Issue Date:
02/24/1989

Type:
LICENSED PHYSICIAN

CURRICULUM VITAE

NAME: David Hughes Walker, MD

**PRESENT POSITION
AND ADDRESS:**

07/87-present
Professor and Chairman
The Carmage and Martha Walls Distinguished University Chair in
Tropical Diseases
Department of Pathology
Executive Director,
UTMB Center for Biodefense and Emerging Infectious Diseases
University of Texas Medical Branch
301 University Boulevard
Galveston, Texas 77555-0609
Office Telephone (409) 772-3989
Office Fax (409) 772-1850
Office E-mail dwalker@utmb.edu

BIOGRAPHICAL:

Date of Birth: 
Place of Birth: Nashville, Tennessee
Home Address: 
Citizenship: United States

EDUCATION:

09/1961-05/1965 History, B.A. (Valedictorian)
Davidson College
Davidson, North Carolina
09/1965-05/1969 Professional Curriculum, M.D.
Vanderbilt University, School of Medicine
Nashville, Tennessee
07/1969-06/1973 Pathology, Residency
Peter Bent Brigham Hospital
Boston, Massachusetts
07/1970-06/1971 Pathology, Junior Assistant Resident
Peter Bent Brigham Hospital
Boston, Massachusetts

01/1971-06/1971	Tropical Pathology, Research Gorgas Memorial Laboratory Panama City, Republic of Panama
07/1971-012/1971	Pathology, Chief Resident Peter Bent Brigham Hospital Boston, Massachusetts
07/1971-06/1973	Clinical Pathology, Senior Assistant Resident Peter Bent Brigham Hospital Boston, Massachusetts
07/1971-06/1972	Pathology, Research Fellow Harvard University, School of Medicine Boston, Massachusetts
07/1972-06/1973	Pathology, Clinical Fellow Harvard University, School of Medicine Boston, Massachusetts

BOARD CERTIFICATION:

07/1974	American Board of Pathology Anatomic and Clinical Pathology
07/1970	National Board of Medical Examiners, Diplomate Certificate #106912

LICENSURE INFORMATION:

10/1989	State of Texas, License # H5380 Expires November 2012
---------	--

PROFESSIONAL AND TEACHING EXPERIENCE:

06/2002 - present	Director, UTMB Center for Biodefense and Emerging Infectious Disease University of Texas Medical Branch Galveston, Texas
1994 – 12/2010	Director, WHO Collaborating Center for Tropical Diseases University of Texas Medical Branch Galveston, Texas
1992 - 1994	Acting Director, Hematopathology Department of Pathology University of Texas Medical Branch Galveston, Texas
1992 - 1993	Acting Director, Clinical Chemistry Department of Pathology University of Texas Medical Branch Galveston, Texas

- 01/1991 - present Member, Graduate School of Biomedical Sciences
University of Texas Medical Branch
Galveston, Texas
- 1989 - 1991 Director, Pathology Residency Program
Department of Pathology
University of Texas Medical Branch
Galveston, Texas
- 1989 - 1990 Surgical Pathology Attending
Department of Pathology
University of Texas Medical Branch
Galveston, Texas
- 09/1987 - present Autopsy Attending Pathologist
Department of Pathology
University of Texas Medical Branch
Galveston, Texas
- 9/11/1987 - present Professor and Chairman
Department of Pathology
University of Texas Medical Branch
Galveston, Texas
- 9/1/1986 – 8/31/1987 Professor
Department of Pathology
University of North Carolina
Chapel Hill, North Carolina
- 9/1/1980 – 8/31/1986 Associate Professor
Department of Pathology
University of North Carolina
Chapel Hill, North Carolina
- 7/1/1975 – 8/31/1980 Assistant Professor
Department of Pathology
University of North Carolina
Chapel Hill, North Carolina
- 1/1/1974 – 6/30/1975 Clinical Assistant Professor
Emory University, School of Medicine
Atlanta, Georgia
- 7/1/1973 – 12/31/1975 Surgeon (USPHS)
Virology Division, Centers for Disease Control
Atlanta, Georgia

RESEARCH ACTIVITIES:

Current Grant Support:

RO1 AI 21242-25 National Institute of Allergy and Infectious Diseases
"Spotted Fever Rickettsial Antigens"
PI; 15% effort; \$373,714 (current year total costs)
07-01-84 to present

1 U54 A1057156-08 National Institutes of Health
"Western Regional Center of Excellence for Biodefense and Emerging Infectious Diseases
Research"
PI; 10% effort; \$8,465,412 (year 8 total costs)
09-04-03 to present

Clayton Foundation for Research
"Vaccines and Diagnostics for the Ehrlichioses"
PI: Jere McBride; \$200,000 (current year)
01-01-97 to present

HHSN2722010000401 Task Order HHSN27200001 National Institutes of Health
"Development of a Mouse Model of Scrub Typhus"
PI: Donald Bouyer, 5% effort, \$1,530,868 (total costs)
09-13-10 to 09-12-14

1 R25 TW008009-01 National Institutes of Health
"Galveston Global Health Consortium"
PI: A. Clinton White, \$135,000
09-10-08 to 08-31-12

1 U01 AI078213-01 National Institutes of Health
"Multiplex Serodiagnostic Protein Microarray"
PI: Philip Felgner, \$90,600
08-01-08 to 07-31-2013

Past Grant Support:

1 UO1 A1071283-02 National Institutes of Health
"Vaccine for Epidemic Typhus"
PI: Xue-Jie Yu; 15% effort; \$417,394 (current year)
09-30-06 to 08-31-11

RO1 AI 31431-18 National Institutes of Health
"*Ehrlichia chaffeensis* Surface Proteins"
PI; 11.25% effort; \$351,137 (total costs)
09-30-91 to 04-30-11

AI 30065-01 National Institutes of Health and National Institutes of Allergy and Infectious
Diseases
"Small Animal Model Development and Proof-of-Concept Testing of Therapeutics and Vaccines
in Small Animal Models of *Burkholderia* and *Rickettsial* Diseases"
Consultant; PIs: J.W. Peterson, N. Bourne; 2.5% effort; \$2,094,643 (current year)
09-30-06 to 07-31-10

D43 TW006590-04 National Institutes of Health
“Tropical Vector-borne Viral and Rickettsial Infections”
PI; 5% effort; \$133,950 (total costs)
07-01-03 to 03-31-10

1 S10 RR022450-01 National Institutes of Health
“Gammacell-220 Excel Refurbished Research Irradiator
PI; \$354,795 (total direct costs)
04-01-06 to 09-23-07

DAMD 170210198 U.S. Army
“Molecular Pathogenesis of Rickettsioses and Development of Novel Anti-rickettsial Treatment by
Combinatorial Peptide-based Libraries”
PI; 5% effort; \$232,131
02-01-02 to 01-31-06

DARPA
“Generating Advanced Diagnostics and Countermeasures for Individuals Most Vulnerable to
Biothreats”
PI: E. Wang (Co-PI: David H. Walker); \$134,879 (total direct costs)
04-02-03 to 03-31-04

1 D43 TW00903 Fogarty International Research Award
“Emerging and Re-Emerging Rickettsioses in Latin America”
PI; \$118,288
09-01-97 to 08-31-03

Centers for Disease Control and Prevention
“Texas-Mexico Border Infectious Disease Monitoring Program”
PI: R. B. Tesh; \$339,316 (total costs)
08-01-01 to 07-31-02

UO1 AI 49940 National Institute of Allergy and Infectious Diseases
“Complete Genome Sequence of *Rickettsia typhi*”
PI; \$276,294
8/15/00 – 07/31/02

R01 AI31431 National Institutes of Health Minority Supplement
“*Ehrlichia chaffeensis* Surface Proteins”
PI; \$ 64,232.00
05-01-98 to 04-30-01

HR8/CCH613372 National Center for Infectious Diseases
“Epidemiology of Human Monocytic Ehrlichiosis”
PI; \$202,484
09/10/96 – 09/30/00

3 AI31431 National Institute of Allergy and Infectious Diseases Supplement
“Production and Sharing of Ehrlichial Research Reagents”
PI: \$121,989.
09/01/97 - 08/31/98

TW31431-05A1 Fogarty International Research Award
"Identification of the Etiology of an Emerging SFG Rickettsiosis in the Yucatan"
PI: \$49,849
10/01/96 - 09/30/97

John Sealy Memorial Endowment Fund - Bridging Grant
"*Ehrlichia chaffeensis*"
PI; \$15,000
02/01/96 - 05/01/96

TW00384-01 Fogarty International Research Award
"SFG Rickettsial Pathogenicity: Ticks, Mammals, and Cells"
PI (in collaboration with Irina V. Tarasevich, Ph.D., Gamaleya Institute of Microbiology and
Epidemiology, Moscow, Russia); \$20,000
09/30/93 - 09/29/94

The Rockefeller Foundation
"Pathogenesis of Dengue Hemorrhagic Fever"
PI; \$33,034
05/01/90 - 05/01/91

John Sealy Memorial Endowment Fund - Bridging grant
"Antigens and DNA of East Asian SFG Rickettsiae"
PI: \$15,000
04/01/89 - 03/31/90

John Sealy Memorial Endowment Fund
"*Ehrlichia* species: The Etiology of an Important New Human Rickettsiosis"
PI; \$60,000
12/01/88 - 11/30/91

AI 22224 National Institutes of Health
"Antigens and DNA of East Asian SFG Rickettsiae"
PI; \$264,141
04/01/85 - 03/31/88

DAMD 17-83-C-3211 U.S. Army Medical Research and Development Command
"Pathogenesis of Cell Injury by *Rickettsia conorii*"
PI; \$235,971
04/01/83 - 03/31/86

Centers for Disease Control
Contract to furnish appropriate tissue processing, professional pathology services to examine
slides for Lassa fever, and to prepare and examine selected tissue by electron microscopy.
\$8,000
04/01/81 - 09/30/83

Centers for Disease Control
Contract to provide professional pathologist services to examine pathological slides of human and
experimental monkey material for Lassa fever.
PI; \$6,500
02/01/80 - 10/31/80

RO1-AI-16203 National Institutes of Health
"Pathogenesis of Cell Injury in Spotted Fever"
PI; \$120,545
09/01/79 - 08/31/82

RO1-AI-92613 National Institutes of Health
"Rocky Mountain Spotted Fever Vaccine in an Animal Model"
PI; \$332,265
06/30/79 - 06/20/82

COMMITTEE RESPONSIBILITIES:

International:

2009-present Global Risk Network
2008-2009 World Economic Forum's Global Agenda Council on Pandemics

National:

2012 President-elect, American Society of Tropical Medicine and Hygiene
2010 Member, National Science Advisory Board for Biosecurity (NSABB) Dual Use Research Oversight Roundtable
2009-present Member, Viral and Rickettsial Diseases Panel, Military Infectious Diseases Research Program (MIDRP)
2009-present Member, Advisory Board, Accacia International, Inc.
2009-present Member, Target Selection Board, NIAID Structural Genomics Centers for Infectious Diseases
2009-2015 Member, Vector Biology Study Section, Center for Scientific Review, NIH
2008-present Scientific Working Group, Seattle Structural Genomics Center for Infectious Disease
2007-present National Center for Foreign Animal and Zoonotic Disease Defense (FAZD Center)
2007-2010 External Advisory Committee, National Research Council Standing Committee on Biodefense for the U.S. Department of Defense
2006-present Defense Health Board
2006 Armed Forces Epidemiological Board
2005-2009 Member, Scientific Steering and Review Committee Rocky Mountain Regional Center of Excellence
2003-present National Biodefense Network

- 1997-2000 Eli Lilly and Company Research Award Selection Committee of the American Society for Microbiology
Member
- 1996-2005 Scientific Advisory Board for the Armed Forces Institute of Pathology
Member
- 1994-1998 American Board of Pathology
Member, Test Committee for Immunopathology
- 1991 Institute of Medicine, Task Force on Microbial Threats to Health (Bacteria, Rickettsiae, and Chlamydia)
Consultant
- 1991-1994 American Association of Pathologists
Member, Publications Committee

UTMB:

- 2011-present Member, Faculty Group Practice Clinical Operations Committee
- 2011-present Member, Physician and Provider Recruiting and Retention Committee
- 2011-present Member, Internal Advisory Committee, Sealy Center on Aging
- 2011-present Member, Sealy Center for Molecular Medicine Internal Advisory Council
- 2010-2011 Member, Medical Service, Research and Development Plan Board of Directors
- 2010-2011 Member, Medical Service, Research and Development Plan Budget and Finance Committee
- 2009-present Member, Advisory Board, Center for Population Health and Health Disparities
- 2009-present Member, Internal Advisory Committee, UTMB Cancer Center
- 2009-present Chair, Tumor Bank Advisory Board
- 2009-present University Core Development Committee
- 2008-present UTMB Health System Advisory Board
- 2008-2009 Department of Pharmacology and Toxicology
Director Search Committee, Chair
- 2008-present M.D.-Ph.D. Program Advisory Committee
- 2008-present Research Executive Committee
- 2005-present Biocontainment, Risk, and Safety Committee
- 2004-present Advisory Board for the World Health Organization Collaborating Center for Nursing and Midwifery Development in Primary Health Care

2004-present	Sealy Center for Molecular Science Advisory Board
2003	Executive Committee for the National Biocontainment Laboratory
2003	Anatomy and Neurosciences Chair Search Committee
2001	Senior Associate Dean for Faculty Practice Search Committee
1997	Biosafety Level-4 Committee
1996-present	Graduate School of Biomedical Sciences Dean's Advisory Council
1995-2000	Steering Committee, Sealy Center for Molecular Cardiology
1994-1997	Academic Technology Committee
1995-1996	Academic Technology Committee Chairman
1996-1997	Academic Technology Committee Co-Chairman
1994-1998 1989-1992	MSRDP Executive Committee
1994-1995	Search Committee for Chair of Department of Surgery
1994-1997	Search Committee for Chair of Department of Microbiology and Immunology Chairman
1994-1995	Search Committee for Director of Centennial Center for Environmental Toxicology
1992-1994	Space Advisory Committee
1991-1994	John Sealy Memorial Endowment Fund Committee Representative of the Clinical Sciences
1990-1991	Chairmen's Caucus Chairman
1989-1990	UTMB Hospitals Laboratory Services Task Force Chairman
1989-1994	Trauma Center Advisory Committee
1989-1990	Chairmen's Caucus Secretary
1988-1998	Immunology Task Force
1988-1989	Acquired Immune Deficiency Syndrome Task Force
1988-1997	Editorial Advisory Board, Biomedical Inquiry

- 1988-1990 Steering Committee, 1991-1997 UTMB Strategic Plan
- 1988 Graduate School Curriculum and Program Review
- 1987-present MSRDP Board of Directors
- 1987-present Executive Committee of the Medical Staff
- 1987-present Executive Committee of the Faculty of Medicine
- 1987-1999 Chairmen's Caucus

Departmental:

- 1996-present Residency Advisory Committee, ex-officio
- 1994-present Pathology Graduate Program:
Student Evaluation and Advisory Committee, ex-officio
Curriculum and Academic Planning Committee, ex-officio
Admissions and Recruitment Committee, ex-officio
- 1994-1999 Medical School Pathology Course Committee
- 1994-1995 Center for Tropical Diseases Search Committee, Chairman
- 1988-1993 Laboratory Information System Advisory Committee
- 1987-present Appointment, Promotion, and Tenure Committee

Other:

- 2005 External Peer Review Panel of the Viral and Rickettsial Zoonoses Branch (VRZB)
Centers for Disease Control and Prevention
Atlanta, Georgia
- 1996 Chair of Review Team
External Review of Special Pathogens Branch
Centers for Disease Control and Prevention
Atlanta, Georgia
- 1992 Consultant, Rickettsiology Group
Ben Gurion University of the Negev
Beer Sheva, Israel
- 1991 NIAID's Middle East Regional Cooperation in Epidemiology and Control of Vector Borne Diseases Project
Primary Reviewer of the Rickettsiology Module
Cairo, Egypt and Jerusalem and Beer Sheva, Israel
- 1989 Site Visit - Review of the Pathology Branch, Division of Host Factors, Centers for Infectious Diseases Centers for Disease Control, Atlanta, Georgia

1988-present Houston Society of Clinical Pathologists
Harlan J. Spjut Award Committee

TEACHING RESPONSIBILITIES:

University of Texas Medical Branch-Galveston:

School of Medicine:

Pathobiology and Host Defenses Lecturer – Congestion and Edema; Thrombosis and Embolism

1991-1995 Microbiology Course Lecturer - Rickettsiae

1987-1995 Pathology Course Lecturer - Pathology of Infectious Diseases

Graduate School:

Microbiology and Immunology Course Lecturer – Pathogenic Bacteriology 6315

Pathology Course Lecturer – Microorganisms and Infectious Diseases 6205

2002- Pathology Course Lecturer – Biothreat Agents and Biodefense

1994- Pathology Course Lecturer - Colloquium of Frontiers of Infectious Disease and Tropical Medicine

1994- Pathology Course Lecturer - Pathogenesis of Infectious Diseases

1992- Pathology Course Lecturer - Fundamentals of Pathology

1988-1991 Pathology Course Lecturer and Co-Course Director - Fundamentals of Pathology

1987- Microbiology Course Lecturer - Pathology Introduction to Research Rickettsiology

Post-doctoral fellows (20):

2009- Lucas Blanton, M.D.

2009- Tais Saito, D.V.M., Ph.D. (Fogarty Training Grant Fellowship)

2007-2008 Adriano Pinter dos Santos, D.V.M., Ph.D. (Fogarty Training Grant Fellowship)

2005- Nagaraja Thirumalapura, D.V.M., MS, Ph.D.

2005-2009 Rong Fang, M.D., Ph.D.

2003-2005 Jorge E. Zavala-Castro, Ph.D. (Fogarty Training Grant Fellowship)

2002-2003 Marcelo Labruna, D.V.M., Ph.D. (Fogarty Training Grant Fellowship)

2000-2002 Virginia Alcantara, M.D. (Fogarty Training Grant Fellowship)

1998-2000 Cecilia Moron, M.D. (Fogarty Training Grant Fellowship)

1998-1999	Juan P. Olano, M.D.
1998-2001	Donald H. Bouyer, Ph.D.
1997-1999	Jere W. McBride, Ph.D.
1996-1998	John Stenos, Ph.D.
1993-1996	Xue-Jie Yu, M.D., Ph.D.
1992-1993	Suzana Radulovic, M.D., Ph.D. (McLaughlin Fellowship)
1992-1995	Sheng-Min Chen, M.D.
1990-1991	Robert Speed, Ph.D.
1990-1991	Philippe Brouqui, M.D.
1989-1992	J. Stephen Dumler, M.D.
1989-1990	Jose I. Herrero-Herrero, M.D., Ph.D. (Fulbright Fellowship)
1987-1990	Kenneth L. Gage, Ph.D. (McLaughlin Fellowship)
1987-1988	Xue-Jie Yu, M.D.

Ph.D. degree students (Primary advisor for 9 students at UTMB):

2011-	Guang Xu
2008-2011	Jeeba Kuriakose (Committee Member for Ph.D.)
2007-	Thomas Shelite (Primary Advisor for Ph.D.)
2006-	Emily Crossley (Primary Advisor for Ph.D.)
2005-2007	Michael E. Woods (Committee Member for Ph.D.)
2004-2006	Jason Comer (Committee Member for Ph.D.)
2002-2006	Kim Nethery (Co-Advisor for M.S.)
2002-2007	Jeffrey Jordan (Primary Advisor for M.D.-Ph.D.)
2002-2007	Heather Stevenson (Primary Advisor for M.D.-Ph.D.)
2001-2009	Ted Whitworth (Primary Advisor for Ph.D.)
2001-2007	Michele Zacks (Committee Member for Ph.D.)
2000-2006	S. Wesley Long (Co-advisor for M.D.-Ph.D.)
1997-2003	Gustavo Valbuena (Primary Advisor for Ph.D.)
1997-2001	C. Marcela Diaz (Primary Advisor for Ph.D.)

1998-1999	Jian-Ying Chen (Committee Member for Ph.D.)
1996-1998	Chessley Atchison (Committee Member for Ph.D.)
1996-2000	Jason Huang (Committee Member for Ph.D.)
1995-1998	Adrian N. Billings (Primary Advisor for Ph.D.)
1995-1999	Shannon Langford (Committee Member for Ph.D.)
1995	Bi-Hung Peng (Committee Member for M.S.)
1987-1994	Han Li (Primary Advisor for Ph.D.)

Master's degree students:

2007	Edgar Rodriguez
------	-----------------

Visiting Scientists:

2011	Eunmi Kim, Ph.D.
2010, 2011	Natacha Milhano (Instituto Nacional de Saude Dr. Ricardo Jorge)
2008-2009	Karla Andrade de Oliveira (Universidade Federal de Vicosa, Brazil)
2008	Kome Ndelle (University of Buea)
2006-2007	Marie Ebob Bissong Nee Agbortabot (University of Buea)
2005-2006	Eric Fokam (University of Buea)
2003-2004 2005-2007	Aaron Medina (Ph.D. Student, Universidad Autonoma de Nuevo Leon)
2001, 2005	Lucy Ndip (Ph.D. student, University of Buea)
2001, 2004 2010	Claudio L. Mafra de Siqueira, D.V.M., Ph.D.
2000	Riva Oliveira, Ph.D.
1999-2000 2006	Carlos Perez-Osorio
1998-2000	Marcio Galvao, M.D.
1998	Elizabeth Anaya
1996-1997	Jose Alfredo Ruiz-Sosa
1994	Jorge E. Zavala-Velazquez, M.D.
1994	Bi Hu Lin, M.D.

1993	Lev M. Grinberg, M.D.
1993	Irina Tarasevich, Ph.D.
1992-1993	Jamal Saada, M.S.
1992-1993	Vsevolod L. Popov, Ph.D.
1989-1991	Tsuneo Uchiyama, M.D.
1988-1989	Hui-Min Feng, M.D.
1988-1989	Qing-Huai Liu, M.D.
1987-1988	Takahiro Uchida, M.D.

Medical Students:

2006	Ziad Peerwanii (Research Co-preceptor)
1998-1999	Damon Black (Clinical Advisor)
1995-1996	Allison Loudermilk (Clinical Advisor)
1995-1996	Paul Bannister (Clinical Advisor)
1995-1996	Stephen Ladner (Clinical Advisor)
1994-1996	Trae Mattison (Clinical Advisor)
1993-1995	Mark J. Florian (Clinical Advisor)
1992-1994	Tim Haselmen (Clinical Advisor)
1992-1994	Ran H. Bang (Clinical Advisor)
1992-1994	William Perkison (Clinical Advisor)
1992-1993	Theresa Martin (Clinical Advisor)
1992-1993	Wendy Jones (Clinical Advisor)
1992	Gregg Leonard (Clinical Advisor)
1991	Ran H. Bang (Research Preceptor) NIH Medical Student Research Training Program - Summer
1990	Glen Hurlston (Research Preceptor) NIH Medical Student Research Training Program - Summer
1990	Michael Holland (Clinical Advisor)
1989-1991	Virginia San Miguel (Clinical Advisor)

- 1989 George Smith (Research Preceptor)
 NIH Medical Student Research Training Program - Summer
- 1988 Natalie Marshall (Research Preceptor)
 NIH Medical Student Research Training Program - Summer

Faculdade de Ciencias Medicas da Universidade Nova de Lisboa

Graduate Student:

2003–2008 Rita de Sousa

The Open University, Oxford, United Kingdom

Dissertation Exmination Committee, Member

2010 Daniel H. Paris

Murdoch University, Geelong, Victoria, Australia

Ph.D. Examiner

2011 Yazid Abdad

University of North Carolina:

Teaching:

1975-1987 Lecturer - Pathology and Microbiology Medical School Courses

Post-doctoral fellows:

1986 Jose I. Herrero-Herrero, M.D., Ph.D.

1985-1986 Jia Gang Wang, M.D.

1985-1986 Han Li, M.D.

Ph.D. degree students:

1985-1993 Kimberly Weiss (Primary Advisor for Ph.D.)

1979-1983 James V. Lange (Primary Advisor for Ph.D.)

Master's degree students:

1984-1987 Otis Speight (Primary Advisor for M.S.)

Visiting scientists:

1986-1987 Ming-Yuan Fan, M.D.

1985 Giuseppe Tringali, M.D.

1984 Hui-Min Feng, M.D.

1982-1983 Mario Montenegro, M.D.

1976 Yair Akov, Ph.D.

MEMBERSHIPS IN SCIENTIFIC SOCIETIES/PROFESSIONAL ORGANIZATIONS (* denotes elected membership):

2008- The American Association of Immunologists

2002-2009 American Clinical and Climatological Association*

1996- Texas Society of Pathologists
Member, Liaison Committee to Texas Department of Health

1991- Texas Branch, American Society for Microbiology

1991- Chauncey Leake History of Medicine Society
1989- Texas Society of Pathologists, Inc.*

1989- American Society of Clinical Pathologists, Inc.*

1988- American Association for the Advancement of Science

1988- Association of Pathology Chairs

1988- Houston Society of Clinical Pathologists

1988- Galveston County Medical Society*

1988- Texas Medical Association (H5380)*

1988- College of American Pathologists*
Fellow

1988- Binford-Dammin Society of Infectious Disease Pathologists
President-elect, 1988-89; President, 1989-90; Secretary-Treasurer, 1995-2001

1987- Sigma Xi, The Scientific Research Society

1984 American Society of Tropical Medicine and Hygiene
Nominating Committee, 1996-1998, Chair 1998

1981- Infectious Diseases Society of America
Fellow*

1979- American Society of Rickettsiology
Vice President, 1988-89; President, 1989-91

1978-1996 Society for Pediatric Pathology

1977- American Society for Investigative Pathology

1975- United States-Canadian Division of the International Academy of Pathology
Council Member 1996-2000

1975 American Society for Microbiology

HONORS:

2012 Who's Who in Academia
2012 Who's Who in America
2011 Leading Scientists of the World
2011 Texas Super Doctors
2011 America's Top Doctors
2010 Who's Who for Executives and Professionals
2010 John J. Andujar Citation of Merit
Texas Society of Pathologists
2010 Who's Who in America
2010 America's Top Doctors
2009-2012 Best Doctors in America
2009-2012 Who's Who in Medicine and Healthcare
2009 America's Top Doctors
2008-2009 Presidential Who's Who
2008 America's Top Doctors
2008 The Global Directory of Who's Who
2007-2008 Best Doctors in America
2007 America's Top Pathologists
2007 America's Top Doctors
2007 Who's Who among American Teachers & Educators
2007 Distinguished Faculty Research Award
Graduate School of Biomedical Sciences
University of Texas Medical Branch
Galveston, Texas
2006 America's Top Doctors
2006 Harlan J. Spjut Award
Houston Society of Clinical Pathologists
2005 America's Top Doctors

- 2004 America's Top Doctors
- 2003 America's Top Doctors
- 2002 America's Top Doctors
- 2002 Alpha Omega Alpha
- 2001 America's Top Doctors
- 1997 Mustard Seed Award in Research
Sealy Society
University of Texas Medical Branch
Galveston, Texas
- 1996 Docteur Honoris Causa
Universite de la Mediterranee
Marseille, France
- 1991-1995 Designated Technical Advisor, Epidemiology and Etiology of Spotted Fever
Rickettsiosis in Inner Mongolia Project
Inner Mongolia Anti-epidemic Station
The People's Republic of China
- 1990-1992 Designated Visiting Professor
Department of Microbiology
Sun Yat-sen University of Medical Sciences
Gangzhou, The People's Republic of China
- 1981-present Infectious Diseases Society of America
Fellow
- 1965 - 1969 Justin Potter Merit Scholarship
Vanderbilt University, School of Medicine
Nashville, Tennessee
- 1963 Phi Beta Kappa

ADDITIONAL INFORMATION:

Editorial Board:

- 2011-present *Encyclopedia of Pathology and Human Disease*
- 2009-present *PLoS Neglected Tropical Diseases*
Associate Editor
- 2005-present *Archives of Pathology and Laboratory Medicine*,
Executive Advisory Board
- 2002-present *The American Journal of Tropical Medicine and Hygiene*
- 2000-present *Vector Borne and Zoonotic Diseases*
- 1996-2002 *Clinical & Diagnostic Laboratory Immunology*

1998-present *Emerging Infectious Diseases*
2003-present Associate Editor

1995-2000 *Infection and Immunity*

1981-1987 Year Book of Pathology and Clinical Pathology
Year Book Medical Publishers, Inc.

1995-Present *Modern Pathology*

1995-2000 Pathology Case Reviews
Lippincott-Raven Publishers

Journal Reviewer for:

International Journal of Systematic and Evolutionary Microbiology

2004- *Transactions of the Royal Society of Tropical Medicine and Hygiene*

1997- *Emerging Infectious Diseases*

1995- *The Western Journal of Medicine*

1995- *Modern Pathology*

1994 *Archives of Dermatology*

1994 *Laboratory Investigation*

1994 *Vaccine*

1993- *American Journal of Pathology*

1993- *Clinical & Diagnostic Laboratory Immunology*

1993 *Journal of Travel Medicine*

1993- *Gene*

1993 *Antimicrobial Agents & Chemotherapy*

1993- *New England Journal of Medicine*

1993- *International Journal of Systematic Bacteriology*

1993 *Journal of Investigative Dermatology*

1993 *Immunology & Infectious Diseases*

1993 *Archives of Virology*

1990- *Journal of Clinical Microbiology*

1990- *Archives of Pathology and Laboratory Medicine*

- 1990- *American Journal of Tropical Medicine and Hygiene*
- 1989 *Journal of Medical Entomology*
- 1989 *Proceedings of the National Academy of Sciences*
- 1988- *Infection and Immunity*
- 1988- *Archives of Internal Medicine*
- 1988- *Laboratory Medicine*
- 1988 *Chest*
- 1987- *The Journal of Infectious Diseases*
- 1987- *Clinical Infectious Diseases*

Grant Reviewer for:

- 2011 Vector Biology Study Section, National Institutes of Health
- 2010 Vector Biology Study Section, IRG/SRG, National Institutes of Health
- 2010-2012 Military Infectious Disease Research Program (NIDRP), American Institute of Biological Sciences
- 2008 Chair, NIH *ad hoc* Study Section, Bacterial Pathogens and Host Responses
- 2007 Missouri Life Science Research Board
- 2007 *ad hoc* Member, NIH Study Section, BACP Study Section
- 1999 *ad hoc* Member, Fogarty International Center
- 1994 & 1998 *ad hoc* Member, NIH Study Section, Bacteriology and Mycology
- 1993 & 1994 Chairman, *ad hoc* NIH Study Section, Tropical Medicine and Parasitology
- 1993- International Science Foundation, Gerson S. Sher, Chief Operating Officer
- 1993 Chairman, *ad hoc* NIH Study Section, Tropical Medicine and Parasitology
- 1988- UTMB Small Grants Proposals
- 1988-1991 John Sealy Memorial Endowment Fund, Internal Reviewer
- 1987- Shriners Burns Institute Research Advisory Committee

PATENTS:

- 11/10 Patent No. 7,824,692
"Ehrlichia Disulfide Bond Formation (Dsb) Proteins and Uses Thereof"
Inventors: Jere W. McBride and David H. Walker
- 07/10 Patent No. 7,754,224
"P153 and P156 Antigens for the Immunodiagnosis of Canine and Human Ehrlichioses"
Inventory: Jere W. McBride and David H. Walker
- 05/10 Patent No. 7,722,880
"An Immunoreactive Ferric Binding Protein of *Ehrlichia canis* and Uses Thereof"
Inventors: Jere W. McBride, David H. Walker, and C. Kuyler Doyle
- 10/08 Patent No. 7,432,081
"Ehrlichia Disulfide Bond Formation (Dsb) Proteins and Uses Thereof"
Inventors: Jere W. McBride and David H. Walker
- 03/08 Patent No. 7,344,719
"Homologous 28-kDa Immunodominant Protein Genes of *Ehrlichia canis* and Uses Thereof"
Inventory: David H. Walker, Xue-jie Yu, and Jere W. McBride
- 12/07 Patent No. 7,309,583
"Homologous 28-kDa Immunodominant Protein Genes of *Ehrlichia canis* and Uses Thereof"
Inventors: David H. Walker, Xue-Jie Yu, and Jere W. McBride
- 04/17/07 Patent No. 7,204,992
"P153 and P156 Antigens for the Immunodiagnosis of Canine and Human Ehrlichioses and Uses Thereof"
Inventors: Jere W. McBride, David H. Walker
- 11/24/05 Patent No. 2005/0260621 A1
"Immunoreactive 38-KDA Ferric Binding Protein of *Ehrlichia canis* and Uses Thereof"
Inventors: Jere W. McBride, David H. Walker, Christopher K. Doyle
- 10/19/2004 Patent No. 6,806,065
"*Rickettsia felis* Outer Membrane Protein"
Inventors: David H. Walker, M.D., Donald H. Bouyer, Ph.D., Patricia Crocquet-Valdes, and John Stenos, M.D.
- 12/01/2003 Patent No. 6,660,269
"Homologous 28-kDa Immunodominant Protein Genes of *Ehrlichia canis* and Uses Thereof"
Inventors: David H. Walker, M.D., Xue-Jie Yu, Ph.D., Jere W. McBride, Ph.D.
- 10/01/2002 Patent No. 6,458,942
"28-kDa Immunoreactive Protein Gene of *Ehrlichia canis* and Uses Thereof"
Inventors: David H. Walker, M.D., Jere W. McBride, Ph.D., and Xue-Jie Yu, M.D., Ph.D.

- 03/12/2002 Patent No. 6,355,777
"P43 Antigen for the Immunodiagnosis of Canine Ehrlichiosis and Uses Thereof"
Inventors: David H. Walker, M.D., Jere W. McBride, Ph.D.
- 02/07/2002 Patent No. 6,403,780
"Homologous 28-Kilodalton Immunodominant Protein Genes of *Ehrlichia canis*
and Uses Thereof"
Inventors: David H. Walker, M.D., Jere W. McBride, Ph.D., and Xue-Jie Yu, M.D.,
Ph.D.
- 02/07/2002 Patent No. 6,392,023
"28-kDa Immunoreactive Protein Gene of *Ehrlichia canis* and Uses Thereof"
Inventors: David H. Walker, M.D., Jere McBride, Ph.D., and Xue-Jie Yu, M.D.,
Ph.D.
- 03/28/2000 Patent No. 6,043,085
"*Ehrlichia canis* 120-kDa Immunodominant Antigenic Protein and Gene"
Inventors: David H. Walker, M.D. and Xue-Jie Yu, M.D., Ph.D.
- 01/18/2000 Patent No. 6,015,691
"Immunodominant 120 kDa Surface-Exposed Adhesion Protein Genes of
Ehrlichia chaffeensis"
Inventors: David H. Walker, M.D. and Xue-Jie Yu, M.D., Ph.D.

PUBLISHED PRIMARY ARTICLES IN PEER-REVIEWED JOURNALS:

1. Knight SC, WALKER DH, Ling NR. 1971. Factors affecting the activation of rabbit peripheral, spleen, thymus and bone marrow cells by homologous lymphoid cells and heterologous erythrocytes. *Cytobios* 3:65-76.
2. WALKER DH, Gill TJ III, Corson JM. 1971. Leiomyosarcoma in a renal allograft recipient treated with immunosuppressive drugs. *JAMA* 215:2084-2086.
3. Edgcomb JH, WALKER DH, Johnson CM. 1973. Pathological features of *Trypanosoma cruzi* infections of *Rattus rattus*. *Arch Pathol* 96:36-38.
4. WALKER DH, Murphy FA, Whitfield SG, Bauer SP. 1975. Lymphocytic choriomeningitis: ultrastructural pathology. *Exp Mol Pathol* 23:245-265.
5. WALKER DH, Wulff H, Murphy FA. 1975. Experimental Lassa virus infection in the squirrel monkey. *Am J Pathol* 80:261-272.
6. WALKER DH, Wulff H, Lange JV, Murphy FA. 1975. Comparative pathology of Lassa virus infection in monkeys, guinea pigs, and *Mastomys natalensis*. *Bull World Health Organ* 52:523-535.
7. Winn WC Jr, WALKER DH. 1975. The pathology of human Lassa fever. *Bull World Health Organ* 52:535-545.
8. Edgcomb JH, WALKER DH, Johnson CM. 1976. *Klossiella* in the opossum. *Vet Pathol* 13:315-318.

9. Murphy FA, Winn WC Jr, WALKER DH, Flemister MR, Whitfield SG. 1976. Early lymphoreticular viral tropism and antigen persistence. Tamiami virus infection in the cotton rat. *Lab Invest* 34:125-140.
10. WALKER DH, Harrison A, Murphy K, Flemister M, Murphy FA. 1976. Lymphoreticular and myeloid pathogenesis of Venezuelan equine encephalitis in hamsters. *Am J Pathol* 84:351-370.
11. Camenga DL, WALKER DH, Murphy FA. 1977. Anticonvulsant prolongation of survival in adult murine Lymphocytic choriomeningitis. I. Drug treatment and virologic studies. *J Neuropath Exp Neurol* 36:9-20.
12. WALKER DH, Camenga DL, Whitfield S, Murphy FA. 1977. Anticonvulsant prolongation of survival in adult murine lymphocytic choriomeningitis. II. Ultrastructural observations of pathogenetic events. *J Neuropath Exp Neurol* 36:21-40.
13. WALKER DH, Harrison A, Henderson F, Murphy FA. 1977. Identification of *Rickettsia rickettsii* in a guinea pig model by immunofluorescent and electron microscopic techniques. *Am J Pathol* 86:343-358.
14. Green WR, WALKER DH, Cain BG. 1978. Fatal viscerotropic Rocky Mountain spotted fever: report of a case diagnosed by immunofluorescence. *Am J Med* 64:523-528.
15. WALKER DH, Adamec T, Krigman M. 1978. Disseminated petriellidosis (allescheriosis). *Arch Pathol Lab Med* 102:158-160.
16. WALKER DH, Henderson FW. 1978. Effect of immunosuppression on *Rickettsia rickettsii* infection in guinea pigs. *Infect Immun* 20:221-227.
17. WALKER DH, Cain BG. 1978. A method for specific diagnosis of Rocky Mountain spotted fever on fixed, paraffin-embedded tissue by immunofluorescence. *J Infect Dis* 137:206-209.
18. WALKER DH, Cain BG, Olmstead PM. 1978. Specific diagnosis of Rocky Mountain spotted fever by immunofluorescent demonstration of *Rickettsia rickettsii* in biopsy of skin. *Public Health Lab* 36:96-100.
19. WALKER DH, Cain BG, Olmstead PM. 1978. Laboratory diagnosis of Rocky Mountain spotted fever by immunofluorescent demonstration of *Rickettsia rickettsii* in cutaneous lesions. *Am J Clin Pathol* 69:619-623.
20. Fischer JJ, WALKER DH. 1979. Invasive pulmonary aspergillosis associated with influenza. *JAMA* 241:1493-1494.
21. WALKER DH, Mattern WD. 1979. Acute renal failure in Rocky Mountain spotted fever. *Arch Intern Med* 139:443-448.
22. Krauss JS, WALKER DH. 1979. Miliary tuberculosis and consumption of clotting factors by multifocal vasculopathic coagulation. *South Med J* 72:1479-1481.
23. WALKER DH, Akov Y, Cain BG. 1979. Ultrastructural and virological aspects of Langkat virus-induced SSPE in suckling hamsters. *Br J Exp Pathol* 60:604-612.
24. WALKER DH, Cain BG. 1980. The rickettsial plaque. Evidence for direct cytopathic effect of *Rickettsia rickettsii*. *Lab Invest* 43:388-396.

25. WALKER DH, Paletta CE, Cain BG. 1980. Pathogenesis of myocarditis in Rocky Mountain spotted fever. Arch Pathol Lab Med 104:171-174.
26. Powell DA, WALKER DH. 1980. Nontuberculous mycobacterial endobronchitis in children. J Pediatr 96:268-270.
27. WALKER DH, Crawford CG, Cain BG. 1980. Rickettsial infection of the pulmonary microcirculation: the basis for interstitial pneumonitis in Rocky Mountain spotted fever. Hum Pathol 11:263-272.
28. McGinnis MR, WALKER DH, Folds JD. 1980. *Hansenula polymorpha* infection in a child with chronic granulomatous disease. Arch Pathol Lab Med 104:290-292.
29. Sanders KL, WALKER DH, Lee TJ. 1980. Relapse of Legionnaires' disease in a renal transplant recipient. Arch Int Med 140:833-834.
30. Donohue JF, Scott RJ, WALKER DH, Bromberg PA. 1980. Phycomycosis: A cause of bronchial obstruction. South Med J 73:734-736.
31. WALKER DH, Kirkman HN. 1980. Rocky Mountain spotted fever and deficiency in glucose-6-phosphate dehydrogenase. J Infect Dis 142:771.
32. WALKER DH, Burday MS, Folds JD. 1980. Laboratory diagnosis of Rocky Mountain spotted fever. South Med J 73:1443-1447.
33. Wheeler MS, McGinnis MR, Schell WA, WALKER DH. 1981. *Fusarium* infection in burned patients. Am J Clin Pathol 75:304-311.
34. Adams JS, WALKER DH. 1981. The liver in Rocky Mountain spotted fever. Am J Clin Pathol 75:156-161.
35. Stephens DS, WALKER DH, Schaffner W, Kaplowitz LG, Brashear HR, Roberts R, Spickard WA Jr. 1981. Pseudodiphtheria: prominent pharyngeal membrane associated with fatal paraquat ingestion. Ann Intern Med 94:202-204.
36. Bowdre JH, Campbell JL, WALKER DH, Tart DE. 1981. American mucocutaneous leishmaniasis: culture of a leishmania species from peripheral blood leukocytes. Am J Clin Pathol 75:435-438.
37. WALKER DH, Gay RM, Valdes-Dapena M. 1981. The occurrence of eschars in Rocky Mountain spotted fever. J Am Acad Dermatol 4:571-576.
38. Lange JV, WALKER DH, Wester TB. 1982. Documented Rocky Mountain spotted fever in wintertime. JAMA 247:2403-2404.
39. WALKER DH, McCormick JB, Johnson KM, Webb PA, Komba-Kono G, Elliott LH, Gardner JJ. 1982. Pathologic and virologic study of fatal Lassa fever in man. Am J Pathol 107:349-356.
40. McGinnis MR, WALKER DH, Dominy IE, Kaplan W. 1982. Zygomycosis caused by *Cunninghamella bertholletiae*: Clinical and pathological aspects. Arch Pathol Lab Med 106:282-286.
41. WALKER DH, Firth WT, Edgell C-JS. 1982. Human endothelial cell culture plaques induced by *Rickettsia rickettsii*. Infect Immun 37:301-306.

42. WALKER DH, Johnson KM, Lange JV, Gardner JJ, Kiley MP, McCormick JB. 1982. Experimental infection of rhesus monkeys with Lassa virus and a closely related arenavirus, Mozambique virus. *J Infect Dis* 146:360-368.
43. Smith GW, WALKER DH. 1982. Disseminated infection with *Aspergillus flavus* in an alcoholic patient. *South Med J* 75:1148-1150.
44. WALKER DH, Hawkins HK, Hudson P. 1983. Fulminant Rocky Mountain spotted fever. Its pathologic characteristics associated with glucose-6-phosphate dehydrogenase deficiency. *Arch Pathol Lab Med* 107:121-125.
45. WALKER DH, Firth WT, Ballard JG, Hegarty BC. 1983. Role of the phospholipase-associated penetration mechanism in cell injury by *Rickettsia rickettsii*. *Infect Immun* 40:840-842.
46. WALKER DH, Okiye G. 1983. Chronic granulomatous disease involving the central nervous system. *Pediatr Pathol* 1:159-167.
47. Folds JD, WALKER DH, Hegarty BC, Banasiak D, Lange JV. 1983. Rocky Mountain spotted fever vaccine in an animal model. *J Clin Microbiol* 18:321-326.
48. Kaplowitz LG, Lange JV, Fischer JJ, WALKER DH. 1983. Correlation of rickettsial titers, circulating endotoxin, and clinical features in Rocky Mountain spotted fever. *Arch Intern Med* 143:1149-1151.
49. Montenegro MR, Mansueto S, Hegarty BC, WALKER DH. 1983. The histology of "taches noires" of boutonneuse fever and demonstration of *Rickettsia conorii* in them by immunofluorescence. *Virchows Arch* 400:309-317.
50. Tracy SL, McGinnis MR, Peacock JE Jr., Cohen MS, WALKER DH. 1983. Disseminated infection by *Aspergillus terreus*. *Am J Clin Pathol* 80:728-733.
51. Cohen MS, Jaques PF, Wall SD, WALKER DH. 1983. A fatal eosinophilic process in a Laotian refugee. *Am J Clin Pathol* 80:738-743.
52. Butts JD, Bouldin TW, WALKER DH. 1984. Morphological characteristics of a unique intracytoplasmic neuronal inclusion body. *Acta Neuropathol (Berl)* 62:345-347.
53. WALKER DH, Montenegro MR, Hegarty BC, Tringali GR. 1984. Rocky Mountain spotted fever vaccine: a regional need. *South Med J* 77:447-449.
54. Mansueto S, Tringali G, DiLeo R, Maniscalco M, Montenegro MR, WALKER DH. 1984. Demonstration of spotted fever group rickettsiae in the *tache noire* of a healthy person in Sicily. *Am J Trop Med Hyg* 33:479-482.
55. WALKER DH, Tidwell RR, Rector TM, Geratz JD. 1984. Effect of synthetic protease inhibitors of the amidine type on cell injury by *Rickettsia rickettsii*. *Antimicrob Agents Chemother* 25:582-585.
56. WALKER DH, Firth WT, Hegarty BC. 1984. Injury restricted to cells infected with spotted fever group rickettsiae in parabiologic chambers. *Acta Trop* 41:307-312.
57. Randall MB, WALKER DH. 1984. Rocky Mountain spotted fever: Gastrointestinal and pancreatic lesions and rickettsial infection. *Arch Pathol Lab Med* 108:963-967.
58. Lange JV, WALKER DH. 1984. Production and characterization of monoclonal antibodies to *Rickettsia rickettsii*. *Infect Immun* 46:289-294.

59. Montenegro NR, WALKER DH, Hegarty BC. 1984. Infection of genetically immunodeficient mice with *Rickettsia conorii*. Acta Virol 23:508-514.
60. WALKER DH, Gear JHS. 1985. Correlation of the distribution of *Rickettsia conorii*, microscopic lesions, and clinical features in South African tick bite fever. Am J Trop Med Hyg 34:361-371.
61. Lange JV, Mitchell SW, McCormick JB, WALKER DH, Evatt BL, Ramsey RR. 1985. Kinetic study of platelets and fibrinogen in Lassa virus-infected monkeys and early pathologic events in mopeia virus-infected monkeys. Am J Trop Med Hyg 34:999-1007.
62. Breitschwerdt EB, Meuten DJ, WALKER DH, Levy M, Kennedy K, King M, Curtis B. 1985. Canine Rocky Mountain spotted fever: a kennel epizootic. Am J Vet Res 46:2124-2128.
63. WALKER DH, Lesesne HR, Varma VA, Thacker WC. 1985. Rocky Mountain spotted fever mimicking acute cholecystitis. Arch Intern Med 145:2194-2196.
64. Roggli VL, Keener S, Bradford WD, WALKER DH, Pratt PC. 1985. Pulmonary pathology of Rocky Mountain spotted fever (RMSF) in children. Pediatr Pathol 4:47-57.
65. WALKER DH, Staiti A, Mansueto S, Tringali G. 1986. Frequent occurrence of hepatic lesions in boutonneuse fever. Acta Trop 43:175-181.
66. Williams JC, WALKER DH, Peacock MG, Stewart ST. 1986. Humoral immune response to Rocky Mountain spotted fever in experimentally infected guinea pigs: immunoprecipitation of lactoperoxidase ¹²⁵I-labeled proteins and detection of soluble antigens of *Rickettsia rickettsii*. Infect Immun 52:120-127.
67. Feng HM, Kirkman C, WALKER DH. 1986. Radioimmunoprecipitation of [³⁵S] methionine-radiolabeled proteins of *Rickettsia conorii* and *Rickettsia rickettsii*. J Infect Dis 154:717-721.
68. Tringali G, Intonazzo V, Perna AM, Mansueto S, Vitale G, WALKER DH. 1986. Epidemiology of boutonneuse fever in western Sicily: distribution and prevalence of spotted fever group rickettsial infection in dog ticks (*Rhipicephalus sanguineus*). Am J Epidemiol 123:721-727.
69. Jackson MD, Kirkman C, Bradford WD, WALKER DH. 1986. Rocky Mountain spotted fever: hepatic lesions in childhood cases. Pediatr Pathol 5:379-388.
70. Raoult D, Lena D, Perrimont H, Gallais H, WALKER DH, Casanova P. 1986. Haemolysis with Mediterranean spotted fever and glucose-6-phosphate dehydrogenase deficiency. Trans R Soc Trop Med Hyg 80:961-962.
71. McCormick JB, WALKER DH, King IJ, Webb PA, Elliott LH, Whitfield SG, Johnson KM. 1986. Lassa virus hepatitis: a study of fatal Lassa fever in humans. Am J Trop Med Hyg 35:401-407.
72. Feng HM, WALKER DH, Wang JG. 1987. Analysis of T-cell-dependent and -independent antigens of *Rickettsia conorii* with monoclonal antibodies. Infect Immun 55:7-15.
73. Li H, Jerrells TR, Spitalny GL, WALKER DH. 1987. Gamma interferon as a crucial host defense against *Rickettsia conorii* in vivo. Infect Immun 55:1252-1255.
74. WALKER DH, Herrero-Herrero JI, Ruiz-Beltrán R, Bullón-Sopelana A, Ramos-Hidalgo A. 1987. The pathology of fatal Mediterranean spotted fever. Am J Clin Pathol 87:669-672.

75. Fan M-Y, WALKER DH, Liu Q-H Li, H, Bai H-C, Jia-Ke Z, Lenz B, Cai H. 1987. Rickettsial and serologic evidence for prevalent spotted fever rickettsiosis in Inner Mongolia. *Am J Trop Med Hyg* 36:615-620.
76. Fan M-Y, Wang J-G, Jiang Y-X, Zong D-G, Lenz B, WALKER DH. 1987. Isolation of a spotted fever group rickettsia from a patient and related ecologic investigations in Xinjiang Uygur Autonomous Region of China. *J Clin Microbiol* 25:628-632.
77. Wang JG, WALKER DH. 1987. Identification of spotted fever group rickettsiae from human and tick sources in the People's Republic of China. *J Infect Dis* 156:665-669.
78. Tringali G, Mansueto S, Barba G, Occhino C, Farinella E, Vitale G, WALKER DH. 1987. Familial cases of boutonuse fever. *Eur J Epidemiol* 3:414-418.
79. Wang J-G, WALKER DH, Han L, Lenz B, Jerrells, TR. 1987. Barbash strain spotted fever group rickettsia is a strain of *Rickettsia conorii* and differs from *Rickettsia sibirica*. *Acta Virol* 31:489-498.
80. Herrero-Herrero JI, WALKER DH, Ruiz-Beltran R. 1987. Immunohistochemical evaluation of the cellular immune response to *Rickettsia conorii* in *taches noires*. *J Infect Dis* 155:802-805.
81. Breitschwerdt EB, WALKER DH, Levy MG, Burgdorfer W, Corbett WT, Hurlbert SA, Stebbins ME, Curtis BC, Allen DA. 1988. Clinical, hematologic, and humoral immune response in female dogs inoculated with *Rickettsia rickettsii* and *Rickettsia montana*. *Am J Vet Res* 49:70-6.
82. Horney LF, WALKER DH. 1988. Meningoencephalitis as a major manifestation of Rocky Mountain spotted fever. *South Med J* 81:915-918.
83. Li H, Lenz B, WALKER DH. 1988. Protective monoclonal antibodies recognize heat-labile epitopes on surface proteins of spotted fever group rickettsiae. *Infect Immun* 56:2587-2593.
84. Fan MY, Yu XJ, WALKER DH. 1988. Antigenic analysis of Chinese strains of spotted fever group rickettsiae by protein immunoblotting. *Am J Trop Med Hyg* 39:497-501.
85. WALKER DH, Occhino C, Tringali GR, DiRosa S, Mansueto S. 1988. Pathogenesis of rickettsial eschars: the *tache noire* of boutonuse fever. *Hum Pathol* 19:1449-1454.
86. Jerrells TR, Li H, WALKER DH. 1988. *In vivo* and *in vitro* role of gamma interferon in immune clearance of *Rickettsia* species. *Adv Exp Med Biol* 239:193-200.
87. Nichols MM, WALKER DH, Frates RC, Davis A. 1989. Three-month-old infant with diarrhea, fever, and rash. *J Pediatr* 114:154-160.
88. Uchida T, Yu XJ, Uchiyama T, WALKER DH. 1989. Identification of a unique spotted fever group rickettsia from humans in Japan. *J Infect Dis* 159:1122-1126.
89. WALKER DH, Parks FM, Betz TG, Taylor JP, Muehlberger, JW. 1989. Histopathology and immunohistologic demonstration of the distribution of *Rickettsia typhi* in fatal murine typhus. *Am J Clin Pathol* 91:720-724.
90. Davidson MG, Breitschwerdt EB, WALKER DH, Nasisse MP, Sussman WE. 1989. Identification of rickettsiae in cutaneous biopsy specimens from dogs with experimental Rocky Mountain spotted fever. *J Vet Intern Med* 3:8-11.

91. Smith, JH, Rotterdam, HZ, Christie JD, Lindner LE, Braunstein H, Hackman RC, Moskowitz LB, WALKER DH. 1990. Specialty Conference. Infectious and Inflammatory Diseases. Mod Pathol 3:223-233.
92. Uchiyama T, Uchida T, WALKER DH. 1990. Species-specific monoclonal antibodies to *Rickettsia japonica*, a newly identified spotted fever group rickettsia. J Clin Microbiol 28:1117-1180.
93. Davidson MG, Breitschwerdt EB, WALKER DH, Levy MG, Carlson CS, Hardie EM, Grindem CA, Nasisse MP. 1990. Vascular permeability and coagulation during *Rickettsia rickettsii* infection in dogs. Am J Vet Res 51:165-170.
94. Ruiz-Beltran R, Herrero-Herrero JI, WALKER DH, Cunado-Rodriguez A. 1990. Mechanism of upper gastrointestinal hemorrhage in Mediterranean spotted fever. Trop Geogr Med 42:78-82.
95. Breitschwerdt EB, Levy MG, Davidson MG, WALKER DH, Burgdorfer W, Curtis BC, Babineau CA. 1990. Kinetics of IgM and IgG responses to experimental and naturally acquired *Rickettsia rickettsii* infection in dogs. Am J Vet Res 51:1312-1316.
96. Yu XJ, WALKER DH, Jerrells TR. 1990. Polypeptides constituting the antigenic basis for identification of *Rickettsia sibirica* species by the standard serotyping method for spotted fever group rickettsiae. Acta Virol 34:71-79.
97. Dumler JS, Taylor JP, WALKER DH. 1991. Clinical and laboratory features of murine typhus in South Texas, 1980 through 1987. JAMA 266:1365-1370.
98. Li H, WALKER DH. 1992. Characterization of rickettsial attachment to host cells by flow cytometry. Infect Immun 60:2030-2035.
99. Brouqui P, Dumler JS, Raoult D, WALKER DH. 1992. Antigenic characterization of ehrlichiae: protein immunoblotting of *Ehrlichia canis*, *Ehrlichia sennetsu*, and *Ehrlichia risticii*. J Clin Microbiol 30:1062-1066.
100. WALKER DH, Watkins NG, Dumler JS, Vishwanath S. 1992. Experimental skin lesion (*tache noire*) in guinea-pigs after intradermal inoculation of *Rickettsia conorii*. Immunol Infect Dis 2:51-59.
101. Uchida T, Uchiyama T, Kumano K, WALKER DH. 1992. *Rickettsia japonica* sp. nov., the etiological agent of spotted fever group rickettsiosis in Japan. Int J Syst Bacteriol 42:303-305.
102. WALKER DH, Liu QH, Yu XJ, Li H, Taylor C, Feng HM. 1992. Antigenic diversity of *Rickettsia conorii*. Am J Trop Med Hyg 47:78-86.
103. Herrero-Herrero JI, WALKER DH, Ruiz-Beltrán R. 1992. Use of Western blot to analyze the reactivity of sera from patients with Mediterranean spotted fever. Eur J Clin Microbiol Infect Dis 11:939-942.
104. Abramova FA, Grinberg LM, Yampolskaya OV, WALKER DH. 1993. Pathology of inhalational anthrax in 42 cases from the Sverdlovsk outbreak of 1979. Proc Natl Acad Sci USA 90:2291-2294.
105. Kirkland KB, Marcom PK, Sexton DJ, Dumler JS, WALKER DH. 1993. Rocky Mountain spotted fever complicated by gangrene: report of six cases and review. Clin Infect Dis 16:629-634.
106. Dumler JS, Dawson JE, WALKER DH. 1993. Human ehrlichiosis: Hematopathology and immunohistologic detection of *Ehrlichia chaffeensis*. Hum Pathol 24:391-396.

107. Feng H-M, Wen J, WALKER DH. 1993. *Rickettsia australis* infection: A murine model of a highly invasive vasculopathic rickettsiosis. *Am J Pathol* 142:1471-1482.
108. Herrero JI, Ruiz R, WALKER DH. 1993. La técnica de Western immunoblotting en situaciones atípicas de infección por *Rickettsia conorii*. Presentación de 2 casos. *Enferm Infecc Microbiol Clin* 11:139-142.
109. Herrero-Herrero JI, Ruiz-Beltrán R, WALKER DH. 1993. Antigens of *Rickettsia conorii* recognized by seropositive healthy people from Salamanca (Central-West Spain). *Eur J Epidemiol* 9:59-63.
110. Radulovic S, WALKER DH, Weiss K, Dzelalija B, Morovic M. 1993. Prevalence of antibodies to spotted fever group rickettsiae along the Eastern Coast of the Adriatic Sea. *J Clin Microbiol* 31:2225-2227.
111. Sexton DJ, Muniz M, Corey GR, Breitschwerdt EB, Hegarty BC, Dumler JS, WALKER DH, Pecanha PM, Dietze R. 1993. Brazilian spotted fever in Espirito Santo, Brazil: description of a focus of infection in a new endemic region. *Am J Trop Med Hyg* 49:222-226.
112. Feng H-M, WALKER DH. 1993. Interferon- γ and tumor necrosis factor- α exert their antirickettsial effect via induction of synthesis of nitric oxide. *Am J Pathol* 143:1016-1023.
113. Radulovic S, Speed R, Feng H-M, Taylor C, WALKER DH. 1993. EIA with species-specific monoclonal antibodies: a novel seroepidemiologic tool for determination of the etiologic agent of spotted fever rickettsiosis. *J Infect Dis* 168:1292-1295.
114. Dumler JS, Sutker WL, WALKER DH. 1993. Persistent infection with *Ehrlichia chaffeensis*. *Clin Infect Dis* 17:903-905.
115. Chen S-M, Dumler JS, Bakken JS, WALKER DH. 1994. Identification of a granulocytotropic *Ehrlichia* species as the etiologic agent of human disease. *J Clin Microbiol* 32:589-595.
116. Chen S-M, Dumler JS, Feng H-M, WALKER DH. 1994. Identification of the antigenic constituents of *Ehrlichia chaffeensis*. *Am J Trop Med Hyg* 50:52-58.
117. Schuenke K, WALKER DH. 1994. Cloning, sequencing, and expression of the gene coding for an antigenic 120-kilodalton protein of *Rickettsia conorii*. *Infect Immun* 62:904-909.
118. Crocquet-Valdes PA, Weiss K, WALKER DH. 1994. Sequence analysis of the 190-kDa antigen-encoding gene of *Rickettsia conorii* (Malish 7 strain). *Gene* 140:115-119.
119. WALKER DH, Popov VL, Wen J, Feng HM. 1994. *Rickettsia conorii* infection of C3H/HeN mice: a model of endothelial-target rickettsiosis. *Lab Invest* 70:358-368.
120. Feng H-M, Popov VL, WALKER DH. 1994. Depletion of gamma interferon and tumor necrosis factor alpha in mice with *Rickettsia conorii*-infected endothelium: impairment of rickettsicidal nitric oxide production resulting in fatal, overwhelming rickettsial disease. *Infect Immun* 62:1952-1960.
121. Radulovic S, Feng H-M, Crocquet-Valdes P, Morovic M, Dzelalija B, WALKER DH. 1994. Antigen-capture enzyme immunoassay: a comparison with other methods for the detection of spotted fever group rickettsiae in ticks. *Am J Trop Med Hyg* 50:359-364.
122. Williams WJ, Radulovic S, Dasch GA, Lindstrom J, Kelly DJ, Oster CN, WALKER DH. 1994. Identification of *Rickettsia conorii* infection by a polymerase chain reaction in a soldier returning from Somalia. *Clin Infect Dis* 19:93-99.

123. Bakken JS, Dumler JS, Chen S-M, Eckman MR, Van Etta LL, WALKER DH. 1994. Human granulocytic ehrlichiosis in the upper midwest United States. A new species emerging? *JAMA* 272:212-218.
124. Uchiyama T, Uchida T, WALKER DH. 1994. Analysis of major surface polypeptides of *Rickettsia japonica*. *Microbiol Immunol* 38:575-579.
125. Uchiyama T, Uchida T, Wen JW, WALKER DH. 1994. Demonstration of heat-labile and heat-stable epitopes of *Rickettsia japonica* on ultrathin sections. *Lab Invest* 71:432-437.
126. Trilar T, Radulovic S, and WALKER DH. 1994. Identification of a natural cycle involving *Rickettsia typhi* infection of *Monopsyllus sciurorum sciurorum* fleas from the nest of the fat dormouse (*Glis glis*). *Eur J Epidemiol* 10:757-762.
127. Chen S-M, Popov V, Feng H-M, Wen J, WALKER DH. 1995. Cultivation of *Ehrlichia chaffeensis* in mouse embryo, Vero, BGM, and L929 cells and study of *Ehrlichia*-induced cytopathic effect and plaque formation. *Infect Immun* 63:647-655.
128. Hove MGM, WALKER DH. 1995. Persistence of rickettsiae in the partially viable gangrenous margins of amputated extremities 5 to 7 weeks after onset of Rocky Mountain spotted fever. *Arch Pathol Lab Med* 119:429-431.
129. Dumler JS, Chen S-M, Asanovich K, Trigiani E, Popov VL, WALKER DH. 1995. Isolation and characterization of a new strain of *Ehrlichia chaffeensis* from a patient with near-fatal monocytic ehrlichiosis. *J Clin Microbiol* 33:1704-1711.
130. WALKER DH, Feng H-M, Saada JI, Crocquet-Valdes P, Radulovic S, Popov VL, Manor E. 1995. Comparative antigenic analysis of spotted fever group rickettsiae from Israel and other closely related organisms. *Am J Trop Med Hyg* 52:569-576.
131. Liu Q-H, Chen G-Y, Jin Y, Te M, Niu L-C, Dong S-P, WALKER DH. 1995. Evidence for a high prevalence of spotted fever group rickettsial infections in diverse ecologic zones of Inner Mongolia. *Epidemiol Infect* 115:177-183.
132. Popov VL, Chen S-M, Feng H-M, WALKER DH. 1995. Ultrastructural variation of cultured *Ehrlichia chaffeensis*. *J Med Microbiol* 43:411-421.
133. WALKER DH, Barbour AG, Oliver JH, Lane RS, Dumler JS, Dennis DT, Persing DH, Azad AF, McSweegan E. 1996. Emerging bacterial zoonotic and vector-borne diseases: Ecological and epidemiological factors. *JAMA* 275:463-469.
134. Radulovic S, Feng H-M, Morovic M, Djelalija B, Popov V, Crocquet-Valdes P, WALKER DH. 1996. Isolation of *Rickettsia akari* from a patient in a region where Mediterranean spotted fever is endemic. *Clin Infect Dis* 22:216-220.
135. Chen S-M, Popov V, Feng H-M, WALKER DH. 1996. Analysis and ultrastructural localization of *Ehrlichia chaffeensis* proteins with monoclonal antibodies. *Am J Trop Med Hyg* 54:405-412.
136. Zavala-Velazquez JE, Yu X-J, WALKER DH. 1996. Unrecognized spotted fever group rickettsiosis masquerading as dengue fever in Mexico. *Am J Trop Med Hyg* 55:157-159.
137. Barenfanger J, Patel PG, Dumler JS, WALKER DH. 1996. Identifying human ehrlichiosis. *Lab Med* 27:372-374.

138. Yu X-J, Crocquet-Valdes P, Cullman LC, WALKER DH. 1996. The recombinant 120-kilodalton protein of *Ehrlichia chaffeensis*, a potential diagnostic tool. *J Clin Microbiol* 34:2853-2855.
139. Stenos J, Ross B, Feng H-M, Crocquet-Valdes P, WALKER DH. 1997. Protein characterization of Australian spotted fever group rickettsiae and monoclonal antibody typing of *Rickettsia honei*. *J Clin Microbiol* 35:261-263.
140. WALKER DH, Popov VL, Crocquet-Valdes PA, Welsh CJR, Feng H-M. 1997. Cytokine-induced, nitric oxide-dependent, intracellular antirickettsial activity of mouse endothelial cells. *Lab Invest* 76:129-138.
141. Yu X-J, Crocquet-Valdes PA, WALKER DH. 1997. Cloning and sequencing of the gene for a 120-kDa immunodominant protein of *Ehrlichia chaffeensis*. *Gene* 184:149-154.
142. Chen S-M, Yu X-J, Popov VL, Westerman EL, Hamilton FG, WALKER DH. 1997. Genetic and antigenic diversity of *Ehrlichia chaffeensis*: comparative analysis of a novel human strain from Oklahoma and previously isolated strains. *J Infect Dis* 175:856-863.
143. Feng H-M, Popov VL, Yuoh G, WALKER DH. 1997. Role of T lymphocyte subsets in immunity to spotted fever group rickettsiae. *J Immunol* 158:5314-5320.
144. Yu X-J, Piesman JF, Olson JG, WALKER DH. 1997. Geographic distribution of different genetic types of *Ehrlichia chaffeensis*. *Am J Trop Med Hyg.* 56:679-680.
145. WALKER DH, Dumler JS. 1997. Human monocytic and granulocytic ehrlichioses: Discovery and diagnosis of emerging tick-borne infections and the critical role of the pathologist. *Arch Pathol Lab Med* 121:785-791.
146. Yu X-J, WALKER DH. 1997. Sequence and characterization of an *Ehrlichia chaffeensis* gene encoding 314 amino acids highly homologous to the NAD A enzyme. *FEMS Letters* 154:53-58.
147. Chen S-M, Cullman LC, WALKER DH. 1997. Western immunoblotting analysis of the antibody responses of patients with human monocytotropic ehrlichiosis to different strains of *Ehrlichia chaffeensis* and *Ehrlichia canis*. *Clin Diagn Lab Immunol* 4:731-735.
148. WALKER DH, Feng H-M, Ladner S, Billings AN, Zaki SR, Wear DJ, Hightower B. 1997. Immunohistochemical diagnosis of typhus rickettsioses using an anti-lipopolysaccharide monoclonal antibody. *Mod Pathol* 10:1038-1042.
149. Ghorbani RP, Ghorbani AJ, Jain MK, WALKER DH. 1997. A case of scrub typhus probably acquired in Africa. *Clin Infect Dis* 25:1473-1474.
150. Angeloni VL, Keller RA, WALKER DH. 1997. Rickettsialpox-like illness in a traveler. *Military Med* 162:636-639.
151. Popov VL, Han VC, Chen S-M, Dumler JS, Feng H-M, Andreadis TG, Tesh RB, WALKER DH. 1998. Ultrastructural differentiation of the genogroups in the genus *Ehrlichia*. *J Med Microbiol* 47:235-251.
152. Sexton DJ, Corey GR, Carpenter C, Kong LQ, Gandhi T, Breitschwerdt E, Hegarty B, Chen S-M, Feng H-M, Yu X-J, Olano J, WALKER DH, Dumler JS. 1998. Dual infection with *Ehrlichia chaffeensis* and a spotted fever group rickettsia: A case report. *Emerg Infect Dis* 4:311-316.
153. Billings AN, Teltow G, Weaver SC, WALKER DH. 1998. Molecular characterization of a novel *Rickettsia* species from *Ixodes scapularis* in Texas. *Emerg Infect Dis* 4:305-309.

154. Billings AN, Yu X-J, Teel PD, WALKER DH. 1998. Detection of a spotted fever group rickettsia in *Amblyomma cajennense* (Acari: Ixodidae) in south Texas. *J Med Entomol* 35:474-478.
155. Li H, WALKER DH. 1998. rOmpA is a critical protein for the adhesion of *Rickettsia rickettsii* to host cells. *Microbial Pathogen* 24:289-298.
156. Stenos J, Roux V, WALKER DH, Raoult D. 1998. *Rickettsia honei* sp. nov., the aetiologic agent of Flinders Island spotted fever in Australia. *Inter J Syst Bacteriol* 48:1399-1404.
157. Billings AN, Rawlings JA, WALKER D. 1998. Tick-borne diseases in Texas: a 10-year retrospective examination of cases. *Tex Med* 94:66-76.
158. Yu X-J, McBride JW, WALKER DH. 1999. Genetic diversity of the 28-kilodalton outer membrane protein gene in human isolates of *Ehrlichia chaffeensis*. *J Clin Microbiol* 37:1137-1143.
159. McBride JW, Yu X-J, Walker DH. 1999. Molecular cloning of the gene for a conserved major immunoreactive 28-kilodalton protein of *Ehrlichia canis*: a potential serodiagnostic antigen. *Clin Diagn Lab Immunol* 6:392-399.
160. WALKER DH, Hudnall SD, Szaniawski WK, Feng HM. 1999. Monoclonal antibody-based immunohistochemical diagnosis of rickettsialpox: The macrophage is the principal target. *Mod Pathol* 12:529-533.
161. Yu X-J, Crocquet-Valdes PA, Cullman LC, Popov VL, Walker DH. 1999. Comparison of *Ehrlichia chaffeensis* recombinant proteins for serologic diagnosis of human monocytotropic ehrlichiosis. *J Clin Micro* 37:2568-2575.
162. Zavala-Velazquez JE, Ruiz-Sosa J, Vado-Solis I, Billings AN, WALKER DH. 1999. Serologic study of the prevalence of rickettsiosis in Yucatán: Evidence for a prevalent spotted fever group rickettsiosis. *Am J Trop Med Hyg* 61:405-408.
163. Carpenter CF, Gandhi TK, Kong LK, Corey GR, Chen S-M, WALKER DH, Dumler JS, Breitschwerdt E, Hegarty B, Sexton DJ. 1999. The incidence of ehrlichial and rickettsial infection in patients with unexplained fever and recent history of tick bite in central North Carolina. *J Infect Dis* 180:900-903.
164. McGinnis MR, Lemon SM, WALKER DH, de Hoog GS, Haase G. 1999. Fatal cerebritis caused by a new species of *Cladophialophora*. *Studies in Mycology* 43:166-171.
165. McBride JW, Yu X-J, WALKER DH. 2000. Glycosylation of homologous immunodominant proteins of *Ehrlichia chaffeensis* and *Ehrlichia canis*. *Infect Immun* 68:13-18.
166. Yu X-J, McBride JW, Diaz CM, WALKER DH. 2000. Molecular cloning and characterization of the 120-kilodalton protein gene of *Ehrlichia canis* and application of the recombinant 120-kilodalton protein for serodiagnosis of canine ehrlichiosis. *J Clin Micro* 38: 369-374.
167. Popov VL, Yu X-J, WALKER DH. 2000. The 120-kDa outer membrane protein of *Ehrlichia chaffeensis*: preferential expression on dense-core cells and gene expression in *Escherichia coli* associated with attachment and entry. *Microbial Pathogen* 28:71-80.
168. Yu X-J, McBride JW, Zhang XF, WALKER DH. 2000. Characterization of the complete transcriptionally active *Ehrlichia chaffeensis* 28 kDa outer membrane protein multigene family. *Gene* 248:59-68.

169. McBride JW, Yu XJ, WALKER DH. 2000. A conserved, transcriptionally active *p28* multigene locus of *Ehrlichia canis*. *Gene* 254:245-252.
170. Stenos J, WALKER DH. 2000. The rickettsial outer membrane protein A and B genes of *Rickettsia australis*, the most divergent rickettsia of the spotted fever group. *Int J Syst Bacteriol* 50:1761-1766.
171. Zavala-Velazquez JE, Ruiz-Sosa JA, Sánchez-Elias RA, Becerra-Carmona G, Walker DH. 2000. *Rickettsia felis* rickettsiosis in Yucatán. *Lancet* 356:1079-1080.
172. WALKER DH, Popov VL, Feng H-M. 2000. Establishment of a novel endothelial target mouse model of a typhus group rickettsiosis: evidence of critical roles for gamma interferon and CD8 T lymphocytes. *Lab Invest* 80:1361-1372.
173. Feng HM, WALKER DH. 2000. Mechanisms of intracellular killing of *Rickettsia conorii* in infected human endothelial cells, hepatocytes, and macrophages. *Infect Immun* 68:6729-6736.
174. McBride JW, Corstvet RE, Breitschwerdt EB, WALKER DH. 2001. Immunodiagnosis of *Ehrlichia canis* infection with recombinant proteins. *J Clin Micro* 39:315-322.
175. Moron CG, Bouyer DH, Yu X-J, Foil LD, Crocquet-Valdes P, Walker DH. 2001. Phylogenetic analysis of the *rompB* genes of *Rickettsia felis* and *Rickettsia prowazekii* European human and North American flying-squirrel strains. *Am J Trop Med Hyg* 62:598-603.
176. Bouyer DH, Stenos J, Crocquet-Valdes P, Moron CG, Popov VL, Zavala-Velazquez JE, Foil LD, Stothard DR, Azad AF and Walker DH. 2001. *Rickettsia felis*: molecular characterization of a new member of the spotted fever group. *Int J Syst Evol Microbiol* 51:339-347.
177. Sotomayor EA, Popov VL, Feng H-M, WALKER DH, Olano JP. 2001. Animal model of fatal human monocytotropic ehrlichiosis. *Am J Pathol* 158:757-769.
178. WALKER DH, Olano JP, Feng H-M. 2001. Critical role of cytotoxic T lymphocytes in immune clearance of rickettsial infection. *Infect Immun* 69:1841-1846.
179. Ventura KC, Hawkins H, Smith MB, WALKER DH. 2001. Fatal neonatal echovirus 6 infection: Autopsy case report and review of the literature. *Mod Pathol* 14:85-90.
180. Grinberg LM, Abramova FA, Yampolskaya OV, WALKER DH, Smith JH. 2001. Quantitative pathology of inhalational anthrax 1: Quantitative microscopic findings. *Mod Pathol* 14:482-495.
181. Moron CL, Feng HM, Wear DJ, WALKER DH. 2001. Identification of the target cells of *Orientia tsutsugamushi* in human cases of scrub typhus. *Mod Pathol* 14:752-759.
182. Yu X-J, Zhang X-F, McBride JW, Zhang Y, WALKER DH. 2001. Phylogenetic relationships of *Anaplasma marginale* and '*Ehrlichia platys*' to other *Ehrlichia* species determined by GroEL amino acid sequences. *Int J Syst Evol Microbiol* 51:1143-1146.
183. Billings AN, Feng H-M, Olano JP, WALKER DH. 2001. Rickettsial infection in murine models activates an early anti-rickettsial effect mediated by NK cells and associated with production of gamma interferon. *Am J Trop Med Hyg* 65:52-56.
184. Schmaier AH, Srikanth S, Elghetany MT, Normolle D, Gokhale S, Feng H-M, WALKER DH. 2001. Hemostatic/fibrinolytic protein changes in C3H/HeN mice infected with *Rickettsia conorii* – A model for Rocky Mountain spotted fever. *Thromb Haemost* 86:871-879.

185. Diaz CM, Feng HM, Crocquet-Valdes P, Walker DH. 2001. Identification of protective components of two major outer membrane proteins of spotted fever group rickettsiae. *Am J Trop Med Hyg* 65:371-378.
186. WALKER DH, Feng H-M, Popov VL. 2001. Rickettsial phospholipase A₂ as a pathogenic mechanism in a model of cell injury by typhus and spotted fever group rickettsiae. *Am J Trop Med Hyg* 65:936-942.
187. Crocquet-Valdes PA, Diaz-Montero CM, Feng H-M, Li H, Barrett ADT, WALKER DH. 2002. Immunization with a portion of rickettsial outer membrane protein A stimulates protective immunity against spotted fever rickettsiosis. *Vaccine* 20:979-988.
188. Long SW, Zhang X-F, Qi H, Standaert S, WALKER DH, Yu X-J. 2002. Antigenic variation of *Ehrlichia chaffeensis* resulting from differential expression of the 28-kilodalton protein gene family. *Infect Immun* 70:1824-1831.
189. McBride JW, Ndip LM, Popov VL, WALKER DH. 2002. Identification and functional analysis of an immunoreactive DsbA-like thio-disulfide oxidoreductase of *Ehrlichia* spp. *Infect Immun* 70:2700-2703.
190. Mueller RN, Uretsky BF, Hao L, WALKER DH, Panomitros GE, Zornow MH. 2002. Cardiac arrest on induction of anesthesia due to triple vessel coronary artery disease despite a "negative" angiogram. *Anesthesiology* 97:745-749.
191. Oliveira RP, Galvao MAM, Mafra CL, Chamone CB, Calic SB, Silva SU, WALKER DH. 2002. *Rickettsia felis* in *Ctenocephalides* spp. fleas, Brazil. *Emerg Infect Dis* 8:317-319.
192. Zavala-Velazquez JE, Zavala-Castro J, Vado-Soliz I, Ruiz-Sosa JA, Moron C, Bouyer D, WALKER DH. 2003. Identification of *Ctenocephalides felis* fleas as the reservoir of *Rickettsia felis*, the agent of spotted fever rickettsioses in Yucatán Mexico. *Vector Borne and Zoonotic Diseases*. 2:69-75.
193. Galvão MAM, Lamounier JA, Bonomo E, Tropia MS, Rezende EG, Calic SB, Chamone CB, Machado MC, Otoni MEA, Leite RC, Caram C, Mafra CL, WALKER DH. 2003. Rickettsioses emergentes e reemergentes numa região endêmica do estado de Minas Gerais, Brazil. *Cad. Saúde Pública*. 18:1593-1597.
194. Li Z, Diaz-Montero CM, Yu X-J, Valbuena G, Olano JP, Feng H-M, WALKER DH. 2003. Identification of CD8 T-lymphocyte epitopes in *ompB* of *Rickettsia conorii*. *Infect Immun* 71:3920-3926.
195. Feng H-M, WALKER DH. 2003. Cross-protection between distantly related spotted fever group rickettsiae. *Vaccine*. 21:3901-3905.
196. Olano JP, Hogrefe W, Cullman L, Seaton B, WALKER DH. 2003. Clinical manifestations, epidemiology, and laboratory diagnosis of human monocytotropic ehrlichiosis in a commercial laboratory setting. *Clin Diag Lab Immunol*. 10:891-896.
197. Valbuena G, Bradford W, WALKER DH. 2003. Expression analysis of the T-cell targeting chemokines CXCL9 and CXCL1 in mice and humans with endothelial infections caused by rickettsiae of the spotted fever group. *Am J Pathol*. 163:1357-1369.
198. Galvao M, Dumler JS, Mafra CL, Calic SB, Chamone CB, Cesarino Filho G, Olano JP, WALKER DH. 2003. Fatal spotted fever rickettsiosis, Minas Gerais, Brazil. *Emerg Infect Dis*. 9:1402-1405.

199. Galvão MAM, Mafra CL, Chamone CB, Calic SB, Cesarino Filho G, Olano JP, WALKER DH. 2003. Spotted fever rickettsiosis in Coronel Fabriciano, Minas Gerais state. *Revista da Sociedade Brasileira de Medicina Tropical*. 36:479-481.
200. Lewin MR, Bouyer DH, WALKER DH, Musher DM. 2003. *Rickettsia sibirica* infection in members of scientific expeditions to northern Asia. *Research Letter. Lancet*. 362:1201-1202.
201. McBride JW, Corstvet RE, Gaunt SD, Boudreaux C, Guedry T, WALKER DH. 2003. Kinetics of antibody response to *Ehrlichia canis* immunoreactive proteins. *Infect Immun* 71:2516-24.
202. Stenos J, Graves S, Popov VL, WALKER DH. 2003. *Aponomma hydrosauri*, the reptile-associated tick reservoir of *Rickettsia honei* on Flinders Island, Australia. *Am J Trop Med Hyg* 69:314-317.
203. Olano JP, Masters E, Hogrefe W, WALKER DH. 2003. Human monocytotropic ehrlichiosis, Missouri. *Emerg Infect Dis* 9:1579-1586.
204. WALKER DH. 2003. Fatal cardiac failure in a 7-month-old child. *Pediatr Dev Pathol* 6: 582-584.
205. Labruna MB, Whitworth T, Horta MC, Bouyer DH, McBride JW, Pinter A, Popov V, Gennari SM, WALKER DH. 2004. *Rickettsia* species infecting *Amblyomma cooperi* ticks from an area in the State of Sao Paulo, Brazil, where Brazilian spotted fever is endemic. *J Clin Microbiol* 42:90-98.
206. Ismail N, Soong L, Valbuena G, McBride JW, Olano JP, WALKER DH. 2004. Overproduction of TNF- α by CD8⁺ type-1 cells and downregulation of IFN- γ production by CD4⁺ Th1 cells contribute to toxic shock-like syndrome in an animal model of fatal monocytotropic ehrlichioses. *J Immunol* 172:1786-1800.
207. Feng H-M, WALKER DH. 2004. Mechanisms of immunity to *Ehrlichia muris*: a model of human monocytotropic ehrlichiosis. *Infect Immun* 72:966-971.
208. Ndip LM, Bouyer DH, Travossos Da Rosa APA, Titanji V, Tesh RB, WALKER DH. 2004. Acute spotted fever rickettsiosis among febrile patients, Cameroon. *Emerg Infect Dis* 10:432-436.
209. Feng H-M, Whitworth T, Olano JP, WALKER DH. 2004. Fc-dependent polyclonal antibodies and antibodies to outer membrane proteins A and B, but not to lipopolysaccharide protect SCID mice against fatal *Rickettsia conorii* infection. *Infect Immun* 72: 2222-2228.
210. Alcantara VE, Gallardo EG, WALKER DH. 2004. Typhus group rickettsiae antibodies in rural Mexico. *Emerg Infect Dis* 10:549-550.
211. Jang W-J, Kim J-H, Choi Y-J, Jung K-D, Lee S-H, Choi M-S, Kim I-S, WALKER DH, Park K-H. 2004. First serologic evidence of human spotted fever group rickettsiosis in Korea. *J Clin Microbiol* 42:2310-2313.
212. Feng H-M, Whitworth T, Popov V, WALKER DH. 2004. Effect of antibody on the rickettsia-host cell interaction. *Infect Immun* 72:3524-3530.
213. Labruna MB, Bouyer DH, McBride JW, Camargo LMA, Camargo EP, WALKER DH. 2004. Molecular evidence for a spotted fever group *Rickettsia* species in the tick *Amblyomma longirostre* in Brazil. *J Med Entomol* 41:533-537.

214. Horta MC, Labruna MB, Sangioni LA, Vianna M, Gennari SM, Galvao M, Mafra CL, Vidotto O, Schumaker T, Walker DH. 2004. Prevalence of antibodies to spotted fever group rickettsiae in humans and domestic animals in a Brazilian spotted fever-endemic area in the State of São Paulo, Brazil: serologic evidence for infection by *Rickettsia rickettsii* and another spotted fever group rickettsia. *Am J Trop Med Hyg* 71:93-97.
215. Olano J, Feng HM, McBride JW, Wen G, WALKER DH. 2004. Histologic, serologic, and molecular analysis of persistent ehrlichiosis in a murine model. *Am J Pathol* 165:997-1006.
216. Valbuena G, Jordan JM, WALKER DH. 2004. T cells mediate cross-protective immunity between spotted group rickettsiae and spotted fever group rickettsiae. *J Infect Dis* 190:1221-1227.
217. McLeod MP, Qin X, Karpathy SE, Gioia J, Highlander SK, Fox GE, McNeill TZ, Jiang H, Muzny D, Jacob LS, Hawes AC, Sodergren E, Gill R, Hume J, Morgan M, Fan G, Amin AG, Gibbs RA, Hong C, Yu XJ, WALKER DH, Weinstock GM. 2004. Complete genome sequence of *Rickettsia typhi* and comparison with sequences of other rickettsiae. *J Bacteriol* 186:5842-5855.
218. Ndip L, Fokam E, Bouyer DH, Ndip R, Titanji PK, WALKER DH, McBride J. 2004. Detection of *Rickettsia africae* in patients and ticks along the coastal region of Cameroon. *Am J Trop Med Hyg* 71:363-366.
219. Calic SB, Galvão MAM, Bacellar F, Mafra CL, Rocha CMBM, Chamone CB, Leite RC, WALKER DH. 2004. Human ehrlichioses in Brazil: first suspect cases. *Braz J Infect Dis* 8:256-262.
220. Valbuena G, WALKER DH. 2004. Effect of blocking the CXCL9/10-CXCR3 chemokine system in the outcome of endothelial-target rickettsial infections. *Am J Trop Med Hyg*. 71:393-399.
221. Labruna MB, Whitworth T, Bouyer DH, McBride J, Camargo LMA, Camargo EP, Popov V, WALKER DH. 2004. *Rickettsia bellii* and *Rickettsia amblyommii* in *Amblyomma* ticks from the state of Rondônia, Western Amazon, Brazil. *J Med Entomol* 41:1073-1081.
222. Valbuena G, WALKER DH. 2005. Expression of CX3CL1 (fractalkine) in mice with endothelial-target rickettsial infection of the spotted fever group. *Virchows Arch* 446:21-27.
223. Labruna MB, Camargo LMA, Camargo EP, WALKER DH. 2005. Detection of a spotted fever group *Rickettsia* in the tick *Haemaphysalis juxtakochi* in Rondonia, Brazil. *Vet Parasitol* 127:169-174.
224. Lai S, WALKER DH, Elghetany MT. 2005. Catastrophic antiphospholipid syndrome: a rare cause of disseminated microvascular thrombotic injury – a case report with pathological and molecular correlative studies. *Pathol Int* 55:144-149.
225. Stevenson HL, Labruna MB, Montenieri JA, Kosoy MY, Gage KL, WALKER, DH. 2005. Detection of *Rickettsia felis* in a New World Flea species, *Anomiopsyllus nudata* (Siphonaptera: Ctenophthalmidae). *J Med Entomol* 42:163-167.
226. Mattner J, DeBord KL, Ismail N, Goff RD, Cantu C, III, Zhou D, Saint-Mezard P, Wang V, Gao Y, Yin N, Hoebe K, Schneewind O, WALKER DH, Beutler B, Teyton L, Savage PB, Bendelac A. 2005. Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections. *Nature* 434:525-529.
227. Valbuena G, WALKER DH. 2005. Changes in the adherens junctions of human endothelial cells infected with spotted fever group rickettsiae. *Virchows Arch* 446:379-382.

228. Whitworth T, Popov VL, Yu XJ, Walker DH, Bouyer DH. 2005. Expression of *Rickettsia prowazekii* *pld* or *tlyC* gene in *Salmonella enterica* serovar typhimurium mediates phagosomal escape. *Infect Immun* 73:6668-6673.
229. Zavala-Castro JE, Small M, Keng C, Bouyer DH, Zavala-Velázquez J, WALKER DH. 2005. Transcription of the *Rickettsia felis ompA* gene in naturally infected fleas. *Am J Trop Med Hyg* 73:662-666.
230. Doyle CK, Labruna MB, Breitschwerdt EB, Tang Y, Corstvet RE, Hegarty B, Bloch KC, Li P, WALKER DH, McBride JW. 2005. Detection of medically important *Ehrlichia* by quantitative multicolor Taqman real-time PCR of the *dsb* gene. *J Mol Diag* 7:504-510.
231. Ndip LM, Ndip RN, Esemu SN, Dickmu VL, Fokam EB, WALKER DH, McBride JW. 2005. Ehrlichial infection in Cameroonian canines by *Ehrlichia canis* and *Ehrlichia ewingii*. *Vet Microbiol* 111:59-66.
232. Guedes E, Leite RC, Prata MCA, Pacheco RC, WALKER DH, Labruna MB. 2005. Detection of the tick *Rickettsia rickettsii* in *Amblyomma cajennense* in a new Brazilian spotted fever-endemic area in the state of Minas Gerais. *Mem Inst Oswaldo Cruz* 100:841-845.
233. Ismail N, Stevenson HL, WALKER DH. 2006. The role of TNF- α and IL-10 in the pathogenesis of severe murine monocytotropic ehrlichiosis: increased resistance of TNF receptor p55- and p75-deficient mice to fatal ehrlichial infection. *Infect Immun* 74:1846-1856.
234. Zavala-Velazquez J, Laviada-Molina H, Zavala-Castro J, Perez-Osorio C, Becerra-Carmona G, Ruiz-Sosa JA, Bouyer DH, WALKER DH. 2006. *Rickettsia felis*, the agent of an emerging infectious disease: report of a new case in Mexico. *Arch Med Res* 37:419-422.
235. Zhang J-Z, Hao J-F, WALKER DH, Yu XJ. 2006. A mutation inactivating the methyltransferase gene in avirulent Madrid E strain *Rickettsia prowazekii* reverted to wild type in the virulent revertant strain Evir. *Vaccine* 24:2317-2323.
236. Zavala-Castro JE, Zavala-Velazquez JE, WALKER DH, Arcila EER, Laviada-Molina H, Olano JP, Ruiz-Sosa JA, Small MA, Azul-Rosado KR. 2006. Fatal human infection with *Rickettsia rickettsii* in Yucatán, Mexico. *Emerg Infect Dis* 12:672-674.
237. Cardoso LD, Freitas RN, Mafrá CL, Neves CVB, Figueira FCB, Labruna MB, Gennari SM, WALKER DH, Galvão MAM. 2006. Characterization of *Rickettsia* spp. circulating in a silent peri-urban focus for Brazilian spotted fever in Caratinga, Minas Gerais, Brazil. *Cad Saúde Pública* 22:495-501.
238. Mavromatis K, Doyle CK, Lykidis A, Ivanova N, Francino MP, Chain P, Shin M, Malfatti S, Larimer F, Copeland A, Detter JC, Land M, Richardson PM, Yu X.J., WALKER DH, McBride JW, Kyripides NC. 2006. The genome of the obligately intracellular bacterium *Ehrlichia canis* reveals themes of complex membrane structure and immune evasion strategies. *J Bacteriol* 188:4015-4023. PMID 16707693. PMCID: 1482910.
239. de Sousa R, Barata C, Vitorino L, Santos-Silva M, Carrapato C, Torgal J, WALKER D, Bacellar F. 2006. *Rickettsia sibirica* isolation from a patient and detection in ticks, Portugal. *Emerg Infect Dis* 12:1103-1108.
240. Stevenson HL, Jordan JM, Peerwani Z, Wang H-Q, WALKER, DH, Ismail N. 2006. An intradermal environment promotes a protective type-1 response against systemic monocytotropic ehrlichial infection. *Infect Immun* 74:4856-4864.

241. Labruna MB, McBride JW, Camargo LM, Aguiar DM, Yabsley MJ, Davidson WR, Stromdahl EY, Williamson PC, Stich RW, Long SW, Camargo EP, WALKER DH. 2007. A preliminary investigation of *Ehrlichia* species in ticks, humans, dogs, and capybaras from Brazil. *Vet Parasitol* 143:189-195.
242. Cardenas AM, Doyle CK, Zhang X, Nethery K, Corstvet RE, WALKER DH, McBride JW. 2007. Enzyme-linked immunosorbent assay with conserved immunoreactive glycoproteins gp36 and gp19 has enhanced sensitivity and provides species-specific immunodiagnosis of *Ehrlichia canis* infection. *Clin Vaccine Immunol* 14:123-128. PMID: PMC1797795.
243. Zhang JZ, Popov VL, Gao S, WALKER DH, Yu XJ. 2007. The developmental cycle of *Ehrlichia chaffeensis* in vertebrate cells. *Cell Microbiol* 9:610-618. PMID: 16987329.
244. Fang R, Ismail N, Soong L, Popov VL, Whitworth T, Bouyer DH, WALKER DH. 2007. Differential interaction of dendritic cells with *Rickettsia conorii*: Impact on host susceptibility to murine spotted fever rickettsiosis. *Infect Immun* 75:3112-3123.
245. Ismail N, Crossley E, Stevenson HL, WALKER DH. 2007. Relative importance of T cell subsets in monocytotropic ehrlichiosis: A novel effector mechanism involved in *Ehrlichia*-induced immunopathology in murine ehrlichiosis. *Infect Immun* 75:4608-4620.
246. Ndip LM, Ndip RN, Ndive V, Awuh JA, WALKER DH, McBride JW. 2007. *Ehrlichia* species in *Rhipicephalus sanguineus* ticks in Cameroon. *Vector Borne Zoonotic Dis* 7:221-227.
247. Jordan JM, Woods ME, Feng H-M, Soong, L, WALKER DH. 2007. Rickettsiae-stimulated dendritic cells mediate protection against lethal rickettsial challenge in an animal model of spotted fever rickettsiosis. *J Infect Dis* 196:629-638.
248. de Sousa R, Ismail N, Nobrega SD, Franca A, Amaro M, Anes M, Pocas J, Coelho R, Torgai J, Bacellar F, WALKER DH. 2007. Intralesional expression of mRNA of interferon- γ , tumor necrosis factor- α , interleukin-10, nitric oxide synthase, indoleamine-2, 3-dioxygenase, and RANTES is a major immune effector in Mediterranean spotted fever rickettsiosis. *J Infect Dis* 196:770-781.
249. Hidalgo M, Sanchez R, Orejuela L, Hernandez J, Castaneda E, WALKER DH, Valbuena G. 2007. Prevalence of antibodies against spotted fever group rickettsiae in a rural area of Colombia. *Am J Trop Med Hyg* 77:378-380.
250. de Sousa R, Santos-Silva M, Santos AS, Barros SC, Torgal J, WALKER DH, Bacellar F. 2007. *Rickettsia conorii* Israeli tick typhus strain isolated from *Rhipicephalus sanguineus* ticks in Portugal. *Vector Borne Zoonotic Dis* 7:444-447. PMID 17767403.
251. Popov VL, Korenberg EI, Nefedova VV, Han VC, Wen JW, Kovalevskii YV, Gorelova NB, WALKER DH. 2007. Ultrastructural evidence of the ehrlichial developmental cycle in naturally infected *Ixodes persulcatus* ticks in the course of coinfection with rickettsia, *Borrelia*, and a flavivirus. *Vector Borne Zoonotic Dis* 7:699-716. PMID 18171109.
252. Hidalgo M, Orejuela L, Fuya P, Carrillo P, Hernandez J, Parra E, Keng C, Small M, Olano JP, Bouyer DH, Castaneda E, WALKER DH, Valbuena G. 2007. Rocky Mountain spotted fever, Colombia. *Emerg Infect Dis* 13:1058-1060.
253. Thirumalapura NR, Stevenson HL, WALKER DH, Ismail N. 2008. Protective heterologous immunity against fatal ehrlichiosis and lack of protection following homologous challenge. *Infect Immun* 76:1920-1930. PMID: PMC2346691.

254. Stevenson HL, Crossley EC, Thirumalapura N, WALKER DH, Ismail N. 2008. Regulatory roles of CD1d-restricted NKT cells in the induction of toxic shock-like syndrome in an animal model of fatal ehrlichiosis. *Infect Immun* 76:1434-1444. PMID: PMC2292873.
255. de Sousa R, Duque L, Anes M, Pocas J, Torgal J, Bacellar F, Olano J, WALKER DH. 2008. Lymphangitis in a Portuguese patient infected with *Rickettsia sibirica*. *Emerg Infect Dis* 14:529-531. PMID: PMC2570837.
256. Jordan JM, Woods ME, Olano J, WALKER DH. 2008. Absence of toll-like receptor 4 signaling in C3H/HeJ mice predisposes them to overwhelming rickettsial infection and decreased protective Th1 responses. *Infect Immun* 76:3717-3724. PMID: PMC2493240.
257. Zhu Y, Medina-Sanchez A, Bouyer D, Walker DH, Yu X-J. 2008. Genotyping *Rickettsia prowazekii* isolates. *Emerg Infect Dis* 14:1300-1302. PMID: PMC2600365.
258. Sousa R, Franca A, Doria NS, Belo A, Amaro M, Abreu T, Pocas J, Proenca P, Vaz J, Torgal J, Bacellar F, Ismail N, WALKER DH. 2008. Host- and microbe-related risk factors for and pathophysiology of fatal *Rickettsia conorii* infection in Portuguese patients. *J Infect Dis* 198:576-585. PMID: PMC2614375.
259. Zavala-Castro JE, Dzul-Rosado KR, Arias Leon JJ, WALKER DH, Zavala-Velazquez JE. 2008. Short report: *Rickettsia felis* outer membrane protein A: A potential tool for diagnosis of patients with flea-borne spotted fever. *Am J Trop Med Hyg* 79:903-906. PMID 19052301.
260. Zavala-Castro JE, Dzul-Rosado KR, Leon JJ, WALKER DH, Zavala-Velazquez JE. 2008. An increase of human cases of spotted fever rickettsiosis in Yucatán, Mexico, involving children. *Am J Trop Med Hyg* 79:907-910. PMID 19052302.
261. Jordan JM, Woods ME, Soong L, WALKER DH. 2009. Rickettsiae stimulate dendritic cells through toll-like receptor 4, leading to enhanced NK cell activation *in vivo*. *J Infect Dis* 199:236-242. PMID: PMC2613164.
262. Gracner M, Avsic-Zupan T, Punda-Polic V, Dolinsek J, Bouyer D, WALKER DH, Zavala-Castro JE, Bradaric N, Crocquet-Valdes PA, Duh D. 2009. Comparative *ompA* gene sequence analysis of *Rickettsia felis*-like bacteria detected in *Haemaphysalis sulcata* ticks and isolated in the mosquito C6/36 cell line. *Clin Microbiol Infect* 15:265-266. PMID 19298401.
263. Pena DCH, Mafra CL, Calic SB, Labruna MB, Milagres BS, WALKER DH, Galvao MAM. 2009. Serologic survey for antibodies to *Rickettsia* among domestic and wild animal populations in Brazil. *Clin Microbiol Infect* 15:243-244. Doi: 10.1111/j.1469-0691.2008.02165.x PMID 19392893.
264. Thomas S, Thirumalapura N, Crossley EC, Ismail N, WALKER DH. 2009. Antigenic protein modifications in *Ehrlichia*. *Parasite Immunol* 31:296-303. PMID: PMC2731653.
265. Yu X-J, WALKER DH, Liu Y, Zhang L. 2009. Amino acid biosynthesis deficiency in bacteria associated with humans and animals. *Infect Genet Evol* 9:514-517. PMID: PMC2723833.
266. Zavala-Castro J, Zavala-Velazquez J, WALKER D, Perez-Osorio J, Peniche-Lara G. 2009. Severe human infection with *Rickettsia felis* associated with hepatitis. *Int J Med Microbiol* 299:529-533 Doi:10.1016/j.ijmm.2009.03.002. PMID 19481502.
267. Driskell LO, Yu X, Zhang L, Liu Y, Popov VL, WALKER DH, Tucker AM, Wood DO. 2009. Directed mutagenesis of the *Rickettsia prowazekii* *pld* gene encoding phospholipase D. *Infect Immun* 77:3244-3248. PMID: PMC2715659.

268. Fang R, Ismail N, Shelite T, WALKER DH. 2009. CD4⁺CD25⁺ Foxp3⁻ T regulatory cells produce both IFN- γ and IL-10 during acute severe murine spotted fever rickettsiosis. *Infect Immun* 77:3838-3849. Doi: 10.1128/IAI.00349-09. PMID: PMC2738046.
269. Thirumalapura NR, Crossley EC, WALKER DH, Ismail N. 2009. Persistent infection contributes to heterologous protection against fatal ehrlichiosis. *Infect Immun* 77:5682-5689. PMID: PMC2786466.
270. Ndip LM, Labruna M, Ndip RN, WALKER DH, McBride J. 2009. Molecular and clinical evidence of *Ehrlichia chaffeensis* infection in Cameroonian patients with undifferentiated febrile illness. *Ann J Trop Med Parasitol* 103:719-725. PMID: PMC2913319.
271. Zhang S, Song H, Liu Y, Li Q, Wang Y, Wu J, Wan J, Li G, Yu C, Li X, Yin W, Xu Z, Liu B, Zhang Q, Wan K, Li G, Fu X, Zhang J, He J, Hai R, Yu D, WALKER DH, Xu J, Yu XJ. 2010. Scrub typhus in previously unrecognized endemic areas in China. *J Clin Microbiol* 48:1241-1244. PMID: PMC2849583.
272. Ndip L, McBride JW, WALKER DH. 2010. Predominance of *Ehrlichia chaffeensis* in *Rhipicephalus sanguineus* ticks from kennel-confined dogs in Limbe, Cameroon. *J Appl Exp Aracol* 50:163-168. PMID: PMC2797824.
273. Duh D, Punda-Polic V, Avsic-Zupanc T, Bouyer D, WALKER DH, Popov VL, Jelovsek M, Gracner M, Trilar T, Bradaric N, Jurtii TJ, Strus J. 2010. *Rickettsia hoogstraalii* sp. nov., isolated from hard- and soft-bodied ticks. *Int J Syst Evol Microbiol* 60:977-984. PMID 19666817.
274. Stevenson HL, Estes DM, Thirumalapura NR, WALKER DH, Ismail N. 2010. Natural killer cells promote tissue injury and systemic inflammatory responses during fatal *Ehrlichia*-induced toxic shock-like syndrome. *Am J Pathol* 177:766-776. PMID: PMC2913354.
275. Oliveira K, Pinter A, Medina-Sanchez A, Boppana VD, Wikel SK, Saito TB, Shelite T, Blanton L, Popov V, Teel PD, WALKER DH, Galvao MAM, Mafra C, Bouyer DH. 2010. *Amblyomma imitator* ticks as vectors of *Rickettsia rickettsii*, Mexico. *Emerg Infect Dis* 16:1282-1284. PMID: 20678325.
276. Milagres BS, Padilha AF, Barcelos RM, Gomes GG, Montandon CE, Pena DCH, Nieri Bastos FA, Silveira I, Pacheco R, Labruna MB, Bouyer DH, Freitas RN, WALKER DH, Mafra CL, Galvao MAM. 2010. *Rickettsia* in synanthropic and domestic animals and their hosts from two areas of low endemicity for Brazilian spotted fever in the eastern region of Minas Gerais, Brazil. *Am J Trop Med Hyg* 83:1305-1307. PMID 21118939.
277. Ceballos G, Manzano P, Mendez-Harclerode FM, Haynie ML, WALKER DH, Bradley RD. 2010. Geographic distribution, genetic diversity, and conservation status of the southern flying squirrel (*Glaucomys volans*) in Mexico. *Occasional Papers, Museum of Texas Tech University* 299:1-15.
278. Thomas S, Popov VL, WALKER DH. 2011. Exit mechanisms of the intracellular bacterium *Ehrlichia*. *PLoS One* 5:e15775. PMID: PMC 3004692.
279. Yu, X-J, Liang M-F, Zhang S-Y, Liu Y, Li J-D, Sun Y-L, Zhang L, Zhang Q-F, Popov VL, Li C, Qu, J, Li Q, Zhang YP, Hai R, Wu W, Wang Q, Zhan F-X, Wang X-J, Khan B, Wang S-W, Wan K-L, Jing H-Q, Lu J-X, Yin W-W, Zhou H, Guan X-H, Liu J-F, Bi Z-Q, Liu G-H, Ren J, Wang H, Zhao Z, Song J-D, He, J-R, Wan T, Zhang J-S, Fu, X-I, Sun L, Dong X-P, Feng, Z-J, Yang W-Z, Hong T, Zhang Y, WALKER DH, Wang Y, Li D-X. 2011. Fever with thrombocytopenia associated with novel bunyavirus in China. *N Eng J Med* 364:1523-1532. PMID: PMC3113718.

280. Liu Y, Zhang Z, Jiang Y, Zhang L, Popov VL, Zhang J, WALKER DH, Yu X-J. 2011. Obligate intracellular bacterium *Ehrlichia* inhibiting mitochondrial activity. *Microbes Infect* 13:232-238. PMID: PMC3031727.
281. Crocquet-Valdes PA, Thirumalapura NR, Ismail N, Yu X, Saito TB, Stevenson HL, Pietzsch CA, Thomas S, WALKER DH. 2011. Immunization with *Ehrlichia* outer membrane P28 proteins confers protection in a mouse model of ehrlichiosis. *Clin Vaccine Immunol* 18:2018-2025. PMID: PMC3232687.
282. Liu Y, Li Q, Hu W, Wu J, Wang Y, Mei L, WALKER DH, Ren J, Wang Y, Yu XJ. 2011. Person-to-person transmission of severe fever with thrombocytopenia syndrome virus. *Vector-borne Zoonotic Dis.* PMID 21955213
283. WALKER DH. Paddock CD. 2011. Fatal Rocky Mountain spotted fever in a 2-year-old child. *Path Case Rev* 16:238-241.
284. Thomas S, Thirumalapura NR, Crocquet-Valdes PA, Luxon B, WALKER DH. 2011. Structure-based vaccines provide protection in a mouse model of ehrlichiosis. *PLoS One* 6:e27981. PMID: PMC2731653.

PUBLISHED PROCEEDINGS OF SCIENTIFIC CONFERENCES

1. WALKER DH, Kirkman HN, Wittenberg PH. 1981. Genetic states possibly associated with enhanced severity of Rocky Mountain spotted fever. In: *Rickettsiae and Rickettsial Diseases*. Burgdorfer W, Anacker RL, eds. Academic Press, New York, NY, 621-630.
2. WALKER DH, Cain BG, Lange JV, Harrison A. 1981. Pathologic and rickettsial events in tetracycline-treated experimental Rocky Mountain spotted fever. In: *Rickettsiae and Rickettsial Diseases*. Burgdorfer W, Anacker RL, eds. Academic Press, New York, NY, 347-362.
3. WALKER DH, Lange JV, Hanff PA, Tidwell RR, Hegarty BC. 1984. Antigens of *Rickettsia rickettsii* and *Rickettsia conorii*. In: *Microbiology 1984*. Lieve L, Schlessinger D, eds. Am Soc Microbiology, Washington, D.C., 244-247.
4. Li H, WALKER DH. 1990. Biological characterization of major polypeptides on the surface of spotted fever group rickettsiae. *Ann NY Acad Sci* 590:389-394.
5. Liu QH, WALKER DH, Zhou G-F. 1990. Serologic survey for antibodies to *Rickettsia sibirica* in Inner Mongolia, China. *Ann N Y Acad Sci* 590:237-242.
6. Aronson J, Scimeca J, Harris D, WALKER DH. 1990. Immunohistologic demonstration of *Ehrlichia canis*. *Ann N Y Acad Sci* 590:148-156.
7. Li H, WALKER DH. 1990. Biological characterization of major polypeptides on the surface of spotted fever group rickettsiae. *Ann N Y Acad Sci* 570:389-394.
8. Uchida T, Uchiyama T, Koyama AH, Yu XJ, WALKER DH, Funato T, Kitamura Y. 1991. Isolation and identification of *Rickettsia japonica*, causative agent of spotted fever group rickettsial infections in Japan. In: *Rickettsiae and Rickettsial Diseases*. Kazar J, Raoult D, eds. Publishing House of the Slovak Academy of Sciences, Bratislava, Slovak Republic, 389-395.
9. WALKER DH, Fishbein DB. 1991. Epidemiology of rickettsial diseases. In: *Rickettsiae and Rickettsial Diseases*. Kazar J, Raoult D, eds. Publishing House of the Slovak Academy of Sciences, Bratislava, Slovak Republic, 370-382.

10. Uchiyama T, Uchida T, WALKER DH. 1991. Analysis of antigens of *Rickettsia japonica* with species-specific monoclonal antibodies. In: *Rickettsiae and Rickettsial Diseases*. Kazar J, Raoult D, eds. Publishing House of the Slovak Academy of Sciences, Bratislava, Slovak Republic, 396-400.
11. WALKER DH. 1996. Advances in understanding of typhus group rickettsial infections. In: *Rickettsiae and Rickettsial Diseases*. Kazar J, Toman R, eds. Slovak Academy of Sciences, Bratislava, Slovak Republic, 16-27.
12. WALKER DH, Popov VL, Welsh CJR, Feng H-M. 1996. Mechanisms of rickettsial killing within cytokine-stimulated endothelial cells. In: *Rickettsiae and Rickettsial Diseases*. Kazar J, Toman R, eds. Slovak Academy of Sciences, Bratislava, Slovak Republic, 51-56.
13. Feng H-M, Popov VL, Billings A, Yuoh G, WALKER DH. 1996. Role of T-lymphocyte subsets in immunity to SFG rickettsiae. In: *Rickettsiae and Rickettsial Diseases*. Kazar J, Toman R, eds. Slovak Academy of Sciences, Bratislava, Slovak Republic, 255-260.
14. Yu X-J, Crocquet-Valdes P, Cullman LC, Piesman JF, Olson JG, WALKER DH. 1996. Genetic diversity of a 120-kDa immunodominant protein of *Ehrlichia chaffeensis*: a potential recombinant diagnostic tool. In: *Rickettsiae and Rickettsial Diseases*. Kazar J, Toman R, eds. Slovak Academy of Sciences, Bratislava, Slovak Republic, 324-328.
15. Chen S-M, Popov VL, Westerman EL, Hamilton FG, Dumler JS, Feng H-M, WALKER DH. 1996. Antigenic diversity among strains of *Ehrlichia chaffeensis*. In: *Rickettsiae and Rickettsial Diseases*, Kazar J, Toman R, eds. Slovak Academy of Sciences, Bratislava, Slovak Republic, 329-334.
16. Diaz M, Feng H-M, WALKER DH. 1999. *Rickettsia conorii* antigen presentation to CD8 T-lymphocytes by a murine endothelial cell line. In: *Rickettsiae and Rickettsial Diseases at the Turn of the Third Millenium*. Raoult D, Brouqui P, eds. Elsevier, Paris, France, 123-127.
17. Feng H-M, WALKER DH. 1999. Mechanisms of immunity to *Ehrlichia chaffeensis* in mice. In: *Rickettsiae and Rickettsial Diseases at the Turn of the Third Millenium*. Raoult D, Brouqui P, eds. Elsevier, Paris, France, 145-150.
18. Galvao M, Chamone CB, Calic SB, Machado MC, Otoni MEA, Dietze R, Moron C, Feng H-M, Olano JP, WALKER DH. Serologic evidence of spotted fever group Rickettsia in Novo Cruzeiro Municipality-Minas Gerais State-Brazil. In: *Rickettsiae and Rickettsial Diseases at the Turn of the Third Millenium*. Raoult D, Brouqui P, eds. Elsevier, Paris, France, 240-243, 1999.
19. McBride JW, Yu X-J, WALKER DH. Molecular characterization of a new 28-kilodalton protein gene and a multigene locus encoding five homologous 28-kilodalton immunodominant outer membrane proteins of *Ehrlichia canis*. In: *Rickettsiae and Rickettsial Diseases at the Turn of the Third Millenium*. Raoult D, Brouqui P, eds. Elsevier, Paris, France, 43-47, 1999.
20. Moron CG, Yu X-J, Crocquet-Valdes P, Walker DH. 1999. Sequence analysis of the *romp B* gene of *Rickettsia prowazekii* isolated from flying squirrels. In: *Rickettsiae and Rickettsial Diseases at the Turn of the Third Millenium*. Raoult D, Brouqui P, eds. Elsevier, Paris, France, 48-51.
21. Olano JP, Masters E, Cullman L, Hogrefe W, Yu X-J, WALKER DH. 1999. Human monocytotropic ehrlichiosis (HME): Epidemiological, clinical and laboratory diagnosis of a newly emergent infection in the United States. In: *Rickettsiae and Rickettsial Diseases at the Turn of the Third Millenium*. Raoult D, Brouqui P, eds. Elsevier, Paris, France, 262-268.

22. Rudakov NV, Samoilenko IE, Yakimenko VV, Reshetnikova TA, Chpynov SN, WALKER DH. 1999. The re-emergence of Siberian tick typhus: field and experimental observations. In: *Rickettsiae and Rickettsial Diseases at the Turn of the Third Millenium*. Raoult D, Brouqui P, eds. Elsevier, Paris, France, 269-273.
23. WALKER DH, Crocquet-Valdes PA, Feng H-M. 1999. Intracellular anti-rickettsial mechanisms of chemokine- and cytokine-activated human macrophages and hepatocytes. In: *Rickettsiae and Rickettsial Diseases at the Turn of the Third Millenium*. Raoult D, Brouqui P, eds. Elsevier, Paris, France, 189-194.
24. WALKER DH, Zavala-Velazquez JE, Ramirez G, Olano JP. 1999. Emerging infectious diseases in the Americas. In: *Rickettsiae and Rickettsial Diseases at the Turn of the Third Millenium*. Raoult D, Brouqui P, eds. Elsevier, Paris, France, 274-277.
25. Bouyer DH, Stenos J, Crocquet-Valdes P, Foil L, WALKER DH. 1999. The identification and characterization of a previously undiscovered rOmpA encoding gene in *Rickettsia felis*. In: *Rickettsiae and Rickettsial Diseases at the Turn of the Third Millenium*. Raoult D, Brouqui P, eds. Elsevier, Paris, France, 11-15.
26. Yu X-J, McBride JW, WALKER DH. 1999. Characterization of the genus-common outer membrane proteins in *Ehrlichia*. In: *Rickettsiae and Rickettsial Diseases at the Turn of the Third Millenium*. Raoult D, Brouqui P, eds. Elsevier, Paris, France, 103-108.
27. WALKER DH. 2001. Vector-borne zoonotic diseases in the U.S.: Ehrlichioses and rickettsioses. Am Heartworm Soc Mtg. 89-96.
28. Galvão MAM, Mafra CL, Moron C, Anaya E, WALKER DH. 2003. Rickettsiosis of the genus *Rickettsia* in South America. *Ann N Y Acad Sci.* 990:57-61.
29. Whitworth T, Popov V, Han V, Bouyer D, Stenos J, Graves S, Ndip L, WALKER DH. 2003. Ultrastructural and genetic evidence of a reptilian tick, *Aponomma hydrosauri*, as a host of *Rickettsia honei* in Australia. *Ann N Y Acad Sci.* 990:67-74.
30. McBride JW, Comer JE, WALKER DH. 2003. Novel immunoreactive glycoprotein orthologs of *Ehrlichia* spp. *Ann N Y Acad Sci.* 990:678-684.
31. Crocquet-Valdes PA, McBride JW, Yu X-J, WALKER DH. 2003. Molecular characterization of the 28 kDa multigene locus of *Ehrlichia muris*. *Ann N Y Acad Sci.* 990:714-716.
32. WALKER DH, Ismail N, Olano JP, McBride JW, Yu X, Feng H-W. 2004. *Ehrlichia chaffeensis*: A prevalent, life-threatening, emerging pathogen. *Trans Am Clin Climatol Assoc.* 115: 375-384.
33. WALKER DH. 2004. Current situation and trends of rickettsiosis in the Americas. PAHO/WHO Experts Consultation on Rickettsiosis in the Americas. Ouro Preto, Minas Gerais, Brazil. 19-21.
34. WALKER DH. 2005. Emerging and re-emerging treatable, but often untreated, vector-borne bacterial diseases in the Tropics. *Rev Inst Nac de Salud* 25:18-20.
35. WALKER DH. 2005. Enfermedades frecuentemente olvidadas transmitidas por vectores. *Rev Inst Nac de Salud* 25: 60-61.
36. Crocquet-Valdes PA, McBride JW, Feng HM, Ismail N, Small MA, Yu XJ, WALKER DH. 2005. Analysis of ehrlichial p28 gene expression in a murine model of persistent infection. *Ann N Y Acad Sci* 1063:420-424.

37. Long SW, Whitworth TJ, WALKER DH, Yu XJ. 2005. Overcoming barriers to the transformation of the genus *Ehrlichia*. *Ann N Y Acad Sci* 1063:403-410.
38. Sousa R, Ismail N, Dória-Nóbrega S, Costa P, Abreu T, Franca A, Amaro M, Proenca P, Brito, Pocas J, Ranos T, Christina G, Pombo G, Vitorino L, Torgal J, Bacellar F, WALKER DH. 2005. The presence of eschars but not greater severity in Portuguese patients infected with Israeli tick typhus strain of *Rickettsia conorii*. *Ann N Y Acad Sci* 1063:197-202.
39. Ismail N, WALKER DH. 2005. Balancing protective immunity and immunopathology: a unifying model of moncytotropic ehrlichiosis. *Ann N Y Acad Sci* 1063:383-394.
40. Medina-Sanchez A, Bouyer DH, Alcantara-Rodriguez A, Mafra C, Zavala-Castro J, Whitworth T, Popov VL, Fernandez-Salas I, WALKER DH. 2005. Detection of a typhus group *Rickettsia* in *Amblyomma* ticks in the state of Nuevo Leon, Mexico. *Ann N Y Acad Sci* 1063:327-332.
41. WALKER DH, Yu X-J. 2005. Progress in rickettsial genome analysis from pioneering of *Rickettsia prowazekii* to the recent *Rickettsia typhi*. *Ann N Y Acad Sci* 1063:13-25.
42. Galvao MAM, Zavala-Velazquez JE, Zavala-Castro JE, Mafra CL, Calic SB, WALKER DH. 2006. *Rickettsia felis* in the Americas. In: Hechemy KE, Oteo JA, Raoult DA, Silverman DJ, Blanco JR (eds) *Century of Rickettsiology: Emerging, Reemerging Rickettsioses, Molecular Diagnostics, and Emerging Veterinary Rickettsioses*. *Ann NY Acad Sci* 1078:156-158.
43. Galvao MAM, Cardoso LD, Mafra CL, Calic SB, WALKER DH. 2006. Revisiting Brazilian spotted fever focus of Caratinga, Minas Gerais State, Brazil. In: Hechemy KE, Oteo JA, Raoult DA, Silverman DJ, Blanco JR (eds) *Century of Rickettsiology: Emerging, Reemerging Rickettsioses, Molecular Diagnostics, and Emerging Veterinary Rickettsioses*. *Ann NY Acad Sci* 1078:255-256.
44. Popov VL, Han VC, Wen JW, WALKER DH. 2008. Electron microscopy in identification of novel environmental microorganisms potentially dangerous for humans and animals. *Miscros Microanal* 14 Suppl 2:1534-1535.
45. WALKER DH. Rickettsial diseases of the Americas. 2011. *Biomedica Revista del Instituto Nacional de Salud* 31:11.

REVIEW ARTICLES:

1. Hine PF, WALKER DH. 1978. Diagnosis of Rocky Mountain spotted fever and other rickettsial diseases. *Bull Lab Med (NC Memorial Hospital, Chapel Hill, NC)*, No. 30 (April).
2. WALKER DH, Mattern WD. 1980. Rickettsial vasculitis. *Am Heart J* 100:896-906.
3. Groben P, WALKER DH. 1983. Legionnaires' disease: Laboratory approach to the diagnosis of the unusual pneumonias. *Bull Lab Med (NC Memorial Hospital, Chapel Hill, NC)*, No. 69.
4. Tringali GR, Montenegro MR, WALKER DH, Mansueto S. 1983. Immunity and rickettsial infection: A review. *Acta Trop* 40:311-320.
5. WALKER DH. 1986. Gastroenterology of Rocky Mountain spotted fever. *Practical Gastroenterology* 10:25-39.
6. Fan MY, WALKER DH, Yu SR, Liu QH. 1987. Epidemiology and ecology of rickettsial diseases in the People's Republic of China. *Rev Infect Dis* 9:823-840.

7. WALKER DH. 1988. Infectious Disease. How do rickettsiae cause disease? 1988 Year Book of Pathol Clin Pathol 1:17-21.
8. WALKER DH. 1989. Rocky Mountain spotted fever: a disease in need of microbiological concern. Clin Microbiol Rev 2:227-240.
9. WALKER DH. 1989. Rickettsioses of the spotted fever group around the world. J Dermatol 16:169-177.
10. WALKER DH. 1990. The role of host factors in the severity of spotted fever and typhus rickettsioses. Ann NY Acad Sci 590:10-19.
11. WALKER DH, Fishbein DB. 1991. Epidemiology of rickettsial diseases. Eur J Epidemiol 7:237-245.
12. Dumler JS, WALKER DH. 1991. Human ehrlichiosis. Curr Opin Infect Dis 4: 597-602.
13. WALKER DH, Yampolska O, Grinberg LM. 1994. Death at Sverdlovsk: What have we learned? Am J Pathol 144: 1135-1141.
14. WALKER DH. 1995. Rocky Mountain spotted fever: a seasonal alert. Clin Infect Dis 20:1111-1117.
15. WALKER DH. 1995. Animal model of human disease: Endothelial-target rickettsial infection. Comparative Pathology Bulletin XXVII:4-6.
16. WALKER DH, Dumler JS. 1996. Emergence of the ehrlichioses as human health problems. Emerg Infect Dis 2:18-29.
17. Woods GL, WALKER DH. 1996. Detection of infection or infectious agents by use of cytologic and histologic stains. Clin Microbiol Rev 9:382-404.
18. Walker DH. 1998. Tick-transmitted infectious diseases in the United States. Annu Rev Public Health 19:237-269.
19. Thorner AR, WALKER DH, Petri WA, Jr. 1998. Rocky Mountain spotted fever. Clin Infect Dis 27:1353-1360.
20. Elghetany MT, WALKER DH. 1999. Hemostatic changes in Rocky Mountain spotted fever and Mediterranean spotted fever. Am J Clin Pathol 112:159-168.
21. Dumler JS, WALKER DH. 2001. Tick-borne ehrlichioses. Lancet Infect Dis (Preview Issue) pgs 21-28.
22. Ismail N, Olano JP, Feng H-M, WALKER DH. 2002. Current status of immune mechanisms of killing of intracellular microorganisms. FEMS Microbiol Lett 207:111-120.
23. Valbuena G, Feng H-M, WALKER DH. 2002. Mechanisms of immunity against rickettsiae. New perspectives and opportunities offered by unusual intracellular parasites. Microbes Infect 4:625-633.
24. Olano JP, WALKER DH. 2002. Human ehrlichioses: Diagnostic challenges and therapeutic recommendations. Infect Med. 19:318-325.
25. WALKER DH. 2003. Rickettsial diseases in travelers. J Travel Med Infect Dis. 1:35-40.

26. WALKER DH, Valbuena GA, Olano JP. 2003. Pathogenic mechanisms of diseases caused by *Rickettsia*. *Ann N Y Acad Sci*. 990:1-11.
27. WALKER DH. 2003. Principles of the malicious use of infectious agents to create terror: reasons for concern for organisms of the genus *Rickettsia*. *Ann N Y Acad Sci*. 990:739-742.
28. WALKER DH. 2004. Ricketts creates rickettsiology, the study of vector-borne obligately intracellular bacteria. *J Infect Dis*. 189: 938-955.
29. Galvão MAM, Mafrá CL, Chamone CB, Calic SB, Zavala-Velázquez J, WALKER DH. 2004. Clinical and laboratorial evidence of *Rickettsia felis* infections in Latin America. *Revista da Sociedade Brasileira de Medicina Tropical*. 37: 238-240.
30. WALKER DH. 2005. Ehrlichia under our noses and no one notices. *Arch Virol Supp* 19:147-156.
31. Valbuena GA, WALKER DH. 2006. Endothelium as a target for infections. *Annu Rev Pathol Mech Dis* 1:171-198.
32. WALKER DH. Targeting *Rickettsia*. 2006. *N Engl J Med* 354:1418-1420.
33. Chapman AS, Bakken JS, Bloch KC, Buckingham SC, Dasch GA, Dumler JS, Ereemeeva ME, Folk SM, Krusell A, Marshall GS, McQuiston JH, Nicholson WL, Ohl CA, Paddock CD, Sexton DJ, Storch GA, Swerdlow DL, WALKER DH. 2006. Diagnosis and management of tickborne rickettsial diseases: Rocky Mountain spotted fever, ehrlichioses, and anaplasmosis – United States. A practical guide for physicians and other health care and public health professionals. *MMWR* 55:RR-4.
34. Yu XJ, McBride JW, WALKER DH. 2007. Restriction and expansion of *Ehrlichia* strain diversity. *Vet Parasitol* 143:337-346.
35. WALKER DH. 2007. Rickettsiae and rickettsial infections: The current state of knowledge. *Clin Infect Dis* 45S:39-44.
36. Dong J, Olano JP, McBride JW, WALKER DH. 2008. Emerging pathogens: Challenges and success of molecular diagnostics. *J Mol Diag* 10:185-197. PMID 1840306.
37. WALKER DH, Ismail N. 2008. Emerging and re-emerging rickettsioses: Endothelial cell infection and early disease events. *Nat Rev Microbiol* 6:375-386. PMID 18414502.
38. WALKER DH, Paddock CD, Dumler JS. 2008. Emerging and re-emerging tick-transmitted rickettsial and ehrlichial infections. *Med Clin N Am* 92:1345-1361.
39. WALKER DH. 2009. The realities of biodefense vaccines against *Rickettsia*. *Vaccine* 27:D52-D55. PMID: PMC2909128.
40. Valbuena G, WALKER DH. 2009. Infection of the endothelium by members of the order Rickettsiales. *Thromb Haemost* 102:1071-1079. ISSN: 0340-6245. PMID: PMC2913309.
41. McBride JW, WALKER DH. 2010. Progress and obstacles in vaccine development for the ehrlichioses. *Expert Rev Vaccines* 9:1071-1082. PMID 20822349.

42. McBride JW, WALKER DH. 2011. Molecular and cellular pathobiology of *Ehrlichia* infection: Targets for new therapeutics and immunomodulation strategies. *Expert Rev Mol Med* 13:3e. PMID 21276277.
43. Olano J, WALKER DH. 2011. Diagnosing emerging and re-emerging infectious diseases: The pivotal role of the pathologist. *Arch Pathol* 135:83-91. PMID 21204714.
44. Mansueto P, Vitale G, Cascio A, Seidita A, Pepe H, Carroccio A, di Rosa S, Rini GB, Cillari E, WALKER D. 2012. New insight into immunity and immunopathology of rickettsial diseases. *Clin Dev Immunol* 2012:697852. PMCID: PMC 3170826.

MISCELLANEOUS: (Letters, Editorials, Non-peer Reviewed Articles, Book Reviews)

1. WALKER DH, Mattern WD. 1980. Renal failure in Rocky Mountain spotted fever. Reply to letter. *Arch Intern Med* 140:867.
2. Kirkman HN, WALKER DH. 1982. Glucose-6-phosphate dehydrogenase deficiency and Mediterranean fever in northern Sardinia. Reply to letter. *J Infect Dis* 146:301-302.
3. Riley HD Jr, Shepard CC, WALKER DH. 1982. Think Rocky Mountain spotted fever! *Patient Care* 16:21-38.
4. Cancelosi SE, WALKER DH, Folds JD. 1982. Rocky Mountain spotted fever in siblings. *Clin Microbiol Newsletter* 4:29-30.
5. WALKER DH, Kaplowitz LG. 1982. Significance of serum lactic dehydrogenase in Rocky Mountain spotted fever. *Acta Medit Patol Inf Trop* 1:159-166.
6. WALKER DH, Kirkman HN. 1983. Glucose-6-phosphate dehydrogenase deficiency in male patients with Mediterranean spotted fever in Sardinia. Reply to letter. *J Infect Dis* 147:608.
7. Montenegro MR, Hegarty BC, Tringali G, WALKER DH, Mansueto S. 1983. Identification of *Rickettsia conorii* in tissues by immunofluorescence. *Acta Medit Patol Inf Trop* 2:161-168.
8. WALKER DH, Bradford WD. 1983. Unusual abdominal involvement in rickettsial diseases. Reply to letter. *JAMA* 249:1710.
9. WALKER DH. 1983. Book Review. *Legionnaires' Disease*, by Gary L. Lattimer and Richard A. Ormsbee. *Arch Pathol Lab Med* 107:104.
10. WALKER DH, Radisch DL, Kirkman HN. 1983. Haemolysis with rickettsiosis and glucose-6-phosphate dehydrogenase deficiency. *Lancet* 23 Jul:217.
11. WALKER DH. Book Review. 1984. The pathology of opportunistic infections with pathogenetic, diagnostic, and clinical correlations, by R.L. Myerowitz. *Arch Pathol Lab Med* 108:761.
12. Mansueto S, Grisham J, Staiti A, WALKER DH, Tringali G. 1984. Tentativi di dimostrazione diretta di *R. conorii* in biopsie epatiche di pazienti con FB. *Acta Medit Pathol Inf Trop* 3:12.
13. Benson M, WALKER DH. 1984. Rocky Mountain spotted fever in the differential diagnosis of the acute abdomen. *Contemp Surg* 24:79-83.
14. Tringali G, WALKER DH, Mansueto S, Portera M, Intonazzo V, Barba G. 1984. Isolamento ed identificazione di *Rickettsia conorii* da casi di febbre bottonosa: reperti istopatologici nella *tache noire* umana e nel modello sperimentale in cavia. *Acta Medit Patol Inf Trop* 3:57-64.

15. Tringali G, WALKER DH, Di Leo R, Bruno F, Mansueto S. 1985. Extracutaneous manifestations of *R. rickettsii* and *R. conorii*. *Giornale di Malattie Infettive e Parassitarie* 37:161-163.
16. Mansueto S, Di Leo R, Montenegro MR, Tringali G, Maniscalco M, WALKER DH. 1985. Tick-bite and *Rickettsia conorii* inoculation without subsequent illness. *Giornale di Malattie Infettive e Parassitarie*, 37:159-160.
17. Mansueto S, Tringali G, WALKER DH. 1986. Widespread, simultaneous increase in the incidence of spotted fever group rickettsioses. *J Infect Dis* 154:539-540.
18. Fan MY, Yu SR, WALKER DH. 1986. Rickettsiology in China: a personal account. *ASM News* 52:469-471.
19. WALKER DH, Henderson FW, Hutchins GM. 1986. Rocky Mountain spotted fever: mimicry of appendicitis or acute surgical abdomen? *Am J Dis Child* 140:742-744.
20. Tringali G, Occhino C, Mansueto S, WALKER DH, Raoult D. 1986. Fievre boutonneuse méditerranéenne diagnostiquée pendant la saison froide: quatre cas. *Medecine et Maladies Infectieuses* 3:183-184.
21. Tringali G, WALKER DH, Mansueto S: 1986. Approche diagnostique du patient suspect de fièvre boutonneuse méditerranéenne. *Mediterranee Medicale* 347:9-11.
22. Mansueto S, Vitale G, WALKER DH, Tringali G. 1986. C-reactive protein in boutonneuse fever. Letter to the editor. *Eur J Clin Microbiol* 5:545-546.
23. Riley HD, WALKER DH. 1988. Is it Rocky Mountain spotted fever? *Patient Care* 22:172-189.
24. WALKER DH, Liu Q-H, Feng H-M. 1990. Update on rickettsiae and rickettsial diseases in China. Letter. *Rev Infect Dis* 12:562-563.
25. WALKER DH. 1990. Foreword. In: *Rocky Mountain Spotted Fever: History of a Twentieth Century Disease*. VA Harden, ed, Baltimore, The Johns Hopkins University Press; xi-xii.
26. Dumler JS, Brouqui P, Aronson J, Taylor JP, WALKER DH. 1991. Identification of ehrlichia in human tissue. Letter to the editor. *N Engl J Med* 325:1109-1110.
27. Woodward TE, Walker DH, Dumler JS. 1992. The remarkable contributions of S. Burt Wolbach on rickettsial vasculitis updated. *Trans Am Clin Climatol Assoc* 103:78-94.
28. WALKER DH and Dumler JS. 1994. Emerging and reemerging rickettsial diseases. *N Engl J Med* 331:1651-1652.
29. WALKER DH, Dumler JS. 1995. Will pathologists play as important a role in the future as they have in the past against the challenge of infectious disease? *Infect Agents Dis* 4:167-170.
30. WALKER DH. 1996. Human ehrlichiosis: more trouble from ticks. *Hospital Practice* 31:47-57.
31. WALKER DH. 1996. Rickettsial diseases, nearly impossible to diagnose early: clues to pragmatic clinical success. *Mediguide to Infectious Diseases*. 16:1-6.
32. Kalish R, Persing DH, Segreti J, WALKER DH. 1997. How to recognize and treat tick-borne infections. *Patient Care* 31:184-204.

33. Lottenberg R, Höök M, WALKER DH. 1998. Microbes, hemostasis and vascular biology. *Trends Microbiol* 6:428-430.
34. WALKER DH and the Task Force on Consensus Approach for Ehrlichiosis. 2000. Diagnosing human ehrlichioses: Current status and recommendations. *ASM News* 66:287-290.
35. WALKER DH. 2002. *Rickettsia rickettsii*: as virulent as ever. (Editorial) *Am J Trop Med Hyg* 66:448-449.
36. Murphy FA, Calisher CM, Tesh RB, WALKER DH. 2004. In memoriam – Robert Ellis Shope. *Emerg Infect Dis* 10:762-765.
37. Dumler JS, WALKER DH. 2005. Rocky Mountain spotted fever - changing ecology and persisting virulence. *N Engl J Med* 353:551-553.
38. WALKER DH. 2008. Foreword. In Cooke RA (ed): *Infectious Diseases: Atlas, Cases, Text*. Australia: McGraw-Hill Australia Pty Ltd.
39. WALKER DH. 2008. Education interrupted: UTMB faces long road of recovery from Ike. *ASIP Pathways*. 3:4.
40. WALKER DH. 2009. Sennetsu neorickettsiosis: A potentially prevalent, treatable, acutely incapacitating tropical infectious disease. *Am J Trop Med Hyg* 81:187-188. PMID 19635866
41. WALKER DH, de Sousa R. 2009. Reply to Fournier and Raoult. *J Infect Dis* 199:11098-1099.
42. WALKER DH. 2010. The 2009 H1N1 pandemic adds to our knowledge of influenza pathogenesis. *Am J Pathol* 177:13-14. PMID 20489147.
43. WALKER DH. 2011. Editorial for III Congreso Latinoamericano de Enfermedades Rickettsiales, Bogota, Colombia, July 2011. *Biomedica Revista del Instituto Nacional de Salud* 31:9.
44. WALKER DH, LaSala R, Pritt B, Koneman E, Miller JM. 2011. In memoriam: Washington C. (Wash) Winn, Jr., (1941-2011). *Emerg Infect Dis* 17:2400-2401.

BOOKS:

1. WALKER D. 1988. *Biology of Rickettsial Diseases*. Boca Raton (FL): CRC Press, Inc. Vols I&II,
2. WALKER DH. 1992. *Global Infectious Diseases: Prevention, Control and Eradication*. New York (NY): Springer-Verlag Wien.
3. Guerrant RL, WALKER DH, Weller PF. 1999. *Tropical Infectious Diseases: Principles, Pathogens, & Practice*. 1st Ed. Philadelphia (PA): Churchill Livingstone.
4. Woods GL, Schnadig V, WALKER DH, Winn W. 1999. *Pathology of Infectious Diseases: Clinical Cases*. Philadelphia (PA): Butterworth Heinemann.
5. Guerrant RL, WALKER DH, Weller PF. 2001. *Essentials of Tropical Infectious Diseases*. Philadelphia (PA): Churchill Livingstone.
6. Guerrant RL, WALKER DH, Weller PF. 2001. *Enfermedades Infecciosas Tropicales*. Philadelphia (PA): Churchill Livingstone.

7. Guerrant RL, WALKER DH, Weller PF. 2006. Tropical Infectious Diseases: Principles, Pathogens, and Practice. 2nd Ed Philadelphia (PA): Elsevier Churchill, Livingstone.
8. WALKER DH. Deadly Diseases and Epidemics: Rocky Mountain Spotted Fever. 2008. New York (NY): Chelsea House.
9. Guerrant RL, WALKER DH, Weller PF. 2011. Tropical Infectious Diseases: Principles, Pathogens, and Practice, 3rd Ed, London: Saunders Elsevier.

BOOK CHAPTERS:

1. Murphy FA, WALKER DH. 1978. Arenaviruses: persistent infection and viral survival in reservoir hosts. In: Kurstak E, Maramorosch K, editors. Viruses and Environment. New York (NY): Academic Press. p 155-180.
2. WALKER DH, Bradford WD. 1981. Rocky Mountain spotted fever in childhood. In: Rosenberg HS, Bernstein J, editors. Perspectives in Pediatric Pathology. vol. 6. New York (NY): Masson Publishing USA, Incorporate. p. 35-61.
3. WALKER DH. 1982. Rickettsial diseases: an update. In: Majno G, Cotran R, editors. Current Topics in Inflammation and Infection. Baltimore (MD): Lippincott Williams & Wilkins Co. p. 188-204.
4. Ishak KG, WALKER DH, Coetzer JAW, Gardner JJ, Gorelkin L. 1982. Viral hemorrhagic fevers with hepatic involvement: pathologic aspects with clinical correlations. In: Popper H, Schaffner F, editors. Progress in Liver Disease. New York (NY): Grune and Stratton. p. 495-515.
5. WALKER DH, McGinnis MR. 1982. Opportunistic fungal infection. Symposium on Respiratory Infections. In: Winn WC Jr, editor. Clinics in Laboratory Medicine. Philadelphia (PA): WB Saunders Co. p. 407-413.
6. Durack DT, WALKER DH. 1983. Rickettsial diseases. In: Stein JH, editor. Internal Medicine. 1st ed. Boston (MA): Little, Brown and Co, 1315-1320.
7. WALKER DH. 1984. Rocky Mountain spotted fever. In: Rakel RE, editor. Conn's Current Therapy. Philadelphia (PA): WB Saunders Co. p. 57-58.
8. WALKER DH. 1985. Rickettsial and chlamydial diseases. In: Kissane JM, editor. Anderson's Pathology. 8th ed. vol I. St. Louis (MO): CV Mosby Company. p. 335-344.
9. WALKER DH. 1985. Rickettsiae. Prepared for the ASM Committee on Educational Materials. Clin Microbiol. Bethesda (MD): Health and Education Resources, Inc., p. 233-238.
10. WALKER DH, Murphy FA. 1987. Pathology and pathogenesis of arenavirus infections. In: Oldstone MBA, editor. Current Topics of Microbiology and Immunology. vol. 133. New York (NY): Springer-Verlag. p. 93-113.
11. Winn WC, WALKER DH. 1987. Viral infections. In: Dail DH, Hammar SP, editors. Pulmonary Pathology. New York (NY): Springer-Verlag, 259-293.
12. Durack DT, WALKER DH. 1987. Rickettsial infections. In: Stein JH, editor. Internal Medicine. 2nd ed. Boston (MA): Little, Brown and Co. 1629-1634.

13. WALKER DH. 1988. The pathogenesis and pathology of the hemorrhagic state in viral and rickettsial infections. In: Gear JHS, editor. Handbook of Viral and Rickettsial Hemorrhagic Fevers. Boca Raton (FL): CRC Press, Inc. p. 9-45,
14. WALKER DH. 1988. Diagnosis of rickettsial diseases. In: Rosen PP, Fechner RE, editors. Pathology Annual. 2nd ed. vol. 2. Norwalk (CT): Appleton & Lange. p. 69-96.
15. WALKER DH, Lane TW. 1988. Rocky Mountain spotted fever: clinical signs, symptoms, and pathophysiology. In: WALKER DH, editor. Biology of Rickettsial Diseases. vol 1. Boca Raton (FL): CRC Press, Inc. p. 63-78.
16. WALKER DH. 1988. Pathology and pathogenesis of the vasculotropic rickettsioses. In: WALKER DH, editor. Biology of Rickettsial Diseases. vol. 1. Boca Raton (FL): CRC Press, Inc. 115-138.
17. WALKER DH. 1988. Pathology of Q fever. In: WALKER DH, editor. Biology of Rickettsial Diseases. vol 2. Boca Raton (FL): CRC Press, Inc. p. 17-27.
18. WALKER DH. 1988. Role of the composition of rickettsiae in rickettsial immunity: typhus and spotted fever group. In: WALKER DH, editor. Biology of Rickettsial Diseases. vol 2. Boca Raton (FL) CRC Press, Inc. p. 101-109.
19. WALKER DH, Peacock MG. 1988. Laboratory diagnosis of rickettsial diseases. In: WALKER DH, editor. Biology of Rickettsial Diseases. vol 2. Boca Raton (FL): CRC Press, Inc. p. 135-155.
20. Shapiro HL, WALKER DH. 1988. Diagnosis of infectious diseases by immunohistology, immunocytology, and *in situ* hybridization. In: Jennette JC, editor. Immunohistology and Diagnostic Pathology. Boca Raton (FL): CRC Press, Inc. 257-292.
21. WALKER DH. 1989. Spotted fevers. In: Hoeprich P, editor. Infectious Diseases. Philadelphia, (PA): JB Lippincott Co. p. 961-967.
22. WALKER DH. 1989. Rickettsialpox. In: Hoeprich P, editor. Infectious Diseases. Philadelphia, (PA): JB Lippincott Co. p. 968-970.
23. WALKER DH. 1989. The rickettsia-host interaction. In: Moulder JW, editor. Intracellular Parasitism. Boca Raton (FL): CRC Press, Inc. p. 79-92.
24. WALKER DH. 1989. Rickettsial infections. In: Demis DJ, editor. Clinical Dermatology. Vol. 3. Philadelphia, (PA): JB Lippincott Co. p. 1-17.
25. WALKER DH. 1989. Ehrlichiosis. In: Mandell GL, Douglas RG, Bennett J, editors. Principles & Practice of Infectious Diseases. Update 5. New York (NY): Churchill Livingstone. p. 3-10.
26. WALKER DH. 1990. Rickettsial and chlamydial diseases. In: Kissane JM, editor. Anderson's Pathology. 9th ed. vol 1. St. Louis (MO): CV Mosby Co. p. 348-361.
27. Durack DT, WALKER DH. 1990. Rickettsial infections. In: Stein JH, editor. Internal Medicine. 3rd ed. Boston (MA) Little, Brown & Co. p. 1425-1430.
28. Raoult D, WALKER DH. 1990. *Rickettsia rickettsii* (Rocky Mountain spotted fever and other spotted fevers). In: Mandell GL, Douglas RG, Bennett J, editors. Principles and Practice of Infectious Diseases. New York (NY): Churchill Livingstone. p. 1465-1471.

29. Weiss KL, WALKER DH. 1990. New and improved vaccines against rickettsial infections. Rocky Mountain spotted fever, epidemic typhus, and scrub typhus. In: Woodrow GC, Levine MM, editors. *New Generation Vaccines*. Marcel Dekker, Inc. New York (NY): p. 357-374.
30. Weber DJ, WALKER DH. 1991. Rocky Mountain spotted fever. In: Weinberg AN, Weber DJ, editors. *Infectious Disease Clinics of North America: Diseases Transmitted from Animals to Man*. Philadelphia (PA): WB Saunders Co. p. 19-35.
31. WALKER DH. 1991. Rickettsiae. In: Baron S, editor. *Medical Microbiology*. 3rd ed. New York (NY): Churchill Livingstone. p. 517-532.
32. Gage KL, WALKER DH. 1992. Rickettsia. In: Greenwood D, Slack R, Peutherer J, editors. *Medical Microbiology*. 14th ed. United Kingdom: Churchill Livingstone. p. 447-457.
33. Kaplowitz LG, WALKER DH. 1992. Rocky Mountain spotted fever and critical care. In: Hall JB, Schmidt GA, Wood LDH, editors. *Principles of Critical Care Medicine*. New York (NY): McGraw-Hill, Inc. p. 1368-1372.
34. WALKER DH, Murphy FA. 1992. Infectious diseases in developing countries. In: WALKER DH, editor. *Global Infectious Diseases: Prevention, Control, and Eradication*. New York (NY): Springer-Verlag. p. 1-3.
35. WALKER DH. 1992. Rickettsial diseases: from epidemiology to molecules, the pathway toward disease control. In: WALKER DH, editor. *Global Infectious Diseases: Prevention, Control, and Eradication*. New York (NY): Springer-Verlag. p. 75-86.
36. WALKER DH. 1993. Rocky Mountain spotted fever and other rickettsioses. In: Schaechter M, Eisenstein B, Schlessinger D, editors. *Mechanisms of Microbial Disease*. Baltimore (MD): Lippincott Williams & Wilkins. p. 358-367.
37. WALKER DH. 1993 Rickettsiae. In: Woods GL, Gutierrez Y, editors. *Diagnostic Pathology of Infectious Diseases*. Philadelphia (PA): Lea and Febiger. p. 194-213.
38. Winn WC Jr, WALKER DH. 1994. Viral infections. In: Dail DH, Hammar SP, editors. *Pulmonary Pathology*. 2nd ed. New York (NY): Springer-Verlag. p. 429-464.
39. WALKER DH. 1994. Mycoplasmal, chlamydial, and rickettsial pneumonias. In: Dail DH, Hammer SP, editors. *Pulmonary Pathology*. 2nd ed. New York (NY): Springer-Verlag. p. 465-474.
40. Dumler JS, WALKER DH. 1994. Diagnostic tests for Rocky Mountain spotted fever and other rickettsias. In: Dudlick B, Rapini RP, editors. *Dermatologic Clinics*. vol. 12. Philadelphia (PA): WB Saunders Co. p. 25-36.
41. Durack DT, WALKER DH. 1994. Rickettsial infections. In: Stein JF, editor. *Internal Medicine*. 4th ed. Boston (MA): Little, Brown & Company. p. 2062-2068.
42. WALKER DH, Dumler JS, Radulovic S. 1994. Spotted fevers and rickettsialpox. In: Hoepflich PD, Jordan MC, Ronald AL, editors. *Infectious Diseases: A Modern Treatise of Infectious Processes*. 5th ed. Philadelphia (PA) JB Lippincott Company. p. 969-978.
43. WALKER DH, Dumler JS. 1995. *Ehrlichia chaffeensis* (human ehrlichiosis) and other ehrlichiae. In: Mandell GL, Bennett JE, Dolin R, editors. *Principles and Practice of Infectious Diseases*. 4th ed. New York (NY): Churchill Livingstone Inc. p. 1747-1752.

44. WALKER DH, Raoult D. 1995. *Rickettsia rickettsii* and other spotted fever group rickettsiae (Rocky Mountain spotted fever and other spotted fevers). In: Mandell GL, Bennett JE, Dolin R, editors. Principles and Practice of Infectious Diseases. 4th ed. New York (NY): Churchill Livingstone Inc. p. 1721-1727.
45. Dumler JS, WALKER DH. 1995. Murine typhus. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and Practice of Infectious Diseases. 4th ed. New York (NY): Churchill Livingstone Inc. p. 1737-1739.
46. Woodward TE, Sexton DJ, WALKER DH. 1995. Cutaneous manifestations of rickettsial infections. In: Mandell GL, Stevens D, editors. Atlas of Infectious Diseases: Skin, Soft Tissue, Bone and Joint Infections. vol 2. Philadelphia (PA): Current Medicine. p. 9.0-9.13.
47. WALKER DH, Dasch G. 1995. Classification and identification of *Chlamydia*, *Rickettsia*, and related bacteria. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Tenover FC, editors. Manual of Clinical Microbiology. 6th ed. Washington (DC): American Society for Microbiology. p. 665-668.
48. WALKER DH. 1995. Rickettsial Disease. In: Warrell DA, editor. Oxford Textbook of Medicine. 3rd ed. Oxford University Press, Oxford. p. 728-739.
49. WALKER DH, Dumler JS. 1995. Rickettsial and chlamydial diseases. In: Damjanov I, Linder J, editors. Anderson's Pathology. 10th ed. vol 1. Chicago (IL): Mosby Year Book, Inc. p. 866-885.
50. WALKER DH, Dumler JS. 1995. Rickettsiae: Spotted fever and typhus group. In: Lennette EH, Lennette DA, Lennette ET, editors. Diagnostic Procedures for Viral, Rickettsial, and Chlamydial Infections. 7th ed. Washington (DC): American Public Health Association. p. 575-582.
51. WALKER DH, Dumler JS. 1995. Rickettsiae: Scrub typhus. In: Lennette EH, Lennette DA, Lennette ET, editors. Diagnostic Procedures for Viral, Rickettsial, and Chlamydial Infections. 7th ed. Washington (DC): American Public Health Association. p. 571-574.
52. Dumler JS, WALKER DH. 1995. Rickettsiae: *Coxiella burnetii*. In: Lennette EH, Lennette DA, Lennette ET, editors. Diagnostic Procedures for Viral, Rickettsial, and Chlamydial Infections. 7th ed. Washington (DC): American Public Health Association. p. 565-570.
53. WALKER DH. 1996. Rickettsiae. In: Baron S, editor. Medical Microbiology. 4th ed. Galveston (TX): The University of Texas Medical Branch. p. 487-501.
54. Woods GL, WALKER DH. 1996. Chlamydial, rickettsial, and mycoplasmal infections. In: Henry JB, editor. Clinical Diagnosis and Management by Laboratory Methods. 19th ed. Philadelphia (PA): W.B. Saunders Company. p. 1115-1131.
55. Landry GA, WALKER DH. 1996. Ehrlichiosis: an emerging infectious disease. In: Reese RE, Betts RF, editors. A Practical Approach to Infectious Diseases. 4th ed. Boston (MA): Little, Brown and Company. p. 1399-1405.
56. Dumler JS, WALKER DH. 1997. Ehrlichial infections. In: Connor DH, Chandler FW, Schwartz D, Manz HJ, Lack EE, editors. Pathology of Infectious Diseases. vol 1. Stamford (CT): Appleton & Lange, Inc. p. 543-548.
57. WALKER DH, Dumler JS. 1997. Rickettsial infections. In: Connor DH, Chandler FW, Schwartz D, Manz HJ, Lack EE, editors. Pathology of Infectious Diseases. vol 1. Stamford (CT): Appleton & Lange, Inc. p. 789-799.

58. Schuenke KL, WALKER DH. 1997. Vaccine development for rickettsial infections: Rocky Mountain spotted fever, epidemic typhus, and scrub typhus. In: Levine MM, Woodrow GC, Kaper JB, Cobon GS, editors. *New Generation Vaccines*. 2nd ed. New York (NY): Marcel Dekker, Inc. p. 527-543.
59. WALKER DH, Raoult D, Brouqui P, Marrie TJ. 1997. Rickettsial diseases. In: Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, editors. *Harrison's Principles of Internal Medicine*. 14th ed. New York (NY): McGraw-Hill. p. 1045-1052.
60. WALKER DH, Gage KL. 1997. Rickettsia, orientia, ehrlichia and coxiella. In: Greenwood D, Slack R, Peutherer J, editors. *Medical Microbiology. A guide to microbial infections: pathogenesis, immunity, laboratory diagnosis and control*. 15th Edition, Churchill Livingstone, New York (NY): 371-380.
61. WALKER DH. 1998. Emerging human ehrlichioses: recently recognized, widely distributed, life-threatening tick-borne diseases. In: Scheld WM, Armstrong D, Hughes JM, editors. *Emerging Infections I*. 1st Edition. ASM Press, Washington (DC): 81-91.
62. Durack DT, WALKER DH. 1998. Rickettsial infections. In: Stein JH, Eisenberg JM, Hutton JJ, Klippel JH, Kohler PO, LaRusso NF, O'Rourke RA, Reynolds HY, Samuels MA, Sande MA, Zvaifler NJ, editors. *Internal Medicine*. 5th ed. Baltimore (MD): Mosby Press. p. 1541-1546.
63. WALKER DH. 1998. Rocky Mountain spotted fever and other rickettsioses. In: Schaechter M, Engleberg NC, Eisenstein BI, Medoff G, editors. *Mechanisms of Microbial Disease*. 3rd ed. Baltimore (MD): Williams & Wilkins Publishers. p. 268-274.
64. WALKER DH. 1998. Cat scratch disease, bacillary angiomatosis, and other bartonellosis. In: Schaechter M, Engleberg NC, Eisenstein BI, Medoff G, editors. *Mechanisms of Microbial Disease*. 3rd ed. Baltimore (MD): Williams & Wilkins Publishers. p. 257-260.
65. WALKER DH, Sexton DJ. 1998. *Rickettsia rickettsii*. In: Yu VL, Merigan TC, Barriere SL, editors. *Antimicrobial Chemotherapy*. Baltimore (MD): Williams & Wilkins Publishers. 562-568.
66. WALKER DH. 1999. Rickettsia. In: Baron EJ, Murray PR, Ferraro MJ, Gilligan P, von Graevenitz A, Janda JM, editors. *Manual of Clinical Microbiology*. 7th ed. Washington (DC): American Society for Microbiology Press. p. 807-820.
67. WALKER DH. 1999. Anthrax. In: Guerrant RL, WALKER DH, Weller PF, editors. *Tropical Infectious Diseases, Principles, Pathogens, and Practice*. Philadelphia (PA): Churchill Livingstone. p. 486-491.
68. WALKER DH, Maguina C, Guerra H. 1999. Bartonellosis. In: Guerrant RL, WALKER DH, Weller PF, editors. *Tropical Infectious Diseases, Principles, Pathogens, and Practice*. Philadelphia (PA): Churchill Livingstone. p. 492-497.
69. Sexton DJ, WALKER DH. 1999. Spotted fever group rickettsioses. In: Guerrant RL, WALKER DH, Weller PF, editors. *Tropical Infectious Diseases, Principles, Pathogens, and Practice*. Philadelphia (PA): Churchill Livingstone. p. 579-584.
70. WALKER DH. 1999. Typhus group rickettsioses. In: Guerrant RL, WALKER DH, Weller PF, editors. *Tropical Infectious Diseases, Principles, Pathogens, and Practice*. Philadelphia (PA): Churchill Livingstone. p. 585-591.

71. Dumler JS, WALKER DH. 1999. Ehrlichiosis In: Guerrant RL, WALKER DH, Weller PF, editors. Tropical Infectious Diseases, Principles, Pathogens, and Practice. Philadelphia (PA): Churchill Livingstone. p. 598-604.
72. Watt G, WALKER DH. 1999. Scrub typhus. In: Guerrant RL, WALKER DH, Weller PF, editors. Tropical Infectious Diseases, Principles, Pathogens, and Practice. Philadelphia (PA): Churchill Livingstone. p. 592-597.
73. Olano JP, Krogstad DJ, Guerrant RL, Weller PF, WALKER DH. 1999. Principles of parasitism: host-parasite interactions. In: Guerrant RL, WALKER DH, Weller PF, editors. Tropical Infectious Diseases, Principles, Pathogens, and Practice. Philadelphia (PA): Churchill Livingstone. p. 3-15.
74. John TJ, WALKER DH. 1999. Enterovirus infections, including poliomyelitis. In: Guerrant RL, WALKER DH, Weller PF, editors. Tropical Infectious Diseases, Principles, Pathogens, and Practice. Philadelphia (PA): Churchill Livingstone. p. 1123-1132.
75. WALKER DH. 1999. Rickettsial Infections. In: Demis DJ, editor. Clinical Dermatology. Vol. 3. Philadelphia (PA): Lippincott Williams & Wilkins. (Unit 15:1) 1-18.
76. Olano JP, WALKER D. 1999. Ehrlichial Infections. In: Demis DJ, editor. Clinical Dermatology. Vol. 3. Philadelphia (PA): Lippincott Williams & Wilkins. p. (15-2) 1-10.
77. WALKER DH, Raoult D. 2000. *Rickettsia rickettsii* and other spotted fever group rickettsiae (Rocky Mountain spotted fever and other spotted fevers). In: Mandell GL, Bennett JE, and Dolin R, editors. Principles and Practice of Infectious Diseases. New York (NY): Churchill Livingstone. p. 2035-2042.
78. Dumler JS, WALKER DH. 2000. *Rickettsia typhi* (Murine typhus). In: Mandell GL, Bennett JE, and Dolin R, editors. Principles and Practice of Infectious Diseases. New York (NY): Churchill Livingstone. p. 2053-2055.
79. WALKER DH, Dumler JS. 2000. *Ehrlichia chaffeensis* (Human monocytotropic ehrlichiosis), *Ehrlichia phagocytophila* (Human granulocytotropic ehrlichiosis), and other ehrlichiae. In: Mandell GL, Bennett JE, and Dolin R, editors. Principles and Practice of Infectious Diseases. New York (NY): Churchill Livingstone. p. 2057-2064.
80. WALKER DH. 2000. Rickettsial diseases including ehrlichioses. In: Ledingham JGG, Warrell DA, editors. Concise Oxford Textbook of Medicine. New York (NY): Oxford University Press. p. 1691-1698.
81. WALKER DH. 2001. Anthrax. In: Guerrant RL, WALKER DH, Weller PF, editors. Essentials of Tropical Infectious Diseases. Philadelphia (PA): Churchill Livingstone. p. 227-230.
82. WALKER DH, Guerra H, Maguiña C. 2001. Bartonellosis. In: Guerrant RL, WALKER DH, Weller PF, editors. Essentials of Tropical Infectious Diseases. Philadelphia (PA): Churchill Livingstone. p. 230-233.
83. Sexton DF, WALKER DH. 2001. Spotted fever group rickettsioses. In: Guerrant RL, WALKER DH, Weller PF, editors. Essentials of Tropical Infectious Diseases. Philadelphia (PA): Churchill Livingstone. p. 271-274.
84. WALKER DH. 2001. Typhus group rickettsioses. In: Guerrant RL, WALKER DH, Weller PF, editors. Essentials of Tropical Infectious Diseases. Philadelphia (PA): Churchill Livingstone. p. 274-278.

85. Watt G, WALKER DH. 2001. Scrub typhus. In: Guerrant RL, WALKER DH, Weller PF, editors. Essentials of Tropical Infectious Diseases. Philadelphia (PA): Churchill Livingstone. p. 278-281.
86. Dumler JS, WALKER DH. 2001. Ehrlichioses. In: Guerrant RL, WALKER DH, Weller PF, editors. Essentials of Tropical Infectious Diseases. Philadelphia (PA): Churchill Livingstone. p. 281-283.
87. John TJ, WALKER DH. 2001. Enterovirus infections, including poliomyelitis. In: Guerrant RL, WALKER DH, Weller PF, editors. Essentials of Tropical Infectious Diseases. Philadelphia (PA): Churchill Livingstone. p. 530-535.
88. Molina CP, WALKER DH. 2001. The pathology of community-acquired pneumonia. In: Marrie T, editor. Community-acquired Pneumonia. New York: Kluwer Academic/Plenum Publishers. p. 101-129.
89. WALKER DH, Raoult D, Dumler JS, Marrie T. 2001. Rickettsia, mycoplasma, and chlamydia. In: Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL, editors. Harrison's Principles of Internal Medicine. 15th ed. New York (NY): McGraw-Hill. p. 1065-1073.
90. Olano JP, WALKER DH. 2002. Human ehrlichiosis. In: Edlow JA, editor. Medical Clinics of North America. Philadelphia (PA): W.B. Saunders Company. 86:375-392.
91. WALKER DH, Sexton D. 2002. *Rickettsia rickettsii*. In: Yu VL, Weber R, Raoult D, Rex JH, Shafer RW, White NJ, Treanor JJ, Seenivasan MH, editors. Antimicrobial Therapy and Vaccines. 2nd ed. New York (NY): Apple Trees Productions, LLC. p. 899-906.
92. Eyzaguirre EJ, WALKER DH. 2002. Immunohistochemistry of infectious diseases. In: Zorab R, Strauss M, editors. Dabbs Diagnostic Immunohistochemistry. Philadelphia (PA): Churchill Livingstone. p. 640-650.
93. WALKER DH, Yu XJ. 2002. Rickettsia, orientia, ehrlichia and coxiella. Typhus; spotted fevers; scrub typhus; ehrlichioses; Q fever. In: Greenwood D, Slack RCB, Peutherer JF, editors. Medical Microbiology. A guide to microbial infections: pathogenesis, immunity, laboratory diagnosis and control. New York (NY): Churchill Livingstone. 16th ed. p. 369-378.
94. WALKER DH. 2003. Rickettsial diseases including ehrlichioses. In: Warrell DA, Cox TM, Firth JD, Benz EJ, editors. Oxford Textbook of Medicine. 4th ed. Oxford: Oxford University Press. 7:623-629.
95. WALKER DH, Bouyer DH. 2003. Rickettsia. In: Murray PR, Baron EJ, Jorgensen JH, Pfaller MA, Tenover FC, White O, editors. Manual of Clinical Microbiology. 8th ed. Washington (DC): ASM Press. p. 1005-1014.
96. Marrie TJ, Campbell GD, WALKER DH, Low DE. 2004. Pneumonia. In: Kasper DL, Braunward E, Fauci AS, Hauser SL, Longo DL, Jameson JL, editors. Harrison's Principles of Internal Medicine. 16th ed. New York (NY): McGraw-Hill. p. 1528-1541.
97. WALKER DH, Raoult D, Dumler JS, Marrie T. 2004. Rickettsial diseases. In: Kasper DL, Braunward E, Fauci AS, Hauser SL, Longo DL, Jameson JL, editors. Harrison's Principles of Internal Medicine. 16th ed. New York (NY): McGraw-Hill. p. 999-1008.
98. Raoult D, WALKER DH. 2004. *Rickettsia prowazekii* (epidemic or louse-borne typhus). In: Mandell GL, Bennett JE, Dolin R, editors. Principles and Practice of Infectious Diseases. 6th ed. Philadelphia (PA): Churchill Livingstone. p. 2303-2306.

99. WALKER DH, Dumler SJ. 2004. *Ehrlichia chaffeensis* (human monocytotropic ehrlichiosis), *Anaplasma phagocytophilum* (human granulocytotropic anaplasmosis), and other ehrlichiae. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and Practice of Infectious Diseases. 6th ed. Philadelphia (PA): Churchill Livingstone. p. 2310-2318.
100. Dumler JS, WALKER DH. 2004. *Rickettsia typhi* (murine typhus). In: Mandell GL, Bennett JE, Dolin R, editors. Principles and Practice of Infectious Diseases. 6th ed. Philadelphia (PA): Churchill Livingstone. p. 2306-2310.
101. WALKER DH, Raoult D. 2004. *Rickettsia rickettsii* and other spotted fever group rickettsiae (Rocky Mountain spotted fever and other spotted fevers). In: Mandell GL, Bennett JE, Dolin R, editors. Principles and Practice of Infectious Diseases. 6th ed. Philadelphia (PA): Churchill Livingstone. p. 2287-2295.
102. WALKER DH. 2004. Ehrlichiosis. In: Heymann DL, editor. Control of Communicable Diseases Manual. 18th ed. Washington, D.C. APHA/WHO, p. 187-190.
103. Yu XJ, WALKER DH. 2005. Family I. Rickettsiaceae. In: Brenner DJ, Kreig NR, Staley JT, editors. Bergey's Manual of Systematic Bacteriology. 2nd ed. vol 2. New York (NY): Springer Science+Business Media, Inc., p. 96-116.
104. Olano JP, Weller PF, Guerrant RL, WALKER DH. 2006. Principles of parasitism: Host—parasite interactions. In: Guerrant RL, WALKER DH, Weller PF, editors. Tropical Infectious Diseases: Principles, Pathogens, and Practice. 2nd ed. Philadelphia (PA): Elsevier Churchill Livingstone, p. 1-12.
105. WALKER DH. 2006. Anthrax. In: Guerrant RL, WALKER DH, Weller PF, editors. Tropical Infectious Diseases: Principles, Pathogens, and Practice. 2nd ed. Philadelphia (PA): Elsevier Churchill Livingstone, p. 448-453.
106. WALKER DH, Maguiña C, Minnick M. 2006. Bartonellosis. In: Guerrant RL, WALKER DH, Weller PF, editors. Tropical Infectious Diseases: Principles, Pathogens, and Practice. 2nd ed. Philadelphia (PA): Elsevier Churchill Livingstone, p. 454-462.
107. Sexton DJ, WALKER DH. 2006. Spotted fever group rickettsioses. In: Guerrant RL, WALKER DH, Weller PF, editors. Tropical Infectious Diseases: Principles, Pathogens, and Practice. 2nd ed. Philadelphia (PA): Elsevier Churchill Livingstone, p. 539-547.
108. WALKER DH, Raoult D. 2006. Typhus group rickettsioses. In: Guerrant RL, WALKER DH, Weller PF, editors. Tropical Infectious Diseases: Principles, Pathogens, and Practice. 2nd ed. Philadelphia (PA): Elsevier Churchill Livingstone, p. 548-556.
109. Watt G, WALKER DH. 2006. Scrub typhus. In: Guerrant RL, WALKER DH, Weller PF, editors. Tropical Infectious Diseases: Principles, Pathogens, and Practice. 2nd ed. Philadelphia (PA): Elsevier Churchill Livingstone, p. 557-563.
110. Dumler JS, WALKER DH. 2006. Ehrlichiosis and anaplasmosis. In: Guerrant RL, WALKER DH, Weller PF, editors. Tropical Infectious Diseases: Principles, Pathogens, and Practice. 2nd ed. Philadelphia (PA): Elsevier Churchill Livingstone. p. 564-573.
111. Olano JP, Peters CJ, WALKER DH. 2006. Distinguishing tropical infectious diseases from bioterrorism. In: Guerrant RL, WALKER DH, Weller PF, editors. Tropical Infectious Diseases: Principles, Pathogens, and Practice. 2nd ed. Philadelphia (PA): Elsevier Churchill Livingstone, p. 1386-1399.

112. Bouyer DH, WALKER DH. 2006. *Rickettsia rickettsii* and other members of the spotted fever group as potential bioweapons. In: Anderson B, Friedman H, Bendinelli M, editors. *Microorganisms and Bioterrorism*. New York (NY): Springer, p. 227-235.
113. Eyzaguirre E, WALKER DH, Zaki SR. 2006. Immunohistochemistry of infectious diseases. In: Dabbs DJ, editor. *Diagnostic Immunohistochemistry*. 2nd ed. Philadelphia (PA): Elsevier, p. 43-64.
114. WALKER DH. 2006. Rickettsial and ehrlichial infections. In: Rakel RE, Bope ET, editors. *Conn's Current Therapy 2006*. Philadelphia (PA): Elsevier, p. 218-221.
115. WALKER DH. 2007. Cat scratch disease, bacillary angiomatosis, and other bartonellosis. In: Engleberg NC, DiRita V, Dermody TS, editors. *Schaecter's Mechanisms of Microbial Disease*, 4th ed. Baltimore (MD): Lippincott Williams & Wilkins, p. 280-283.
116. WALKER DH. 2007. Rocky Mountain spotted fever and other rickettsioses. In: Engleberg NC, DiRita V, Dermody TS, editors. *Schaecter's Mechanisms of Microbial Disease*, 4th ed. Baltimore (MD): Lippincott Williams & Wilkins, p. 292-299.
117. Woods GL, WALKER DH. 2007. Chlamydial, rickettsial, and mycoplasmal infections. In: McPherson RA, Pincus MR, editors. *Henry's Clinical Diagnosis and Management by Laboratory Methods*, 21st ed. Philadelphia (PA): Saunders Elsevier, p. 1000-1015.
118. McBride JW, WALKER DH. 2007. Human ehrlichiosis and anaplasmosis. In: Fong IW, Alibek K, editors. *Emerging Infectious Diseases of the 21st Century: New and Evolving Infections of the 21st Century*. New York (NY): Springer Science+Business Media, LLC, p. 93-127.
119. WALKER DH, Bouyer DH. 2007. *Rickettsia* and *Orientia*. In: Murray PR, Baron EJ, Jorgensen JH, Landry ML, Pfaller MA, editors. *Manual of Clinical Microbiology*, 9th ed. ASM Press, Volume 1, p. 1036-1045.
120. WALKER DH. Rickettsial and ehrlichial infections. 2007. In: Rakel RE, Bope ET, editors. *Conn's Current Therapy 2007*. Philadelphia (PA): Saunders Elsevier, p. 206-209
121. WALKER DH, Ismail N, Olano JP, Valbuena GA, McBride J. 2007. Pathogenesis, immunity, pathology, and pathophysiology in rickettsial diseases. In: Raoult D, Parola P, eds. *Rickettsial Diseases*, New York (NY): Informa Healthcare, Inc., p. 15-26.
122. WALKER DH, Yu XJ. 2007. *Rickettsia*, *orientia*, *ehrlichia* and *coxiella*. Typhus; spotted fevers; scrub typhus; ehrlichiosis; Q fever. In: Greenwood D, Slack RCB, Peutherer JF, eds. *Medical Microbiology. A Guide to Microbial Infections: Pathogenesis, Immunity, Laboratory Diagnosis and Control*. 17th ed. New York (NY): Churchill Livingstone, p. 385-394.
123. McBride JW, WALKER DH. 2007. Pathogenesis of and immunity to the rickettsioses. In: Alexandrov E, Kazar J, Hechemy K, Kantardjiev T, eds. *Contemporary State of the Rickettsioses in the World and in Bulgaria*. Bulgaria: Prof. Marin Drinov Academic Publishing House, p. 63-70.
124. WALKER DH. 2008. Rickettsial diseases. In: Bologna JL, Jorizzo JL, Rapini RP, eds. *Dermatology* 2nd ed. Spain: Mosby Elsevier, p. 1127-1133.
125. WALKER DH, Dumler JS, Marrie T. 2008. Rickettsial diseases. In: Fauci AS, Kasper DL, Longo DL, Braunwald E, Hauser SL, Jameson JL, Loscalzo J, eds. *Harrison's Principles of Internal Medicine*. 17th ed. New York: McGraw-Hill Companies, Inc., p. 1059-1067.

126. Stevenson HL, Ismail N, WALKER DH. 2008. *Ehrlichia* and ehrlichioses: Pathogenesis and vector biology. In: St. Georgiev V, Western KA, McGowan JJ, eds. National Institute of Allergy and Infectious Diseases: Frontiers in Research, Volume I. Totowa (NH): Humana Press, p. 37-46.
127. WALKER DH. 2008. Mycoplasmal, chlamydial, rickettsial, and ehrlichial pneumonias. In: Tomaszewski FJ, Jr, Cagel PH, Farver CF, Fraire AE, eds. Dial and Hammar's Pulmonary Pathology, Volume 1, Nonneoplastic Lung Disease, 3rd ed. New York (NY): Springer, p. 476-486.
128. WALKER DH. 2008. Chlamydial, mycoplasmal, rickettsial, and ehrlichial diseases. In: Zander DS, Farver CF, eds. Pulmonary Pathology. Philadelphia (PA): Churchill Livingstone Elsevier, p. 315-329.
129. Crossley E, Jordan J, WALKER DH. 2008. *Rickettsia*. Encyclopedia of Public Health 5:582-590.
130. Olano JP, WALKER DH. 2009. Agents of emerging infectious diseases. In: Barrett ADT, Stanberry LR, eds. Vaccines for Biodefense and Emerging and Neglected Diseases. London: Elsevier, p. 3-20.
131. Yu X, Ismail N, WALKER DH. 2009. *Rickettsia*. In: Barrett ADT, Stanberry LR, eds. Vaccines for Biodefense and Emerging and Neglected Diseases. London: Elsevier, p. 1121-1145.
132. WALKER DH. 2010. *Rickettsia rickettsii* and other spotted fever group rickettsiae (Rocky Mountain spotted fever and other spotted fevers). In: Mandell GL, Bennett, JE, Dolin R, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 7th ed. Philadelphia, PA: Churchill Livingstone Elsevier, p. 2499-2507.
133. WALKER DH, Raoult D. 2010. *Rickettsia prowazekii* (epidemic or louse-borne typhus). In: Mandell GL, Bennett, JE, Dolin R, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 7th ed. Philadelphia, PA: Churchill Livingstone Elsevier, p. 2521-2524.
134. Dumler JS, WALKER DH. 2010. *Rickettsia typhi* (murine typhus). In: Mandell GL, Bennett, JE, Dolin R, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 7th ed. Philadelphia, PA: Churchill Livingstone Elsevier, p. 2525-2528.
135. Dumler JS, WALKER DH. 2010. *Ehrlichia chaffeensis* (human monocytotropic ehrlichiosis), *Anaplasma phagocytophilum* (human granulocytotropic anaplasmosis), and other anaplasmataceae. In: Mandell GL, Bennett, JE, Dolin R, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 7th ed. Philadelphia, PA: Churchill Livingstone Elsevier, p. 2531-2538.
136. Eyzaguirre E, WALKER DH, Zaki SR. 2010. Immunohistochemistry of infectious diseases. In: Dabbs D, ed. Diagnostics Immunohistochemistry, 3rd edition, Philadelphia, PA: Elsevier, p. 58-82
136. WALKER DH, Dumler JS, Marrie G. Rickettsial diseases. 2010. In: Kasper DL, Fauci AS, eds. Harrison's Infectious Diseases. New York, NY: McGraw Hill Medical, p. 676-688.
137. Olano JP, Weller PF, Guerrant RL, WALKER DH. Principles of parasitism: Host-parasite interactions. 2011. In: Guerrant RL, WALKER DH, Weller PF, eds. Tropical Infectious Diseases: Principles, Pathogens, and Practice, 3rd edition, London: Saunders Elsevier, p. 1-7.

138. Rao GR, WALKER DH. Anthrax. 2011. In: Guerrant RL, WALKER DH, Weller PF, eds. Tropical Infectious Diseases: Principles, Pathogens, and Practice, 3rd edition, London: Saunders Elsevier, p. 261-264.
139. Dehio C, Maguina C, WALKER DH. Bartonellosis. 2011. In: Guerrant RL, WALKER DH, Weller PF, eds. Tropical Infectious Diseases: Principles, Pathogens, and Practice, 3rd edition, London: Saunders Elsevier, p. 265-270.
140. Sexton DJ, WALKER DH. Spotted fever group rickettsioses. 2011. In: Guerrant RL, WALKER DH, Weller PF, eds. Tropical Infectious Diseases: Principles, Pathogens, and Practice, 3rd edition, London: Saunders Elsevier, p. 323-328.
141. WALKER DH, Raoult D. Typhus group rickettsioses. 2011. In: Guerrant RL, WALKER DH, Weller PF, eds. Tropical Infectious Diseases: Principles, Pathogens, and Practice, 3rd edition, London: Saunders Elsevier, p. 329-333.
142. Kim I-S, WALKER DH. Scrub typhus. 2011. In: Guerrant RL, WALKER DH, Weller PF, eds. Tropical Infectious Diseases: Principles, Pathogens, and Practice, 3rd edition, London: Saunders Elsevier, p. 334-338.
143. Olano JP, Peters CJ, WALKER DH. Distinguishing tropical infectious diseases from bioterrorism. 2011. In: Guerrant RL, WALKER DH, Weller PF, eds. Tropical Infectious Diseases: Principles, Pathogens, and Practice, 3rd edition, London: Saunders Elsevier, p. 879-886.
144. WALKER DH, Bouyer DH. *Rickettsia* and *Orientia*. 2011. In: Versalovic J, Carroll KC, Funke G, Jorgensen JH, Landry ML, Warnock DW, eds. Manual of Clinical Microbiology, 10th edition, Washington, D.C.: ASM Press, p. 1001-1012.
145. WALKER DH, Woods GL, Smith MD. 2011. Chlamydial, rickettsial, and mycoplasmal infections. In: McPherson RA, Pincus MR, eds. Henry's Clinical Diagnosis and Management by Laboratory Methods. 22nd Edition. Philadelphia: Elsevier, p. 1065-1078.
146. WALKER DH, Marrie T, Dumler JS. Rickettsial diseases. 2012. In: Longo DL, Fauci AS, Kasper DL, Hauswer SL, Jameson JL, Loscalzo J, eds. Harrison's Principles of Internal Medicine, 18th edition. New York: McGraw Hill Medical, p. 1407-1417.

ABSTRACTS:

1. WALKER DH, Wulff HT, Lange JV, Murphy FA. Experimental Lassa virus pathogenesis. Abstracts of the Third International Congress for Virology meeting, Madrid, Spain, September 10-17, 1975.
2. WALKER DH, Harrison A, Henderson F, Murphy FA. Rickettsial pathogenesis: Rocky Mountain spotted fever. XI International Congress, International Academy of Pathology, Book of Abstracts. Washington, DC, October 17-23, 1976. P. 253.
3. WALKER DH, Henderson FW. The role of the immune response in the pathogenesis of *Rickettsia rickettsii* infection in guinea pigs. Am J Pathol 86:20A, 1977.
4. WALKER DH, Cain BG, Mattern WB. Acute renal failure in Rocky Mountain spotted fever. Lab Invest 38:370, 1978.
5. WALKER DH, Cain BG, Olmstead PM. Experience with skin biopsy immunofluorescent demonstration of *Rickettsia rickettsii* in the diagnosis of Rocky Mountain spotted fever. Lab Invest 38:370, 1978.

6. WALKER DH, Fischer JJ. Fatal invasive pulmonary aspergillosis occurring in previously healthy persons. *Lab Invest* 38:371, 1978.
7. WALKER DH, Hudson P. Fulminant Rocky Mountain spotted fever: new developments and techniques. Abstracts for the American Academy of Forensic Sciences meeting, 1979.
8. Okiye GS, WALKER DH, Lipper S. Chronic granulomatous disease: early fatalities associated with central nervous system lesions. *Lab Invest* 42:176, 1980.
9. WALKER DH, Adams JS. The liver in fatal Rocky Mountain spotted fever. *Lab Invest* 42:158, 1980.
10. WALKER DH, Johnson KM, Lange JV, Gardner JJ, Kiley MP. Histopathologic observations in experimental Lassa virus infections of rhesus monkeys. *Lab Invest* 42:158, 1980.
11. Steuterman MC, WALKER DH. Congenital alveolar dysplasia: unrecognized cause of congenital lobar emphysema. *Lab Invest* 44:8P, 1981.
12. WALKER DH, McCormick JB, Johnson KM, Webb PA, Gardner JJ. Histopathologic study of human Lassa fever. *Lab Invest* 44:72A, 1981.
13. WALKER DH, Firth WT, Edgell C-JS. Human endothelial cell culture cytopathic plaques induced by *Rickettsia rickettsii*. *Fed Proc (Part I)* 40:776, 1981.
14. WALKER DH, Kirkman HN. Fulminant Rocky Mountain spotted fever: a disease of G6PD deficient black males. Abstracts for the Pediatric Pathology Club, Durham, NC, October 22-23, 1981.
15. WALKER DH, Firth WT, Hegarty BC. Pathogenic mechanisms of cell injury by *Rickettsia rickettsii*. *Lab Invest* 46:86A, 1982.
16. WALKER DH, Firth WT. Role of phospholipase and penetration in the pathogenesis of cell injury by *Rickettsia rickettsii*. Abstracts of the Annual Meeting of the American Society of Microbiology. 82nd Annual Meeting. Atlanta, GA, March 7-12, 1982.
17. Folds JD, Baniyak B, Hegarty B, Lange JV, WALKER DH. Rocky Mountain spotted fever vaccine in an animal model. Abstracts of the Annual Meeting of the American Society of Microbiology. 82nd Annual Meeting. Atlanta, GA, March 7-12, 1982.
18. Montenegro M, Mansueto S, WALKER DH. Histopathology and identification of *Rickettsia conorii* by immunofluorescence in *tache noire* of boutonuse fever. *Lab Invest* 48:60A, 1983.
19. WALKER DH, Kirkman HN. Glucose-6-phosphate dehydrogenase deficiency predisposes to severe and fatal Rocky Mountain spotted fever. *Lab Invest* 48:90A, 1983.
20. WALKER DH, Lesesne H, Varma V, Thacker W, Grisham J. Rocky Mountain spotted fever (RMSF) leading to emergent cholecystectomy: pathologic and rickettsial evidence for direct involvement of the gastrointestinal tract. *Gastroenterology* 86:1345, 1984.
21. WALKER DH, Gear JHS. Distribution of *Rickettsia conorii* and lesions in fatal South African tick bite fever. Abstracts of the 33rd Annual Meeting of the American Society of Tropical Medicine and Hygiene, Baltimore, MD, December 2-6, 1984, p. 199.

22. Feng HM, WALKER DH. Development of monoclonal antibodies to T-dependent and T-independent antigens of *Rickettsia conorii*. Abstracts of the 34th Annual Meeting of the American Society of Tropical Medicine and Hygiene, Miami, FL, November 3-7, 1985, abstract 202.
23. WALKER DH, Kirkman C, Feng HM. Radioimmunoprecipitation of [³⁵S] methionine-radiolabelled *Rickettsia conorii* and *Rickettsia rickettsii* proteins. Abstracts of the 86th Annual Meeting of the American Society for Microbiology, Washington, DC, March 23-28, 1986, abstract E97:112.
24. WALKER DH. A prevalent spotted fever group rickettsiosis in Inner Mongolia. Abstracts of the 35th Annual Meeting of the American Society of Tropical Medicine and Hygiene, Denver, CO, December 7-11, 1986, abstract 146.
25. Li H, Lenz B, WALKER DH. Relationship between antigenic specificity and protection against spotted fever group rickettsiae infection. Abstracts of the International College of Rickettsiologists, Palermo, Italy, 1987.
26. WALKER DH, Fan MY, Wang JG, Uchida T. Etiology and epidemiology of spotted fever group rickettsioses in the Orient. Abstracts of the International College of Rickettsiologists, Palermo, Italy, 1987.
27. WALKER DH. Pathophysiology of Rocky Mountain spotted fever. Abstracts of the International College of Rickettsiologists, Palermo, Italy, 1987.
28. Horney LF, WALKER DH. Meningoencephalitis as a major manifestation of Rocky Mountain spotted fever. Abstracts of the International College of Rickettsiologists, Palermo, Italy, 1987.
29. Tidwell RR, Kilgore SG, WALKER DH, Ohemeng KA, Geratz JD. Treatment of *Pneumocystis carinii* pneumonia in rats with analogs of pentamidine. Abstracts for the 27th ICAAC meeting, New York, NY, 1987.
30. Herrero JI, Alam A, WALKER DH. Demonstration and characterization of protease activity in rickettsial species of the spotted fever group. Abstracts of the 37th Annual Meeting of the American Society of Tropical Medicine and Hygiene, Washington, DC, December 4-8, 1988, poster 281.
31. Uchida T, Yu XJ, Uchiyama T, WALKER DH. A unique spotted fever group rickettsia from humans in Japan. Abstracts of the 37th Annual Meeting of the American Society of Tropical Medicine and Hygiene, Washington, DC, December 4-8, 1988, abstract M207:167.
32. WALKER DH, Parks F, Betz T, Taylor J, Muehlberger J. Histopathology and immunohistologic demonstration of the distribution of *Rickettsia typhi* in fatal murine typhus. Abstracts of the 1989 Annual Meeting of the United States and Canadian Academy of Pathology, San Francisco, CA, March 5-10, 1989, abstract/poster 35.
33. Herrero-Herrero JI, WALKER DH, Ruiz-Beltran R, Tacquard E. Humoral immune response in human Mediterranean spotted fever to polypeptides of *Rickettsia conorii*. Abstract of the 1989 American Society for Microbiology Annual Meeting, New Orleans, LA, May 14-18, 1989, abstract/poster D74.
34. WALKER DH, Taylor JP, Buie JS, Dearden C. Fatal human ehrlichiosis. Abstracts of the 1989 American Society for Microbiology Annual Meeting, New Orleans, LA, May 14-18, 1989, abstract/poster D76.

35. Uchiyama T, Uchida T, WALKER DH. Monoclonal antibodies to a new species of spotted fever group rickettsia isolated from a patient in Japan. Abstracts of the 1989 American Society for Microbiology Annual Meeting, New Orleans, LA, May 14-18, 1989, abstract/poster D77.
36. WALKER DH. The role of host factors in severity of spotted fever and typhus rickettsiosis. Symposium I, The American Society for Rickettsiology and Rickettsial Diseases Sesqui-Annual Meeting, Diamond Point, NY, September 22-26, 1989.
37. Gage KL, Jerrells TR, WALKER DH. Flow cytometric analysis of the effect of hemoglobin on the growth of *Rickettsia conorii* in cell culture. Abstract of the American Society for Rickettsiology and Rickettsial Diseases Sesqui-Annual Meeting, Diamond Point, NY, September 22-26, 1989, abstract 2.
38. Aronson J, Scimeca J, Harris D, WALKER DH. An immunohistologic demonstration of *Ehrlichia canis*. Abstract of the American Society for Rickettsiology and Rickettsial Diseases Sesqui-Annual Meeting, Diamond Point, NY, September 22-26, 1989, abstract 6.
39. Liu QH, WALKER DH, Zhou G. Serologic survey for antibodies to *Rickettsia sibirica* in Inner Mongolia, China. Abstract of the American Society for Rickettsiology and Rickettsial Diseases Sesqui-Annual Meeting, Diamond Point, NY, September 22-26, 1989, abstract 16.
40. Uchiyama T, Uchida T, WALKER DH. Analysis of antigens of *Rickettsia japonica* with monoclonal antibodies. Abstract of the American Society for Rickettsiology and Rickettsial Diseases Sesqui-Annual Meeting, Diamond Point, NY, September 22-26, 1989, abstract 39.
41. Li H, WALKER DH. Biological characterization of major polypeptides on the rickettsial surface. Abstract of the American Society for Rickettsiology and Rickettsial Diseases Sesqui-Annual Meeting, Diamond Point, NY, September 22-26, 1989, abstract 40.
42. Weiss K, Jerrells TR, WALKER DH. Expression and characterization of the 135-kDa antigen gene of *Rickettsia conorii*. Abstract of the American Society for Rickettsiology and Rickettsial Diseases Sesqui-Annual Meeting, Diamond Point, NY, September 22-26, 1989, abstract 54.
43. Gage KL, Jerrells TR, WALKER DH. T-lymphocyte proliferative responses and correlation of cross-protection against virulent *Rickettsia rickettsii* by immunization with *Rickettsia rhipicephali*. The 38th Annual Meeting of the American Society of Tropical Medicine and Hygiene, Honolulu, HA, December 10-14, 1989, abstract 226.
44. Weiss K, Jerrells TR, WALKER DH. Stimulation of murine T helper cells with natural and recombinant antigens of *Rickettsia conorii*. Abstract of the 1990 ASBMB/AAI, New Orleans, LA, June 4-8, 1990.
45. Dumler JS, Taylor JP, WALKER DH. Clinical and laboratory features of murine typhus in Texas, 1980-1987. The 39th Annual Meeting of the American Society of Tropical Medicine and Hygiene, New Orleans, LA, November 4-8, 1990, abstract 421.
46. Dumler JS, Aronson JF, WALKER DH. Human ehrlichiosis: Pathologic findings in three fatal cases. Abstract of the 1991 Annual Meeting of the United States and Canadian Academy of Pathology, Chicago, IL, March 17-22, 1991, abstract 510.
47. Brouqui P, Dumler JS, Dobbins M, WALKER DH, Raoult D. Ultrastructural morphology of the cell wall of ehrlichiae. Abstract of the American Society for Rickettsiology and Rickettsial Diseases Sesqui-Annual Meeting, Galveston, TX, May 1-5, 1991, abstract 6.

48. Brouqui P, Dumler JS, Raoult D, WALKER DH. Antigenic characterization of ehrlichia: major antigens and cross-reactive antigens of ehrlichiae. Abstract of the American Society for Rickettsiology and Rickettsial Diseases Sesqui-Annual Meeting, Galveston, TX, May 1-5, 1991, abstract 7.
49. Crocquet De Belligny PA, Weiss K, WALKER DH. Characterization and expression of *Rickettsia conorii* genomic λ gt 11 clones. Abstract of the American Society for Rickettsiology and Rickettsial Diseases Sesqui-Annual Meeting, Galveston, TX, May 1-5, 1991, abstract 9.
50. Dumler JS, Brouqui P, Aronson J, WALKER DH. Immunohistologic demonstration of ehrlichiae in fatal human ehrlichiosis. Abstract of the American Society for Rickettsiology and Rickettsial Diseases Sesqui-Annual Meeting, Galveston, TX, May 1-5, 1991, abstract 15.
51. Dumler JS, Brouqui P, WALKER DH. Antigenic characterization of *ehrlichia*: ehrlichiae lack lipopolysaccharides (LPS). Abstract of the American Society for Rickettsiology and Rickettsial Diseases Sesqui-Annual Meeting, Galveston, TX, May 1-5, 1991, abstract 16.
52. Li H, Jerrells TR, WALKER DH. Characterization of rickettsial attachment to target cells by flow cytometry. Abstract of the American Society for Rickettsiology and Rickettsial Diseases Sesqui-Annual Meeting, Galveston, TX, May 1-5, 1991, abstract 34.
53. Speed RR, WALKER DH. Defined-epitope blocking ELISA and its potential role in the identification of species-specific spotted fever infections. Abstract of the American Society for Rickettsiology and Rickettsial Diseases Sesqui-Annual Meeting, Galveston, TX, May 1-5, 1991, abstract 50.
54. Uchiyama T, Crocquet de Belligny P, Uchida T, WALKER DH. Cloning a genomic library of DNA of *Rickettsia japonica* in β gt 11 which expresses fusion proteins reactive with anti-*Rickettsia japonica* antisera. Abstract of the American Society for Rickettsiology and Rickettsial Diseases Sesqui-Annual Meeting, Galveston, TX, May 1-5, 1991, abstract 59.
55. Uchiyama T, Uchida T, WALKER DH. Analysis of surface polypeptides of *Rickettsia japonica*. Abstract of the American Society for Rickettsiology and Rickettsial Diseases Sesqui-Annual Meeting, Galveston, TX, May 1-5, 1991, abstract 60.
56. WALKER DH, Liu Q-H, Yu X-J, Li H, Taylor C. Antigenic analysis of the major outer membrane proteins of *Rickettsia conorii*, *Rickettsia parkeri*, and the Israel spotted fever group rickettsia. Abstract of the American Society for Rickettsiology and Rickettsial Diseases Sesqui-Annual Meeting, Galveston, TX, May 1-5, 1991, abstract 65.
57. Weiss K, Jerrells TR, WALKER DH. Sequence analysis and immunogenicity of a cloned immunodominant antigen of *R. conorii*. Abstract of the American Society for Rickettsiology and Rickettsial Diseases Sesqui-Annual Meeting, Galveston, TX, May 1-5, 1991, abstract 66.
58. Dumler JS, WALKER DH. Hematopathology of human ehrlichiosis: bone marrow findings in serologically confirmed cases. Abstract of the 1992 Annual Meeting of the United States and Canadian Academy of Pathology, Atlanta, GA, March 14-20, 1992, abstract/poster 539.
59. Dumler JS, WALKER DH. Persistent infection by *Ehrlichia chaffeensis* in a patient with ehrlichiosis. Abstract of the 1992 Annual Meeting of the United States and Canadian Academy of Pathology, Atlanta, GA, March 14-20, 1992, abstract/poster 540.
60. WALKER DH, Wen J, Feng HM. *Rickettsia australis* infection of Balb/c mice: a highly invasive vasculopathic model of SFG rickettsiosis. Abstract of the 92nd General Meeting of the American Society for Microbiology, New Orleans, LA, May 26-30, 1992, abstract 2018.

61. Feng HM, WALKER DH. The effect of temperature on the intracellular growth of *Rickettsia conorii* assayed by a new approach, flow cytometry. Abstract of the 92nd General Meeting of the American Society for Microbiology, New Orleans, LA, May 26-30, 1992, abstract 2015.
62. Sexton DJ, Corey GR, Breitswerdt E, Hegarty B, Muniz M, Dietze R, Dumler S, WALKER DH. Brazilian spotted fever in Espirito Santo, Brazil: description of a focus of infection in a new endemic region. Abstract of the American Society for Rickettsiology and Rickettsial Diseases Sesqui-Annual Meeting, Hamilton, MT, September 17-19, 1992.
63. Weiss K, WALKER DH. Identification of a novel *Rickettsia conorii* antigen-gene. Abstract of the American Society for Rickettsiology and Rickettsial Diseases Sesqui-Annual Meeting, Hamilton, MT, September 17-19, 1992.
64. Feng HM, WALKER DH. Investigation of immunity to *Rickettsia conorii* by use of a T-cell hybridoma and T-cell lines. Abstract of the American Society for Rickettsiology and Rickettsial Diseases Sesqui-Annual Meeting, Hamilton, MT, September 17-19, 1992.
65. WALKER DH, Wen J, Feng HM. *Rickettsia conorii* infection of C3H/HeN mice: a murine model of endothelial-target rickettsiosis. Abstract of the American Society for Rickettsiology and Rickettsial Diseases Sesqui-Annual Meeting, Hamilton, MT, September 17-19, 1992.
66. Novakovic S, Morovic M, Dzelalija B, Crocquet-Valdes P, Feng HM, WALKER DH. Serological typing of spotted fever group rickettsial tick isolates from the Adriatic coast of Croatia. Abstract of the American Society for Rickettsiology and Rickettsial Diseases Sesqui-Annual Meeting, Hamilton, MT, September 17-19, 1992.
67. Novakovic S, Morovic M, Dzelalija B, Feng HM, WALKER DH. Identification of spotted fever group rickettsia of human origin in the Adriatic coast of Croatia. Abstract of the American Society for Rickettsiology and Rickettsial Diseases Sesqui-Annual Meeting, Hamilton, MT, September 17-19, 1992.
68. Crocquet-Valdes P, Weiss K, WALKER DH. Isolation and preliminary sequencing of the *Rickettsia conorii* gene homologous to the *Rickettsia rickettsii* 190 kDa protein gene. Abstract of the American Society for Rickettsiology and Rickettsial Diseases Sesqui-Annual Meeting, Hamilton, MT, September 17-19, 1992.
69. Dumler JS, WALKER DH. Murine sennetsu ehrlichiosis: a model for study of ehrlichial pathogenesis? Abstract of the American Society for Rickettsiology and Rickettsial Diseases Sesqui-Annual Meeting, Hamilton, MT, September 17-19, 1992.
70. Dumler JS, WALKER DH. Isolation and partial characterization of a new *Ehrlichia* isolate from a human patient with ehrlichiosis. Abstract of the American Society for Rickettsiology and Rickettsial Diseases Sesqui-Annual Meeting, Hamilton, MT, September 17-19, 1992.
71. Dumler JS, WALKER DH. Persistent infection by *Ehrlichia chaffeensis* in a patient with ehrlichiosis. Abstract of the American Society for Rickettsiology and Rickettsial Diseases Sesqui-Annual Meeting, Hamilton, MT, September 17-19, 1992.
72. Dumler JS, Dawson JE, WALKER DH. Bone marrow hematopathology and immunohistologic identification of *E. chaffeensis* in human ehrlichiosis. Abstract of the American Society for Rickettsiology and Rickettsial Diseases Sesqui-Annual Meeting, Hamilton, MT, September 17-19, 1992.

73. Manor E, Novakovic S, WALKER DH, Azad, AF. Differentiation of spotted fever group from Israel and Slovenia by RFLP PCR analysis. Abstract of the American Society for Rickettsiology and Rickettsial Diseases Sesqui-Annual Meeting, Hamilton, MT, September 17-19, 1992.
74. Grinberg LM, Abramova FA, Yampolskaya OV, WALKER DH. The pathology of inhalational anthrax in 42 cases from the Sverdlovsk outbreak of 1979. Abstract of the United States and Canadian Academy of Pathology, Annual Meeting, New Orleans, LA, March 13-19, 1993.
75. WALKER DH, Popov VL, Wen J, Feng H-M. A model of boutonneuse fever in inbred mice. Abstract of the United States and Canadian Academy of Pathology, Annual Meeting, New Orleans, LA, March 13-19, 1993.
76. Herrero JI, Ruiz R, WALKER DH. Western blot assay in atypical situations of *Rickettsia conorii* infection report of two cases. Abstract of the Sixth European Congress of Clinical Microbiology and Infectious Diseases, Seville, Spain, March 28-31, 1993.
77. Herrero JI, Ruiz R, WALKER DH. Reactivity of *Rickettsia conorii* antigens with sera from healthy people from Salamanca (Spain). Abstract of the Sixth European Congress of Clinical Microbiology and Infectious Diseases, Seville, Spain, March 28-31, 1993.
78. WALKER DH, Popov VL, Wen JW, Feng H-M. Lysis of cell monolayers by massive simultaneous entry of *Rickettsia conorii* is mediated by phospholipase A₂. American Society for Microbiology, 93rd General Meeting, Atlanta, GA, May 16-20, 1993.
79. Radulovic S, Morovic M, Djelalija B, Feng H-M, Crocquet-Valdes P, WALKER DH. Genetic and antigenic characterization of *Rickettsia akari* isolated from human rickettsialpox in Europe, Croatia. American Society for Microbiology, 93rd General Meeting, Atlanta, GA, May 16-20, 1993.
80. Crocquet-Valdes, Weiss K, WALKER DH. Sequence analysis of the *Rickettsia conorii* (strain Malish 7) 190 kDa antigen gene. American Society for Microbiology, 93rd General Meeting, Atlanta, GA, May 16-20, 1993.
81. Feng H-M, WALKER DH. Analysis of the role of gamma interferon- γ and T-lymphocyte subsets in immunity to *Rickettsia conorii* in an endothelial-target animal model. American Society for Microbiology, 93rd General Meeting, Atlanta, GA, May 16-20, 1993.
82. Chen SM, Dumler JS, Feng H-M, WALKER DH. Identification of the antigenic constituents of *Ehrlichia chaffeensis*. American Society for Microbiology, 93rd General Meeting, Atlanta, GA, May 16-20, 1993.
83. Dumler JS, WALKER DH. Isolation and partial characterization of an *Ehrlichia* isolate from a patient with near-fatal ehrlichiosis. American Society for Microbiology, 93rd General Meeting, Atlanta, GA, May 16-20, 1993.
84. Herrero-Herrero JI, Ruiz Beltran R, WALKER DH. Utilidad de la citometria de flujo en el estudio *in vitro* de la infeccion por *Rickettsia conorii* y *Rickettsia rickettsii*. Sociedad Espanola de Enfermedades Infecciosas y Microbiologia Clinica, V Reunion Nacional de Enfermedades Infecciosas y Microbiologia Clinica, Valladolid, Spain, September 26-29, 1993.
85. WALKER DH, Gile JC, Feng H-M, To T, Muehlberger J. Diagnosis of spotted fever group rickettsioses by immunohistology with a group-specific anti-lipopolysaccharide monoclonal antibody. Lab Invest 70:128A, 1994.

86. Popov VL, Chen S-M, Feng H-M, WALKER DH. Ultrastructure of *Ehrlichia chaffeensis* interaction with different cell lines. American Society for Microbiology, 94th General Meeting, Las Vegas, NV, May 23-27, 1994.
87. Chen S-M, Popov VL, Feng H-M, WALKER DH. Growth of *Ehrlichia chaffeensis* in mouse embryo cells, Vero, BGM and L929 cells and study of *Ehrlichia*-induced cytopathic effect and plaque formation. American Society for Microbiology, 94th General Meeting, Las Vegas, NV, May 23-27, 1994.
88. WALKER DH, Feng H-M. Role of tumor necrosis factor- α (TNF) in the rickettsial mouse toxicity phenomenon. American Society for Microbiology, 94th General Meeting, Las Vegas, NV, May 23-27, 1994.
89. Radulovic S, Li H, Feng H-M, Crocquet-Valdes P, WALKER DH. Characterization of a Somalian isolate of *Rickettsia conorii* from a human patient: Evidence for intraspecies genetic and antigenic diversity. American Society for Microbiology, 94th General Meeting, Las Vegas, NV, May 23-27, 1994.
90. Li H, Crocquet-Valdes PA, WALKER DH. rOmpA is a critical protein for the adhesion of *Rickettsia rickettsii* to the host cell. American Society for Microbiology, 94th General Meeting, Las Vegas, NV, May 23-27, 1994.
91. Feng H-M, WALKER DH. Establishment of T cell clones which recognize the major protein epitopes of *Rickettsia conorii* or *Rickettsia rickettsii*. American Society for Microbiology, 94th General Meeting, Las Vegas, NV, May 23-27, 1994.
92. Crocquet-Valdes PA, Feng H-M, WALKER DH. Expression and purification of *Rickettsia conorii* (Malish 7 strain) recombinant *rompA* antigen in *E. coli* as fusion with glutathione-s-transferase. American Society for Microbiology, 94th General Meeting, Las Vegas, NV, May 23-27, 1994.
93. Dumler JS, Bakken JS, Chen SM, WALKER DH. Clinical, epidemiologic, laboratory, and diagnostic features of human infection caused by a granulocytic ehrlichia. American Society for Microbiology, 94th General Meeting, Las Vegas, NV, May 23-27, 1994.
94. Feng H-M, Peng B-H, Popov VL, WALKER DH. Immune murine cytotoxic T-lymphocytes cause apoptosis of *Rickettsia conorii*-infected MHC-matched endothelial cells. Poster presentation presented at the American Society for Rickettsiology and Rickettsial Diseases, Sesqui-Annual Meeting, St. Simons Island, GA, September 17-20, 1994.
95. WALKER DH, Feng H-M, Saada JI, Radulovic S, Taylor C, Crocquet-Valdes P, Manor E. Israeli SFG rickettsiae: a case for the need to establish provisional criteria for rickettsial species. Poster presentation presented at the American Society for Rickettsiology and Rickettsial Diseases, Sesqui-Annual Meeting, St. Simons Island, GA, September 17-20, 1994.
96. Chen S-M, Feng H-M, WALKER DH. Study of ehrlichia antigens by monoclonal antibodies to *Ehrlichia chaffeensis*. Poster presentation presented at the American Society for Rickettsiology and Rickettsial Diseases, Sesqui-Annual Meeting, St. Simons Island, GA, September 17-20, 1994.
97. Popov VL, Chen S-M, Wen JW, Feng H-M, WALKER DH. Morphological variation of *Ehrlichia chaffeensis*: evidence for ehrlichial pathology. Poster presentation presented at the American Society for Rickettsiology and Rickettsial Diseases, Sesqui-Annual Meeting, St. Simons Island, GA, September 17-20, 1994.

98. Crocquet-Valdes PA, Feng H-M, WALKER DH. Protective immunity studies in mice using recombinant fragments of *Rickettsia conorii* (Malish 7 strain) rOmpA and rOmpB surface antigens. Poster presentation presented at the American Society for Rickettsiology and Rickettsial Diseases, Sesqui-Annual Meeting, St. Simons Island, GA, September 17-20, 1994.
99. Dumler JS, Chen S-M, Bakken JS, WALKER DH. Human granulocytic ehrlichiosis. Oral presentation presented at the American Society for Rickettsiology and Rickettsial Diseases, Sesqui-Annual Meeting, St. Simons Island, GA, September 17-20, 1994.
100. Trigiani ER, Asanovich KM, Chen S-M, WALKER DH, Dumler JS. Antigenic and genetic comparisons of two strains of *Ehrlichia chaffeensis*. Poster presentation presented at the American Society for Rickettsiology and Rickettsial Diseases, Sesqui-Annual Meeting, St. Simons Island, GA, September 17-20, 1994.
101. Sexton DJ, Radulovic S, Duer M, Dietze R, Weingarten NM, WALKER DH. The clinical use of EIA with species-specific monoclonal antibodies to determine the etiology of spotted fever rickettsial disease in Brazil and imported rickettsial infection in North Carolina. Poster presentation presented at the American Society for Rickettsiology and Rickettsial Diseases, Sesqui-Annual Meeting, St. Simons Island, GA, September 17-20, 1994.
102. WALKER DH, Popov VL, Feng H-M. Murine endothelial cells stimulated by γ -interferon and tumor-necrosis factor- α kill *Rickettsia conorii* by synthesis of nitric oxide. American Society of Tropical Medicine and Hygiene, 43rd Annual Meeting, Cincinnati, OH, November 13-17, 1994.
103. Chen S-M, Popov V, WALKER DH. Identification of surface-exposed antigenic molecules of *Ehrlichia chaffeensis* by monoclonal antibodies. American Society of Microbiology, 95th General Meeting, Washington, DC, May 21-25, 1995.
104. Li H, Wen J, WALKER DH. Heparin plays a role in the adhesion of *Rickettsia rickettsii* to host cells. American Society of Microbiology, 95th General Meeting, Washington, DC, May 21-25, 1995.
105. WALKER DH, Hong X, Feng H-M. *In vitro* evidence that cytokine-stimulated human endothelium exerts anti-rickettsial activity. American Society of Microbiology, 95th General Meeting, Washington, DC, May 21-25, 1995.
106. Bakken JS, Tilden RL, Dumler JS, WALKER DH. The spectrum of severity in human granulocytic ehrlichiosis (HGE). Infectious Diseases Society of America, 1995 Annual Meeting, San Francisco, CA, September 16, 1995.
107. WALKER DH. Human ehrlichioses: Tick-transmitted, obligately intracellular bacterial infections of macrophages or neutrophils. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy Annual Meeting, San Francisco, CA, September 16, 1995.
108. Yu XJ, WALKER DH. Molecular cloning and sequencing of a 120 kDA immunodominant protein gene of *Ehrlichia chaffeensis*. American Society of Tropical Medicine and Hygiene, 44th Annual Meeting, San Antonio, TX, November 17-21, 1995.
109. Crocquet-Valdes PA, WALKER DH. Expression of *Rickettsia rickettsii* rOmpA recombinant fragment in mycobacteria. American Society of Tropical Medicine and Hygiene, 44th Annual Meeting, San Antonio, TX, November 17-21, 1995.
110. Popov VL, Han VC, Chen SM, Bakken JS, Dumler JS, Madigan JE, WALKER, DH. Ultrastructure of human granulocytic ehrlichiae. American Society of Tropical Medicine and Hygiene, 44th Annual Meeting, San Antonio, TX, November 17-21, 1995.

111. Billings AN, WALKER DH. Natural killer cell as an effector of non-specific immunity to rickettsiae. American Society of Tropical Medicine and Hygiene, 44th Annual Meeting, San Antonio, TX, November 17-21, 1995.
112. Yu XJ, WALKER DH. Genetic diversity of the 120 kDa protein gene among the strains of *Ehrlichia chaffeensis*. American Society for Rickettsiae and Rickettsial Diseases, Twelfth Sesqui-Annual Meeting, Asilomar, CA, March 10-13, 1996.
113. WALKER DH, Ladner S, Popov VL, Feng H-M. A mouse model for typhus group rickettsiosis. American Society for Rickettsiae and Rickettsial Diseases, Twelfth Sesqui-Annual Meeting, Asilomar, CA, March 10-13, 1996.
114. Chen S-M, Popov VL, Feng H-M, WALKER DH. Isolation and analysis of a new strain of *Ehrlichia chaffeensis*. American Society for Rickettsiae and Rickettsial Diseases, Twelfth Sesqui-Annual Meeting, Asilomar, CA, March 10-13, 1996.
115. WALKER DH. Clinical considerations and taxonomic relevance. American Society for Rickettsiae and Rickettsial Diseases, Twelfth Sesqui-Annual Meeting, Asilomar, CA, March 10-13, 1996.
116. Feng H-M, WALKER DH. Development of CD8 T cell clones and study of their effects on rickettsial immunity. American Society for Rickettsiae and Rickettsial Diseases, Twelfth Sesqui-Annual Meeting, Asilomar, CA, March 10-13, 1996.
117. Yuoh G, Feng H-M, WALKER DH. Experimental and immunohistologic evidence for the roles of CD4 and CD8 T-lymphocytes in the immune clearance of *Rickettsia conorii* from the endothelium of mice. Abstract of the United States and Canadian Academy of Pathology. Annual Meeting, Washington, DC, March 25-29, 1996.
118. Yu X-J, Crocquet-Valdes PA, WALKER DH. Cloning, sequencing, and expressing two immunodominant protein genes of *Ehrlichia chaffeensis* with the capacity of encoding 75 and 28 kDa proteins. American Society for Rickettsiology, Thirteenth Sesqui-Annual Meeting, Champion, PA, September 21-24, 1997.
119. Yu X-J, WALKER DH. Sequence and characterization of an *Ehrlichia chaffeensis* gene encoding 314 amino acids highly homologous to the NAD A enzyme. American Society for Rickettsiology, Thirteenth Sesqui-Annual Meeting, Champion, PA, September 21-24, 1997.
120. Billings AN, Yu X-J, Teel PD, WALKER DH. A spotted fever group rickettsia detected in *Amblyomma cajennense* ticks in south Texas. American Society for Rickettsiology, Thirteenth Sesqui-Annual Meeting, Champion, PA, September 21-24, 1997.
121. Popov VL, Yu X-J, WALKER DH. Dense-core cells of *Ehrlichia chaffeensis* preferentially express the 120 kDa outer membrane protein. American Society for Rickettsiology, Thirteenth Sesqui-Annual Meeting, Champion, PA, September 21-24, 1997.
122. WALKER DH, Feng HM, Popov VL. The role of phospholipase A₂ activity in rickettsial cytotoxicity *in vitro*. American Society for Rickettsiology, Thirteenth Sesqui-Annual Meeting, Champion, PA, September 21-24, 1997.
123. Crocquet-Valdes PA, Ni H, Barrett ADT, WALKER DH. Expression of *Rickettsia rickettsii* rOmpA epitopes in recombinant mycobacteria. American Society for Rickettsiology, Thirteenth Sesqui-Annual Meeting, Champion, PA, September 21-24, 1997.

124. Billings AN, Teltow GJ, WALKER DH. Molecular characterization of a novel spotted fever group rickettsial species from *Ixodes scapularis* in Texas. American Society for Rickettsiology, Thirteenth Sesqui-Annual Meeting, Champion, PA, September 21-24, 1997.
125. Rudakov NV, Tarasevich IV, WALKER DH, Samoilenko IE. Increasing incidence of Siberian tick typhus: an analysis of the ecologic and epidemiological factors. American Society for Rickettsiology, Thirteenth Sesqui-Annual Meeting, Champion, PA, September 21-24, 1997.
126. Samoilenko IE, Rudakov NV, Yakimenko VV, WALKER DH. Results of experimental study of tick-rickettsia interactions in tick-borne rickettsiosis foci. American Society for Rickettsiology, Thirteenth Sesqui-Annual Meeting, Champion, PA, September 21-24, 1997.
127. Billings AN, Feng HM, WALKER DH. Natural killer (NK) cells as a component of the innate immune response to rickettsiae. American Society for Rickettsiology, Thirteenth Sesqui-Annual Meeting, Champion, PA, September 21-24, 1997.
128. Stenos J, WALKER DH. Genetic divergence of *Rickettsia australis* from the other SFG rickettsiae. American Society for Rickettsiology, Thirteenth Sesqui-Annual Meeting, Champion, PA, September 21-24, 1997.
129. Carpenter C, Gandhi T, King LK, Corey GR, Dumler JS, Chen S-M, WALKER DH, Breitschwerdt E, Hegarty B, Sexton DJ. The incidence of ehrlichial and rickettsial infections in patients with unexplained fever and history of recent tick bite in central North Carolina. American Society for Rickettsiology, Thirteenth Sesqui-Annual Meeting, Champion, PA, September 21-24, 1997.
130. WALKER DH, Yu XJ, Chen SM, Cullman L. Expression of the 120-kDa outer membrane protein of *Ehrlichia chaffeensis* in a morphologic subset of organisms. American Society for Tropical Medicine and Hygiene, 46th Annual Meeting, Lake Buena Vista, FL, December 7-11, 1997.
131. Olano JP, Billings AN, Ramirez-Prada G, WALKER DH. Epidemic typhus outbreak in Cuzco, Peru. Conference on microbes, hemostasis, and vascular biology, co-sponsored by American Society for Microbiology, Texas A&M University, and the WHO Collaborating Center for Tropical Diseases at the University of Texas Medical Branch at Galveston, Galveston, TX, March 29-April 1, 1998.
132. WALKER DH. The nature of ehrlichiae and ehrlichial infections. American Society for Microbiology, 98th General Meeting, Atlanta, GA, May 17-21, 1998.
133. Zavala-Velazquez JE, Ruiz-Sosa JA, Jimenez B, Vado-Solis I, Zavala-Castro J, WALKER DH. *Rickettsia felis*: the etiologic agent of a case of rickettsiosis in the Yucatán. 47th Annual Meeting of the American Society for Tropical Medicine and Hygiene, San Juan, Puerto Rico, October 18-22, 1998.
134. Olano JP, Ramirez-Prada G, Moscoso B, Watts D, WALKER DH. Epidemic typhus outbreaks in Cuzco, Peru. 47th Annual Meeting of the American Society for Tropical Medicine and Hygiene, San Juan, Puerto Rico, October 18-22, 1998.
135. Billings AN, Olano JP, Feng H-M, WALKER DH. Natural killer cells: an integral component of the innate immune defenses in two murine models of rickettsiosis. 47th Annual Meeting of the American Society for Tropical Medicine and Hygiene, San Juan, Puerto Rico, October 18-22, 1998.

136. Yu X-J, Crocquet-Valdes P, Popov VL, WALKER DH. Molecular cloning and characterization of a 106-kDa outer membrane protein gene and 37-kDa iron binding protein gene of *Ehrlichia chaffeensis*. 47th Annual Meeting of the American Society for Tropical Medicine and Hygiene, San Juan, Puerto Rico, October 18-22, 1998.
137. McBride JW, Yu XJ, WALKER DH. Evidence for glycosylation of homologous immunoreactive 120-kDa proteins from *Ehrlichia chaffeensis* and *Ehrlichia canis*. 47th Annual Meeting of the American Society for Tropical Medicine and Hygiene, San Juan, Puerto Rico, October 18-22, 1998.
138. Feng H-M, WALKER DH. Studies of immune responses to *Ehrlichia chaffeensis* infection in murine models. 47th Annual Meeting of the American Society for Tropical Medicine and Hygiene, San Juan, Puerto Rico, October 18-22, 1998.
139. Bouyer DH, Crocquet-Valdes P, Stenos J, Foil L, WALKER DH. The identification and characterization of a previously undiscovered rOmpA encoding gene in *Rickettsia felis*. American Society for Rickettsiology and Rickettsial Diseases Sesqui-Annual Meeting, Marseille, France, June 12-23, 1999.
140. Diaz M, Feng H-M, WALKER DH. *Rickettsia conorii* antigen presentation to CD8 T-lymphocytes by a murine endothelial cell line. American Society for Rickettsiology and Rickettsial Diseases Sesqui-Annual Meeting, Marseille, France, June 12-23, 1999.
141. Feng H-M, WALKER DH. Mechanisms of immunity to *Ehrlichia chaffeensis* in mice. American Society for Rickettsiology and Rickettsial Diseases Sesqui-Annual Meeting, Marseille, France, June 12-23, 1999.
142. Galvao M, Chamone CB, Calic SB, Machado MC, Otoni MEA, Dietze R, Moron C, Feng H-M, Olano JP, WALKER DH. Serologic evidence of spotted fever group rickettsia in Novo Cruzeiro Municipality-Minas Gerais State-Brazil. American Society for Rickettsiology and Rickettsial Diseases Sesqui-Annual Meeting, Marseille, France, June 12-23, 1999.
143. Hudson B, Lennox V, Stenos J, WALKER DH. Serological evidence of ehrlichiosis in Australia. American Society for Rickettsiology and Rickettsial Diseases Sesqui-Annual Meeting, Marseille, France, June 12-23, 1999.
144. McBride JW, Yu X-J, WALKER DH. Molecular characterization of a new 28-kilodalton protein gene and a multigene locus encoding five homologous 28-kilodalton immunodominant outer membrane proteins of *Ehrlichia canis*. American Society for Rickettsiology and Rickettsial Diseases Sesqui-Annual Meeting, Marseille, France, June 12-23, 1999.
145. Moron CG, Yu X-J, Crocquet-Valdes P, WALKER DH. Sequence analysis of the *romp B* gene of *Rickettsia prowazekii* isolated from flying squirrels. American Society for Rickettsiology and Rickettsial Diseases Sesqui-Annual Meeting, Marseille, France, June 12-23, 1999.
146. Olano JP, Masters E, Cullman L, Hogrefe W, Yu X-J, WALKER DH. Human monocytotropic ehrlichiosis (HME): Epidemiological, clinical and laboratory diagnosis of a newly emergent infection in the United States. American Society for Rickettsiology and Rickettsial Diseases Sesqui-Annual Meeting, Marseille, France, June 12-23, 1999.
147. Rudakov NV, Samoilenko IE, Yakimenko VV, Reshetnikova TA, Chpynov SN, WALKER DH. The re-emergence of Siberian tick typhus: field and experimental observations. American Society for Rickettsiology and Rickettsial Diseases Sesqui-Annual Meeting, Marseille, France, June 12-23, 1999.

148. Stenos J, WALKER DH. The *Rickettsia australis* outer membrane proteins A and B. American Society for Rickettsiology and Rickettsial Diseases Sesqui-Annual Meeting, Marseille, France, June 12-23, 1999.
149. WALKER DH, Crocquet-Valdes P, Feng H-M. Human Macrophages and Hepatocytes. American Society for Rickettsiology and Rickettsial Diseases Sesqui-Annual Meeting, Marseille, France, June 12-23, 1999.
150. Yu X-J, McBride JW, WALKER DH. Characterization of the Genus-Common Outer Membrane Proteins in *Ehrlichia*. American Society for Rickettsiology and Rickettsial Diseases Sesqui-Annual Meeting, Marseille, France, June 12-23, 1999.
151. Zavala-Velázquez JE, Ruiz-Sosa JA, González-Sosa ER, WALKER DH. *Rickettsia felis*: Identification and molecular characterization in fleas (*Ctenocephalides felis*) in Yucatán. American Society for Rickettsiology and Rickettsial Diseases Sesqui-Annual Meeting, Marseille, France, June 12-23, 1999.
152. Zavala-Velasquez JE, Ruiz-Sosa JA, Jimenez B, Vado-Solis I, Zavala-Castro J, WALKER DH. *Rickettsia felis*: the etiologic agent of a case of rickettsiosis in the Yucatan. American Society for Rickettsiology and Rickettsial Diseases Sesqui-Annual Meeting, Marseille, France, June 12-23, 1999.
153. Bouyer DH, Crocquet-Valdes P, Stenos J, Foil LD, WALKER DH. Evaluation of a recombinant antigen for diagnosis of *Rickettsia felis* infection. In: Program and Abstracts of the 48th Annual Meeting of the American Society of Tropical Medicine and Hygiene. Washington, DC, p424, No. 662, 1999.
154. McBride JW, Yu XJ, WALKER DH. Glycosylation of homologous immunodominant proteins of *Ehrlichia chaffeensis* and *Ehrlichia canis*. In: Program and Abstracts of the 48th Annual Meeting of the American Society of Tropical Medicine and Hygiene, Washington, DC, p358, No. 507, 1999.
155. Moron CG, Bouyer DH, WALKER DH. Comparative phylogenetic analysis of the *romp* B genes of *Rickettsia felis* and *Rickettsia prowazekii* European human and North American flying squirrel strains. In: Program and Abstracts of the 48th Annual Meeting of the American Society of Tropical Medicine and Hygiene, Washington, DC, p359, No. 508, 1999.
156. Olano JP, WALKER DH. Intracellular events after rickettsial internalization. In: Program and Abstracts of the 48th Annual Meeting of the American Society of Tropical Medicine and Hygiene. Washington, DC, p423, No. 660, 1999.
157. Feng HM, WALKER DH. The importance of cytotoxic T-lymphocyte activity in immunity against *Rickettsia* in mouse models. In: Program and Abstracts of the 48th Annual Meeting of the American Society of Tropical Medicine and Hygiene. Washington, DC, p424, No. 661, 1999.
158. Valbuena G, WALKER DH. Changes in permeability of the blood-retinal barrier after rickettsial infection and correlation with endothelial cell activation. Experimental Biology 2000 Meeting, American Society of Investigative Pathology, San Diego, CA, April 15-18, 2000.
159. Olano JP, Masters E, Hogrefe W, WALKER DH. Serologic diagnosis of human monocytotropic ehrlichiosis (HME). In: Program and Abstracts of the American Society for Rickettsiology 15th Meeting. Captiva Island, FL, p23, No. 20, May 2000.
160. Anaya E, Moron C, Falconi E, WALKER DH. Distribution of rickettsioses and rickettsiae in Cuzco, Ancash, and Piura. In: Program and Abstracts of the American Society for Rickettsiology 15th Meeting. Captiva Island, FL, p28, No. 29, May 2000.

161. McBride JW, Corstvet RE, Popov VL, Breitschwerdt EB, WALKER DH. Molecular cloning of an immunodominant 43-kD surface protein of *Ehrlichia canis*: A potential differential serodiagnostic antigen. In: Program and Abstracts of the American Society for Rickettsiology 15th Meeting. Captiva Island, FL, p30, No. 33, May 2000.
162. Tankibaev MA, Rudakov NV, Samoilenko IE, Reshetnikova TA, Yakimenko VV, Chpynov SN, WALKER DH. New data in the study of spotted fever group rickettsiae and arboviruses in Central Kazakhstan. In: Program and Abstracts of the American Society for Rickettsiology 15th Meeting. Captiva Island, FL, p31, No. 36, May 2000.
163. Yu X-J, McBride JW, Zhang X-F, WALKER DH. Complete sequence of the *Ehrlichia chaffeensis* 28 kDa outer membrane protein multigene family. In: Program and Abstracts of the American Society for Rickettsiology 15th Meeting. Captiva Island, FL, p54, No. 78, May 2000.
164. Valbuena G, WALKER DH. *Rickettsia conorii* does not induce changes in the localization of the adherens junction protein complex in infected human endothelial cells. In: Program and Abstracts of the American Society for Rickettsiology 15th Meeting. Captiva Island, FL, p58, No. 86, May 2000.
165. Valbuena G, WALKER DH. Rickettsia-induced increased vascular permeability and endothelial activation in the central nervous system. The retina as a model. In: Program and Abstracts of the American Society for Rickettsiology 15th Meeting. Captiva Island, FL, p58, No. 87, May 2000.
166. Bouyer DH, Crocquet-Valdes PA, WALKER DH. Expression and size determination of the *rompA* protein of *Rickettsia felis*. In: Program and Abstracts of the American Society for Rickettsiology 15th Meeting. Captiva Island, FL, p61, No. 93, May 2000.
167. Moron CG, WALKER DH. Detection of *Orientia tsutsugamushi* in paraffin-embedded tissues by immunohistochemistry. In: Program and Abstracts of the American Society for Rickettsiology 15th Meeting. Captiva Island, FL, p62, No. 94, May 2000.
168. Moron CG, Bouyer DH, Crocquet-Valdes PA, WALKER DH. Identification of the *rompA* gene of *Rickettsia canadensis*. In: Program and Abstracts of the American Society for Rickettsiology 15th Meeting. Captiva Island, FL, p62, No. 95, May 2000.
169. Crocquet-Valdes PA, Diaz CM, Feng H-M, Li H, Barrett ADT, WALKER DH. Immunization with a portion of the tandem repeat domain of rickettsial outer membrane protein A stimulates protective immunity against spotted fever rickettsiosis. In: Program and Abstracts of the American Society for Rickettsiology 15th Meeting. Captiva Island, FL, p64, No. 98, May 2000.
170. WALKER DH, Feng H-M. Immune protection of antibody against *Rickettsia conorii* *in vivo* and investigation of the role of antibody *in vitro*. In: Program and Abstracts of the American Society for Rickettsiology 15th Meeting. Captiva Island, FL, p. 67, No. 104, May 2000.
171. Popov VL, Sotomayor EA, Feng H-F, Olano JP, Yu X-J, Dumler JS, WALKER DH. Interaction of ehrlichiae with host cells in a mouse model of fatal monocytotropic ehrlichiosis. In: Program and Abstracts of the 49th Annual Meeting of the American Society of Tropical Medicine and Hygiene. Houston, TX, p.187, No. 126, 2000.
172. McBride JW, Yu X-J, WALKER DH. Multiple *Ehrlichia canis* p28 genes are transcriptionally active as monocistronic messages. In: Program and Abstracts of the 49th Annual Meeting of the American Society of Tropical Medicine and Hygiene. Houston, TX, p. 188, No. 127, 2000.

173. Diaz CM, Crocquet-Valdes PA, Feng HM, WALKER DH. Presentation of CD8 T-lymphocyte-stimulating rickettsial antigens by cultured endothelial cells and determination of their protective ability. In: Program and Abstracts of the 49th Annual Meeting of the American Society of Tropical Medicine and Hygiene. Houston, TX, p. 129, No. 188, 2000.
174. Feng H-M, Crocquet-Valdes P, WALKER DH. Rickettsial epitopes of recombinant proteins and synthetic peptides recognized by human T-lymphocytes. In: Program and Abstracts of the 49th Annual Meeting of the American Society of Tropical Medicine and Hygiene. Houston, TX, p. 189, No. 130, 2000.
175. WALKER DH, Feng H-M. Crossprotection induced by rickettsiae of the spotted fever group. In: Program and Abstracts of the 49th Annual Meeting of the American Society of Tropical Medicine and Hygiene. Houston, TX, p. 189, No. 131, 2000.
176. Galvao MAM, Lamounier JA, Bonomo E, Tropia MS, Cerqueira Leite R, Garcia ES, Calic SB, Chamone CB, Machado MC, Otoni MEA, Mafra CL, WALKER DH. Seroreactivity to spotted fever rickettsiae among students in an endemic area of Brazilian spotted fever in Minas Gerais State-Brazil. In: Program and Abstracts of the 49th Annual Meeting of the American Society of Tropical Medicine and Hygiene. Houston, TX, p. 335, No. 468, 2000.
177. Bouyer DH, Moron CG, Ceballos G, WALKER DH. Identification of a rickettsia from Mexican flying squirrel ectoparasites. In: Program and Abstracts of the 49th Annual Meeting of the American Society of Tropical Medicine and Hygiene. Houston, TX, p. 337, No. 474, 2000.
178. Moron CG, Feng H-M, WALKER DH. Identification of the target cells of *Orientia tsutsugamushi* in human cases of scrub typhus. In: Program and Abstracts of the 49th Annual Meeting of the American Society of Tropical Medicine and Hygiene. Houston, TX, p. 338, No. 476, 2000.
179. WALKER DH. Vector-borne Zoonoses in the U.S.: Ehrlichioses and Rickettsioses. In: Program of the 2001 American Heartworm Society Symposium. San Antonio, TX, p. 34, April 2001.
180. Bouyer DH, Moron CG, Alcantara V, Whitworth T, Popov V, Ceballos G, WALKER DH. Cultivation and characterization of a *Rickettsia* isolate from Mexican flying squirrel ectoparasites. In: Program and Abstracts of the American Society for Rickettsiology-*Bartonella* as an Emerging Pathogen Group 2001 Joint Conference. Big Sky, MT, p. 30, No. 23, August 2001.
181. Galvao MAM, Mafra CL, Oliveira RP, Chamone CB, Calic SB, WALKER DH. Clinical and laboratorial evidence of *Rickettsia felis* in Latin America. In: Program and Abstracts of the American Society for Rickettsiology-*Bartonella* as an Emerging Pathogen Group 2001 Joint Conference. Big Sky, MT, p. 34, No. 32, August 2001.
182. Ndip LM, Bouyer DH, WALKER DH. Prevalence of antibodies to *Rickettsia africae* in Cameroon. In: Program and Abstracts of the American Society for Rickettsiology-*Bartonella* as an Emerging Pathogen Group 2001 Joint Conference. Big Sky, MT, p. 36, No. 36, August 2001.
183. Alcantara VE, WALKER DH. Present and future of the systems of epidemiological surveillance of the rickettsiosis. In: Program and Abstracts of the American Society for Rickettsiology-*Bartonella* as an Emerging Pathogen Group 2001 Joint Conference. Big Sky, MT, p. 37, No. 37, August 2001.
184. Mafra CL, Vianna MCB, Gennari SM, Alvarenga D, Horta MC, Guerra MLP, Sangioni LA, Bouyer D, Labruna M, Galvao MAM, WALKER DH. Serological evaluation of humans and dogs for rickettsioses in the municipality of Itabira, Minas Gerais State, Brazil. In: Program and Abstracts of the American Society for Rickettsiology-*Bartonella* as an Emerging Pathogen Group 2001 Joint Conference. Big Sky, MT, p. 37, No. 38, August 2001.

185. Yu X-J, Zhang X-F, WALKER DH. Allele variation in an expression site of the *Ehrlichia chaffeensis* 28-kDa outer membrane protein multigene family. In: Program and Abstracts of the American Society for Rickettsiology-*Bartonella* as an Emerging Pathogen Group 2001 Joint Conference. Big Sky, MT, p. 44, No. 52, August 2001.
186. Valbuena G, WALKER DH. Analysis of T-cell –targeting chemokines during rickettsial infection. In: Program and Abstracts of the American Society for Rickettsiology-*Bartonella* as an Emerging Pathogen Group 2001 Joint Conference. Big Sky, MT, p. 55, No. 73, August 2001.
187. Li Z, Diaz-Montero CM, Crocquet-Valdes PA, Feng H-M, WALKER DH. Presentation of CD8 stimulating rickettsial antigens by transfected fibroblast cells. In: Program and Abstracts of the American Society for Rickettsiology-*Bartonella* as an Emerging Pathogen Group 2001 Joint Conference. Big Sky, MT, p. 56, No. 76, August 2001.
188. McBride JW, WALKER DH. Identification of a putative disulfide bond forming protein A of *Ehrlichia chaffeensis* and *Ehrlichia canis*. In: Program and Abstracts of the American Society for Rickettsiology-*Bartonella* as an Emerging Pathogen Group 2001 Joint Conference. Big Sky, MT, p. 34, No. 32, August 2001.
189. Feng H-M, WALKER DH. Mechanisms of immunity to *Ehrlichia muris*, a model of human monocytotropic ehrlichiosis. In: Program and Abstracts of the 50th Annual Meeting of the American Society of Tropical Medicine and Hygiene. Atlanta, GA, p. 413, No. 762, November 2001.
190. Alcantara VE, Mendez JF, WALKER DH. Retrospective study of 55 cases of Rocky Mountain spotted fever in Mexico. In: Program and Abstracts of the 50th Annual Meeting of the American Society of Tropical Medicine and Hygiene. Atlanta, GA, p. 413, No. 763, November 2001.
191. WALKER DH. Diagnosing human ehrlichiosis: current recommendations. In: 41st Annual ICAAC Conference. Chicago, IL. No. 1787. December 2001.
192. Valbuena G, Bradford W, WALKER DH. Expression of T-cell targeting chemokines in fatal Rocky Mountain spotted fever and validation in a mouse model. In: United States and Canadian Academy of Pathology. Chicago, Illinois. Laboratory Investigation. No. 82:9A. February 2002.
193. Valbuena G, WALKER DH. Expression analysis of T-cell targeting chemokines in a mouse model of endothelial-target spotted fever group rickettsiosis. In: Experimental Biology conference. New Orleans, LA. P. A600, No. 459.12. April 2002.
194. Ismail N, WALKER DH. Protection of immunocompetent mice against lethal infection with a highly virulent strain of ehrlichia. In: American Society for Microbiology. Salt Lake City, UT. No. E-22. May 2002.
195. Walker DH. Principles of the malicious use of infectious agents to create terror: reasons for concern for organisms of the genus *Rickettsia*. In: International Conference on Rickettsiae and Rickettsial Diseases. Ljubljana, Slovenia. No. S-2. September 2002.
196. Galvão MAM, Mafrá CL, Moron C, WALKER DH. Rickettsioses of the genus *Rickettsia* in South America during the last 20 years. In: International Conference on Rickettsiae and Rickettsial Diseases joint meeting with the American Society for Rickettsiology Conference. No. O-8. Ljubljana, Slovenia. September 2002.

197. Whitworth T, Popov VL, Han V, Bouyer DH, Stenos J, Graves S, Ndip L, WALKER DH. Ultrastructural evidence of a reptilian tick, *Aponomma hydrosauri*, as a vector of *Rickettsia honei* in Australia (and its transovarial transmission). In: International Conference on Rickettsiae and Rickettsial Diseases joint meeting with the American Society for Rickettsiology Conference. No. O-10. Ljubljana, Slovenia. September 2002.
198. Alcantara VE, Bouyer DH, Valbuena G, Feng H-M, WALKER DH. The effect of treatment of rickettsial infection with sulfamethoxazole. In: International Conference on Rickettsiae and Rickettsial Diseases joint meeting with the American Society for Rickettsiology Conference. No. O-22. Ljubljana, Slovenia. September 2002.
199. McBride JW, Comer JE, WALKER DH. Identification of novel immunoreactive *Ehrlichia canis* and *Ehrlichia chaffeensis* glycoprotein orthologs. In: International Conference on Rickettsiae and Rickettsial Diseases joint meeting with the American Society for Rickettsiology Conference. Ljubljana, Slovenia. No. O-60. September 2002.
200. Crocquet-Valdes PA, McBride JW, Yu X-J, WALKER DH. Molecular characterization of the 28-kDa multigene locus of *Ehrlichia muris*. In: International Conference on Rickettsiae and Rickettsial Diseases joint meeting with the American Society for Rickettsiology Conference. Ljubljana, Slovenia. No. P-102. September 2002.
201. Galvão MAM, Bouyer DH, Olano JP, Cerqueira LR, WALKER DH. *Rickettsia felis* in *Amblyomma cajennense* ticks, Brazil. In: International Conference on Rickettsiae and Rickettsial Diseases joint meeting with the American Society for Rickettsiology Conference. Ljubljana, Slovenia. No. P-29. September 2002.
202. Crocquet-Valdes PA, McBride JW, Ismail N, Yu X-J, WALKER DH. Molecular characterization of the *Ehrlichia muris* p28 multigene locus and comparison with other *Ehrlichia* spp. In: American Society for Rickettsiology. Cumberland, MD. No. 35. September 2003.
203. Whitworth TJ, Feng H-M, Olano JP, Popov VL, WALKER DH. A quantitative ultrastructural analysis of the effects of antibody on *Rickettsia conorii* (Malish 7) vacuolar escape *in vitro*, and correlated *in vivo* with a descriptive ultrastructural and immunohistochemical examination. In: American Society for Rickettsiology. Cumberland, MD. No. 48. September 2003.
204. Bouyer DH, Hong C, Keng C, Small M, Wang E, WALKER DH. Evaluation of the resistance and susceptibility of inbred mouse strains to lethal infection by *Rickettsia conorii*. In: American Society for Rickettsiology. Cumberland, MD. No. 59. September 2003.
205. Zavala-Castro JE, Ruiz-Sosa A, WALKER DH, Zavala-Velázquez J. *Rickettsia felis* rompA gene is expressed in naturally infected fleas. In: American Society for Rickettsiology. Cumberland, MD. No. 75. September 2003.
206. Feng HM, WALKER DH. Mechanisms of immunity to *Ehrlichia muris*: a model of human monocytotropic ehrlichiosis. In: American Society for Rickettsiology. Cumberland, MD. No. 117. September 2003.
207. Doyle CK, Zhang X, WALKER DH, McBride JW. An immunoreactive 37-kDa protein of *Ehrlichia canis* shares structural homology and iron-binding capacity with ferric binding protein family. In: American Society for Rickettsiology. Cumberland, MD. No. 50. September 2003.
208. Labruna MB, Bouyer DH, McBride JW, Camargo LM, Camargo EP, WALKER DH. *Rickettsia* species infecting *Amblyomma* ticks in Rondonia, Western Amazon, Brazil. In: American Society for Rickettsiology. Cumberland, MD. No. 78. September 2003.

209. Labruna MB, Horta MC, Bouyer DH, McBride JW, Gennari SM, WALKER DH. *Rickettsia* species infecting *Amblyomma cooperi* ticks in Brazil. In: American Society for Rickettsiology. Cumberland, MD. No. 79. September 2003.
210. Stevenson HL, Labruna MB, Montenieri JA, Gage KL, WALKER DH. Detection of *Rickettsia felis* in a new world species, *Anomiopsylla nudatus* (Siphonoptera: Ctenophthalmidae). In: American Society for Rickettsiology. Cumberland, MD. No. 92. September 2003.
211. Ismail N, WALKER DH. IL-10 and TNF- α are major mediators of toxic shock-like syndrome in the animal model of fatal human Monocytotropic ehrlichiosis. In: American Society for Rickettsiology. Cumberland, MD. No. 114. September 2003.
212. Ismail N, WALKER DH. Distinct mechanisms for homologous and heterologous protection of immunocompetent mice against fatal infection with monocytotropic *Ehrlichia*. In: American Society for Rickettsiology. Cumberland, MD. No. 115. September 2003.
213. Olano JP, Wen G, Feng HM, McBride JW, WALKER DH. Histopathological, immunohistochemical, serological and quantitative bacterial burden analysis in a murine model of persistent *E. muris* infection. In: American Society for Rickettsiology. Cumberland, MD. No. 116. September 2003.
214. Ndip LM, Bouyer DH, Ndip RN, Titanji VPK, WALKER DH. Detection of rickettsiae in febrile patients along the coastal region of Cameroon. In: American Society of Tropical Medicine and Hygiene. Philadelphia, Pennsylvania. No. 350. December 2003.
215. Feng HM, WALKER DH. Dendritic cells as antigen presenting cells in the immune response to rickettsia. In: American Society of Tropical Medicine and Hygiene. Philadelphia, Pennsylvania. No. 84. December 2003.
216. Alcantara VE, Mendez Galvan J, WALKER DH. The rickettsioses in Mexico. In: American Society of Tropical Medicine and Hygiene. Philadelphia, Pennsylvania. December 2003.
217. Jordan J, WALKER DH. Live and heat-killed *Rickettsia conorii* induced maturation and cytokine production in bone-marrow derived dendritic cells *in vitro*. In: Experimental Biology. Washington, DC. No. 378.1. April 2004.
218. Stevenson HL, WALKER DH, Ismail N. The role of TNF- α and IL-10 in the pathogenesis of severe and fatal murine monocytotropic ehrlichiosis. In: American Society of Tropical Medicine and Hygiene. Miami, FL. November 2004.
219. Stevenson HL, Ismail N, WALKER DH. Route of inoculation influences T cell priming: an intradermal environment promotes a strong protective type-1 response against monocytotropic *Ehrlichia*. In: 4th International Conference on Rickettsiae and Rickettsial Diseases. Logrono, Spain. No. O-58. June 2005.
220. WALKER DH, Yu XJ. Progress in rickettsial genome analysis from pioneering of *Rickettsia prowazekii* to the recent *Rickettsia typhi*. In: 4th International Conference on Rickettsiae and Rickettsial Diseases. Logrono, Spain. No. S-10. June 2005.
221. Ismail N, WALKER DH. Balancing protective immunity and immunopathology: a unifying model of monocytotropic *Ehrlichiosis*. In: 4th International Conference on Rickettsiae and Rickettsial Diseases. Logrono, Spain. No. S-8. June 2005.

222. Zhang J, Hao J, WALKER DH, Yu XJ. Genetic differences between the avirulent and virulent strains of *Rickettsia prowazekii*. In: 4th International Conference on Rickettsiae and Rickettsial Diseases. Logrono, Spain. No. S-212. June 2005.
223. Valbuena G, Olano J, Bouyer DH, WALKER DH. Rocky Mountain spotted fever in Colombia: a forgotten disease strikes again. In: 4th International Conference on Rickettsiae and Rickettsial Diseases. Logrono, Spain. No. P-168. June 2005.
224. Galvão MAM, Cardoso LD, Mafra CL, WALKER DH. Revisiting Brazilian spotted fever focus of Caratinga, Minas Gerais State. In: 4th International Conference on Rickettsiae and Rickettsial Diseases. Logrono, Spain. No. S-10. June 2005.
225. Galvão MAM, Zavala-Velazquez JE, Mafra CL, WALKER DH. *Rickettsia felis* in the Americas. In: 4th International Conference on Rickettsiae and Rickettsial Diseases. Logrono, Spain. No. P-119. June 2005.
226. Crocquet-Valdes PA, McBride JW, Feng HM, Ismail N, Small MA, Yu XJ, WALKER DH. Analysis of ehrlichial p28 expression in a murine model of persistent infection. In: 4th International Conference on Rickettsiae and Rickettsial Diseases. Logrono, Spain. No. P-22. June 2005.
227. Mattner J, DeBord KL, Ismail N, Goff RD, Cantu III C, Zhou D, Saint-Mezard P, Wang V, Gao Y, Yin N, Hoebe K, Schneewind O, WALKER DH, Beutler B, Teyton L, Savage PB, Bendelac A. Both exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections. In: 4th International Conference on Rickettsiae and Rickettsial Diseases. Logrono, Spain. No. O-62. June 2005.
228. Long W, Whitworth TJ, Yu XJ, WALKER DH. Overcoming barriers to the transformation of the genus *Ehrlichia*. In: 4th International Conference on Rickettsiae and Rickettsial Diseases. Logrono, Spain. No. O-61. June 2005.
229. Medina-Sanchez A, Bouyer DH, Mafra C, Zavala-Castro J, Whitworth TJ, Popov VL, Fernandes-Salas I, WALKER DH. Discovery of a typhus group *Rickettsia* in *Amblyomma* ticks in the State of Nuevo Leon, Mexico. In: 4th International Conference on Rickettsiae and Rickettsial Diseases. Logrono, Spain. No. O-53. June 2005.
230. Zavala-Castro JE, Small M, Keng C, Bouyer DH, Zavala-Velazquez JE, WALKER DH. The *Rickettsia felis* truncated gene *OmpA* is actively expressed in infected fleas. In: 4th International Conference on Rickettsiae and Rickettsial Diseases. Logrono, Spain. No. O-28. June 2005.
231. Whitworth TJ, Popov VL, Yu XJ, WALKER DH, Bouyer DH. Expression of the *Rickettsia prowazekii* gene *pld* and *tlyC* in Salmonella results in transformants capable of escaping endosomal vacuoles into the host cell cytosol. In: 4th International Conference on Rickettsiae and Rickettsial Diseases. Logrono, Spain. No. O-27. June 2005.
232. Sousa R, Ismail N, Doria-Nobrega S, Costa P, Abreu T, Franca A, Amaro M, Proenca P, Brito P, Pocas J, Ramos T, Cristina G, Pombo G, Vitorino L, Torgal J, Bacellar F, WALKER DH. The presence of eschars in Portuguese patients infected with Israeli tick typhus strain of *Rickettsia conorii*. In: 4th International Conference on Rickettsiae and Rickettsial Diseases. Logrono, Spain. No. O-22. June 2005.
233. Crocquet-Valdes PA, Ismail N, Yu X-J, Keng C, WALKER DH. Immunization with P28 outer membrane proteins recombinant DNA vaccine results in decreased bacterial load in the spleen and liver of mice infected with *Ehrlichia muris*. 20th Meeting of the American Society for Rickettsiology in conjunction with the 5th International Conference on Bartonella as Emerging Pathogens. Pacific Grove, California. No. 183. September 2006.

234. Duh D, Punda-Polic V, Dolinsek J, Castro-Zavala JE, WALKER DH, Avsic-Zupanc T. The *ompA* gene sequence of *Rickettsia felis*-like bacteria isolated from *Haemaphysalis sulcata* ticks. 20th Meeting of the American Society for Rickettsiology in conjunction with the 5th International Conference on Bartonella as Emerging Pathogens. Pacific Grove, California. No. 149. September 2006.
235. Fang R, Popov VL, Whitworth T, WALKER DH, Ismail N. Interaction of *Rickettsia* with dendritic cells from mice generally susceptible and resistant to fatal murine spotted fever rickettsiosis: uptake, maturation, and antigen presentation. 20th Meeting of the American Society for Rickettsiology in conjunction with the 5th International Conference on Bartonella as Emerging Pathogens. Pacific Grove, California. No. 107. September 2006.
236. Cardenas AM, Doyle CK, Zhang X, Nethery K, Corstvet RE, WALKER DH, McBride JW. Major immunoreactive glycoproteins provide sensitive and specific immunodiagnosis of *Ehrlichia canis* infections. 20th Meeting of the American Society for Rickettsiology in conjunction with the 5th International Conference on Bartonella as Emerging Pathogens. Pacific Grove, California. No. 80. September 2006.
237. Ndip LM, Nfonsam LE, Hamrick H, Fiereck KJ, Bouyer DH, Ndip RN, Martin SK, WALKER DH, Wolfe N. Risk factors for rickettsiosis in rural central Africa. 20th Meeting of the American Society for Rickettsiology in conjunction with the 5th International Conference on Bartonella as Emerging Pathogens. Pacific Grove, California. No. 90. September 2006.
238. Stevenson HL, Jordan JM, WALKER DH, Ismail N. Beneficial and detrimental roles of NKT cells in murine monocytotropic ehrlichiosis. 20th Meeting of the American Society for Rickettsiology in conjunction with the 5th International Conference on Bartonella as Emerging Pathogens. Pacific Grove, California. No. 121. September 2006.
239. Zhang J-Z, Popov VL, Gao S, WALKER DH, Yu X-J. The developmental cycle of *Ehrlichia chaffeensis*. 20th Meeting of the American Society for Rickettsiology in conjunction with the 5th International Conference on Bartonella as Emerging Pathogens. Pacific Grove, California. No. 65. September 2006.
240. Popov VL, Han VC, Wen JW, Nefedova VV, Kovalevskii YV, WALKER DH, Korenberg EG. Ultrastructural evidence of natural co-infection of *Ixodes persulcatus* tick with ehrlichia, rickettsia, borrelia, and a flavivirus in Cisural region, Russia. 20th Meeting of the American Society for Rickettsiology in conjunction with the 5th International Conference on Bartonella as Emerging Pathogens. Pacific Grove, California. No. 41. September 2006.
241. Hidalgo M, Sanchez R, Orejuela L, Hernandez J, WALKER D, Valbuena G. Serosurvey against *Rickettsia rickettsii* among healthy individuals of in Villeta, Colombia. 55th Meeting of the American Society of Tropical Medicine and Hygiene. Atlanta, Georgia. Vol. 75 No. 5. November 2006.
242. Galvao MA, Zavala-Velazquez JE, Zavala-Castro JE, Mafra CL, Calic SB, WALKER DH. 2006. *Rickettsia felis* in the Americas. Ann N Y Acad Sci 1078:156-158.
243. Galvao MA, Cordoso LD, Mafra CL, Calic SB, WALKER DH. 2006. Revising Brazilian spotted fever focus of Caratinga, Minas Gerais State, Brazil. Ann N Y Acad Sci 1078:255-256.
244. Ganapamo F, Aye PP, Ooms T, Bouyer D, Kuroda MJ, WALKER DH, Lackner AA. Innate and acquired immunity in Rhesus monkeys infected with *Rickettsia parkeri*. ASM Biodefense & Emerging Diseases Research Meeting. Washington, D.C. No. 088(F). February 2007.

245. Jordan JM, Woods ME, WALKER D. Mice lacking TLR4 function exhibit enhanced susceptibility to *Rickettsia conorii*, correlated with decreased NK cell activity. 94th Annual Meeting of The American Association of Immunologists, Inc. Miami Beach, FL. No. 44.14. May 2007.
246. Stevenson HL, WALKER DH, Ismail N. NKT cells play a role in inducing toxic shock-like syndrome in severe ehrlichiosis. 94th Annual Meeting of The American Association of Immunologists, Inc. Miami Beach, FL. No. 46.21. May 2007.
247. Fang R, Ismail N, WALKER DH. Characterization of differential innate and adaptive immunity against *Rickettsia conorii* in resistant and susceptible mice. 94th Annual Meeting of The American Association of Immunologists, Inc. Miami Beach, FL. No. 52.14. May 2007.
248. Zhang JZ, WALKER DH, Wood DO, Yu X-J. The target genes for knockout to attenuate *Rickettsia prowazekii*. 21st Meeting of The American Society for Rickettsiology. Colorado Springs, CO. No. 6. September 2007.
249. Crossley EC, Stevenson HL, Ismail N, WALKER DH. Evidence for NK cells but not $\gamma\delta$ cells, as determinants in the outcome of ehrlichiosis. 21st Meeting of The American Society for Rickettsiology. Colorado Springs, CO. No. 104. September 2007.
250. Thirumalapura N, WALKER DH, Ismail N. Protective heterologous immunity against fatal ehrlichiosis and enhanced immunopathogenesis following homologous challenge. 21st Meeting of The American Society for Rickettsiology. Colorado Springs, CO. No. 109. September 2007.
251. Crocquet-Valdes PA, Thirumalapura N, Stevenson HL, Yu X-J, Keng C, Ismail N, WALKER DH. Immunization of *E. muris* P28 outer membrane proteins recombinant DNA provides protection against homologous challenge and is dependent on IFN- γ producing CD4⁺ effector memory T cells. 21st Meeting of The American Society for Rickettsiology. Colorado Springs, CO. No. 112. September 2007.
252. Medina A, Guevara E, Alcantara V, Garza C, Hunt F, Davis J, Gonzalez R, Bouyer D, WALKER DH. Isolation of *Rickettsia amblyommii* and seroprevalence of rickettsia in the state of Veracruz, Mexico. 21st Meeting of The American Society for Rickettsiology. Colorado Springs, CO. No. 132. September 2007.
253. Fang R, Ismail N, Soong L, Popov VL, Whitworth T, Bouyer DH, WALKER DH. Differential interaction of dendritic cells with *Rickettsia*: Impact on host susceptibility to murine spotted fever rickettsiosis. 21st Meeting of The American Society for Rickettsiology. Colorado Springs, CO. No. 142. September 2007.
254. Fang R, Ismail, WALKER DH. Induction of T cell energy contributes to morbidity of murine spotted fever rickettsiosis. Seventh Annual McLaughlin Symposium in Infection and Immunity. Galveston, TX. No. 9. November 2007.
255. Thirumalapura N, WALKER DH, Ismail N. Persistent infection plays a role in conferring heterologous protection against ehrlichiosis. Seventh Annual McLaughlin Symposium in Infection and Immunity. Galveston, TX. No.11. November 2007.
256. Crossley EC, Stevenson H, Ismail N, WALKER DH. Evidence for NK Cells but not gamma-delta T cells as determinants in the outcome of ehrlichiosis. Seventh Annual McLaughlin Symposium in Infection and Immunity. Galveston, TX. No.17. November 2007.
257. Crossley EC, Turner KT, Ismail N, WALKER DH. Regulation of inflammatory immune responses by gamma-delta T cells in chronic ehrlichiosis. 2008 McLaughlin Colloquium on Infection & Immunity. Galveston, TX. No. 4. April 2008.

258. Shelite TR, Fang R, Ismail N, WALKER DH. The effects of tick saliva on the dendritic cell-rickettsia interaction, *in vitro*. 2008 McLaughlin Colloquium on Infection & Immunity. Galveston, TX. No. 22. April 2008.
259. Fang R, Ismail N, WALKER DH. CD4⁺CD25⁺T-BET (+) FOX3 (-) CTLA-4 (+) TH1 cells are the major source of immunosuppressive IL-10 in acute fatal rickettsial infection. 2008 McLaughlin Colloquium on Infection & Immunity. Galveston, TX. No. 34. April 2008.
260. Pinter A, Crossley EC, Ismail N, WALKER DH. Development of a tick-host-*Ehrlichia* model for immunopathology studies. 2008 McLaughlin Colloquium on Infection & Immunity. Galveston, TX. No. 53. April 2008.
261. Thirumalapura N, Crossley E, WALKER DH, Ismail N. TH-1 Immune responses and FOXP3+ T regulatory cells induced during persistent ehrlichiosis synergistically confer heterologous protection against fatal ehrlichiosis. 2008 McLaughlin Colloquium on Infection & Immunity. Galveston, TX. No. 55. April 2008
262. Fang R, Ismail N, WALKER DH. CD4⁺CD25⁺Foxp3-CTLA-4⁺T regulatory cells are the major source of IFN- γ and IL-10 in acute fatal rickettsial infection. 12th Woods Hole Immunoparasitology Meeting. Woods Hole, MA. No. 60. April 2008.
263. Popov VL, Han VC, Wen JW, WALKER DH. Electron microscopy in identification of novel environmental microorganisms potentially dangerous for humans and animals. Microscopy and Microanalysis 2008; 66th Microscopy Society of American Annual Meeting. Albuquerque, New Mexico. Microsc Microanal 14 (Suppl 2). August 2008.
264. Pinter A, Crossley EC, Ismail N, WALKER DH. Development of tick-host-ehrlichia model for immunopathology studies. VI International Conference on Ticks and Tick-borne Pathogens. Buenos Aires, Argentina. Pg. 122. September 2008.
265. Pinter A, Medina-Sanchez A, Bouyer DH, Teel PD, Fernandes-Salas I, WALKER DH. Preliminary data of an *Amblyomma imitator* Kohls, 1958 (acari: Ixodidae) biological study. VI International Conference on Ticks and Tick-borne Pathogens. Buenos-Aires, Argentina. Pg. 190. September 2008.
266. Liu Y, Zhang J, Zhang L, WALKER DHW, Yu, X-J. Obligate intracellular bacterium *Ehrlichia* inhibiting mitochondrial activity. 23rd Meeting of the American Society for Rickettsiology. Hilton Head Island, South Carolina. No. 1. August 2009.
267. Crossley EC, Ismail, N, WALKER DH. $\gamma\delta$ T cells suppress protective immunity in chronic but not acute ehrlichiosis. 23rd Meeting of the American Society for Rickettsiology. Hilton Head Island, South Carolina. No. 20. August 2009.
268. Shelite TR, Fang R, Ismail N, WALKER DH. The effects of tick saliva on the dendritic cell-rickettsia interaction, *in vitro*. 23rd Meeting of the American Society for Rickettsiology. Hilton Head Island, South Carolina. No. 37. August 2009.
269. Thomas S, Crossley E, Thirumamapura N, WALKER DH. Detection of post-translational modifications of ehrlichial antigenic proteins by Eastern blotting technique. 23rd Meeting of the American Society for Rickettsiology. Hilton Head Island, South Carolina. No. 39. August 2009.

270. Andrade-Oliveria K, Pinter A, Medina-Sanchez A, Boppana VD, Wikel SK, WALKER DH, Bouyer DH. *Amblyomma imitator*: Identification of a new vector for *Rickettsia rickettsii* in South Texas and Mexico. 23rd Meeting of the American Society for Rickettsiology. Hilton Head Island, South Carolina. No. 76. August 2009.
271. Thirumalapura NR, Thomas S, Soong L, WALKER DH. Molecular analysis of T-cell repertoire diversity in animal models of persistent and fatal ehrlichiosis. 23rd Meeting of the American Society for Rickettsiology. Hilton Head Island, South Carolina. No. 83. August 2009.
272. Thirumalapura N, Crossley E, WALKER DH, Ismail N. Generation and maintenance of memory T cell responses during persistent ehrlichial infection and the role of CD4+CD25+ T regulatory cells in ehrlichial persistence. 23rd Meeting of the American Society for Rickettsiology. Hilton Head Island, South Carolina. No. 96. August 2009.
273. Stevenson HL, Estes DM, Thirumalapura N, WALKER DH, Ismail N. Natural killer cells mediate tissue injury and inhibit protective immunity during severe acute murine monocytic ehrlichiosis. 23rd Meeting of the American Society for Rickettsiology. Hilton Head Island, South Carolina. No. 98. August 2009.
274. Fang R, Ismail N, Shelite T, WALKER DH. CD4+CD25+ Foxp3⁻ T regulatory T cells produce both IFN- γ and IL-10 during severe acute murine spotted fever rickettsiosis. 23rd Meeting of the American Society for Rickettsiology. Hilton Head Island, South Carolina. No. 99. August 2009.
275. Crocquet-Valdes PA, Thirumalapura NR, WALKER DH. Construction of *Ehrlichia muris* genomic library for identification of vaccine candidates using murine CD4⁺ T cell expression cloning. 23rd Meeting of the American Society for Rickettsiology. Hilton Head Island, South Carolina. No. 106. August 2009.
276. Crocquet-Valdes PA, Thirumalapura NR, Saito TB, WALKER DH. Screening of an *Ehrlichia muris* genomic expression library for identification of protective epitopes. 24th Meeting of the American Society for Rickettsiology. Stevenson, Washington, No. 18. July 2010.
277. Crossley EC, Ismail N, WALKER DH. Gamma-delta T cells act as immune suppressors in ehrlichiosis. 24th Meeting of the American Society for Rickettsiology. Stevenson, Washington, No. 19. July 2010.
278. Fang R, Ismail N, WALKER DH. NK cells contribute greatly to host innate resistance to murine spotted fever rickettsiosis. 24th Meeting of the American Society for Rickettsiology. Stevenson, Washington, No. 21. July 2010.
279. Galvao MAM, Calic SB, Costa PSG, Labruna MB, Mafra CL, Pena DCH, Milagres BS, WALKER DH. Spotted fever rickettsiosis eschar-associated in Brazil: A case report. 24th Meeting of the American Society for Rickettsiology. Stevenson, Washington, No. 31. July 2010.
280. Liu Y, Gao H, Weinstock G, WALKER DH, Yu X-J. Identification of mutations in Madrid E strain of *Rickettsia prowazekii* by comparison of the genome sequences of Madrid E strain and its virulent revertant. 24th Meeting of the American Society for Rickettsiology. Stevenson, Washington, No. 51. July 2010.
281. Saito TB, Wikel SK, Bouyer DH, WALKER DH. Bacterial load and its role of the infection of ticks feeding upon *Ehrlichia muris*- and *Ixodes ovatus Ehrlichia*-infected mice. 24th Meeting of the American Society for Rickettsiology. Stevenson, Washington, No. 74. July 2010.

282. Shelite TR, Saito TB, Gong B, WALKER DH. Development of a scrub typhus disease model via intravenous inoculation of mice. 24th Meeting of the American Society for Rickettsiology. Stevenson, Washington, No. 75. July 2010.
283. Milagres BS, Padilha AF, Montandon C, Barcelos RM, Guimaraes G, Pena DCH, Mafra CL, Freitas RN, Labruna MB, Pacheco R, WALKER DH, Galvao MAM. Serological detection of *Rickettsia* sp. in small rodents from endemic areas for Brazilian spotted fever, Minas Gerais State, Brazil. 24th Meeting of the American Society for Rickettsiology. Stevenson, Washington, No. 107. July 2010.
284. Saito TB, Blanton LS, Thirumalapura N, Bouyer DH, WALKER DH. Effects of route of inoculation of *Ehrlichia* on levels of bacteremia. 59th Annual Meeting of the American Society of Tropical Medicine and Hygiene. Atlanta, Georgia, No. 651, November 2010.
285. Thirumalapura N, Thomas S, Soong L, WALKER DH. 2010. T-cell receptor repertoire diversity during persistent and fatal ehrlichial infections. *J Immunol* 184:40.18.
286. Fang R, Ismail N, Shelite T, WALKER D. Innate immune cells are the major determinants of host-related susceptibility differences to experimental spotted fever rickettsiosis. 97th Annual Meeting of the American Association of Immunologists. Baltimore, Maryland, No. 42.24, May 2010.
287. Fang R, Ismail N, WALKER DH. Activation of differential TLR signaling pathway on dendritic cells contributes to host innate resistance to rickettsial diseases. Keystone Symposia on Molecular and Cellular Biology. Santa Fe, New Mexico, No. 163, February 2011.
288. Milagres BS, Padilha AF, Montandon C, Barcelos RM, Guimaraes G, Mafra CL, Freitas RN, Labruna MB, Pacheco R, WALKER DH, Galvao MAM. Serological detection of spotted fever group *Rickettsia* in small rodents from two areas of low endemicity for Brazilian spotted fever in eastern Minas Gerais State. 6th International Meeting on Rickettsiae and Rickettsial Diseases. Heraklion, Crete, Greece, No. P052, June 2011.
289. Shelite TR, Saito TB, Gong B, WALKER DH. Development of a model of hematogenously disseminated scrub typhus disease in mice. 6th International Meeting on Rickettsiae and Rickettsial Diseases. Heraklion, Crete, Greece, No. P145, June 2011.
290. Crocquet-Valdes PA, Thirumalapura NR, Dadfarnia T, DiCicco B, WALKER DH. Identification and expression of *Ehrlichia muris* for evaluation as vaccine candidates. 6th International Meeting on Rickettsiae and Rickettsial Diseases. Heraklion, Crete, Greece, No. P150, June 2011.
291. Mafra C, Crossley EC, Fang R, Shelite TR, Bouyer D, WALKER D. Systemic cellular immune responses to *Rickettsia conorii* differs between dermal and intravenous routes of inoculation and are suppressed by TLR4 in intradermally inoculated mice. 6th International Meeting on Rickettsiae and Rickettsial Diseases. Heraklion, Crete, Greece, Nos. P178 and O032, June 2011.
292. Thirumalapura NR, Kuriakose JA, WALKER DH. The genome of *Ehrlichia muris*: A model monocytotropic *Ehrlichia*. 6th International Meeting on Rickettsiae and Rickettsial Diseases. Heraklion, Crete, Greece, No. P204, June 2011.
293. Saito TB, Wikel SK, Bouyer DH, WALKER DH. Development of the tick transmission model for monocytotropic ehrlichiosis. 6th International Meeting on Rickettsiae and Rickettsial Diseases. Heraklion, Crete, Greece, No. P209, June 2011.
294. WALKER DH. Pathogenesis of an immunity to diseases caused by *Rickettsia*. 6th International Meeting on Rickettsiae and Rickettsial Diseases. Heraklion, Crete, Greece, No. L14, June 2011.

PUBLICATIONS ON INTERNET:

1. Popov VL, WALKER DH. *Rickettsia*, obligately intracellular bacteria, pathogenic for humans. ASM Digital Image Collection. <http://www.microbelibrary.org> (submissionID=441, submissionID=444).
2. Popov VL, Dumler JS, WALKER DH. *Ehrlichia*, obligately intracellular bacteria, pathogenic for humans. ASMI Digital Image Collection. <http://www.microbelibrary.org> (submissionID=446).
3. WALKER DH. Abstracts & Analysis: Human monocytic ehrlichiosis presenting as acute appendicitis during pregnancy [Clinical Insights]. MD Consult Infectious Disease. June 2, 2003. <http://www.mdconsult.com>.
4. Yu X-J, WALKER DH. The order *Rickettsiales*, in M. Dworkin et al., eds., *The Prokaryotes: An Evolving Electronic Resource for the Microbiological Community*, 3rd edition, New York, Springer-Verlag, 2003. <http://link.springer-ny.com/link/service/books/10125/>.

IN PRESS:

1. WALKER DH. Rickettsial diseases. In: Bologna J, Jorizzo J, Schaffer J, et al (eds). *Dermatology 3rd Edition*. Elsevier. **(MS #529)**
2. WAKER DH. Rocky Mountain spotted fever and other rickettsioses. In: Schaechter's *Mechanisms of Microbial Disease*, Vol 5 **(MS #539)**
3. WALKER DH. *Rickettsia, Orientia, Ehrlichia, Anaplasma and Coxiella*. In: *Medical Microbiology*, 18th edition. **(MS #549)**
4. Yu X-J, WALKER DH. Vaccines for rickettsial diseases. In: Feodorova VA, Motin VL (eds). *Vaccine against Bacterial Biothreat Pathogens*. **(MS #559)**
5. Ndip L, Ndip R, WALKER D, McBride J. Human Ehrlichiosis and Rickettsiosis in Cameroon. In: *Tropical Medicine*. **(MS #575)**
6. WALKER DH. Sverdlovsk revisited: Pulmonary pathology of inhalation anthrax versus anthrax-like *Bacillus cereus* pneumonia. *Arch Pathol Lab Med*. **(MS #595)**

MAJOR INVITED ACTIVITIES:

Symposia and Conferences:

- | | |
|------|---|
| 2011 | Invited lecturer: "The Challenges of Rickettsial Diseases in Latin America"
III Congreso Latamericano de Entermedades Rickettsiales
Bogota, Colombia |
| 2011 | Invited lecturer: "Pathogenesis of and Immunity to Diseases Caused by <i>Rickettsia</i> "
6 th International Meeting on <i>Rickettsia</i> and Rickettsial Diseases
Heraklion, Greece |

- 2011 Invited lecturer: "Pathology of 2009 Pandemic H1N1 Influenza A", "Development and Use of Animal Models of Life Threatening Rickettsiosis to Elucidate Mechanisms of Protective Immunity", and "Infection of Immunocompromised Hosts Diagnosed by Histopathology"
2011 Hangzhou International Clinical Pathology Symposium
Hangzhou, China
- 2010 Invited lecturer: "Rickettsial Diseases in Latin American, Africa, Europe, and Australia"
American Society of Tropical Medicine and Hygiene
Atlanta, GA
- 2010 Invited lecturer: "Rickettsial Infections and Endothelial Pathobiology"
Gordon Research Conference: "Endothelial Cell Phenotypes in Health and Disease"
Biddeford, Maine
- 2010 Invited lecturer: "Pathogenesis of Rickettsial Diseases"
Binford-Dammin Society of Infectious Diseases Pathologist
USCAP
Washington, D.C.
- 2010 Invited lecturer: "History of Typhus"
History of Pathology Society
USCAP
Washington, D.C.
- 2010 Invited lecturer: "Emerging Infections Caused by *Rickettsia*, *Orientia*, *Ehrlichia*, and *Anaplasma* in the 21st Century"
2010 TX-UK Collaborative Research Initiative
Galveston, TX
- 2009 Invited participant and lecturer "Emerging Rickettsioses in the Americas" and "Rickettsial Immunity"
Underserved Bacterial Pathogen Outreach Workshop
Bangkok, Thailand
- 2009 Invited lecturer "Rickettsiae, Obligately Intracellular Pathogens, Targeting the Endothelium"
Infection of the Endothelium
Dresden, Germany
- 2009 Invited lecturer "Rickettsioses as Emerging Infectious Diseases and Bioterror Threats: Mechanisms of Pathogenesis and Immunity"
Bioterrorism-Emerging Infectious Disease Conference
Rocky Mountain Regional Center of Excellence
Bozeman, Montana
- 2009 Invited lecturer "*Ehrlichia canis*, *E. chaffeensis*, their p28 Paralogs, and Mechanism of Persistence"
Antigenic Variation
Annecy, France

- 2008 Invited lecturer "Pathology, and Pathogenesis of Ehrlichiosis: Role of the Pathologist in Discovery and Diagnosis"
Symposium leader "Pathology and Pathogenesis of Infections at the Zoonotic-Human Interface"
XXVIIth International Congress of the International Academy of Pathology
Athens, Greece
- 2008 Invited lecturer "Pets, Vectors, and Biomedical Science"
American College of Veterinary Internal Medicine Forum
San Antonio, Texas
- 2007 Invited lecturer "Rickettsial Agents of Emerging/Re-emerging Vector-borne Diseases and Aerosol-transmitted Bioterror Threats"
11th Medical B Defence Conference
Munich, Germany
- 2007 Invited lecturer "Rickettsial Diseases"
ASM Biodefense Meeting
Washington, D.C.
- 2006 Invited lecturer "Pulmonary Manifestations of Potential Biowarfare Agents"
International Academy of Pathology Centennial Congress
Montreal, Quebec, Canada
- 2006 Invited lecturer "Human Ehrlichiosis: Clinical Aspects and Epidemiology" and "Rickettsioses in the Americas"
II Latin American Simposium of Rickettsioses
Ribeirao Preto, Sao Paulo, Brazil
- 2006 Invited lecturer "*Ehrlichia* and Ehrlichioses: Pathogenesis and Vector Biology"
2006 NIAID Research Conference
Opatija, Croatia
- 2006 Invited lecturer "Opportunities to Improve Health in Developing Countries by Advancing Knowledge of Rickettsial Pathogenesis"
DMID International Research in Infectious Diseases Annual Meeting
Bethesda, MD
- 2005 Invited lecturer "Emerging Pathogens"
Association for Molecular Pathology
Scottsdale, AZ
- 2005 Invited lecturer "Microbiology of Emerging Infections and Bioterrorism"
California Society for Pathologists
San Diego, CA
- 2005 Invited lecturer "Ehrlichiosis"
XII Congreso Colombiano de Parasitologia y Medicina Tropical
Bogota, Colombia
- 2005 Invited lecturer "Rickettsial Diseases in the Americas"
Magistral Conference of La Sociedad Mexicana de Medicina Tropical
Acapulco, Mexico

- 2005 Invited lecturer "Progress in Rickettsial Genome Analysis from Pioneering of *Rickettsia prowazekii*" to the Recent *Rickettsia typhi*"
4th International Conference on Rickettsial Diseases
Logrono, Spain
- 2005 Invited lecturer "Overview of the Western Regional Center of Excellence for Biodefense and Emerging Infectious Disease Research"
Sitlington Infectious Diseases Symposium
Stillwater, OK
- 2005 Invited lecturer "Challenges of the Obvious and the Neglected Biologic Threats"
Seattle International Conference of Primate Genomics
Seattle, WA
- 2004 Craig Lecture "Emerging and Re-emerging Treatable, but often Untreated, Vector-borne Bacterial Diseases in the Tropics"
American Society for Tropical Medicine and Hygiene
Miami, FL
- 2004 Invited Lecturer "Current Situations and Trends of the Rickettsiosis in the Americas"
Organización Panamericana de la Salud,
Oficina Regional de la Organización Mundial de la Salud
Ouro Preto, Minas Gerais, Brazil
- 2004 Invited Lecturer "Clinical, Epidemiologic, and Control Perspective of Human Rickettsiosis and Ehrlichiosis in America"
The 1st Latin American Conference on Rickettsiae and Rickettsial Diseases in
Ouro Preto
Minas Gerais, Brazil
- 2004 Nathan Kaufman Timely Topics Lecture: "Diagnosis of Infectious Diseases: A Clinical Opportunity for Pathology in the Era of Bioterrorism and Emerging Infections:
United States and Canadian Academy of Pathology
Vancouver, B.C.
- 2004 Invited Lecturer "Anthrax"
NIH-NINDS Counterterrorism Workshop
Washington, D.C.
- 2004 Invited Lecturer "The Sverdlovsk Outbreak of Inhalational Anthrax"
Biodefense Clinical Research Workshop
Bethesda, MD
- 2003 Invited Lecturer "Diagnostic Preparedness by Pathologists for a Bioterrorist Attack"
College of American Pathologists
San Diego, CA
- 2003 Invited Lecturer "*Ehrlichia chaffeensis*: A Prevalent, Life-threatening Emerging Pathogen"
American Clinical and Climatological Association Annual Conference
San Diego, CA

- 2003 Invited Lecturer “Dendritic Cells as Antigen Presenting Cells in the Human Response to *Rickettsia*”
American Society for Tropical Medicine and Hygiene Annual Conference
Philadelphia, PA
- 2003 Invited Lecturer “Mechanisms of Immunity to *Ehrlichia muris*: A Model of Human Monocytotropic Ehrlichiosis”
American Society for Rickettsiology
Cumberland, MD
- 2003 Invited Lecturer “Prompt Diagnosis of Aerosol Transmitted Anthrax by the Pathologist: A Public Health Imperative in the Era of Bioterrorism”
United States and Canadian Academy of Pathology Annual Conference
Washington, D.C.
- 2003 Invited Lecturer “Laboratory Diagnosis of Human Ehrlichiosis”
American Society of Microbiology Annual Conference
Washington, DC
- 2002 Invited Lecturer “Bioterrorism – Rickettsiosis”
NIAID Blue Ribbon Panel
Washington, DC
- 2002 Invited Lecturer “Accidental Exposure to Anthrax in Russia, 1979”
54th Annual World Medical Association
Washington, DC
- 2002 Invited Lecturer “Rickettsial Diseases in the Traveler”
Infectious Diseases Society of America 40th Annual Conference
Chicago, Illinois
- 2002 Invited Keynote Lecturer “Mechanisms of Disease Caused by *Rickettsia*”
International Conference on Rickettsiae and Rickettsial Diseases joint with the ASR Conference
Ljubljana, Slovenia
- 2002 Invited Lecturer “Tick-borne Ehrlichiosis: Expanding the Host Range”
American Society for Microbiology Annual Conference
Salt Lake City, Utah
- 2001 Invited Lecturer
XVI Congreso Científico Internacional Federacion Lationamericaana de Sociedades Cientificas de Estudiantes de Medicina
Merida, Mexico
- 1999 Invited Lecturer
VIII Congress Nacional de Investigación en Salud Pública
Enfermedades emergentes y re-emergentes: nuevos retos a la salud pública.
Cuernavaca, Morelos, México
- 1996 Invited Lecturer
American Society of Tropical Medicine and Hygiene 45th Annual Meeting
Baltimore, Maryland

- 1996 Invited Participant
National Institute of Allergy and Infectious Disease Workshop on Human Ehrlichioses
National Institutes of Health
Rockville, Maryland
- 1996 Invited Plenary Speaker
Fifth International Symposium on Rickettsiae and Rickettsial Diseases
Stara Lesna, Slovak Republic
- 1996 Member, Blue Ribbon Panel on Emerging Infectious Diseases
National Institute of Allergy and Infectious Diseases
National Institutes of Health
Bethesda, Maryland
- 1996 Invited Lecturer
Biomedicine '96 Medical Research
National Council for American Federation for Clinical Research
Washington, DC
- 1995 Invited Lecturer
Texas Branch of American Society for Microbiology Fall Meeting
Corpus Christi, Texas
- 1995 Invited Speaker
Justin Potter Scholars Conference
Vanderbilt University
Nashville, Tennessee
- 1995 Invited Participant and Speaker
Emerging Diseases Facing Canada, Mexico, and the U.S.: The Potential Influence of NAFTA on the Emergence of Rare Infectious Diseases
National Institute of Allergy and Infectious Diseases
National Institutes of Health
Hosted by University of Texas Medical Branch
Galveston, Texas
- 1995 Invited Speaker
Texas Association of Hospital Auxiliaries
Galveston, Texas
- 1995 Invited Lecturer
ICAAC and Infectious Disease Society of American
San Francisco, California
- 1995 Workshop Organizer and Lecturer
Scientific Workshop on Emerging Bacterial Zoonoses and Vector-Borne Diseases
National Institute of Allergy and Infectious Diseases
National Institutes of Health
Hosted by University of Texas Medical Branch
Galveston, Texas

- 1995 Invited Lecturer
United States and Canadian Academy of Pathology
Special Course: Contemporary Diagnostic Pathology of Infectious Diseases
- 1995 Invited Speaker
Texas Society for Infectious Diseases 15th Annual Meeting
Houston, Texas
- 1993 Invited Lecturer
Infectious and Inflammatory Disorders
Australasian Division of the International Academy of Pathology Limited
19th Annual Scientific Meeting
Darling Harbour Convention Centre
Sydney, Australia
- 1992 Member, Task Force to Investigate
Sverdlovsk Anthrax Epidemic of 1979
Moscow and Ekaterinburg, Russia
- 1992 Invited Lecturer
Pathology and Pathogenesis of Spotted Fever Rickettsial Infections
Unite des Rickettsies
Centre National de Référence
Centre Collaborateur OMS
Marseille, France
- 1991 - 1995 Invited Lecturer
United States and Canadian Academy of Pathology
Short Course: Etiologic Diagnosis of Infectious Diseases
- 1990 Invited Plenary Speaker
Epidemiology of Rickettsial Diseases, Fourth International Symposium on Rickettsiae and Rickettsial Diseases
Piestany Spa, Czechoslovakia
- 1990 Invited Lecturer
Rickettsiology in the United States, Zdrodovsky Jubilee
Gamaleya Institute of Microbiology and Epidemiology
Moscow, USSR
- 1989 Course Organizer and Presenter
Indiana Association of Pathologists
Indianapolis, Indiana
- 1988 Invited Scientist and Lecturer
Joint Scientific Research Program from the Japanese Ministry of Education,
Science and Culture (Monbusho)
The University of Tokushima School of Medicine
Tokushima, Japan

Shimane Medical University
Shimane, Japan
40th West Japan Dermatological Society Meeting
Kochi, Japan

Niigata College of Pharmacy
Niigata, Japan

National Institute of Health of Japan
Tokyo, Japan

- 1987 Invited Collaborative Field Expedition on Rickettsiosis
Xishuangbanna District, Yunnan Province
People's Republic of China
- 1985 Invited Collaborative Field Expedition
Investigation of Spotted Fever Rickettsiosis
Wangong, Hulunbeier District, Inner Mongolia
People's Republic of China, and Laboratory Analysis of Specimens
Institute of Epidemiology and Microbiology, Beijing
- 1983 Visiting Scientist and Lecturer
Institute of Epidemiology and Microbiology
National Center for Preventive Medicine (Beijing)
and First National Meeting for Rickettsia,
Chlamydia, and Toxoplasma, Nanning
People's Republic of China

Off Campus:

- 2011 Invited lecturer: "Rickettsial Immunity"
Third Medical Military Institute
Beijing, China
- 2011 Invited lecturer: "Rickettsia Diseases in America"
Fourth Medical Military Institute
Xian, China
- 2011 Invited lecturer: "Emerging and Reemerging Ehrlichiosis and Rickettsioses"
Department of Pathology and Laboratory Medicine Grand Rounds
University of Pennsylvania School of Medicine
Philadelphia, PA
- 2010 Invited lecturer: "Emerging and Reemerging Ehrlichioses and Rickettsioses"
ID Advanced Topics Lecture Series
Memorial Sloan-Kettering Cancer Center
New York, NY
- 2010 Invited lecturer: "Pathology and Pathogenesis of Rickettsial Diseases"
Department of Pathology Grand Rounds
University of Texas Health Science Center
Houston, TX

- 2010 Invited lecturer: “Spotted Fever Rickettsioses: Epidemiology, Pathogenesis and Immunity”
 Meharry Medical College
 Nashville, TN
- 2010 Invited lecturer: “Monocytotropic Ehrlichioses: Epidemiology, Pathogenesis, and Immunity”
 Entomology Department Seminar Program
 University of California-Riverside
 Riverside, CA
- 2010 Invited lecturer: “Rickettsial Diseases: Mechanisms of Protective Immunity”
 University of Rochester
 Rochester, NY
- 2008 Invited lecturer “Pathology of Potential Bioterror Infections”
 Pathology and Laboratory Medicine Institute Grand Rounds
 Cleveland Clinic
 Cleveland, Ohio
- 2007 Invited lecturer “Monocytotropic Ehrlichiosis: Immunity and Immunopathogenesis of an Emerging Infectious Disease”
 Department of Pathology Grand Rounds
 Vanderbilt University, School of Medicine
 Nashville, TN
- 2006 Invited lecturer “Emerging Infectious Diseases: Why There Will Always Be More Coming”
 Frank M. Townsend, M.D., Lecture
 University of Texas Health Science Center at San Antonio
 San Antonio, Texas
- 2006 Invited lecturer “Rickettsial Diseases: Pathogenesis and Immunity”
 Gustave Dammin Lecturer
 Brigham and Women’s Hospital
 Boston, MA
- 2006 Invited lecturer “Prioritization of Biologic Agents as Threats for Use in Terrorism”
 Distinguished Seminar Series
 Los Alamos National Laboratory
 Los Alamos, NM
- 2005 Invited lecturer, “Rickettsial Diseases as Public Health and Bioterror Threats”
 Dr. Ricardo Jorge National Institute of Health
 Lisbon, Portugal
- 2005 Invited lecturer “Preparation of Unemphazied Potentially Severe Bioterrorists Threats”
 Massachusetts General Hospital
 Boston, MA
- 2004 Invited Lecturer “Immunity to Ehrlichia”
 University of Texas-Houston, Department of Pathology
 Houston, Texas

- 2004 Invited Lecturer “In the Footsteps of Howard Ricketts: Immunity to Rickettsiae”
University of Chicago
Chicago, IL
- 2004 Invited Lecturer “Bioterrorism: Preparation for the Expected and Unexpected”
University of Arkansas
Little Rock, AK
- 2004 Invited Lecturer “Inhalational Anthrax: Pathogenesis and Diagnosis”
University of Texas-Houston
Houston, Texas
- 2003 Invited Lecturer “Typhus: Current Status of a Classic Scourge”
University of Vermont
Burlington, VT
- 2003 Invited Lecturer “Immunity and Immunopathology in Ehrlichiosis”
Wadsworth Center
New York State Department of Health
Albany, NY
- 2003 Visiting Professor “Diagnostic Preparedness of Pathology and Laboratory
Medicine for a Bioterrorist Attack”
Creighton University
Omaha, NE
- 2003 Invited Lecturer “Rickettsia”
Baylor University
Houston, TX
- 2003 Invited Lecturer “Bioterrorism: Preparation for the Expected and Unexpected”
Gorgas Institute
Gorgas, Panama
- 2003 Invited Lecturer “Human Ehrlichiosis: A Prevalent, Life-threatening Emerging
Infectious Disease”
University of North Carolina, School of Medicine
Chapel Hill, NC
- 2002 Invited Lecturer “Tick-borne Infections”
University of Buea
Buea, Cameroon
- 2002 Invited Lecturer “Molecular Diagnostics”
University of Buea
Buea, Cameroon
- 2001 Invited Lecturer “Rickettsial Infections”
Santiago Center for Geographic Medicine and Emerging Tropical Diseases
Santiago, Panama
- 2001 Invited Lecturer
Universidad Autónoma de Nuevo León
Nuevo León, Mexico

- 2001 Invited Lecturer
 Instituto Nacional de Salud
 Lima, Peru
- 2000 Moon Lecture
 Department of Pathology
 University of California
 San Francisco, California
- 2000 Invited Lecturer
 Department of Pathology and Laboratory Medicine
 University of Cincinnati Hospital
 Cincinnati, Ohio
- 1997 Robert S. Totten Lecture
 Department of Pathology
 University of Pittsburgh
 Pittsburgh, Pennsylvania
- 1997 Invited Lecturer
 Universidad Autonoma de Yucatan
 Merida, Yucatan, Mexico
- 1996 Molecular Pathology and Ultrastructure Activity Program Review for 1991-1996
 Centers for Disease Control and Prevention
 Atlanta, Georgia
- 1996 Invited Lecturer
 Universite de la Mediterranee
 Marseille, France
- 1996 Invited Lecturer for Research Day
 Dalhousie University
 Halifax, Nova Scotia
- 1996 Invited Lecturer
 University of Vermont
 Burlington, Vermont
- 1996 Invited Lecturer
 Scientia Institute, Rice University
 Houston, Texas
- 1995 Invited Lecturer
 University of Missouri
 Columbia, Missouri
- 1995 Invited Lecturer
 Department of Pathology
 University of Texas Health Science Center
 Houston, Texas

- 1994 Invited Lecturer
 Current Status of Rickettsioses
 University of Salamanca School of Medicine
 Salamanca, Spain
- 1985, 1983 Sun Yat-sen University of Medical Sciences
 Guangzhou, The People's Republic of China
- 1983 NATO Visiting Professor of Tropical and Subtropical Diseases
 University of Palermo, Italy

AGENDA ITEM #3.f.

State of Texas

§
§
§

County of Galveston

**First Amendment to
Interlocal Cooperation Agreement by and between
The University of Texas Medical Branch at Galveston and the County of Galveston
Relating to the Galveston County Medical Examiner's Office**

I. Preamble

Whereas, the County of Galveston, Texas (County) and The University of Texas Medical Branch at Galveston (UTMB), for and on behalf of its Department of Pathology, each of whom is a Party hereto and who are collectively referred to herein as the Parties, have heretofore entered into that Interlocal Cooperation Agreement by and between The University of Texas Medical Branch at Galveston (UTMB) and the County of Galveston Relating to the Galveston County Medical Examiner's Office (Agreement) which covers the term of September 1, 2012 through August 31, 2013;

Whereas, the Commissioners Court of Galveston County, Texas, the governing body of the County, has by Order of the Commissioners Court on this day, made changes in the appointments of the Medical Examiner and Deputy Medical Examiners for the Galveston County Medical Examiner's Office; and

Whereas, the Parties wish to amend the Agreement to extend the Agreement for an additional six (6) months (through February 28, 2014), to reflect the correct identity of the persons holding appointments, and to make the conforming changes within the Agreement.

Now Therefore, it is mutually agreed by and between the Parties as follows:

II. Terms

1. **Recitals true.** The Parties acknowledge and agree that the Recitals set forth in the Preamble above are true and correct.
2. **Amended Terms.** The Parties **AMEND** the Agreement as follows:
 - a. **Preamble.** The Preamble, which is Section II of the Agreement, is AMENDED as follows:

The third finding (i.e., "whereas" clause) is DELETED and all other provisions within Section II remain unchanged.
 - b. **Subsection III(A)(1).** Subsection III(A)(1) is AMENDED as follows:

Subsection III(A)(1.1)(a). The text of Subsection III(A)(1.1)(a) is DELETED in its entirety and REPLACED with the following:

Medical Examiner. A qualified faculty physician, who shall perform the duties and responsibilities and serve as the Galveston County Medical Examiner. Such physician is currently _____, who has been appointed as the Galveston County Medical Examiner by the Commissioners Court of Galveston County. UTMB acknowledges and agrees that the appointment of the Galveston County Medical Examiner is made solely by the Commissioners Court of Galveston County and no person may serve as the Galveston County Medical Examiner unless such appointment has been made by the Commissioners Court of Galveston County, Texas.

Comment [I.T.1]: Identity of person is not known at time of drafting.

Subsection III(A)(1.1)(b). The text of Subsection III(A)(1.1)(b) is DELETED in its entirety and REPLACED with the following:

Deputy Medical Examiners. One or more qualified staff physicians to act as Deputy Medical Examiners under the direction of the Medical Examiner. UTMB acknowledges and agrees that the current Deputy Medical Examiners are the following physicians: Judith F. Aronson, Paul J. Boor, Gerald A. Campbell, Benjamin B. Gelman, Hal K. Hawkins, Nobby C. Mambo, Harminder S. Narula, Juan P. Olano, Bill A. Rampy, Landon C. Stout, Jr., and David H. Walker. UTMB further acknowledges and agrees that the appointment of any Deputy Medical Examiner is made through appointment by the Commissioners Court of Galveston County, and no person may serve as a Deputy Medical Examiner unless such appointment has been made by the Commissioners Court.

Comment [I.T.2]: Deputy ME's subject to change since do not know who will be appointed as the Medical Examiner

Subsection III(A)(1.1)(c). Subsection III(A)(1.1)(c) remains unchanged.

Subsection III(A)(1.3). Subsection III(A)(1.3) is AMENDED by DELETING the second sentence within this Subsection and REPLACING it with the following as the second sentence of Subsection III(A)(1.3). The second sentence, as amended, is the following:

In this regard, the UTMB faculty physician serving as the Medical Examiner shall be licensed by the Texas Medical Board and shall, to the greatest extent possible, be board certified in the field of forensic pathology.

All other provisions within Subsection III(A)(1.3) remain unchanged.

c. Subsection III(B)(1). Subsection III(B)(1) is AMENDED as follows:

Subsection III(B)(1.1) is AMENDED by DELETING the provision in its entirety and REPLACING with the following as Subsection III(B)(1.1):

Compensation for services. For services performed by UTMB, the County will pay the sum of Five Hundred Ninety-Seven Thousand Five Hundred Twelve

Dollars and No Cents (\$597,512.00) covering the period on and from September 1, 2012 through August 31, 2013, and the sum of \$298,756.00 covering the period on and from September 1, 2013 through February 28, 2014. Such sums total \$896,268.00 for the eighteen months of the Agreement as extended through this First Amendment, and remains based on an annual rate of \$597,512.00.

Subsection III(B)(1.4) is AMENDED by DELETING the second sentence in its entirety and REPLACING it with the following as the second sentence:

The County Auditor or the County Auditor's designee shall have the right to audit these records for up to three (3) years after the close of the County's 2013-2014 fiscal year (September 30, 2014).

All other provisions of Subsection III(B)(1.4) remain unchanged.

- d. Subsection III(C)(6). Subsection III(C)(6) is AMENDED as follows:

Subsection III(C)(6) is AMENDED by DELETING the first sentence in its entirety and REPLACING it with the following as the first sentence:

Regardless of the date of execution of this Agreement, this Agreement shall be in effect from September 1, 2012 through February 28, 2014, unless terminated earlier as provided herein.

All other provisions of Subsection III(C)(6) remain unchanged.

3. **Effective Date.** This First Amendment shall be effective on and from August 26, 2013.
4. **Amending of Agreement.** By signing this First Amendment, the Parties expressly understand and agree that its terms shall become a part of the Agreement as if they were set forth word for word therein and all provisions in the Agreement that are contrary to the provisions in this First Amendment are deemed amended so as to be in compliance with the terms of this First Amendment. This First Amendment shall be binding upon the Parties hereto and their respective successors and assigns.
5. **Authority to Bind.** Each Party represents and warrants for itself that the individual executing this First Amendment on its behalf has the full power and authority to do so and to legally bind the Party to all the terms and provisions of this First Amendment and that this First Amendment constitutes the legal, valid, and binding agreement of each Party hereto.

**Execution page follows this page
The rest of this page is intentionally left blank**

This First Amendment to the Agreement referenced herein is hereby **EXECUTED** by the Parties hereto, each Party acting by and through its duly official as required by law, in *triplicate counterparts* each of which shall be deemed to be an original.

Galveston County:

**The University of Texas Medical
Branch at Galveston:**

By: _____
Mark Henry, County Judge

By: _____
William R. Elger, *CPA*
Executive Vice President,
Chief Business and Finance
Officer

Date: _____

Date: _____

ATTEST:

Content Reviewed: _____

Dwight D. Sullivan, County Clerk

By: _____
Danny O. Jacobs, MD, MPH
Executive Vice President and Provost
Dean, School of Medicine

Date: _____

Date: _____

By: _____
Rex McCallum, MD, FACP, FACR,
Vice President, Chief Physician
Executive

Date: _____

AGENDA ITEM #3.g.

State of Texas

§

County of Galveston

§

§

**RESOLUTION ADOPTING ELIGIBILITY STANDARDS,
APPLICATION, DOCUMENTATION, AND VERIFICATION PROCEDURES,
OPTIONAL HEALTH CARE SERVICES, AND
AUTHORIZING PUBLICATION OF PUBLIC NOTICE**

On this, the 26th day of August, 2013, the Commissioners Court of Galveston County, Texas, convened in a **Special Meeting** with the following members present:

Mark Henry, County Judge;
Ryan L. Dennard, Commissioner, Precinct No. 1;
Kevin O'Brien, Commissioner, Precinct No. 2;
Stephen D. Holmes, Commissioner, Precinct No. 3;
Kenneth Clark, Commissioner, Precinct No. 4; and
Dwight D. Sullivan, County Clerk

when the following proceedings, among others, were had, to-wit:

Whereas, the Indigent Health Care and Treatment Act is codified at Chapter 61 of the Texas Health and Safety Code;

Whereas, in accordance with Section 61.023 of the Texas Health and Safety Code, not later than the beginning of the State of Texas fiscal year, Galveston County must adopt the eligibility standards it will use during the State fiscal year and shall make a reasonable effort to notify the public of the standards;

Whereas, in accordance with Section 61.023 of the Texas Health and Safety Code, Galveston County may change the eligibility standards to make them more or less restrictive than the preceding standards, but may not make the standards more restrictive than the standards adopted by the Texas Department of Health pursuant to its authority under Section 61.006 of the Texas Health and Safety Code;

Whereas, in accordance with Section 61.024 of the Texas Health and Safety Code, not later than the beginning of the State of Texas fiscal year, Galveston County shall specify the procedure it will use during the State of Texas fiscal year to verify eligibility and the documentation required to support a request for assistance and shall make a reasonable effort to notify the public of the application procedure;

Whereas, House Bill 2292, 78th Legislature, R.S. (2003), inter alia, abolished the Texas Department of Health and the duties, functions, programs, and powers regarding county indigent health care were transferred to the Texas Department of State Health Services and the subsequent Rules Transfer was effective September 1, 2004 and the Texas Department of State Health Services (TDSHS) is the State agency with authority over county indigent health care services;

Whereas, in accordance with Section 61.006 of the Texas Health and Safety Code, current minimum TDSHS standards allow a net income eligibility level equal to 21% of the federal poverty level as such level is based on the federal Office of Management and Budget poverty index;

Whereas, current minimum TDSHS standards provide that expenses allowable for State participation, following the eight percent trigger, are a net income eligibility level equal to 21% of the federal poverty level;

Whereas, the State of Texas 2013-2014 fiscal year runs from September 1, 2013 through August 31, 2014;

Whereas, Galveston County's 2013-2014 fiscal year runs from October 1, 2013 through September 30, 2014 and thus the County's adoption herein overlaps between two different Galveston County fiscal years; and

Whereas, the Director of Community Services has prepared a Public Notice, which is attached hereto as Exhibit 1 and has completed the TDSHS Form 120, the reporting form that must be used to report the optional health care services to the TDSHS, and which TDSHS Form 120 is attached hereto as Exhibit 2.

Now, Therefore, be it RESOLVED, by the Commissioners Court of Galveston County, Texas, that:

- 1) On June 25, 2013, the Commissioners Court adopted the qualifying income level for indigent health care benefits through its Indigent Health Care Program mandated under Chapter 61 of the Health and Safety Code at 35% of the federal poverty level and this Resolution continues such adoption;
- 2) Continuing September 1, 2013 and through August 31, 2014 thereafter, unless changed by subsequent Resolution of the Commissioners Court, the County of Galveston's eligibility standards for receiving medical care benefits under its Indigent Health Care Program shall remain at 35% of the federal poverty level and the County of Galveston shall follow the minimum State of Texas standards adopted by the TDSHS pursuant to Section 61.006 of the Texas Health and Safety Code;
- 3) Provided however, that continuing September 1, 2013 and through August 31, 2014 thereafter, the County of Galveston's eligibility standards for receiving primary medical care benefits at Coastal Health and Wellness, which is located at the Galveston County Health District, will remain at 100% of the federal poverty level and at a discounted rate for income greater than 100% and up to 200% of the federal poverty level, and the Galveston County Health District shall follow the requirements for Federally Qualified Health Centers for such primary medical care benefits;
- 4) These eligibility standards will remain at this level until such time as the Commissioners Court provides additional funding to increase this level or is advised that sufficient funds remain unspent to enable an increase;

- 5) Also continuing September 1, 2013 and through August 31, 2014 thereafter, in accordance with Section 61.0285 of the Texas Health and Safety Code, the following optional health care services will be provided:
- Diabetic supplies with physicians written order and pre-authorization;
 - Durable medical equipment limited to home oxygen equipment with written prescription and pre-authorization;
 - Home and community health care with physicians written order and pre-authorization;
 - Dental care;
 - Services provided by the Coastal Health and Wellness Center, which is a federally qualified health center, as defined by 42 U.S.C.A. § 1396d(l)(2)(B); and
 - Transportation as needed for out-of-county medically scheduled referrals on scheduled transportation services or utilizing Connect Transportation services when determined to be cost effective;
- 6) Continuing September 1, 2013 and through August 31, 2014 thereafter, the procedures to be used to verify eligibility and the documentation required to support a request for assistance shall be the application, documentation, and verification procedures adopted by the TDSHS under Sections 61.006, 61.007, and 61.008 of the Texas Health and Safety Code;
- 7) The Public Notice that is attached as Exhibit 1 is hereby **APPROVED** and the Director of Community Services or her designee is authorized to publish the Public Notice in the Galveston County Daily News newspaper;
- 8) The completed TDSHS Form 120 that is attached as Exhibit 2 is hereby **APPROVED** and the County Judge of Galveston County, Texas is authorized to sign the TDSHS Form 120 and the Director of Community Services or her designee is Ordered to, forthwith thereafter, submit said TDSHS Form 120 to the TDSHS; and
- 9) The County Judge of Galveston County, Texas, is hereby **AUTHORIZED** to **EXECUTE** this Resolution on behalf of the Commissioners Court of Galveston County, Texas.

Upon Motion Duly Made and Seconded, the above Resolution is hereby **ADOPTED**, on this, the 26th day of August, 2013.

County of Galveston, Texas, By:

Mark Henry, County Judge

ATTEST:

Dwight D. Sullivan, County Clerk

Public Notice

Galveston County Indigent Health Care Program

Coastal Health and Wellness Center
9850- C Emmett F. Lowry Expwy
Texas City, Texas 77591
409-938-2234 Or 281-309-0255

Coastal Health and Wellness Center
4700 Broadway, Suite F #100
Galveston, Texas 77550
409-763-7200

8:00 am -5:00pm Monday-Friday- Clinic Hours

10:00am-5:00pm Saturday- (Walk-Ins Only)

Eligibility, application, documentation, and verification procedures in accordance with Texas Department of State Health Services standards and published in the County Indigent Health Care Program Handbook published by the Texas Department of State Health Services

Eligibility Requirements:

35% Federal Poverty Level - County Resident – Income – Resources - Household Composition

Services:

- Physician's Service- Primary Care Providers (Coastal Health & Wellness at 100% of Federal Poverty Level, above 100% up to 200% Federal Poverty Level at Discounted Rate)
- Inpatient/Outpatient Hospital Care
- Prescriptions at Walgreens with co-payment
- Family Planning Services
- Laboratory
- X-rays Services
- Immunizations

All Services Must Be Medically Necessary

Information Needed to Apply:

- Social security numbers for all members of the household
- Proof of identification
- Proof of ALL household income- (w-9, check stubs, unemployment vouchers, unearned income)
- Proof of residency
- Proof of resources (checking/saving account statements)

All Changes must be reported within 14 days

You have the right to:

- Obtain an application - Have assistance in preparing forms
- Eligibility determined within 14-days after completion of application
- Written notification of determination
- Appeal a denial of acceptance
- Submit an application anytime
- Equal treatment regardless of race, color, religion, creed, national origin, age, sex, disability, or political belief
- These rules are subject to change with revision of the County Indigent Health Care Program Handbook published by the Texas Department of State Health Services

YOU MAY NOT BE ELIGIBLE IF YOU TRANSFER OWNERSHIP OF PROPERTY TO MAKE YOURSELF ELIGIBLE FOR ASSISTANCE.

Definitions of CIHCP Optional Health Care Services

- 1. Advanced Practice Nurse (APN)** services must be medically necessary and provided within the scope of practice of an APN and covered by the Texas Medicaid Program when provided by a licensed physician.
- 2. Ambulatory Surgical Center (ASC)** services must be provided in a freestanding ASC, and are limited to items and services furnished in reference to an ambulatory surgical procedure, including those services on the Center for Medicare and Medicaid Services (CMS)-approved list and selected Medicaid-only procedures.
- 3. Colostomy medical supplies and/or equipment** must be medically necessary and prescribed by a physician or an APN if this is within the scope of their practice in accordance with the standards established by the Board of Nurse Examiners and published in 22 TAC §221.13. Items covered are colostomy bags/pouches, cleansing irrigation kits, paste or powder, and skin barriers with flange/wafers. The county may require the supplier to receive prior authorization.
- 4. Counseling (psychotherapy)** services must be medically necessary based on a referral from a physician or an APN if this is within the scope of their practice in accordance with the standards established by the Board of Nurse Examiners and published in 22 TAC §221.13. Psychotherapy services must be provided by a Licensed Clinical Social Worker (LCSW), Licensed Marriage Family Therapist (LMFT), Licensed Professional Counselor (LPC), or a Ph.D. Psychologist.
- 5. Dental care** must be medically necessary and provided by a DDS, DMD, or DDM. Items covered are: an annual routine exam, annual routine cleaning, one set of annual x-rays, and the least costly service for emergency dental conditions for the removal or filling of a tooth due to abscess, infection, or extreme pain. The county may require prior authorization.
- 6. Diabetic supplies and/or equipment** must be medically necessary and prescribed by a physician or an APN if this is within the scope of their practice in accordance with the standards established by the Board of Nurse Examiners and published in 22 TAC §221.13. Items covered are: test strips, alcohol prep pads, lancets, glucometers, insulin syringes, humulin pens, and the needles required for the humulin pens. The county may require the supplier to receive prior authorization.
- 7. Durable medical equipment (DME)** must be medically necessary; meet the Medicare/Medicaid requirements; and be provided under a written, signed and dated prescription from a physician or an APN if this is within the scope of their practice in accordance with the standards established by the Board of Nurse Examiners and published in 22 TAC §221.13. Items may be purchased or rented, whichever is least costly. Items covered are: blood pressure measuring appliances that are reasonable and appropriate, canes, crutches, home oxygen equipment (including masks, oxygen hose, and nebulizers), hospital beds, walkers, and standard wheelchairs. The county may require the supplier to receive prior authorization.
- 8. Emergency medical service** covers ground transportation only for medically necessary, life-threatening conditions.
- 9. Federally Qualified Health Center (FQHC)** services must be provided in an approved FQHC by a physician, physician's assistant, nurse practitioner, clinical psychologist, or clinical social worker.
- 10. Occupational therapy** services must be medically necessary and may be covered if provided in a physician's office, a therapist's office, in an outpatient rehabilitation or free-standing rehabilitation facility, or in a licensed hospital. Services must be within the provider's scope of practice, as defined by Occupations Code, Chapter 454.
- 11. Physical therapy** services must be medically necessary and may be covered if provided in a physician's office, a therapist's office, in an outpatient rehabilitation or free-standing rehabilitation facility, or in a licensed hospital. Services must be within the provider's scope of practice, as defined by Occupations Code, Chapter 453.
- 12. Home and community health care** must be medically necessary, meet the Medicare/Medicaid requirements; and be provided by a certified home health agency. A plan of care must be recommended, signed, and dated by the recipient's attending physician prior to care being given. Items covered are R.N. visits for skilled nursing observation, assessment, evaluation, and treatment provided by a physician who specifically requests the R.N. visit for this purpose. A home health aide to assist with administering medication is also covered. Visits made for performing housekeeping services are not covered. A county may require prior authorization.
- 13. Physician Assistant (PA)** services must be medically necessary and provided by a PA under the direction of an M.D. or a D.O. and must be billed by and paid to the supervising physician.
- 14. Vision care** covers one exam by refraction and one pair of prescribed glasses every 24 months that meet Medicaid criteria.
- 15. Other** medically necessary services or supplies that the local governmental municipality/entity determines to be cost effective.



Form 120, Optional Health Care Services Notification, Page 3 of 3

Instructions for Form 120

Mark an "X" in the appropriate column to indicate each optional health care service the county chooses to provide or chooses to discontinue providing. Sign and date the bottom of the form, and submit the Form 120 electronically to the TDSHS Primary Care Group by emailing it to: CIHCP@dshs.state.tx.us.

If you are unable to submit the form electronically, you may fax it to the TDSHS at 512/776-7713.

It is not necessary to submit the Form 120 by mail once it has been faxed and received by TDSHS Primary Care Group.

Maintain the records at least until the end of the third complete state fiscal year.

AGENDA ITEM #5.a.a.1.

**COUNTY OF GALVESTON
REQUEST FOR BUDGET AMENDMENT/TRANSFER**

Department:	District Attorney	Amendment No. 13-077-0826-A
Date Submitted:	August 21, 2013	(Assigned by Budget Office)

COMMISSIONER'S COURT ACTION:
Please complete the following form in its entirety and submit to the Budget Office at least eleven (11) days prior to the first regularly scheduled Tuesday Commissioners Court meeting date each month. Emergency amendments will be processed at the earliest available Court meeting date. If information on this form is incomplete, the amendment will be returned to your office for completion. It is suggested that the department requesting the amendment be present on the date of its submittal to the Court for action.

THIS PORTION MUST BE FILLED OUT

GENERAL EXPLANATION:
Request for an exception to the salary policy - Human Resource policy HR009 (H)(1).
This budget amendment does not increase the budget for FY 2013.

Transfer FROM	Account Description	Amount	Auditor Use Only Acct Balance Sufficient? (Y/N)
		Annualized	
Acct. No: General Fund 1101-1271000-5100000	Line Item: Salaries (Salary Lapse)	990	—
TOTAL - Transfer Amount		\$ 990	

Transfer TO	Account Description	Amount	Auditor Use Only Acct Balance Sufficient? (Y/N)
		Annualized	
Acct. No: General Fund 1101-127100-5100000	Line Item: Salaries (Position #71)	990	—
TOTAL - Transfer Amount		\$ 990	

ADDITIONAL COMMENTS:
This is a request from the District Attorney for an exception to the Human Resource policy - HR0009 (H) (1) which provides that promoted County employees shall not be paid more that 10% above their salary at the time of application or be hired at the "A" step. The total increase for this employee from grade/step 23C (Senior Assistant District Attorney) to 25F (Chief Assistant District Attorney) will be \$20,350 if approved. As of August 22, 2013, the salary and fringe benefit lapse is \$282,232.

Position Proposed Title:	Grade	Bi-Weekly Salary	Annualized Salary FY2013	Salary through the end of FY2013
Chief Assistant District Attorney	25F	\$3,278	\$85,556	\$8,522
Present Title:				
Chief Assistant District Attorney	25A	\$2,897	\$75,612	\$7,532
Difference			<u>\$9,944</u>	<u>\$990</u>

Departmental Authorization _____ Date _____
Human Resources Department _____ Date _____

 8/22/2013
Budget Office Authorization _____ Date _____

AUDITOR'S REVIEW

This budget amendment has been reviewed for validity of accounts and sufficiency of account balances used for budget transfer.

Reviewed by: _____ Date: _____

Auditor's Remarks: _____

COMMISSIONERS COURT APPROVAL

Date Submitted: _____ Date Approved: _____

AGENDA ITEM #5.b.



THE COUNTY OF GALVESTON
COUNTY AUDITOR'S OFFICE
P.O. Box 1418
GALVESTON, TEXAS 77553

County Auditor
Randall Rice CPA
CITP CISA CIO CBM DABFA CGMA

Ron Chapa, CPA
First Assistant, Director of Auditing

Jeff Modzelewski, CPA
First Assistant, Director of Accounting

Latoya Jordan
First Assistant, I.T. Systems

August 22, 2013

Honorable County Judge and Commissioners
Galveston County
Galveston, TX 77550

Re: Certification of Revenues Pursuant to Local Government Code Section 111.0706:

Grant from Texas Automobile Burglary and Theft Prevention Authority

Galveston County has received grant revenue in the amount of \$468,779 for the Galveston County Auto Crimes Task Force for the period 09-01-2013 to 08-31-2014 that had not been previously budgeted or anticipated. The total award is \$795,115, with grantee cash from participants in the amount of \$315,016 and grantee in-kind from participants in the amount of \$11,320.

Galveston County may adopt a special budget for the expenditure of this revenue. A budget for the funding received has been prepared based on the Grant Manager's recommendations and the application submitted for the grant for the grant period.

I hereby certify the foregoing statements are true and correct.

A handwritten signature in cursive script, appearing to read "RRice", written over a horizontal line.

Randall Rice CPA
Galveston County Auditor



7/11/2013

Lt Tommy Hansen
601 54th St, #2104
Galveston, Texas 77551

Re: Grant Nbr: 2014-T01-Galvesto-00035 Year of Funding: FY 2014
Application: Galveston County
Title: Galveston County Auto Crimes
Amount: \$468,779.00

Dear Lt Hansen

I am pleased to inform you that the above referenced grant is approved in the amount indicated. The grant award must be accepted within 30 days by completing and returning the enclosed grantee acceptance notice to the Texas Automobile Burglary & Theft Prevention Authority. A copy of the Automobile Burglary & Theft Prevention Authority's Grant Administrative Guide is being forwarded under separate cover to the financial officer designated in your grant application.

I look forward to working with you to ensure the success of your program. Any questions relating to the administration of this grant should be directed to our office by calling the Grant Administrator, Jan Gregg (512) 374-5107.

Sincerely,

Charles Caldwell
Director, ABTPA

GRANTEE ACCEPTANCE NOTICE

AGREEMENT:

That whereas Galveston County, hereinafter referred to as Grantee, has heretofore submitted a grant application to the Automobile Burglary and Theft Prevention Authority, State of Texas, entitled Galveston County Auto Crimes Task Force, and further identified by grant number 2014-T01-Galvesto-00035 And

Whereas, the Automobile Theft Prevention Authority has approved the grant application as evidenced by the Statement of Grant Award from the Automobile Burglary and Theft Prevention Authority dated {Print Date} Certain special requirements; and

Whereas, the Grantee desires to accept the grant award, the Uniformed Grant and Contract Management Standards, and special requirements as evidenced by the Statement of Grant Award;

Now, therefore, the Grantee accepts the aforementioned Statement of Grant Award, the Uniformed Grant and Contract Management Standards and special requirements in the grant application and the Statement of Grant Award as evidenced by the agreement, executed by the project director, the financial officer, and the official authorized to sign the original grant application, of the official's successor, as presiding officer of and on behalf of the governing body of this grantee; and

Now, therefore, the Grantee shall designate either the project director or the financial officer to coordinate and be solely responsible for submission of adjustments pertaining to both program and financial elements of the application, and the POSITION authorized to submit adjustments is Project Director.

NON-LOBBYING CERTIFICATION:


We, the undersigned, certify that none of the grant funds, regardless of their source or character, including local cash assumption of cost funds, shall be used in any manner to influence the outcome of any election or the passage or defeat of any legislative measure.

A finding that a grantee has violated the certification shall result in the immediate termination of funding of the project and the grantee shall not be eligible for future funding from the Automobile Burglary and Theft Prevention Authority.

Certified By:

Date:





Signature of Project Director

Signature of Project Manager

Lt. Tommy Hansen

Sgt. Danny Sheppard, Commander

Name & Title(must print or type)


Name & Title(must print or type)

601 54th St
Official Agency Address(street or post office box)

1620 Gill Rd
Official Agency Address(street or post office box)

Galveston, TX 77510 409-766-4500
City/Zip Code/Telephone Number

Dickinson, TX 77510 409-766-4507
City/Zip Code/Telephone Number





Signature of Authorized Official

Signature of Financial Officer

Mark Henry, County Judge
Name & Title (must print or type)

Randall Rice, County Auditor
Name & Title(must print or type)

722 Moody
Official Agency Address (street or post office box)

722 Moody
Official Agency Address(street or post office box)

Galveston, TX 77550 409-762-8621
City/Zip Code/Telephone Number

Galveston, TX 77550 409-770-5301
City/Zip Code/Telephone Number



Watch Your Car

TEXAS AUTO BURGLARY & THEFT PREVENTION AUTHORITY

Texas Automobile Burglary and Theft Prevention Authority Statement of Grant Award

Grant Number: 2014-T01-Galvesto-00035
Grantee Name: Galveston County
Project Title: Galveston County Auto Crimes Task Force
Grant Period: 09/01/2013 to 08/31/2014

ABTPA Award: \$468,779.00
Grantee Cash: \$315,016.00
Grantee In-Kind: \$11,320.00
Total Project Cost: \$795,115.00

The Texas Automobile Burglary and Theft Prevention Authority (ABTPA) has awarded the above-referenced grant. The approved budget is reflected in the attached Approved Budget Summary. This grant is subject to and conditioned upon acceptance of the ABTPA Grant Administrative Guide promulgated for this specific program fund (referenced above) through the Automobile Theft Prevention Authority a listing of applicable special conditions are listed below. Total project costs must be accounted for in accordance with the Uniform Grant and Contract Management Standards and the Administrative Guide.

GRANTEE REQUEST FOR FUNDS

All Grantee request for funds shall be submitted to ABTPA in accordance with the instructions provided by ABTPA and shall be in the form required by ABTPA. Requests for funds will not be honored until all special conditions outlined on the Statement of Grant Award and action required on the part of the grantee have been satisfied.

GRANT ADJUSTMENTS

Grantee shall submit written requests for grant adjustments, as required by the applicable ABTPA Rule contained in the Grant Administrative Guide for this specific program fund.

Special Conditions and Requirements:

Non-Supplanting Certification

7/11/2013

Chad Cramer



Watch Your Car

TEXAS AUTO BURGLARY & THEFT PREVENTION AUTHORITY

Texas Automobile Burglary and Theft Prevention Authority Approved Budget Summary

Grant Number: 2014-T01-Galvesto-00035
Grantee: Galveston County
Project Title: Galveston County Auto Crimes Task Force
Grante Period: 09/01/2013 to 08/31/2014
Funding Source: Auto Burglary and Theft Prevention Authority

Region:
Date: 7/11/2013

	ABTPA	Cash Match	In-Kind	TOTAL
A. Personnel	\$413,779.00	\$60,435.00	\$0.00	\$474,214.00
A. Fringe	\$0.00	\$164,421.00	\$0.00	\$164,421.00
B. Contractual	\$0.00	\$0.00	\$8,820.00	\$8,820.00
C. Travel	\$10,000.00	\$2,000.00	\$0.00	\$12,000.00
D. Equipment	\$0.00	\$0.00	\$0.00	\$0.00
E. Supplies & DOE	\$45,000.00	\$88,160.00	\$2,500.00	\$135,660.00
F. Indirect Funds				\$0.00
Totals	\$468,779.00	\$315,016.00	\$11,320.00	\$795,115.00

1. **Applicant Information**
- a. **Legal Name:** County of Galveston
- b. **Address**
Street or P.O. Box: 722 Moody, 2nd Floor **City:** Galveston
County: Galveston County **State:** Texas **Zip Code:** 77550
- c. **Organizational Unit:** Galveston County Auto Crimes Task Force
- d. **Contact Person:** Tommy Hansen, Project Director
Telephone Number: 4097662358
2. **State Payee ID Number:** 749000608
3. **Type of Applicant** County
If "Other", please specify:
4. **Type of Application:**
New Continuation Revision
If Revision, check appropriate box(es).
Increase Award Decrease Award Other (specify)
Increase Duration Decrease Duration
If "Other", please specify:
5. **Title of Project:** Galveston County Auto Crimes Task Force
6. **Areas of Project Activities (Cities, Counties, States, etc.):** all of Galveston County; others upon request
Select a County: Brazoria County
Galveston County
Harris County
Matagorda County
7. **Proposed Project:**
Start Date: 9/1/2013
Ending Date: 8/31/2014
8. Is application subject to review by state executive order 12372 process?
YES, this application was made available to the Texas Review and Comment System (TRACS) for review on
Program is not covered by E. O. 12372
Program has not been selected by state for review
 NO
9. **Funding Summary:**
Total State Grant Funds Requested (ABPTA) \$649,268
Cash Match: \$319,947
In-Kind Match: \$11,320
Total: \$980,535
10. Is the applicant delinquent on any federal debt?
YES If "YES" attach an explanation NO
11. To the best of my knowledge and belief, all data in this application is true and correct. The document

has been duly authorized by the governing body of the applicant and the applicant will comply with the attached assurances if the assistance is awarded.

- a. **Authorized Official:** Mark Henry
- b. **Title:** County Judge
- c. **Telephone Number:** 4097662244
- d.
- e.

Item 1.

Does this assistance request require state, local, regional, or other priority rating?

Yes No

If "Yes" please complete

Name of Governing Body:

Priority Rating:

Item 2.

Does this assistance require state, or local advisory, education, or health clearance?

Yes No

If "Yes" please complete

Name of Agency or Board:

Item 3.

Does this assistance request require state, local, regional, or other planning approval? *

Yes No

If "Yes" please complete

Name of Approving Agency:

ABTPA

Item 4.

Will the assistance requested serve a federal installation?

Yes No

If "Yes" please complete

Name of Federal Installation:

Federal Population Benefiting from Project:

Item 5.

Will the assistance requested have an impact on the environment?

Yes No

Item 6.

Will the assistance requested cause the displacement of individuals, families, businesses or farms?

Yes No

If "Yes" please complete

Number of Individuals:

Families:

Businesses:

Farms:

Item 7.

Is there other related assistance on this project (previous, pending, or anticipated)?

Yes No

If "Yes" Explain:

Automobile Burglary & Theft Prevention Authority

Organization: Galveston County

2014-T01-Galvesto-00035

Version Date: 08/19/2013 16:21:47

Budget Summary

Budget Categories		ABTPA Funds	Cash Match	In-Kind Match	Total
A	Personnel (Salaries/Overtime)	\$413,779	\$60,435	\$0	\$474,214
A	Personnel (Fringe Benefits)	\$0	\$164,421	\$0	\$164,421
B	Contractual	\$0	\$0	\$8,820	\$8,820
C	Travel	\$10,000	\$2,000	\$0	\$12,000
D	Equipment	\$0	\$0	\$0	\$0
E	Supplies & Direct Operating Exp.	\$45,000	\$88,160	\$2,500	\$135,660
F	Indirect Costs	\$0	\$0	\$0	\$0
Totals (Sum of 7-8)		\$468,779	\$315,016	\$11,320	\$795,115

Source of Match	Amount
Galveston County	\$210,837
City of Galveston	\$31,941
City of La Marque	\$22,366
Source of Match Total	\$308,947

Program Income	Amount
To Be Utilized (Schedule C \$2000 and Schedule E \$9000)	\$11,000
Program Income Total	

Schedule	In Kind Match	Amount
A	None	\$0
B	Software/Hardware Maintenance \$4800 and Data Line Services \$4020	\$8,820
C	None	\$0
D	None	\$0
E	Office Supplies \$2500	\$2,500
	In Kind Match Total	\$11,320

Automobile Burglary & Theft Prevention Authority

Organization: Galveston County

2014-T01-Galvesto-00035

Version Date: 08/19/2013 16:21:47

Personnel: Project Director: GCSO Reserve

Title or Position	% of Salary	ABTPA Funds	Cash Match	In-Kind	Total
Project Director: GCSO Reserve	100%	\$0	\$5,000	\$0	\$5,000
Commander: GCSO	100%	\$58,849	\$0	\$0	\$58,849
Asst Commander: GCSO	100%	\$58,849	\$0	\$0	\$58,849
Agent: Galveston PD	100%	\$60,048	\$0	\$0	\$60,048
Agent: Santa Fe PD	100%	\$45,300	\$0	\$0	\$45,300
Agent : La Marq ue PD	100%	\$44,000	\$0	\$0	\$44,000
Agent: GC Constable, Pct 8	100%	\$42,690	\$0	\$0	\$42,690
Agent: GCSO	1000%	\$58,849	\$0	\$0	\$58,849
Agent: GCSO Environmental Office Manager / Analyst	20%	\$11,770	\$47,079	\$0	\$58,849
	80%	\$33,424	\$8,356	\$0	\$41,780
	%				\$0
	%				\$0
Total Direct Salaries		\$413,779	\$60,435	\$0	\$474,214
Total Requested Amounts					

Narrative

Project Director: Administrative and advisory position. The Project Director acts as a liaison between the Governing Board (Chiefs and Sheriff) and the Task Force. Maintains a line of communication with the Texas Automobile Burglary and Theft Prevention Authority Board and staff. Lt. Hansen's employment is part time and the match amount is based on the estimated amount of time he will spend in FY 2014 working for the Galveston County Auto Crimes Task Force. No portion of his salary will be funded by grant funds.

Unit Commander (Galveston County Sheriffs Office): The Unit Commander supervises the daily operations of the Task Force including strategy development and case assignment / review. The Commander maintains communication with the Governing Board, Project Director, Field Agents, and office personnel. The Unit Commander stays in contact with the County Auditor and Purchasing Agent to ensure compliance with the appropriate State and County regulations. The Commander provides both tactical and strategic analytical support to all Local, County, State, and Federal Agencies. In addition the Commander coordinates with the Office Manager/Analyst concerning appointments, travel, training, and monitoring of financial records. Attends and conducts Peace Officer Training and Public Awareness Programs as needed. Unit Commander is 100% assigned to Auto Crimes Task Force. (Gross Salary: \$58,849; ABTPA Funding: \$58,849)

Assistant Commander (Galveston County Sheriff's Office): Conduct investigations, both pro-active (self-initiated) and reactive as assigned by the Commander. Operate both overtly and covertly as deemed necessary by the Commander. Attend and conduct Peace Officer Training. Conduct public awareness programs as directed, serve as liaison to their home agency sharing and gathering information related to motor vehicle crimes. Assist all local, county, state, and federal agencies when requested to related Auto

Automobile Burglary & Theft Prevention Authority

Organization: Galveston County

2014-T01-Galvesto-00035

Version Date: 08/19/2013 16:21:47

Personnel: Project Director: GCSO Reserve

Crimes Task Force stated mission assignments. Assumes command in absence of Unit Commander. Assistant Commander is 100% assigned to Auto Crimes Task Force. (Gross Salary: \$58,849, ABTPA Funding: \$58,849)

Agents: The Agents conduct investigations, both pro-active (self-initiated) and reactive as assigned by the Commander. Agents operate both overtly and covertly as deemed necessary by the Commander. Agents attend and conduct Peace Officer Training. They will also conduct public awareness programs as directed, serve as liaison to their home agency sharing and gathering information related to motor vehicle crimes. Agents will also assist all local, county, state, and federal agencies when requested to related Auto Crimes Task Force stated mission assignments. Agents assigned are provided by: Galveston Police Department (Gross Salary: \$60,048, ABTPA Funding: \$60,048); Santa Fe Police Department (Gross Salary: \$45,300, ABTPA Funding: \$45,300); La Marque Police Depart (Gross Salary: \$44,000, ABTPA Funding: \$44,000); Galveston County Sheriff's Office (Gross Salary: \$58,849 ABTPA Funding: \$58,849); and Galveston County Precinct 8 Constables Office (Gross Salary: \$42,690, ABTPA Funding: \$42,690) These agents are 100% assigned to Auto Crimes Task Force. Their respective agencies pay for their benefits and maintain assigned vehicles. An Environmental Sheriff's Investigator assigned to Auto Crimes Task Force works 20% for Auto Crimes Task Force assisting in inspections (Gross Salary: \$58,849, ABTPA Funding: \$11,770).

Office Manager/Analyst: Manages Auto Crimes Task Force office by organizing files, paying bills, maintaining schedules, and performing intelligence analysis for Agents and other departments when requested. The Office Manager assists in monitoring the unit funds to ensure appropriate records of expenditures and assists the Commander and Project Director with appointments, travel, itineraries, training, and the monitoring of financial records. The Office Manager maintains an accurate ledger of all expenditures and schedule balances. Office Manager performs duties for Auto Crimes Task Force 80% of time; 20% of time Office Manager performs duties for Nuisance Abatement and Environmental Crimes. (Gross Salary: \$41,780; ABTPA Funding: \$33,424)

Nuisance Abatement Officer: This position is now a licensed Texas Peace Officer housed in the same building with Galveston County Auto Crimes. Primary assignment is Nuisance Abatement and may assist during salvage yard inspections and Criminal Investigations as needed. No funding from ABTPA.

Note 1: Salaries and benefits listed are based on existing salary/benefit scales and/or contractual agreements between governmental entities and employees with respect to the percentage of their time dedicated to Auto Crimes Task Force. Potential cost of living adjustments, step increases, and potential salary increases due to contract negotiations of the varying agencies are not included in the amounts estimated for FY 2014. Most agencies are anticipating large increases for the coming fiscal year.

Automobile Burglary & Theft Prevention Authority

Organization: Galveston County

2014-T01-Galvesto-00035

Version Date: 08/19/2013 16:21:47

Fringe/Overtime

Fringe Benefits	% or \$ Rate	ABTPA Funds	Cash Match	In-Kind	Total
Overtime		\$0			\$0
Total Overtime		\$0	\$0	\$0	\$0

No overtime allowed

Narrative

We will not be able to pay any overtime for FY2014

Note: Your Total ABTPA Funds for Fringe Benefits may only be a maximum of 25% of your Total ABTPA Direct Salaries.

Fringe Benefits	% or \$ Rate	ABTPA Funds	Cash Match	In-Kind	Total
FICA	3.2165	\$0	\$14,639	\$0	\$14,639
Retirement	16.8242	\$0	\$76,572	\$0	\$76,572
Insurance	10.8022	\$0	\$49,164	\$0	\$49,164
Other (Explain) See narrative for complete breakdown of estimated benefits	5.2834	\$0	\$24,046	\$0	\$24,046
Total Fringe Benefits		\$0	\$164,421	\$0	\$164,421
Total Fringe/Overtime Budget		\$0	\$164,421	\$0	\$164,421

Narrative

Benefits used as cash match were estimated using Fiscal Year 2013 County and City funds and do not reflect any anticipated increases which may take effect in FY 2014. These benefits include, but are not limited to, retirement, medical, incentive, unemployment, workman's compensation, supplemental death, alternate and/or Social Security, Medicare, longevity, uniform/clothing/equipment allowances. Each of the participating agencies has their own benefits packages and incentives and estimates are broken down as follows:

Commander (Galveston County Sheriff's Office): Calculated based on bi-weekly or monthly payroll deduction. Health Insurance - \$493/month ; Medicare/FICA - \$32.82/pay period; Pension -\$237/pay period; Alternate Plan (retirement) - \$199/pay period; Unemployment Insurance: \$11.09/pay period; Workers Compensation: \$100/month. Total estimated annually: \$19,593

Assistant Commander (Galveston County Sheriff's Office): Calculated based on bi-weekly or monthly payroll deduction. Health Insurance - \$493/month; Medicare/FICA - \$32.82/pay period; Pension -\$237/pay period; Alternate Plan (retirement) - \$199/pay period; Unemployment Insurance: \$11.09/pay period; Workers Compensation: \$100/month. Total estimated annually: \$19,593

Agent (Galveston Police Department): Calculated based on annual estimated benefits letter submitted for FY 2013 by Galveston Police Department. Certificate Pay - \$2,496; FICA Old - \$3928; FICA Medicare -

Automobile Burglary & Theft Prevention Authority

Organization: Galveston County

2014-T01-Galvesto-00035

Version Date: 08/19/2013 16:21:47

Fringe/Overtime

\$919; Workman's Comp - \$5,861; Pension -\$7,604; Health Insurance - \$3,705; Dental Insurance - \$288; Uniform Reimbursement - \$1,000. Total estimated annually: \$25,801

Agent (Santa Fe Police Department): Calculated based on averages of amounts listed on invoices submitted for FY 2013 thus far by Santa Fe Police Department. FICA /Medicare - \$654; Health Insurance - \$5,682; Cleaning Allowance - \$480; Longevity Pay - \$900; Retirement - \$5,537. Total estimated annually: \$13,253

Agent (La Marque Police Department): Calculated based on averages of amounts listed on invoices submitted for FY 2013 thus far by La Marque Police Department. FICA /Medicare - \$3,729; Health Insurance - \$4,446; Equipment/Cleaning - \$780; Certificate Pay - \$2,580; Retirement - \$4,691. Total estimated annually: \$16,226

Agent (Galveston County Constable, Pct 8): Calculated based on bi-weekly or monthly payroll deduction. Health Insurance - \$493/month ; Medicare/FICA - \$23.81/pay period; Pension -\$172/pay period; Alternate Plan (retirement) - \$144/pay period; Unemployment Insurance: \$8.05/pay period; Workers Compensation: \$100/month. Total estimated annually: \$16,160

Agent (Galveston County Sheriff's Office Environmental Crimes): Calculated based on bi-weekly or monthly payroll deduction. Health Insurance - \$493/mo ; Medicare/FICA - \$32.82/pay period; Pension -\$237/pay period; Alternate Plan (retirement) - \$199/pay period; Unemployment Insurance: \$11.09/pay period; Workers Compensation: \$100/mo. Total estimated annually: \$19,593

Office Manager/Analyst (Galveston County Sheriff's Office): Calculated based on bi-weekly or monthly payroll deduction. Health Insurance - \$493/month ; Medicare/FICA - \$23.22/pay period; Pension -\$168/pay period; Alternate Plan (retirement) - \$140/pay period; Unemployment Insurance: \$7.85/pay period; Workers Compensation: \$100/month. Total estimated annually: \$15,932

Agent (Open Position): Position open due to vacancy created by Hitchcock PD. It is currently unknown which agency will fill the vacancy and what benefits will be provided. However, all benefits will be used as a match, and numbers representing FICA, Retirement, Insurance, and Other Benefits were calculated by averaging the amounts currently matched by all the other participating agencies.

Upload additional information:

Grant Staff Only:

Check to disable 25% match error check.

Automobile Burglary & Theft Prevention Authority

Organization: Galveston County

2014-T01-Galvesto-00035

Version Date: 08/19/2013 16:21:47

Professional and Contractual Services: Software / Hardware Maintenance

Description of Service	ABTPA Funds	Cash Match	In-Kind Match	Total
Software / Hardware Maintenance	\$0	\$0	\$4,800	\$4,800
Data Line Services	\$0	\$0	\$4,020	\$4,020
			\$0	\$0
			\$0	\$0
			\$0	\$0
			\$0	\$0
Total Professional & Contractual Services	\$0	\$0	\$8,820	\$8,820

Briefly describe any anticipated contractual arrangement and work products expected.

Describe basis for arriving at the cost of each line item.

Professional services (such as consultants, trainers, counselors, evaluators, etc.)

should be described by type of service, number of hours, rate per hour, and travel costs.

A. Software / Hardware Maintenance **In-Kind match using Fiscal Year 2014 County Funds **

Auto Crimes Task Force maintains a local area network consisting of a server, workstations, and network printers to facilitate its operations and record keeping, multiple software packages, FAX/Modem operations, access to Texas Crime Information Center and access to the County of Galveston mainframe via connection to the County of Galveston county wide area network. The Galveston County Auto Crimes Task Force utilizes the OSSI multi-jurisdictional records management and mobile data systems. Direct and immediate access to appropriate technical and maintenance assistance is paramount in an investigative / intelligence based unit such as the Auto Crimes Task Force. Information concerning upgrades to hardware, software, and services are critical. The Galveston County Information Technology department will assist in a time of crisis or hardware failure and immediately send us a replacement until that piece of equipment is repaired.

B. Data Line Service: **In-Kind match using Fiscal Year 2014 County Funds **

Auto Crimes Task Force is connected to the County's Wide Area Network via high speed data line from our office in League City to the Galveston County Court House located in Galveston. This line provides a vital link allowing access to the jail information management system, warrant information, County and District Clerk, and financial management information system of Galveston County. Internet access is attainable for research. An Auto Crimes Task Force web site is maintained for information on vehicle thefts, prevention and other services provided by Auto Crimes Task Force is available on line at www.co.galveston.tx.us/actf. The Galveston County Auto Crimes Task Force also maintains a FACEBOOK page.

This line also provides our link to telephone service through the Galveston County Switchboard reducing our long distance costs substantially, thus removing base telephone service entirely.

Upload additional information:

Automobile Burglary & Theft Prevention Authority

Organization: Galveston County

2014-T01-Galvesto-00035

Version Date: 08/19/2013 16:21:47

Travel

✓ We are following our City / County Travel Policy

In-State Travel

Purpose	Destination	ABTPA Funds	Cash Match	In-Kind Match	Total
ABTPA Meetings / Conference	TBA	\$3,840	\$0	\$0	\$3,840
TAVTI	Houston	\$1,700	\$0	\$0	\$1,700
Southwest NATIA	San Antonio	\$570	\$0	\$0	\$570
DPS Auto Theft Training	Austin	\$890	\$0	\$0	\$890
IAATI	Fort Worth	\$2,000	\$2,000	\$0	\$4,000
		\$0	\$0	\$0	\$0
		\$0	\$0	\$0	\$0
		\$0	\$0	\$0	\$0
In-State Travel Total		\$9,000	\$2,000	\$0	\$11,000

Out-of-State Travel

Purpose	Destination	ABTPA Funds	Cash Match	In-Kind Match	Total
		\$0	\$0	\$0	\$0
NAEC	TBA	\$1,000	\$0	\$0	\$1,000
		\$0	\$0	\$0	\$0
Out-of-State Travel Total		\$1,000	\$0	\$0	\$1,000

Total Travel Budget	\$10,000	\$2,000	\$0	\$12,000
----------------------------	-----------------	----------------	------------	-----------------

Briefly describe the applicant's travel policy (i.e., mileage rates and per diem rates). Specify Purposes for each item of travel. Break out costs of each in-state and each out-of-state trip to separately show the specific costs of transportation and per diem.

A copy of the Travel Policy for Galveston County is attached. County employees will utilize the most economical and effective means of transportation, housing and meals that are available. When evaluating travel costs, it is important to include employee costs. That is, savings from inexpensive travel agenda can more than be offset by excessive travel time that keeps the employee away from normal County duties. Saving a few dollars on airline tickets is not warranted if the employee must leave a day early and the cost of the employee's salary for that day exceeds the airline ticket savings. Nevertheless, whenever justifiable employees will utilize transportation that is the most economical in total trip cost. Hotel shuttles are preferred over taxis and taxis are preferred over rental cars, etc. The current per diem rate for the county is \$45 per day and the mileage rate is \$.555 per mile.

**ABTPA Funds for Fiscal Year 2014- \$10,000 **

** Program Income Funds for FY 2014 - \$2,000 **

Automobile Burglary & Theft Prevention Authority

Organization: Galveston County

2014-T01-Galvesto-00035

Version Date: 08/19/2013 16:21:47

Travel

Investigative: Investigations will likely necessitate both In-State and Out of State travel during the fiscal year. They include participation in Operation Gate / Spider Web type projects as they develop, assisting other projects or following investigative leads.

Training: The travel expenses listed for training will be to attend the following schools and other as yet to be announced training schools to expand the level of training and knowledge of the agents assigned to Auto Crimes Task Force.

a. Texas Automobile Burglary & Theft Prevention Authority: Quarterly meetings, annual meetings and any Texas Automobile Theft Prevention Authority sponsored event or meeting.

Meetings: 2 people x \$45/day per Diem x 2 days x 3 meetings = \$ 540
2 hotel rooms x 2 days x \$100/night x 3 meetings= \$1200
Conference: 4 people x \$45/day per diem x 5 days= \$ 900
3 hotel rooms x 4 days x \$100/night= \$1200
Total: \$3,840.00

b. Texas Association of Auto Theft Investigators (TAVTI): South Regional Chapter of Texas Association of Auto Theft Investigators will conduct its annual seminar providing training, intelligence sharing and investigative contacts.

4 people x \$45/day per diem x 5 days= \$ 900
2 hotel rooms x 4 days x \$100/night= \$ 800
Total: \$1,700.00

c. Southwest Technical Investigators: Auto Crimes Task Force sends two agents to this school. The school/conference updates and shows new technology in surveillance technology.

2 people x \$45/day per diem x 3 days= \$270
1 hotel room x 3 days x \$100/night= \$300
Total: \$570.00

d. Advanced and Specialized Auto Theft: Auto Crimes Task Force anticipates a change of two personnel from the participating agencies due to normal rotation. New agents are sent to the schools held by Texas Department of Public Safety.

2 people x \$45/day per diem x 5 days= \$450
1 hotel room x 5 days x \$88/night= \$440
Total: \$890.00

e. International Association of Auto Theft Investigators (IAATI): IAATI will conduct its annual seminar providing training, intelligence sharing and investigative contacts.

** FY 2014 Program Income Funds - \$2,000 **

**ABTPA Funds for Fiscal Year 2014- \$2,000 **

Automobile Burglary & Theft Prevention Authority

Organization: Galveston County

2014-T01-Galvesto-00035

Version Date: 08/19/2013 16:21:47

Travel

4 people x \$45/day per diem x 9 days= \$ 1,620

2 hotel rooms x 8 days x \$149/night= \$ 2,380

Total: \$4,000.00

f. North American Export Committee: Project Director will represent the Auto Crimes Task Force and ABTPA at the North American Export Committee meetings. Port inspections have become a major focus of the committee meetings due to homeland security. The task force has a vested interest in new trends involving importing/exporting stolen vehicles as we perform port inspections for the coastal area.

****ABTPA Funds for Fiscal Year 2014- \$1,000 ****

Total: \$1,000

Upload additional information:

https://www.dmv.state.tx.us/apps/intelligrants_TXATP/_Upload/8540-GalvestonCountyTravelPolicyFY2014.pdf

Automobile Burglary & Theft Prevention Authority

Organization: Galveston County

2014-T01-Galvesto-00035

Version Date: 08/19/2013 16:21:47

Supplies and DOE: (a) Fuel (match includes all agencies)

maintenance provided by each participating agency for 8 agent's vehicles used as cash match is estimated at \$2500/year for each.

(C) Wireless Communications **ABTPA Funds for Fiscal Year 2014 - \$18,600**

This year Galveston County Auto Crimes Task Force would like to combine two previous line items (Cellular Phones and Aircards) to one account to cover all wireless phone/data lines. Cellular telephones are used by Auto Crimes Task Force agents to support field activities, sharing information and requesting analytical assistance. With the use of cellular telephones we are able to contact and share information or request assistance from multiple agencies, local, state and federal, instantly, unlike a radio that may not have radio contact/frequencies or are out of radio range. Our current provider is Verizon and our projected annual cost is \$12,748 which includes cellular data links in 2 bait vehicles and other data links for our LPR and tracking units to operate our GPS system. GCACTF maintains two IP video cameras which are used for surveillance. This system utilizes two air cards. We will continue to use air cards (cellular data link) with our mobile laptop computers to allow Auto Crimes Task Force agents to function in the field as in the office by sending and receiving data related to identifying motor vehicles, suspects, or relaying information in surveillance situations in a timely and secure method. This service is currently provided by Sprint and costs approximately \$436/month for a total of \$5,232 annually. Finally, we have one data line through AT&T at a cost of \$51.66/month, total of \$620 annually, which is necessary for our 980 GPS tracker. Some of the various surveillance equipment is proprietary to particular service providers so we will continue to have separate providers for FY 2014.

(D) Departmental (expendable) Supplies **ABTPA Funds for Fiscal Year 2014- \$2,500 **

This category deals with replacement of cleaners (degreasers), damaged hand tools, and many other items used by Auto Crimes Task Force Agents in the course of their assigned duties.

(E) Registration Fees **ABTPA Funds for Fiscal Year 2014 - \$2,100 **

Each of the below listed schools are discussed under Schedule C – travel in detail. Additional training seminars may become available, both in Texas and in neighboring states that provide valuable information, expertise and contacts to the attending agents.

Texas Automobile Prevention Authority & Conference: Date: TBA 2012 - 2013 \$0/person \$ 00

Texas Association of Vehicle Theft Investigators: Date: October 2013

\$150/person x 4 people \$ 600.00

Southwest Technical Investigators: Date: February 2014

\$50/person x 2 people \$100.00

Advanced and Specialized Auto Theft: Date: TBA 2012 - 2014

\$0/person \$0.00

International Association of Auto Theft Investigators: Date: August 2014

\$300/person X 4 people \$1200.00

North American Export Committee: Date: TBA 2014

\$200/person x 1 person \$200.00

Automobile Burglary & Theft Prevention Authority

Organization: Galveston County

2014-T01-Galvesto-00035

Version Date: 08/19/2013 16:21:47

Supplies and DOE: (a) Fuel (match includes all agencies)

(F) Crime Prevention Supplies **ABTPA Funds for Fiscal Year 2014 - \$3,000 **

** Cash match using Fiscal Year 2014 Program Income Funds - \$3,000 **

Crime prevention give-aways are used to deliver the message and philosophy of Automobile Burglary and Theft Prevention Authority and Auto Crimes Task Force during crime prevention programs and presentations. The items will be embossed with the Texas Automobile Burglary and Theft Prevention Authority logo along with Auto Crimes Task Force identifiers. The give-aways may consist of pencils, koozies, notepads, fans, pens, and hats to name a few as well as all Texas Automobile Burglary and Theft Prevention Authority literature. These funds will also be used to purchase supplies such as VIN etching stencil refills and etching cream. Work clothes will be purchased utilizing Program Income funds.

(G) Office Supplies ** In-Kind match using Fiscal Year 2014 County Funds **

**ABTPA Funds for Fiscal Year 2014 - \$3,000 **

Routine desktop supplies, computer paper, fax paper, batteries for electronics, audio/videotapes, and blank CD's/DVD's, etc. These items will be utilized to assist the agents and office manager to perform their work efficiently and professionally. Estimated cost for office supplies has increased to approximately \$3,000 due to accommodate more expensive printer cartridges for agent's printer, which was provided by the County. Galveston County Information Technology will support and maintain the black and white laser printers and provide ink cartridges.

(H) Building Maintenance ** ABTPA Funds for Fiscal Year 2014 - \$0**

Galveston County provides building maintenance and facility support such as lawn care, custodial services and air-conditioning/heating.

(I) Evidence Towing **ABTPA Funds for Fiscal Year 2014 - \$500 **

Auto Crimes Task Force has a car hauler that we utilize for most recoveries, however, some circumstances, such as fully stripped vehicles with no tires, necessitate the use of a contract wrecker service. It is estimated that these instances should not exceed \$500.00 in towing fees.

(J) Service Contracts **ABTPA Funds for Fiscal Year 2014 - \$8,300 **

Auto Crimes Task Force maintains service contracts with Vigilant Video, Susteen and Bender Enterprises for continued services to our technical equipment. We will have an annual renewal with Vigilant Video of \$2,500 for upgrades to the existing License Plate Reader system and continued access to the LEARN data servers. Additionally, NVLS Tier I access (originally provided for 2 years with purchase) will be expiring. The annual renewal for access to this data will be \$5,000 beginning in FY 2014. We will renew our contract with Susteen, \$800 annually for upgrades to the Cellular Phone Data Retrieval system which provides continued additions for the retrieval of data from new models by all makers of cell phones.

(K) Radio Maintenance **Cash match using Fiscal Year 2014 Program Income Funds **

These funds provide for replacement of antennas, reprogramming expenses, and service fees associated with the maintenance of the 800 MHz Trunk Radio System and mobile data computers. Estimated maintenance costs are \$3500.00. The County is operating in the Smart Zone and has finalized the upgrade in Fiscal Year 2012.

Automobile Burglary & Theft Prevention Authority

Organization: Galveston County

2014-T01-Galvesto-00035

Version Date: 08/19/2013 16:21:47

Supplies and DOE: (a) Fuel (match includes all agencies)

(L) Confidential Funds ** Cash match using Fiscal Year 2014 Program Income Funds **

This money is used for the payment of confidential informants, purchase of stolen property during covert operations and to cover expenses incurred by agents working covert operations. These funds will be utilized from our program income account.

(M) Utilities ** Cash match using Fiscal Year 2014 County Funds **

Galveston County will maintain utility services (electrical, water, sewer, garbage disposal, etc...) for the Auto Crimes Task Force.

(N) Building Alarm Service ** Cash match using Fiscal Year 2014 County Funds **

This is a 24-hour monitoring and call-out service for our office building and storage/inspection garage. Galveston County provides all fees and costs of the system for Auto Crimes Task Force.

Upload additional information:

Automobile Burglary & Theft Prevention Authority

Organization: Galveston County

2014-T01-Galvesto-00035

Version Date: 08/19/2013 16:21:47

Indirect Cost

	ABTPA Funds	Cash Match	In-Kind Match	Total
Indirect Costs				\$0
Total Indirect Costs				\$0

Currently ABTPA does not fund indirect costs, except for the Council of Government agencies. Applicants may not use option (A) without having an official cost allocation plan developed in accordance with OMB Circular No. A-87. The amount may be entered as ABTPA funds or cash match for those applicants having such an approved plan.

Automobile Burglary & Theft Prevention Authority

Organization: Galveston County

2014-T01-Galvesto-00035

Version Date: 08/19/2013 16:21:47

Problem Statement & Historical Information

- a. Provide an assessment of the auto theft and burglary problem in the areas of coverage and existing activities that address the problem. Identify the target population and the geographical target area.

Since 1993, the GCACTF has provided full service to Galveston County (pop. 291,309 per 2010 Census). Additionally, Brazoria, Southern Harris and Matagorda counties have been serviced on a request basis. Recently there has been an increase in requests from Brazoria County agencies. In 2011, we saw a 72% reduction in auto theft from 1991. GCACTF was tasked with Burglaries to Motor Vehicles in 2007. Since, there has been an almost 16% reduction in BMV's. These reductions are attributed to increased public awareness, pro-active LPR patrols, surveillance and bait vehicle operations. Joining forces with Texas DMV Regional investigators and state and local law enforcement agencies has helped significantly. Providing local law enforcement training has also assisted in the decline of vehicle theft and burglary. Despite the reduction, Galveston County has experienced an increase in incidences of violence associated with motor vehicle crimes. Much of this is due to increased gang activity throughout the region.

- b. Describe the extent to which this project will duplicate or overlap existing activities, and why that (if any) is necessary.

None

- c. Describe and document trends of the problem and the need that makes this grant necessary.

Galveston County's tourism industry includes multiple cruise lines, entertainment venues, proximity to the beach and the Houston Metropolitan area. The Ports of Galveston and Freeport are in the program area as well and export vehicles and accessories all over the world. The north end of Galveston County continues to grow rapidly. A new outlet shopping mall opened in Texas City in 2012. The City of League City also has new shopping and entertainment venues that have opened in the past year. As long as Galveston County continues to grow and remains a hub for travelers, there will continue to be an increased risk for vehicle thefts and burglaries. With the downturn in the economy and increased fuel costs, Galveston County now ranks in the top five travel destination in the State of Texas.

- d. Using the spreadsheet below, provide accurate statistical data for problem in project area. (e.g. cite 3 years of UCR data) Please provide all data that is available for your agency or agencies:

Vehicle Theft Data	Year 1	Year 2	Year 3
	2009	2010	2011
Number of Stolen Vehicles	648	617	479
Number of Recovered Vehicles	174	142	126
Number of Arrests	179	149	103

Automobile Burglary & Theft Prevention Authority

Organization: Galveston County

2014-T01-Galvesto-00035

Version Date: 08/19/2013 16:21:47

Problem Statement & Historical Information

Number of Auto Theft Training Classes	6	12	5
Number of (other)			

Theft from a Motor Vehicle Data	Year 1	Year 2	Year 3
	2009	2010	2011
Number of Burglaries of a Vehicle	2497	2644	2060
Number of Recovered Items	23	40	34
Number of Arrests	23	21	13
Number of (other) value of property recovered (in whole dollars)	40000	7750	35249
Number of (other)			

Other Motor Vehicle Crimes	Year 1	Year 2	Year 3
	2009	2010	2011
68A Inspections	70	97	145
Salvage Inspections	6	12	11
Number of Stolen Vehicle Inquiries	156	128	202
Number of (other)			

Automobile Burglary & Theft Prevention Authority

Organization: Galveston County

2014-T01-Galvesto-00035

Version Date: 08/19/2013 16:21:47

Proposed Objectives

a. Select the standard goal and describe the specific objectives of the project. Include any quantifiable data by which activities measure.

Auto Theft Goal

GOAL 1: REDUCE THE INCIDENT OF MOTOR VEHICLE THEFT.

OB1: (06) Initiate keys left in vehicle operations.

OB2: (15) Initiate Bait Vehicle operations.

OB3: (50) Conduct field operations utilizing LPR

Auto Burglary Goal

GOAL 2: REDUCE THE INCIDENT OF THEFT FROM A MOTOR VEHICLE.

OB1: (15) Initiate Bait Vehicle operations.

OB2: (06) Surveillance operations during high traffic (parking lot) events I.E. Mardi Gras, Dickens on the Strand, Bike Rally, Black Friday and Spring Break.

OB3: (04) Meet with Apartment and Neighborhood associations to promote Lock, Take and Hide

Public Awareness Goal

GOAL 3: PUBLIC AWARENESS METHODS USED TO EDUCATE THE CITIZENS OF TEXAS AND TRAINING OF QUALIFIED PERSONNEL IN THE DETECTION AND PREVENTION OF AUTO BURGLARY & THEFT.

OB1: (20) Work Public Awareness events

OB2: (25) Display Promotional Vehicle – trailer, truck and Crime Prevention Trailer.

OB3: (02) Train Crime Prevention Officers and Citizen Academy Associations on Auto Theft and Burglary prevention methods.

Grantee Goals

GOAL 4: HELP INCREASE THE RECOVERY RATE OF STOLEN MOTOR VEHICLES.

OB1: (50) Inspect vehicles – 68 A inspections and Salvage Yards / Vehicle Storage Facilities (VSF)

OB2: (50) Utilize LPR

OB3: (06) Conduct shift briefing sessions with Patrol Supervisors throughout the county.

Grantee Goals

GOAL 5: THE NUMBER OF PERSONS ARRESTED FROM MOTOR VEHICLE THEFT.

OB1: (15) Conduct Bait Vehicle Operations

OB2: (25) Conduct proactive / re – active field operations

OB3: (50) Utilize LPR

Grantee Goals

GOAL 6: THE CLEARANCE RATE OF MOTOR VEHICLE THEFTS.

Automobile Burglary & Theft Prevention Authority

Organization: Galveston County

2014-T01-Galvesto-00035

Version Date: 08/19/2013 16:21:47

Proposed Objectives

OB1: (20) Theft and recovery status verification and update.

OB2: (15) File Auto Theft cases

OB3: (10) Review unsolved local stolen reports to verify status – non referral.

Grantee Goals

GOAL 7: PREVENT THE INCIDENT OF FRAUDULENT TITLES AND REGISTRATION OF STOLEN VEHICLES.

OB1: (50) Inspect vehicles 68 A and Salvage Yards

OB2: (20) Work Public Awareness events

OB3: (05) Strategic planning with Texas DMV Investigators and Regional Tax Offices(Galveston and Brazoria Counties).

Grantee Goals

GOAL 8: REDUCE THE INCIDENT OF AUTOMOBILE INSURANCE FRAUD.

OB1: (02) Conduct Briefings to educate Law Enforcement Personnel on signs of Insurance Fraud.

OB2: (06) Conduct suspected Insurance Fraud / False Report investigations.

OB3: (04) Collaborate with NICB on quarterly basis.

OB4: (04) Increase interaction with Insurance SIU groups.

b. Describe how the project will impact the stated problem.

Although our project area has been historically successful, we have to adapt to changing trends in our coverage area. There are 2 target areas in the county that have seen dramatic changes which we intend to address. The north end of Galveston County and eastern Brazoria County are ever-growing in population and retail business creating a target rich environment. The tourist industry in the southern part of Galveston County has seen record increases since the decline of the economy. Both of these areas have seen increases in the incidences of violence associated with motor vehicle crimes.

Through increased communication with law enforcement agencies and interaction directly with citizens and civic groups, along with increased visibility through the LPR and crime prevention displays, we hope to continue to see reductions in the numbers of motor vehicle thefts and burglaries. The proposed additions of increased crime prevention and education activities should have a positive impact on the changing trends as well.

c. Describe proposed plan for auto theft crime prevention, education and training.

Pro-active and re-active enforcement has always, and will always be an important part of our project. However, the changing trends in our area dictate that we must place a higher priority on crime prevention education and training initiatives to include:

- Operations targeting vehicles left with keys in them
- Apartments and neighborhood watch associations, home owners associations, etc
- Citizens police and sheriffs academy associations

Automobile Burglary & Theft Prevention Authority

Organization: Galveston County

2014-T01-Galvesto-00035

Version Date: 08/19/2013 16:21:47

Proposed Objectives

- Increased communications and training of crime prevention and patrol officers
- Increased visibility through ACTF/ABTPA display vehicles

Automobile Burglary & Theft Prevention Authority

Organization: Galveston County

2014-T01-Galvesto-00035

Version Date: 08/19/2013 16:21:47

Functions Of Proposed Project

The functions of the project should:

Identify the service needs to be met by the project and the applicant's experience or qualifications.

Describe how this project will cooperate/coordinate activities with other appropriate agencies/projects.

Describe in what way (if any) is this project innovative and what methods taken to assure that the project demonstrates cross-cultural awareness in all project activities and in its staffing and training.

Since 1993 the GCACTF has continually thought outside the box to enact new and innovative programs to combat motor vehicle theft and burglary. Currently, GCACTF agents are specially trained in vehicle fire investigations, cellular phone examinations, and standard and electronic surveillance measures in addition to traditional auto theft and burglary investigation methods.

All operations and services are provided to all law enforcement agencies in Galveston County as well as the counties serviced on a request basis.

The applicant's experience originated before the first task force was ever formed. The ABTPA concept originated in Galveston County and we were one of the first projects in 1993.

The GCACTF was the first to have a stripped vehicle display; crime prevention trailer; to integrate environmental crimes into auto theft; and hosted 4 grantee conferences. The GCACTF has also hosted three International Law Enforcement Conferences.

GCACTF was one of the first programs to initiate bait vehicle operations and has one of the most active LPR programs.

The GCACTF has continued to produce statistics comparable to much larger areas. GCACTF has remained innovative and vigilant in the legislative process.

Evaluation Design

The program evaluation should indicate how the applicant will assess the success of the project and the extent to which the strategy achieved the project's goals and objectives.

a. Describe the design of a plan for local evaluation of this project.

- goals and objectives to be evaluated monthly,
- design and implement an in-house long term calendar to tentatively schedule operations, crime prevention activities, and special projects outlined in our grant objectives
- utilize monthly report as a measuring stick to evaluate the status of our goals to allow for adjustment of objectives if needed

b. Cite relevant data that will be used to measure the effectiveness of this project.

The obvious measurable data that will evaluate our effectiveness include UCR statistics, local theft, recovery, and arrest statistics, and the values of recovered properties. However, the ultimate compliment to our program is receiving repeated calls requesting assistance from law enforcement agencies worldwide, prosecuting agencies, other government departments/agencies, and the community. We will continue to document these on our monthly progress reports.

c. Describe the mechanism to evaluate the programs progress.

The GCACTF will continue to document vehicle theft and burglary statistics in an excel spreadsheet that allows for easy and quick identification of statistical trends and comparisons to previous periods and/or locations.

Automobile Burglary & Theft Prevention Authority

Organization: Galveston County

2014-T01-Galvesto-00035

Version Date: 08/19/2013 16:21:47

Designation of Grant Officials

Project Title: Galveston County Auto Crimes Task Force
Organization Name Galveston County
Address 1620 Gill Road
Galveston, TX 77539
Phone: (409) 766-4517
Fax: (409) 766-4510
Federal Tax ID 17460009081033
ABTPA Funds Requested \$649,268
New Continuation

Project Director

Prefix Lt First Name: Tommy Last Name: Hansen
Title Lieutenant, Galveston County Sheriff's Office Business Address: 601
54th St, #2104
City Galveston State: Texas Zip: 77551
Phone 4097662358 Fax: 4097662600
E-Mail: Tommy.Hansen@co.galveston.tx.us
Alternate Signature Name Danny Sheppard
Phone 4097664507

Project Manager

Prefix Sgt First Name: Danny Last Name: Sheppard
Title Sergeant, Galveston County Sheriff's Office Business Address 1620 Gill
Rd
City Dickinson State Texas Zip 77539
Phone 4097664507 Fax: 4097664510
E-Mail: Sheppard.Danny@co.galveston.tx.us
Alternate Signature Name Hal Barrow
Phone 4097664501

Financial Officer

Prefix Mr First Name Jeff Last Name Modzelewski
Title First Asst in Charge, Director of Accounting Business Address 722
Moody, 4th Floor
City Galveston State Texas Zip 77550
Phone 4097705328 Fax 4097664583
E-Mail Jeff.Modzelewski@co.galveston.tx.us
Alternate Signature Name Jocelyn Paz
Phone 4097705324

Authorized Official

Prefix Honorable First Name Mark Last Name Henry
Title County Judge, County of Galveston Business Address 722 Moody, 2nd
Floor
City Galveston State Texas Zip 77550

Automobile Burglary & Theft Prevention Authority

Organization: Galveston County

2014-T01-Galvesto-00035

Version Date: 08/19/2013 16:21:47

Designation of Grant Officials

Phone

4097662244 Fax 4097664590 E-Mail Mark.Henry@co.galveston.tx.us

Alternate Signature

Name Ryan Dennard

Phone 4097705474

Automobile Burglary & Theft Prevention Authority

Organization: Galveston County

2014-T01-Galvesto-00035

Version Date: 08/19/2013 16:21:47

Americans w/ Disabilities Act (ADA)

The Grantee hereby assures and certifies compliance with Subchapter II, Part A of the Americans with Disabilities Act (ADA), 42 U.S.C., Sections 12131-12134, and Department of Justice ADA regulations, 28 CFR Part 35.

✓ I have read and understood the instructions provided.

Automobile Burglary & Theft Prevention Authority

Organization: Galveston County

2014-T01-Galvesto-00035

Version Date: 08/19/2013 16:21:47

Non-Supplanting Certification

I certify that the programs proposed in this application meet all the requirements of the Texas Civil Statutes, Article 4413(32a), §6(a)(7), (a) Texas Civil Statutes, Article 4413(32a), §6(a)(7), requires that state funds provided by this Act shall not be used to supplant state or local funds. Public Law 98-473 requires that federal funds provided by that Act shall not be used to supplant state or local funds.

I further certify that ABTPA funds have not been used to replace state or local funds that would have been available in the absence of ABTPA funds. The certification shall be incorporated in each grantee's report of expenditure and status of funds referred to under §57.3(6) of this title (relating to Adoption by Reference).

✓ I have read and understood the instructions provided.

Automobile Burglary & Theft Prevention Authority

Organization: Galveston County

2014-T01-Galvesto-00035

Version Date: 08/19/2013 16:21:47

Compliances

The attached digest of your grant application represents the Automobile Burglary & Theft Prevention Authority Board's approved amount. The digest represents budgeted amounts only and does not approve any items that conflict with the participating agency's personnel, procurement, travel, or local government code policies and procedures.

The grantee will be responsible in determining that the following requirements are being met prior to the release of funds:

1. Salaries are in accordance with local policy of the participating agencies.
2. Personnel are classified in accordance with the needed qualification for the position.
3. Fringe Benefits are in accordance with local policy of the participating agencies.
4. Travel Policy is in accordance with the travel policy of the participating agencies.

✓ I have read and understand the instructions provided.

Automobile Burglary & Theft Prevention Authority

Organization: Galveston County

2014-T01-Galvesto-00035

Version Date: 08/19/2013 16:21:47

Equal Employment Opportunities (EEO)

Agencies that employ fewer than 50 people are not required to file an equal opportunity program in accordance with 28 CFR 42.301 etseq., Subpart E.

Agencies that employ 50 or more people and has received or applied to the Automobile Burglary & Theft Prevention Authority for total funds in excess of \$25.000 are considered to have formulated an equal employment opportunity program in accordance with 28 CFR 42.301 et seq.

This agency employs fewer than 50 people.

✓ No Yes

If yes above, please provide the office of record.

Name

Title

Address

City

State

Zip Code

Automobile Burglary & Theft Prevention Authority

Organization: Galveston County

2014-T01-Galvesto-00035

Version Date: 08/19/2013 16:21:47

Assurances

ASSURANCES CERTIFICATION

I certify that the programs proposed in this application meet all the requirements of the Texas Automobile Burglary & Theft Prevention Authority Program, that all the information presented is correct, and that the applicant will comply with the provisions of the Automobile Burglary & Theft Prevent Authority and all other federal and state laws, regulations, and guidelines. By appropriate language incorporated in each grant, subgrant, or other document under which funds are to be disbursed, the undersigned shall assure that the applicable conditions above apply to all recipients of assistance.

✓ I have read and understand the instructions provided.

Automobile Burglary & Theft Prevention Authority

Organization: Galveston County

2014-T01-Galvesto-00035

Version Date: 08/19/2013 16:21:47

Independent Annual Audit Certification

The grantee assures compliance by itself and its applicable sub-recipients (contractors) with the Single Audit Act Amendments of 1996, P.L. 104 - 156 and, particularly, with the requirements of OMB Circular A-133 as follows (check one):

1. Grant(s) expenditures of \$300,000 or more in federal funds-
An annual single audit by an independent auditor made in accordance with the Single Audit Act Amendments of 1996 and OMB Circular A-133.
- ✓ 2. Grant(s) expenditures of \$300,000 or more in state funds-
An annual single audit by an independent auditor made in accordance with the Uniform Grant and Contract Management Standards (UGCMS).
3. Grant(s) expenditures of less than \$300,000 in federal funds-
Exempt from the Single Audit Act. However, ABTPA may require a limited scope audit as defined in OMB Circular A-133.
4. Grant(s) expenditures less than \$300,000 but \$50,000 or more in state funds. A
program-specific audit.
5. Grant(s) expenditures less than a total of \$50,000 in state funds-
Financial Statements audited in accordance with Generally Accepted Audited Standards (GAAS).

NOTE: Grantees exempt from the Single Audit Act requirements (i.e. those expending less than \$300,000 in total federal financial assistance) are prohibited from charging the cost of a Single Audit to a Federal award.

Regardless of items checked above, the grantee should, within 60 days following the date of the grant award, furnish the following information:

1. The identity of the organization conducting the audit.
2. Approximate time audit will be conducted.
3. Audit coverage to be provided.

Automobile Burglary & Theft Prevention Authority

Organization: Galveston County

2014-T01-Galvesto-00035

Version Date: 08/19/2013 16:21:47

Award Packet

Amount Awarded		\$0			
	Budget Categories	ABTPA Funds	Cash Match	In-Kind Match	Total
A	Personnel (Salaries/Overtime)	\$413,779	\$60,435	\$0	\$474,214
A	Personnel (Fringe Benefits)	\$0	\$164,421	\$0	\$164,421
B	Contractual	\$0	\$0	\$8,820	\$8,820
C	Travel	\$10,000	\$2,000	\$0	\$12,000
D	Equipment	\$0	\$0	\$0	\$0
E	Supplies & Direct Operating Exp.	\$45,000	\$88,160	\$2,500	\$135,660
F	Indirect Costs	\$0	\$0	\$0	\$0
	Totals	\$468,779	\$315,016	\$11,320	\$795,115

Grant Agreement/Award Binder

AGENDA ITEM #6.a.


Special Condition

COOPERATIVE WORKING AGREEMENT


This is to certify that the objectives of the Galveston County Auto Crimes Task Force grant application for fiscal year **2014** funding by the Automobile Theft Prevention Authority have been reviewed and that it is mutually agreed to cooperate to whatever extent is necessary in carrying out the work plan described in that application.

Additionally, the City of Galveston is cognizant of the rules and regulations governing the operation of the grant and agrees to abide by any and all such rules or special conditions relating to the application.

Signed:


Tommy Hansen, Project Director
Galveston County Auto Crimes Task Force
(name of applicant organization or its contractor who operates the program)

Signed:


Henry Porretto, Chief of Police
City of Galveston
(name of external organization)

Date:

6/4/13

INTERAGENCY AGREEMENT

STATE OF TEXAS

COUNTY OF GALVESTON

This **Agreement** is entered into by and between the County of Galveston, a political subdivision of the State of Texas, hereinafter referred to as “**County**”, and the City of Galveston, a municipal corporation situated in Galveston County, Texas, hereinafter called “**City**”, pursuant to the Interlocal Cooperation Act, Texas Government Code, Chapter 791.

WITNESSETH

WHEREAS, the County of Galveston and City of Galveston wish to file a joint grant application with the Automobile Theft Prevention Authority of the State of Texas, for funding in the amount of \$649,268 for the Galveston County Auto Crimes Task Force, and

WHEREAS, the County and City have agreed to contribute the total of \$254,098 in matching funds if said joint application is approved; and

WHEREAS, the source of funds would not normally be used for this purpose; and each party making payments under this Agreement shall make payments from current revenues available to it; and

WHEREAS, the County and City believe it to be in their best interests to join in the application to develop an Auto Crimes Task Force.

WHEREAS, the County and City agree to each accept the responsibility to adhere to all pertinent federal, state, and local laws or regulations.

NOW THEREFORE, IT IS HEREBY AGREED AS FOLLOWS:

ARTICLE I

PURPOSE

1.2 The purpose of this **Agreement** is to allow County and City to file joint application for a Grant, with the Automobile Theft Prevention Authority, which creates The Galveston County Auto Crimes Task Force which application is attached hereto as **Exhibit "A"** and made a part hereof for all purposes.

ARTICLE II

TERM

2.01 The term of this **Agreement** is to commence on the execution of this **Agreement** and to end August 31, 2014.

ARTICLE III

CONSIDERATION

3.01 As consideration for this agreement, County and City agree to contribute a total of \$254,098 in matching funds for the enhancement of the Galveston County Auto Crimes Task Force in the amount as follows:

<u>County</u>	Cash Match <u>\$210,837</u>	In-Kind Match <u>\$11,320</u>
<u>City</u>	Cash Match <u>\$31,941</u>	In-Kind Match <u>\$0</u>

ARTICLE IV
ALLOCATION OF FUNDS

4.1 The specific allocation of the County and City fund is set out in the attachments to this agreement, marked as **Exhibit “A”** and made a part hereof for all purposes.

ARTICLE V
OWNERSHIP OF EQUIPMENT

5.1 Upon termination of this **Agreement**, ownership of equipment, hardware, and other non-expendable items will revert to the applicant for which it was acquired, subject to the approval of the Automobile Theft Prevention Authority of the State of Texas.

ARTICLE VI
AMENDMENTS

6.1 This **Agreement** may be amended by the mutual agreement of the parties hereto in writing to be attached to and incorporated into this agreement.

ARTICLE VII
LEGAL CONSTRUCTIONS

7.1 In case any one or more of the provisions contained in this **Agreement** shall be held to be invalid, illegal, or unenforceable in any respect of such invalidity, illegality, or unenforceability


shall not affect any other provision thereof and this **Agreement** shall be construed as if such invalid, illegal, or unenforceable provision had never been contained herein.

ARTICLE VIII
ENTIRE AGREEMENT

8.1 This **Agreement** supersedes any and all other agreements, either oral or in writing, between parties hereto with respect to the subject matter hereof, and no other agreement, statement, or promise relating to the subject matter of this **Agreement** which is not contained herein shall be valid or binding.

EXECUTED IN DUPLICATE ORIGINALS, EACH OF WHICH SHALL HAVE THE FULL FORCE AND EFFECT OF AN ORIGINAL, ON THIS 20th DAY OF August, 2013.

ATTEST



ATTEST


Mark Henry

Lewis Rosen

County Judge, Galveston County

Mayor, City of Galveston

APPROVED

APPROVED


AGENDA ITEM #6.b.


Special Condition

COOPERATIVE WORKING AGREEMENT

This is to certify that the objectives of the Galveston County Auto Crimes Task Force grant application for fiscal year **2014** funding by the Automobile Theft Prevention Authority have been reviewed and that it is mutually agreed to cooperate to whatever extent is necessary in carrying out the work plan described in that application.

Additionally, the City of La Marque is cognizant of the rules and regulations governing the operation of the grant and agrees to abide by any and all such rules or special conditions relating to the application.

Signed: 
Tommy Hansen, Project Director
Galveston County Auto Crimes Task Force
(name of applicant organization or its contractor who operates the program)

Signed: 
Randall Aragon, Chief of Police
City of La Marque
(name of external organization)

Date: 8.15.13

INTERAGENCY AGREEMENT

STATE OF TEXAS

COUNTY OF GALVESTON

This **Agreement** is entered into by and between the County of Galveston, a political subdivision of the State of Texas, hereinafter referred to as “**County**”, and the City of La Marque, a municipal corporation situated in Galveston County, Texas, hereinafter called “**City**”, pursuant to the Interlocal Cooperation Act, Texas Government Code, Chapter 791.

WITNESSETH

WHEREAS, the County of Galveston and City of La Marque wish to file a joint grant application with the Automobile Burglary and Theft Prevention Authority of the State of Texas, for funding in the amount of \$649,268 for the Galveston County Auto Crimes Task Force, and

WHEREAS, the County and City have agreed to contribute the total of \$244,523 in matching funds if said joint application is approved; and

WHEREAS, the source of funds would not normally be used for this purpose; and

WHEREAS, the County and City believe it to be in their best interests to join in the application to develop an Auto Crimes Task Force.

WHEREAS, the County and City agree to each accept the responsibility to adhere to all pertinent federal, state, and local laws or regulations.

NOW THEREFORE, IT IS HEREBY AGREED AS FOLLOWS:

ARTICLE I

PURPOSE

1.1 The purpose of this **Agreement** is to allow County and City to file joint application for a Grant, with the Automobile Theft Prevention Authority, which creates The Galveston County Auto Crimes Task Force which application is attached hereto as **Exhibit "A"** and made a part hereof for all purposes.

ARTICLE II

TERM

2.01 The term of this **Agreement** is to commence on the execution of this **Agreement** and to end August 31, 2014.

ARTICLE III

CONSIDERATION

3.01 As consideration for this agreement, County and City agree to contribute a total of \$244,523 in matching funds for the enhancement of the Galveston County Auto Crimes Task Force in the amount as follows:

<u>County</u>	Cash Match <u>\$210,837</u>	In-Kind Match <u>\$11,320</u>
<u>City</u>	Cash Match <u>\$22,366</u>	In-Kind Match <u>\$0</u>

ARTICLE IV
ALLOCATION OF FUNDS

4.1 The specific allocation of the County and City fund is set out in the attachments to this agreement, marked as **Exhibit “A”** and made a part hereof for all purposes.

ARTICLE V
OWNERSHIP OF EQUIPMENT

5.1 Upon termination of this **Agreement**, ownership of equipment, hardware, and other non-expendable items will revert to the applicant for which it was acquired, subject to the approval of the Automobile Theft Prevention Authority of the State of Texas.

ARTICLE VI
AMENDMENTS

6.1 This **Agreement** may be amended by the mutual agreement of the parties hereto in writing to be attached to and incorporated into this agreement.

ARTICLE VII
LEGAL CONSTRUCTIONS


7.1 In case any one or more of the provisions contained in this **Agreement** shall be held to be invalid, illegal, or unenforceable in any respect of such invalidity, illegality, or unenforceability shall not affect any other provision thereof and this **Agreement** shall be construed as if such invalid, illegal, or unenforceable provision had never been contained herein.

ARTICLE VIII
ENTIRE AGREEMENT


8.1 This **Agreement** supersedes any and all other agreements, either oral or in writing, between parties hereto with respect to the subject matter hereof, and no other agreement, statement, or promise relating to the subject matter of this **Agreement** which is not contained herein shall be valid or binding.

EXECUTED IN DUPLICATE ORIGINALS, EACH OF WHICH SHALL HAVE THE FULL FORCE AND EFFECT OF AN ORIGINAL, ON THIS 20th DAY OF August, 2013.

ATTEST



ATTEST


Mark Henry

Bobby Hocking

County Judge, Galveston County

Mayor, City of La Marque

APPROVED

APPROVED


AGENDA ITEM #6.c.


Special Condition

COOPERATIVE WORKING AGREEMENT

This is to certify that the objectives of the Galveston County Auto Crimes Task Force grant application for fiscal year **2014** funding by the Automobile Theft Prevention Authority have been reviewed and that it is mutually agreed to cooperate to whatever extent is necessary in carrying out the work plan described in that application.

Additionally, the City of Santa Fe is cognizant of the rules and regulations governing the operation of the grant and agrees to abide by any and all such rules or special conditions relating to the application.

Signed: 
Tommy Hansen, Project Director
Galveston County Auto Crimes Task Force
(name of applicant organization or its contractor who operates the program)

Signed: 
Kenneth Campbell, Chief of Police
City of Santa Fe
(name of external organization)

Date: 7 / 17 / 2013

INTERAGENCY AGREEMENT

STATE OF TEXAS

COUNTY OF GALVESTON

This **Agreement** is entered into by and between the County of Galveston, a political subdivision of the State of Texas, hereinafter referred to as “**County**”, and the City of Santa Fe, a municipal corporation situated in Galveston County, Texas, hereinafter called “**City**”, pursuant to the Interlocal Cooperation Act, Texas Government Code, Chapter 791.

WITNESSETH

WHEREAS, the County of Galveston and City of Santa Fe wish to file a joint grant application with the Automobile Theft Prevention Authority of the State of Texas, for funding in the amount of \$649,268 for the Galveston County Auto Crimes Task Force, and

WHEREAS, the County and City have agreed to contribute the total of \$241,550 in matching funds if said joint application is approved; and

WHEREAS, the source of funds would not normally be used for this purpose; and

WHEREAS, the County and City believe it to be in their best interests to join in the application to develop an Auto Crimes Task Force.

WHEREAS, the County and City agree to each accept the responsibility to adhere to all pertinent federal, state, and local laws or regulations.

NOW THEREFORE, IT IS HEREBY AGREED AS FOLLOWS:

ARTICLE I

PURPOSE

1.3 The purpose of this **Agreement** is to allow County and City to file joint application for a Grant, with the Automobile Theft Prevention Authority, which creates The Galveston County Auto Crimes Task Force which application is attached hereto as **Exhibit "A"** and made a part hereof for all purposes.

ARTICLE II

TERM

2.01 The term of this **Agreement** is to commence on the execution of this **Agreement** and to end August 31, 2014.

ARTICLE III

CONSIDERATION

3.01 As consideration for this agreement, County and City agree to contribute a total of \$241,550 in matching funds for the enhancement of the Galveston County Auto Crimes Task Force in the amount as follows:

<u>County</u>	Cash Match <u>\$210,837</u>	In-Kind Match <u>\$11,320</u>
<u>City</u>	Cash Match <u>\$19,393</u>	In-Kind Match <u>\$0</u>

ARTICLE IV
ALLOCATION OF FUNDS

4.1 The specific allocation of the County and City fund is set out in the attachments to this agreement, marked as **Exhibit “A”** and made a part hereof for all purposes.

ARTICLE V
OWNERSHIP OF EQUIPMENT

5.1 Upon termination of this **Agreement**, ownership of equipment, hardware, and other non-expendable items will revert to the applicant for which it was acquired, subject to the approval of the Automobile Theft Prevention Authority of the State of Texas.

ARTICLE VI
AMENDMENTS

6.1 This **Agreement** may be amended by the mutual agreement of the parties hereto in writing to be attached to and incorporated into this agreement.

ARTICLE VII
LEGAL CONSTRUCTIONS


7.1 In case any one or more of the provisions contained in this **Agreement** shall be held to be invalid, illegal, or unenforceable in any respect of such invalidity, illegality, or unenforceability shall not affect any other provision thereof and this **Agreement** shall be construed as if such invalid, illegal, or unenforceable provision had never been contained herein.

ARTICLE VIII
ENTIRE AGREEMENT

8.1 This **Agreement** supersedes any and all other agreements, either oral or in writing, between parties hereto with respect to the subject matter hereof, and no other agreement, statement, or promise relating to the subject matter of this **Agreement** which is not contained herein shall be valid or binding.

EXECUTED IN DUPLICATE ORIGINALS, EACH OF WHICH SHALL HAVE THE FULL FORCE AND EFFECT OF AN ORIGINAL, ON THIS 20th DAY OF August, 2013.

ATTEST



ATTEST



Mark Henry

Ralph Stenzel

County Judge, Galveston County

APPROVED

Mayor, City of Santa Fe

APPROVED 6-27-13

**CITY OF SANTA FE
RESOLUTION #2013-13**

**A RESOLUTION OF THE CITY COUNCIL OF THE CITY OF SANTA FE,
TEXAS, SUPPORTING AND ENDORSING THE APPLICATION OF THE
GALVESTON COUNTY AUTO CRIMES TASK FORCE FOR
CONTINUED GRANT FUNDING**

* * * * *

WHEREAS, the citizens of the City of Santa Fe support the fight against auto theft and support our respected law enforcement agencies in this effort; and

WHEREAS, a coordinated county-wide effort in the fight against auto theft is necessary in order to achieve the maximum impact on these types of activities; and


WHEREAS, continued grant funding for the Galveston County Auto Crimes Task Force is essential in sustaining this effort;



NOW, THEREFORE, BE IT RESOLVED BY THE CITY COUNCIL OF THE CITY OF SANTA FE, TEXAS:

SECTION 1. The City Council supports and endorses the application of the Galveston County Auto Crimes Task Force for continued grant funding by the Texas Automobile Burglary & Theft Prevention Authority (ABTPA) for September 1, 2013, to August 31, 2014; and

SECTION 2. The Mayor is authorized to execute the Interagency Agreement between the County of Galveston and the City of Santa Fe for the filing of a joint application for funding of the Galveston County Auto Crimes Task Force.

PASSED, ADOPTED, AND EXECUTED IN DUPLICATE ORIGINALS THIS 27th DAY OF JUNE, 2013.


Ralph Stenzel, Mayor


ATTEST

Janet L. Davis, City Secretary